<SEC-DOCUMENT>0001802768-22-000035.txt : 20220804
<SEC-HEADER>0001802768-22-000035.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804091046
ACCESSION NUMBER:		0001802768-22-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Royalty Pharma plc
		CENTRAL INDEX KEY:			0001802768
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39329
		FILM NUMBER:		221134967

	BUSINESS ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 883-0200

	MAIL ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rprx-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1,d:f7303c6bf0bc4b328e9b48bcb6a7c139--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rprx="http://royaltypharma.com/20220630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rprx-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8xLTEtMS0xLTEzNDUwNQ_414bc690-26ee-4c7d-8694-9ab5640e261b">0001802768</ix:nonNumeric><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8yLTEtMS0xLTEzNDUwNQ_df00d29f-7e38-4815-b826-3020fec96544">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8zLTEtMS0xLTEzNDUwNQ_6efce71f-4030-4281-92a3-a41b60656159">2022</ix:nonNumeric><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF80LTEtMS0xLTEzNDUwNQ_d1150f60-e168-4a8d-a3ce-1505aa2af076">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF81LTEtMS0xLTEzNDUwNQ_9de2f501-c782-44f7-b230-57c19394a3a2">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rprx-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52760d2b07c440c88f705e4f29492dfe_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i6f1203bc2aec47828c8f208e84b90129_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96a29a0235747acb515705fba4cd81f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if43def283e414c978ef1f9e00d58466d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19484314d7814df68d24568f06200a2d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d4df0714f34eb1a565d4c996780d0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i31b8cd4406014f3c9e543595ef591d8a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9152e53d53c4a94b5dc2379eada56ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89465228e464b4db926b3506aa69ce5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab0e06da69042fa9b6cd6f4ccbca52c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fe3fac5bec4e398fc4873084eba949_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9d15ae87c34585a03ab9e32a13a2e0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64033553961b494aa24564bcfa09d64e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad03cc6dacc54582a74b8ee9859a3668_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf93cd9df7684053a5502441454a22cc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id535c2ad3d594a9ea96cbabcc62e08eb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9bea35421f24cb28ad1d0b36f56b112_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33f02594c6141be947d8164ca9d9c2f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib533fb4284214d818817d4f74f5eadba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc41c410425b42d7abcdade3c8154e0c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f91e61c3dd491c96060d2cd0475caa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24af4b775fdd421ca76221754d6cc72b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie033c0ebfe694b18a9324c6432dfa2cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3131abfb53a454494b73f6ebe89c392_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb23fabb1e14fb78211172951d31a08_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45953d0a97b4ab4a331eebb7376a3cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1f6430e214497599d013c1c8969e8d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22fe98e0e7a94704ac3fdfff181f9502_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5339fc8ea38b46fa9a86916bc074eca4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2527d56cd62046479c1173dcb0b0f5b2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02556876a6a14a828978826651a01c40_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefecccbe9aeb4eda97cf4d50e61ebc9d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0a2c2185f841d1bd0ae1256b144310_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ebb3a392fb49adaca1a85bc203cbec_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176f226ee22a48e38c48b5d77aff5fe1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f7632b52e24947b5542bc50c2d3c30_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2105ff37cbf54c04ba010a8c52924650_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica342df70a2842ffb246d1630ba9eb5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305f1861941e45fbb293aa1942d05488_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622a95bdb08e47f7acf229df1afae29b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71ca76e55df4684b26c0aa01421d9bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c89af6243f0463eb180fef51c293c8c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b43a0bf90e547dbb6fbf1dd47972a2a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b916b52b23472ba3549f7931482243_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade2ebd58086471fbf60d5e06704e135_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff3e647fe0147108d0196b5815a9c6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1a04cc8cc84280933c35ae3b8d8d94_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffade55c2b5644739b00e4201220367e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b8266d2b4a41d0a8dab2958a2d956f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100aaaeaffba486fa3044462ac9475b3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2ae29b2c9b4f06af0cf0034f33a3a4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e39280da19945f6afec914c5d523b2b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7ac128c7c744138c4d180baa58e508_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48ab397b18842dea811ef845e7f9159_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030828ed817644a789470b5495e7c36e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589baf01d5dd4c2caae101de2f597840_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia146a7ffd9eb4c388b427f68bf59099a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5332e18aae41968464d7e40f3879b0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d0005fb24b41b7be1fed5796c78265_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f837639fd8f42d18127b22713c22bff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1903e1e4384e289320f606987686f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb49e5d1da64984b7dab1f207cb821b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48669715cbaa4a4ca2f245e9fb5f1995_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290a4cb4e651436abde84028a4766f89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e401b08b73c499dbf77eb4e227d5e2f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96dac154fa240898e743b8ff8fc9059_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05594336aff54167b344569f8bc28d05_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509463e2205845eb855c04c67b225ba8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7f0975039c4b47a8013da696977787_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74012a9aba134af29fa48477d04dde00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1b46dfcb7f40ebb639788c968daf3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7b784e492241448627593176cad967_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972173b5752144889ef69fee1cfc51dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf7802275df47c59d3e1f7df579b50e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592c6aa1733545c6a94d49a0144e42e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3f673cf22e4af289ea139885dca16b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b19f0203cf486094b8b552ce743af7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cade76361ba4fcba710604a8c023a58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660048b273ba434f82a3033be439995d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d05a9e48b54e568c0c8b5a3e8ab180_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8047411077489696941648f5280f81_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6a414fd23744eb89554b7564759f43_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aec56c066c44c0c9505da67fbc972b1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15dd32149b64228b3e0062543709fcd_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc135510e2d49c6b0cd406c917f4076_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4664ea2072fe497b9a2bdfd6d8b604dc_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3af9b0efe9a24584a5d0beab8491a70b_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870dbc439abc462d939ae18d7d1c13f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-07</xbrli:startDate><xbrli:endDate>2022-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>rprx:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i902af37f112d47b59465fb1587d35546_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia97d19761a80439aaf1c248d0d1cc56e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b647dc49674f03b93aec721c35aafb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50973d0a69a4908932e02a923662f68_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5c1bcea18e4e42a9671f6beadbf2fa_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01bf1c77beb0485bba6517474b519b3a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e38949c6aa4cd6866cb944e9722714_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75ac419666144e9ac3c194e9261e33c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id978345eb4784af985d02a10ba404dc9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578d8f8ce4bc4f43841fb347caa2a50d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49f4fcd2b764a89bc0488726370049d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a47ace66d74b15afbe0039fd04291d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9290af25cfb841918df88507b267637a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6700642e5b124bf1a3547c30d346a79b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ac760695004feebc1b6b592162d7c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10b1800e67dc44a981720a7b46c2e79d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0870484004364ecb8b093f2046454b41_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2e274fed7a481fba6833bfbf3cce5f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c80a2ae1ba645d8abc23c5ce5fd6c3a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3505ef986d8e447e9494c8ba914f66d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd435d72f144bbcb6e42e3f0d53768f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3de23eaeb284126b429fb1b2832c3dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5576abf606bb4661bbc57aac01aa20ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8546e9f6e24b4217b84ced51c46b1e0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ef74a0dac44216a515c0217153b14a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb473791033401b851d996ace3fb0d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08423e6c0ac54c738abebce60150775e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694256d7751f443599a66a50b84c5c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335547d431054d37aa47757fec28e211_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9d3fdba80d4a0ab2392959204e54f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274c91a324f74a50b47e0f39cc9a6471_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dcaa33e9c8c454ea8d9ad358405d5c0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a0b0bfcc4f426fb9507705a90045ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e68fb94a79461caa836857c65a594b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ad8d24abf44259b70281a4a03fd5ab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e4ce8bb43f44bd81105b431942f8a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5229c7a11d840c385003a2de7d5a560_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0f2a63eea644fc9b8acb08a1096965_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a3c10ce0834373af301afc9cb06554_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f7d2dc311341ed8ab580778cfb7424_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40a5bcf20dbe4092b31de7276a1233af_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164534f9debb47d283bba03bb38b42a8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3724a5f5971340ee9b2c75df324f183e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de1f8630b5044af9d51c4a863878a19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae65db56ba049b8b7016f1d57247db5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca01372241f4621b26e3c24a6b0ac4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8847225dbd934083a96c5b022eb001dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4faebbed44242b588fd22db4532d6a2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e2f72945114b8e97557817665eb22a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide527eedf0c8430ebdd7f8b7e178695d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d54454653d14877997e8cc8a446a36b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9240e834904c4b7980784391c35ae5d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057686b000924406a6e92a555bcefbe8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6562ec75eae34ba19dcb404ea71fccac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7cf57e9bdd49e3a5aab2cd19221140_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4c1ac3b3004925ba20d1eb0829987d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a847973ce446648b13fdedff22c715_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia78911c3736d495e8cb2fa5ea8e81e2e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c70858e246f4c259aa4add3106bb74c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42664d0a6f0744bc8d3dc6057491af00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d0d65a59844aa3bee4beb15d323337_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5608ca68f141c5ab7e851371cbc63c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3099777568874b56a4d873cc01719626_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab2e747c9c9b43f69707587cc843a451_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872d2b73bb3b4a8da6deb68b730f21af_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306cb19b43b645968b07140915241260_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if290e213185d45f3b68d456d7bba18b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354de3a504f7447f946701a70bbbdd32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a185b6e27d445c892d2b91c0a23d94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48faa4921ca5490ea5d8274518df219c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id24d238620954975bfcdbdd367836c85_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id366640cb83544df99f3ad8a3131c185_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf20ea8448ab403080a8058146fe9940_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97aa147f94524d7496766953b7a86882_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509709b18bc34c46b002ff7583a3eb02_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40208096a5d4db6b4b3971989763e71_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3efa9883f6e24af785319eb40fa00bfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557255cd129a42a9a7bb3e235e002c30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d47e0f671754f869e7a625979b2f609_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23d4f24f8d04a988e40dbf86515109d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d78244fc88c4181b2440708f971ee96_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfe1cd3f4e7415991895ae425a914d6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316c6f99df2b4a26ba23e4e48f5c3abd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9792ea77bdea40d1ae7f65287f922717_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333a9ec1ff53481696d2280a621e9863_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f25260f20c04074b3fc492d72c935ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4694ad59207646ac874c75e17fd2b37b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69f87b5bc8e4ea1a497545b599999bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9455f5d9a104f0e81d0b8107254f72f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fce1c2f895246eebae070dfcc9e49e9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a38f2819984010b545afc636533f8b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5803bf99b3b473cb7589dbc5dab874f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b8f5d307bb4b9b990828c40cf681b4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf836c86dd4f40bf98e8953f69ac75fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e58c615de2f4b659329480870108ef1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83281e2c15c7428f83706175489d6339_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57b86b9d1184e09887d985686c79f0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0ee976221e43ac94bfd0056a40c5bc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9140bfbcfc3e413ea3287f2bb5976940_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fabb30765e4fef8c46e1acdc00d9dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba21e49a07e840aeb4ca72218e5782fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd0ae0498ad4e29b327a69dfe2286e8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d03139bb3743808afda3b7bddd5bc2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35b86bd79ef41a28f7e6d1d00c42f48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8317e61e1f41c784239c68f2108a60_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3cce41829e46588da12635d7616283_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353de01dbec74abcad269b32e3cdb25f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa854c1e4c4436a8ea3e2512d5ef979_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c70708fcd054afa8e309da96db8d7d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365769dd85514fa18d6a39ba5d363336_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06ed27505284260adf0648d3d31568f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a1621fc32f497988a0e96ba9b1feef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d029a55997348e4a5f520d12893009a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2661ba948f9948bf99cd3662bded664b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82dc1c2627b4d718f85effdf12e3a8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369c65d0b3874042b691cd5c31ea13dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4925acb858a43cc8cc6487a6f052e4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2625fc2cdae04a5a832d2df168c76071_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf40b5c13abe46518f36da6af058fe32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eaac71ae55f4517bcccf4879bb27679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb1edf8c46140688a4ed0d57e3927b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18d1f6254b04c1eaf3b2e9a61f02662_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7602807328d94e3ea160b1356604c56f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8320a1e985dc497d99e7ee8e4fb2680c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe40e0e708a24e1485c00e06f6c33811_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a44308643464db9804f8317e68d3593_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:CytokineticsCommercialLaunchFundingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c078144e5641bebb3f8f5b775cc14f_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b00b1196a842a18ae4bbfc65e35bca_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5940ed238dbd4c118100d14a7e5ad7a1_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc0e13f8a8149dda55dd457a53e6897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ec77ad5db44776871a0182cf263586_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8b4208854b4a00a19fae7046aab65c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d52494a67e479ebd68a8c3b8f69060_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adddf24c7f04202a9c712798093983a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7caf3f5c79647e18539159493607558_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40b42e2790c47ef8f7f4808b0958e59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280cfe154d93462092b3209bd9f8e4b9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2861968b06bc49ad84cee28144700724_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1fbfcb89cbc4602b2230f697892cd1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814da027f61b45e4b7e1a8b98de0f86b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i212af950addc45e6a29921885da2a4e0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9473a880a5344144a8d65facb9f75109_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68b0902cea7416f9dd59258eb674bc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib719fc62cf904acc863f4c031cfadf8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1ce1553bf74d69818557e322f52767_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898a964c879840d78fe00d3bdfc2571f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618646a4dc484b23bb5596e4471fb6fe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1ee997727d476f941c9f5cb772f235_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb0f3822f7448c3b9edb5542ba8571e_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1652d07294b14089a0592537d2026e6f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373eee1b26c541e8833b248c7988a139_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife00a507d4204c9bbdf7447e8c4d1429_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84eb422d2b40477e9258c52a15372639_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620523eb4a204e25acac2ef3e9967411_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bbd0e73cf3d42dcac55b07236105ba5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fa516152564be089415fb655f74d77_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fef318c94084992aa959a03e78ce32c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156b8175434d4e1db0d0fd57caa92008_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c73e53d86c471680151e41da485930_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdda7de8d7244be2b32f9b7e729092c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691fe772f8474c9883cd86d770776fc5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:CytokineticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e6f22ee9884362b21300a0550d1dea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5277bbde55dc4ff3aac4ba9a24308df5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5db792457664c249f4f34f68ae84ee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3998c09aa68e48dfba459528066155e1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2520a38f28f24d8abe1664a0fa276108_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb3b048ad644ef7a5f6894758c0ec22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473f0b55243f46238d71fb088fbcbd08_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba61f5d65e924374ba352a9226aa644b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6514393b77b142479d7fa249d2437d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246c4d7bf81f4ad88af37091381a6fa0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9de03c81c754dc7bb15c6c52caf92be_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813d79deba2f4673b7dfac7f74be1e42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803cb24ed48a4da1b85d42425a8acf1f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca85d756ed8402091fc1700a7ab767b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54640267ea864316a9bed44de2313208_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89293daeea364b87a0f53da7fa772357_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22abfbc03ed3462fa495b3d35e9f63c2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f4360f02cb429f873526aa4abb90b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i850321a4707144d5aa10067c9606b155_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf45fa61bd9d44eaa6acb1fcc1c764c2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66677b99bf9e422f895af82a4346163b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77ed6261fc14df9845a99e3f1b47d5a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38fcca043734f5c8ff85a24cb230791_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a03d177ab2440997f9376d5899a918_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c7820636114a409ceede5a921b1d09_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3197e12bdd3a4d309fc770d7447285e2_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164ffc87f86f4075b11ef1a172aeefb8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a92e44b4b344661af4757ad9a229064_I20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf036923cf324ce78882338a4fb17702_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e250b66e64341b09584ce80e7cba81e_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba76a3f80e5c49e3948452772ef55ef9_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c364b452a2e4075809d3b9b42a5c9e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022d32cb77944ea29be1667bb225e44a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8378863f6fb54944bdf6267872f7e32a_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc406544d3744be8af475bd920f1691e_I20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia209b3983b4840c0a0ae77de9566e43b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd001fdda914fffa3ca20031e15926d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f318ef84894bd4b707d34d44ab34f1_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a66b8b6943547f2808825744d348a6a_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0545a0e18343f2842f30b29d72abac_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="class"><xbrli:measure>rprx:class</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>rprx:vote</xbrli:measure></xbrli:unit><xbrli:context id="i464e075cb1d04ed28a402c8f7149fe47_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="noncontrolling_interest"><xbrli:measure>rprx:noncontrolling_interest</xbrli:measure></xbrli:unit><xbrli:context id="i63f4135a52e24cdc8a877de0528e91ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957a4d6b1a8f46acaeae11abefb3a081_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ac24325a784997a2a2834a39d26946_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife05da3ee4b44968baca4702397077dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ff712c0f0e4721b11f310c9a7ba814_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac973f489d7a4fc9ac38195a2164de93_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie068a9d4a59444e886f94818184da48d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e0d9dd3824945d09335073108634a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d62fb2227b41378a04fa7cf96ec2e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac8a13c10554d4e8c579493cc60ccd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff4eb9e0f8c94eca9757ffe4eb666c7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094b01ea23224dbd8928efbf7993356b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88246dd04abf4793a1634e975c03750b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715821bde2d34b7aa686a6dfe08ae077_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771cb54e67794bd7841999b1e5270715_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8b00699867481fb50c4fef1515ba9e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a9d91774c148d1bb20516e42535cc5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20897a0731394ab39cdbf6f569451ecb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564ee5a80f984273b26344ca0417004e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbbfac68ec4488cbbc6b6f3a3f7e632_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70dd8a979be46a0a140e37dcbc10470_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a1efb8258c4f90b003132a7c806d37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4499f27b8c415c83b4aa5e390c611c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd5518beaff545de976d2821f78d8146_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59134a7c071446a8dc6d06dd7272373_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf25b5c44074bba8349a3ed917b9828_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89da6075574744cd88689bc056f4784d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e85d625927d4a208e60107fcdc3e4d1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1723835775974da9ace43244c9bf89d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839baaa9ddce4c7a8bee9fbd533f440c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e57903f579943a3acd517f95ac47e2d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf2318e4b6145d29623e3758709b640_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716b09853e4a4174a28f2a27d873f6cb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212df1108fca4c628a85996199e48189_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d396452af104e75bfbf02ca11bf7445_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934116fad2e6442e88d42ee191199a43_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade6caaa03d24c1db457fe31fe5a9a4d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib720c19bda424da0a54ac76bd380e694_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e368ed2beeb4e9bbfd7a428cdfe20a7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id600e57f7adf403dabaeb1fd595d2aea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27cc09d1626c4c12831b9b9ed5f1707e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75026c18f8e94d4d89a49b9629256c1e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica95079874234fdbb0b75f9d0967a000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69334c4cb99348768c6cddd1b7d09954_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad559122e374240aa4d76a955a15563_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a96d121b274fbd8dbe1ad563a91052_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9849608bf44ab2b4553b4ce907b20e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia627a511f205448c8f15096957f33520_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6458b426c5a0473fbba13389985422c7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46117034b4ae4c55b35944ccab8ad2b3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89beaee57e374c50b2a774f5e339e12b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf7a05a6178471d83f36a54fc1b58f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTI4_d6bfd733-860f-4bf7-a62d-683f8fa36b33">10-Q</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6ODYwOGY0ODhkMTk1NGM0NDk5ZWU1MWFlMTE1ODZiMGUvdGFibGVyYW5nZTo4NjA4ZjQ4OGQxOTU0YzQ0OTllZTUxYWUxMTU4NmIwZV8wLTAtMS0xLTEzNDUwNQ_ceacc7cb-c5e9-441e-99eb-87a34c506079">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the quarterly period ended <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8xMzQ_f868d0a7-9f87-47b6-90a6-3bb553cc475b">June 30, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6ZGU3YWZjOGI0MGFmNGE1OTk0MTlkYTZkNzg2MGFjNGMvdGFibGVyYW5nZTpkZTdhZmM4YjQwYWY0YTU5OTQxOWRhNmQ3ODYwYWM0Y18wLTAtMS0xLTEzNDUwNQ_1a20497c-fdfa-4a70-8269-fc3e96c091d4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from                                    to                                  </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTI5_898178cd-b4b1-4168-8e7c-a38ca732153e">001-39329</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTMz_c05dea79-9795-4763-bedb-47c82e08df4f">Royalty Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:178.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8wLTAtMS0xLTEzNDUwNQ_e4277bfd-8ff5-4776-bd45-0a8c4c439c3f">England and Wales</ix:nonNumeric></span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8wLTMtMS0xLTEzNDUwNQ_3d62ace1-be7f-4f92-92f9-bfd368672b6f">98-1535773</ix:nonNumeric></span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8zLTAtMS0xLTEzNDUwNQ_d5d32ae5-9b4b-46c6-87c4-f15918a91ad5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Street</span></ix:nonNumeric></div></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzQ_550e598b-dbb2-40a6-88f7-4b0fa8715c28">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzg_285a0213-19ca-4ada-8182-590c668e46c2">New York</ix:nonNumeric> <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzEx_b2c94229-ab53-4c6e-a644-cff5290cb86b">10022</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTMx_fe19548f-22f7-4111-ae49-3f282df34897">212</ix:nonNumeric>) <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM0_3fd2a752-3180-4b71-bff8-cbddd62f9f82">883-0200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTAtMS0xLTEzNDUwNQ_948ab340-85ba-4135-868a-1dd739bee9d8">Class A ordinary shares, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTEtMS0xLTEzNDUwNQ_f8978805-3d3f-4a2b-ad13-8f18d9b34b08">RPRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTItMS0xLTEzNDUwNQ_8ee3c385-c25a-422b-af49-f67884c69d19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;<ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM1_89481da1-a5db-4ceb-bad0-83d8cf5b2fca">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM2_f0f072e5-f623-42d9-8669-9103ffa989b4">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18wLTAtMS0xLTEzNDUwNQ_f37ed9b8-3e86-468a-9bfe-a7aac53cde0c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18xLTMtMS0xLTEzNDUwNQ_86214ab6-d278-4be7-a0ad-f1dc88f21dbe">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18yLTMtMS0xLTEzNDUwNQ_22e17cca-fa21-4fea-b9c8-81696f888111">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;&#160;Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8zNjI4Mzg4MzcxODc4Mg_80707dfd-b21d-468d-969e-24b6bd8d7985">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">As of August 1, 2022, Royalty Pharma plc had <ix:nonFraction unitRef="shares" contextRef="i52760d2b07c440c88f705e4f29492dfe_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMDQ1_0f00c64b-8337-40b2-a021-c1e87c540340">437,139,178</ix:nonFraction> Class A ordinary shares outstanding and <ix:nonFraction unitRef="shares" contextRef="i6f1203bc2aec47828c8f208e84b90129_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMDg4_fef5dd72-1e9a-432a-b98b-f64ac1b3c205">170,080,791</ix:nonFraction> Class B ordinary shares outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_7"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:8.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL INFORMATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_13">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Financial Statements </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_16">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_19">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_22">2</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_25">3</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Shareholders&#8217; Equity for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_28">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_34">6</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_40">7</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_109">30</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_154">61</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_157">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INFORMATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_160">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_163">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_166">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_169">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_172">62</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_175">63</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_178">63</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7303c6bf0bc4b328e9b48bcb6a7c139_181">63</a></span></div></td></tr></table></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Special Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains statements reflecting our views about our future performance that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of the numerous risks outlined in Part I under Item 1A. under &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">These risks and uncertainties include factors related to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales risks of biopharmaceutical products on which we receive royalties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to locate suitable assets to acquire;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the assumptions underlying our business model;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully execute our royalty acquisition strategy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to leverage our competitive strengths;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual and potential conflicts of interest with the Manager and its affiliates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of RP Management, LLC (the &#8220;Manager&#8221;) to attract and retain highly talented professionals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of changes to tax legislation and our tax position; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks, uncertainties and other factors we identify elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the U.S. Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report on Form 10-Q should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results or revised expectations.</span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_13"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 1. &#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNC0xLTEtMS0xMzQ1MDU_204cf68e-fb2f-4174-8965-88a7e83e6486">2,108,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNC0zLTEtMS0xMzQ1MDU_787329c2-2bf4-4987-9b6b-487183df10d4">1,541,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNi0xLTEtMS0xMzQ1MDU_a21c3ba1-c42c-4793-87f5-0b8a3a3f7f96">290,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNi0zLTEtMS0xMzQ1MDU_a645371c-30f1-4808-8684-c7ab8791ec09">581,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNy0xLTEtMS0xMzQ1MDU_dc2eda2e-5622-416b-8c6c-68a90d188e8b">639,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNy0zLTEtMS0xMzQ1MDU_9e107989-6b64-4ed0-96d4-a124b1160320">614,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfOC0xLTEtMS0xMzQ1MDU_000aadcf-2fc3-4d50-9030-de1e3dee44ea">18,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfOC0zLTEtMS0xMzQ1MDU_3ec8d5a2-6f8d-484e-9cdc-be45a517e654">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTAtMS0xLTEtMTM0NTA1_5b62f29c-e48b-4b96-87be-64d5159e1468">363,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTAtMy0xLTEtMTM0NTA1_9d5e50ed-3194-4b2d-84e0-0735c684713a">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTItMS0xLTEtMTM0NTA1_9de81ac1-e634-42a5-8a14-b827668c527b">17,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTItMy0xLTEtMTM0NTA1_6386c830-b56f-4c25-a0e3-f3da300e9bf2">15,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTMtMS0xLTEtMTM0NTA1_ce90bbdc-6d04-4de4-bea1-21340c526388">67,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTMtMy0xLTEtMTM0NTA1_5c48dd65-15bc-43b1-9c6b-bf84e6e6676c">6,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTQtMS0xLTEtMTM0NTA1_54362ce8-e61c-4a2b-9461-4548f668b485">3,503,849</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTQtMy0xLTEtMTM0NTA1_72fbf677-e2b8-43d3-95db-a2541fa2c8aa">2,878,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTYtMS0xLTEtMTM0NTA1_ef2af0ae-1753-41b4-b3f7-dd987df14d4c">13,423,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTYtMy0xLTEtMTM0NTA1_cbfe53a0-6b74-493e-b547-ecbe69ec56b2">13,718,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible royalty assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTctMS0xLTEtMTM0NTA1_20984163-aeff-43bf-93a8-2b7358d2a3c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTctMy0xLTEtMTM0NTA1_89dd5877-8b4c-4cd9-ace0-6ba15e3399d5">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTgtMS0xLTEtMTM0NTA1_655ed78c-cb23-4ff6-b1fc-2c796f15b5e1">304,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTgtMy0xLTEtMTM0NTA1_2e2e4100-d8b0-4929-8020-891fc5265160">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTktMS0xLTEtMTM0NTA1_85aaadc7-7e2a-4c4f-8aed-ec4bd3b4eae1">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTktMy0xLTEtMTM0NTA1_e7ef5a7e-7c1e-4de0-86bb-ca341d064bff">204,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjEtMS0xLTEtMTM0NTA1_ba7b951a-f73d-4e65-8dac-03657f7acc52">412,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjEtMy0xLTEtMTM0NTA1_eda9c6c1-3c8d-4459-8bb1-1c5659e007ce">435,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjItMS0xLTEtMTM0NTA1_5f2b58c9-4b87-402c-bafe-4a38ace5add8">33,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjItMy0xLTEtMTM0NTA1_8715ece1-748f-4885-8ec2-947b118ca81e">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjQtMS0xLTEtMTM0NTA1_363f9100-8c54-4323-a67f-bb96b6947ac2">17,740,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjQtMy0xLTEtMTM0NTA1_7e5ecde7-1f2f-4a32-9ae0-e00ba6a4ae8e">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions payable to non-controlling interests</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjgtMS0xLTEtMTM0NTA1_d396b193-ffbb-4cbb-a8c3-7e5fefa6d115">115,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjgtMy0xLTEtMTM0NTA1_ca518bf8-c9be-4a9a-b376-7ae26c3fc7df">107,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjktMS0xLTEtMTM0NTA1_f88c63c1-c7a5-4699-a6f5-8389b7a9d4e3">12,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjktMy0xLTEtMTM0NTA1_3b84199e-aa33-4ca4-b7ab-38e357cd9cfa">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzAtMS0xLTEtMTM0NTA1_c26b39fe-afde-44bf-8f62-7c4df9463b53">54,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzAtMy0xLTEtMTM0NTA1_1ede38d1-9563-47af-95bf-b62b039c7d2f">57,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzYtMS0xLTEtMTM0NTA1_df5052fe-74f0-4609-9ed4-5b9755ff54b0">182,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzYtMy0xLTEtMTM0NTA1_1dc2b824-5026-4606-9501-faf04c30f9ea">171,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzgtMS0xLTEtMTM0NTA1_29d322dd-4325-4673-a0ea-e4c12a3b03aa">7,106,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzgtMy0xLTEtMTM0NTA1_ae71dbc4-6d72-4416-a32c-9a375531aa0b">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDAtMS0xLTEtMTM0NTA1_def748a2-63c0-4882-ab1c-42cf579c3e04">43,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDAtMy0xLTEtMTM0NTA1_c3a3eac6-e5e0-40c7-8bdc-c78efe51973a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDItMS0xLTEtMTM0NTA1_94d7b3a9-4a6f-43c4-9ff0-322dce64c07c">7,332,226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDItMy0xLTEtMTM0NTA1_11855b5d-9e84-4070-8871-98eb5df558be">7,267,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDQtMS0xLTEtMTM0NTA1_9d430fa6-934b-4189-9893-6371cd545ecd"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDQtMy0xLTEtMTM0NTA1_41057dda-7e9e-430c-99cb-3fa9542eaf94"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class&#160;A ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="if96a29a0235747acb515705fba4cd81f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfMjk_10c1e575-680d-41f7-8abc-cfedc1b7f815"><ix:nonFraction unitRef="usdPerShare" contextRef="if43def283e414c978ef1f9e00d58466d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfMjk_5e86893c-a079-4f7e-bce6-d2f39fdffc35">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="if43def283e414c978ef1f9e00d58466d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNDM_2610e4b8-0f2b-43d8-8c0e-13b7e8f2d9f7"><ix:nonFraction unitRef="shares" contextRef="if43def283e414c978ef1f9e00d58466d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNDM_8af88074-76e6-482a-a6b0-d88fe5ed997a">437,139</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if96a29a0235747acb515705fba4cd81f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNTA_0b57032b-2a2d-4f89-96c2-b206d9e5bfe6"><ix:nonFraction unitRef="shares" contextRef="if96a29a0235747acb515705fba4cd81f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNTA_1e1f2e5f-c1d1-45ab-8229-0f0994d7b6e0">432,963</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43def283e414c978ef1f9e00d58466d_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMS0xLTEtMTM0NTA1_d50ac832-bb43-4d7a-a101-16a0b6ca9388">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96a29a0235747acb515705fba4cd81f_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMy0xLTEtMTM0NTA1_87a17fc2-61e4-4644-b4b5-25de32cdbcea">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class&#160;B ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfMjk_079a05df-18e8-48ba-93d3-45840c23de73"><ix:nonFraction unitRef="usdPerShare" contextRef="i19484314d7814df68d24568f06200a2d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfMjk_2a28a024-c286-4313-9406-1cfc77bf0f3a">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i19484314d7814df68d24568f06200a2d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNDM_2321f4f3-b8af-4332-8aad-a41ad1769241"><ix:nonFraction unitRef="shares" contextRef="i19484314d7814df68d24568f06200a2d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNDM_d9336fe9-1c75-423c-9174-4e877c7ed3ae">170,081</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNTA_ac4917a2-756b-43fe-96f7-84f4c3b227d1"><ix:nonFraction unitRef="shares" contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNTA_f0a523e1-6ac6-48b1-b727-de3a2a6762d0">174,213</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19484314d7814df68d24568f06200a2d_I20220630" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMS0xLTEtMTM0NTA1_9bf46faf-688e-499b-a040-d8029df97d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMy0xLTEtMTM0NTA1_79e93282-7ead-4463-8e28-e764c0086fb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class R redeemable shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfMzE_0c675d08-65d1-44b7-877c-cbfc653f3a77"><ix:nonFraction unitRef="gbpPerShare" contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfMzE_f63525e1-68c1-4ec6-8d6b-3947c8cf1b7e">1</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNDU_0363353b-33ec-45b0-b825-5331552562d4"><ix:nonFraction unitRef="shares" contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNDU_d638b728-4418-48e0-9c30-1195bebbed54">50</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNTI_21a578a4-5dbd-436f-be6a-cf59cd1b8095"><ix:nonFraction unitRef="shares" contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNTI_e3ec3451-5787-4838-8e68-6538a8eb806e">50</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMS0xLTEtMTM0NTA1_749e76b5-e1f8-4083-8fbd-29c1966ef212">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMy0xLTEtMTM0NTA1_5c6cf53e-03fe-48e8-9c3b-f509f502e643">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMjE_13a9999f-ff01-4bea-bb11-27ff5e7aa8ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMjE_30eaa7f5-b862-40ea-a4ab-8829ac99807c">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMzU_73d0e249-087c-43d5-aa6f-598990dfc1a8"><ix:nonFraction unitRef="shares" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMzU_f78c5696-689f-4f83-bb55-6c47fc2303ab">365,302</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfNDI_46870d9f-a37c-48e2-a331-7ce1e622c138"><ix:nonFraction unitRef="shares" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfNDI_ec1c3591-1e94-4699-aeb1-72ec9538b43f">361,170</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMS0xLTEtMTM0NTA1_889679e2-51e6-4d69-9866-8d9b96b9d17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMy0xLTEtMTM0NTA1_6ead2b82-f57d-45e7-a587-c3d0353e3ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTItMS0xLTEtMTM0NTA1_e8d300e9-e39f-43cd-969d-0845338de44d">3,570,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTItMy0xLTEtMTM0NTA1_1569f527-8e4e-43a1-abb6-149dd2d199d7">3,507,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTMtMS0xLTEtMTM0NTA1_8bd71817-ac08-4480-83b6-c76ef33535d9">2,446,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTMtMy0xLTEtMTM0NTA1_84fc1cb1-5c43-4ed9-bd8f-41147c33ab2e">2,255,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTQtMS0xLTEtMTM0NTA1_7109faed-f727-479c-94b1-699da1bfc556">4,380,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTQtMy0xLTEtMTM0NTA1_bcd6c4da-a978-4844-aad4-b8ee012b8489">4,471,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTUtMS0xLTEtMTM0NTA1_1f0b3de9-676e-4482-a973-603294366481">13,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTUtMy0xLTEtMTM0NTA1_04242e7a-93d3-4f11-9f2d-ce27fe58fac9">16,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTYtMS0xLTEtMTM0NTA1_8e2d4aa3-92a2-43c0-a1e1-0c9cd84bb43f">2,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTYtMy0xLTEtMTM0NTA1_0ec9d93f-ce97-45fa-b7d6-c4b3dea9dbcb">2,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTgtMS0xLTEtMTM0NTA1_c76d2092-5774-4c7b-9460-c8855ec74c67">10,408,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTgtMy0xLTEtMTM0NTA1_8e65a01e-8d32-4027-8697-6713f2471c38">10,248,545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNjAtMS0xLTEtMTM0NTA1_ae0f86e8-c55a-45d0-b597-5e19b9542b06">17,740,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNjAtMy0xLTEtMTM0NTA1_912e7d16-36c8-445f-a4b5-735c387b37df">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income and other revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9152e53d53c4a94b5dc2379eada56ba_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy0xLTEtMS0xMzQ1MDU_8e59d508-5cde-4820-b25a-dccfa9274fad">515,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89465228e464b4db926b3506aa69ce5_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy0zLTEtMS0xMzQ1MDU_dc13b182-d22c-4de5-b248-4a031c5f3c08">503,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab0e06da69042fa9b6cd6f4ccbca52c_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy01LTEtMS0xMzQ1MDU_73daf754-4fb5-419c-b6a4-5481f5ba9060">1,026,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fe3fac5bec4e398fc4873084eba949_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy03LTEtMS0xMzQ1MDU_3412ecc0-7319-48a8-b4e8-fd821df8ef62">1,033,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9d15ae87c34585a03ab9e32a13a2e0_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC0xLTEtMS0xMzQ1MDU_0ee8349e-c6ce-49a8-bb28-08f32c5c2bfb">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64033553961b494aa24564bcfa09d64e_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC0zLTEtMS0xMzQ1MDU_199cc3f4-679a-4d6c-8201-1eb92e2830c4">40,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad03cc6dacc54582a74b8ee9859a3668_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC01LTEtMS0xMzQ1MDU_3824d27a-5ba5-461d-9096-fb037d86d4e5">36,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf93cd9df7684053a5502441454a22cc_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC03LTEtMS0xMzQ1MDU_12ea23ab-9473-4b46-a392-eeb076c5cc8a">76,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id535c2ad3d594a9ea96cbabcc62e08eb_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS0xLTEtMS0xMzQ1MDU_6d60e578-f40b-4f76-bd7d-a91fbd420b4d">18,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9bea35421f24cb28ad1d0b36f56b112_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS0zLTEtMS0xMzQ1MDU_a1f732e2-d4bf-493f-b3e6-557521780a8d">11,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33f02594c6141be947d8164ca9d9c2f_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS01LTEtMS0xMzQ1MDU_eb56e492-1704-4d88-9b63-274571d2a3c9">35,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib533fb4284214d818817d4f74f5eadba_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS03LTEtMS0xMzQ1MDU_a40c7aee-00a8-49c1-8dc2-168aff853686">18,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total income and other revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi0xLTEtMS0xMzQ1MDU_a5c863e5-f636-4408-8882-8300e4b1aa87">535,955</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi0zLTEtMS0xMzQ1MDU_9f8f88be-607d-4453-b039-1babd3f87d22">554,963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi01LTEtMS0xMzQ1MDU_3c860d53-4724-43a7-ad32-ba1f178f5a19">1,098,004</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi03LTEtMS0xMzQ1MDU_f12550fa-187e-4145-aee8-9f4c9f13fc03">1,127,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtMS0xLTEtMTM0NTA1_d10fabc0-e8b7-444b-a0b5-b96aeebafdcb">105,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtMy0xLTEtMTM0NTA1_37575766-aca4-4e9b-a99c-49959fee67ad">243,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtNS0xLTEtMTM0NTA1_af9cb821-04b0-4d54-88a2-dba59096e8ab">290,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtNy0xLTEtMTM0NTA1_0abb7384-8949-45a9-9aed-b7dcef53f900">48,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development funding expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtMS0xLTEtMTM0NTA1_8ea6dff7-8bf7-4a47-a712-53a8f9f438c6">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtMy0xLTEtMTM0NTA1_659f6afe-ae33-478c-b50f-7158ad002622">3,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtNS0xLTEtMTM0NTA1_04d127fb-b2fd-47b1-8c79-cbfdf407b2e4">101,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtNy0xLTEtMTM0NTA1_094e1e4c-0d11-40cf-8dd8-1a15ab06d22e">5,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItMS0xLTEtMTM0NTA1_de669f31-0bc2-4e4f-b01f-8f65a467cc15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItMy0xLTEtMTM0NTA1_d094221b-95af-41b1-abb8-b13d4d3f3dfd">5,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItNS0xLTEtMTM0NTA1_f2ac5dc0-988c-4b33-94a0-a321c4533b1b">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItNy0xLTEtMTM0NTA1_bb2b29fe-8168-4d87-a8c8-a03a9213b9ca">11,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtMS0xLTEtMTM0NTA1_702c6524-4aca-47b3-8c17-2bb5464702de">51,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtMy0xLTEtMTM0NTA1_f65408cd-370f-4481-b513-2638ddb54b03">44,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtNS0xLTEtMTM0NTA1_ef57d153-eeb9-443c-b4ed-e6ba82943554">103,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtNy0xLTEtMTM0NTA1_0e1e26e0-b3f1-479f-82f6-8b7742d65e7f">88,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating expenses/(income), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtMS0xLTEtMTM0NTA1_b6a2ff00-a4ea-4977-980a-694b6be267aa">158,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtMy0xLTEtMTM0NTA1_a7b0e0af-efa5-435b-949a-9418c0683e73">189,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtNS0xLTEtMTM0NTA1_eb61e975-667e-4c21-bbe3-1ddfd5e89dfb">500,494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtNy0xLTEtMTM0NTA1_415b580f-8a9f-437a-b015-cf4b644a039f">153,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctMS0xLTEtMTM0NTA1_e3da336e-ec05-4b7f-81e9-a5333c9074c4">377,792</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctMy0xLTEtMTM0NTA1_63bae399-754c-4327-a61e-8f54a6fa9196">744,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctNS0xLTEtMTM0NTA1_381c5d4a-d1fc-4587-baa2-d451d053b530">597,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctNy0xLTEtMTM0NTA1_ce18e3b9-fdcf-48d4-9759-da0058492abf">974,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (income)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtMS0xLTEtMTM0NTA1_ac3cda5f-f47e-4b81-96f0-ebcba061248c">737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtMy0xLTEtMTM0NTA1_5ab5abac-7975-4eda-b5b4-b274450def2c">17,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtNS0xLTEtMTM0NTA1_4b1d97d5-ed8d-43bd-a382-c0c95f91ca6a">1,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtNy0xLTEtMTM0NTA1_8fddbb54-a39e-4152-9677-758bb2b48dde">15,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtMS0xLTEtMTM0NTA1_95007cc0-9343-4b7d-a291-f97e68611294">46,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtMy0xLTEtMTM0NTA1_eeb9e6af-7baa-4308-979c-c50e05ed50f9">37,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtNS0xLTEtMTM0NTA1_f40e08fb-ad7d-48a6-8fb7-96d47a874288">94,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtNy0xLTEtMTM0NTA1_e4b8b47d-1518-46a3-b222-6c8cd8facb47">74,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtMS0xLTEtMTM0NTA1_f02ac26d-ce35-49a0-b607-d14b639ca5e1">71,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtMy0xLTEtMTM0NTA1_04f260db-b3a2-4c7e-bf83-3badcfcaeebe">1,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtNS0xLTEtMTM0NTA1_dcd364eb-0eeb-4403-84ab-41ee7be89f0b">71,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtNy0xLTEtMTM0NTA1_8f2bccda-f285-49ab-9205-4cb3816c38b7">4,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtMS0xLTEtMTM0NTA1_9b12cd0d-35ed-410d-adc4-b6174e18a79c">8,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtMy0xLTEtMTM0NTA1_70f3e603-230f-4249-9ed1-e1fa27520d6d">55,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtNS0xLTEtMTM0NTA1_fead2abe-3b44-45a8-a732-450fc554d580">28,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtNy0xLTEtMTM0NTA1_83027556-6cb1-4d14-a8c9-85ab82368695">1,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtMS0xLTEtMTM0NTA1_29dcb533-f370-4716-a418-83ba7dfb6ad0">70,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtMy0xLTEtMTM0NTA1_739534ac-5587-4afe-9b34-ddebc502aac4">14,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtNS0xLTEtMTM0NTA1_a950babb-363d-4dfa-b799-4cae60e45459">53,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtNy0xLTEtMTM0NTA1_54e530bb-6f56-47dd-bc92-b4b1ce1afab1">23,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctMS0xLTEtMTM0NTA1_85617b0f-a8e6-4496-a728-86f0692eef9d">10,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctMy0xLTEtMTM0NTA1_84856d84-7323-4f00-aff3-82e9b1f1bb05">14,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctNS0xLTEtMTM0NTA1_a6804251-9316-4196-88bb-8e347ca16e24">20,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctNy0xLTEtMTM0NTA1_b6c6ddc2-86b6-4f73-b9a7-89e1d719e785">30,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-operating expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtMS0xLTEtMTM0NTA1_9e66f567-1909-4564-ab08-07541238dfaa">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtMy0xLTEtMTM0NTA1_aaff27ca-5ddd-47ed-a45a-f835ebef36ab">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtNS0xLTEtMTM0NTA1_673293e2-f551-4ab0-bcab-00fc94a96483">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtNy0xLTEtMTM0NTA1_97f26ee1-2243-4d54-9cc9-6e8cd2f49f72">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other (income)/expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktMS0xLTEtMTM0NTA1_21f2b31f-70aa-4de8-a2e6-d45bf36f32cf">113,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktMy0xLTEtMTM0NTA1_877e3545-2108-430f-b5e6-bbbce2c274b1">61,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktNS0xLTEtMTM0NTA1_a83a4620-e8c4-41b9-865d-ec7aa49506d6">22,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktNy0xLTEtMTM0NTA1_aca1c020-726e-4614-a748-5b8982020054">8,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income before tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtMS0xLTEtMTM0NTA1_3404fc5b-e95c-453c-b8e3-9a74ae35948d">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtMy0xLTEtMTM0NTA1_7e70fa21-3452-499c-99ee-fdebb2ed1680">806,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtNS0xLTEtMTM0NTA1_7c959ae2-1bd6-4f3c-bf3d-317c4e846b5e">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtNy0xLTEtMTM0NTA1_aa3b57e9-301b-4f8f-aa54-cb8ec321c35c">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtMS0xLTEtMTM0NTA1_2a32be88-dda7-404e-9aa0-e80668d2ddde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtMy0xLTEtMTM0NTA1_4a9d3a67-b668-4cb1-bed7-c685457870a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtNS0xLTEtMTM0NTA1_6174c34e-af53-48ee-b7da-3873d8c3e36c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtNy0xLTEtMTM0NTA1_5738ac75-2e85-4a31-b708-ff595ca8ad15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItMS0xLTEtMTM0NTA1_e7118f64-25ad-4d4d-bf48-4500b8bbbc69">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItMy0xLTEtMTM0NTA1_98ddf8ae-9df9-4b63-9076-7abc4841db22">806,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItNS0xLTEtMTM0NTA1_cd7d2ecd-f1b1-4009-846e-d63f4ac8233d">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItNy0xLTEtMTM0NTA1_c56ac1d0-e062-4c67-a596-8bb3a1ae3e51">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtMS0xLTEtMTM0NTA1_fc73a3c1-ee37-4f67-85c3-ae1df0e4ef57">187,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtMy0xLTEtMTM0NTA1_72a08491-b692-4e53-88f0-e07061eda6df">365,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtNS0xLTEtMTM0NTA1_2bae658c-f362-4ee4-bc08-015eda3081f4">263,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtNy0xLTEtMTM0NTA1_e21ac6b5-545e-4554-a413-bde0aa91d810">455,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtMS0xLTEtMTM0NTA1_3bb65b34-1aa3-4a30-8b4d-8759a7958bc3">304,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtMy0xLTEtMTM0NTA1_c4b01402-ecdd-4301-b817-1239f5f199d7">440,776</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtNS0xLTEtMTM0NTA1_0540b0d7-04b1-47b9-8c75-cd675cb35ed3">356,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtNy0xLTEtMTM0NTA1_0f2f95b7-20de-47d5-80bc-90cf9ac6838f">509,895</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktMS0xLTEtMTM0NTA1_9337e47c-3af7-4e02-ab20-ac17a74ad78d">0.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktMy0xLTEtMTM0NTA1_21740370-c9a4-4640-908b-9a7972881767">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktNS0xLTEtMTM0NTA1_7209d1f8-0848-4485-8598-7841475a0420">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktNy0xLTEtMTM0NTA1_734fcf22-12b5-45b8-b44e-d259940c39e3">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtMS0xLTEtMTM0NTA1_8bbcb694-16cf-4f7a-b13c-8800ae8e3da0">0.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtMy0xLTEtMTM0NTA1_cc3b599c-ecb7-4402-bee3-a066cfe370e9">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtNS0xLTEtMTM0NTA1_4f63fc7d-191b-42f5-a936-4c0197343595">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtNy0xLTEtMTM0NTA1_7082bea0-5a24-41d0-b6e6-80d981659583">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average Class A ordinary shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItMS0xLTEtMTM0NTA1_bede2af6-5cce-4941-b979-72d50422fd9e">436,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItMy0xLTEtMTM0NTA1_76827603-1aaf-440d-9092-c974d4ac3632">409,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItNS0xLTEtMTM0NTA1_352cf2cb-3cfb-4160-94b5-687f59b05cbf">435,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItNy0xLTEtMTM0NTA1_5a7ec08e-ccfe-4fcb-aeb5-5f74fb309e16">399,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtMS0xLTEtMTM0NTA1_b9f864aa-6707-46a0-b688-02f38423174d">607,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtMy0xLTEtMTM0NTA1_5ae6ce22-e5ed-46e3-945b-4ec4d4127da3">607,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtNS0xLTEtMTM0NTA1_91b7e11b-25ef-4ae9-a19d-6cfdb422c581">607,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtNy0xLTEtMTM0NTA1_ed4701d3-5672-4b6c-b3bf-40445d7892d2">607,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi0xLTEtMS0xMzQ1MDU_e7118f64-25ad-4d4d-bf48-4500b8bbbc69">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi0zLTEtMS0xMzQ1MDU_98ddf8ae-9df9-4b63-9076-7abc4841db22">806,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi01LTEtMS0xMzUwNzE_cd7d2ecd-f1b1-4009-846e-d63f4ac8233d">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi03LTEtMS0xMzUwNzE_c56ac1d0-e062-4c67-a596-8bb3a1ae3e51">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS0xLTEtMS0xMzQ1MDU_0e6cca94-0439-4b75-a421-1078fc6a431b">9,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS0zLTEtMS0xMzQ1MDU_dc532d9c-ce41-4387-809b-078408a7d1b0">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS01LTEtMS0xMzUwOTA_29e48871-d9c4-45e1-9823-8ac0dbb13fe9">10,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS03LTEtMS0xMzUwOTA_f5fb4e72-dcf6-4be3-96c2-3fcb076269c5">11,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi0xLTEtMS0xMzQ1MDU_b29dfbe1-a04d-4fb3-9939-03afbb065334">7,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi0zLTEtMS0xMzQ1MDU_454b58e7-11dd-4b2a-9cd1-73e27a433895">13,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi01LTEtMS0xMzUwOTA_0cb4383e-62af-40ab-8b7e-07f1a2a38303">16,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi03LTEtMS0xMzUwOTA_1231197e-258c-42df-87e2-a8bbc483db20">28,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy0xLTEtMS0xMzQ1MDU_8f0392bc-c1cd-4e4a-bdc7-12040b98452d">1,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy0zLTEtMS0xMzQ1MDU_654916c3-bfd2-4fd2-983e-813e5b2693c0">7,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy01LTEtMS0xMzUwOTA_3ab46fe3-670e-40d3-bc94-abf7bd9d2bdf">5,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy03LTEtMS0xMzUwOTA_e6ddc4cd-3cd8-4106-9c12-0319f0e15113">17,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC0xLTEtMS0xMzQ1MDU_08dde041-1b1d-4cd7-86f0-330877e5f0ab">492,934</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC0zLTEtMS0xMzQ1MDU_ad0e0153-05a6-4f11-a81e-1c0696440730">799,481</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC01LTEtMS0xMzUwOTA_dd0ad472-ec81-41f1-a0b6-7efa1cd6dbb7">613,688</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC03LTEtMS0xMzUwOTA_71746cb3-b1e3-4ddd-8638-063b3e3c97d9">948,094</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS0xLTEtMS0xMzQ1MDU_10648827-d1c4-44da-b425-ed384dd84793">187,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS0zLTEtMS0xMzQ1MDU_187cf806-0b8e-462a-9914-f276a1d1385d">362,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS01LTEtMS0xMzUwOTc_6e2cb6d6-aabb-4bf1-94d7-c688fb82b339">260,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS03LTEtMS0xMzUwOTc_3810514f-d73b-40f2-9d6f-81613b9911a9">447,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive income attributable to Royalty Pharma plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtMS0xLTEtMTM0NTA1_bd02c2ec-693c-440f-a280-9132a4336726">305,296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtMy0xLTEtMTM0NTA1_61c79c93-debc-4632-b4e6-6dc86718b0cf">436,733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtNS0xLTEtMTM1MDk3_1c097814-7d0c-4952-bc6c-a23b5f95a01f">352,740</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtNy0xLTEtMTM1MDk3_5a30d5cd-8734-4e92-a95e-972962f4dcec">500,367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.156%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc41c410425b42d7abcdade3c8154e0c_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xLTEtMS0xMzQ1MDU_1d217ea9-c2cc-4640-b8b2-423b7fadd2fe">435,316</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc41c410425b42d7abcdade3c8154e0c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0yLTEtMS0xMzQ1MDU_3f3519c2-dd9d-4f19-8ec9-fcd5bec6a24d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43f91e61c3dd491c96060d2cd0475caa_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0zLTEtMS0xMzQ1MDU_a2a8eefe-a6e5-43ae-9272-af0154135c35">171,862</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f91e61c3dd491c96060d2cd0475caa_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi00LTEtMS0xMzQ1MDU_e2acdd60-2197-4489-834c-ac8028d2d06b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24af4b775fdd421ca76221754d6cc72b_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi01LTEtMS0xMzQ1MDU_18df262b-f49c-412f-8d4f-62735756be5f">50</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24af4b775fdd421ca76221754d6cc72b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi02LTEtMS0xMzQ1MDU_7e132cb0-6d3e-472a-a572-339879a9e7db">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi03LTEtMS0xMzQ1MDU_05641e53-f332-4998-930a-092768b4e075">363,521</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi04LTEtMS0xMzQ1MDU_ced48435-eb50-4687-915c-3a787d9c2eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie033c0ebfe694b18a9324c6432dfa2cb_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi05LTEtMS0xMzQ1MDU_14437f87-d832-45e8-8feb-3210c76c6b06">3,543,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3131abfb53a454494b73f6ebe89c392_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMC0xLTEtMTM0NTA1_8256dca7-7f84-4658-b55d-3f0175464ff4">2,224,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb23fabb1e14fb78211172951d31a08_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMS0xLTEtMTM0NTA1_ce2e0d19-7d60-4266-b54b-7c58f158e38a">12,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMi0xLTEtMTM0NTA1_91408530-0463-48f5-9970-72384eb904c6">4,364,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if45953d0a97b4ab4a331eebb7376a3cc_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMy0xLTEtMTM0NTA1_0bc56999-4624-4a86-a618-49eee77eba5a">2,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1f6430e214497599d013c1c8969e8d_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xNC0xLTEtMTM0NTA1_493b857e-1958-4c01-ba6e-5a5ce46b3a18">10,141,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMy0xMi0xLTEtMTM0NTA1_a4c2eaa5-7bfc-47f7-8d80-f718b119793b">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMy0xNC0xLTEtMTM0NTA1_e0cf8042-0939-4bb1-bd89-fa6e724dcb07">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNC0xMi0xLTEtMTM0NTA1_d217e1ee-22d3-41ad-b97e-63d1ab7a0b2a">146,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNC0xNC0xLTEtMTM0NTA1_40a0f472-d536-4c1e-b97d-23fb7bb44125">146,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="i22fe98e0e7a94704ac3fdfff181f9502_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0NTZiZDFjNjQ3ZDM0YmZlOTZhNDk4NmNlZDZjNDQ2OF8xNQ_01800b65-b1a2-4112-97bd-b2aae6e15082">0.19</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0xMC0xLTEtMTM0NTA1_06366f90-4eee-4c17-b12a-a59ad45a48c8">83,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0xNC0xLTEtMTM0NTA1_b8334441-caef-479d-b189-4a3ab7b86f1f">83,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xLTEtMS0xMzQ1MDU_47190b0d-1d2e-4343-8257-3ef5d6b30247">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0yLTEtMS0xMzQ1MDU_28510bd2-ed85-4269-8241-0e2080a48cac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5339fc8ea38b46fa9a86916bc074eca4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0zLTEtMS0xMzQ1MDU_cbeff7f7-67b4-4364-8881-b68fc4a2942a">1,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2527d56cd62046479c1173dcb0b0f5b2_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi03LTEtMS0xMzQ1MDU_2eec1137-2fd4-4c6a-b50a-13f882c2a2ee">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi05LTEtMS0xMzQ1MDU_adcaedfd-7686-47c0-96f5-efb187402cca">26,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMS0xLTEtMTM0NTA1_8d6b606d-13a6-46ab-be49-053870a207ba">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMi0xLTEtMTM0NTA1_6ae741c0-c6a1-4b62-b021-38251c997296">26,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefecccbe9aeb4eda97cf4d50e61ebc9d_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMy0xLTEtMTM0NTA1_d235fa41-378f-4d31-8fbe-bfe20f22445a">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xNC0xLTEtMTM0NTA1_4ee4f79c-73f6-4180-b868-281dcb5037c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy0xLTEtMS0xMzQ1MDU_f9139fb5-5280-4aae-bbb0-09a7273586e8">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy05LTEtMS0xMzQ1MDU_fe27e73b-06e0-45c0-be72-1fb888f87ce4">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy0xNC0xLTEtMTM0NTA1_25b6c798-ac70-4bed-a949-1b4215f5fc45">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xMC0xLTEtMTM0NTA1_8ef405c9-4517-4962-8ea7-4f35f9c15500">304,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xMi0xLTEtMTM0NTA1_a091d21e-2f3a-4fd3-9d3c-5b724596bacb">187,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xNC0xLTEtMTM0NTA1_419267c3-20d7-4e27-ad5e-42e38db7f1f6">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTEtMS0xLTEzNDUwNQ_344570d0-2d84-475d-b451-5e346bd1d5cd">5,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTItMS0xLTEzNDUwNQ_2cf2c932-bd5c-4fcd-bdf3-8bf2f50ed5cd">3,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTQtMS0xLTEzNDUwNQ_c9faada9-76ea-4de3-8bd2-8a7ce878348a">9,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTEtMS0xLTEzNDUwNQ_6003ce7b-b6cb-4e9d-9180-260f2127981c">4,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTItMS0xLTEzNDUwNQ_437b2d12-6272-437a-95cb-f70d7d6ef4aa">3,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTQtMS0xLTEzNDUwNQ_e6581669-3a4f-4879-834c-bda216e1fa98">7,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMS0xLTEtMTM0NTA1_edcd3f1a-eaa9-42e2-b81e-de4a2b864617">437,139</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMi0xLTEtMTM0NTA1_e9720ebc-0962-448e-98ca-0c00af52edf8">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMy0xLTEtMTM0NTA1_e6642fe3-5cd4-4711-9eba-acbf3263647a">170,081</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNC0xLTEtMTM0NTA1_e9f4a252-efa4-41cf-828b-ad6f4b99ed77">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNS0xLTEtMTM0NTA1_6fc0a706-d42c-441f-b74f-03ec741d7d7a">50</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNi0xLTEtMTM0NTA1_0d1865a8-a610-4b06-a616-cd64a598cf47">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNy0xLTEtMTM0NTA1_721248db-5dc6-4963-9407-d34aa1e5373b">365,302</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtOC0xLTEtMTM0NTA1_a84d9569-7800-4024-a61f-9c37a1913f26">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtOS0xLTEtMTM0NTA1_b5c5f202-aff7-43c5-ae9d-2c94973a818c">3,570,585</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTAtMS0xLTEzNDUwNQ_440ff3da-7eee-40a2-a32b-99969d77486e">2,446,132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f7632b52e24947b5542bc50c2d3c30_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTEtMS0xLTEzNDUwNQ_6e111fa3-e6c8-41f6-a204-65fc27c1e54a">13,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTItMS0xLTEzNDUwNQ_5e102793-f890-4af3-bd71-07a78282a6d0">4,380,938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTMtMS0xLTEzNDUwNQ_981d6cd1-98ea-42c7-847f-14ae36ee5936">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTQtMS0xLTEzNDUwNQ_efb4866c-e476-4c9b-b476-101d0dc12df7">10,408,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.157%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica342df70a2842ffb246d1630ba9eb5a_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xLTEtMS0xMzQ1MDU_fec06683-90b6-4816-ba13-90850169cc5d">392,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica342df70a2842ffb246d1630ba9eb5a_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0yLTEtMS0xMzQ1MDU_e7628499-b15b-4330-a75b-28007f0706d9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i305f1861941e45fbb293aa1942d05488_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0zLTEtMS0xMzQ1MDU_855e3032-2628-4388-b68f-6c47734a29f3">214,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305f1861941e45fbb293aa1942d05488_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi00LTEtMS0xMzQ1MDU_fab1ae5d-0b44-4292-a19b-115eeafa3566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i622a95bdb08e47f7acf229df1afae29b_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi01LTEtMS0xMzQ1MDU_0c90b542-f98f-4918-9d0e-275f66315213">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i622a95bdb08e47f7acf229df1afae29b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi02LTEtMS0xMzQ1MDU_d83dbfeb-41e8-4323-9681-7c9c1ce18978">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia71ca76e55df4684b26c0aa01421d9bd_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi03LTEtMS0xMzQ1MDU_949a3c96-8c06-4f7b-b7e1-9652dd07d47e">321,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71ca76e55df4684b26c0aa01421d9bd_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi04LTEtMS0xMzQ1MDU_c5b9e113-fdc2-4159-826e-5eed7e40d775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c89af6243f0463eb180fef51c293c8c_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi05LTEtMS0xMzQ1MDU_e1be3d0a-bedd-4475-b465-028fb1a1effc">2,931,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b43a0bf90e547dbb6fbf1dd47972a2a_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMS0xLTEtMTM0NTA1_192cdc17-39be-4c85-bf0d-1931b86ebc14">1,923,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b916b52b23472ba3549f7931482243_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMi0xLTEtMTM0NTA1_afce0f6f-b348-4434-9a48-e1dedb7f201a">29,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2ebd58086471fbf60d5e06704e135_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMy0xLTEtMTM0NTA1_52182079-e61a-42ff-83c4-049e5dd779e3">4,954,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieff3e647fe0147108d0196b5815a9c6b_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xNC0xLTEtMTM0NTA1_00f035db-3bfa-46c5-87ee-c93d13492e3c">2,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1a04cc8cc84280933c35ae3b8d8d94_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xNS0xLTEtMTM0NTA1_07cde7e5-a250-4fe3-8e4c-472469b2fe8f">9,837,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMy0xMy0xLTEtMTM0NTA1_de60fd35-d9d5-4371-a6d4-5b2aab3245f9">11,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMy0xNS0xLTEtMTM0NTA1_7a285c91-0f6e-4a9a-9c44-8590f5d61b1f">11,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNC0xMy0xLTEtMTM0NTA1_e59fa629-17a3-460d-ab01-efc653e68fc5">170,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNC0xNS0xLTEtMTM0NTA1_4201c32a-6bc2-4ce1-9008-39b6239f0d92">170,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="iffade55c2b5644739b00e4201220367e_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo3YWMwMDRjYzZhM2U0MjcwOGE1MjJlNzAxNThiNzZjNl8xNQ_192a2c64-b031-4a7e-8d25-6f6a585e3b31">0.17</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0xMS0xLTEtMTM0NTA1_9cb74076-cb69-484a-88b2-a5e7e68730dd">72,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0xNS0xLTEtMTM0NTA1_b373554d-9d4d-41fc-85b9-d331215be8df">72,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xLTEtMS0xMzQ1MDU_288c5975-609f-47c0-bab8-7c0add18f5b7">34,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0yLTEtMS0xMzQ1MDU_53176d41-4732-43d6-b809-34d1ae9d3b02">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib2b8266d2b4a41d0a8dab2958a2d956f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0zLTEtMS0xMzQ1MDU_306a704f-acb2-4bfd-b4d0-71e92c0c4f92">34,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i100aaaeaffba486fa3044462ac9475b3_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi03LTEtMS0xMzQ1MDU_2afd1182-7af0-49e6-9c95-bf49cbb4500d">34,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi05LTEtMS0xMzQ1MDU_1a162b7a-1285-4f2a-8e73-08932eae8ea5">483,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xMi0xLTEtMTM0NTA1_25e1033f-4aa1-4122-8c10-fd6b7db385a1">3,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xMy0xLTEtMTM0NTA1_bc60009d-9d53-419e-9143-a02a118350d3">486,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2ae29b2c9b4f06af0cf0034f33a3a4_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xNC0xLTEtMTM0NTA1_9331c545-f5b7-40c3-ac6c-bc27c6fb2ba1">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xNS0xLTEtMTM0NTA1_b57cedfd-bb95-44d3-a07e-1d00d8b14c3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy0xLTEtMS0xMzQ1MDU_d2bc46fe-17a7-47d3-9a26-20c8481c3062">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy05LTEtMS0xMzQ1MDU_b8646b84-3170-4807-a471-dac7c06c8875">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy0xNS0xLTEtMTM0NTA1_2da2cf03-51d8-462d-a045-2e36aa4d20b2">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xMS0xLTEtMTM0NTA1_832a028a-d99d-479f-aa6f-ae73a0a39a41">440,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xMy0xLTEtMTM0NTA1_fbaf5a6c-de28-497f-9a60-ca4ef5f5ac5f">365,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xNS0xLTEtMTM0NTA1_1d676334-9aa4-4d8e-81fb-6ff2774e227e">806,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTItMS0xLTEzNDUwNQ_748d9f4e-67d6-445d-81fd-645882037d3a">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTMtMS0xLTEzNDUwNQ_9bdcb776-4b93-407e-81fa-4c0c3cee8c71">2,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTUtMS0xLTEzNDUwNQ_601f1f7d-4a6f-4886-8ae5-d7f609cd3811">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTItMS0xLTEzNDUwNQ_60153c55-9726-47b4-85e1-2e0bab93ba3d">7,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTMtMS0xLTEzNDUwNQ_99d6c953-5c89-4dc8-80e2-2b041ce5b79c">5,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTUtMS0xLTEzNDUwNQ_4f847ef5-920c-4aa1-9d27-a662c3ebae3a">13,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMS0xLTEtMTM0NTA1_8b626bcc-a9ea-4c89-aa48-763beaaa3989">427,006</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMi0xLTEtMTM0NTA1_cb86424f-f485-4066-bc7a-e5f3c0a1b8aa">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMy0xLTEtMTM0NTA1_9f9f97e2-0d55-4a9c-bbe0-bd9468b477f4">180,166</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNC0xLTEtMTM0NTA1_636123d8-8c1f-4851-8691-73e80a6e9d0d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNS0xLTEtMTM0NTA1_dec1e185-d97b-4e3a-a6fb-4f8a7948c158">50</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNi0xLTEtMTM0NTA1_bfb7bf32-276c-4d81-b0db-9dacf1607931">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNy0xLTEtMTM0NTA1_ebcf524a-8152-424e-ad82-322cc8992aa1">355,217</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtOC0xLTEtMTM0NTA1_2e70bf03-87e4-479a-9348-4247650cbba5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030828ed817644a789470b5495e7c36e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtOS0xLTEtMTM0NTA1_79730bee-1b09-4b60-883d-0c722def9704">3,415,598</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589baf01d5dd4c2caae101de2f597840_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTEtMS0xLTEzNDUwNQ_8093f7ab-9c9e-45ec-93e0-f0d32d11b227">2,291,966</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTItMS0xLTEzNDUwNQ_9b17ae62-6f28-4aee-b8ff-97c57f54030f">28,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTMtMS0xLTEzNDUwNQ_6f6ea74f-3675-4db2-818c-adcca7a8671d">4,671,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTQtMS0xLTEzNDUwNQ_b7fead45-319e-42c8-8fbb-42b4461a0203">2,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTUtMS0xLTEzNDUwNQ_60ec8c5a-15e2-40b9-af53-cedac1b38566">10,405,365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.156%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31d0005fb24b41b7be1fed5796c78265_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xLTEtMS0xMzg4MzY_cebf2e77-77c7-4c8c-9738-308fa5e1a3e9">432,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31d0005fb24b41b7be1fed5796c78265_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0yLTEtMS0xMzg4MzY_a3f0a442-92ff-40cb-a3ae-994131ddf838">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0zLTEtMS0xMzg4MzY_5b1811ef-230b-48a2-ac12-7f5b7276bb8e">174,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi00LTEtMS0xMzg4MzY_7b42a723-9719-43be-8d84-15652287e44b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi01LTEtMS0xMzg4MzY_4bc07b16-b8af-4788-bb9e-30a08bfd440a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi02LTEtMS0xMzg4MzY_2538def6-9863-4f34-a782-faccbc796cdd">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f837639fd8f42d18127b22713c22bff_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi03LTEtMS0xMzg4MzY_2d7aa30c-e018-4815-811a-01d7505eb75d">361,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f837639fd8f42d18127b22713c22bff_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi04LTEtMS0xMzg4MzY_d85e3220-81e7-4558-8f73-3eb713c7bde5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1903e1e4384e289320f606987686f9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi05LTEtMS0xMzg4MzY_5a9a97c5-8836-42e5-ad0f-b5df135a3fc3">3,507,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb49e5d1da64984b7dab1f207cb821b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMC0xLTEtMTM4ODM2_ba3b5f25-35a9-4ed2-9ca7-c12e20af1e8a">2,255,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48669715cbaa4a4ca2f245e9fb5f1995_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMS0xLTEtMTM4ODM2_249b8686-6d04-4f74-90aa-37f4fd23a028">16,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMi0xLTEtMTM4ODM2_53e07f68-dcc9-488c-b81f-f9e1018174d8">4,471,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290a4cb4e651436abde84028a4766f89_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMy0xLTEtMTM4ODM2_3e648161-9402-4668-8cac-b8631ba61e28">2,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xNC0xLTEtMTM4ODM2_c2fe9e42-f36d-46eb-aeef-a3ef3048ac6e">10,248,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMy0xMi0xLTEtMTM4ODM2_0822c4c1-f603-4718-a0f3-3f3fa9751535">6,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMy0xNC0xLTEtMTM4ODM2_8b5da761-2564-4681-b15f-f4516d7ccd60">6,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNC0xMi0xLTEtMTM4ODM2_ae6aebd0-5230-443f-a554-32ae1dd96f9f">295,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNC0xNC0xLTEtMTM4ODM2_dbd2c4b9-36d2-42c6-a96a-605b47b1d899">295,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9e401b08b73c499dbf77eb4e227d5e2f_D20220101-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0wLTEtMS0xMzg4MzYvdGV4dHJlZ2lvbjpkZmU3ODk2MzliMjM0NDI4YWZjNjliNjE3NTg5ZDBmM18xMDk5NTExNjI3ODQx_3614ee78-d82d-4b2b-9ab5-1f83d447c1e3">0.38</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0xMC0xLTEtMTM4ODM2_c421ad9a-e487-48ca-bf61-6eb5d93c3c3e">165,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0xNC0xLTEtMTM4ODM2_dcb72e00-2793-4e8f-966a-15bc482220ba">165,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xLTEtMS0xMzg4MzY_54bb6213-1891-48fe-910f-7066c0349d82">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0yLTEtMS0xMzg4MzY_52042dd7-eb18-4fa4-a65c-2c41da1eb01e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if96dac154fa240898e743b8ff8fc9059_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0zLTEtMS0xMzg4MzY_0e832f9a-350a-40eb-bff4-4fac1822ab98">4,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05594336aff54167b344569f8bc28d05_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi03LTEtMS0xMzg4MzY_c32ebf5d-9643-416c-a96e-8e1123b890fd">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi05LTEtMS0xMzg4MzY_9bf996e4-91e0-4726-8333-ca9d0517ebba">62,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMS0xLTEtMTM4ODM2_68bc6241-bd40-4fc4-9359-a2988c5740d3">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMi0xLTEtMTM4ODM2_4364cc80-d76e-41e9-81f6-1ccb041dd68a">62,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f7f0975039c4b47a8013da696977787_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMy0xLTEtMTM4ODM2_fe0b01a6-b354-43c3-a406-4b14743f03a0">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xNC0xLTEtMTM4ODM2_6d2ed285-98c5-42a5-8c25-c712bd4d642a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy0xLTEtMS0xMzg4MzY_44cde20f-b4fa-41da-8c10-d911176df3e6">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy05LTEtMS0xMzg4MzY_1832783b-7438-42e3-aa09-b7bfc263d2a6">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy0xNC0xLTEtMTM4ODM2_0f1acd11-004f-47ac-8526-2f47119e9bfd">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xMC0xLTEtMTM4ODM2_e00e9ff4-3ad2-482e-bc74-df6d47384b3c">356,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xMi0xLTEtMTM4ODM2_2a433aa2-73a3-47f4-8aae-33977542469d">263,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xNC0xLTEtMTM4ODM2_dab6044f-9e71-49f5-8ff6-be1872d53b95">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTEtMS0xLTEzODgzNg_83d946fe-4ab4-45d1-90fd-93168da0e48c">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTItMS0xLTEzODgzNg_dba8e2a8-d3e0-4a4e-ae4f-2f89ce87b4d3">4,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTQtMS0xLTEzODgzNg_86fff252-f2e5-485c-97a9-98942dfeeded">10,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTEtMS0xLTEzODgzNg_6a98bea9-4f5a-4c88-8884-f506156419f8">10,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTItMS0xLTEzODgzNg_837ac4d7-223a-46f6-90e6-b12d787663e2">6,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTQtMS0xLTEzODgzNg_d7c92554-36ac-4a3c-9d95-88b65f66a17e">16,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMS0xLTEtMTM4ODM2_251f1662-118d-4047-bbdc-ab6a9a0070bd">437,139</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMi0xLTEtMTM4ODM2_b787644d-d623-446e-8edb-3b79a3ab99a5">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMy0xLTEtMTM4ODM2_a187e381-62fa-4c22-933a-334da099beef">170,081</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNC0xLTEtMTM4ODM2_a6832655-1550-4912-b2af-1144680649ca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNS0xLTEtMTM4ODM2_234bf0bb-8235-4e5b-b297-202db1e5c376">50</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNi0xLTEtMTM4ODM2_e7d125fc-00b3-4125-a9f2-22ef208b4b45">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNy0xLTEtMTM4ODM2_4776f912-4078-40a1-a322-98ecc0511f45">365,302</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtOC0xLTEtMTM4ODM2_3c063624-7864-4355-b14d-68c9e2b3d42f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtOS0xLTEtMTM4ODM2_2cab498c-584d-4606-ba8e-7da72060106d">3,570,585</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTAtMS0xLTEzODgzNg_a29d8433-c19c-4f65-8206-c33a2cbbdee5">2,446,132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f7632b52e24947b5542bc50c2d3c30_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTEtMS0xLTEzODgzNg_ec3fbf84-3205-4175-8cbe-a918e9d10cc7">13,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTItMS0xLTEzODgzNg_c1a06aeb-75a2-44d1-b407-5a3e78d1edd3">4,380,938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTMtMS0xLTEzODgzNg_c273293e-89ce-4738-8ca5-e2ddf6a0d3b4">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTQtMS0xLTEzODgzNg_ebaa5791-3991-4a98-a0b1-91a228e19af4">10,408,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.048%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74012a9aba134af29fa48477d04dde00_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xLTEtMS0xMzU1MzE_588691d0-65ea-4377-8bb1-b9955d14c95b">388,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74012a9aba134af29fa48477d04dde00_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0yLTEtMS0xMzU1MzE_8f5d4857-e9a3-4f12-8e2c-77e6507aec50">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0zLTEtMS0xMzU1MzE_ebbd8ead-b1f9-4561-98d3-2f804eec9ec5">218,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi00LTEtMS0xMzU1MzE_04fe06d1-3511-43d1-9af1-fd778a251b79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad1b46dfcb7f40ebb639788c968daf3a_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi01LTEtMS0xMzU1MzE_2ed6414e-aabf-4c90-8673-5fab861b70cc">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1b46dfcb7f40ebb639788c968daf3a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi02LTEtMS0xMzU1MzE_b263c648-567f-4524-9c33-676065a22948">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice7b784e492241448627593176cad967_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi03LTEtMS0xMzU1MzE_32f68db0-4a12-43ae-a39e-fcd2d26f6c3f">316,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7b784e492241448627593176cad967_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi04LTEtMS0xMzU1MzE_3627aa03-7356-4ee1-b363-b86b9de10c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972173b5752144889ef69fee1cfc51dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi05LTEtMS0xMzU1MzE_1b702c35-91a5-4cd1-8f25-0dc132b03296">2,865,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf7802275df47c59d3e1f7df579b50e_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMS0xLTEtMTM1NTMx_f7dc6957-4548-4c5e-9d6f-a4d17311b2fa">1,920,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592c6aa1733545c6a94d49a0144e42e2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMi0xLTEtMTM1NTMx_c86ee86f-1705-4eb5-be78-020313ed23f3">34,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3f673cf22e4af289ea139885dca16b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMy0xLTEtMTM1NTMx_2fca4618-a725-4cdb-b36e-848361e23dc1">5,077,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0b19f0203cf486094b8b552ce743af7_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xNC0xLTEtMTM1NTMx_52d9587a-e3ba-430a-bbae-40ce2ff3824e">2,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cade76361ba4fcba710604a8c023a58_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xNS0xLTEtMTM1NTMx_04692c30-d067-437d-998b-95444fbedcaa">9,895,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMy0xMy0xLTEtMTM1NTMx_03015d56-edfb-442f-98cd-0f124796dee7">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMy0xNS0xLTEtMTM1NTMx_f00f0a3c-730b-4b53-95ea-f26849f392d0">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xMS0xLTEtMTM1NTMx_d44f09e3-5d13-4876-b4e2-3affdb25517c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xMy0xLTEtMTM1NTMx_7b1a6ea9-15ad-4bb0-aeca-db646e3a742d">316,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xNS0xLTEtMTM1NTMx_0dc5d17b-ea1f-4909-9e11-b6db10e1f070">316,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="i35d05a9e48b54e568c0c8b5a3e8ab180_D20210101-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMC0xLTEtMTM1NTMxL3RleHRyZWdpb246ZmNiZTA5MmNkMWU3NGRjNGI3ZDIyOWQ3NTBjYzcyNDZfMTU_e48dc214-5940-4b5d-bc85-24027ae98808">0.34</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMTEtMS0xLTEzNTUzMQ_354350bf-cdab-4397-b30e-e012b0382d07">138,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMTUtMS0xLTEzNTUzMQ_50f2915d-e487-4ff0-89fa-63cc5db39a69">138,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMS0xLTEtMTM1NTMx_06f4963c-0060-48f5-bc15-019a734bc6f8">38,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMi0xLTEtMTM1NTMx_3fbb8e3d-3409-4799-a571-b0b006f3d5f3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice8047411077489696941648f5280f81_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMy0xLTEtMTM1NTMx_b4cac470-eddb-4c88-bb5e-1299f88baab7">38,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee6a414fd23744eb89554b7564759f43_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtNy0xLTEtMTM1NTMx_f795b64a-b9e4-4e7b-bb90-ca91d1c3f023">38,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtOS0xLTEtMTM1NTMx_f47c724b-a233-4343-bfc4-39a62b5c69a5">548,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTItMS0xLTEzNTUzMQ_9c7b4b3a-6bee-4165-b72b-eb7d3db7fe3f">3,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTMtMS0xLTEzNTUzMQ_8e27e1c4-c30f-41c6-b389-36afd2613c36">551,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8aec56c066c44c0c9505da67fbc972b1_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTQtMS0xLTEzNTUzMQ_284b9803-2a55-441f-8dcd-6f5de0f7d7d1">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTUtMS0xLTEzNTUzMQ_e40116a5-6fdd-4f6d-b285-f1d34b3e6144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtMS0xLTEtMTM1NTMx_7eb01821-3f3d-4bf1-90e5-6b16a4841a42">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtOS0xLTEtMTM1NTMx_900dffc3-3135-4e82-adc5-d2bc7d508f93">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtMTUtMS0xLTEzNTUzMQ_41e137f2-7961-4bc7-81ce-0be3c48f3ace">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTEtMS0xLTEzNTUzMQ_4ddb25ec-f194-4fe0-9d36-46053fc083d0">509,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTMtMS0xLTEzNTUzMQ_858247d8-e471-4d23-8c11-a3212671dae4">455,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTUtMS0xLTEzNTUzMQ_8babef5c-7a45-4411-b3d0-6bbe1671e336">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTItMS0xLTEzNTUzMQ_ca6bcc6b-335b-499d-a11a-5553431f2e9e">6,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTMtMS0xLTEzNTUzMQ_22366f51-2514-420d-bc49-f050bdde60ee">5,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTUtMS0xLTEzNTUzMQ_17ac338a-fbed-49f7-b81d-3114de33fbd9">11,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTItMS0xLTEzNTUzMQ_eda71da3-e3e1-4a47-b9ca-1361dea71f63">15,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTMtMS0xLTEzNTUzMQ_84091417-aa02-4148-8cbf-db815697e290">13,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTUtMS0xLTEzNTUzMQ_7b733a43-b512-4623-aa2d-7560c590d2bd">28,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMS0xLTEtMTM1NTMx_ec57398a-feb1-4d91-935a-120d8f0ff37c">427,006</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMi0xLTEtMTM1NTMx_038dfb1b-548d-4b14-a778-b58dc8185ddb">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMy0xLTEtMTM1NTMx_cee8aa3f-6704-4261-ac6a-63d1ecfd0206">180,166</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNC0xLTEtMTM1NTMx_6b8da8df-fa23-4549-b038-8e8a4efe832b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNS0xLTEtMTM1NTMx_1c17bfb5-349c-40d6-81c0-533a25befae9">50</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNi0xLTEtMTM1NTMx_163bb248-7f90-4f38-a97a-f0bb4788803d">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNy0xLTEtMTM1NTMx_d98013bd-02d8-49fa-9693-6380df5f4ce8">355,217</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtOC0xLTEtMTM1NTMx_f7bd6c54-3c51-46d6-aad4-4da4fccc9fc2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030828ed817644a789470b5495e7c36e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtOS0xLTEtMTM1NTMx_802883a8-0107-411a-a2b8-e2a0421f7c2a">3,415,598</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589baf01d5dd4c2caae101de2f597840_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTEtMS0xLTEzNTUzMQ_3674ae55-1bc0-4a89-82b1-d67856874f14">2,291,966</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTItMS0xLTEzNTUzMQ_c876b173-2e29-4574-98cf-421dad1878c2">28,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTMtMS0xLTEzNTUzMQ_5a7b1389-6caa-443b-89eb-bb53ac05b01c">4,671,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTQtMS0xLTEzNTUzMQ_96016756-50d1-4e6f-8993-aac266551836">2,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTUtMS0xLTEzNTUzMQ_c2358b62-829a-4f2a-8562-debae37d207a">10,405,365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:144%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMy0xLTEtMS0xMzQ1MDU_8bad4510-69e0-49ef-ae2f-536431df9c46">1,181,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMy0zLTEtMS0xMzQ1MDU_83984bb4-f52e-41da-b2dc-1e495c5e1b23">1,094,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNC0xLTEtMS0xMzQ1MDU_0f94cdec-36fc-4973-9c47-c57758ae8b71">71,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNC0zLTEtMS0xMzQ1MDU_f0af3f05-1099-4b2b-b602-2cc96cb79c39">75,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty cash collections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNS0xLTEtMS0xMzQ1MDU_b86fd12b-861c-4330-81d7-d139dffdc2d9">32,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNS0zLTEtMS0xMzQ1MDU_9abe3f6e-26a8-4bb3-aab0-39c23013e526">14,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNi0xLTEtMS0xMzQ1MDU_fa68a810-587c-41ce-a005-4f249607912e">27,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNi0zLTEtMS0xMzQ1MDU_854ea47e-5e3f-45bf-8caa-32cc25264a34">22,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNy0xLTEtMS0xMzQ1MDU_049e3786-94b7-445a-8c8c-3e6d1e786bcd">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNy0zLTEtMS0xMzQ1MDU_8356c856-7f15-471e-864a-8a87571a8308">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOC0xLTEtMS0xMzQ1MDU_c69c8d08-46b6-477d-837a-25a49a75a9bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOC0zLTEtMS0xMzQ1MDU_e8d95e16-256a-4644-bb5c-99b41b2763ab">11,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral posted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOS0xLTEtMS0xMzQ1MDU_03e2f4d0-12a9-4582-88c2-279bcd1d8b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOS0zLTEtMS0xMzQ1MDU_8effe013-29d8-4c3d-803a-8301a7b9b9de">9,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTEtMS0xLTEtMTM0NTA1_34221826-30d2-4067-bea5-a31df0a6e84a">1,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTEtMy0xLTEtMTM0NTA1_58a85c27-96e4-4592-b4f4-258c45fe40ea">5,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTItMS0xLTEtMTM0NTA1_ad2440e2-bb54-4a92-a204-8756f2539600">100,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTItMy0xLTEtMTM0NTA1_509acf66-4b2d-465f-a42a-ad126bcefe3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTMtMS0xLTEtMTM0NTA1_7f2bbb05-790c-481e-9200-0ef802545473">93,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTMtMy0xLTEtMTM0NTA1_b6b0f8c3-df77-421f-b58d-af6a4d6651eb">81,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTUtMS0xLTEtMTM0NTA1_8208144c-7d41-410c-b9bf-e119ca6b524a">86,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTUtMy0xLTEtMTM0NTA1_a27d7a6e-0813-424f-9f13-e0a2823b5070">64,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTYtMS0xLTEtMTM0NTA1_6c3c23c6-7902-418e-a64c-c1787a9f30ce">1,035,222</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTYtMy0xLTEtMTM0NTA1_6f283401-3f97-4de3-910d-febc677ab2a6">1,057,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTktMS0xLTEtMTM0NTA1_2b4d1707-bcd3-40db-a289-4e8ee1796b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTktMy0xLTEtMTM0NTA1_4544931a-81d4-463f-aaa9-0eae23255295">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjAtMS0xLTEtMTM0NTA1_9617a876-590b-421e-bf2b-66112bbac1c4">3,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjAtMy0xLTEtMTM0NTA1_835c8b18-3bf3-4fd2-bf08-21bd5a0e9385">17,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjEtMS0xLTEtMTM0NTA1_9aee6330-2d92-45da-961c-03603a31bc69">62,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjEtMy0xLTEtMTM0NTA1_a4dd82bd-e95f-4d6c-ba2b-516d31fe7641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjItMS0xLTEtMTM0NTA1_2a00b831-e723-4151-8012-6216a6569db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjItMy0xLTEtMTM0NTA1_386adc0d-f3ef-4f7a-839b-acda3cc01587">109,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjMtMS0xLTEtMTM0NTA1_e322f688-63da-491d-8dfe-18cf45f341fb">79,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjMtMy0xLTEtMTM0NTA1_9a5a2823-8990-4268-af54-ca3c0a11f504">35,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjQtMS0xLTEtMTM0NTA1_4b54d40d-cd7a-4963-b503-36f6fa37017d">31,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjQtMy0xLTEtMTM0NTA1_ec2e5ee9-26fa-4fd8-9b7f-4873857b1ced">31,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjUtMS0xLTEtMTM0NTA1_62acc1e4-0057-4a96-a8a3-bfc59b405386">234,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjUtMy0xLTEtMTM0NTA1_f39100e9-4f59-4413-91f9-7ee5907be44a">728,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjYtMS0xLTEtMTM0NTA1_7e65ac77-4cf6-4432-8635-0208e189a154">525,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjYtMy0xLTEtMTM0NTA1_873d896a-80ae-4cf1-a45a-e4600d281df8">868,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjgtMS0xLTEtMTM0NTA1_36ae6d20-8d53-4394-aefb-a631427e6c4f">175,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjgtMy0xLTEtMTM0NTA1_c50eaff8-dd81-4f4b-bd08-408550ee5d6b">683,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of other financial assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMS0xLTEtMTQ2MzA3_7b1d5c9c-f8e5-4cad-96b5-c6e3f6e894f4">21,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMy0xLTEtMTQ2MzA3_8e947f53-ef2a-44a6-ba74-a66db174589b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMS0xLTEtMTM0NTA1_27a7683b-d8f7-46b2-8570-7e74d73c0540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMy0xLTEtMTM0NTA1_c041b567-4598-478c-ade1-8cdafaa4b45e">18,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzAtMS0xLTEtMTM0NTA1_a3958cb8-4df9-48f1-90d2-6a1025b04ea6">19,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzAtMy0xLTEtMTM0NTA1_75b06f57-ca8f-4331-8ddd-2f6bf48f4882">473,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzQtMS0xLTEtMTM0NTA1_2ca537f4-69ec-442c-a5f8-2b38f9f40799">215,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzQtMy0xLTEtMTM0NTA1_ecfe26b5-437f-4a88-be89-6d95e255927f">238,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests- other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzUtMS0xLTEtMTM0NTA1_34c8d1c1-d7b5-44e9-9c3f-97e90c2ff6e8">72,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzUtMy0xLTEtMTM0NTA1_80791d88-89c5-4f5d-b50e-bb94928813e3">86,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzYtMS0xLTEtMTM0NTA1_2ba818ef-3369-4ff5-be9e-7124f5a5fe8b">165,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzYtMy0xLTEtMTM0NTA1_7cdd23ce-9d60-49be-a5bc-55d7abb66db2">138,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from non-controlling interests- R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzgtMS0xLTEtMTM0NTA1_e378327b-13ea-4fd4-840e-4ba0ec7477f4">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzgtMy0xLTEtMTM0NTA1_7952638f-1dbb-46d5-bc6e-e358875d8e6d">4,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from non-controlling interests- other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzktMS0xLTEtMTM0NTA1_79c1007c-1750-4550-b6c8-62ce6e375176">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzktMy0xLTEtMTM0NTA1_b86ef173-2edb-433c-9a15-8dba68a7ac6b">8,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDctMS0xLTEtMTM0NTA1_8dec7306-9d4d-4ea2-8143-2c31be53309b">449,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDctMy0xLTEtMTM0NTA1_54bd46d6-0738-4739-97cf-ce41cf8c2703">451,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDgtMS0xLTEtMTM0NTA1_75d796c9-46fb-4b21-9942-d8f7db87dc90">566,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDgtMy0xLTEtMTM0NTA1_be7d209f-0d8a-40e5-8062-c934b83538cd">133,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDktMS0xLTEtMTM0NTA1_c1a4770e-3fa8-4ac7-aeab-8345af584aa9">1,541,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cade76361ba4fcba710604a8c023a58_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDktMy0xLTEtMTM0NTA1_3d0eaa65-2bfb-46e8-8b7b-09abb61babc5">1,008,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNTAtMS0xLTEtMTM0NTA1_656208ae-eaae-4e4e-a9eb-bb5145f24587">2,108,037</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNTAtMy0xLTEtMTM0NTA1_e702c11d-7e40-4ad0-b163-f655a4050baf">1,142,281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_37"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfNDI0NQ_226d8f2e-f2a9-4209-bbba-1f356e97595e" continuedAt="i53ef7079f7e9449bad4244b111665633" escape="true">Organization and Purpose </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i53ef7079f7e9449bad4244b111665633" continuedAt="i590fbac95ef245b7bcd2feeaf3924bf5"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (&#8220;IPO&#8221;) of our Class A ordinary shares. &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd. (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#8217; Class A ordinary shares and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;).  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#8220;Management Agreement&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented <ix:nonFraction unitRef="number" contextRef="ic15dd32149b64228b3e0062543709fcd_D20200211-20200211" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMjg1NA_73388fb1-89f2-4731-84fc-c9c8ca3edd8e">82</ix:nonFraction>% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i590fbac95ef245b7bcd2feeaf3924bf5">As a result of the Exchange Offer Transactions, we own indirectly an <ix:nonFraction unitRef="number" contextRef="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMTA5OTUxMTYzMzIzNw_a8a43eeb-43d3-457e-8b6d-8905652b9a29">82</ix:nonFraction>% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;). We are legally entitled to <ix:nonFraction unitRef="number" contextRef="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMzczNA_0a3add85-207f-402f-9f79-97630a73e1b1">82</ix:nonFraction>% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and <ix:nonFraction unitRef="number" contextRef="i8fc135510e2d49c6b0cd406c917f4076_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMzk1MA_c947bba7-2b48-456d-b42d-9739111bcf52">66</ix:nonFraction>% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining <ix:nonFraction unitRef="number" contextRef="i4664ea2072fe497b9a2bdfd6d8b604dc_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfNDA0MA_f3af57db-d805-4a3c-948f-5788b7dce870">34</ix:nonFraction>% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU1Mg_881d7af0-f98c-41a5-87e4-e2ffdf36b6a9" continuedAt="iacb8fbe8dfe049d796452a9fcdfb2d27" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iacb8fbe8dfe049d796452a9fcdfb2d27" continuedAt="iebe0dc3cac2a4a47b10a0c0248cdde79"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Preparation and Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0Nw_8e238798-c49d-4e18-af51-61d1a7c67188" continuedAt="i4555fb0aeddb47fdad03bfc3a8c33d3c" escape="true">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </ix:nonNumeric></span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="iebe0dc3cac2a4a47b10a0c0248cdde79" continuedAt="iad3e45a8d0d3481f841d22263e8c0b3e"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4555fb0aeddb47fdad03bfc3a8c33d3c">In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0OA_8e89f09a-b97c-4f61-a05c-0be8297757e7" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0NQ_e432a150-6412-4e6f-b8de-5b9aec93d1c2" continuedAt="i6f54d5fe881a4ee0bef5a315c1d95c1b" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="i3af9b0efe9a24584a5d0beab8491a70b_I20200229" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMjk3OA_ec61dd5b-38cc-4706-abd5-3c72a5ce62ce">18</ix:nonFraction>% in Old RPI, (2) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). Income will not be allocated to EPA Holdings until certain conditions are met.  </span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6f54d5fe881a4ee0bef5a315c1d95c1b">All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU1NQ_09f99103-f3b2-408a-b6e0-e8060b744e14" continuedAt="i8ab19fdebaca4b988465b0469da95f25" escape="true">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ab19fdebaca4b988465b0469da95f25">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead.</ix:continuation> As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for <ix:nonFraction unitRef="number" contextRef="i870dbc439abc462d939ae18d7d1c13f2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMTA5OTUxMTYzMzM1OA_93ef3be4-9986-4a9d-817a-0a1e7a3a6c29"><ix:nonFraction unitRef="number" contextRef="i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMTA5OTUxMTYzMzM1OA_f33e53da-c5b1-4c9e-84d3-0c7f9775f13d">32</ix:nonFraction></ix:nonFraction>% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="iad3e45a8d0d3481f841d22263e8c0b3e" continuedAt="ieb50487d74004aa2b94081f9be17d757"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieb50487d74004aa2b94081f9be17d757">There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzMxNQ_f14a63f6-b7af-42ba-a9b8-26f15c5392eb" continuedAt="i268476ca67954629ba53315fcbdd9daf" escape="true">Available for Sale Debt Securities </ix:nonNumeric></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i268476ca67954629ba53315fcbdd9daf" continuedAt="if83fbe4a12014ff9b3447c56ea839c61"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) of up to $<ix:nonFraction unitRef="usd" contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzY5NjU4MTQxMTg3MA_cdab2622-049e-40aa-a7b3-a4dfde40ed46">300</ix:nonFraction>&#160;million, which is comprised of <ix:nonFraction unitRef="tranche" contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107" decimals="INF" name="rprx:LongTermFundingPartnershipNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5_50201c1e-66d5-4e27-b555-f5655400fdb3">five</ix:nonFraction> tranches, including an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipInitialPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDg0_b525793c-c9e1-4aa8-8e8e-1454d3305989">50</ix:nonFraction>&#160;million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipCovenantRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTUw_a18ed830-74f0-4f3f-984f-40beb597f9e5">50</ix:nonFraction>&#160;million if a certain contingency is met and has the option to draw the remaining $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzE0NjgyNTU5ODY0Ng_78532465-18b5-46ee-8d57-88cc10c3ddc1">200</ix:nonFraction>&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#8220;Cytokinetics Funding Commitments&#8221;). As of June 30, 2022, we expect $<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipExpectedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTMxOTQxMzk1NTI4NzM_e39fa64b-4da0-4261-a998-4591acebc955">125</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzY5NjU4MTQxMzE1MQ_78532465-18b5-46ee-8d57-88cc10c3ddc1">200</ix:nonFraction>&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling <ix:nonFraction unitRef="number" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="INF" name="rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfODk4_76ad7772-c331-47fd-ac3d-70aa34ef0408">1.9</ix:nonFraction> times the amount drawn. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $<ix:nonFraction unitRef="usd" contextRef="i902af37f112d47b59465fb1587d35546_I20220630" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTgzNg_9bd8c49e-e1fe-4628-82f8-138c68bbcd16">350</ix:nonFraction>&#160;million of capital (the &#8220;Development Funding Bonds&#8221;) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $<ix:nonFraction unitRef="usd" contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjAyOA_f221d9fb-41ed-4a2d-a9c7-6f61043f06ec">150</ix:nonFraction>&#160;million. Our commitment to fund at least $<ix:nonFraction unitRef="usd" contextRef="ia97d19761a80439aaf1c248d0d1cc56e_D20220401-20220630" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjA2NA_c7f77a20-38ae-46c5-8e48-e4ae171302c5">150</ix:nonFraction>&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of <ix:nonFraction unitRef="number" contextRef="if3b647dc49674f03b93aec721c35aafb_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjIwMA_cdc5e1a7-62a1-4d00-be05-854d2cf176a0">2.2</ix:nonFraction> times the amount funded on the Development Funding Bonds payable on a quarterly basis over <ix:nonNumeric contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjI5NA_d9b3cc88-4037-43be-a11c-10ac48733c52">nine years</ix:nonNumeric>, with the first payment beginning <ix:nonNumeric contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjMzMQ_a11e6ee7-d0a8-4343-aeee-c9590cc8b6c0">two years</ix:nonNumeric> after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $<ix:nonFraction unitRef="usd" contextRef="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731" decimals="INF" name="rprx:CollaborativeArrangementExpectedProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTI2NDQzODM3NjQzMzg_2ab8b718-f42b-49ba-81a2-e670b47a0a3d">300</ix:nonFraction>&#160;million under the Development Funding Bonds to be funded in September 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="if83fbe4a12014ff9b3447c56ea839c61" continuedAt="ideacf5987cd24245b8e2eedb28e6de44"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, RPIFT funded the purchase of <ix:nonFraction unitRef="shares" contextRef="if50973d0a69a4908932e02a923662f68_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTIwOA_0f08881b-dbe8-4966-b5d6-ddba4a892a8b">2,495</ix:nonFraction> Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if50973d0a69a4908932e02a923662f68_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTI3NA_ddcb91bb-98ad-4ecf-8583-2fc6334bbbcd">50,100</ix:nonFraction> per preferred share for a total of $<ix:nonFraction unitRef="usd" contextRef="icd5c1bcea18e4e42a9671f6beadbf2fa_D20190405-20190405" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTMxMw_b33344e4-75eb-4804-a1e7-c9b2c979822f">125</ix:nonFraction>&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 resulted in a payment due to us of <ix:nonFraction unitRef="number" contextRef="i01bf1c77beb0485bba6517474b519b3a_D20220101-20220331" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTQ0NQ_764b48b2-924b-4c73-a2de-4673e0f24258">two</ix:nonFraction> times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to <ix:nonFraction unitRef="number" contextRef="ic9e38949c6aa4cd6866cb944e9722714_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNjAwNw_fe54b931-4115-42b5-9a2f-b8c75364e429">two</ix:nonFraction> times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="id75ac419666144e9ac3c194e9261e33c_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjA0NA_c84c6b53-f5a1-453e-8a66-7e9d4b2d5833">8.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id978345eb4784af985d02a10ba404dc9_D20220101-20220630" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjA1NA_51f0cb18-1811-4ba1-a678-cf2609b6573e">16.9</ix:nonFraction>&#160;million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i578d8f8ce4bc4f43841fb347caa2a50d_D20210401-20210630" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjI2OA_e20eb38f-f621-4057-b71b-76990a1bb58d">13.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id49f4fcd2b764a89bc0488726370049d_D20210101-20210630" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjI3Nw_ef374e79-3405-4288-9111-b342addc4faf">28.8</ix:nonFraction> million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire <ix:nonFraction unitRef="shares" contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzI4NTA_893ed017-8446-4503-b78e-a5c2c0996a47">3,992</ix:nonFraction> shares of Series B Biohaven Preferred Shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0Mzk2NQ_0665323c-bbb8-4a27-a70e-2a87686f6eda">50,100</ix:nonFraction> per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;) for a total of $<ix:nonFraction unitRef="usd" contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0Mzk4Nw_d70ff466-86d3-43c2-8b5c-990aa36e797b">200</ix:nonFraction>&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately <ix:nonFraction unitRef="number" contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAwNQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443">1.8</ix:nonFraction> times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately <ix:nonFraction unitRef="number" contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAxMQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443">1.8</ix:nonFraction> times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately <ix:nonFraction unitRef="number" contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAxNQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443">1.8</ix:nonFraction> times the original issue price for the Series B Biohaven Preferred Shares. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have acquired <ix:nonFraction unitRef="shares" contextRef="ie7a47ace66d74b15afbe0039fd04291d_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjUzNzExOQ_da298403-21d0-465b-8585-0d0397842f9b">1,988</ix:nonFraction> shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="ideacf5987cd24245b8e2eedb28e6de44" continuedAt="ie4577520676840598c124d6c68c748bc"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzMxMw_344ab0b0-3c90-4e68-a04e-bfc7a332e005" continuedAt="i432bd193d2564341bdfee28b88a8d274" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities (3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xLTEtMS0xMzQ1MDU_9b7e93fc-d705-42ec-a913-668bfd24d90f">278,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0zLTEtMS0xMzQ1MDU_6d191e19-2744-4d40-a57f-8aa6e02e181b">84,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi01LTEtMS0xMzQ1MDU_89b9bb15-00c9-4484-91e4-9701c2cf0888">363,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi03LTEtMS0xMzQ1MDU_66670a38-ea3a-4184-a558-d5fdc336aa3c">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi05LTEtMS0xMzQ1MDU_d22816a9-ebb9-4c08-8b27-67327afd6127">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMS0xLTEtMTUzOTg4_92c587e4-fe94-42e2-8fda-df3ccacc7c49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMy0xLTEtMTUzOTk1_ebf52313-6cf7-40bc-a530-ae2b8e16f5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9290af25cfb841918df88507b267637a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMS0xLTEtMTM0NTA1_89d6fe5f-e885-460a-aa76-bc6b4ca008fa">363,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xLTEtMS0xMzQ1MDU_146046a3-a798-4d46-bbf2-9444ca6c4b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0zLTEtMS0xMzQ1MDU_1982b645-3784-41bf-979c-73404811ef0c">28,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy01LTEtMS0xMzQ1MDU_a9604482-dccc-427c-93ab-4341955d5a23">28,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy03LTEtMS0xMzQ1MDU_443c612e-0c81-4ad5-bcc8-eb2d3ff42037">63,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy05LTEtMS0xMzQ1MDU_9e90741d-7cdc-4bd1-a037-bacb06d6796a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMS0xLTEtMTUzOTg4_4efffd2a-a843-4ce0-b9ff-2c202bbdf7c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMy0xLTEtMTUzOTk1_796c682e-f691-49af-804d-b38ed6be857e">35,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMS0xLTEtMTM0NTA1_49e5a4aa-2689-4e15-807b-ee1517ff9c83">28,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" sign="-" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xLTEtMS0xMzQ1MDU_6a59adb3-05c4-46c6-9e94-ba1ee23b07f9">9,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0zLTEtMS0xMzQ1MDU_1c1cdafe-c977-4614-918b-84f961791d16">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC01LTEtMS0xMzQ1MDU_820ddafb-08aa-4281-8eb7-59c25d60c9d0">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC03LTEtMS0xMzQ1MDU_262f9a6b-2ba7-4458-a2e6-69ea24945839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC05LTEtMS0xMzQ1MDU_d0c9235c-e683-428f-aa7b-f38ec47c3b8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMS0xLTEtMTUzOTg4_f956a04c-9c87-4bb9-87d7-f4ed9ab05d3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMy0xLTEtMTUzOTk1_d0276414-bbb8-4c82-9c23-fd1f5bba643d">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMS0xLTEtMTM0NTA1_540cb1b8-5ed2-4d0b-ab43-c5563ad1e575">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xLTEtMS0xMzQ1MDU_ac54d21a-8009-46d3-b9f6-cd45394e2a15">269,359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0zLTEtMS0xMzQ1MDU_fda22c93-2859-44fd-b54d-319859768239">113,641</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS01LTEtMS0xMzQ1MDU_54c9e5b7-79a0-4ac5-b592-2b5f0fa805f2">383,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS03LTEtMS0xMzQ1MDU_a0460e5c-c6d2-4c31-9993-0038a9a51877">363,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS05LTEtMS0xMzQ1MDU_4f889c7b-b8eb-4429-bfd8-015bfff2b875">63,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMS0xLTEtMTUzOTg4_1b2b8698-6c20-4073-a2dc-38dbeedc8a53">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMy0xLTEtMTUzOTk1_07e081e0-cc3b-488b-a519-4d0e51689d5a">43,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMS0xLTEtMTM0NTA1_cd684c1c-064a-45ba-9caf-a99e91f2e9b7">383,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xLTEtMS0xMzQ1MDU_0cf0b2ad-6e44-46d5-86b9-c737124da78f">204,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0zLTEtMS0xMzQ1MDU_42157ce6-6094-4325-b80e-4da1d79cbbc3">49,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC01LTEtMS0xMzQ1MDU_48db7109-4723-46f8-845e-b689d8451c25">253,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC03LTEtMS0xMzQ1MDU_4d478b22-008a-434c-b008-0c83c67bc41f">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC05LTEtMS0xMzQ1MDU_75b3d22c-2722-4618-ac82-897e887bc22a">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMS0xLTEtMTUzOTg4_fe76fe67-8917-4312-a525-9727fa4465bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMy0xLTEtMTUzOTk1_b73f68fa-3204-4236-a855-43e1cfcdc007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMS0xLTEtMTM0NTA1_b731aeb2-96f9-4b61-b14f-5e74be32d701">253,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xLTEtMS0xMzQ1MDU_5ee2fa34-bd3f-4b9b-8c1a-41cdc9e82bc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0zLTEtMS0xMzQ1MDU_1141b697-aa60-4673-8615-7dacbe289676">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS01LTEtMS0xMzQ1MDU_3de02466-c221-4c92-b36b-c375892d9c03">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS03LTEtMS0xMzQ1MDU_84cebba0-4398-415e-a1f1-42435acfa806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS05LTEtMS0xMzQ1MDU_e4558242-e50c-4bd4-bb74-76566edac91b">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMS0xLTEtMTUzOTg4_7d5c7aca-20c0-484b-8cfd-2a4487da67a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMy0xLTEtMTUzOTk1_d5401807-4698-4a78-8f2e-ee1fa45f3d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMS0xLTEtMTM0NTA1_f9346280-f72f-43c0-b09c-35c1c7579fd3">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMS0xLTEtMTM0NTA1_db6ff97c-9086-422c-b427-979dc679999a">204,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMy0xLTEtMTM0NTA1_11b6a5cb-2c88-44fe-b168-838336f7652d">65,891</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtNS0xLTEtMTM0NTA1_53c54315-a0a6-4254-a517-f542b1c40d15">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtNy0xLTEtMTM0NTA1_c188e095-0195-4b47-852c-856fd2f3f941">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtOS0xLTEtMTM0NTA1_bf2abef9-734e-4e45-bb1c-5ee6ad08409c">204,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTEtMS0xLTE1Mzk4OA_0e3645e3-459b-4da6-b782-4ac0e925e58b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTMtMS0xLTE1Mzk5NQ_73440e7b-1230-4573-bf7c-ced9ea29eddf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTEtMS0xLTEzNDUwNQ_3a2de279-31c7-47e0-9aec-e18f28e3eec5">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. </span></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><ix:continuation id="ie4577520676840598c124d6c68c748bc" continuedAt="i18bf4666f70b4743849f0ce7d2436355"><ix:continuation id="i432bd193d2564341bdfee28b88a8d274" continuedAt="if3a1da159bf94ec1b473fd3d1dec6be2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i18bf4666f70b4743849f0ce7d2436355"><ix:continuation id="if3a1da159bf94ec1b473fd3d1dec6be2"> on the condensed consolidated balance sheet.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4<ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzk_42151bc3-7eb4-4f95-8f11-eeee520e929d" continuedAt="i59852f2f6e0f4d12b5fd8c985ade5b95" escape="true">. Fair Value Measurements and Financial Instruments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i59852f2f6e0f4d12b5fd8c985ade5b95" continuedAt="ie3c7ed0111cb4480a67d4df3fd87b9a9"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzg_977c70cd-04eb-4d6c-850a-04f9d7df7f4e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="ie3c7ed0111cb4480a67d4df3fd87b9a9" continuedAt="i8828fa2ced154bf695eb6120fd47b2a1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0NzY_5418afb4-d716-4dfa-91f5-5b57ef3e614a" continuedAt="ic37d9f3b720e497ba84edcd8e7b8ffee" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b1800e67dc44a981720a7b46c2e79d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xLTEtMS0xMzQ1MDU_caaf1a5b-0935-4e68-9cef-58e087494de4">307,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0870484004364ecb8b093f2046454b41_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0zLTEtMS0xMzQ1MDU_6f9f3249-e479-4050-a7dd-3feae6d61316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide2e274fed7a481fba6833bfbf3cce5f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi01LTEtMS0xMzQ1MDU_c7e5a742-f6a6-42b0-bb60-ef800d2e2459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c80a2ae1ba645d8abc23c5ce5fd6c3a_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi03LTEtMS0xMzQ1MDU_0ef40ba8-5f5c-4b4f-8193-08bea8c9f1ec">307,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3505ef986d8e447e9494c8ba914f66d4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi05LTEtMS0xMzQ1MDU_b9a89258-2e36-48b4-af2e-0a3fdd1e9687">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd435d72f144bbcb6e42e3f0d53768f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xMS0xLTEtMTM0NTA1_e93fdc04-a48a-4f40-b181-9e137d51a439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3de23eaeb284126b429fb1b2832c3dd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xMy0xLTEtMTM0NTA1_6a176349-4e92-4cc7-8bc1-5e62392bf954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5576abf606bb4661bbc57aac01aa20ef_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xNS0xLTEtMTM0NTA1_ea599a5a-9869-46d7-b028-bb0694c80173">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8546e9f6e24b4217b84ced51c46b1e0f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xLTEtMS0xMzQ1MDU_30019ae3-87d6-4d51-91d0-dd5c3ee33164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef74a0dac44216a515c0217153b14a_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0zLTEtMS0xMzQ1MDU_d7ff8a32-3783-4222-b918-c1073883f993">181,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb473791033401b851d996ace3fb0d5_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy01LTEtMS0xMzQ1MDU_26d7a18a-e107-4ec0-bd1e-ea96ddd4eb2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08423e6c0ac54c738abebce60150775e_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy03LTEtMS0xMzQ1MDU_e0a8b8c1-15f2-44be-b770-8065ac9fc00e">181,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694256d7751f443599a66a50b84c5c04_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy05LTEtMS0xMzQ1MDU_3a5c7781-073b-4d95-8431-c9dc143301b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335547d431054d37aa47757fec28e211_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xMS0xLTEtMTM0NTA1_cad22de9-1516-4d99-aec5-41fee0924274">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9d3fdba80d4a0ab2392959204e54f6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xMy0xLTEtMTM0NTA1_56e1376d-1d33-4207-87e6-2e5112ca8227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274c91a324f74a50b47e0f39cc9a6471_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xNS0xLTEtMTM0NTA1_21e799d3-1b3f-40a5-9a51-e35083e675fb">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcaa33e9c8c454ea8d9ad358405d5c0_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xLTEtMS0xMzQ1MDU_22c91557-656c-456b-af03-c0fd013bfae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a0b0bfcc4f426fb9507705a90045ed_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0zLTEtMS0xMzQ1MDU_454137c8-4284-4ea1-8b45-ec6f781370e1">36,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e68fb94a79461caa836857c65a594b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC01LTEtMS0xMzQ1MDU_7e58ded8-9070-4785-bee9-b2af5a742f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ad8d24abf44259b70281a4a03fd5ab_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC03LTEtMS0xMzQ1MDU_b1262f6f-6fa5-4f70-959b-7f93b8b257ad">36,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e4ce8bb43f44bd81105b431942f8a4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC05LTEtMS0xMzQ1MDU_e7ebca27-4035-443e-bdd1-86ed77d4102c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5229c7a11d840c385003a2de7d5a560_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xMS0xLTEtMTM0NTA1_6bb8d294-0c73-48a4-b929-ce4d0fe53989">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0f2a63eea644fc9b8acb08a1096965_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xMy0xLTEtMTM0NTA1_588e13ae-a223-4bcb-88dd-b79bcee34efd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a3c10ce0834373af301afc9cb06554_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xNS0xLTEtMTM0NTA1_b78209d2-b599-4a2d-831e-ff95cd9b7f0a">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f7d2dc311341ed8ab580778cfb7424_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMS0xLTEtMTM0NTA1_3442bb41-79ef-4aca-a528-741a2664ff24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a5bcf20dbe4092b31de7276a1233af_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMy0xLTEtMTM0NTA1_55d1499a-f7cf-4d43-861a-c03412ba720d">87,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164534f9debb47d283bba03bb38b42a8_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItNS0xLTEtMTM0NTA1_6cee224b-1ac5-4cbc-8d57-6b1601e97f50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3724a5f5971340ee9b2c75df324f183e_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItNy0xLTEtMTM0NTA1_e481c7c8-89b0-4fc3-8568-005feeacb333">87,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de1f8630b5044af9d51c4a863878a19_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItOS0xLTEtMTM0NTA1_f2987b21-2a1d-4bd7-b1b2-490fd56c4c95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae65db56ba049b8b7016f1d57247db5_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTEtMS0xLTEzNDUwNQ_ae4d4af9-e1ef-498c-a95b-c24598a2f0a8">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca01372241f4621b26e3c24a6b0ac4c_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTMtMS0xLTEzNDUwNQ_06b366c6-fdd0-4fce-b552-b7b35830c233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8847225dbd934083a96c5b022eb001dd_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTUtMS0xLTEzNDUwNQ_708bd7ea-cc04-49a8-a82e-f0c95a704f3a">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4faebbed44242b588fd22db4532d6a2_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMS0xLTEtMTM0NTA1_afdfa9e9-6c5f-4bc7-be8d-593e19478bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e2f72945114b8e97557817665eb22a_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMy0xLTEtMTM0NTA1_1497fd96-c93a-4f3a-9eb1-4d9842523fbc">178,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide527eedf0c8430ebdd7f8b7e178695d_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtNS0xLTEtMTM0NTA1_901f7aeb-c84e-44a6-8626-6df088ee3b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d54454653d14877997e8cc8a446a36b_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtNy0xLTEtMTM0NTA1_e27e0a5e-ec7e-48d8-930f-4189ad6de477">178,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9240e834904c4b7980784391c35ae5d7_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtOS0xLTEtMTM0NTA1_85edc5cb-bda1-49cf-ac35-0b0f8e1aedbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057686b000924406a6e92a555bcefbe8_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTEtMS0xLTEzNDUwNQ_e62d6c56-94dd-4474-95d3-24fd75208375">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6562ec75eae34ba19dcb404ea71fccac_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTMtMS0xLTEzNDUwNQ_b8322781-9333-43c8-a0d3-e074f59694d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7cf57e9bdd49e3a5aab2cd19221140_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTUtMS0xLTEzNDUwNQ_fa1aff1a-28de-4eb0-99cb-a420ec43b15a">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4c1ac3b3004925ba20d1eb0829987d_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMS0xLTEtMTM0NTA1_e85f8019-c092-4b49-aa6b-14f680cf002d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a847973ce446648b13fdedff22c715_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMy0xLTEtMTM0NTA1_f9828efb-193f-4bad-aa6d-dbea770b33bc">24,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia78911c3736d495e8cb2fa5ea8e81e2e_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtNS0xLTEtMTM0NTA1_161ddbca-3a83-4585-825f-e9051b627a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c70858e246f4c259aa4add3106bb74c_I20220630" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtNy0xLTEtMTM0NTA1_7e39ae71-1d5e-4038-b56c-43e9199126d4">24,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42664d0a6f0744bc8d3dc6057491af00_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtOS0xLTEtMTM0NTA1_3b39ad25-6c6d-4d54-bcae-07672dbcacaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d0d65a59844aa3bee4beb15d323337_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTEtMS0xLTEzNDUwNQ_512b43af-2809-4daa-aa17-ce26e54d93e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5608ca68f141c5ab7e851371cbc63c_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTMtMS0xLTEzNDUwNQ_a2f4f84f-6855-464b-9543-e24997fbfe38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3099777568874b56a4d873cc01719626_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTUtMS0xLTEzNDUwNQ_a2513892-9e9c-4b67-9ac0-e09640db28fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2e747c9c9b43f69707587cc843a451_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMS0xLTEtMTM0NTA1_3e7de4e5-8ee3-4e66-9291-d5b69828d1dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872d2b73bb3b4a8da6deb68b730f21af_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMy0xLTEtMTM0NTA1_3d0e3725-8277-4931-9008-f04fdac76e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cb19b43b645968b07140915241260_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtNS0xLTEtMTM0NTA1_aae88864-2384-4a24-8f85-78e035755b72">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtNy0xLTEtMTM0NTA1_55f314f0-422d-4c1c-a971-16ffb8711157">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if290e213185d45f3b68d456d7bba18b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtOS0xLTEtMTM0NTA1_d3d6487e-2e79-4d36-89db-97a9a7321193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354de3a504f7447f946701a70bbbdd32_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTEtMS0xLTEzNDUwNQ_2fe7e640-6d77-4e27-9d6c-d187f383c20d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a185b6e27d445c892d2b91c0a23d94_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTMtMS0xLTEzNDUwNQ_966d6e26-5575-4e80-baf6-0521f45ea019">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTUtMS0xLTEzNDUwNQ_3ef8c3f9-b8ba-4cae-b441-cc7dd179907c">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMS0xLTEtMTU0NDgw_14297aec-50c8-4c4e-962e-d615f13f65b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24d238620954975bfcdbdd367836c85_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMy0xLTEtMTU0NDgw_6681bea8-f2d8-444a-aef9-ed8b27c74b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id366640cb83544df99f3ad8a3131c185_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctNS0xLTEtMTU0NDgw_feee0471-5332-4041-b3d1-a311179f97f6">63,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctNy0xLTEtMTU0NDgw_f1f6495b-9cb6-4593-bfb8-652cd3890cde">63,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa147f94524d7496766953b7a86882_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctOS0xLTEtMTU0NDg4_65aa24f9-b51e-45fc-949f-d9da8eafd92e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTEtMS0xLTE1NDQ4OA_294eaf4f-1ae7-4b25-b15c-cfa748ed0ba2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTMtMS0xLTE1NDQ4OA_b2a462fb-2c42-4b20-aba9-9417e48a856e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTUtMS0xLTE1NDQ4OA_a718f964-7cf4-416f-abd8-3b6ed7524660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMS0xLTEtMTU0NDgw_ab459557-ec1a-4450-96a8-cfe423bf91be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMy0xLTEtMTU0NDgw_d8a27a5d-6246-4cb0-a2ae-9c21bf48950d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNS0xLTEtMTU0NDgw_d10f61af-f646-4857-a083-f2525ca6c8b7">63,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNy0xLTEtMTU0NDgw_edb3bca6-0fef-4333-abb8-7e1a21e21ec7">63,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtOS0xLTEtMTU0NDg4_f996a06f-b37b-41bd-aad1-3497eaf8f151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTEtMS0xLTE1NDQ4OA_e552b3f5-4a83-4584-b172-4ec897086814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTMtMS0xLTE1NDQ4OA_7126b3aa-72af-4aa0-85ee-c50019ca3680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTUtMS0xLTE1NDQ4OA_f579bc23-f91c-4528-b448-9ae0a30935c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMS0xLTEtMTM0NTA1_202f0191-6ebd-494b-9cfc-89ff927c4797">307,797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMy0xLTEtMTM0NTA1_37d6e99c-421e-4076-a2eb-0567798494f2">508,084</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNS0xLTEtMTM0NTA1_dc4a72a6-27e0-4434-9a6b-cda8ed9f966e">426,900</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNy0xLTEtMTM0NTA1_89d035e7-8072-4360-bd73-15a167f53595">1,242,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtOS0xLTEtMTM0NTA1_6b01815a-b455-4a1c-9e37-4cda4f0f8f0f">598,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTEtMS0xLTEzNDUwNQ_393420af-8681-4880-b8ad-b46b0b732231">636,823</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTMtMS0xLTEzNDUwNQ_b6da07e6-0117-4405-80a5-e292febcf389">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTUtMS0xLTEzNDUwNQ_7dac3afe-8901-489d-a52c-dce48efb867b">1,301,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMS0xLTEtMTM0NTA1_8ed12804-b81c-4353-bc3f-46143b90a399">275,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMy0xLTEtMTM0NTA1_1e358b6a-5e83-4f3a-bfe6-547dbf59e26d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtNS0xLTEtMTM0NTA1_776e2f76-e858-4388-bc32-f325825d04c3">28,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtNy0xLTEtMTM0NTA1_968a680c-85a0-4b99-9992-1b92948f7cbe">304,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtOS0xLTEtMTM0NTA1_b37f1403-95ca-4966-b94c-567d8b3e1b07">226,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTEtMS0xLTEzNDUwNQ_f31cf5f1-867b-41d1-95ab-4084adf5cc63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTMtMS0xLTEzNDUwNQ_fad00ecd-d5f4-43a9-a305-1f1dcb5eaf1b">43,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTUtMS0xLTEzNDUwNQ_5236fc5d-2f9c-450f-943e-cde6ede6cbc2">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2e747c9c9b43f69707587cc843a451_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMS0xLTEtMTM0NTA1_65575166-06ab-435f-b3f1-28103233dca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872d2b73bb3b4a8da6deb68b730f21af_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMy0xLTEtMTM0NTA1_6d94fc91-ef55-4926-bd11-7793c55a1660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cb19b43b645968b07140915241260_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItNS0xLTEtMTM0NTA1_9d0b46d3-abe7-4271-a799-df585dd67756">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItNy0xLTEtMTM0NTA1_a32300d4-b4c6-4724-b48c-299a02af56f7">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if290e213185d45f3b68d456d7bba18b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItOS0xLTEtMTM0NTA1_0fc15260-ad13-4833-9dd2-4c790a924a11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354de3a504f7447f946701a70bbbdd32_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTEtMS0xLTEzNDUwNQ_8ff15ad7-c01d-41fa-b476-8cdd877c8499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a185b6e27d445c892d2b91c0a23d94_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTMtMS0xLTEzNDUwNQ_4ea83734-93fe-4478-87c3-908741e9d9ba">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTUtMS0xLTEzNDUwNQ_f5a73cb0-3428-48d7-a01b-8db53ed3afd9">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMS0xLTEtMTM0NTA1_3291518f-5665-4a5c-a98b-b98ad09e95c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24d238620954975bfcdbdd367836c85_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMy0xLTEtMTM0NTA1_51a853bf-7765-4d2c-a476-ed2e5e11762c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id366640cb83544df99f3ad8a3131c185_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtNS0xLTEtMTM0NTA1_549fd8ad-36d6-4f0c-bba5-80a9a1fb3f54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtNy0xLTEtMTM0NTA1_d6c56535-9616-43b5-8bb3-35651f51e58b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa147f94524d7496766953b7a86882_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtOS0xLTEtMTM0NTA1_b4be7934-2938-447c-af81-8a1805550c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTEtMS0xLTEzNDUwNQ_c8dcf46f-9e5f-4301-8cd0-3f1eca339de2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTMtMS0xLTEzNDUwNQ_c152b70e-5634-49b2-8d18-6af58ef4f7fa">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTUtMS0xLTEzNDUwNQ_37cf8a87-5181-4440-bfa3-4af4e28e5c0e">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMS0xLTEtMTU3OTk1_b799905d-41ee-43ff-b9ab-85aa1b288dd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMy0xLTEtMTU3OTk1_1aaf4d5b-f4ed-4ef0-8473-d2b161eaf0a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNS0xLTEtMTU3OTk1_57eb65ff-90a9-4f94-b212-5cb7db09a95f">8,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNy0xLTEtMTU3OTk1_fad4b5be-5549-4956-aa2f-ea5a9042ac0b">8,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctOS0xLTEtMTU4MDAy_40c9eddc-3c78-40d7-9cac-d0d1a41b8a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTEtMS0xLTE1ODAwMg_50a99d4c-bdd4-409e-8d98-b27c748cf200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTMtMS0xLTE1ODAwMg_861e2422-1569-4094-b2a3-522c3e3d2e46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTUtMS0xLTE1ODAwMg_378ae19e-8c47-4f82-906a-47b64dfc54cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfe1cd3f4e7415991895ae425a914d6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMS0xLTEtMTM0NTA1_2e509cae-e3e4-4af5-882f-5bff986bcdfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316c6f99df2b4a26ba23e4e48f5c3abd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMy0xLTEtMTM0NTA1_05350ca5-1edb-400d-a080-f68ce8f2fc3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9792ea77bdea40d1ae7f65287f922717_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtNS0xLTEtMTM0NTA1_bbecd2c2-536c-4c13-a50c-baa16279657b">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333a9ec1ff53481696d2280a621e9863_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtNy0xLTEtMTM0NTA1_0958b0ca-8219-42b0-a6f8-3a8cd1120354">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f25260f20c04074b3fc492d72c935ff_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtOS0xLTEtMTM0NTA1_03f82f27-699f-4299-881a-fe6cb4bc43c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4694ad59207646ac874c75e17fd2b37b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTEtMS0xLTEzNDUwNQ_e3e02857-bac4-44c2-a6a2-2caab8d7da70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69f87b5bc8e4ea1a497545b599999bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTMtMS0xLTEzNDUwNQ_1a2019dc-e4f7-4610-82bc-a1ef3ce190c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9455f5d9a104f0e81d0b8107254f72f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTUtMS0xLTEzNDUwNQ_368caee3-a2ca-4b54-8f31-eec4f1685fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMS0xLTEtMTM0NTA1_6c919aa4-f302-48fc-8a54-db3e12b425fc">275,662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMy0xLTEtMTM0NTA1_3c937a2e-da66-4a7e-9816-673b0783fd9e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNS0xLTEtMTM0NTA1_997fa5c0-f4ab-455b-85ac-8d9b09c6a426">121,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNy0xLTEtMTM0NTA1_146705ce-6778-49f1-8919-324ef8286cf5">397,262</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctOS0xLTEtMTM0NTA1_a861b66d-1325-4afc-b9d8-54647a082716">226,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTEtMS0xLTEzNDUwNQ_963a8f58-2a5b-4e47-be02-3b594d14d5f7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTMtMS0xLTEzNDUwNQ_51b7f310-3c19-4c0c-8384-3c4045c8e8de">247,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTUtMS0xLTEzNDUwNQ_78ad0136-7e61-4a4c-9c2c-db861a77a13a">474,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtMS0xLTEtMTU0NTEx_4cfc44ab-40b4-45de-9fd5-68c4dcade8d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24d238620954975bfcdbdd367836c85_I20220630" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtMy0xLTEtMTU0NTEx_e6582985-f3a9-4e8e-8999-846d59805dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id366640cb83544df99f3ad8a3131c185_I20220630" decimals="-3" sign="-" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtNS0xLTEtMTU0NTEx_6da732e1-adcf-4b88-b8f3-f3250e35918d">35,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630" decimals="-3" sign="-" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtNy0xLTEtMTU0NTEx_e71e73b0-9236-4e5f-9ff9-d36817a05be5">35,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa147f94524d7496766953b7a86882_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtOS0xLTEtMTU2Njg1_f9378dd0-6b69-4265-abad-ee9faff11ef2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTEtMS0xLTE1NjY4NQ_d170702c-5a34-4241-884c-6afec2347b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTMtMS0xLTE1NjY4NQ_793f86a0-b43e-4aaa-81c0-cda0a1af3e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTUtMS0xLTE1NjY4NQ_5b33dbc1-f7b6-406d-9c62-684e75752cf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fce1c2f895246eebae070dfcc9e49e9_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMS0xLTEtMTU0NTEx_94cf8153-08ca-409b-8616-b41395bdd735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a38f2819984010b545afc636533f8b_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMy0xLTEtMTU0NTEx_421da6f4-7c16-4416-a4cd-55452f10fcbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5803bf99b3b473cb7589dbc5dab874f_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtNS0xLTEtMTU0NTEx_90eb2349-6615-4963-9f51-1e4bb54dae80">8,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b8f5d307bb4b9b990828c40cf681b4_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtNy0xLTEtMTU0NTEx_bd9b76c6-0633-43e7-a8c2-2feb18bb81ec">8,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf836c86dd4f40bf98e8953f69ac75fd_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtOS0xLTEtMTU0NTE4_fc12f7dc-78a2-462f-9adc-df3d83e05c3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e58c615de2f4b659329480870108ef1_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTEtMS0xLTE1NDUxOA_110eebe6-ecba-4aa8-a287-f4f787f04c91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83281e2c15c7428f83706175489d6339_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTMtMS0xLTE1NDUxOA_1e97bdbe-912f-4239-9684-ff151e16cd87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57b86b9d1184e09887d985686c79f0a_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTUtMS0xLTE1NDUxOA_ead25be1-f741-4884-b7ba-c78db9f16208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMS0xLTEtMTU0NTEx_de5a8594-e367-443c-bc37-33475dd05737">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40208096a5d4db6b4b3971989763e71_I20220630" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMy0xLTEtMTU0NTEx_3ce5a370-d2bb-4c1b-9961-7be2699cbb93">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctNS0xLTEtMTU0NTEx_894d02ce-5ef8-4912-8c0e-08a257521cc2">43,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctNy0xLTEtMTU0NTEx_2a1470ca-448d-469f-9342-0afdc71b32f2">43,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctOS0xLTEtMTU0NTE4_033fc2b7-c031-4c67-9bf4-a93bfe0c611e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTEtMS0xLTE1NDUxOA_d0503ccf-1409-4dca-8440-30cce26d5e46">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTMtMS0xLTE1NDUxOA_ede317ba-8fb5-45f7-8e99-22168f135a2b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTUtMS0xLTE1NDUxOA_2b890611-514d-4e34-9693-1d041d839edd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Milestone Acceleration Option (defined below) recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet. See Note 8&#8211;Non-Consolidated Affiliates for additional discussion.</span></div></ix:nonNumeric><div style="padding-left:36pt;text-indent:-18pt"><ix:continuation id="ic37d9f3b720e497ba84edcd8e7b8ffee" continuedAt="i38b65ea3935543839ae67424acb6b60f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments as reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i38b65ea3935543839ae67424acb6b60f">June 30, 2022.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized gains of $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI0Mw_1924d930-b57d-4321-9468-7ec3107ac57f">8.0</ix:nonFraction>&#160;million and losses of $<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI1Mg_8efb5c4f-5a22-4be9-8300-0cd5a16e6b82">28.1</ix:nonFraction>&#160;million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI2MQ_268595f0-de6e-478e-8be1-d70bc1435d14">28.3</ix:nonFraction>&#160;million and losses of $<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI3MA_ac2d664a-2336-48b1-9ad2-51d88eb102eb">10.7</ix:nonFraction>&#160;million, respectively, on equity securities still held as of June 30, 2022.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="i8828fa2ced154bf695eb6120fd47b2a1" continuedAt="idf68a859e0e744e9b841c9bc8f13040b"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0ODE_df372bd9-3f0c-4668-b41e-1a0357f67264" continuedAt="id9f9f03bacc644c5a82b41b410578936" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the underlying debt securities, related forwards and funding commitments (in thousands): </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0ee976221e43ac94bfd0056a40c5bc_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xLTEtMS0xMzQ1MDU_78d04caa-60bc-4510-a63f-623d40515e40">62,538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9140bfbcfc3e413ea3287f2bb5976940_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0zLTEtMS0xMzQ1MDU_334a5b2d-74e1-496c-ae7e-e2b770a85ae3">314,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4fabb30765e4fef8c46e1acdc00d9dc_I20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi01LTEtMS0xMzQ1MDU_01abab29-d893-4f3e-9067-60fe4f70e6f8">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba21e49a07e840aeb4ca72218e5782fe_I20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi03LTEtMS0xMzQ1MDU_4ac6f24d-e5e9-49b7-b066-3585cfefa038">8,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd0ae0498ad4e29b327a69dfe2286e8_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi05LTEtMS0xNTQyNDU_03ae4c04-0baa-4fc5-a22c-13aec12a563a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d03139bb3743808afda3b7bddd5bc2_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi05LTEtMS0xMzQ1MDU_29b9a250-f628-4ef6-bc11-b553b5d554d4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35b86bd79ef41a28f7e6d1d00c42f48_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xMy0xLTEtMTM0NTA1_a66879f4-eb49-463c-a530-0a0b5c13bbc2">226,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8317e61e1f41c784239c68f2108a60_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xNS0xLTEtMTM0NTA1_9ae7017f-be27-491d-8bca-d7f38f4c7d45">22,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0xLTEtMS0xMzQ1MDU_c6b9e0b1-ebbc-40ed-9151-da0a51b1744d">28,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0zLTEtMS0xMzQ1MDU_ba74b5da-0065-4cef-90b3-d010ee14e966">14,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cce41829e46588da12635d7616283_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy05LTEtMS0xMzQ1MDU_9e4f0705-1c10-4521-ab7b-a2bac7d511f1">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0xMy0xLTEtMTM0NTA1_cfa0c690-11a3-4ec3-8858-00a6dd65134f">17,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNS0xLTEtMS0xMzQ1MDU_dfbcf76a-931c-485d-b0b2-135c0acf8031">21,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353de01dbec74abcad269b32e3cdb25f_D20220401-20220630" decimals="-3" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi05LTEtMS0xNTU2Nzc_7406521f-b7a4-4e3f-8a77-c5004a7dd273">71,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (1) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi0zLTEtMS0xMzQ1MDU_787fc43f-7c17-4aa8-88dd-e60bf48fd2ce">9,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi0xMy0xLTEtMTM0NTA1_7a66c011-55bc-44b5-868c-94fac0847893">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0zLTEtMS0xMzQ1MDU_3bee7869-579a-4ea2-a3a3-03e0b2c4af3d">31,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy01LTEtMS0xMzQ1MDU_75bb872b-80d9-458b-85de-29bc6dd5420a">38,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa854c1e4c4436a8ea3e2512d5ef979_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy03LTEtMS0xMzQ1MDU_ecd28a31-fe83-450b-967e-8e3e087f4bef">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0xMy0xLTEtMTM0NTA1_b69a8669-cfd8-4de7-9365-d79b20f38250">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0xNS0xLTEtMTM0NTA1_7b91e413-ac81-46e8-b83e-c487e102ac91">13,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0zLTEtMS0xMzQ1MDU_c5cdab8d-c7f2-4483-b73a-43250bd4dc87">8,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC01LTEtMS0xMzQ1MDU_9a9c7885-8fa8-4bcc-bda1-f05b951fad75">8,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0xMy0xLTEtMTM0NTA1_aedd764a-9f55-446a-9e4b-939f2e893faf">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0xNS0xLTEtMTM0NTA1_419e8f62-cc57-4f9d-8faa-38493962c772">5,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0xLTEtMS0xMzcyNTk_a175a561-f1f4-430c-a39b-19fc19f74de6">40,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0zLTEtMS0xMzQ1MDU_aeb04367-f362-4bb6-b507-b4a9ddbd8dfa">15,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0xMy0xLTEtMTM0NTA1_0fb6f2d4-b217-483b-a117-3b2570b440de">15,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c70708fcd054afa8e309da96db8d7d5_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMS0xLTEtMTM0NTA1_01ea2717-4246-4fe5-9f7a-2d40ec36b440">28,785</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365769dd85514fa18d6a39ba5d363336_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMy0xLTEtMTM0NTA1_bab84060-5ba1-4afa-b736-06c171577eee">363,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtNS0xLTEtMTM0NTA1_6d9a0475-0b96-43bd-9394-45f3a3b13bc6">28,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie06ed27505284260adf0648d3d31568f_I20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtNy0xLTEtMTM0NTA1_6261351d-8e87-4d16-9f16-db96d6dd8d84">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTItOS0xLTEtMTU0MjQ1_b7a24184-0ade-42e9-a7d7-0973361eb17a">71,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a1621fc32f497988a0e96ba9b1feef_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtOS0xLTEtMTM0NTA1_96e1f514-6224-4850-b6a7-8a69d238c654">21,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d029a55997348e4a5f520d12893009a_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMTMtMS0xLTEzNDUwNQ_c6cc323f-a7dd-43ac-8297-e9ee1afd276d">240,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2661ba948f9948bf99cd3662bded664b_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMTUtMS0xLTEzNDUwNQ_f5364520-7be1-43d6-adaa-6d23463d281c">30,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82dc1c2627b4d718f85effdf12e3a8a_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xLTEtMS0xMzc0NTY_7c45fd03-da6c-4781-91e6-2a09839eb80a">43,013</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369c65d0b3874042b691cd5c31ea13dd_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0zLTEtMS0xMzc0NTY_cba5b80b-0894-46f4-8352-97317db19a2f">253,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4925acb858a43cc8cc6487a6f052e4a_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi01LTEtMS0xMzc0NTY_230d3ea5-9d58-4d6b-9373-480e0b656f89">16,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2625fc2cdae04a5a832d2df168c76071_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi03LTEtMS0xMzc0NTY_a4d24253-ee83-465c-830f-61bacef7944d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf40b5c13abe46518f36da6af058fe32_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi05LTEtMS0xNTQyNjk_068dff00-5d75-404c-8f76-4009e436b8a5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eaac71ae55f4517bcccf4879bb27679_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xMS0xLTEtMTM3NDcz_c90e52f5-23fe-4765-8807-65254f86919e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb1edf8c46140688a4ed0d57e3927b1_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xNS0xLTEtMTM3NDc1_4b46d4cf-a3d0-4a85-8e58-e340fa9715a8">214,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18d1f6254b04c1eaf3b2e9a61f02662_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xNy0xLTEtMTM3NDc1_bbb719ec-70e4-47c6-8164-1c0f3f66d991">18,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xLTEtMS0xMzc0NTY_2ada3eb4-9a8f-46fd-8d59-b7ef3c694f0b">28,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0zLTEtMS0xMzc0NTY_aca7bce3-d193-4d6f-b09d-047ef24e156c">79,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8320a1e985dc497d99e7ee8e4fb2680c_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xMS0xLTEtMTM3NDcz_8bc63012-beaa-416b-b961-70f1e061b68d">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xNS0xLTEtMTM3NDc1_5108b7f3-1adf-4c6e-b49c-3be2bf8ef22c">35,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNC0zLTEtMS0xMzc0NTY_e46e2086-f032-46cb-9936-5ab7a5cd7ee5">9,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNC03LTEtMS0xMzc0NTY_0a16fdcb-3397-4b99-b467-2e6e72014936">9,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNS0xLTEtMS0xMzc0NTY_12f15e37-d81b-410d-b098-eefa63a86cbf">2,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe40e0e708a24e1485c00e06f6c33811_D20220101-20220630" decimals="-3" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi05LTEtMS0xNTU2ODg_4e75656e-cd0d-4c39-9b72-46c7b7ccbffd">71,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi0zLTEtMS0xMzc0NTY_b0ae9039-f82d-4822-b59d-2470537d2f0a">10,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi0xNS0xLTEtMTM3NDc1_84e570c6-077c-4ad4-87f2-61bb9c189b2f">11,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0zLTEtMS0xMzc0NTY_2f485fbd-ecc1-461f-b842-baebf8ca212d">30,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy01LTEtMS0xMzc0NTY_3aed7439-871a-4b10-8527-79b9fac273c2">22,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy03LTEtMS0xMzc0NTY_cdedd0c0-9d98-47ab-97bb-9b4acbcb77ae">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0xNS0xLTEtMTM3NDc1_02413f0c-1f7a-4274-89c7-6d275bfc3f7a">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0xNy0xLTEtMTM3NDc1_a712cbb6-c309-4a70-b946-7e71f82e994d">22,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0zLTEtMS0xMzc0NTY_e2fdf13d-865c-4c74-a172-1dd57940e585">10,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC01LTEtMS0xMzc0NTY_f27c3896-3b91-41cc-b20c-b653d8e31f85">10,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0xNS0xLTEtMTM3NDc1_d37bc46c-ac98-4026-9dfe-dc0c0ebb06ba">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0xNy0xLTEtMTM3NDc1_e103ea5e-7d63-4499-abf8-cdfe0ced5054">10,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (5) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOS0xLTEtMS0xMzc0NTY_ee130cf9-0f1e-4705-8a51-e42eaea96868">40,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTAtMy0xLTEtMTM3NDU2_c8613d5c-600e-4189-8c02-a308ddc76b24">31,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTAtMTUtMS0xLTEzNzQ3NQ_659a3877-2365-4e17-a10e-adb9eab795ff">31,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c70708fcd054afa8e309da96db8d7d5_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMS0xLTEtMTM3NDU2_002f2f7e-882e-4b88-8c3e-0dcaa3aa87f3">28,785</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365769dd85514fa18d6a39ba5d363336_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMy0xLTEtMTM3NDU2_670442c6-5eaa-45b2-b0ee-75943e99649d">363,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtNS0xLTEtMTM3NDU2_b3306a5f-3a27-47ee-9067-b08a17a55cb0">28,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie06ed27505284260adf0648d3d31568f_I20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtNy0xLTEtMTM3NDU2_89f6d4fd-6ab4-41a7-8cda-1560e7c6cedf">8,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTItOS0xLTEtMTU0MjY5_8432beb3-6222-498b-9c76-79f2a60b1362">71,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a1621fc32f497988a0e96ba9b1feef_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTEtMS0xLTEzNzQ3Mw_7b513c1d-fd21-41be-b625-d37e7c46fac0">21,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d029a55997348e4a5f520d12893009a_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTUtMS0xLTEzNzQ3NQ_b5e4b750-7447-45aa-8df5-dd00685dd745">240,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2661ba948f9948bf99cd3662bded664b_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTctMS0xLTEzNzQ3NQ_d136b8e4-3af1-42f3-80cc-42c8d2d41c24">30,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="idf68a859e0e744e9b841c9bc8f13040b" continuedAt="ie8f1cacb2fe84e40889913d74d679664"><ix:continuation id="id9f9f03bacc644c5a82b41b410578936"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ApiJect Investment</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (&#8220;ApiJect&#8221;) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8&#8211;Non-Consolidated Affiliates for additional discussion. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#8217;s assumed cost of debt, which would impact Cytokinetics&#8217; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of <ix:nonFraction unitRef="number" contextRef="i2a44308643464db9804f8317e68d3593_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzg0ODI5MDcxNjUyNA_302df34f-36f4-4361-b344-159254539b7c">30</ix:nonFraction>% and an assumed risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i2a44308643464db9804f8317e68d3593_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzg0ODI5MDcxNjUyOQ_b62a8123-e827-4726-a2a9-f8528ddca6ee">15.2</ix:nonFraction>%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ie8f1cacb2fe84e40889913d74d679664" continuedAt="ie91f850be0b04ffbb75f2766d01b91e3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we purchased <ix:nonFraction unitRef="shares" contextRef="i62c078144e5641bebb3f8f5b775cc14f_D20211101-20211130" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfNjI1OA_f818197d-24e5-4541-95bf-c19065217e0a">3,846</ix:nonFraction> thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;), calculated based on the volume-weighted average price of BioCryst&#8217;s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for <ix:nonNumeric contextRef="ic5b00b1196a842a18ae4bbfc65e35bca_D20211101-20211130" name="rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfNjU0Nw_41337f28-1bab-4439-ba0d-746f7f79f59c">six months</ix:nonNumeric> following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#8217;s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of <ix:nonFraction unitRef="number" contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzU3MzQxMjc5NjE4NTU_0543c8cd-b33d-44fb-a47a-b96776b99bc3">two</ix:nonFraction> times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630" decimals="-5" name="rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfOTQwNw_0ab61c84-bc8c-4d98-b1cb-985314588aee">15.6</ix:nonFraction>&#160;million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $<ix:nonFraction unitRef="usd" contextRef="i5940ed238dbd4c118100d14a7e5ad7a1_D20200201-20200229" decimals="-6" name="rprx:DebtSecuritiesAvailableForSaleFixedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfOTY0Ng_0d6356ae-445c-4a56-99fd-b76034afbaee">250</ix:nonFraction>&#160;million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630" decimals="3" name="rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTA0MDg_ebaef0c4-41c6-4d2e-9611-cb25f4ab427f">13.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1dc0e13f8a8149dda55dd457a53e6897_D20210101-20211231" decimals="3" name="rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTA0MTU_b6f94d50-7174-41c3-b4aa-08ad141c589d">9.5</ix:nonFraction>% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="ie91f850be0b04ffbb75f2766d01b91e3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (&#8220;Milestone Acceleration Option&#8221;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $<ix:nonFraction unitRef="usd" contextRef="i49ec77ad5db44776871a0182cf263586_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUzMw_2187986c-ab7c-4e74-b55c-2be20f11c52b">71.8</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUxNw_d10f61af-f646-4857-a083-f2525ca6c8b7">63.2</ix:nonFraction> million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUyNQ_57eb65ff-90a9-4f94-b212-5cb7db09a95f">8.6</ix:nonFraction> million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i49ec77ad5db44776871a0182cf263586_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUzNw_2187986c-ab7c-4e74-b55c-2be20f11c52b">71.8</ix:nonFraction> million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the &#8220;with-and-without&#8221; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzc_465f9ce6-c45f-4fb3-b855-ada96b633a39" continuedAt="i6c359410d5e743768f97b4cdee2e5854" escape="true">Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i6c359410d5e743768f97b4cdee2e5854"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8b4208854b4a00a19fae7046aab65c_I20220630" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi0xLTEtMS0xMzQ1MDU_e9b9d671-82f6-4006-8036-fb998f21ea6f">18,254,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d52494a67e479ebd68a8c3b8f69060_I20220630" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi0zLTEtMS0xMzQ1MDU_761c246a-e4e6-4b66-865b-3ce7654c80bd">13,423,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adddf24c7f04202a9c712798093983a_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi01LTEtMS0xMzQ1MDU_ec004fde-eb26-42d5-b69a-0e76c536ff2a">19,047,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caf3f5c79647e18539159493607558_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi03LTEtMS0xMzQ1MDU_b0e0fa64-1f0c-4cf7-91f8-b38632a235e8">13,718,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:FinancingReceivablesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjcyNQ_2a11fa6e-00fb-43b0-b5d9-cb40ec53152a" continuedAt="i045de1ab0c5842c7b009f203b0c6e86c" escape="true">Financial Royalty Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i045de1ab0c5842c7b009f203b0c6e86c"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjcyNg_b94538ad-c0ea-404c-8979-98dac2a368a9" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy00LTEtMS0xMzQ1MDU_75219c8a-ec54-4a21-ae87-3424f348be72">5,347,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy02LTEtMS0xMzQ1MDU_a0973ad9-4d47-4008-a217-ae5b5fbb959e">54,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy04LTEtMS0xMzQ1MDU_2cae58d8-26a3-4af8-85d4-1f8fc450225d">5,293,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC00LTEtMS0xMzQ1MDU_8e316cb1-4a17-4fc3-83d1-4a28b048b07e">1,759,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC02LTEtMS0xMzQ1MDU_9cf41af8-2470-420d-96fe-e1c052791085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC04LTEtMS0xMzQ1MDU_ccd7a554-38b1-4e4b-9c21-42c2071b3bb6">1,759,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861968b06bc49ad84cee28144700724_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS00LTEtMS0xMzQ1MDU_61251ca3-c1ec-4f10-a63c-5ec69f5acc37">1,439,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2861968b06bc49ad84cee28144700724_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS02LTEtMS0xMzQ1MDU_52324e8e-6336-4d7c-9c5a-a14d69c922be">417,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861968b06bc49ad84cee28144700724_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS04LTEtMS0xMzQ1MDU_a4071429-5f43-4d07-b0b8-51c389a26a74">1,022,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi00LTEtMS0xMzQ1MDU_80e73025-9c88-4d5b-9b39-6fa1e7aa12b4">1,053,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi02LTEtMS0xMzQ1MDU_acaf5fca-fe44-4a7e-bdc2-bcb8ad7c6034">153,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi04LTEtMS0xMzQ1MDU_c9002b20-4eb0-43dc-8c1e-1286bad6309f">900,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy00LTEtMS0xMzQ1MDU_fea6078e-63a0-404f-b7fd-5849af116086">876,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy02LTEtMS0xMzQ1MDU_3814b5b9-d192-4cd0-bed2-76848e4f8d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy04LTEtMS0xMzQ1MDU_5a7778f6-f884-495a-89cf-3cd2286a269c">876,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC00LTEtMS0xMzQ1MDU_cd4bb549-43bd-4acf-b798-ac3bf1183ebe">746,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC02LTEtMS0xMzQ1MDU_901e6896-eea0-44fa-814f-c94a91c95130">1,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC04LTEtMS0xMzQ1MDU_ef0a272d-e8bd-47bb-ac4d-8442980c8b2d">744,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212af950addc45e6a29921885da2a4e0_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS00LTEtMS0xMzQ1MDU_cbb1abc7-9bbc-4c65-9381-5985db8c6b5a">4,824,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212af950addc45e6a29921885da2a4e0_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS02LTEtMS0xMzQ1MDU_0928882f-a46e-4600-b61d-18457ad03484">1,110,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212af950addc45e6a29921885da2a4e0_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS04LTEtMS0xMzQ1MDU_9bcea861-83d9-4fad-8efb-f55cc327bb0d">3,713,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtNC0xLTEtMTM0NTA1_c6f4c1d3-d6d8-483a-98f2-3a695198a518">16,048,153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtNi0xLTEtMTM0NTA1_935a910f-d75d-4cda-9f71-0d7ad8d8fa7a">1,737,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtOC0xLTEtMTM0NTA1_497eb7b3-fd47-4bd2-a76f-c93b98b2ff2e">14,310,718</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTEtOC0xLTEtMTM0NTA1_79bf8094-4c24-422b-8ed4-3f6cf30463fd">247,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTItOC0xLTEtMTM0NTA1_5c332427-71a9-4ff5-8811-6461020cad70">14,062,873</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $<ix:nonFraction unitRef="usd" contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630" decimals="-8" name="rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMTUzMQ_5ae7fbdb-9c6f-479f-9ae4-045ee9ea44be">1.3</ix:nonFraction>&#160;billion. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy00LTEtMS0xMzQ1MDU_af5b21a2-cb94-4e5e-b3d2-58f3ae22e468">5,335,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy02LTEtMS0xMzQ1MDU_a6e3e477-ea96-4cdc-8080-665c3eff9488">48,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy04LTEtMS0xMzQ1MDU_4b1bcd65-d8c5-40c1-a6f3-ef21a5735c6d">5,287,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9473a880a5344144a8d65facb9f75109_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC00LTEtMS0xMzQ1MDU_038faadd-c507-4af7-be25-713c9b28f0b7">1,846,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9473a880a5344144a8d65facb9f75109_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC02LTEtMS0xMzQ1MDU_06409fe8-25e1-478c-8cac-f1b724373e3f">16,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9473a880a5344144a8d65facb9f75109_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC04LTEtMS0xMzQ1MDU_4c1898e8-7411-49e2-8be4-1b3283833a6e">1,829,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS00LTEtMS0xMzQ1MDU_b8335ea1-5f64-4d30-b967-fff6919d0880">1,438,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS02LTEtMS0xMzQ1MDU_701b27f3-9a4a-4868-aa0f-3b313c50b13c">236,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS04LTEtMS0xMzQ1MDU_558cd39e-7aff-4512-a2dd-3e68496105ef">1,201,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi00LTEtMS0xMzQ1MDU_af226c96-0712-4881-8cd9-a37ca0060094">1,100,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi02LTEtMS0xMzQ1MDU_9408f105-b571-4d36-b8e1-01fe10e7ae23">172,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi04LTEtMS0xMzQ1MDU_607bc52f-7641-42ad-8057-4d0890aecca3">927,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy00LTEtMS0xMzQ1MDU_0e8cde75-ccd1-4c61-9247-b3d780be7b29">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy02LTEtMS0xMzQ1MDU_6d7aaac2-55df-4105-9c65-8ff80063d965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy04LTEtMS0xMzQ1MDU_0e646ee6-a2b6-4819-b439-d295b2edb4d2">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC00LTEtMS0xMzQ1MDU_afbdd0e9-7d82-443d-982e-b6f45bf6d304">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC02LTEtMS0xMzQ1MDU_a2ba76ba-7a84-4b24-b4f8-1c55f0679ab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC04LTEtMS0xMzQ1MDU_ba99c2d3-46a3-4d35-b675-0587995744a7">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS00LTEtMS0xMzQ1MDU_636d978b-b3cb-494e-a384-08ad18187439">4,697,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS02LTEtMS0xMzQ1MDU_83d9acb3-3a32-498e-85ef-262542d6587f">909,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS04LTEtMS0xMzQ1MDU_08229189-e0c6-473b-8fc4-8105cb4be281">3,787,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtNC0xLTEtMTM0NTA1_4ec8b753-fc15-473a-98cd-7ff6381209e5">16,027,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtNi0xLTEtMTM0NTA1_d6df23cb-7138-46a9-b279-02adc458711e">1,384,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtOC0xLTEtMTM0NTA1_cdce5ca5-4444-4bd4-8a40-751068805f27">14,643,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTEtOC0xLTEtMTM0NTA1_31ca04b1-fe32-4b4e-8b6a-a502e94020ee">310,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTItOC0xLTEtMTM0NTA1_cc4c1a69-44f8-4755-8fad-7c99fc19ed25">14,332,596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $<ix:nonFraction unitRef="usd" contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231" decimals="-8" name="rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjU5Nw_b36b7eb4-dc9d-40d1-8fcd-5419e6dcd271">1.3</ix:nonFraction>&#160;billion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTM3MQ_dd506a5a-e552-4ad5-9554-842696330f1f" continuedAt="i2b9a230d44aa4777ac128f4686966bab" escape="true">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2b9a230d44aa4777ac128f4686966bab"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets and includes the following activities:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTM3Mg_b474b0b0-7c98-4acc-826f-1fb7ee8cc2d9" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfMS0xLTEtMS0xMzQ1MDU_68c89a0f-d9df-4a36-b0d6-afd2904c8333">1,694,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfMy0xLTEtMS0xMzQ1MDU_bb9d3cc7-2931-4083-93a2-8b0bc0ccc752">556,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNC0xLTEtMS0xMzQ1MDU_473702cf-5929-4d40-84ac-66e4309c46cc">202,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNi0xLTEtMS0xMzQ1MDU_690f7133-2145-44bd-83dd-14decb99285d">62,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNy0xLTEtMS0xMzQ1MDU_4d7bc90b-1d0f-4ccf-a262-a0e908abd880">1,985,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-5" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTE1MQ_00f72ee9-d46e-416c-b305-811cf4414fda">310.8</ix:nonFraction>&#160;million related to cumulative allowance for credit losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTE3NA_7b6fc11e-53dc-4f00-b4e0-9d1002f6fca0" continuedAt="i4dd13cbcccf44f03baf39450dda2b5ad" escape="true">Intangible Royalty Assets, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4dd13cbcccf44f03baf39450dda2b5ad" continuedAt="i91dc83a812334599980fd6759b428abe"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTE3NQ_5c7f1dbf-1fc9-4c2a-8385-969467e0825a" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi0xLTEtMS0xMzQ1MDU_8ad13d25-5dd4-45a7-808e-36a1855f14d2">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi0zLTEtMS0xMzQ1MDU_f0518f47-a1fb-4c67-8d96-9160ad3bf487">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi01LTEtMS0xMzQ1MDU_f35996ce-42d4-435b-8976-7a2e00d2d86d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC0xLTEtMS0xMzQ1MDU_90c6fba4-131c-4eb4-bbaf-a6c43545697e">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC0zLTEtMS0xMzQ1MDU_cdea0c26-0576-4efb-9261-99186204c99a">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC01LTEtMS0xMzQ1MDU_d690f8e1-889f-414d-bdb1-03edfff10c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi0xLTEtMS0xMzQ1MDU_d07ec405-102d-415d-8f4a-b8d413e58a2e">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi0zLTEtMS0xMzQ1MDU_661899bb-4ebe-41ab-8d89-8b457eb0bf32">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi01LTEtMS0xMzQ1MDU_00736960-bf9f-4d57-a8ba-f9f51406cc15">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC0xLTEtMS0xMzQ1MDU_a70515a7-ec72-4370-aa61-08ab05783688">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC0zLTEtMS0xMzQ1MDU_3b0ab977-3980-4151-ad7d-1dc4de5112ad">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC01LTEtMS0xMzQ1MDU_33a730b0-5d87-4edd-84da-eba6a0f5d630">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91dc83a812334599980fd6759b428abe">Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for <ix:nonFraction unitRef="number" contextRef="i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTA5MQ_4e61bd4b-1053-4a93-9ac9-abe499791eff">90</ix:nonFraction>% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for <ix:nonFraction unitRef="number" contextRef="i618646a4dc484b23bb5596e4471fb6fe_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMzI5ODUzNDg4NDgxNw_a1c477f2-c52d-47a9-a28b-1e3d50dcf79a">93</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7a1ee997727d476f941c9f5cb772f235_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMzI5ODUzNDg4NDgxMQ_572bf45d-a6da-4710-8281-39bef5c2ce19">94</ix:nonFraction>% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzgxNw_0666193a-d3bd-4fdc-95bb-06653a0b5585" continuedAt="ic1381892adf047d6a2ba09b30cdc3839" escape="true">Non-Consolidated Affiliates</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic1381892adf047d6a2ba09b30cdc3839" continuedAt="i053c38f9b30f4d8a8a030b1e6876f0a1"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the fair value of the revenue participation right was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $<ix:nonFraction unitRef="usd" contextRef="i9fb0f3822f7448c3b9edb5542ba8571e_I20200211" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNDQy_a0ad8f5d-98d3-4310-a38d-d633b6108bda">303.7</ix:nonFraction>&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $<ix:nonFraction unitRef="usd" contextRef="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjczMg_a2c2ac07-8e89-4571-af67-53632087151a">4.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1652d07294b14089a0592537d2026e6f_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjcyMw_16ede580-146e-4bef-8c5d-62bedd07227a">9.3</ix:nonFraction>&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded income allocations of $<ix:nonFraction unitRef="usd" contextRef="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc2MA_6f75b05e-7af5-4f3a-a95f-1de47ec62faa">25.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i373eee1b26c541e8833b248c7988a139_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc3OA_3d5ea6dc-83de-44c7-9a65-f3033df3c7fa">30.8</ix:nonFraction>&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received cash distributions from the Legacy SLP Interest of $<ix:nonFraction unitRef="usd" contextRef="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc4Ng_45c20585-e8c9-483f-a3ad-05d5f7d07312">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1652d07294b14089a0592537d2026e6f_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc5MA_6ce016be-c238-4f03-bbc3-a34bdec9fe46">14.1</ix:nonFraction>&#160;million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $<ix:nonFraction unitRef="usd" contextRef="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjgxMg_634aaad6-d27b-45d1-96e6-3f6b5f1feb41">4.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i373eee1b26c541e8833b248c7988a139_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjgzMA_93de74b8-76fc-492c-a52b-e351a2967209">8.6</ix:nonFraction>&#160;million in the three and six months ended June 30, 2021, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (&#8220;Avillion I&#8221;), BAv Financing II, LP and its related entities (&#8220;Avillion II,&#8221; together with Avillion I, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $<ix:nonFraction unitRef="usd" contextRef="ife00a507d4204c9bbdf7447e8c4d1429_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjQ3Mw_9993cbea-b1e6-40bd-bfa4-e8689f002f93">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i84eb422d2b40477e9258c52a15372639_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjQ3Nw_700274dc-e9f4-43e0-aac6-b1e1cb8b24c7">8.2</ix:nonFraction>&#160;million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $<ix:nonFraction unitRef="usd" contextRef="i620523eb4a204e25acac2ef3e9967411_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjI5Nw_302f2163-5cd0-422e-8e3e-a5845e78731a">7.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1bbd0e73cf3d42dcac55b07236105ba5_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjMwMg_c5128122-4108-42b7-bd93-471db5145a45">15.0</ix:nonFraction>&#160;million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $<ix:nonFraction unitRef="usd" contextRef="i79fa516152564be089415fb655f74d77_D20210101-20210630" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMjk1Mw_0085ee38-76b2-48dd-87c5-fcee8122f3dc"><ix:nonFraction unitRef="usd" contextRef="i8fef318c94084992aa959a03e78ce32c_D20220101-20220630" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMjk1Mw_e8733eed-6971-492d-bd04-988982902174">13.4</ix:nonFraction></ix:nonFraction>&#160;million during each of the six months ended June 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i053c38f9b30f4d8a8a030b1e6876f0a1" continuedAt="if1d3af0917324fd9bf37940b4f8d2b36">In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $<ix:nonFraction unitRef="usd" contextRef="i156b8175434d4e1db0d0fd57caa92008_I20220630" decimals="-5" name="rprx:OtherCommitmentIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzI5ODUzNDg5NzAwNQ_b4dacb61-70fa-45b0-930d-c0e966ece60f">27.5</ix:nonFraction> million, which totaled $<ix:nonFraction unitRef="usd" contextRef="i156b8175434d4e1db0d0fd57caa92008_I20220630" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzIwMg_52b1be59-9887-447b-a2d2-42261b6ddb97">150.0</ix:nonFraction>&#160;million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.</ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if1d3af0917324fd9bf37940b4f8d2b36">Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $<ix:nonFraction unitRef="usd" contextRef="i30c73e53d86c471680151e41da485930_I20220630" decimals="-5" sign="-" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzU4Mw_aeaaa7a3-d148-490d-a4bd-d5109f24e430">35.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibdda7de8d7244be2b32f9b7e729092c6_I20211231" decimals="-5" sign="-" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzU5MA_13b91990-ec33-497c-a06a-a20320487d49">11.2</ix:nonFraction>&#160;million, respectively, of unfunded commitments related to the Avillion Entities.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTE1NA_b5e3787a-5b98-410b-8152-9eb62615a83a" continuedAt="i5b42f03b32f24eaa87692cd099c46803" escape="true">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="i5b42f03b32f24eaa87692cd099c46803" continuedAt="id9fe811f8eac4befb25c39f72f176355">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&amp;D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&amp;D funding arrangements. </ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9fe811f8eac4befb25c39f72f176355">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ2Mw_ca6cd136-0e2a-4167-aad1-c5f4f4d02a05">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ2Nw_b726acce-e516-4768-ae23-3b0b25a2af73">101.1</ix:nonFraction> million for the three and six months ended June 30, 2022, respectively. We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ3MA_2b059804-6fac-4dea-b663-da8cd0f1842a">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfNjQ5_1983e0ba-1ac2-4ba6-9e16-3bbb7ff3a870">5.8</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&amp;D funding expense primarily related to upfront and milestone development-stage funding payments of $<ix:nonFraction unitRef="usd" contextRef="i691fe772f8474c9883cd86d770776fc5_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfODM4_b238926b-5ba0-499e-8998-bf52040d3431">100.0</ix:nonFraction>&#160;million to Cytokinetics to acquire a royalty on a development-stage product candidate.</ix:continuation>  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1Mg_4f245d60-a137-4722-99c5-da09ffcabec3" continuedAt="ife1247db59f544a4941baa5b11c3884c" escape="true">Borrowings</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ife1247db59f544a4941baa5b11c3884c" continuedAt="i384b7bb3f7f64eeba81a2645f4d468f8"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1MA_91abeddc-7257-47a1-9c8c-cfaa4ab2eaa8" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N180_e4b91e22-fa13-4527-9052-772f2293d233">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N184_2ee4eb60-1a62-4423-9f84-45828cbcab35">0.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i5277bbde55dc4ff3aac4ba9a24308df5_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N18yMg_cd065912-8f52-48b6-b1db-95707fd028a2">99.322</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi02LTEtMS0xMzQ1MDU_4de273f5-ea97-407d-99a5-49ad5569e1ef">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5db792457664c249f4f34f68ae84ee7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi04LTEtMS0xMzQ1MDU_c4756ff8-5ca0-475f-a0e1-9d7cb357e458">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3998c09aa68e48dfba459528066155e1_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV80_138b6fdf-9a68-44cb-8d66-a44d5d6380eb">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i3998c09aa68e48dfba459528066155e1_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV84_1a007df8-a1aa-43da-a8a5-4b7ee31f909a">1.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i2520a38f28f24d8abe1664a0fa276108_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV8yMg_55ebd9ba-2fd6-4f48-b5c3-9e4a90fb0ea1">98.875</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3998c09aa68e48dfba459528066155e1_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy02LTEtMS0xMzQ1MDU_8ae693f8-2112-4fac-bc39-7466abbe7e1d">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb3b048ad644ef7a5f6894758c0ec22_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy04LTEtMS0xMzQ1MDU_25eb21e7-6cf5-41b1-a5a3-16e14d01336a">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM180_1e2db740-ba9f-4012-b035-339903fdef5c">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM184_37df300d-ae0b-4f9c-8d03-e7fe9bd87be8">1.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="iba61f5d65e924374ba352a9226aa644b_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM18yMg_45eb5d3c-84a8-4461-9935-f1f03129af3b">98.284</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC02LTEtMS0xMzQ1MDU_03465f21-edf9-4593-bb4a-3abcb2440cfe">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6514393b77b142479d7fa249d2437d74_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC04LTEtMS0xMzQ1MDU_04b3b615-4528-4944-b8cc-bc35c954aebf">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y180_6f47dfd3-91c6-4fe4-8c84-05dbe255e129">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y184_f8149a9b-5d5b-4c84-b3ae-598a0dfe83b4">2.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="id9de03c81c754dc7bb15c6c52caf92be_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y18yMg_b14ac08e-dd13-4f5d-bca0-79a072458227">97.760</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS02LTEtMS0xMzQ1MDU_b9e6fc36-ca1b-4382-8fad-5fff61de32fc">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813d79deba2f4673b7dfac7f74be1e42_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS04LTEtMS0xMzQ1MDU_c4306426-deaf-40e0-a97a-9b9b9ef1c26b">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM180_e6ef2460-7ca1-4bff-ad33-515538263429">600,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM184_eeeb5f58-d8e5-4572-9e3c-190e2128baf4">2.15</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i9ca85d756ed8402091fc1700a7ab767b_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM18yMg_3cb7581c-671d-4e97-a822-03259363402c">98.263</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi02LTEtMS0xMzQ1MDU_18737704-0dd9-4b4b-8cc7-ce2c447b5ffe">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54640267ea864316a9bed44de2313208_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi04LTEtMS0xMzQ1MDU_a83fcbc1-ce51-45a5-bba9-55498f601701">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i89293daeea364b87a0f53da7fa772357_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y180_c88e7a83-a295-4ceb-9d99-e096682de22c">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i89293daeea364b87a0f53da7fa772357_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y184_86abcbf0-3cfc-46cd-b58c-7a1896fa33c5">3.30</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i22abfbc03ed3462fa495b3d35e9f63c2_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y18yMg_240140e5-f696-4d6b-90fa-abf3a2216247">95.556</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89293daeea364b87a0f53da7fa772357_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy02LTEtMS0xMzQ1MDU_8a58a07e-997e-497f-a208-1f9e6c1c07b8">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f4360f02cb429f873526aa4abb90b4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy04LTEtMS0xMzQ1MDU_3a0b4e1f-7b7f-4453-83d6-588c5f15ea1e">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i850321a4707144d5aa10067c9606b155_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV80_b788e105-76da-4bad-981d-572938724deb">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i850321a4707144d5aa10067c9606b155_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV84_47ecb2f6-8ab1-466b-aee1-9087f7ed8700">3.55</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ibf45fa61bd9d44eaa6acb1fcc1c764c2_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV8yMg_8f733cbb-5d2a-4bc8-8545-d4f0a8f53bb6">95.306</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i850321a4707144d5aa10067c9606b155_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC02LTEtMS0xMzQ1MDU_3e90f607-26c3-44e3-821d-98451103d925">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66677b99bf9e422f895af82a4346163b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC04LTEtMS0xMzQ1MDU_4ee01477-8651-48a8-8268-a0ee556dd1e5">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM180_ddd019f1-721d-4bc8-b88a-b8af4294f92b">700,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM184_b6fa5999-edf3-4379-b964-56c5d8afed5a">3.35</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="id77ed6261fc14df9845a99e3f1b47d5a_D20220101-20220630" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM18yMg_0df47ac9-e038-4795-af1a-788ecbf10db3">97.565</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS02LTEtMS0xMzQ1MDU_a631b87d-34d1-4dda-a858-cd8a0bfa48d1">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38fcca043734f5c8ff85a24cb230791_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS04LTEtMS0xMzQ1MDU_5006b54b-d74e-42fb-8c74-365a5d46ff28">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTItNi0xLTEtMTM0NTA1_ca72079d-1ba0-473d-86f0-8fa48a454a60">193,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTItOC0xLTEtMTM0NTA1_cd9f9816-d248-40ca-bc6a-204d44a234b0">203,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTMtNi0xLTEtMTM0NTA1_17c32ba1-864f-4d90-9f10-8d19033e3b15">7,106,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTMtOC0xLTEtMTM0NTA1_5b702fa4-066d-4506-9458-67ac9930210b">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTQtNi0xLTEtMTM0NTA1_2f04ebaf-850d-413e-9b94-a36d5a57a223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTQtOC0xLTEtMTM0NTA1_b7af7ab4-267e-4c8d-9433-2d08d77a4a74">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTUtNi0xLTEtMTM0NTA1_9a50ff86-8115-462c-ac6e-b992d320852c">7,106,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTUtOC0xLTEtMTM0NTA1_fe0b3f47-d4a0-44f1-81d0-d46a944e990e">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="i384b7bb3f7f64eeba81a2645f4d468f8" continuedAt="i8c7ce5344aa74f5a85098906e9c5e3c1"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="ie5a03d177ab2440997f9376d5899a918_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTUy_8566e543-3c48-49db-ad51-e5cf59952e79">1.3</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $<ix:nonFraction unitRef="usd" contextRef="ia0c7820636114a409ceede5a921b1d09_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjEz_55ea0708-b9d6-4f83-98a0-eb7d56642555">600.0</ix:nonFraction>&#160;million principal amount of notes due September 2031 and $<ix:nonFraction unitRef="usd" contextRef="i3197e12bdd3a4d309fc770d7447285e2_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjY1_a28cdbca-309c-4aba-9342-5d138d687c9a">700.0</ix:nonFraction>&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="ie5a03d177ab2440997f9376d5899a918_I20210726" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTU2_cd3503ca-a855-41a5-8d6a-f05ddd8eef5c">27.5</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i3197e12bdd3a4d309fc770d7447285e2_I20210726" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTky_637b831a-c627-4e7b-8202-81675a9b91ae">12.3</ix:nonFraction>&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i164ffc87f86f4075b11ef1a172aeefb8_I20220630" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNzYw_e149412f-bda8-4db3-8404-8e53f489a30d">2.80</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i164ffc87f86f4075b11ef1a172aeefb8_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNzY3_2f40b976-d613-45cf-99ec-76e10d76a5f6">3.06</ix:nonFraction>%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfODE5_f9e1d5cb-f7ef-4f3b-ba8d-0be2392f1273">6.0</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTMzNw_e9be1bbd-e994-418c-a3aa-700f60403b03">149.0</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTM3Mw_ae76c43b-d962-4174-b4f6-abd696509a23">40.4</ix:nonFraction>&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="5" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTU0Mg_5993b85e-9c05-48f0-82ad-6531c785013c">2.125</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTU0OQ_484627b1-61ff-4abf-8130-6b1d1b6829e8">2.50</ix:nonFraction>%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i1e250b66e64341b09584ce80e7cba81e_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTg5Nw_54af2e21-cd66-4090-ae02-cdcdec1e4fd8">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="iba76a3f80e5c49e3948452772ef55ef9_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjU5Ng_a589ed3e-66eb-4b03-8723-4a84f2fd1654">101</ix:nonFraction>% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $<ix:nonFraction unitRef="usd" contextRef="i4c364b452a2e4075809d3b9b42a5c9e7_I20220630" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzA4Ng_28126d2e-e57f-4cc6-ad0c-8fbca5dd15b2">5.9</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i022d32cb77944ea29be1667bb225e44a_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzA5Mw_4a76d525-83d7-43a0-bd1c-d69d01bfab94">7.2</ix:nonFraction>&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a <ix:nonNumeric contextRef="i8378863f6fb54944bdf6267872f7e32a_D20200918-20200918" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1MQ_3f92e421-9ba0-4f7e-9a36-ebc0da14d455">five-year</ix:nonNumeric> unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="ifc406544d3744be8af475bd920f1691e_I20200918" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzU1OA_bf6ccaf0-3487-4c51-9e51-a1c7bd64431b">1.5</ix:nonFraction>&#160;billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="ia209b3983b4840c0a0ae77de9566e43b_I20220630" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzcxOQ_01f65993-7dfb-4ecf-b3ce-b5549a58b465"><ix:nonFraction unitRef="usd" contextRef="i1cd001fdda914fffa3ca20031e15926d_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzcxOQ_28be45b8-8fb8-4206-af2d-be1b8d418708">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus <ix:nonFraction unitRef="number" contextRef="id3f318ef84894bd4b707d34d44ab34f1_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA1Mg_3a949644-57df-4ebc-a657-3038cf594e1f"><ix:nonFraction unitRef="number" contextRef="i2a66b8b6943547f2808825744d348a6a_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA1Mg_7ce12486-f2c6-462e-93a5-6cdd7bb5b689">0.5</ix:nonFraction></ix:nonFraction>% and (3) the one month adjusted LIBOR, plus <ix:nonFraction unitRef="number" contextRef="i3b0545a0e18343f2842f30b29d72abac_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA5OA_9da36584-3121-4713-aa87-00ef23284f6a">1</ix:nonFraction>% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="i8c7ce5344aa74f5a85098906e9c5e3c1" continuedAt="i4283302ceff0473f9087d3cd810a9c14"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below <ix:nonFraction unitRef="number" contextRef="ifc406544d3744be8af475bd920f1691e_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDc1MQ_08157693-13e4-44b9-93d0-3178b17b78ae">4.00</ix:nonFraction> to 1.00 (or at or below <ix:nonFraction unitRef="number" contextRef="ifc406544d3744be8af475bd920f1691e_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDc3OA_50de9472-5334-494b-99e2-aca3c77c7a73">4.50</ix:nonFraction> to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above <ix:nonFraction unitRef="number" contextRef="ifc406544d3744be8af475bd920f1691e_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTA2Mg_53c6392c-e8db-4a32-b9ab-b68ca637f599">2.50</ix:nonFraction> to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1NQ_b6bfc054-d9f2-4915-9749-09d9d7bd41e1" continuedAt="i2fd489e1390244fbae4e5851c2f59552" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfMi0yLTEtMS0xMzQ1MDU_852edc94-a0dc-4af8-9757-e776e35bcb61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfMy0yLTEtMS0xMzQ1MDU_0c95d7fe-8ea9-4890-882e-0992e44eea85">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNC0yLTEtMS0xMzQ1MDU_3a53d909-0c16-41c9-a58d-c9036a94e2df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNS0yLTEtMS0xMzQ1MDU_f79460be-8554-4fc1-b1e3-7224a6ccee95">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNi0yLTEtMS0xMzQ1MDU_668bbf90-c730-44eb-81e3-6d13b71d6ce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="rprx:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNy0yLTEtMS0xMzQ1MDU_1b9ed2b2-91c8-42d3-b5e8-3b115ffa780e">5,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfOC0yLTEtMS0xMzQ1MDU_a30ca25e-ce45-46fc-96f6-785894515067">7,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i4283302ceff0473f9087d3cd810a9c14" continuedAt="i9d244cb3fc654c01935565d43d6b34c6"><ix:continuation id="i2fd489e1390244fbae4e5851c2f59552" continuedAt="i111d97ebb90f4a8baf4cbc586a32f628">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="i9d244cb3fc654c01935565d43d6b34c6"><ix:continuation id="i111d97ebb90f4a8baf4cbc586a32f628">Excludes unamortized debt discount and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icf036923cf324ce78882338a4fb17702_I20220630" decimals="-5" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjAzMQ_70bf26f6-2b0e-4e46-afeb-2d9678133942">193.8</ix:nonFraction> million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTI5NA_5441d47a-50c4-4ed1-945c-65655e5921b9" continuedAt="i208b72757d244444b4283f6e965689dd" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i208b72757d244444b4283f6e965689dd" continuedAt="i4e15512857db49e6b9fef8fe6079664a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="class" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:NumberOfClassesOfVotingStock" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTg_ca22c2ec-2f6a-4937-a8e4-650962be4fc2">two</ix:nonFraction> classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has <ix:nonFraction unitRef="vote" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:CommonStockVotingRightsNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTU4_3f1b9511-404d-438b-97f5-c6c923001c2f">one</ix:nonFraction> vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had <ix:nonFraction unitRef="shares" contextRef="if43def283e414c978ef1f9e00d58466d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTA5OTUxMTY0NTU0OQ_cca67210-1f64-4597-b1df-72e85f810501">437,139</ix:nonFraction> thousand Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="i19484314d7814df68d24568f06200a2d_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTA5OTUxMTY0NTU4MQ_89d6fc08-0168-42ed-98ed-2399524ec2a8">170,081</ix:nonFraction> thousand Class B ordinary shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a <ix:nonFraction unitRef="shares" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:CommonStockQuarterlyConversionBasis" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfODI0NjMzNzIyODY0NQ_a07b0282-b657-4570-94a7-ff827db580d0">one</ix:nonFraction>-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of <ix:nonFraction unitRef="shares" contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTM1Nw_7b8cce4f-de33-44ab-b3b4-c54adef05c71">365,302</ix:nonFraction> thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue <ix:nonFraction unitRef="shares" contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTM5Mw_188e2982-5c4c-4a6b-98fc-378135bed760">50</ix:nonFraction> thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i464e075cb1d04ed28a402c8f7149fe47_D20220101-20220630" decimals="2" name="rprx:RedeemableStockRedemptionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTYxMw_94a7366e-ace1-46a7-ac91-467721065777">1</ix:nonFraction> each.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="i4e15512857db49e6b9fef8fe6079664a" continuedAt="ifc943dafc4d94ed2a9b700a6b022af72"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTI5NQ_6e314a88-c276-43a4-983d-07e118ae9f26" continuedAt="i42156d5afc414f2ebd1f3bc1ff2eb0e2" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in the balance of our <ix:nonFraction unitRef="noncontrolling_interest" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:NumberOfNoncontrollingInterests" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTY4Nw_b5c9ac30-0bdd-47e4-9240-83bb897ea340">four</ix:nonFraction> non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f4135a52e24cdc8a877de0528e91ef_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS0xLTEtMS0xMzc3MTg_e41de92e-7437-4a64-9766-a4a732ce5e3d">8,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957a4d6b1a8f46acaeae11abefb3a081_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS0zLTEtMS0xMzc3MTg_cc688db5-edb9-4d3f-a086-bc6f231c2d40">1,756,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ac24325a784997a2a2834a39d26946_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS01LTEtMS0xMzc3MTg_5a6844a3-ce8c-4d24-a6b4-192710318d62">2,599,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife05da3ee4b44968baca4702397077dc_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS03LTEtMS0xMzc3MTg_160c5086-435f-48f2-b561-41aabeefc3c8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS05LTEtMS0xMzc3MTg_8fe5442b-a303-4ae8-b415-1fadc306df93">4,364,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi0xLTEtMS0xMzc3MTg_b95c9a4b-427d-4225-b2a9-521a94bb7326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi0zLTEtMS0xMzc3MTg_bf7ca6be-f4fa-4cf6-bc0f-c324c5075cd7">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi01LTEtMS0xMzc3MTg_554aedac-58e5-47e3-acd5-bee7684cdd54">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi03LTEtMS0xMzc3MTg_4d63fd75-ab6b-4f9f-a384-3e78b28f7e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi05LTEtMS0xMzc3MTg_80e20955-8fa5-46ac-b5ae-2a341adbf582">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy0xLTEtMS0xMzc3MTg_9b9f1d79-05df-4268-b3b2-1db78d0c0861">5,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy0zLTEtMS0xMzc3MTg_4b04c0ca-21ed-450c-b197-49a7e01d85c2">103,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy01LTEtMS0xMzc3MTg_14417410-9e3c-457e-ad31-9895d1d3d68e">37,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy03LTEtMS0xMzc3MTg_8366e96d-d1bf-427d-af0e-1fdf34e8ee64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy05LTEtMS0xMzc3MTg_b0801318-f89a-4584-9c13-234cbf421f69">146,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC0xLTEtMS0xMzc3MTg_577f81e8-efe8-485b-aea8-0fb463fa917a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC0zLTEtMS0xMzc3MTg_1cb752d5-9f19-4841-8660-d674dfec3066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC01LTEtMS0xMzc3MTg_7db0a167-bc12-48c2-ae05-c877e3939331">26,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC03LTEtMS0xMzc3MTg_909225e5-07a8-4a2d-a9bc-191f2c2df2ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC05LTEtMS0xMzc3MTg_e258ce30-edaa-42a8-9308-ab532aaa9942">26,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS0xLTEtMS0xMzc3MTg_0eccef71-7f69-4717-a09a-71dba92f2299">6,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS0zLTEtMS0xMzc3MTg_3981be84-f4bc-4b3e-9c33-cf9806cc1f6d">61,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS01LTEtMS0xMzc3MTg_d255cded-1bc0-462d-8dd9-86be7a008d85">119,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS03LTEtMS0xMzc3MTg_6d1949f1-bebd-4b8d-938c-9c71c274769f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS05LTEtMS0xMzc3MTg_52e267f4-8322-491a-97b2-1b44abab0ee2">187,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy0xLTEtMS0xMzc3MTg_67fa1400-d26e-4245-9a82-04ac5a8aa114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy0zLTEtMS0xMzc3MTg_0648c41d-4740-4318-9c0c-2875187e7731">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy01LTEtMS0xMzc3MTg_13859898-e1c7-424b-9097-7bf6c9fd0949">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy03LTEtMS0xMzc3MTg_c97c2eef-6915-45fa-b55f-724b7980d329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy05LTEtMS0xMzc3MTg_c21f336e-7ae1-449c-a5c7-d3678ac068e8">3,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC0xLTEtMS0xMzc3MTg_22fec25f-35d4-478d-b1d5-3728277ecb8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC0zLTEtMS0xMzc3MTg_7ae9cc58-bd43-4b00-bf86-bb1445d292a2">1,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC01LTEtMS0xMzc3MTg_ffe090be-8991-4289-802f-e314202e5c19">1,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC03LTEtMS0xMzc3MTg_36435eeb-2ecd-4e38-91a6-9ad41ffa2615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC05LTEtMS0xMzc3MTg_b63b86ea-6b31-4b1f-940f-9315948f8a26">3,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ff712c0f0e4721b11f310c9a7ba814_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS0xLTEtMS0xMzc3MTg_a3dfcce7-69c7-4400-8765-2dbcc12d5d45">8,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS0zLTEtMS0xMzc3MTg_3d673c09-991f-44d8-8a76-985af8601abb">1,716,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac973f489d7a4fc9ac38195a2164de93_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS01LTEtMS0xMzc3MTg_27ecab41-f6de-4139-a9e7-92437cc82846">2,655,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie068a9d4a59444e886f94818184da48d_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS03LTEtMS0xMzc3MTg_59465d97-7eec-4ecf-8a6f-7b3ac1b7f9d4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS05LTEtMS0xMzc3MTg_6012390d-f650-46d0-95fa-2b21eee357ef">4,380,938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0d9dd3824945d09335073108634a8b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS0xLTEtMS0xMzQ1MDU_c1f7ca5f-ddb8-41d6-b1cf-f3317ecdb204">13,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d62fb2227b41378a04fa7cf96ec2e1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS0zLTEtMS0xMzQ1MDU_e7dde938-1c73-47c1-b03f-8366aa4d00d1">1,809,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac8a13c10554d4e8c579493cc60ccd0_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS01LTEtMS0xMzQ1MDU_92de21c6-deee-4c4b-a799-3fbb73e66bc5">2,649,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4eb9e0f8c94eca9757ffe4eb666c7f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS03LTEtMS0xMzQ1MDU_c54c15d8-b64f-4c68-8707-2e3cc54dfe75">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS05LTEtMS0xMzQ1MDU_f2a8d462-7441-4cd4-8487-0ac01a1d0303">4,471,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi0xLTEtMS0xMzQ1MDU_ef0ed4c6-403b-4cf9-94f4-84dcdf0ddd92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi0zLTEtMS0xMzQ1MDU_3d3e94ed-38f6-465c-9364-166359550533">3,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi01LTEtMS0xMzQ1MDU_87d422dd-0d86-44cd-a47c-a642f5882c2a">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi03LTEtMS0xMzQ1MDU_fe1e17b0-c918-4350-a000-125495bef16d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi05LTEtMS0xMzQ1MDU_1256e588-c6c1-4fbd-a12e-a279081a319c">6,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy0xLTEtMS0xMzQ1MDU_c5ca4749-c29a-4320-8e59-796f43ac8c2e">16,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy0zLTEtMS0xMzQ1MDU_59686974-57ff-4b6f-b567-3e692f9b7900">207,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy01LTEtMS0xMzQ1MDU_d68dbcfe-c40a-4a4b-bb46-6bf19aa00a66">72,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy03LTEtMS0xMzQ1MDU_12b0a6a0-2a0a-4f59-bdc8-9d55c75b7c0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy05LTEtMS0xMzQ1MDU_7fcb40ef-a304-4d50-8b32-f3fa3d08bc6f">295,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC0xLTEtMS0xMzQ1MDU_afe55ff2-40e7-4dfb-91fb-0001e5660210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC0zLTEtMS0xMzQ1MDU_c0587210-3ab0-4abb-8ee3-72bf069565b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC01LTEtMS0xMzQ1MDU_62a48790-db2e-45ce-8b73-5506f9e36b41">62,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC03LTEtMS0xMzQ1MDU_de62901a-d17c-47c6-b743-d4c7aa2014eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC05LTEtMS0xMzQ1MDU_b37ecf77-7bc1-4305-9557-75ddf7318f45">62,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS0xLTEtMS0xMzQ1MDU_ea082929-6060-45b3-9c71-c745c521b439">11,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS0zLTEtMS0xMzQ1MDU_a8225916-d77b-4efa-a548-dff4e002acbc">112,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS01LTEtMS0xMzQ1MDU_e20c74ef-b26e-4e14-984e-231676abcf58">139,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS03LTEtMS0xMzQ1MDU_2be4a858-7ee9-4699-8388-ae364c024f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS05LTEtMS0xMzQ1MDU_5b15aca7-ad39-4520-ae5b-a2f5a69db50a">263,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy0xLTEtMS0xMzQ1MDU_c3a51e7f-4eec-492a-8601-b69defac1b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy0zLTEtMS0xMzQ1MDU_da1c2a5d-b34a-42d1-85c2-a3f97359045d">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy01LTEtMS0xMzQ1MDU_dd34d82c-3440-4043-af9b-a51c4d8b1756">2,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy03LTEtMS0xMzQ1MDU_10226780-5fcf-44cf-9615-996ec1556f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy05LTEtMS0xMzQ1MDU_4ba81249-72f7-4b57-8b45-74afa413a02e">4,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC0xLTEtMS0xMzQ1MDU_01d4bb83-2ecb-4bf9-8ac3-74a64a2ca668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC0zLTEtMS0xMzQ1MDU_ed3e9f57-e0fe-43b1-a0c8-9f0e1c3fba5c">2,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC01LTEtMS0xMzQ1MDU_89fde489-282c-4bfc-8384-2b14a90b24a4">3,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC03LTEtMS0xMzQ1MDU_39c83f25-6b0b-434c-afb7-53fdd3adc2cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC05LTEtMS0xMzQ1MDU_9e6c728e-b817-498c-94f0-2b5172ec18cb">6,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ff712c0f0e4721b11f310c9a7ba814_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS0xLTEtMS0xMzQ1MDU_51a5fdb1-c095-4413-b806-2d59a3181b85">8,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS0zLTEtMS0xMzQ1MDU_45a16ac3-e920-4621-9b83-9f1265bd23ce">1,716,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac973f489d7a4fc9ac38195a2164de93_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS01LTEtMS0xMzQ1MDU_f028377e-d9da-458f-832e-733657ce1666">2,655,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie068a9d4a59444e886f94818184da48d_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS03LTEtMS0xMzQ1MDU_12291253-ae65-400a-a448-8494e7bbb038">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS05LTEtMS0xMzQ1MDU_45bced38-dc69-4629-9153-d7b1abf04265">4,380,938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094b01ea23224dbd8928efbf7993356b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS0xLTEtMS0xMzc3MDM_f2825f15-6d35-4283-b24e-16716f3e16ac">13,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88246dd04abf4793a1634e975c03750b_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS0zLTEtMS0xMzc3MDM_f13f7e43-4ed9-471f-a9e4-fe67552d8566">1,882,655</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715821bde2d34b7aa686a6dfe08ae077_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS01LTEtMS0xMzc3MDM_f0cdc320-494a-4971-b7ab-d106114fbe41">3,058,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771cb54e67794bd7841999b1e5270715_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS03LTEtMS0xMzc3MDM_53b17080-5837-43be-8520-b053dbe970ee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2ebd58086471fbf60d5e06704e135_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS05LTEtMS0xMzc3MDM_ebbc3c88-eefa-418c-90c8-6c945dc18170">4,954,818</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi0xLTEtMS0xMzc3MDM_a803ff0d-6004-4ca2-a713-716a559dc9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi0zLTEtMS0xMzc3MDM_b7855884-b617-4d4c-996f-2bbb0288b70c">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi01LTEtMS0xMzc3MDM_85c34ab8-8214-498b-92ff-5126dd1449b7">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi03LTEtMS0xMzc3MDM_62ad463b-3865-48a4-9261-693a7bf9e899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi05LTEtMS0xMzc3MDM_6c83eef2-e1ec-4f04-8b27-7545ad23fc1b">11,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy0xLTEtMS0xMzc3MDM_15422376-76eb-4ecb-ac11-e32c45da1223">12,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy0zLTEtMS0xMzc3MDM_1fba16fa-9088-418f-9404-9ca3dd662b00">127,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy01LTEtMS0xMzc3MDM_ff46aecf-1101-4cc5-9257-39807bc2fba6">30,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy03LTEtMS0xMzc3MDM_7c1323c5-3aaf-4955-b39d-e4af7b5dc5dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy05LTEtMS0xMzc3MDM_9da5ba06-5171-48b5-8a98-38cf42dc7278">170,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC0xLTEtMS0xMzc3MDM_a023a9b4-24de-4d49-a592-3ba645ee92ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC0zLTEtMS0xMzc3MDM_337fe10c-5316-4e28-a006-92236b418147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC01LTEtMS0xMzc3MDM_b224ae0f-af5e-49b1-bc27-74d8389b651e">486,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC03LTEtMS0xMzc3MDM_8d8e31da-cf95-4583-a791-5040b2d6b942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC05LTEtMS0xMzc3MDM_15c52d0c-4f44-4bed-80f2-2b07f57b4b87">486,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS0xLTEtMS0xMzc3MDM_a2d7cadf-b678-4e97-a3d4-e67074c8602e">19,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS0zLTEtMS0xMzc3MDM_a258f282-c84f-41a7-a0e3-ee06250e63f2">133,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS01LTEtMS0xMzc3MDM_862d9d4e-9c8e-473e-8ea9-e8a9c58ce4ab">212,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS03LTEtMS0xMzc3MDM_451fe8bb-a8ed-4c5c-8cc1-5fe85c05698a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS05LTEtMS0xMzc3MDM_76ea38aa-b04c-4c49-aee1-48cf60abcd87">365,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy0xLTEtMS0xMzc3MDM_d339fdd4-6918-4fc0-be50-3a766efe6d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy0zLTEtMS0xMzc3MDM_1c12cf14-ed2e-4850-84fb-ca21fc40ec28">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy01LTEtMS0xMzc3MDM_be10319a-c622-4c34-ace7-038b57b16d9e">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy03LTEtMS0xMzc3MDM_33729060-d174-45be-a467-e425889e4583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy05LTEtMS0xMzc3MDM_3c5d1133-5a73-42f4-bf10-d12a9262f1ac">2,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC0xLTEtMS0xMzc3MDM_268457a5-372f-45ca-b6b3-e04f00c063c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC0zLTEtMS0xMzc3MDM_cf1ec595-d867-4e03-9db3-2bbf88375c31">2,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC01LTEtMS0xMzc3MDM_7ddeaf25-ce4d-48d9-8f28-f70e7aea7867">3,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC03LTEtMS0xMzc3MDM_5c324dfc-503d-4357-ba9e-ce4c27fd1fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC05LTEtMS0xMzc3MDM_4da59712-64ee-4b0e-a62a-98861c1b18b9">5,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8b00699867481fb50c4fef1515ba9e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS0xLTEtMS0xMzc3MDM_b5053d77-7db5-4b51-ab02-c8c6ccc3a288">20,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a9d91774c148d1bb20516e42535cc5_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS0zLTEtMS0xMzc3MDM_df332561-71e2-481b-bfa8-ee7fbc73f56d">1,894,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS01LTEtMS0xMzc3MDM_f09aba59-15da-44eb-a49d-4afb072e9aea">2,757,019</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20897a0731394ab39cdbf6f569451ecb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS03LTEtMS0xMzc3MDM_e4ce1fb8-0414-4050-822b-2ede9c28b155">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS05LTEtMS0xMzc3MDM_e6a99d5f-c902-4f7e-9d95-837f1fd9d157">4,671,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="ifc943dafc4d94ed2a9b700a6b022af72" continuedAt="i339f7e435cc64a71b870379a1f997396"><ix:continuation id="i42156d5afc414f2ebd1f3bc1ff2eb0e2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564ee5a80f984273b26344ca0417004e_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS0xLTEtMS0xMzQ1MDU_db0a337a-e720-49b7-b42e-2962e0e6ad43">12,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbbfac68ec4488cbbc6b6f3a3f7e632_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS0zLTEtMS0xMzQ1MDU_6e422040-14d7-4fae-b624-47fe458d5be3">1,939,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70dd8a979be46a0a140e37dcbc10470_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS01LTEtMS0xMzQ1MDU_9a8ba915-4f81-4960-a7f7-12798174c034">3,125,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a1efb8258c4f90b003132a7c806d37_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS03LTEtMS0xMzQ1MDU_11bb9b14-2ff0-4e8b-912f-97b348e86458">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3f673cf22e4af289ea139885dca16b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS05LTEtMS0xMzQ1MDU_446a7462-5016-40b5-81e1-3f263c631a6a">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi0xLTEtMS0xMzQ1MDU_96727dfb-8743-492c-bfec-f75da4f1261d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi0zLTEtMS0xMzQ1MDU_55baded5-a6cc-4c55-98ed-e411ab5c381f">9,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi01LTEtMS0xMzQ1MDU_5ded4d76-2b40-4c5f-900d-733a40ebbb01">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi03LTEtMS0xMzQ1MDU_30c647be-319f-4438-95fc-1892511185de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi05LTEtMS0xMzQ1MDU_62e8ffdf-9233-4900-91b7-1af8dc19280c">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy0xLTEtMS0xMzQ1MDU_e5607c13-58d1-45f0-a2c8-26b84368ef4f">26,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy0zLTEtMS0xMzQ1MDU_b8461c37-110a-4e16-9237-597022c4f011">222,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy01LTEtMS0xMzQ1MDU_c0290032-0b73-4a21-af02-8c111c88843a">67,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy03LTEtMS0xMzQ1MDU_a27168c1-dbe1-4ea2-bb1e-e1a11629bf77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy05LTEtMS0xMzQ1MDU_8c384712-7f67-4abb-a388-57fe0c933793">316,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC0xLTEtMS0xMzQ1MDU_d1584274-578b-4123-bd20-a84ebc0683a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC0zLTEtMS0xMzQ1MDU_2b832f11-d582-4ef6-adbe-ccea1a3da3c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC01LTEtMS0xMzQ1MDU_547d629a-eb7c-42a6-8fa4-2057acd51454">551,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC03LTEtMS0xMzQ1MDU_6f9f8d8a-1f60-4627-9482-7d44a4e0c24d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC05LTEtMS0xMzQ1MDU_99a1f894-5cb8-48d7-b6c5-3e7b744041b4">551,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS0xLTEtMS0xMzQ1MDU_901c0269-c34d-4d9f-827c-3096df42e5e0">34,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS0zLTEtMS0xMzQ1MDU_214c641b-85b5-4dca-9a3d-c9a83389a329">170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS01LTEtMS0xMzQ1MDU_89d1905f-178c-4d0b-8169-cbdc5d3e4e77">251,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS03LTEtMS0xMzQ1MDU_fbf6f5c4-203b-4e87-a2a8-a45001d619a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS05LTEtMS0xMzQ1MDU_5e0466dd-212f-4e57-a5be-022c4d895db5">455,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy0xLTEtMS0xMzQ1MDU_41175d46-cf05-4c1b-ad5e-c2426c3fd964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy0zLTEtMS0xMzQ1MDU_8710328b-a850-4a12-a32f-0c2229655f1f">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy01LTEtMS0xMzQ1MDU_23f29124-62ab-44b2-aa48-0ffe3702e715">3,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy03LTEtMS0xMzQ1MDU_9a3c373b-b926-46c0-a1b1-5703573c691f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy05LTEtMS0xMzQ1MDU_66cb7c07-2e38-4ab6-b07a-a2cdbf5ee580">5,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC0xLTEtMS0xMzQ1MDU_222282b0-e562-427b-bc15-da7ec42f2e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC0zLTEtMS0xMzQ1MDU_1340947e-11f5-4596-958a-141d47acf7b0">5,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC01LTEtMS0xMzQ1MDU_191cf229-9a16-46c6-9e34-bd5eadaf86cb">8,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC03LTEtMS0xMzQ1MDU_cde7563f-bb32-4fcf-9170-be49a5be2102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC05LTEtMS0xMzQ1MDU_bd2851e7-d460-424b-bde5-5cc370330d3f">13,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8b00699867481fb50c4fef1515ba9e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS0xLTEtMS0xMzQ1MDU_57347799-0dfb-4932-9ba4-7e2d7299b422">20,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a9d91774c148d1bb20516e42535cc5_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS0zLTEtMS0xMzQ1MDU_0ea8b760-4661-44d4-9a21-dfef7d200662">1,894,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS01LTEtMS0xMzQ1MDU_97b09304-e461-4fcc-ba78-58133214cbda">2,757,019</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20897a0731394ab39cdbf6f569451ecb_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS03LTEtMS0xMzQ1MDU_e273b1e7-1079-4614-9003-09da28f3087b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS05LTEtMS0xMzQ1MDU_f50e6bac-4366-46be-acb3-98017d80e5e5">4,671,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Continuing Investors Partnerships&#8217; ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately <ix:nonFraction unitRef="number" contextRef="icd4499f27b8c415c83b4aa5e390c611c_I20220630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNzE0NjgyNTU5NDA1Ng_8c79126d-aba4-4ab8-8b7b-f17f36a9bf83">28</ix:nonFraction>% of RP Holdings with the remaining <ix:nonFraction unitRef="number" contextRef="ibd5518beaff545de976d2821f78d8146_I20220630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNzE0NjgyNTU5NDE3NQ_98ba299c-114c-498e-9a88-f4a91a8d1a1f">72</ix:nonFraction>% owned by Royalty Pharma plc.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest Held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDIwOA_4eda9c66-945a-49fc-a677-b00509bd6865">0.19</ix:nonFraction> per Class A ordinary share for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDI2NQ_3c4b2898-4ec4-4d22-9acd-ea5fbb538037">165.3</ix:nonFraction>&#160;million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDM3NA_da24dfbf-fa7f-4c3a-86bc-cacab63214c1">0.17</ix:nonFraction> per Class A ordinary share for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDQzMQ_54a96a9c-c1fe-4d8a-bf23-bb0e04ca75ce">138.6</ix:nonFraction> million to holders of our Class A ordinary shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby <ix:nonFraction unitRef="shares" contextRef="ie59134a7c071446a8dc6d06dd7272373_I20200615" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDY0Mg_1b846291-962d-4428-ba25-0903fab2a433">800</ix:nonFraction> thousand Class A ordinary shares have been reserved for future issuance to our independent directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:continuation id="i339f7e435cc64a71b870379a1f997396" continuedAt="i18354c633fcc467d9e8f8fc5e6d9d8fe"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTA3OA_49672dfd-6f0f-46b6-9d0a-09fcc25661d4">one year</ix:nonNumeric> as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18354c633fcc467d9e8f8fc5e6d9d8fe"> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMjA1MQ_09f626f7-d705-47b2-b3ca-1ed4362ee55e" continuedAt="ic880bd5ca0e1407aaa357ffdf8aa1631" escape="true">Earnings per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic880bd5ca0e1407aaa357ffdf8aa1631"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a <ix:nonFraction unitRef="number" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="INF" name="rprx:CommonStockExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMTE5NQ_a850c1ec-95cb-484b-8295-a1e7fce1893d">one</ix:nonFraction>-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMjA1Mw_7a05a003-8ffb-4bb7-bd2d-c6f8b52d2bb8" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy0xLTEtMS0xMzQ1MDU_166d6015-ac44-45cd-8c45-5ec810850332">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy0zLTEtMS0xMzQ1MDU_5978da10-a60d-4e00-9981-d472b50af96a">806,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy01LTEtMS0xMzQ1MDU_ea9b762b-b812-4f09-9d19-a8f324ec1beb">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy03LTEtMS0xMzQ1MDU_a5d0e3e7-b591-4230-ab33-c009aa3fe27d">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf25b5c44074bba8349a3ed917b9828_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC0xLTEtMS0xMzQ1MDU_af3dc8c1-088c-4501-8e1a-256328061f14">119,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da6075574744cd88689bc056f4784d_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC0zLTEtMS0xMzQ1MDU_4d17e0e3-3238-4f9a-9ea1-f83a6f095dee">212,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e85d625927d4a208e60107fcdc3e4d1_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC01LTEtMS0xMzQ1MDU_959faeb2-7b09-4a4a-bbb0-900f466c2227">139,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1723835775974da9ace43244c9bf89d4_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC03LTEtMS0xMzQ1MDU_be8dea14-3d41-49e3-acf2-5724b7fac0eb">251,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839baaa9ddce4c7a8bee9fbd533f440c_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS0xLTEtMS0xMzQ1MDU_b513dba1-8ab5-49e0-9556-eb27f564d513">67,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e57903f579943a3acd517f95ac47e2d_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS0zLTEtMS0xMzQ1MDU_d245232e-7de8-4d0d-bc06-85e542237db7">153,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf2318e4b6145d29623e3758709b640_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS01LTEtMS0xMzQ1MDU_01cefe2a-63e8-49c2-8f15-99bd340d4615">123,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716b09853e4a4174a28f2a27d873f6cb_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS03LTEtMS0xMzQ1MDU_11b51600-b9b9-4c58-a9dc-e25929e775ab">204,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi0xLTEtMS0xMzQ1MDU_360701bb-0067-4561-a4ac-fd3f7ea60a91">304,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi0zLTEtMS0xMzQ1MDU_727eddaa-49a4-43d7-acd1-590fabe3e08b">440,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi01LTEtMS0xMzQ1MDU_1d02b7c4-057a-4866-82d1-3ec5904eece3">356,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi03LTEtMS0xMzQ1MDU_9d87c56f-0975-418a-8ccc-fe99f54b7ac8">509,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy0xLTEtMS0xMzQ1MDU_0c0afd09-fd77-4204-8531-0e9097ee6d9a">119,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy0zLTEtMS0xMzQ1MDU_3df9b32d-5e1c-4982-91b1-33eee0b6ba56">212,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy01LTEtMS0xMzQ1MDU_fa2b61d6-4635-49d0-ba19-692cf58ae8b4">139,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy03LTEtMS0xMzQ1MDU_01f8b50c-3c87-4310-b168-baf134914a0e">251,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC0xLTEtMS0xMzQ1MDU_d390d06f-86a2-445d-807e-154f91beb7b8">423,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC0zLTEtMS0xMzQ1MDU_fd0cec41-217f-46fe-9c98-d2e9f73f1c2c">653,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC01LTEtMS0xMzQ1MDU_89189e3b-4412-4329-9ccc-56bfda5b40e0">496,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC03LTEtMS0xMzQ1MDU_74a68ff2-d8fa-48b7-9691-ddf1b231c22f">761,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtMS0xLTEtMTM0NTA1_1fd73a6e-a5b6-4055-b664-97acae6de46c">436,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtMy0xLTEtMTM0NTA1_0fabe635-298d-412d-b359-67b5226899c0">409,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtNS0xLTEtMTM0NTA1_599f00c0-2a68-4979-9675-0b2bdf84f8e8">435,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtNy0xLTEtMTM0NTA1_80f956cb-3eca-45f1-857f-654d64b0c616">399,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtMS0xLTEtMTM0NTA1_e0fbfd32-ca4e-4c6c-aa15-fc81a19c8a3c">170,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtMy0xLTEtMTM0NTA1_144bd189-7f59-42a7-a85d-4fd0565c27fe">197,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtNS0xLTEtMTM0NTA1_43130d09-0bfa-49da-8fa6-770d30d66718">172,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtNy0xLTEtMTM0NTA1_a8b49034-5538-4544-ad6f-cc5bc39a0ad0">207,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtMS0xLTEtMTM0NTA1_6f4acb05-d12a-4a57-8058-ca9a30853d4f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtMy0xLTEtMTM0NTA1_dea64a33-672b-4d06-ba2f-85a0dda1584b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtNS0xLTEtMTM0NTA1_efd46d93-da5a-4dbd-adf8-611671e53ce5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtNy0xLTEtMTM0NTA1_db43d133-b8b0-42c3-bd99-7501e0b663f5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtMS0xLTEtMTM0NTA1_ba4daf7d-4b9f-4b15-9c8e-5d0305a73510">607,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtMy0xLTEtMTM0NTA1_6a31d207-7909-4945-9f3e-c7062a389b23">607,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtNS0xLTEtMTM0NTA1_124762d3-cfd2-4a5b-8aef-93e264bf413b">607,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtNy0xLTEtMTM0NTA1_f7149a7d-c7e2-4685-ba18-a8403ec37d99">607,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctMS0xLTEtMTM0NTA1_1efe5991-c094-4bb5-95e8-cb81444388f5">0.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctMy0xLTEtMTM0NTA1_bfefc636-7691-430a-9f83-e87be8239514">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctNS0xLTEtMTM0NTA1_d73ba742-d119-4b92-9d6d-82e17a65f019">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctNy0xLTEtMTM0NTA1_363ec1e0-8b1c-4fc8-8388-fd230a4fa807">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtMS0xLTEtMTM0NTA1_7a0c0f1a-ea9d-4891-9743-b09d00e12f67">0.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtMy0xLTEtMTM0NTA1_cc79e26d-97dd-4fc5-b7aa-f822547785e5">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtNS0xLTEtMTM0NTA1_66fccad6-2f0f-4f1c-80b7-558f6ac855e3">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtNy0xLTEtMTM0NTA1_fc8a6a36-2c13-4b5a-bad0-65ca172376bc">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RleHRyZWdpb246NzI4M2I3ZTA3ZDY0NDc2MmE0NWQ2MjgzZDMyZWY5MjBfMTYx_90ceb5da-c6ab-40a8-9766-66d6aadb4fac" continuedAt="icf119d90b5c04bdb9275050b1e5bb27b" escape="true">Indirect Cash Flow</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="icf119d90b5c04bdb9275050b1e5bb27b"><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RleHRyZWdpb246NzI4M2I3ZTA3ZDY0NDc2MmE0NWQ2MjgzZDMyZWY5MjBfMTYz_74ee92b1-410f-47e6-821f-b6f27cd65b60" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMy0xLTEtMS0xMzQ1MDU_f5e71968-5416-4305-a590-2af122c004b7">619,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMy0zLTEtMS0xMzQ1MDU_094c304f-2b80-43d2-b263-c1a6e716b6f2">965,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNS0xLTEtMS0xMzQ1MDU_fe0f28ea-127e-47ed-bf70-c16986a55234">1,026,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNS0zLTEtMS0xMzQ1MDU_796246ff-24ec-4cf6-b9c3-87d78481c028">1,033,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNi0xLTEtMS0xMzQ1MDU_fddadb11-3117-4d32-be4e-fb9210139ba0">290,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNi0zLTEtMS0xMzQ1MDU_cc93ddca-978c-4609-8ee6-c45175a369fb">48,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNy0xLTEtMS0xMzQ1MDU_d161b735-b1a1-4302-8481-95385ab34200">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNy0zLTEtMS0xMzQ1MDU_8f7a1db2-ef48-46d9-ab43-48b6fdb88cd0">11,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfOC0xLTEtMS0xMzQ1MDU_a725cf94-51e8-4d37-b84f-efe85882a431">10,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfOC0zLTEtMS0xMzQ1MDU_96a2fcfb-1d58-4fb6-a8cf-058bc3d818fe">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTAtMS0xLTEtMTM0NTA1_ba531287-837e-48eb-80a1-bab03723fba4">71,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTAtMy0xLTEtMTM0NTA1_b88c6601-b7da-4026-862f-8abd48c90dad">4,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTEtMS0xLTEtMTM0NTA1_cc87a7be-8579-482d-a5d4-348337f3e6bb">28,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTEtMy0xLTEtMTM0NTA1_06964671-0310-49b6-a121-788a98387456">1,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTItMS0xLTEtMTM0NTA1_ce1573e1-ee09-405a-a8b2-4f92183f644a">1,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTItMy0xLTEtMTM0NTA1_e8f9a712-cdee-47e5-8953-576a1522617e">15,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTUtMS0xLTEtMTM0NTA1_6768d5a7-decf-4f6c-96c2-aad82d374e69">27,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTUtMy0xLTEtMTM0NTA1_d7268fc1-0065-4289-ae6d-5b4c9e81cd2f">22,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTktMS0xLTEtMTM0NTA1_8c953192-b183-4a74-880c-f5234f5cc998">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTktMy0xLTEtMTM0NTA1_3a05d0fc-0c13-4e27-8230-ecd4df355052">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjAtMS0xLTEtMTM0NTA1_00a4cc04-ec57-42fa-8a23-0787f2f1c617">16,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjAtMy0xLTEtMTM0NTA1_710d550b-45b1-452f-883e-528153234362">28,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjEtMS0xLTEtMTM0NTA1_7a7eb9cc-bf4c-4496-99b9-170c32145f79">53,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjEtMy0xLTEtMTM0NTA1_a343f920-63d7-4094-811a-ea87b40f6e86">23,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjQtMS0xLTEtMTM0NTA1_57632a90-eb9f-4438-9b27-186f90618223">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjQtMy0xLTEtMTM0NTA1_0a004f40-3d44-45ff-934f-3e487ee95835">2,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjYtMS0xLTEtMTM0NTA1_d1941593-4875-41ab-82b7-93d2c1a5ea2b">1,181,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjYtMy0xLTEtMTM0NTA1_82439d8c-7f82-4c95-a3f5-6dd3dec1bf76">1,094,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjgtMS0xLTEtMTM0NTA1_eaaccb50-64ac-43a2-81d0-e31d2c05dec5">35,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjgtMy0xLTEtMTM0NTA1_0949c627-c994-42fa-9400-267e20a512e4">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzAtMS0xLTEtMTM0NTA1_04811894-bf87-43c4-8a51-b0af1e941861">2,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzAtMy0xLTEtMTM0NTA1_445fd180-352f-4ee3-b845-324b3d84ac7b">4,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzEtMS0xLTEtMTM0NTA1_47b8fb06-1614-4933-adbd-71ba5e66f9ac">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzEtMy0xLTEtMTM0NTA1_21f1328b-9ffe-4d8d-9336-b3cb44a54865">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzMtMS0xLTEtMTM0NTA1_8a19ed21-4bbf-4306-a847-ec3329743559">6,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzMtMy0xLTEtMTM0NTA1_52cf4bfa-f00c-4ef6-95a6-8e0fb544da2a">913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzQtMS0xLTEtMTM0NTA1_b710fcac-505e-48be-85fc-5732f9362451">3,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzQtMy0xLTEtMTM0NTA1_f7cceb58-3ce5-4c1f-8ab3-0fe463e563b9">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzUtMS0xLTEtMTM0NTA1_d673c9f6-e6e6-4fcb-8cae-f9a60ee4a289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzUtMy0xLTEtMTM0NTA1_cd387cb7-75e3-43ec-9f3e-1de8c21154ba">2,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzctMS0xLTEtMTM0NTA1_c225d782-aa33-49d2-bae0-c3f773d6b7ee">1,035,222</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzctMy0xLTEtMTM0NTA1_7b29461e-4173-448f-874d-87c81f744834">1,057,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMjgyOA_095387b8-0937-48c5-b7f0-eeabe92406af" continuedAt="i0adf13f2368049cb80e10e3a715b2489" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i0adf13f2368049cb80e10e3a715b2489" continuedAt="ic1aa5f6b30a74f1fa801c0bd7e0ba1a8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitments</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various funding commitments as of June 30, 2022 as described below. See Note 3&#8211;Available for Sale Debt Securities for additional discussion of the respective arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-6" name="rprx:LongTermFundingCommitmentAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMjQ0_11aceaa2-7ab0-4c98-8040-91299b3b04d6">250</ix:nonFraction>&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipCovenantRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMzQ1_a18ed830-74f0-4f3f-984f-40beb597f9e5">50</ix:nonFraction>&#160;million if a certain contingency is met and has the option to draw the remaining $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNDIx_78532465-18b5-46ee-8d57-88cc10c3ddc1">200</ix:nonFraction>&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $<ix:nonFraction unitRef="usd" contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipExpectedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMTA0NDUzNjA0Njk3NTc_e39fa64b-4da0-4261-a998-4591acebc955">125</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMTA0NDUzNjA0Njk3Njg_78532465-18b5-46ee-8d57-88cc10c3ddc1">200</ix:nonFraction>&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i902af37f112d47b59465fb1587d35546_I20220630" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNTUy_9bd8c49e-e1fe-4628-82f8-138c68bbcd16">350</ix:nonFraction>&#160;million of the MorphoSys Development Funding Bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $<ix:nonFraction unitRef="usd" contextRef="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731" decimals="INF" name="rprx:CollaborativeArrangementExpectedProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNDM5ODA0NjUxOTEwNg_2ab8b718-f42b-49ba-81a2-e670b47a0a3d">300</ix:nonFraction>&#160;million under the Development Funding Bonds to be funded in September 2022.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="ic1aa5f6b30a74f1fa801c0bd7e0ba1a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Series B Biohaven Preferred Shares</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, we have a remaining commitment of $<ix:nonFraction unitRef="usd" contextRef="i212df1108fca4c628a85996199e48189_I20220630" decimals="-5" name="rprx:LongTermPurchaseCommitmentAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfODM2_7c1a7b3d-7647-4682-8464-a4e253e2c716">100.4</ix:nonFraction>&#160;million under the Commercial Launch Preferred Equity to purchase <ix:nonFraction unitRef="shares" contextRef="i212df1108fca4c628a85996199e48189_I20220630" decimals="INF" name="rprx:LongTermPurchaseCommitmentShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMzI5ODUzNDg4NjI3NA_dd37a0fd-5a1c-490d-b6a7-59b0f1cc5d17">2,004</ix:nonFraction> shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8&#8211;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15&#8211;Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQ4NDk_4d606b24-bcff-4f57-9251-0d4f4e9cd0d4" continuedAt="ide5fbd375d714f9982b5e58d69ade84d" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ide5fbd375d714f9982b5e58d69ade84d" continuedAt="i8109d019abb6421bb4f7ab5f991ae021"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to <ix:nonFraction unitRef="number" contextRef="i2d396452af104e75bfbf02ca11bf7445_I20220630" decimals="INF" name="rprx:RelatedPartyTransactionRateAdjustedCashReceipts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzY4MQ_6f0e4c7c-7535-4572-a535-650239edbb52">6.5</ix:nonFraction>% of the cash receipts from royalty investments for such quarter and <ix:nonFraction unitRef="number" contextRef="i2d396452af104e75bfbf02ca11bf7445_I20220630" decimals="INF" name="rprx:RelatedPartyTransactionRateValueOfSecurityInvestments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2Xzc1MQ_84ed3fc0-8e53-406f-b019-f670992af2d2">0.25</ix:nonFraction>% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $<ix:nonFraction unitRef="usd" contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630" decimals="-6" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzEwODI_8c4464b6-2a71-4ef4-9147-38788d7aa6a5">1</ix:nonFraction>&#160;million per quarter and <ix:nonFraction unitRef="number" contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630" decimals="INF" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzExMDE_3d60c510-3d25-40e4-a824-684cfb657ea9">0.3125</ix:nonFraction>% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $<ix:nonFraction unitRef="usd" contextRef="iade6caaa03d24c1db457fe31fe5a9a4d_D20220401-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2MTA_66878e82-0523-4b24-8551-a30bcdd02c18">36.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2MzI_93309179-aaf4-4025-9d54-762c8e2d0766">77.2</ix:nonFraction>&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $<ix:nonFraction unitRef="usd" contextRef="ib720c19bda424da0a54ac76bd380e694_D20210401-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2NTQ_44cc94d2-8c45-4865-aa80-06dd1b0df1fb">32.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e368ed2beeb4e9bbfd7a428cdfe20a7_D20210101-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2Nzg_9b995f92-5a29-4b91-b0df-6fcb385f5209">68.1</ix:nonFraction>&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><ix:continuation id="i8109d019abb6421bb4f7ab5f991ae021"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQ4NTA_c989a929-0ded-4f19-9298-b5d1d21f47fe" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPSFT&#8217;s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:56.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id600e57f7adf403dabaeb1fd595d2aea_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzEtMS0xLTEtMTM0NTA1_c6b85238-23bb-4bc1-b150-e6ebf3507667">107,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27cc09d1626c4c12831b9b9ed5f1707e_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzEtMy0xLTEtMTM0NTA1_d6b27050-7930-45f8-a2ee-cd0310affd54">92,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75026c18f8e94d4d89a49b9629256c1e_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzItMS0xLTEtMTM0NTA1_b0492972-6df6-4d75-b309-6795b469dfae">8,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica95079874234fdbb0b75f9d0967a000_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzItMy0xLTEtMTM0NTA1_d75b2d61-0959-475f-ab40-11d4c8f3a17b">15,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzMtMS0xLTEtMTM0NTA1_725b1944-027b-4f2d-b63c-e628751721d5">115,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzMtMy0xLTEtMTM0NTA1_9c863d89-800c-4f00-ab28-2578585008fd">107,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of <ix:nonFraction unitRef="number" contextRef="i69334c4cb99348768c6cddd1b7d09954_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI1Nzg_09a5a9c0-5f14-4781-92f7-6170272dbda8">50</ix:nonFraction>% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting <ix:nonFraction unitRef="number" contextRef="ibad559122e374240aa4d76a955a15563_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI2NjM_a8001d19-7c7b-4a15-ac05-8b27c628c843">50</ix:nonFraction>% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the financial royalty asset of $<ix:nonFraction unitRef="usd" contextRef="ie1a96d121b274fbd8dbe1ad563a91052_I20220630" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI3ODU_a37ffc02-1165-41d7-8da3-6e2e0a92eb00">118.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd9849608bf44ab2b4553b4ce907b20e_I20211231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI3OTI_7ae01b08-e295-4156-a3ca-92d952fd1c34">130.9</ix:nonFraction>&#160;million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of <ix:nonNumeric contextRef="ia627a511f205448c8f15096957f33520_D20210416-20210416" name="rprx:RelatedPartyTransactionInitialTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzMxODI_32d1c1a7-0958-4f11-a18e-2b0170d997b0">seven years</ix:nonNumeric> to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8&#8211;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns <ix:nonFraction unitRef="shares" contextRef="i6458b426c5a0473fbba13389985422c7_D20220101-20220630" decimals="INF" name="rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzM5NjE_b6d83a68-3182-48b3-b7d1-27e0c335a715">27,210</ix:nonFraction> limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $<ix:nonFraction unitRef="usd" contextRef="i46117034b4ae4c55b35944ccab8ad2b3_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxMzQ_73688632-74cb-48bc-af6e-38a84e501eca">4.3</ix:nonFraction>&#160;million is recorded as treasury interests, of which $<ix:nonFraction unitRef="usd" contextRef="i89beaee57e374c50b2a774f5e339e12b_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxODE_36787c25-8733-4fe9-be5c-7271c7418bde">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0bf7a05a6178471d83f36a54fc1b58f4_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxODg_61785a3c-575b-4ac5-a49d-910c5b0dab38">1.6</ix:nonFraction>&#160;million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzMw_87602324-6cc0-496f-ad9e-b2b947bbb577" continuedAt="i01b5884b455d4b629efd3a5333080fb8" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01b5884b455d4b629efd3a5333080fb8">In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (&#8220;Theravance&#8221;) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731" decimals="-7" name="rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1Nzc3_f5684b00-15b0-4dd1-9a14-0ef359b6f307">1.31</ix:nonFraction>&#160;billion in July 2022 and committed up to $<ix:nonFraction unitRef="usd" contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731" decimals="-6" name="rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1Nzky_203daf4a-f139-4c26-9482-1fec55f02fb2">300</ix:nonFraction>&#160;million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $<ix:nonFraction unitRef="usd" contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731" decimals="-6" name="rprx:LongTermFundingPartnershipInitialPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1ODA2_78a4be39-9771-4389-9ec5-de2d362d66a0">25</ix:nonFraction>&#160;million in upfront funding and a potential $<ix:nonFraction unitRef="usd" contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731" decimals="-6" name="rprx:LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1ODE5_79cc6a84-49db-42d9-946a-7aa587f008d0">15</ix:nonFraction>&#160;million regulatory milestone payment to support the clinical development of ampreloxetine.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q and in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (&#8220;IPO&#8221;) of our Class A ordinary shares. &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. </span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies, which includes royalties on more than 35 commercial products, including Vertex&#8217;s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen&#8217;s Tysabri, AbbVie and Johnson &amp; Johnson&#8217;s Imbruvica, Astellas and Pfizer&#8217;s Xtandi, GSK&#8217;s Trelegy, Novartis&#8217; Promacta, Biohaven and Pfizer&#8217;s Nurtec ODT, Johnson &amp; Johnson&#8217;s Tremfya, Roche&#8217;s Evrysdi,</span><span style="color:#626c80;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Gilead&#8217;s Trodelvy, and 11 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Approved Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2021, we have deployed $15.0 billion of cash to acquire royalties on approved products. From 2012 through 2021, we have acquired $10.2 billion of royalties on approved products. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Development-Stage Product Candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed $7.8 billion to acquire royalties on development-stage product candidates. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we classify our acquisitions in these two broad categories, several of our acquisitions of royalties on approved products were driven by the long-term potential of these products in other, unapproved indications. Similarly, some of our royalty acquisitions in development-stage product candidates are for products that are approved in other indications. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties. </span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Synthetic Royalties/R&amp;D Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing research and development (&#8220;R&amp;D&#8221;), typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved.</span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:19pt">Launch and Development Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company.</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:19pt">Mergers and Acquisitions (&#8220;M&amp;A&#8221;) Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities. One example is our strategic alliance with MSCI Inc. (&#8220;MSCI&#8221;) to develop thematic life sciences indices.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Background and Format of Presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consummated an exchange offer on February 11, 2020 to facilitate our IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the various partnerships (the &#8220;Legacy Investors Partnerships&#8221;) that owned Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221; </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We control Royalty Pharma Holdings Ltd (&#8220;RP Holdings&#8221;) through our ownership of RP Holdings&#8217; Class A ordinary shares and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions, and is the successor to Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;). We are legally entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Most of the royalties we acquire are treated as investments in cash flow streams and are classified as financial assets measured under the effective interest method in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The measurement of income from our financial royalty assets requires significant judgments and estimates, including management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts&#8217; consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity can be volatile and unpredictable. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long term horizon can result in an immediate non-cash income statement expense recognition which generates a corresponding cumulative allowance that reduces the gross asset balance, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty and beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense. Over the course of 10 quarters, we recognized non-cash provision expense as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts&#8217; consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income over the course of 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts&#8217; consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, due to the nature of our effective interest methodology, there is no direct correlation between our income from financial royalty assets and our royalty receipts. Therefore, management believes investors should not look to income from royalties and the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends. Our operations have historically been financed primarily with cash flows generated by our royalties. Given the importance of cash flows and their predictability to management&#8217;s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP consolidated statements of cash flows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash collections from financial royalty assets, Cash collections from intangible royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty cash collections, Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled &#8220;Non-GAAP Financial Results.&#8221; </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the section titled &#8220;Non-GAAP Reconciliations&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Portfolio Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 marketed therapies and 11 development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty receipts for the three and six months ended June 30, 2022 and 2021 by product in order of contribution to royalty receipts for the six months ended June 30, 2022 (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketer(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie, Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Astellas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., others</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biohaven, Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Ipsen, Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ultragenyx, Kyowa Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alnylam</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">633,168</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">587,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,344,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237,158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">We have received quarterly redemption payments of $15.6 million beginning in the first quarter of 2021 related to the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> on the statements of cash flows). The remaining cash receipts related to royalty receipts from Nurtec ODT.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> on the statements of cash flows), Cimzia, Entyvio, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and contributions from the Legacy SLP Interest (defined below). </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Highlights </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Net cash provided by operating activities totaled $1.0 billion and $1.1 billion for the six months ended June 30, 2022 and 2021, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted Cash Receipts (a non-GAAP metric) totaled $1.1&#160;billion and $999.0&#160;million for the six months ended June 30, 2022 and 2021, respectively.  </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted EBITDA (a non-GAAP metric) totaled $1.0&#160;billion and $917.2&#160;million for the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted Cash Flow (a non-GAAP metric) totaled $848.6&#160;million and $838.0&#160;million for the six months ended June 30, 2022 and 2021, respectively.  </span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Results of Operations </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. &#160;&#160;&#160;&#160;The Legacy Investors Partnerships&#8217; 18% ownership interest in Old RPI. The value of this non-controlling interest will decline over time as the assets in Old RPI expire. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. &#160;&#160;&#160;&#160;The RP Holdings Class B Interests held indirectly by the Continuing Investors Partnerships, which represent an approximate 28% ownership interest in RP Holdings as of June 30, 2022 and are exchangeable for our Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. &#160;&#160;&#160;&#160;A de minimis interest in RPCT held by RPSFT as a result of a 2011 reorganization transaction. The value of this non-controlling interest will decline over time as the royalty assets owned by RPCT expire and is expected to be substantially eliminated by the end of 2022.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. &#160;&#160;&#160;&#160;The RP Holdings Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;) held by RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;), an affiliate of RP Management, LLC (the &#8220;Manager&#8221;). Income will not be allocated to this non-controlling interest until certain conditions are met. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the results of operations of RP Holdings, Old RPI and RPCT are consolidated into our financial statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and other revenues </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income generally arising from successful commercialization of products developed through R&amp;D funding arrangements. Most of our royalties on both approved products and development-stage product candidates that are not accounted for as R&amp;D funding expense are classified as financial assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV products for which the patent rights have been licensed to various counterparties. For the three and six months ended June 30, 2022 and 2021, the royalty payors accounting for greater than 10% of our total income and other revenues in any one period are shown in the table below: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Payor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">       Income from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts&#8217; consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts&#8217; consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts&#8217; consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (i.e., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Revenue from intangible royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees. Our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on other DPP-IVs have also substantially ended and we do not expect any material revenue from our DPP-IV in the future periods. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Other royalty income </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income primarily includes income from financial royalty assets that have been fully amortized by the expected expiration date and royalty income from synthetic royalties arising out of R&amp;D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated duration by which the financial asset was fully amortized. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Other royalty income also includes income from royalties that are recorded at fair value on our condensed consolidated balance sheets.  </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes the following: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expense or income related to the provision for current expected credit losses, which reflects the activity for the period, primarily due to new financial royalty assets with limited protective rights and changes to cash flow estimates for financial royalty assets with limited protective rights. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision). </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of the same variables and management&#8217;s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts&#8217; consensus sales forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the estimated duration of the royalty (i.e., patent expiration date) and (4) changes in amounts and timing of projected royalty receipts and milestone payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates, and includes development-stage funding payments that are made upfront or upon pre-approval milestones, and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General and administrative expenses </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative (&#8220;G&amp;A&#8221;) expenses include primarily Operating and Personnel Payments (defined below), legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the management agreements (collectively, the &#8220;Management Agreement&#8221;), we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in G&amp;A expenses, are calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in earnings of equity method investees </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Equity in earnings of equity method investees primarily includes the results of our share of income or loss from the following non-consolidated affiliates: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legacy SLP Interest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Avillion Entities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Avillion Entities (as defined below) partner with global biopharmaceutical companies to perform R&amp;D in exchange for success-based milestones and royalties if products are commercialized. Our investments in Avillion Financing I, LP (&#8220;Avillion I&#8221;) and BAv Financing II, LP (&#8220;Avillion II&#8221;, or, together with Avillion I, the &#8220;Avillion Entities&#8221;) are accounted for using the equity method. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other income, net </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income, net primarily includes the change in fair market value of our equity securities, the unrealized gains or losses on derivative instruments and available for sale debt securities, including related forwards and funding commitments, and interest income. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interests </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net income attributable to non-controlling interests includes the Legacy Investors Partnerships&#8217; approximately 18% share of earnings in Old RPI. As the Legacy Investors Partnerships no longer participate in investment opportunities, the related net income attributable to this non-controlling interest is expected to decline over time. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to non-controlling interests includes the RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the RP Holdings Class C Special Interest held by EPA Holdings once certain conditions have been met. Future net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to non-controlling interests also includes RPSFT&#8217;s 20% share of earnings in RPCT, which is a consolidated subsidiary of Old RPI. We expect net income attributable to this non-controlling interest to decline over time as the royalty assets owned by RPCT expire and to be substantially eliminated by the end of 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to non-controlling interests above can fluctuate significantly from period to period, primarily driven by volatility in the income statement activity of the respective underlying entity as a result of the non-cash charges associated with applying the effective interest accounting methodology as described in section titled &#8220;Understanding Our Financial Reporting.&#8221;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For the Three and Six Months Ended June 30, 2022 and 2021 </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The comparison of our historical results of operations for the three and six months ended June 30, 2022 and 2021 is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income and other revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income and other revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,098,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,127,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development funding expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses/(income), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(367,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(376,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income)/expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other (income)/expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113,805)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,999)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,683)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,597&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(346,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178,886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136,272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*Percentage change is not meaningful. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and other revenues </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income from financial royalty assets </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets by top products for the three and six months ended June 30, 2022 and 2021 is as follows, in order of contribution to income for the six months ended June 30, 2022: </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total income from financial royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">515,350</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503,414</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,026,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,033,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets increased by $11.9&#160;million, or 2.4%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by income related to newly acquired assets, primarily Tremfya, for which there was no comparable activity in the three months ended June 30, 2021, and the performance of the cystic fibrosis franchise. The increase was partially offset by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts&#8217; consensus sales forecasts for Imbruvica.    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets decreased by $6.2&#160;million, or 0.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts&#8217; consensus sales forecasts for Imbruvica. The decrease in income was partially offset by income from newly acquired assets, primarily Tremfya, for which there was no comparable activity in the six months ended June 30, 2021, and the performance of the cystic fibrosis franchise and Promacta. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from intangible royalty assets </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets decreased by $37.6&#160;million, or 93.7%, in the three months ended June 30, 2022 compared to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three months ended June 30, 2021, primarily driven by the maturity of our royalties on Januvia and Janumet in the three months ended March 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets decreased by $40.1&#160;million, or 52.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the maturity of our royalties on Januvia and Janumet in the three months ended March 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty income </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income increased by $6.6&#160;million, or 58.2%, in the three months ended June 30, 2022 compared to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three months ended June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, primarily related to growth in the ongoing product launches of Trodelvy and Nurtec ODT that arose from our R&amp;D funding agreements with Immunomedics and Biohaven, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income increased by $16.2&#160;million, or 86.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily related to income from Trodelvy and Nurtec ODT.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The breakdown of our provision for changes in expected future cash flows includes the following: </span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and </span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">expense or income related to the provision for current expected credit losses.</span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the provision activity is a combination of income and expense items, the provision breakdown by royalty, exclusive of the provision for current expected credit losses, is as follows, based on the largest contributors to each period&#8217;s provision income or expense: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114,354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,092)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lexiscan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">119,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(243,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(243,762)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDHIFA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">353,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">290,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we record</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed provision expense </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $105.7&#160;million, comprised of $119.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in provision expense for changes in expected cash flows and $13.4&#160;million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica and the cystic fibrosis franchise primarily due to significant declines in sell-side equity research analysts&#8217; consensus sales forecasts, which was partially offset by provision income for Xtandi and Tysabri due to a significant increase in sell-side equity research analysts&#8217; consensus sales forecasts. The provision income for credit losses was primarily driven by a decrease in current expected credit losses related to Tazverik as a result of the corresponding decline in the financial asset value. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2021, we recorded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provision income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $243.8&#160;million, of which $243.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.7&#160;million related to provision income for changes in expected cash flows and current expected credit losses, respectively. We recorded provision income primarily due to increases in sell-side equity research analysts&#8217; consensus sales forecasts for Tysabri, Xtandi and the cystic fibrosis franchise. Offsetting the provision income was provision expense related to Imbruvica, primarily due to declines in sell-side equity research analysts&#8217; consensus forecasts. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the six months ended June 30, 2022, we recorded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> provision expense </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of $290.3&#160;million, comprised of $353.3&#160;million in provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> expense </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for changes in expected cash flows and $63.0&#160;million in provisio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n income </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for current expected credit losses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We recorded provision expense for changes in expected cash flows for Imbruvica and Tazverik, primarily due to declines in sell-side equity research analysts&#8217; consensus sales forecasts. The provision income for credit losses was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">six months ended June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> we recorded provision expense of $48.5 million, of which $13.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and $35.2&#160;million related to provision expense for changes in expected cash flows and current expected credit losses, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded provision expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for Imbruvica, primarily due to declines in sell-side equity research analysts&#8217; consensus sales forecasts, and for Tazverik as a result of a slower than expected product launch. Offsetting the provision expense was provision income from a significant increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sell-side equity research analysts&#8217; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consensus forecasts for Tysabri and Xtandi. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">uring the six months ended June 30, 2021, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provision expense for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current expected credit losses was primarily driven by certain additions to our portfolio of financial royalty assets, including the incremental $100.0 million financial royalty asset related to the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense was relatively flat in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021 </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense increased by $95.3&#160;million, for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">six months ended June 30, 2022 as compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">six months ended June 30, 2021, primarily driven by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product in the three months ended March 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">G&amp;A expenses </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses increased by $6.9&#160;million, or 15.4%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">G&amp;A expenses increased by $15.3&#160;million, or 17.4%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in earnings of equity method investees </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in earnings of equity method investees decreased by $17.0&#160;million, or 95.8%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by a $20.9&#160;million decrease in equity in earnings from the Legacy SLP Interest.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity in earnings of equity method investees decreased by $14.6&#160;million, or 92.8%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a $21.5&#160;million decrease in equity in earnings from the Legacy SLP Interest. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest expense </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased by $9.5&#160;million, or 25.5%, in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by the issuance of $1.3&#160;billion senior unsecured notes in July 2021 (&#8220;2021 Notes&#8221;). The weighted average coupon rate was 2.245% and 2.125% in the three months ended June 30, 2022 and 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense increased by $19.2&#160;million, or 25.6% in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the issuance of the 2021 Notes. The weighted average coupon rate was 2.245% and 2.125% in the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the &#8220;Liquidity and Capital Resources&#8221; section for additional discussion of the Notes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other income, net </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income, net increased by $78.5&#160;million, or 96.3%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by gains on derivative instruments of $71.8 million and higher gains on available for sale debt securities in the three months ended June 30, 2022 partially offset by lower gains on equity securities. The gains on derivative instruments and higher gains on available for sale debt securities are primarily driven by an estimated high probability of a change of control event for Biohaven within the next year.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income, net increased by $64.5&#160;million, or 127.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by gains on derivative instruments of $71.8 million and higher gains on available for sale debt securities partially offset by losses on equity securities of $28.1 million and lower interest income in the six months ended June 30, 2022. The gains on derivative instruments and higher gains on available for sale debt securities are primarily driven by an estimated high probability of a change of control event for Biohaven within the next year.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interests </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Three months ended June 30, 2022 and 2021 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to the Legacy Investors Partnerships decreased by $72.1&#160;million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by lower net income attributable to Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to the Continuing Investors Partnerships decreased by $93.7&#160;million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the three months ended June 30, 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships&#8217; ownership of RP Holdings. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to RPSFT decreased by $13.0&#160;million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021. We expect net income attributable to RPSFT to continue to decline as the assets held by RPCT mature. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Legacy Investors Partnerships decreased by $57.8&#160;million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by lower net income attributable to Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Continuing Investors Partnerships decreased by $111.6&#160;million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the six months ended June 30, 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships&#8217; ownership of RP Holdings. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to RPSFT decreased by $23.0&#160;million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021. We expect net income attributable to RPSFT to continue to decline as the assets held by RPCT mature. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Key Developments and Upcoming Events Relating to Our Portfolio</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Products</span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Cystic fibrosis franchise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2021, Vertex announced European Commission (&#8220;EC&#8221;) approval for Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 and older who have at least one F508del mutation.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Vertex announced that U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved Trikafta for the treatment of children with cystic fibrosis ages 6 through 11 who have at least one F508del mutation or have certain mutations that are responsive to Trikafta based on in vitro data. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Vertex announced that the EC granted approval for the label expansion of Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Tysabri.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a complete response letter from the FDA for its supplemental biologics license application for subcutaneous Tysabri. The complete response letter indicated that the FDA was unable to approve Biogen&#8217;s filing as submitted. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Biogen announced results from Phase 3b NOVA study evaluation every six-week dosing with Tysabri intravenous administration in relapsing-remitting multiple sclerosis. Results show that every six-week Tysabri intravenous administration provides a high level of efficacy in controlling multiple sclerosis disease activity in patients who switched from the approved every four-week dosing regimen.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Imbruvica. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Johnson and Johnson announced Phase 3 GLOW study results for Imbruvica in combination with Venetoclax for the treatment of first-line chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of chronic lymphocytic leukemia. The study also showed improved duration of remission and significantly improved depth of remis</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sion. Johnson &amp; Johnson had indicated that approval could occur in 2022.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Johnson &amp; Johnson announced primary results from the Phase 3 SHINE study, which demonstrated that the combination of once-daily oral Imbruvica plus bendamustine-rituximab (BR) and rituximab maintenance significantly reduced the risk of disease progression or death by 25% compared to patients who received placebo plus BR and rituximab maintenance in patients aged 65 years or older with newly diagnosed mantle cell lymphoma. With a median follow-up of 84.7 months, the Imbruvica plus BR and rituximab maintenance combination showed a statistically significant and clinically meaningful 2.3 year improvement in median progression-free survival (6.7 years) vs. BR (4.4 years). The safety profile of the Imbruvica plus BR regimen was consistent with the known safety profiles of Imbruvica as well as BR.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Xtandi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2021, Astellas and Pfizer announced that the EC approved Xtandi for the treatment of patients with metastatic hormone-sensitive prostate cancer.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Astellas and Pfizer announced that Xtandi plus androgen deprivation therapy reduced the risk of death by 34% compared to placebo plus androgen deprivation therapy in the Phase 3 ARCHES study in men with metastatic hormone-sensitive prostate cancer. The primary results from the ARCHES trial were published in 2019.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Pfizer indicated that there could be a potential readout of the Phase 3 EMBARK trial for high-risk non-metastatic prostate cancer in the second half of 2022. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Nurtec ODT. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Biohaven announced that the FDA approved Nurtec ODT for the preventative treatment of migraine, indicated for adult patients with episodic migraine who experience less than 15 headache days per month.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Pfizer and Biohaven announced that the EC has granted marketing authorization for Vydura (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Pfizer and Biohaven announced that they entered into a definitive agreement under which Pfizer will acquire Biohaven. Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash for a total of approximately $11.6 billion. Pfizer will also make payments at closing to settle Biohaven&#8217;s third-party debt and for the redemption of all outstanding shares of Biohaven&#8217;s redeemable preferred stock. The transaction is expected to close by early 2023.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Trodelvy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2021, Gilead announced the FDA granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase 3 ASCENT study.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>In April 2021, Gilead announced that the FDA granted an accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. </span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>In June 2021, Gilead announced superior outcomes to standard of care in second-line treatment of metastatic TNBC in the Phase 3 ASCENT study. Trodelvy more than doubled overall survival as a second-line treatment in the new ASCENT subgroup analysis.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Gilead announced a collaboration with Merck &amp; Co. to investigate Trodelvy in combination with Keytruda as a first-line treatment for people with locally advanced or metastatic TNBC. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC&#8217;s decision is supported by results from the Phase 3 ASCENT study where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician&#8217;s choice of chemotherapy.   </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck &amp; Co. to evaluate the combination of Trodelvy and Merck &amp; Co.&#8217;s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck &amp; Co. will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Gilead and Merck &amp; Co. established an agreement where Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Gilead announced results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy versus physicians&#8217; choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint of progression-free survival with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death. The first interim analysis of the key secondary endpoint of overall survival demonstrated a trend in improvement. Patients will be followed for a subsequent overall survival analysis. The safety profile for Trodelvy was consistent with prior studies.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Cabometyx. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb&#8217;s Opdivo. The approval was based on the Phase 3 CheckMate 9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.<br/><br/>In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Exelixis announced that their partners Takeda and Ono received approval in Japan for Cabometyx in combination with Opdivo for the treatment of unresectable or metastatic RCC. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer, which included patients with metastatic castration-resistant prostate cancer who had been previously treated with novel hormone therapies enzalutamide or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis announced that it will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. Exelixis believes that CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Exelixis announced FDA approved Cabometyx for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. The approval was based on the Phase 3 COSMIC-311 pivotal trial.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Exelixis announced results from the final analysis of the second primary endpoint of overall survival from the Phase 3 COSMIC-312 trial, which evaluated cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The final analysis showed neither improvement nor detriment in overall survival for cabozantinib in combination with atezolizumab versus sorafenib.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Ipsen announced that it received approval from the EC for Cabometyx as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Exelixis announced that COSMIC-313, an ongoing Phase 3 trial evaluating Cabometyx, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, met its primary endpoint, demonstrating significant improvement in progression-free survival at the primary analysis. At a prespecified interim analysis for the secondary endpoint of overall survival, the combination of Cabometyx, nivolumab and ipilimumab did not demonstrate a significant benefit. The trial will continue to the next analysis of overall survival. Exelixis intends to discuss the results with the FDA to determine next steps toward a potential regulatory submission.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis has indicated it expects initial Phase 3 data in the second half of 2022 from CONTACT-01 in metastatic NSCLC and CONTACT-03 in advanced or metastatic RCC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Evrysdi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2021, Roche announced that the EC approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four splicing modifier of motor neuron 2 copies. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Evrysdi was approved in Japan for the treatment of SMA.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Roche announced that the FDA has approved a label extension for Evrysdi to include infants under two months old with SMA. The approval is based on the interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic infants treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Orladeyo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic hereditary angioedema (HAE) medication approved in the region.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, BioCryst announced that the EC approved Orladeyo for the prevention of recurrent HAE attacks in patients 12 years and older.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, BioCryst announced approval of Japanese National Health Insurance System price listing of Orladeyo for prophylactic treatment of HAE.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Oxlumo.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FDA accepted Alnylam&#8217;s supplemental New Drug Application (&#8220;NDA&#8221;) for lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1. The FDA has set an action date for October 6, 2022. Additionally, a Type II Variation for lumasiran to amend the label in patients with advanced primary hyperoxaluria Type 1 was submitted and validated by the European Medicines Agency (&#8220;EMA&#8221;) in December 2021. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Tremfya.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Johnson &amp; Johnson announced results from the Phase 2a VEGA proof-of-concept study. Results showed that the combination of Tremfya and golimumab, a tumor necrosis factor-alpha antagonist, induced higher rates of clinical response, clinical remission, endoscopic improvement and a composite histologic-endoscopic endpoint at 12 weeks than either treatment alone in adults with moderately to severely active ulcerative colitis. Rates of adverse events were comparable among treatment groups.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Johnson &amp; Johnson announced results from the Phase 2b QUASAR Induction Study 1. Results showed that a significantly greater proportion of adults with moderately to severely active ulcerative colitis who previously had an inadequate response or intolerance to conventional therapies or selected advanced therapies and were treated with Tremfya achieved clinical response at week 12 (Tremfya 200 mg: 61.4% and Tremfya 400 mg: 60.7%), the study&#8217;s primary endpoint compared with placebo (27.6%). Safety data at week 12 was consistent with the safety profile for Tremfya in approved indications.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Tazverik</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In June 2022, Ipsen and Epizyme announced that they had entered into a definitive merger agreement under which Ipsen will acquire Epizyme. Ipsen intends to initiate a tender offer to acquire all outstanding shares of Epizyme at a price of $1.45 per share in cash at the closing of the transaction for an initial estimated aggregate consideration of $247 million plus a contingent value right of $1 per share. The transaction is anticipated to close by the end of the third quarter of 2022.</span></div><div style="padding-left:45pt;text-indent:-58.5pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development-Stage Product Candidates</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Aficamten. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Cytokinetics announced the FDA granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) based on results from REDWOOD-HCM. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting left ventricular outflow tract pressure gradient (LVOT-G) as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of greater than 50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">BCX9930.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2022, BioCryst announced that it is pausing enrollment in clinical trials with BCX9930, while BioCryst investigates elevated serum creatinine levels seen in some patients. BioCryst will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are expected to continue on the study drug.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, BioCryst announced that it plans to discuss with regulators whether clinical trials with amended protocols could resume using stepped dosing to 400 milligrams twice-daily of BCX9930 by the end of the third quarter of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Gantenerumab.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2021, Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted breakthrough therapy designation by the FDA for the treatment of people living with Alzheimer&#8217;s disease. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer&#8217;s disease, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Roche announced a new Phase 3 Alzheimer&#8217;s disease prevention trial (SKYLINE). Roche has stated that it intends to enter into a collaboration agreement with Banner Alzheimer&#8217;s Institute&#8217;s Alzheimer&#8217;s Prevention Initiative, Massachusetts General Hospital and the University of Southern California Alzheimer&#8217;s Therapeutic Research Institute to further exchange scientific insights and advance the trial goals. SKYLINE aims to evaluate the potential of gantenerumab to slow disease progression in people with the earliest biologic signs of Alzheimer&#8217;s disease and who show no signs of cognitive impairment.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roche has indicated it expects Phase 3 data from the GRADUATE 1/2 trial in Alzheimer&#8217;s disease in the fourth quarter of 2022. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Omecamtiv mecarbil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2022, Cytokinetics announced that FDA has accepted and filed its NDA for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction who were receiving standard of care plus omecamtiv mecarbil.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Cytokinetics announced results from METEORIC-HF, a Phase 3 trial evaluating the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity in patients with heart failure with reduced ejection fraction. After 20 weeks of treatment, there was no change in peak oxygen uptake in patients treated with omecamtiv mecarbil versus placebo.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Cytokinetics announced that the FDA had informed the company that the Cardiovascular and Renal Drugs Advisory Committee will review its NDA on December 13, 2022. Additionally, the FDA has assigned the NDA a PDUFA date of February 28, 2023.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Otilimab.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GlaxoSmithKline has indicated it expects Phase 3 data from the contRast trials in rheumatoid arthritis in the second half of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Pelabresib. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, MorphoSys presented the latest data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibitor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume from baseline at week 24 and 60% (n=47) maintained a greater than or equal to 35% reduction in spleen volume at week 48. Most patients also saw their symptoms reduced with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">PT027.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating PT027 (albuterol/budesonide) in patients with asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, PT027 demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, PT027 showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of PT027 in both trials was consistent with the known profiles </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the components.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announced that FDA accepted for filing the NDA for AstraZeneca&#8217;s PT027. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation of asthma. The co-development partnership between AstraZeneca and Avillion also recently expanded to include the BATURA study, a randomized Phase 3b decentralized trial to further assess the role of PT027 in preventing asthma exacerbations.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Zavegepant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2021, Biohaven announced that it enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine. Accordingly, per the agreement with Biohaven announced in August 2020, Royalty Pharma paid $100 million to Biohaven for the achievement of this milestone, bringing total zavegepant funding to $250 million.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at two hours and showed broad efficacy by demonstrating statistica</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lly significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Biohaven announced that the FDA accepted for review a NDA for zavegepant nasal spray for the acute treatment of migraine in adults. The PDUFA date is in the first quarter of 2023.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Results </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Reconciliations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty cash collections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">less (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distributions to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT. Adjusted Cash Receipts is most directly comparable to the GAAP measure of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Payments for rebates</span><span style="color:#626c80;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the statements of cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Flow is defined as Adjusted EBITDA less (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Development-stage funding payments - ongoing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development-stage funding payments - upfront and milestone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest received, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in equity method investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (5) Other (including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative collateral posted, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivative collateral received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) plus (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contributions from non-controlling interests- R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all directly reconcilable to the statements of cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the royalty receipts and non-GAAP financial results for the six months ended June 30, 2022 and 2021 by product in order of contribution to royalty receipts for the six months ended June 30, 2022 (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.687%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalties </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Year-to-Date Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">633,168</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">587,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,344,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237,158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">524,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,128,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">998,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,101)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,604)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,003)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,764)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,239)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479,909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">435,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">917,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">118,456</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,122)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,763)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest received/(paid), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interests- R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">481,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">428,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">848,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">838,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,561</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,214</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,207</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,151</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*Percentage change is not meaningful. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have received quarterly redemption payments of $15.6 million beginning in the first quarter of 2021 related to the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows). The remaining cash receipts related to royalty receipts from Nurtec ODT.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows), Cimzia, Entyvio, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and contributions from the Legacy SLP Interest.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted Cash Receipts (non-GAAP) </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Receipts increased by $129.7 million to $1.1 billion in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by an increase in royalty receipts from the cystic fibrosis franchise and newly acquired royalties, which was partially offset by a decline in royalty receipts from matured royalties, primarily the HIV franchise, and unfavorable foreign exchange movements. The increase in Adjusted Cash Receipts also reflects a decline in distributions to non-controlling interests due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below we discuss the key drivers of royalty receipts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Royalty Receipts </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Cystic fibrosis franchise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $61.0 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. The increase was primarily driven by the launch of Kaftrio in additional countries outside the United States and the performance of Trikafta in the United States, including its uptake in children 6 through 11 years old.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Tysabri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, increased by $11.6&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily driven by continued global patient growth and positive channel dynamics in the United States.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Imbruvica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson &amp; Johnson for the treatment of blood cancers and chronic graft versus host disease, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by $8.9&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. The decrease was largely due to a slower-than-anticipated recovery of the chronic lymphocytic leukemia market from COVID-19 and increased competition from newer therapies in the United States. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Xtandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $18.6&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily due to a true-up of royalties from prior periods.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Promacta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia purpura (ITP) and aplastic anemia, increased by $6.1&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. This growth was primarily driven by increased use in ITP and further uptake as first-line treatment for severe aplastic anemia in the United States.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Januvia, Janumet, Other DPP-IVs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty receipts from the DPP-IVs for type 2 diabetes, which includes Januvia and Janumet, both marketed by Merck &amp; Co., decreased by $3.8&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Tremfya </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Royalty receipts from Tremfya, which is marketed by Johnson &amp; Johnson for the treatment of plaque psoriasis and active psoriatic arthritis, were $46.7&#160;million in the six months ended June 30, 2022 primarily driven by continued market share gains. We acquired the Tremfya royalty in July 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Nurtec ODT/Biohaven payment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Royalty receipts from Nurtec ODT, marketed by Biohaven and Pfizer for the acute and preventative treatment of migraine, increased by $5.9&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by prescription volume growth. In addition, we received $31.3 million in fixed payments from Biohaven related to the Series A Biohaven Preferred Shares during each of the six months ended June 30, 2022 and 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Cabometyx/Cometriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, were $25.9&#160;million in the six months ended June 30, 2022, primarily driven by uptake of Cabometyx in combination with Opdivo as a first-line treatment for patients with advanced renal cell carcinoma. We acquired the Cabometyx/Cometriq royalty in March 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions to Non-Controlling Interests</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributions to non-controlling interests decreased by $22.7&#160;million to $215.5&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interests is primarily due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBITDA (non-GAAP)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA increased by $118.5&#160;million to $1.0 billion in the six months ended June 30, 2022 compared to the six months ended June 30, 2021 as a result of the factors noted above in &#8220;Adjusted Cash Receipts (Non-GAAP).&#8221; Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments from increased cash receipts from royalty investments.</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted Cash Flow (non-GAAP)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Six Months Ended June 30, 2022 and 2021</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Flow increased by $10.6 million to $848.6 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the factors noted above in &#8220;Adjusted Cash Receipts (non-GAAP)&#8221; and &#8220;Adjusted EBITDA (non-GAAP).&#8221; The increase was partially offset by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate and a $21.5&#160;million increase in net interest paid in the six months ended June 30, 2022 due to the first interest payment on the 2021 Notes.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-GAAP Reconciliations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA, and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses our performance, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within our credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate our performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company&#8217;s metric may not be directly comparable to another&#8217;s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-GAAP financial measures used in this Quarterly Report on Form 10-Q have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To arrive at Adjusted Cash Receipts, we start with the GAAP line item, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and adjust for the following items from the statements of cash flows: to add back (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are classified as cash inflows from investing activities, (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (4) Development-stage funding payments, (5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (6) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and to deduct (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distributions to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which represents distributions to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT, and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or Adjusted Cash Receipts.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To arrive at Adjusted EBITDA, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and adjust for the following items from the statements of cash flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (redemption of Biohaven Preferred Shares), (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are classified as cash inflows from investing activities, (3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest received,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (4) Development-stage funding payments and (5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (2) Derivative collateral posted or (received), net.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To arrive at Adjusted Cash Flow, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and adjust for the following items from the statements of cash flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (redemption of Biohaven Preferred Shares), (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classified as cash inflows from investing activities and (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contributions from non-controlling interests-R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments in equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees &#8211; investing (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (received)/paid, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interests (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral received, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">524,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475,204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,128,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">998,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees &#8211; investing (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (received)/paid, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interests (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral received, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479,909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">435,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">917,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees &#8211; investing (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interests-R&amp;D (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interests (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity method investees (2), (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">481,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">428,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">848,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">838,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The table below shows the line item for each adjustment and the direct location for such line item on the statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statements of Cash Flows Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Distributions to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (received)/paid, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral received, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ollateral received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivative collateral posted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Contributions from non-controlling interests- R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees - investing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Our lenders consider all payments made to support R&amp;D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing development-stage funding payments and upfront and milestone development-stage funding payments are reported in R&amp;D funding expense in net income and are added back in aggregate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We consider all payments to fund our operating joint ventures that are performing R&amp;D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investments Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for royalties on products that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. We have established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, we invested $442.4&#160;million in royalties and related assets. While volatility exists in the total amount of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Summary of Royalty Acquisition Activity </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (&#8220;Theravance&#8221;) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy for an upfront payment of $1.31 billion and up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2022, we acquired an ex-U.S. royalty interest in Gavreto from Blueprint Medicines for an upfront payment of $175 million and contingent sales-based milestones up to $165 million. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, we acquired common stock and a revenue participation right from ApiJect Holdings, Inc. for $50 million.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) for $150 million comprised of an upfront payment of $50 million and two additional $50 million payments, conditional upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. In February 2022, Cytokinetics announced that it initiated the clinical trial for oHCM, which triggered a $50 million payment from us in March 2022. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (&#8220;Cytokinetics Commercial Launch Funding&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846 thousand shares of BioCryst common stock, which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. The funds from this transaction will enable further advancement of BCX9930 and support additional investment in the global launch of Orladeyo (berotralstat). </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support its acquisition of Constellation Pharmaceuticals, Inc. (&#8220;Constellation&#8221;), which closed on July 15, 2021. We agreed to provide up to $2.025&#160;billion of funding to MorphoSys, comprised of an upfront payment of $1.425&#160;billion, additional milestone payments of up to $150&#160;million, up to $350&#160;million of capital (&#8220;Development Funding Bonds&#8221;). Following an amendment in June 2022, MorphoSys may draw the funding by September 12, 2022. MorphoSys is required to draw a minimum of $150&#160;million of Development Funding Bonds. In connection with the closing of its acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, we acquired a royalty interest in Oxlumo from Dicerna Pharmaceuticals, Inc. for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. Oxlumo, which has been approved by the FDA and EMA for the treatment of primary hyperoxaluria type 1, is marketed by Alnylam.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GSK plc for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the United States and Europe.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson &amp; Johnson. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in April 2021, we entered into an agreement with MSCI, a leading provider of critical decision support tools and services, to assist MSCI in the design of a classification framework and index methodologies to expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a portion of MSCI&#8217;s revenues from those indexes. The financial impact associated with this transaction has not been material to date and is not expected to be material for the year ended December 31, 2022.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of liquidity is cash provided by operations. For both the six months ended June 30, 2022 and 2021, we generated $1.0&#160;billion and $1.1&#160;billion, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility (defined below) will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&amp;D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&amp;D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In July 2021, we issued $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility (defined below) which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of June 30, 2022. As of June 30, 2022 and December 31, 2021, we had total long-term debt outstanding of $7.1&#160;billion and $7.1&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and analysis of cash flow changes presents a summary of our cash flow activity for the six months ended June 30, 2022 and 2021: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,057,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(451,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Analysis of Cash Flow Changes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Activities </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased by $22.6&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by upfront and milestone development-stage funding payments of $100.0&#160;million to Cytokinetics to acquire a royalty on a development-stage product candidate in the six months ended June 30, 2022. Additionally, interest paid increased by $22.4&#160;million in the six months ended June 30, 2022 due to the first interest payment made on the 2021 Notes. The higher use of cash was partially offset by an increase in cash collections from financial royalty assets of $87.3&#160;million. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities decreased by $454.1&#160;million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a $508.6&#160;million decrease in cash used to acquire financial royalty assets and a $150.4&#160;million increase in the overall net cash provided by marketable securities. Additionally, we paid approximately $62.8 million to acquire equity securities during the six months ended June 30, 2022 compared to the receipt of proceeds of $109.4 million from the sale of all of our Cytokinetics common stock and a portion of our Biohaven common shares during the six months ended June 30, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was relatively consistent in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Capital </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, our cash and cash equivalents and marketable securities totaled $2.1&#160;billion and $290.4&#160;million, respectively. As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5&#160;billion and $581.9&#160;million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Borrowings </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our borrowings at June 30, 2022 and December 31, 2021 consisted of the following (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total senior unsecured debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,106,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we issued the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. On September 2, 2020, we issued $6.0 billion of senior unsecured note (the &#8220;2020 Notes&#8221;) with a weighted average coupon rate of 2.125% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. We refer to the 2020 Notes and 2021 Notes, collectively, as the &#8220;Notes.&#8221; Indentures governing the Notes contain certain covenants with which w</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ere in compliance as of June 30, 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amends and restates the credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured Revolving Credit Facility with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains certain customary covenants which we were in compliance as of June 30, 2022. The Revolving Credit Facility remains undrawn and available to us as of June 30, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Uses of Capital </span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of Royalties </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Synthetic Royalties/R&amp;D Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&amp;D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Launch and Development Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">M&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities. One example is our strategic alliance with MSCI to develop thematic life sciences indices.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions to Shareholders </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid dividends to holders of our Class A ordinary shares of $165.3&#160;million and $138.6&#160;million in the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June 30, 2022 and 2021, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Arrangements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into a long-term funding agreement with Cytokinetics to provide capital up to $300 million of capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) available in five tranches to support Cytokinetics for further development of aficamten and potential commercialization of omecamtiv mecarbil. We funded the initial tranche of $50 million of the Cytokinetics Commercial Launch Funding upon closing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125&#160;million of the $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced a long-term strategic funding partnership with MorphoSys to support its acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the required draw date, we agreed to provide MorphoSys up to $350&#160;million of Development Funding Bonds to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150&#160;million. In return, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of June 30, 2022, MorphoSys has not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300&#160;million under the Development Funding Bonds to be funded in September 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;) for a total of $200&#160;million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares and have a remaining commitment of $100.4 million under our Commercial Launch Preferred Equity as of June 30, 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have other funding arrangements where we are contractually obligated to fund R&amp;D activities performed by our development partners. We also have funding arrangements related to our equity method investment in the Avillion Entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements, which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximate $52.7&#160;million as of June 30, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. As such, these contingent milestone payments are not considered contractual obligations. In the six months ended June 30, 2022, we made a $50 million payment to Cytokinetics in connection with its initiation of the first pivotal clinical trial in oHCM. In the six months ended June 30, 2021, we made a $100 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Service </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the future principal and interest payments under our Notes over the next five years and thereafter are as follows: </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Payments</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,070,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,773,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes unamortized debt discount and issuance costs of $193.8&#160;million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating and Personnel Payments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments are determined based on cash receipts, the amounts are variable. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantor Financial Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the &#8220;Guarantor Subsidiary&#8221;). Our remaining subsidiaries (the &#8220;Non-Guarantor Subsidiaries&#8221;) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of June 30, 2022, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3&#160;billion and $7.1&#160;billion, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information presents summarized combined balance sheet information as of June 30, 2022 and December 31, 2021 and summarized combined statement of operations information for the six months ended June 30, 2022 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings&#8217; most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of June 30, 2022 and December 31, 2021 or for the six months ended June 30, 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Summarized Combined Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,039,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,105,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,095,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current intercompany notes payable due to Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,993,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,039,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.883%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Summarized Combined Statement of Operations</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Use of Estimates </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most critical accounting policies relate to our financial royalty assets. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. There have been no material changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2&#8211;Summary of Significant Accounting Policies to our condensed consolidated financial statements for additional information on recently issued accounting standards. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_154"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in &#8220;Item 7A. Quantitative and Qualitative Disclosures about Market Risk&#8221; in the Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the three months ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness Of Controls</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a description of our legal proceedings, refer to Note 14&#8211;Commitments and Contingencies, which is incorporated herein by reference. </span></div><div><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes with respect to the risk factors disclosed in the Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition and results of operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuer Purchases of Equity Securities</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_181"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following exhibits are filed as a part of this Quarterly Report on Form 10-Q:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:15.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline">Exhibit No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline">Description of Exhibit</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex311.htm">Certification of the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex311.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex311.htm">s Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.2*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex312.htm">Certification of the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex312.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex312.htm">s Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">32*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20220630ex32.htm">Certification of the Registrant&#8217; Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Schema Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">XBRL Presentation Linkbase</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">* Filed or furnished herewith </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div id="if7303c6bf0bc4b328e9b48bcb6a7c139_184"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:252pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="padding-left:288pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROYALTY PHARMA PLC</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Pablo Legorreta</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pablo Legorreta</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:   August 4, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrance Coyne</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrance Coyne</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:   August 4, 2022</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>rprx-20220630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i222e668ba8f149d3814ea6d4b418fe42_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Pablo Legorreta, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></div><div style="padding-left:72pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.545%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>rprx-20220630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i972cbe3849d34ba8aa8de348ccd5f78f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Terrance Coyne, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.545%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>rprx-20220630ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i99a332e5014045c2bac7eaf9f5b1a794_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with Royalty Pharma plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the &#8220;Report&#8221;), Pablo Legorreta, the Chief Executive Officer and Terrance Coyne, the Chief Financial Officer of Royalty Pharma plc, each does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to his knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Royalty Pharma plc.</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;August 4, 2022</font></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rprx-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rprx="http://royaltypharma.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://royaltypharma.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://royaltypharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurpose" roleURI="http://royaltypharma.com/role/OrganizationandPurpose">
        <link:definition>2101101 - Disclosure - Organization and Purpose</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurposeDetails" roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails">
        <link:definition>2402401 - Disclosure - Organization and Purpose (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecurities" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities">
        <link:definition>2106103 - Disclosure - Available for Sale Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesTables" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Available for Sale Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesNarrativeDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails">
        <link:definition>2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstruments" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments">
        <link:definition>2110104 - Disclosure - Fair Value Measurements and Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsTables" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables">
        <link:definition>2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
        <link:definition>2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssets" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssets">
        <link:definition>2116105 - Disclosure - Financial Royalty Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsTables" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables">
        <link:definition>2317303 - Disclosure - Financial Royalty Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails">
        <link:definition>2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets">
        <link:definition>2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables">
        <link:definition>2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails">
        <link:definition>2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNet" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet">
        <link:definition>2122107 - Disclosure - Intangible Royalty Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetTables" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables">
        <link:definition>2323305 - Disclosure - Intangible Royalty Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
        <link:definition>2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetNarrativeDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails">
        <link:definition>2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliates" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates">
        <link:definition>2126108 - Disclosure - Non-Consolidated Affiliates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliatesDetails" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails">
        <link:definition>2427413 - Disclosure - Non-Consolidated Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpense" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense">
        <link:definition>2128109 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpenseDetails" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails">
        <link:definition>2429414 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://royaltypharma.com/role/Borrowings">
        <link:definition>2130110 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://royaltypharma.com/role/BorrowingsTables">
        <link:definition>2331306 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails">
        <link:definition>2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails_1" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1">
        <link:definition>2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails">
        <link:definition>2433416 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofRepaymentsofDebtbyYearDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
        <link:definition>2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://royaltypharma.com/role/ShareholdersEquity">
        <link:definition>2135111 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://royaltypharma.com/role/ShareholdersEquityTables">
        <link:definition>2336307 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2437418 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquitySummaryofNoncontrollingInterestsDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
        <link:definition>2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://royaltypharma.com/role/EarningsperShare">
        <link:definition>2139112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://royaltypharma.com/role/EarningsperShareTables">
        <link:definition>2340308 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://royaltypharma.com/role/EarningsperShareDetails">
        <link:definition>2441420 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlow" roleURI="http://royaltypharma.com/role/IndirectCashFlow">
        <link:definition>2142113 - Disclosure - Indirect Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowTables" roleURI="http://royaltypharma.com/role/IndirectCashFlowTables">
        <link:definition>2343309 - Disclosure - Indirect Cash Flow (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowDetails" roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails">
        <link:definition>2444421 - Disclosure - Indirect Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://royaltypharma.com/role/CommitmentsandContingencies">
        <link:definition>2145114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2446422 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://royaltypharma.com/role/RelatedPartyTransactions">
        <link:definition>2147115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables">
        <link:definition>2348310 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2449423 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://royaltypharma.com/role/SubsequentEvents">
        <link:definition>2150116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://royaltypharma.com/role/SubsequentEventsDetails">
        <link:definition>2451424 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rprx_ContinuingInvestorsPartnershipMember" abstract="true" name="ContinuingInvestorsPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ClassBHoldersMember" abstract="true" name="ClassBHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RedeemableStockRedemptionPricePerShare" abstract="false" name="RedeemableStockRedemptionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CommonStockVotingRightsNumberOfVotes" abstract="false" name="CommonStockVotingRightsNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_FinancingReceivablesFairValueDisclosure" abstract="false" name="FinancingReceivablesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingCommitmentAmountOutstanding" abstract="false" name="LongTermFundingCommitmentAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" abstract="true" name="OnePointSevenFivePercentSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAmount" abstract="false" name="LongTermFundingPartnershipAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesParOrStatedValuePerShare" abstract="false" name="DeferredSharesParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" abstract="false" name="RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_PaymentsForUpfrontDevelopmentStageFunding" abstract="false" name="PaymentsForUpfrontDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" abstract="false" name="CollaborativeArrangementRightsAndObligationsPeriodOfReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsOther" abstract="false" name="ProceedsFromNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireEquitySecuritiesFNNI" abstract="false" name="PaymentsToAcquireEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_DebtInstrumentIssuanceAsAPercentOfPar" abstract="false" name="DebtInstrumentIssuanceAsAPercentOfPar" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipCovenantRequiredAmount" abstract="false" name="LongTermFundingPartnershipCovenantRequiredAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" abstract="false" name="ProceedsFromCollateralReceivedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AssignmentAgreementFundingObligationsMember" abstract="true" name="AssignmentAgreementFundingObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" abstract="false" name="IncreaseDecreaseInOtherRoyaltyIncomeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FundingCommitmentsMember" abstract="true" name="FundingCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyPharmaCollectionTrustMember" abstract="true" name="RoyaltyPharmaCollectionTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DerivativeAssetMember" abstract="true" name="DerivativeAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CytokineticsMember" abstract="true" name="CytokineticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ThreePointThreeFiveZeroPercentDue2051Member" abstract="true" name="ThreePointThreeFiveZeroPercentDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" abstract="true" name="OnePointTwoZeroPercentSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" abstract="false" name="InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" abstract="false" name="LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_ExchangeOfferTransactionMember" abstract="true" name="ExchangeOfferTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" abstract="false" name="PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesSharesOutstanding" abstract="false" name="DeferredSharesSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_OtherFinancialRoyaltyAssetMember" abstract="true" name="OtherFinancialRoyaltyAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsMember" abstract="true" name="LegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AccruedRoyaltyReceivable" abstract="false" name="AccruedRoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" abstract="false" name="IncreaseDecreaseInAccruedRoyaltyReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SeniorUnsecuredRevolvingCreditFacilityMember" abstract="true" name="SeniorUnsecuredRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DPPIVInhibitorsMember" abstract="true" name="DPPIVInhibitorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleFixedPayment" abstract="false" name="DebtSecuritiesAvailableForSaleFixedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSalePricePerShare" abstract="false" name="DebtSecuritiesAvailableForSalePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_TheNotesMember" abstract="true" name="TheNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OtherCommitmentIncreaseDecrease" abstract="false" name="OtherCommitmentIncreaseDecrease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToNoncontrollingInterestsOther" abstract="false" name="PaymentsToNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OvernightBankFundingRateMember" abstract="true" name="OvernightBankFundingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancialRoyaltyAssetsMember" abstract="true" name="FinancialRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" abstract="true" name="AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" abstract="false" name="RelatedPartyTransactionRateValueOfSecurityInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" abstract="false" name="FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SeniorNotesDue2031Member" abstract="true" name="SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyPharmaInvestmentsOldRPIMember" abstract="true" name="RoyaltyPharmaInvestmentsOldRPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureNoncurrent" abstract="false" name="AssetsFairValueDisclosureNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" abstract="true" name="ThreePointFiveFivePercentSeniorNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForCollateralPostedOnDerivativeInstruments" abstract="false" name="PaymentsForCollateralPostedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForOngoingDevelopmentStageFunding" abstract="false" name="PaymentsForOngoingDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" abstract="true" name="LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateAdjustedCashReceipts" abstract="false" name="RelatedPartyTransactionRateAdjustedCashReceipts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" abstract="false" name="FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" abstract="false" name="DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_RoyalPharmacySelectFinanceTrustMember" abstract="true" name="RoyalPharmacySelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OtherRoyaltyIncomeReceivableCurrent" abstract="false" name="OtherRoyaltyIncomeReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TysabriMember" abstract="true" name="TysabriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyIncomeOtherMember" abstract="true" name="RoyaltyIncomeOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" abstract="false" name="LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ImbruvicaMember" abstract="true" name="ImbruvicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentShares" abstract="false" name="LongTermPurchaseCommitmentShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInitialPayment" abstract="false" name="LongTermFundingPartnershipInitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CytokineticsFundingCommitmentMember" abstract="true" name="CytokineticsFundingCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureCurrent" abstract="false" name="AssetsFairValueDisclosureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OperatingAndPersonnelPaymentsMember" abstract="true" name="OperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionEntitiesMember" abstract="true" name="AvillionEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionIMember" abstract="true" name="AvillionIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" abstract="true" name="RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_EquityMethodInvestmentsUnfundedCommitments" abstract="false" name="EquityMethodInvestmentsUnfundedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentAmountOutstanding" abstract="false" name="LongTermPurchaseCommitmentAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRPSFTMember" abstract="true" name="LegacyInvestorsPartnershipsAndRPSFTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IntangibleRoyaltyAssetsMember" abstract="true" name="IntangibleRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NumberOfNoncontrollingInterests" abstract="false" name="NumberOfNoncontrollingInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_SeniorNotesDue2051Member" abstract="true" name="SeniorNotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssignmentAgreementBenefitOfPaymentStreamMember" abstract="true" name="AssignmentAgreementBenefitOfPaymentStreamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_RPHoldingsMember" abstract="true" name="RPHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" abstract="false" name="ProceedsFromIssuanceOfEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" abstract="false" name="FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CommonStockQuarterlyConversionBasis" abstract="false" name="CommonStockQuarterlyConversionBasis" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipExpectedPayment" abstract="false" name="LongTermFundingPartnershipExpectedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" abstract="true" name="RoyaltyDistributionPayableToRPSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_MerckAssetPhaseIIClinicalTrialMember" abstract="true" name="MerckAssetPhaseIIClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" abstract="false" name="FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_MilestoneAccelerationMember" abstract="true" name="MilestoneAccelerationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ClassRRedeemableStockMember" abstract="true" name="ClassRRedeemableStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" abstract="false" name="DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_RoyaltyInvestmentsMember" abstract="true" name="RoyaltyInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionInitialTerm" abstract="false" name="RelatedPartyTransactionInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_NumberOfClassesOfVotingStock" abstract="false" name="NumberOfClassesOfVotingStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipNumberOfTranches" abstract="false" name="LongTermFundingPartnershipNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_IndividualLicenseesConcentrationRiskMember" abstract="true" name="IndividualLicenseesConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_XtandiMember" abstract="true" name="XtandiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionIIMember" abstract="true" name="AvillionIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" abstract="true" name="TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" abstract="false" name="ProceedsFromNoncontrollingInterestsResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PointSevenFivePercentSeniorNotesDue2023Member" abstract="true" name="PointSevenFivePercentSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FormerOperatingAndPersonnelPaymentsMember" abstract="true" name="FormerOperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_MorphoSysMember" abstract="true" name="MorphoSysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForOperatingCostsAndProfessionalServices" abstract="false" name="PaymentsForOperatingCostsAndProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EPAHoldingsMember" abstract="true" name="EPAHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesSharesIssued" abstract="false" name="DeferredSharesSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" abstract="true" name="LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" abstract="false" name="CollaborativeArrangementRightsAndObligationsPaymentOfCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForMilestones" abstract="false" name="PaymentsForMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" abstract="false" name="LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInFinancialRoyaltyAssets" abstract="false" name="IncreaseDecreaseInFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" abstract="true" name="TwoPointTwoZeroPercentSeniorNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" abstract="true" name="ThreePointThreeZeroPercentSeniorNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AgreementWithMSCIMember" abstract="true" name="AgreementWithMSCIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementExpectedProceeds" abstract="false" name="CollaborativeArrangementExpectedProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_BioCrystPharmaceuticalsIncMember" abstract="true" name="BioCrystPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" abstract="false" name="IncreaseDecreaseInCashCollectionsOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CysticFibrosisFranchiseMember" abstract="true" name="CysticFibrosisFranchiseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" abstract="false" name="DebtSecuritiesAvailableForSaleQuarterlyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesValueIssued" abstract="false" name="DeferredSharesValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CytokineticsCommercialLaunchFundingMember" abstract="true" name="CytokineticsCommercialLaunchFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentOfDividendsToShareholders" abstract="false" name="PaymentOfDividendsToShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EvrysdiMember" abstract="true" name="EvrysdiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rprx-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0febec77-c345-4713-be0a-9bf11cc48395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_5b65acc4-fd8b-43c2-ac89-607d31e32695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0febec77-c345-4713-be0a-9bf11cc48395" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_5b65acc4-fd8b-43c2-ac89-607d31e32695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_78ce5e3a-658e-434c-b2f8-e74ee5e4451a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0febec77-c345-4713-be0a-9bf11cc48395" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_78ce5e3a-658e-434c-b2f8-e74ee5e4451a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_f819563b-cb78-4d14-8abb-bd1f18d0662c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0febec77-c345-4713-be0a-9bf11cc48395" xlink:to="loc_us-gaap_InterestPayableCurrent_f819563b-cb78-4d14-8abb-bd1f18d0662c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9131f004-b436-41c7-bede-e343aa84ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc7f80af-c3bd-4765-b49d-9811ac8767e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9131f004-b436-41c7-bede-e343aa84ef51" xlink:to="loc_us-gaap_Liabilities_bc7f80af-c3bd-4765-b49d-9811ac8767e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_416adeae-b034-4cfe-9689-4fb4c3bb416a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9131f004-b436-41c7-bede-e343aa84ef51" xlink:to="loc_us-gaap_CommitmentsAndContingencies_416adeae-b034-4cfe-9689-4fb4c3bb416a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_175a076e-67b3-47d6-a452-c2b7ccc6c2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9131f004-b436-41c7-bede-e343aa84ef51" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_175a076e-67b3-47d6-a452-c2b7ccc6c2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_954864eb-b221-413f-b1aa-7b32d8f9761f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_AssetsCurrent_954864eb-b221-413f-b1aa-7b32d8f9761f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_799d2b52-f559-4577-9a1d-809dabd42920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_799d2b52-f559-4577-9a1d-809dabd42920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a70a7c-31bb-40fb-b44e-cc8f7e28faf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a70a7c-31bb-40fb-b44e-cc8f7e28faf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f916265f-16aa-4520-9242-108741d977ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f916265f-16aa-4520-9242-108741d977ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_80c78530-51f0-4b45-912f-5dbef5aea750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_80c78530-51f0-4b45-912f-5dbef5aea750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4087d0f3-e006-44ab-8535-1448194f76e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_EquityMethodInvestments_4087d0f3-e006-44ab-8535-1448194f76e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_822c447f-4baf-498f-ab71-84fa604b19b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1b74a3c-9c6c-47ca-b0e4-429e66a74b4f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_822c447f-4baf-498f-ab71-84fa604b19b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e98f3283-008c-4de6-9f61-89ae259705f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_53a31ef7-9691-491f-8e0c-0c38bc5fc9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e98f3283-008c-4de6-9f61-89ae259705f1" xlink:to="loc_us-gaap_LiabilitiesCurrent_53a31ef7-9691-491f-8e0c-0c38bc5fc9d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8c735041-eb1d-4ff5-97b3-0ca60ed459f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e98f3283-008c-4de6-9f61-89ae259705f1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8c735041-eb1d-4ff5-97b3-0ca60ed459f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_d7013702-e398-4ef1-9a43-2966f018f31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e98f3283-008c-4de6-9f61-89ae259705f1" xlink:to="loc_us-gaap_OtherLiabilities_d7013702-e398-4ef1-9a43-2966f018f31b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_120568b4-d33b-42a1-8167-10e0e9804b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_CommonStockValue_120568b4-d33b-42a1-8167-10e0e9804b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_6e71520a-8726-4fd1-8e31-8de5530b2de3" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesValueIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_rprx_DeferredSharesValueIssued_6e71520a-8726-4fd1-8e31-8de5530b2de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_312a9fda-c213-4cf9-ad31-d5cef2145aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_312a9fda-c213-4cf9-ad31-d5cef2145aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e956da21-fc11-4abe-bdb8-485420d2d6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e956da21-fc11-4abe-bdb8-485420d2d6b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d67bdca3-fd0d-452f-a0e4-a27731dbd3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_MinorityInterest_d67bdca3-fd0d-452f-a0e4-a27731dbd3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190c241e-8992-4360-98da-62c5d76cb39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190c241e-8992-4360-98da-62c5d76cb39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3e74565b-eda6-4a28-a62b-ee8d12776c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb007f6-cd58-435e-91e7-c03cadd185b9" xlink:to="loc_us-gaap_TreasuryStockValue_3e74565b-eda6-4a28-a62b-ee8d12776c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b9590ff-dca9-44ab-b7da-de389fc2ad08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b9590ff-dca9-44ab-b7da-de389fc2ad08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_9c2d97f2-4757-4552-a5dc-b9f1ec850e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_us-gaap_TradingSecuritiesDebt_9c2d97f2-4757-4552-a5dc-b9f1ec850e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_08a7e403-bb11-4fd9-8a06-b818d2e8cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_08a7e403-bb11-4fd9-8a06-b818d2e8cea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_67a449d3-23cc-4fb5-b73b-54d0cf13b619" xlink:href="rprx-20220630.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_rprx_AccruedRoyaltyReceivable_67a449d3-23cc-4fb5-b73b-54d0cf13b619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_886f5bc2-a5c8-4f38-b7c5-b42cd27c65c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_886f5bc2-a5c8-4f38-b7c5-b42cd27c65c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_d04595b8-e482-4fd3-8243-7ad7fc3d67ed" xlink:href="rprx-20220630.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_d04595b8-e482-4fd3-8243-7ad7fc3d67ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2cbcc262-9e97-4002-b311-ce52a493bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05c6699e-5dc4-45e7-aae4-a9c377e79017" xlink:to="loc_us-gaap_OtherAssetsCurrent_2cbcc262-9e97-4002-b311-ce52a493bb70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f33b0d7-cb77-45c3-b6e4-ada7a8ec6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49975f5a-0d6b-445f-a4ea-1f9642e1dc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7f33b0d7-cb77-45c3-b6e4-ada7a8ec6ab6" xlink:to="loc_us-gaap_ProfitLoss_49975f5a-0d6b-445f-a4ea-1f9642e1dc45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_56ff1212-cfbe-4f7a-b560-7da14723fe40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7f33b0d7-cb77-45c3-b6e4-ada7a8ec6ab6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_56ff1212-cfbe-4f7a-b560-7da14723fe40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_10552127-8530-4615-953f-2062db716fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_10552127-8530-4615-953f-2062db716fa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9cb2b8b8-efe9-4674-8e8a-44a96b9a25f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_InterestExpense_9cb2b8b8-efe9-4674-8e8a-44a96b9a25f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7b1f8e52-6724-46c5-9ee8-197c944323e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7b1f8e52-6724-46c5-9ee8-197c944323e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cea92338-f06b-402e-b1a3-2d25804dc1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cea92338-f06b-402e-b1a3-2d25804dc1f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_a533e588-c648-499d-9fe5-29bb1e157da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_a533e588-c648-499d-9fe5-29bb1e157da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b8fdc3fb-2f5c-451e-b06a-ab3c1e1032ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_InvestmentIncomeNet_b8fdc3fb-2f5c-451e-b06a-ab3c1e1032ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7f85489d-a4be-45a6-b0b3-a5e827e910c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_49792d50-04d9-406c-adfe-5f398e83c2bc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7f85489d-a4be-45a6-b0b3-a5e827e910c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83c820c0-5045-4995-b3c1-226d7f768fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8ef882dd-7b48-43b2-8559-c6e4ebabe66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83c820c0-5045-4995-b3c1-226d7f768fe2" xlink:to="loc_us-gaap_OperatingIncomeLoss_8ef882dd-7b48-43b2-8559-c6e4ebabe66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6571fe36-786e-44c7-82cd-99808484392a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83c820c0-5045-4995-b3c1-226d7f768fe2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6571fe36-786e-44c7-82cd-99808484392a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ac33c72-82dd-4b3a-a698-4f71b102910d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_917db9b7-4f44-4fd6-a746-258941682f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3ac33c72-82dd-4b3a-a698-4f71b102910d" xlink:to="loc_us-gaap_Revenues_917db9b7-4f44-4fd6-a746-258941682f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_326a0387-5457-4b0d-866c-3dba8e47b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3ac33c72-82dd-4b3a-a698-4f71b102910d" xlink:to="loc_us-gaap_CostsAndExpenses_326a0387-5457-4b0d-866c-3dba8e47b7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1a23dcf6-96b6-4b18-a162-e9bbe670f782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b204be47-1374-48a5-a543-aec18d2408a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1a23dcf6-96b6-4b18-a162-e9bbe670f782" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b204be47-1374-48a5-a543-aec18d2408a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1101bfa-24e2-4b16-ba74-673f2e5a0576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1a23dcf6-96b6-4b18-a162-e9bbe670f782" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1101bfa-24e2-4b16-ba74-673f2e5a0576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3d956abc-382f-44e3-be75-de8d0db6ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_31a3e99e-0368-4819-a7d6-bea49f74d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d956abc-382f-44e3-be75-de8d0db6ac35" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_31a3e99e-0368-4819-a7d6-bea49f74d438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_af5a5dd2-01c9-4c26-98eb-c128b0213a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d956abc-382f-44e3-be75-de8d0db6ac35" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_af5a5dd2-01c9-4c26-98eb-c128b0213a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_29f3e627-bff7-4f45-9c18-557ce63dedc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d956abc-382f-44e3-be75-de8d0db6ac35" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_29f3e627-bff7-4f45-9c18-557ce63dedc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_974dd5ba-fc55-4282-8570-55ab70bcb106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3d956abc-382f-44e3-be75-de8d0db6ac35" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_974dd5ba-fc55-4282-8570-55ab70bcb106" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cf246922-ce0c-4055-9a6c-6c9510a5ce8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d910f8c3-aca8-4b1a-b813-0c5a79571228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cf246922-ce0c-4055-9a6c-6c9510a5ce8a" xlink:to="loc_us-gaap_ProfitLoss_d910f8c3-aca8-4b1a-b813-0c5a79571228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cddf7c3e-9000-4c30-8ef4-9beda87b1839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cf246922-ce0c-4055-9a6c-6c9510a5ce8a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cddf7c3e-9000-4c30-8ef4-9beda87b1839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e0f981a-3ebd-48e7-b55f-5f96913b25c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e016c989-0594-4604-bdc3-5e8e5c285127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e0f981a-3ebd-48e7-b55f-5f96913b25c5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e016c989-0594-4604-bdc3-5e8e5c285127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_5ccb4105-a1cc-4e95-8bb7-7d0eead75cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e0f981a-3ebd-48e7-b55f-5f96913b25c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_5ccb4105-a1cc-4e95-8bb7-7d0eead75cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a84ac3f7-e2a5-43a6-a4b0-825ef2319207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e30fe7d9-7ab3-4ed5-a3f2-5ec8a04ba774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a84ac3f7-e2a5-43a6-a4b0-825ef2319207" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e30fe7d9-7ab3-4ed5-a3f2-5ec8a04ba774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bd9348a-f02f-46a3-bedf-608b5f9b7dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a84ac3f7-e2a5-43a6-a4b0-825ef2319207" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bd9348a-f02f-46a3-bedf-608b5f9b7dc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72a33df3-5cbc-4ff3-a9d9-f864ac0cf2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_950246f7-8b9d-4b35-ace9-c2d0e1d2d802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72a33df3-5cbc-4ff3-a9d9-f864ac0cf2d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_950246f7-8b9d-4b35-ace9-c2d0e1d2d802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b533ab3-6a7a-4b7f-8b84-b610dd689a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72a33df3-5cbc-4ff3-a9d9-f864ac0cf2d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b533ab3-6a7a-4b7f-8b84-b610dd689a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd2bc6e5-7265-4e85-92cc-6fc4f213ff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72a33df3-5cbc-4ff3-a9d9-f864ac0cf2d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd2bc6e5-7265-4e85-92cc-6fc4f213ff19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_a5d7ca2a-2423-487d-8a16-8d11186972da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_a5d7ca2a-2423-487d-8a16-8d11186972da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_16d161bc-e59a-4982-8867-192b6901d803" xlink:href="rprx-20220630.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_16d161bc-e59a-4982-8867-192b6901d803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_92532a8d-189d-404d-bf09-121334ee8d6d" xlink:href="rprx-20220630.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_92532a8d-189d-404d-bf09-121334ee8d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_a5ad8735-f779-42ee-b64e-13d570a8c1c6" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_a5ad8735-f779-42ee-b64e-13d570a8c1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_886a184d-76fa-4fb9-a769-16d932108b22" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30856aca-3fd0-44b3-8d60-59445c78e4d5" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_886a184d-76fa-4fb9-a769-16d932108b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_3975bcf7-457c-45ee-a504-3f07401e69f8" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_3975bcf7-457c-45ee-a504-3f07401e69f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_765e2400-ad59-44dd-a38c-e0c3096d8eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_765e2400-ad59-44dd-a38c-e0c3096d8eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_c3160027-8a34-434d-9408-03979622132e" xlink:href="rprx-20220630.xsd#rprx_PaymentsForMilestones"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_rprx_PaymentsForMilestones_c3160027-8a34-434d-9408-03979622132e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cbe67ab9-8b73-4283-aab5-566de2355bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cbe67ab9-8b73-4283-aab5-566de2355bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0f8e11e-d3c9-4458-9597-501bba03debe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0f8e11e-d3c9-4458-9597-501bba03debe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94f37765-20f0-4dad-beba-80aff6206a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94f37765-20f0-4dad-beba-80aff6206a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b6de23d3-f39e-4b3b-a65b-680f0df4aa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b6de23d3-f39e-4b3b-a65b-680f0df4aa5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fc1703ba-403e-4daf-a6de-3b240eea352a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fc1703ba-403e-4daf-a6de-3b240eea352a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_81383b35-b8be-419e-8ae9-353c0cb71e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_81383b35-b8be-419e-8ae9-353c0cb71e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_73cd416b-ba07-476e-8ded-b4503a665135" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_73cd416b-ba07-476e-8ded-b4503a665135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_b2ad4d8d-c815-4272-b4d1-3ca3c02c3e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_661d453e-cde1-4024-b7d8-776d573d7594" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_b2ad4d8d-c815-4272-b4d1-3ca3c02c3e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_b625a70a-d6af-4622-a026-d76079bcb520" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_b625a70a-d6af-4622-a026-d76079bcb520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_2db0f8a6-8f31-4676-baf5-86e9a3199057" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_2db0f8a6-8f31-4676-baf5-86e9a3199057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_a1c7b4ae-a1ee-4f19-bb51-2798ba31e3a8" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_a1c7b4ae-a1ee-4f19-bb51-2798ba31e3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_b41dc927-dec2-4ba8-a1d8-478b6c16516e" xlink:href="rprx-20220630.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_b41dc927-dec2-4ba8-a1d8-478b6c16516e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_206a18a4-fd39-4ad0-808f-5b3b5ea86727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_206a18a4-fd39-4ad0-808f-5b3b5ea86727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_530681af-1756-4757-b58d-4fb13f94a4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_us-gaap_InterestPaidNet_530681af-1756-4757-b58d-4fb13f94a4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_a10e556c-bcf3-4a9f-b2be-f24083442f5c" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_a10e556c-bcf3-4a9f-b2be-f24083442f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_29b68a9b-d10b-47c6-8bf9-ee9088438d47" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_29b68a9b-d10b-47c6-8bf9-ee9088438d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0fea4312-3c1f-4eb7-8a43-a547d9378f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0fea4312-3c1f-4eb7-8a43-a547d9378f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_54177ff4-a4e2-4b6e-8ff2-445b4f018275" xlink:href="rprx-20220630.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_54177ff4-a4e2-4b6e-8ff2-445b4f018275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_daa38351-0230-464b-8809-19805fa04f3f" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0c1d4f4-bd87-4d0e-b284-5fad727497ed" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_daa38351-0230-464b-8809-19805fa04f3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0b22030-8515-40b9-9635-b26f6aa21b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8928185e-0bce-42cf-8754-a8da278fbd54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0b22030-8515-40b9-9635-b26f6aa21b2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8928185e-0bce-42cf-8754-a8da278fbd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bec97-3334-4790-9470-b9b375144caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0b22030-8515-40b9-9635-b26f6aa21b2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bec97-3334-4790-9470-b9b375144caa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_b951c346-59ac-4508-a4c3-2120c04dc466" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_180809e2-2125-40a7-88f5-ba324abb1e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_b951c346-59ac-4508-a4c3-2120c04dc466" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_180809e2-2125-40a7-88f5-ba324abb1e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4e58c964-df0b-4da3-85d3-6ec4f4298b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_b951c346-59ac-4508-a4c3-2120c04dc466" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4e58c964-df0b-4da3-85d3-6ec4f4298b56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_b0552099-702b-4011-95ff-b486b479666b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_b951c346-59ac-4508-a4c3-2120c04dc466" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_b0552099-702b-4011-95ff-b486b479666b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_47522744-37a5-4f63-86cf-1ffa457b4154" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64fb5b4c-2a41-48ed-9047-d7d401e5009a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_47522744-37a5-4f63-86cf-1ffa457b4154" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64fb5b4c-2a41-48ed-9047-d7d401e5009a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_dc8fd20f-c549-47ff-a625-a71c01971092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_47522744-37a5-4f63-86cf-1ffa457b4154" xlink:to="loc_us-gaap_TradingSecuritiesDebt_dc8fd20f-c549-47ff-a625-a71c01971092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_51a974f9-01a5-44a2-a77d-204f19ff634b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_47522744-37a5-4f63-86cf-1ffa457b4154" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_51a974f9-01a5-44a2-a77d-204f19ff634b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_6ffd43bc-c1a5-4320-8a2d-d6ac88a83792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_47522744-37a5-4f63-86cf-1ffa457b4154" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_6ffd43bc-c1a5-4320-8a2d-d6ac88a83792" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_411ffeb9-cc50-4ac0-adb2-5a4dc6522c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_ca26d1fb-e092-42eb-a03a-3ec7c96a50de" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_411ffeb9-cc50-4ac0-adb2-5a4dc6522c67" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_ca26d1fb-e092-42eb-a03a-3ec7c96a50de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_af9f6f4c-e96e-4206-b2b5-0d8523fc66bf" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_411ffeb9-cc50-4ac0-adb2-5a4dc6522c67" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_af9f6f4c-e96e-4206-b2b5-0d8523fc66bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_b0b45d3d-898a-4fde-811f-e6e616ac4146" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ab64fcf2-6374-400c-88be-01ca910b6594" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_b0b45d3d-898a-4fde-811f-e6e616ac4146" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ab64fcf2-6374-400c-88be-01ca910b6594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_f8062c20-bab5-45fe-abac-282bc835694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_b0b45d3d-898a-4fde-811f-e6e616ac4146" xlink:to="loc_us-gaap_NotesReceivableGross_f8062c20-bab5-45fe-abac-282bc835694f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a53f0e51-476f-4a70-96f3-a4ae40ded062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c345e24-edbb-4e69-8bed-83939dafd473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a53f0e51-476f-4a70-96f3-a4ae40ded062" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c345e24-edbb-4e69-8bed-83939dafd473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a812d0b6-7e19-46ec-ae6f-5f765479c81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a53f0e51-476f-4a70-96f3-a4ae40ded062" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a812d0b6-7e19-46ec-ae6f-5f765479c81d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_415985d4-0f04-4abf-8f87-7f8735a8d098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_59f7a4a4-9857-44a4-8a5f-57f341a25364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_415985d4-0f04-4abf-8f87-7f8735a8d098" xlink:to="loc_us-gaap_LongTermDebtCurrent_59f7a4a4-9857-44a4-8a5f-57f341a25364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_63059090-05ff-4076-973a-4e2ecbc0f946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_415985d4-0f04-4abf-8f87-7f8735a8d098" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_63059090-05ff-4076-973a-4e2ecbc0f946" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_699d5111-e9ea-49c4-92eb-9b832995be04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_38c731bb-8e0d-4102-9656-9b64851e7c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_699d5111-e9ea-49c4-92eb-9b832995be04" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_38c731bb-8e0d-4102-9656-9b64851e7c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c2c9431b-8b3d-4243-80b6-b637ca2405e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_699d5111-e9ea-49c4-92eb-9b832995be04" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c2c9431b-8b3d-4243-80b6-b637ca2405e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f4a9a725-3344-4c53-8a60-035d1ce54483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f4a9a725-3344-4c53-8a60-035d1ce54483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7c22f5aa-a331-4f5d-8d84-7ef9a4c53d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7c22f5aa-a331-4f5d-8d84-7ef9a4c53d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0aa2a061-dcb5-4e4a-aa8e-45209face5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0aa2a061-dcb5-4e4a-aa8e-45209face5aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_773ed569-eb94-458d-9dbb-35dc686d79ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_773ed569-eb94-458d-9dbb-35dc686d79ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2f7fa9c6-8590-47ea-9593-b81be3a86bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2f7fa9c6-8590-47ea-9593-b81be3a86bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermDebtMaturityAfterYearFour_3bc02841-07e7-4c43-85aa-ff031ac70b84" xlink:href="rprx-20220630.xsd#rprx_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1234f0fc-7bf0-491f-a419-b521dd191739" xlink:to="loc_rprx_LongTermDebtMaturityAfterYearFour_3bc02841-07e7-4c43-85aa-ff031ac70b84" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_870e0127-35cb-46ba-b58b-dfb7a933c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3eaf01a3-67f4-4f35-bad4-9fe258b424ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_870e0127-35cb-46ba-b58b-dfb7a933c5a9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3eaf01a3-67f4-4f35-bad4-9fe258b424ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_fe5dbae7-292f-4307-893f-cad428998a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_870e0127-35cb-46ba-b58b-dfb7a933c5a9" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_fe5dbae7-292f-4307-893f-cad428998a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41161869-3c1f-44dd-878c-d8eaa7ea91dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d293a75e-9abd-49a0-ada8-80404a7adc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41161869-3c1f-44dd-878c-d8eaa7ea91dc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d293a75e-9abd-49a0-ada8-80404a7adc06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ba8c645-b262-4bc0-8376-e8bb42285b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_41161869-3c1f-44dd-878c-d8eaa7ea91dc" xlink:to="loc_us-gaap_ProfitLoss_2ba8c645-b262-4bc0-8376-e8bb42285b51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6376dd-9ae9-4c34-9532-dc30e2a8f644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f4e45ef9-e953-4151-87db-ff61e28dc746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6376dd-9ae9-4c34-9532-dc30e2a8f644" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f4e45ef9-e953-4151-87db-ff61e28dc746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_6c114470-3ee2-4bca-b10d-048035c46f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6376dd-9ae9-4c34-9532-dc30e2a8f644" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_6c114470-3ee2-4bca-b10d-048035c46f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0ea6afde-2941-49e0-9090-42cab49fe66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd6376dd-9ae9-4c34-9532-dc30e2a8f644" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0ea6afde-2941-49e0-9090-42cab49fe66d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IndirectCashFlowDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9fc6c4ab-5970-42d7-838b-4321c83e1e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9fc6c4ab-5970-42d7-838b-4321c83e1e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_c50202f4-e889-4655-8751-3112c49f8b49" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_c50202f4-e889-4655-8751-3112c49f8b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_a260b0ad-56ee-4035-8899-4ce1df8726d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_a260b0ad-56ee-4035-8899-4ce1df8726d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b6a7d1c2-749a-41c6-87b8-876688162389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b6a7d1c2-749a-41c6-87b8-876688162389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79af9a97-f7b9-4a86-b32b-770de5974eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79af9a97-f7b9-4a86-b32b-770de5974eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_3f9c1b87-7458-4a96-b173-450b75a1a22f" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_3f9c1b87-7458-4a96-b173-450b75a1a22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_7f32a3fd-a767-477c-b277-ed8df06c0425" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_7f32a3fd-a767-477c-b277-ed8df06c0425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3acf5fbd-e8c8-4071-a26a-4a0eb5422923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3acf5fbd-e8c8-4071-a26a-4a0eb5422923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7f409d90-04b6-4409-8212-872304b2612c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7f409d90-04b6-4409-8212-872304b2612c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_505c4d51-b42c-4bc0-b466-5379f84a26ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_505c4d51-b42c-4bc0-b466-5379f84a26ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9d46cc35-7439-4d4d-a4b9-0a8c93865757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9d46cc35-7439-4d4d-a4b9-0a8c93865757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_2bbca7f6-aa2f-407f-b0fb-8a15b60b7623" xlink:href="rprx-20220630.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_2bbca7f6-aa2f-407f-b0fb-8a15b60b7623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8eb48731-edbb-4a8d-870c-34328926896b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8eb48731-edbb-4a8d-870c-34328926896b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f407aa42-2030-4ec7-bb9f-186f2dd05138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_ShareBasedCompensation_f407aa42-2030-4ec7-bb9f-186f2dd05138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_576f7b15-953d-4368-af5f-c18137a3aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_576f7b15-953d-4368-af5f-c18137a3aabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_f36e2070-4e3f-4f57-a05a-7466233aaed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_f36e2070-4e3f-4f57-a05a-7466233aaed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_7e54c770-b904-45a0-8490-93a9ab4e5f9c" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_7e54c770-b904-45a0-8490-93a9ab4e5f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9e179440-80e4-407b-8010-9881f53052fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_ProfitLoss_9e179440-80e4-407b-8010-9881f53052fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_124ee593-606f-47c3-9ff1-432bcd6339d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_124ee593-606f-47c3-9ff1-432bcd6339d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_402cff76-f669-43e7-905b-19c743051b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e5d4326-e206-4302-bfcf-90f8b4db7c9e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_402cff76-f669-43e7-905b-19c743051b06" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rprx-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20220630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended" id="i808c9d33510d4d4ba47564e7c134a887_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_553d31f2-e781-4a6e-9b5a-9dd99bc960cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentType_553d31f2-e781-4a6e-9b5a-9dd99bc960cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d3a21fda-d8fc-4c05-a987-98394c9efb97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentQuarterlyReport_d3a21fda-d8fc-4c05-a987-98394c9efb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_da590c7b-546c-4c88-b8e7-f9f739b7f723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentPeriodEndDate_da590c7b-546c-4c88-b8e7-f9f739b7f723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d345f175-9ea1-4a3a-ba7d-f7a2859c59c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentTransitionReport_d345f175-9ea1-4a3a-ba7d-f7a2859c59c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_16a7e70b-3005-4d84-82e7-0f41cf556308" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityFileNumber_16a7e70b-3005-4d84-82e7-0f41cf556308" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e3a1aaf0-6e9b-4397-9888-e41de69a4207" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityRegistrantName_e3a1aaf0-6e9b-4397-9888-e41de69a4207" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8b5214f4-56bc-4b40-9ce8-1fdd386502b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8b5214f4-56bc-4b40-9ce8-1fdd386502b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1a20b71-25a3-4391-964e-157390060f16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1a20b71-25a3-4391-964e-157390060f16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f6eb40d2-7435-41b6-9fa9-dc18351623aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressAddressLine1_f6eb40d2-7435-41b6-9fa9-dc18351623aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a3d848f5-2b24-479d-9155-2148030e1909" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressCityOrTown_a3d848f5-2b24-479d-9155-2148030e1909" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5c0d2684-73ef-414b-8872-b3ae06c13525" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressStateOrProvince_5c0d2684-73ef-414b-8872-b3ae06c13525" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7c349ed-1172-4257-b204-181e26b3a1b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressPostalZipCode_d7c349ed-1172-4257-b204-181e26b3a1b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0e1caf8b-20db-450e-a938-9e68518622d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_CityAreaCode_0e1caf8b-20db-450e-a938-9e68518622d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68bbef2c-1516-4801-a62c-2c880e6d3568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_LocalPhoneNumber_68bbef2c-1516-4801-a62c-2c880e6d3568" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9bdcf227-1720-40a3-86d8-3fba469f0d4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_Security12bTitle_9bdcf227-1720-40a3-86d8-3fba469f0d4f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_88349fe1-85c8-4f78-80b8-ece738447829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_TradingSymbol_88349fe1-85c8-4f78-80b8-ece738447829" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_946e9ca3-8137-4257-b436-8473eec41174" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_SecurityExchangeName_946e9ca3-8137-4257-b436-8473eec41174" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_29b19435-784d-494a-8362-4e39ebd07a93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCurrentReportingStatus_29b19435-784d-494a-8362-4e39ebd07a93" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cbcc5091-2f31-4f15-a9dd-af3cb252fafa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityInteractiveDataCurrent_cbcc5091-2f31-4f15-a9dd-af3cb252fafa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6df2039f-48f1-49be-8a35-1bb38f25f42a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityFilerCategory_6df2039f-48f1-49be-8a35-1bb38f25f42a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a64e220e-e974-4f9b-9ff6-8c49c7787b0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntitySmallBusiness_a64e220e-e974-4f9b-9ff6-8c49c7787b0a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0a09e90a-12aa-4529-b015-1e90511dffd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_0a09e90a-12aa-4529-b015-1e90511dffd8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_61aa5fef-1c47-4ecc-9d20-c08b9cfaed7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityShellCompany_61aa5fef-1c47-4ecc-9d20-c08b9cfaed7d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2f66a335-2a93-4881-8715-6e8c7818353d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2f66a335-2a93-4881-8715-6e8c7818353d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_58eb61d3-d992-493b-b7f1-2275041feec5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCentralIndexKey_58eb61d3-d992-493b-b7f1-2275041feec5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d0bf3620-b710-4b54-8188-d0f36feb3fef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_CurrentFiscalYearEndDate_d0bf3620-b710-4b54-8188-d0f36feb3fef" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_786f6b41-8d57-4679-8333-5a87f23ebcd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentFiscalYearFocus_786f6b41-8d57-4679-8333-5a87f23ebcd5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2900377f-2d0a-473d-a6df-a7d24586d8cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2900377f-2d0a-473d-a6df-a7d24586d8cf" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_127f7245-06cf-48fd-8525-583bfeaa6900" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_AmendmentFlag_127f7245-06cf-48fd-8525-583bfeaa6900" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e9ec9b75-d1c8-484a-8965-55b273d26867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:to="loc_us-gaap_ClassOfStockDomain_e9ec9b75-d1c8-484a-8965-55b273d26867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:to="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf191bb4-138a-41e2-82b1-1db729076967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:to="loc_us-gaap_CommonClassAMember_bf191bb4-138a-41e2-82b1-1db729076967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8da4f463-4b45-4d94-aa03-263641662a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:to="loc_us-gaap_CommonClassBMember_8da4f463-4b45-4d94-aa03-263641662a2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i8907963aed704bfe9e2d7c12d240ac94_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:to="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a82e20f0-3008-4292-8d57-61c9f768edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a82e20f0-3008-4292-8d57-61c9f768edd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_de989412-ab49-4173-9d67-3d8cb08703fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_TradingSecuritiesDebt_de989412-ab49-4173-9d67-3d8cb08703fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0f6c27b0-4b29-4e17-b45c-2f6767bb2451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0f6c27b0-4b29-4e17-b45c-2f6767bb2451" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_b8538b61-3f91-415c-825b-515865986c33" xlink:href="rprx-20220630.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_rprx_AccruedRoyaltyReceivable_b8538b61-3f91-415c-825b-515865986c33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33750175-f1c1-462f-9ad2-69bcc8c58fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33750175-f1c1-462f-9ad2-69bcc8c58fe9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_cfc841d9-f68f-465b-8143-abca2763f857" xlink:href="rprx-20220630.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_cfc841d9-f68f-465b-8143-abca2763f857" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bea18d4b-10b7-41f2-a4db-020c71f1e697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_OtherAssetsCurrent_bea18d4b-10b7-41f2-a4db-020c71f1e697" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f4d3ba78-5ed7-45af-a983-ad7e9e32cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_AssetsCurrent_f4d3ba78-5ed7-45af-a983-ad7e9e32cdb2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_f976c46d-6c53-4aea-8700-bc4419ef9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_f976c46d-6c53-4aea-8700-bc4419ef9f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ea88b2c-ee0d-4be5-be73-febb7996907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ea88b2c-ee0d-4be5-be73-febb7996907a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e75ab12d-516e-4c21-91f0-aa17c8ea6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e75ab12d-516e-4c21-91f0-aa17c8ea6f2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c0a4bdd-9f9b-4438-a991-7ff0e88641b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c0a4bdd-9f9b-4438-a991-7ff0e88641b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e918dbc-a65a-447c-a6eb-1172a121127e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_EquityMethodInvestments_9e918dbc-a65a-447c-a6eb-1172a121127e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_890f5e5f-6cbf-45cd-9b73-2cd8c18bb0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_890f5e5f-6cbf-45cd-9b73-2cd8c18bb0e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eba50be1-d4f2-469b-ad3f-d51341bb03ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_Assets_eba50be1-d4f2-469b-ad3f-d51341bb03ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_62172064-68cd-4792-a7d4-10b48be5ef6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_62172064-68cd-4792-a7d4-10b48be5ef6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bc1d4fc-f5c3-415b-82a2-496f4ed7ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bc1d4fc-f5c3-415b-82a2-496f4ed7ab00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_ae8e8160-e944-44e1-989a-f35f5217f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_InterestPayableCurrent_ae8e8160-e944-44e1-989a-f35f5217f459" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8530d929-3bb0-40a6-81cf-0f5602e06a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_LiabilitiesCurrent_8530d929-3bb0-40a6-81cf-0f5602e06a2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c983711c-5f07-46f5-ad50-7dfc795aed72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c983711c-5f07-46f5-ad50-7dfc795aed72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_f1870279-3d09-4cf3-aeb3-4506c97cfc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_OtherLiabilities_f1870279-3d09-4cf3-aeb3-4506c97cfc2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_daa6d5db-01b2-4103-ae5a-76e8e709d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_Liabilities_daa6d5db-01b2-4103-ae5a-76e8e709d7a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_203ce0d6-a346-479c-a0a9-f9d3ba53720a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_203ce0d6-a346-479c-a0a9-f9d3ba53720a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_33444ba0-0314-4ba2-b3cd-1b3591879259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_CommonStockValue_33444ba0-0314-4ba2-b3cd-1b3591879259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_4cec2e90-8d21-4553-9741-b49bf8b7b487" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_rprx_DeferredSharesValueIssued_4cec2e90-8d21-4553-9741-b49bf8b7b487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_addc29d4-3939-40a2-ab12-e71fc998d775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_AdditionalPaidInCapital_addc29d4-3939-40a2-ab12-e71fc998d775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117500c1-29db-4eb7-8c01-fdbb285d90d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117500c1-29db-4eb7-8c01-fdbb285d90d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d36c1e7d-c4c5-4843-984e-d0a95bb081cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_MinorityInterest_d36c1e7d-c4c5-4843-984e-d0a95bb081cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afe7eb20-fa8d-4338-86cf-7e128d9932be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afe7eb20-fa8d-4338-86cf-7e128d9932be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5da1d4a2-b363-4acb-ad23-fee04b4e0fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_TreasuryStockValue_5da1d4a2-b363-4acb-ad23-fee04b4e0fca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b582750-497d-4044-a799-7385c27e8eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b582750-497d-4044-a799-7385c27e8eaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8253a07f-4169-4cf0-8f70-455c79c350f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8253a07f-4169-4cf0-8f70-455c79c350f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:to="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:to="loc_us-gaap_ClassOfStockDomain_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:to="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf991ebb-c00e-4371-a502-348e5d8aa616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_us-gaap_CommonClassAMember_bf991ebb-c00e-4371-a502-348e5d8aa616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8bec0dd1-7014-48af-a272-13ba3099e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_us-gaap_CommonClassBMember_8bec0dd1-7014-48af-a272-13ba3099e59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_72375e6c-c661-4a1b-adf4-b5a2b314cc82" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_rprx_ClassRRedeemableStockMember_72375e6c-c661-4a1b-adf4-b5a2b314cc82" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i7510ace0906f422898884dca10527db2_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_32a9f38f-69e3-4e53-b239-03db736d47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_32a9f38f-69e3-4e53-b239-03db736d47f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c692d3a9-c94e-4cea-bff1-7cdcb6568991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockSharesIssued_c692d3a9-c94e-4cea-bff1-7cdcb6568991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c666cd7-8853-4d92-8f7d-0fd80417c6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c666cd7-8853-4d92-8f7d-0fd80417c6f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_ee386e45-735f-4d90-b8b6-4a63df92d379" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_ee386e45-735f-4d90-b8b6-4a63df92d379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_86830e1c-84b5-43b1-888c-6985f16d759c" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesSharesIssued_86830e1c-84b5-43b1-888c-6985f16d759c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_0e2fa3f5-8189-4893-8305-8195d68ae77d" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_0e2fa3f5-8189-4893-8305-8195d68ae77d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1718f9bc-2325-4fc5-9766-70ba0a7c273b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:to="loc_us-gaap_ClassOfStockDomain_1718f9bc-2325-4fc5-9766-70ba0a7c273b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:to="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_2b1e0d0c-0b1e-479e-8c4c-cdb7737fec45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_us-gaap_CommonClassAMember_2b1e0d0c-0b1e-479e-8c4c-cdb7737fec45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2722f1cf-bda8-42d1-ab4d-c5dbc0012814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_us-gaap_CommonClassBMember_2722f1cf-bda8-42d1-ab4d-c5dbc0012814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_e305f569-4e20-401e-8b7d-0163678d6a23" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_rprx_ClassRRedeemableStockMember_e305f569-4e20-401e-8b7d-0163678d6a23" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i0c3bd9c00b5445039f5759cfdf132b41_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d84fe314-e98d-4057-9f14-fb83716fb06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_Revenues_d84fe314-e98d-4057-9f14-fb83716fb06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_be6b9cb7-22d8-43c7-aabb-8c9e2c860da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_be6b9cb7-22d8-43c7-aabb-8c9e2c860da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2c21059-f816-403a-a3b9-20c20e273eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2c21059-f816-403a-a3b9-20c20e273eae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ac34159e-7473-4a9c-bb4e-9c34569a3471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ac34159e-7473-4a9c-bb4e-9c34569a3471" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_24e8c29d-bfe6-453a-af3c-c5817b00036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_24e8c29d-bfe6-453a-af3c-c5817b00036e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0a4d40ab-a59e-414d-8b91-8ddf8042992e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_CostsAndExpenses_0a4d40ab-a59e-414d-8b91-8ddf8042992e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6438e859-0a63-46f9-b7ab-5f337b182acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6438e859-0a63-46f9-b7ab-5f337b182acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6049406e-b4cd-4cea-84f1-25f2ab7342e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6049406e-b4cd-4cea-84f1-25f2ab7342e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ed2379cc-f365-400f-b162-514d3b256b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_InterestExpense_ed2379cc-f365-400f-b162-514d3b256b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3211172f-839c-4a9a-af60-d27b1333e007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3211172f-839c-4a9a-af60-d27b1333e007" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd60bcc-79d3-414f-a110-0de632a5f630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd60bcc-79d3-414f-a110-0de632a5f630" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_41fd00bb-34fe-491b-a05c-dbb28219e916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_41fd00bb-34fe-491b-a05c-dbb28219e916" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_eaa4b003-b13f-4c3e-b7ab-6effdec0aa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_InvestmentIncomeNet_eaa4b003-b13f-4c3e-b7ab-6effdec0aa6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_53d6d41c-b041-4524-b8be-cf2b4b662ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_53d6d41c-b041-4524-b8be-cf2b4b662ade" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61b846c5-953a-4a8e-a303-68e22537d199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61b846c5-953a-4a8e-a303-68e22537d199" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f04413b3-7086-4e25-902c-c4b35e44f322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f04413b3-7086-4e25-902c-c4b35e44f322" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_adf7d050-0e5b-4255-b1d2-049e396479ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_adf7d050-0e5b-4255-b1d2-049e396479ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_012f9ce0-6828-4195-8b1f-b389f90900cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_ProfitLoss_012f9ce0-6828-4195-8b1f-b389f90900cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ab008e69-70d7-40b3-92fd-db6aeba0fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ab008e69-70d7-40b3-92fd-db6aeba0fce7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e042bc7e-6d31-4376-b39d-aaee84028348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_NetIncomeLoss_e042bc7e-6d31-4376-b39d-aaee84028348" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1a40a5d8-a242-4738-b545-7a1134440e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:to="loc_us-gaap_EarningsPerShareBasic_1a40a5d8-a242-4738-b545-7a1134440e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_746fdbf2-55a9-4f05-8251-11161a075a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:to="loc_us-gaap_EarningsPerShareDiluted_746fdbf2-55a9-4f05-8251-11161a075a4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b338c83-5a7a-44d8-ae6b-a9562bf03907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b338c83-5a7a-44d8-ae6b-a9562bf03907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e95d1709-7e02-4f69-a8fa-78a0720633af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e95d1709-7e02-4f69-a8fa-78a0720633af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:to="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e35a36bf-1bcb-441b-88ff-555200dcfb59_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:to="loc_srt_ProductsAndServicesDomain_e35a36bf-1bcb-441b-88ff-555200dcfb59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:to="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_240502cc-36e5-4ea7-81b0-cba7999c8589" xlink:href="rprx-20220630.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_240502cc-36e5-4ea7-81b0-cba7999c8589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_2c7bdafb-fe2e-4c53-90ac-fcd30137b9a3" xlink:href="rprx-20220630.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_2c7bdafb-fe2e-4c53-90ac-fcd30137b9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_ff5c34e1-05c7-459f-9603-77e0afd80f43" xlink:href="rprx-20220630.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_ff5c34e1-05c7-459f-9603-77e0afd80f43" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i3cd75fb1520c4ba3b0395b2fcaa65fe2_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b4bdca49-4fc0-41c2-bf48-7291984b7415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_SharesOutstanding_b4bdca49-4fc0-41c2-bf48-7291984b7415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc296365-88c3-4939-8e0a-25e7485ee7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc296365-88c3-4939-8e0a-25e7485ee7d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_42b32617-115b-4f34-bfc6-832381e8119a" xlink:href="rprx-20220630.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_42b32617-115b-4f34-bfc6-832381e8119a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_7b6758f9-f770-4312-8f99-4e27135e4085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_7b6758f9-f770-4312-8f99-4e27135e4085" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_55863c17-0ace-4212-85f8-2cedf3fb7b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_DividendsCash_55863c17-0ace-4212-85f8-2cedf3fb7b6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_d6e54e80-92af-416d-a21e-fcee54943a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_d6e54e80-92af-416d-a21e-fcee54943a56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e4a6beeb-ee94-4b62-aa7e-b2e3c23748ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityOther_e4a6beeb-ee94-4b62-aa7e-b2e3c23748ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb8a03c4-3807-48e7-85dd-5d46759b2d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb8a03c4-3807-48e7-85dd-5d46759b2d36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e65df832-e34f-46f1-bf3f-463f8116f848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e65df832-e34f-46f1-bf3f-463f8116f848" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_170ce244-a74e-4e98-a851-bda7cdb7cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_ProfitLoss_170ce244-a74e-4e98-a851-bda7cdb7cd6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d260f03e-2a69-432c-871e-92c2841367c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d260f03e-2a69-432c-871e-92c2841367c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_09139b62-bbee-4fd2-8063-c00b30f209c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_09139b62-bbee-4fd2-8063-c00b30f209c2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b2be223a-38f3-4959-a501-26e0be3bc02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1ab965c-9cc9-4cfa-a20f-80e8d2ce30c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:to="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_16a3b7b1-42d7-466f-8559-1eb7f145c7b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:to="loc_us-gaap_EquityComponentDomain_16a3b7b1-42d7-466f-8559-1eb7f145c7b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:to="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3538d585-105b-44a8-92f0-08436b9add25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_CommonStockMember_3538d585-105b-44a8-92f0-08436b9add25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_aa34364f-2376-4529-a10a-1dff2f08a4ea" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_rprx_DeferredSharesMember_aa34364f-2376-4529-a10a-1dff2f08a4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de257c86-dfd8-42df-aa4f-0b4afa3a72ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de257c86-dfd8-42df-aa4f-0b4afa3a72ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0299a04d-f5e1-46f9-9801-898bbacf4fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_RetainedEarningsMember_0299a04d-f5e1-46f9-9801-898bbacf4fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_cdc8239c-00a9-4501-975a-31add3fd8200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_cdc8239c-00a9-4501-975a-31add3fd8200" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_41d19c55-b15c-41d2-aada-c021fd1cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_NoncontrollingInterestMember_41d19c55-b15c-41d2-aada-c021fd1cb20b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92c814da-4776-4175-9ffd-e67f54d54d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_TreasuryStockMember_92c814da-4776-4175-9ffd-e67f54d54d8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7686cf6f-a5f8-42d5-8f01-3af798c1e404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:to="loc_us-gaap_ClassOfStockDomain_7686cf6f-a5f8-42d5-8f01-3af798c1e404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:to="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bdbb0931-d1f5-42de-a242-39f63187b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_us-gaap_CommonClassAMember_bdbb0931-d1f5-42de-a242-39f63187b7fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_d42315ae-3b47-4dd0-83a6-018f8b2426cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_us-gaap_CommonClassBMember_d42315ae-3b47-4dd0-83a6-018f8b2426cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_c11aaf16-cf32-4912-b4f2-e08b6b1adbbb" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_rprx_ClassRRedeemableStockMember_c11aaf16-cf32-4912-b4f2-e08b6b1adbbb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended" id="i5133458315414406bbcc2c805ab05250_CondensedConsolidatedStatementsofShareholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_2a120f75-8cf4-4edb-9b4a-e4a9441086cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_2a120f75-8cf4-4edb-9b4a-e4a9441086cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:to="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9193fea9-d284-4c1d-88b0-2a4e72af3cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:to="loc_us-gaap_ClassOfStockDomain_9193fea9-d284-4c1d-88b0-2a4e72af3cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:to="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8c1bf598-f35b-4f09-a845-747ab9d07aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:to="loc_us-gaap_CommonClassAMember_8c1bf598-f35b-4f09-a845-747ab9d07aae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#OrganizationandPurposeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended" id="if66be1358080414582f1ca08d9b0d87a_OrganizationandPurposeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_489284b8-2a67-44c5-a8a5-8422efff9ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_489284b8-2a67-44c5-a8a5-8422efff9ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_979cec06-fadf-446f-8dc7-157cbe3dc6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_979cec06-fadf-446f-8dc7-157cbe3dc6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_08250aba-1a62-4887-899e-bdab1a1fc924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_08250aba-1a62-4887-899e-bdab1a1fc924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54038d22-75c0-436e-a27e-2390ca94aa4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54038d22-75c0-436e-a27e-2390ca94aa4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_5d369ab9-39a5-4fa6-b82a-505de95c7985" xlink:href="rprx-20220630.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:to="loc_rprx_ExchangeOfferTransactionMember_5d369ab9-39a5-4fa6-b82a-505de95c7985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8e3810d5-95d1-498a-93ec-30a88dee9327_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:to="loc_dei_EntityDomain_8e3810d5-95d1-498a-93ec-30a88dee9327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:to="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_f5939349-c6fa-4c14-84a7-365e50f8f607" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_f5939349-c6fa-4c14-84a7-365e50f8f607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_2f2e1e7f-d2bb-41ec-8591-15b4f4bb7eb2" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_2f2e1e7f-d2bb-41ec-8591-15b4f4bb7eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a445bfa4-e78a-4191-b799-308242b0054f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:to="loc_srt_OwnershipDomain_a445bfa4-e78a-4191-b799-308242b0054f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:to="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_773ebb51-3fec-42fa-a807-b3edfc68dce6" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_773ebb51-3fec-42fa-a807-b3edfc68dce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_dbedb1d9-7008-4b59-88aa-65a9fb7332d5" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_dbedb1d9-7008-4b59-88aa-65a9fb7332d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="if83097ccefd2492d9544eb6792a0269a_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_a443b755-e174-4d0b-b3f4-eafbf3e5eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_a443b755-e174-4d0b-b3f4-eafbf3e5eb24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c11f0b39-fe05-4548-9d6b-c2361d0ed483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c11f0b39-fe05-4548-9d6b-c2361d0ed483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:to="loc_dei_EntityDomain_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:to="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_cc5a413c-bc43-4464-81ca-7974a19f4268" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_cc5a413c-bc43-4464-81ca-7974a19f4268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d74d5ee2-604c-479a-8407-047b9f44594c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d74d5ee2-604c-479a-8407-047b9f44594c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2b3be6e-c15d-46be-bcf8-ed88cb2d31bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2b3be6e-c15d-46be-bcf8-ed88cb2d31bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b839c4e-a887-4445-a988-a6624bf7e89d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7b839c4e-a887-4445-a988-a6624bf7e89d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_d8e0c199-25ee-47dd-84ff-d6ef1f68802d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:to="loc_us-gaap_FinanceReceivablesMember_d8e0c199-25ee-47dd-84ff-d6ef1f68802d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_47aa9393-aac2-4abd-9a9b-266e2b5ae647_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:to="loc_srt_OwnershipDomain_47aa9393-aac2-4abd-9a9b-266e2b5ae647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:to="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_396c9794-b332-4a4a-9e0a-1b2837639db3" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_396c9794-b332-4a4a-9e0a-1b2837639db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c1221eb-41c9-4ea5-8e3b-5e367928a556_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c1221eb-41c9-4ea5-8e3b-5e367928a556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:to="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_4c985510-db61-4f09-82af-61279893d501" xlink:href="rprx-20220630.xsd#rprx_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:to="loc_rprx_VertexMember_4c985510-db61-4f09-82af-61279893d501" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended" id="iad51abfbbea34aa4904629af8f98023a_AvailableforSaleDebtSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_ff00b3ec-91aa-4a91-8242-131fdd57a97c" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_ff00b3ec-91aa-4a91-8242-131fdd57a97c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_1d9b2843-8c98-4f63-985c-68761cc23b9a" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_1d9b2843-8c98-4f63-985c-68761cc23b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_06732ba4-eb2b-478a-8db7-5361b969cad3" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_06732ba4-eb2b-478a-8db7-5361b969cad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_3ba3c423-9c0b-41fe-9cb0-d20d7cc773e8" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_3ba3c423-9c0b-41fe-9cb0-d20d7cc773e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_6c2cdcb6-c36e-4c3f-a4fd-fa32fb71f622" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_6c2cdcb6-c36e-4c3f-a4fd-fa32fb71f622" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_45c530e6-3aa4-4f45-be7b-ab68931b66a0" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_45c530e6-3aa4-4f45-be7b-ab68931b66a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_f187e609-281a-4759-912d-9476f7943d59" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_f187e609-281a-4759-912d-9476f7943d59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_700e0e40-3b85-40ef-bd53-95bffb5ec5e1" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_700e0e40-3b85-40ef-bd53-95bffb5ec5e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_999bc87c-2892-4a75-84f1-1fdf90fdc995" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_999bc87c-2892-4a75-84f1-1fdf90fdc995" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_057e0704-c3e6-4a81-841e-c8f5668858b3" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_057e0704-c3e6-4a81-841e-c8f5668858b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_db426798-6c78-457c-afb0-5e324a853744" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_db426798-6c78-457c-afb0-5e324a853744" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_0a139f96-f76b-49a0-bc28-618e69e91632" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_0a139f96-f76b-49a0-bc28-618e69e91632" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementExpectedProceeds_f6d58fe2-863a-4a59-905d-98a3f4055045" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementExpectedProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementExpectedProceeds_f6d58fe2-863a-4a59-905d-98a3f4055045" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_4670c05c-e360-4138-a992-a039bc6c0a0a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_4670c05c-e360-4138-a992-a039bc6c0a0a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_6f79b0a7-607c-49e3-9161-8e10115227b1" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_6f79b0a7-607c-49e3-9161-8e10115227b1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad5a34fa-8bf6-47f2-b800-752fedc9fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad5a34fa-8bf6-47f2-b800-752fedc9fb01" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_102c1545-161e-40c7-b56a-be443b18ef01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_us-gaap_InvestmentIncomeNet_102c1545-161e-40c7-b56a-be443b18ef01" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c75bbb41-1c3a-4ad4-a596-51a49956a07c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c75bbb41-1c3a-4ad4-a596-51a49956a07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6e225491-d586-410e-9c19-8f588734a323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:to="loc_us-gaap_PreferredStockMember_6e225491-d586-410e-9c19-8f588734a323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_68b1ee03-dc54-45cf-a308-6f67d139a24e_default" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_68b1ee03-dc54-45cf-a308-6f67d139a24e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_36bba05d-8226-4016-b361-bf91859b5bab" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_36bba05d-8226-4016-b361-bf91859b5bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_50062018-0ef2-44d6-a38a-17f87471fd65" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_50062018-0ef2-44d6-a38a-17f87471fd65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_49fe2fe0-7e98-49ef-9da5-8ede76fef399_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:to="loc_us-gaap_ClassOfStockDomain_49fe2fe0-7e98-49ef-9da5-8ede76fef399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:to="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5cdc0a6b-c2a1-4e57-bd7a-283a0912db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5cdc0a6b-c2a1-4e57-bd7a-283a0912db2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2aefc544-8183-49ee-bead-9c34c337186f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2aefc544-8183-49ee-bead-9c34c337186f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25cb7664-fc86-40dd-935f-343af6d464fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25cb7664-fc86-40dd-935f-343af6d464fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_9d47e339-7c55-44d1-bae4-7b683e99657f" xlink:href="rprx-20220630.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:to="loc_rprx_MorphoSysMember_9d47e339-7c55-44d1-bae4-7b683e99657f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_47293dd7-b56e-40d1-b8b2-4b938ad5eec9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_47293dd7-b56e-40d1-b8b2-4b938ad5eec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5a9b59a9-ebe6-4723-8c6f-d4d86b12e77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5a9b59a9-ebe6-4723-8c6f-d4d86b12e77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0baa7f77-e516-4f83-913a-ec7517bd365f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0baa7f77-e516-4f83-913a-ec7517bd365f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_356338c4-ca44-426a-978d-061bb9acf7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_356338c4-ca44-426a-978d-061bb9acf7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_18bac02f-4e8c-49fa-a3fc-3e4022979350_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:to="loc_us-gaap_EquityComponentDomain_18bac02f-4e8c-49fa-a3fc-3e4022979350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:to="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b9988808-c374-4932-8b51-36bcae11edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b9988808-c374-4932-8b51-36bcae11edc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27b9b896-460d-4cb9-bae8-cc60aa94c615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27b9b896-460d-4cb9-bae8-cc60aa94c615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bb913fc3-102c-48bb-b399-f2dee2720a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:to="loc_us-gaap_SubsequentEventMember_bb913fc3-102c-48bb-b399-f2dee2720a1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i3a5136381c334d05bb4d1124d341add0_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bac85938-a2c1-4e4c-aef7-5a57eb165458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bac85938-a2c1-4e4c-aef7-5a57eb165458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78b8173f-fb8f-4335-bb1a-7f87e0cc9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78b8173f-fb8f-4335-bb1a-7f87e0cc9d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ae1fdd4b-840a-4fca-b983-a698c5b6f0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ae1fdd4b-840a-4fca-b983-a698c5b6f0dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6ac070ca-71e8-443d-888f-d92b0ae858a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6ac070ca-71e8-443d-888f-d92b0ae858a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8430c5ee-6458-4e9c-a841-de24972383b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8430c5ee-6458-4e9c-a841-de24972383b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_d3e03f32-00b5-441b-a2c3-aba1caefd19a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_d3e03f32-00b5-441b-a2c3-aba1caefd19a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_fba0138c-0d01-4573-a041-7bb528d6f899" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_fba0138c-0d01-4573-a041-7bb528d6f899" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b188c90-1cae-4cb8-a273-07fa984a0768_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b188c90-1cae-4cb8-a273-07fa984a0768_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0d96860f-9e3e-4f6e-a5a9-e7a19541a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_us-gaap_PreferredStockMember_0d96860f-9e3e-4f6e-a5a9-e7a19541a19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_2776b7d0-3a6e-4251-b0c9-0918311502c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_us-gaap_ForwardContractsMember_2776b7d0-3a6e-4251-b0c9-0918311502c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_bc5bb13c-53df-48f1-8b09-d0efb3ed8609" xlink:href="rprx-20220630.xsd#rprx_FundingCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_rprx_FundingCommitmentsMember_bc5bb13c-53df-48f1-8b09-d0efb3ed8609" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended" id="ib2c17facd61d4ad1801b449d629130e6_FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e684af55-7088-4c22-90ea-4a502e321537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e684af55-7088-4c22-90ea-4a502e321537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_2edfb52a-28c6-4154-872f-4db54a6983bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_TradingSecuritiesDebt_2edfb52a-28c6-4154-872f-4db54a6983bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12106edc-518c-43d7-9e92-53b77d654f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12106edc-518c-43d7-9e92-53b77d654f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_1246fa0f-fa7e-4ce6-8430-0209401e6a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_1246fa0f-fa7e-4ce6-8430-0209401e6a42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_a18b9679-253d-451b-85ad-6bf8af7187b3" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_a18b9679-253d-451b-85ad-6bf8af7187b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e82187af-1eb2-453c-aeb6-c17681702943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e82187af-1eb2-453c-aeb6-c17681702943" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_090d60b1-aba3-4ac6-9c0c-d4249a28d37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_090d60b1-aba3-4ac6-9c0c-d4249a28d37a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_bceff668-1caa-4f77-8867-cddf8a7c1691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_bceff668-1caa-4f77-8867-cddf8a7c1691" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_58dd2791-1a3e-4d21-b175-d62ca2d56cee" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_58dd2791-1a3e-4d21-b175-d62ca2d56cee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d1d6a31c-ac92-4066-adb8-3e92d5a86f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_us-gaap_DerivativeLiabilities_d1d6a31c-ac92-4066-adb8-3e92d5a86f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_0d9ab7c6-51b6-4301-b94c-4c146186c45c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_0d9ab7c6-51b6-4301-b94c-4c146186c45c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_5420d442-5c46-48aa-a83f-640a1aeae21c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_5420d442-5c46-48aa-a83f-640a1aeae21c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_6339345b-4797-4e9c-815b-bdbfbd0d9209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_MoneyMarketFundsMember_6339345b-4797-4e9c-815b-bdbfbd0d9209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f1fe593b-ed54-4a80-8375-06396cfc39b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_CommercialPaperMember_f1fe593b-ed54-4a80-8375-06396cfc39b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_c7a09547-6428-425b-a30a-ac506a4b20da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_CertificatesOfDepositMember_c7a09547-6428-425b-a30a-ac506a4b20da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_223c8bc1-2ecc-4c86-b6ee-1966b4cf6874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_223c8bc1-2ecc-4c86-b6ee-1966b4cf6874" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_459cd430-dd58-483a-b3ab-b4bee0161f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_CommercialPaperMember_459cd430-dd58-483a-b3ab-b4bee0161f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_747cf2e9-ac35-4cbd-b7b5-d43b3de864d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_CertificatesOfDepositMember_747cf2e9-ac35-4cbd-b7b5-d43b3de864d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_16ced758-6cca-4cfb-bb3d-1b7496591597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_16ced758-6cca-4cfb-bb3d-1b7496591597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b7d200ed-4d0f-44e7-8b17-cb16b9bfd8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_DebtSecuritiesMember_b7d200ed-4d0f-44e7-8b17-cb16b9bfd8ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_a12b489e-f58d-4ba9-b247-50d25e550b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_ForwardContractsMember_a12b489e-f58d-4ba9-b247-50d25e550b8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_24b1c020-bfd3-4990-804b-662caa5ba0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_24b1c020-bfd3-4990-804b-662caa5ba0ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fb59a892-c1be-4791-8fb2-b853eab9954b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fb59a892-c1be-4791-8fb2-b853eab9954b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5141f71f-1e40-48f0-bce2-59d8416731fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5141f71f-1e40-48f0-bce2-59d8416731fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dcdac034-3493-429f-827d-36e20ee19882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dcdac034-3493-429f-827d-36e20ee19882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bb35204f-708c-4f06-866d-13f2afa8d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bb35204f-708c-4f06-866d-13f2afa8d1d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9bebe684-9258-4856-ba38-4c114c6b862c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9bebe684-9258-4856-ba38-4c114c6b862c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember_f2625c38-05e0-47b2-90c1-caaae2329854" xlink:href="rprx-20220630.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:to="loc_rprx_RoyaltyInvestmentsMember_f2625c38-05e0-47b2-90c1-caaae2329854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember_0e0eaca9-d70c-4a4c-b4c1-932c7bbeefc5" xlink:href="rprx-20220630.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:to="loc_rprx_CytokineticsFundingCommitmentMember_0e0eaca9-d70c-4a4c-b4c1-932c7bbeefc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9676a1c-6c2b-40a2-acc0-6eb89b468b19_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9676a1c-6c2b-40a2-acc0-6eb89b468b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_d7ca98c4-2d85-4dff-86b2-9d6c0521f3e7" xlink:href="rprx-20220630.xsd#rprx_MilestoneAccelerationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:to="loc_rprx_MilestoneAccelerationMember_d7ca98c4-2d85-4dff-86b2-9d6c0521f3e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ic58b26a040f9459c880608103da03433_FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_506c89dc-89a9-4599-9631-b4b6533466a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_506c89dc-89a9-4599-9631-b4b6533466a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed3e63af-a256-4a62-b167-5ff726afba93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed3e63af-a256-4a62-b167-5ff726afba93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c25eca09-1e35-4995-941a-dab2bc53907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c25eca09-1e35-4995-941a-dab2bc53907a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_493161b3-97a8-4be1-941a-02647a0303aa" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_493161b3-97a8-4be1-941a-02647a0303aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_6592d567-41f9-4a30-9d1d-3b611b9a3b16" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_6592d567-41f9-4a30-9d1d-3b611b9a3b16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_9a0f5225-f80f-4ecd-a962-daafdb2ffa6a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_9a0f5225-f80f-4ecd-a962-daafdb2ffa6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_848eeb62-72bd-442e-b4f7-2cbde1600ddc" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_848eeb62-72bd-442e-b4f7-2cbde1600ddc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_0998cda7-3a6d-4e36-8fa6-ffd48e51ef1d" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_0998cda7-3a6d-4e36-8fa6-ffd48e51ef1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_07ba04e3-17d8-4084-8265-4b9a4c1e631c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_07ba04e3-17d8-4084-8265-4b9a4c1e631c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_955d40b6-caa2-4b07-bc4a-23f8653cbdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_955d40b6-caa2-4b07-bc4a-23f8653cbdb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_d7834552-e7bb-48b1-9927-0eab62a2964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_d7834552-e7bb-48b1-9927-0eab62a2964c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_c0c82218-6568-455c-9a5e-89779c550a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_c0c82218-6568-455c-9a5e-89779c550a45" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_613459fd-e9d2-41d6-b6a2-ec0902d6796c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_613459fd-e9d2-41d6-b6a2-ec0902d6796c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eab9314b-d70f-4dbf-bcb2-b8e2f2b1052d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eab9314b-d70f-4dbf-bcb2-b8e2f2b1052d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab416edc-2ee4-49d6-b0f5-c40c63d9691a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab416edc-2ee4-49d6-b0f5-c40c63d9691a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember_63dc3131-a428-435b-97c7-cc599709401f" xlink:href="rprx-20220630.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:to="loc_rprx_CytokineticsCommercialLaunchFundingMember_63dc3131-a428-435b-97c7-cc599709401f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_08c12bde-f8ab-45b9-a850-3393e0b2d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:to="loc_us-gaap_PreferredStockMember_08c12bde-f8ab-45b9-a850-3393e0b2d79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bdeac132-503c-411a-86ea-06b754568c10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:to="loc_us-gaap_ClassOfStockDomain_bdeac132-503c-411a-86ea-06b754568c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:to="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_55ac044f-4178-454b-b65b-239916f18b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_55ac044f-4178-454b-b65b-239916f18b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d7fba99-063b-4902-a0b7-4ab45e42fbe0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d7fba99-063b-4902-a0b7-4ab45e42fbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_f4f5aae4-4aad-4264-980f-2ef2db447b08" xlink:href="rprx-20220630.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_f4f5aae4-4aad-4264-980f-2ef2db447b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_a1cd4e60-57a9-42de-8861-9a224f591013" xlink:href="rprx-20220630.xsd#rprx_MilestoneAccelerationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:to="loc_rprx_MilestoneAccelerationMember_a1cd4e60-57a9-42de-8861-9a224f591013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4362c5e1-7af8-4d5b-9b09-1f79624ec074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4362c5e1-7af8-4d5b-9b09-1f79624ec074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6ad35566-62e6-4ad7-90be-6913c4efebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6ad35566-62e6-4ad7-90be-6913c4efebf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1058033a-2246-4181-b937-e28c9a438771_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1058033a-2246-4181-b937-e28c9a438771_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_513e6a65-8f4a-4cd9-9990-feed224c3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_513e6a65-8f4a-4cd9-9990-feed224c3744" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i90e4d37cebbd47e487c2349ad84413bf_FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_44326fbf-02ea-4746-9a7c-88b205fe11dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_44326fbf-02ea-4746-9a7c-88b205fe11dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_447f936c-74e6-4722-a8c9-3819956902d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_447f936c-74e6-4722-a8c9-3819956902d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_72059aaf-32a6-4862-b7df-d98402b6cc28" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_72059aaf-32a6-4862-b7df-d98402b6cc28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_aef24a3c-2198-4f14-a7e1-f16eddff63a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_aef24a3c-2198-4f14-a7e1-f16eddff63a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6204c57e-11a3-43bc-8bc5-040b53b05b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6204c57e-11a3-43bc-8bc5-040b53b05b67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_7caeb015-7250-40ab-bc2a-b87f154dd467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_7caeb015-7250-40ab-bc2a-b87f154dd467" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_92ce5704-5111-4f47-95c3-7cf94a5bc7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_92ce5704-5111-4f47-95c3-7cf94a5bc7ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_76aebe8f-d82b-4796-8c0b-83cc231f0d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_76aebe8f-d82b-4796-8c0b-83cc231f0d61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2f007c63-6cba-4dd1-a7ea-523135462e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2f007c63-6cba-4dd1-a7ea-523135462e6d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_6502f4c0-b11b-433d-8675-2c25b6ef1b5f" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_6502f4c0-b11b-433d-8675-2c25b6ef1b5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ef4ebf3a-48be-4d9a-9a9f-2c3d036128f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4c3bcca-5852-4931-8339-048a9f016d45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4c3bcca-5852-4931-8339-048a9f016d45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0ff0286b-f7e9-4754-ac90-c2181620bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_EquitySecuritiesMember_0ff0286b-f7e9-4754-ac90-c2181620bb6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_cdfbfa57-52c1-40e0-8ac7-a1a370433ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_cdfbfa57-52c1-40e0-8ac7-a1a370433ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3f35eeb7-c7b1-42d3-989a-d3d66e98d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_ForwardContractsMember_3f35eeb7-c7b1-42d3-989a-d3d66e98d3f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_ec936124-1652-43b1-9e18-862450e08f19" xlink:href="rprx-20220630.xsd#rprx_FundingCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_rprx_FundingCommitmentsMember_ec936124-1652-43b1-9e18-862450e08f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember_68a5fe72-25b7-4291-95ce-958cd08187f2" xlink:href="rprx-20220630.xsd#rprx_DerivativeAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_rprx_DerivativeAssetMember_68a5fe72-25b7-4291-95ce-958cd08187f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_68b99e6c-18cd-43aa-9872-f87551a502aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_RoyaltyMember_68b99e6c-18cd-43aa-9872-f87551a502aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ebca2352-eb6f-4df6-9889-1d786aeb77c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ebca2352-eb6f-4df6-9889-1d786aeb77c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_62ade9d0-d9b6-4b24-a0b7-9fa1ef1a668b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_62ade9d0-d9b6-4b24-a0b7-9fa1ef1a668b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended" id="ia00e8b74b8274133ac62d335df37e6a8_FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ffc1b733-fca5-484a-a1b8-33924d95abc3" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ffc1b733-fca5-484a-a1b8-33924d95abc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a17e17c-929c-44d2-a903-51304b30f473_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a17e17c-929c-44d2-a903-51304b30f473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e326b44d-6adf-4386-acd2-f3d277e7f065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e326b44d-6adf-4386-acd2-f3d277e7f065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c09e517a-4da0-4440-8f75-37276639bdf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c09e517a-4da0-4440-8f75-37276639bdf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8db94c5d-5384-40f7-ad39-5049911d38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8db94c5d-5384-40f7-ad39-5049911d38d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c29e843d-7f63-4113-8cf7-1b528ff08631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c29e843d-7f63-4113-8cf7-1b528ff08631" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended" id="i95db584d3e7f4c4586198091a93b15db_FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_dd6a7779-87a4-4320-92a2-bd67614b55e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_us-gaap_NotesReceivableGross_dd6a7779-87a4-4320-92a2-bd67614b55e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ae7bc426-4198-4389-b29a-027e62e19fb4" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ae7bc426-4198-4389-b29a-027e62e19fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8c53fcda-49d7-4b38-a5ae-0521e3b0b870" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8c53fcda-49d7-4b38-a5ae-0521e3b0b870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_ffd5f81f-5a4d-4886-931b-197cc7169ef3" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_ffd5f81f-5a4d-4886-931b-197cc7169ef3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_6955f58c-d47a-43b4-b7cf-a0ede915b4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_us-gaap_NotesReceivableNet_6955f58c-d47a-43b4-b7cf-a0ede915b4a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_c5f163c9-3f65-4624-bb1c-a2facd81f66f" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_c5f163c9-3f65-4624-bb1c-a2facd81f66f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:to="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cebbb6d1-cf99-46c3-8c61-32930113c1b0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:to="loc_srt_NameOfMajorCustomerDomain_cebbb6d1-cf99-46c3-8c61-32930113c1b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_5bf06487-a20c-434b-9ffb-6e9d5d035819" xlink:href="rprx-20220630.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_5bf06487-a20c-434b-9ffb-6e9d5d035819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_45ec33c5-6afe-42d0-ba32-dc7bc6dfdca3" xlink:href="rprx-20220630.xsd#rprx_TysabriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_TysabriMember_45ec33c5-6afe-42d0-ba32-dc7bc6dfdca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_0ab63dae-ac85-47df-9ed5-98ee32f0bcc7" xlink:href="rprx-20220630.xsd#rprx_ImbruvicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_ImbruvicaMember_0ab63dae-ac85-47df-9ed5-98ee32f0bcc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_5a83591d-5de7-4637-b249-23ce1ae1682f" xlink:href="rprx-20220630.xsd#rprx_XtandiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_XtandiMember_5a83591d-5de7-4637-b249-23ce1ae1682f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_7807583e-f227-4009-82fb-595d63f24309" xlink:href="rprx-20220630.xsd#rprx_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_TremfyaMember_7807583e-f227-4009-82fb-595d63f24309" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_9ad3c062-8f1a-4db3-b38c-f53bce587448" xlink:href="rprx-20220630.xsd#rprx_EvrysdiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_EvrysdiMember_9ad3c062-8f1a-4db3-b38c-f53bce587448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_8d4b0a92-1085-4831-92f7-67952461fd1f" xlink:href="rprx-20220630.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_8d4b0a92-1085-4831-92f7-67952461fd1f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended" id="i2a8da7c7137e464ab04b519b3d2f8ff8_IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a88bcc9e-537a-4436-b634-7c085db7a710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a88bcc9e-537a-4436-b634-7c085db7a710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8a96766-a8f6-4102-9cd3-de4c852e3992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8a96766-a8f6-4102-9cd3-de4c852e3992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2376fdb-1677-4fb6-8bc6-a1e4166d49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2376fdb-1677-4fb6-8bc6-a1e4166d49b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d84a6b57-43bf-49bb-b737-83b293d6d275_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d84a6b57-43bf-49bb-b737-83b293d6d275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVInhibitorsMember_17f744e4-2651-4aa2-8a47-f1e13dafb08c" xlink:href="rprx-20220630.xsd#rprx_DPPIVInhibitorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:to="loc_rprx_DPPIVInhibitorsMember_17f744e4-2651-4aa2-8a47-f1e13dafb08c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended" id="i089c0ca75f3d4536af85c1081fd8e78c_IntangibleRoyaltyAssetsNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_afd7a492-576d-42d6-b1bd-c0123331ee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_afd7a492-576d-42d6-b1bd-c0123331ee9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_362c9ebe-edb2-472c-9e5d-48d8d6706e9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_362c9ebe-edb2-472c-9e5d-48d8d6706e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVInhibitorsMember_a5ee311a-7e2b-4795-a310-6ac749bd3b62" xlink:href="rprx-20220630.xsd#rprx_DPPIVInhibitorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:to="loc_rprx_DPPIVInhibitorsMember_a5ee311a-7e2b-4795-a310-6ac749bd3b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1004f0d8-b7a4-4526-93cf-8fa7578e5700_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1004f0d8-b7a4-4526-93cf-8fa7578e5700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1572b2e5-b202-4738-8e3e-1ea24f11e574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:to="loc_us-gaap_SalesRevenueNetMember_1572b2e5-b202-4738-8e3e-1ea24f11e574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5172d35c-cfe1-4127-a80f-9919dccad81c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5172d35c-cfe1-4127-a80f-9919dccad81c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_61726ebd-7d03-4ef3-9a46-845136c96364" xlink:href="rprx-20220630.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_61726ebd-7d03-4ef3-9a46-845136c96364" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended" id="i1cff3de56df84c8aadef36c61510f883_NonConsolidatedAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2c1934ed-d8cf-4cab-8a4f-4d7f9793e645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_EquityMethodInvestments_2c1934ed-d8cf-4cab-8a4f-4d7f9793e645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1361a962-1592-409e-9eaf-87004ad08f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1361a962-1592-409e-9eaf-87004ad08f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4f29d6ac-39d1-435e-8565-ae8836292d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4f29d6ac-39d1-435e-8565-ae8836292d4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7de9aea7-65cc-4508-a118-3cc0949dce77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7de9aea7-65cc-4508-a118-3cc0949dce77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_fc0e443a-d1a3-4040-b249-0309ca8db919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_OtherCommitment_fc0e443a-d1a3-4040-b249-0309ca8db919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentIncreaseDecrease_2925d695-84b5-473a-a9da-c4be660fdd47" xlink:href="rprx-20220630.xsd#rprx_OtherCommitmentIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_rprx_OtherCommitmentIncreaseDecrease_2925d695-84b5-473a-a9da-c4be660fdd47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_20adcdd3-9579-496a-b14c-d56c23c95fc2" xlink:href="rprx-20220630.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_20adcdd3-9579-496a-b14c-d56c23c95fc2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0e4c16ae-d2f9-40ad-8745-0865e8a3023f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0e4c16ae-d2f9-40ad-8745-0865e8a3023f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_f6d53291-c1f8-4553-8d3b-4ec911e0c063" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_f6d53291-c1f8-4553-8d3b-4ec911e0c063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_4e05ae00-d1cb-4eea-a52c-d801eb07c464" xlink:href="rprx-20220630.xsd#rprx_AvillionEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionEntitiesMember_4e05ae00-d1cb-4eea-a52c-d801eb07c464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_7512181a-a2fe-4178-bac0-665bfcb8a7bb" xlink:href="rprx-20220630.xsd#rprx_AvillionIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionIMember_7512181a-a2fe-4178-bac0-665bfcb8a7bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_f2f12b88-f278-4964-9b79-337987775bd1" xlink:href="rprx-20220630.xsd#rprx_AvillionIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionIIMember_f2f12b88-f278-4964-9b79-337987775bd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:to="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_19afba29-85c5-4e3a-9649-304a49617eef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:to="loc_us-gaap_OtherCommitmentsDomain_19afba29-85c5-4e3a-9649-304a49617eef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:to="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_26d99088-6c01-40b9-9c6b-6d40a02e1d70" xlink:href="rprx-20220630.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_26d99088-6c01-40b9-9c6b-6d40a02e1d70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended" id="ibec372263aec4549a5419fe0957983e1_ResearchDevelopmentRDFundingExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cc43e75a-7a1a-4551-b97b-b69ef2e38d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cc43e75a-7a1a-4551-b97b-b69ef2e38d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:to="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3444bd81-e6a5-4bab-819d-9cb7833f92b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3444bd81-e6a5-4bab-819d-9cb7833f92b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember_df0d1d4e-068d-46b5-b585-d356ff8a6745" xlink:href="rprx-20220630.xsd#rprx_CytokineticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:to="loc_rprx_CytokineticsMember_df0d1d4e-068d-46b5-b585-d356ff8a6745" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended" id="i6f58bc6b9ec3451a8de681ba07111677_BorrowingsScheduleofBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1da66a8a-e3a1-4447-9c22-ea0b6eb7ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1da66a8a-e3a1-4447-9c22-ea0b6eb7ed07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_ca017951-2023-4711-a824-ac0cc808f24b" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_ca017951-2023-4711-a824-ac0cc808f24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_867e977f-cac0-4d03-b3f8-aec40f321f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_867e977f-cac0-4d03-b3f8-aec40f321f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cafd7b97-62d8-45a8-9214-a8439720c600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cafd7b97-62d8-45a8-9214-a8439720c600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_054f8eeb-7a7d-408d-af32-e691184713f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebt_054f8eeb-7a7d-408d-af32-e691184713f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_82500122-ce62-4a58-97a3-15c6c788ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebtCurrent_82500122-ce62-4a58-97a3-15c6c788ca7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e4c5e050-4594-49ab-835d-9750cd7c5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e4c5e050-4594-49ab-835d-9750cd7c5644" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e4f8d87-16e6-4552-985c-c244000406a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e4f8d87-16e6-4552-985c-c244000406a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_66d3b750-6cd5-45d4-a1e9-b788c8aa4e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:to="loc_us-gaap_UnsecuredDebtMember_66d3b750-6cd5-45d4-a1e9-b788c8aa4e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_072f9aa8-91eb-4282-ab7d-251e9a6aabc8" xlink:href="rprx-20220630.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_072f9aa8-91eb-4282-ab7d-251e9a6aabc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_b4280445-4502-4953-9885-dd835480d069" xlink:href="rprx-20220630.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_b4280445-4502-4953-9885-dd835480d069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_a1871779-8b7e-4d35-ae66-fcd367e83273" xlink:href="rprx-20220630.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_a1871779-8b7e-4d35-ae66-fcd367e83273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_5aae9dc8-0518-4cf3-ba4b-384e470f4d3d" xlink:href="rprx-20220630.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_5aae9dc8-0518-4cf3-ba4b-384e470f4d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_1ec7ae04-3389-4208-b9a8-2dbe5e893029" xlink:href="rprx-20220630.xsd#rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_1ec7ae04-3389-4208-b9a8-2dbe5e893029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_341265e2-3c7f-4ea4-bbf2-eef9142efecc" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_341265e2-3c7f-4ea4-bbf2-eef9142efecc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_38bfed64-1fd3-4f7f-91e4-8b543e46b41b" xlink:href="rprx-20220630.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_38bfed64-1fd3-4f7f-91e4-8b543e46b41b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member_b5769c44-10e9-48e3-a097-302779282f02" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeFiveZeroPercentDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member_b5769c44-10e9-48e3-a097-302779282f02" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i259a3a7b5eb5429bb4dc40c9492dda4b_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_559ed552-cd5d-4cfa-a060-bf9de6d4c7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_559ed552-cd5d-4cfa-a060-bf9de6d4c7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1ff9ca3-f525-4fc0-89c3-a548e4239876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1ff9ca3-f525-4fc0-89c3-a548e4239876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_eda5bf23-8a43-4892-8789-4b7d3e4ed681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_eda5bf23-8a43-4892-8789-4b7d3e4ed681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_545fe513-7c76-4173-bbc5-29dcb81d94e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_545fe513-7c76-4173-bbc5-29dcb81d94e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_de5a48ba-e033-4769-9089-1a454971e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_de5a48ba-e033-4769-9089-1a454971e8e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5c064f7b-518e-4836-8fc7-83f3581c844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5c064f7b-518e-4836-8fc7-83f3581c844e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_2f4aa91a-089c-46d1-b056-a8fb96ec34a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LongTermDebtFairValue_2f4aa91a-089c-46d1-b056-a8fb96ec34a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a208bd7e-8a24-4487-8054-0efba43935c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentTerm_a208bd7e-8a24-4487-8054-0efba43935c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e5a80ad0-0feb-4103-bb1b-ec1dd92eaa44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e5a80ad0-0feb-4103-bb1b-ec1dd92eaa44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a50ba63c-4565-4c0a-b664-b93f8e6ee7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LineOfCredit_a50ba63c-4565-4c0a-b664-b93f8e6ee7f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d8455d2a-4832-47b1-922c-b2afd272d194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d8455d2a-4832-47b1-922c-b2afd272d194" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_197a288e-50a9-4456-915d-877b061ebea9" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_197a288e-50a9-4456-915d-877b061ebea9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_64b3f0f2-bd42-4106-abe0-d378aff48612" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_64b3f0f2-bd42-4106-abe0-d378aff48612" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_afbb423d-562c-4ac9-a34c-d4509fec2192" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_afbb423d-562c-4ac9-a34c-d4509fec2192" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa8cee72-a866-4ee4-9aa6-770157a2c2c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa8cee72-a866-4ee4-9aa6-770157a2c2c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8d7cf39e-62d1-4ad3-8aec-7b61d5bd619c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:to="loc_us-gaap_SeniorNotesMember_8d7cf39e-62d1-4ad3-8aec-7b61d5bd619c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b60cb20b-a6d5-4d8e-9e83-798193675874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:to="loc_us-gaap_UnsecuredDebtMember_b60cb20b-a6d5-4d8e-9e83-798193675874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_657fd4fb-869d-4104-b043-9b97db90e163_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_657fd4fb-869d-4104-b043-9b97db90e163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_eee32934-3a3a-4f9b-aa0a-b9f945990f00" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorNotesDue2031Member_eee32934-3a3a-4f9b-aa0a-b9f945990f00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_9393aa6f-abc5-4894-9d46-4298e966bc64" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorNotesDue2051Member_9393aa6f-abc5-4894-9d46-4298e966bc64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_ec196804-c68c-4a5e-a24a-3d45c7d7950d" xlink:href="rprx-20220630.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_TheNotesMember_ec196804-c68c-4a5e-a24a-3d45c7d7950d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_f5533f7d-74b1-413c-a857-24234a077794" xlink:href="rprx-20220630.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_f5533f7d-74b1-413c-a857-24234a077794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8f00ae34-424e-4d44-ab89-a046de81174b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:to="loc_us-gaap_VariableRateDomain_8f00ae34-424e-4d44-ab89-a046de81174b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:to="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_983c8055-779f-4136-a423-5194ba525c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_983c8055-779f-4136-a423-5194ba525c89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_4c718807-0853-4994-8f0a-6f702ac39240" xlink:href="rprx-20220630.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_rprx_OvernightBankFundingRateMember_4c718807-0853-4994-8f0a-6f702ac39240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_12bf0047-13db-45fc-b74d-4f332ae638f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_12bf0047-13db-45fc-b74d-4f332ae638f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8259f7fc-ded5-49a0-bad5-1a3da160b07a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8259f7fc-ded5-49a0-bad5-1a3da160b07a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81111d86-b475-4032-8956-12e8e69532c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81111d86-b475-4032-8956-12e8e69532c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_eddd6e70-f6c4-4f09-93a7-211826adaf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_eddd6e70-f6c4-4f09-93a7-211826adaf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_606b64cc-d237-41af-8ebd-877db0c9d708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:to="loc_us-gaap_CreditFacilityDomain_606b64cc-d237-41af-8ebd-877db0c9d708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:to="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_83d1018d-ff8a-44cc-9375-050d77c66257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_83d1018d-ff8a-44cc-9375-050d77c66257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3356e29b-a9ca-4616-8925-cdf489c45144_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3356e29b-a9ca-4616-8925-cdf489c45144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7da53c46-d5f6-4d39-b06c-3e6d558e21d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7da53c46-d5f6-4d39-b06c-3e6d558e21d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended" id="i686be89e896345a2a414dd192c8e7e3c_BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_585ac47c-d280-48b0-8b5e-c7a9630a62ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_585ac47c-d280-48b0-8b5e-c7a9630a62ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6669944e-70ce-4be2-8f6e-8545ae3c9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6669944e-70ce-4be2-8f6e-8545ae3c9f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d109dd95-fa6c-47ac-99d5-0ae8831714ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d109dd95-fa6c-47ac-99d5-0ae8831714ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_14c0e33f-f4e7-4532-83d5-48d1cbe5c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_14c0e33f-f4e7-4532-83d5-48d1cbe5c8ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07ba7181-7a41-43f9-9356-25337082eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07ba7181-7a41-43f9-9356-25337082eed7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermDebtMaturityAfterYearFour_a7c85c78-5d54-4d98-8d59-77571b5ad35e" xlink:href="rprx-20220630.xsd#rprx_LongTermDebtMaturityAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_rprx_LongTermDebtMaturityAfterYearFour_a7c85c78-5d54-4d98-8d59-77571b5ad35e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_051f2880-69e4-45a8-96d9-5dc3d11f4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_051f2880-69e4-45a8-96d9-5dc3d11f4c65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_794d4e72-9780-4ba6-95a8-dbf45062b81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_794d4e72-9780-4ba6-95a8-dbf45062b81d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe1da78e-f038-423a-b2cf-20bc9a0ee239_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe1da78e-f038-423a-b2cf-20bc9a0ee239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9f86c45b-1f5d-4223-b6ec-42e0f433420d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:to="loc_us-gaap_UnsecuredDebtMember_9f86c45b-1f5d-4223-b6ec-42e0f433420d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_513a1e72-848d-4f64-b5ac-b7db5a4c2df7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_513a1e72-848d-4f64-b5ac-b7db5a4c2df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_0a46075b-2f5a-4915-83db-005752602bc6" xlink:href="rprx-20220630.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:to="loc_rprx_TheNotesMember_0a46075b-2f5a-4915-83db-005752602bc6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i4429083dcb5d4aa08ce95d788c16f025_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_6564590d-1291-4dac-8aa1-5b20c56b0823" xlink:href="rprx-20220630.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_6564590d-1291-4dac-8aa1-5b20c56b0823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes_4097d3ff-f358-4882-b753-88ef5619d39d" xlink:href="rprx-20220630.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_CommonStockVotingRightsNumberOfVotes_4097d3ff-f358-4882-b753-88ef5619d39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_50330900-eabc-4535-8644-8ae604486eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_50330900-eabc-4535-8644-8ae604486eed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis_910b323f-9daf-499b-9bab-b62c9e500b39" xlink:href="rprx-20220630.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_CommonStockQuarterlyConversionBasis_910b323f-9daf-499b-9bab-b62c9e500b39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4461a0fe-a399-4aa5-b075-1d0f2bd5cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_SharesOutstanding_4461a0fe-a399-4aa5-b075-1d0f2bd5cf78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_6700a22e-3028-48f4-aaa7-498417e53391" xlink:href="rprx-20220630.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_6700a22e-3028-48f4-aaa7-498417e53391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_7386bd56-914e-445f-a073-c38c32727f61" xlink:href="rprx-20220630.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_7386bd56-914e-445f-a073-c38c32727f61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_fdc4e581-92ea-4777-a419-c9aed3e567b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_fdc4e581-92ea-4777-a419-c9aed3e567b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_12f0ae77-362d-4dec-9207-d4035f886eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_DividendsCommonStockCash_12f0ae77-362d-4dec-9207-d4035f886eaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baac1a90-27f5-4fde-a93c-8b643921c1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baac1a90-27f5-4fde-a93c-8b643921c1c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dd5194cd-9604-4a6c-b375-5603fbd67d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dd5194cd-9604-4a6c-b375-5603fbd67d89" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f163acfc-8266-4882-b106-fd404cda77c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:to="loc_us-gaap_ClassOfStockDomain_f163acfc-8266-4882-b106-fd404cda77c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:to="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1abc1860-4487-478a-a860-b7573918e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_us-gaap_CommonClassAMember_1abc1860-4487-478a-a860-b7573918e9c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_267f4df9-94c2-44b0-b141-1d86e6ae07db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_us-gaap_CommonClassBMember_267f4df9-94c2-44b0-b141-1d86e6ae07db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_65db2820-a10a-4631-9ff1-f2b878cf6695" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_rprx_ClassRRedeemableStockMember_65db2820-a10a-4631-9ff1-f2b878cf6695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_036b21aa-14f6-4f83-a181-9b6f088985e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:to="loc_us-gaap_PlanNameDomain_036b21aa-14f6-4f83-a181-9b6f088985e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:to="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_b431b4a6-23c8-4b52-ae73-2dbf24721b38" xlink:href="rprx-20220630.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_b431b4a6-23c8-4b52-ae73-2dbf24721b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4cad050-17dd-42b0-a7e3-cd77a7e2f766_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:to="loc_us-gaap_EquityComponentDomain_c4cad050-17dd-42b0-a7e3-cd77a7e2f766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:to="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_e2701582-258b-48a5-a403-40e19314f2cc" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:to="loc_rprx_DeferredSharesMember_e2701582-258b-48a5-a403-40e19314f2cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended" id="i00c1c094ae674e7b925b434483f9a16d_ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af14a9c2-4fd7-48ae-b969-a8490e31a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af14a9c2-4fd7-48ae-b969-a8490e31a692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_60a391f1-6ab5-41b2-b32c-d8db8d76bbdc" xlink:href="rprx-20220630.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_60a391f1-6ab5-41b2-b32c-d8db8d76bbdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bc8a1801-7025-4da7-b4f1-989ce9f669f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bc8a1801-7025-4da7-b4f1-989ce9f669f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2896248-000c-4632-89b7-3c6091b70b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_ProfitLoss_d2896248-000c-4632-89b7-3c6091b70b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_0e09931f-b4d3-4969-a0ae-979f55e0dc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_StockholdersEquityOther_0e09931f-b4d3-4969-a0ae-979f55e0dc7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_36079b98-1014-4dc5-99d9-8efb9150aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_36079b98-1014-4dc5-99d9-8efb9150aa6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_75a19d0f-3706-459f-9e7b-7ffbfb97fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_75a19d0f-3706-459f-9e7b-7ffbfb97fbf7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_69394b61-086b-4351-b964-cc0ffb0e2c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_17928d2b-4ff6-4b5a-b476-5298a24ecac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_17928d2b-4ff6-4b5a-b476-5298a24ecac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f3c1671a-1798-4112-848d-ede840a65733_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:to="loc_us-gaap_EquityComponentDomain_f3c1671a-1798-4112-848d-ede840a65733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:to="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3690e970-f947-4afd-b3a5-f68c3248b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3690e970-f947-4afd-b3a5-f68c3248b98f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95f95893-1c20-43f3-a32f-bd7bacfa4f76_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:to="loc_srt_OwnershipDomain_95f95893-1c20-43f3-a32f-bd7bacfa4f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:to="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_7859a60b-9b5c-4988-88ff-4c091a1ad862" xlink:href="rprx-20220630.xsd#rprx_RPHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:to="loc_rprx_RPHoldingsMember_7859a60b-9b5c-4988-88ff-4c091a1ad862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2611711e-1306-46be-810f-d161afc66ea1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:to="loc_dei_EntityDomain_2611711e-1306-46be-810f-d161afc66ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:to="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_32dc9fab-3a6f-4446-9c0e-03f9a9f3cc2b" xlink:href="rprx-20220630.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_32dc9fab-3a6f-4446-9c0e-03f9a9f3cc2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_de363a6f-51e9-4113-833e-2329c4eabb43" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_de363a6f-51e9-4113-833e-2329c4eabb43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_b0a0ffcb-e0c5-4642-b067-ebe57bfbedb8" xlink:href="rprx-20220630.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_b0a0ffcb-e0c5-4642-b067-ebe57bfbedb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_0cc0e3ae-1c6c-4a71-8a9c-489e1cc60bc8" xlink:href="rprx-20220630.xsd#rprx_EPAHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_EPAHoldingsMember_0cc0e3ae-1c6c-4a71-8a9c-489e1cc60bc8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended" id="if877675f0d82487c98b1ea3377d588c5_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_5b1fb447-44e5-4bfc-8290-888b10ec137f" xlink:href="rprx-20220630.xsd#rprx_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_rprx_CommonStockExchangeRatio_5b1fb447-44e5-4bfc-8290-888b10ec137f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6d6b852f-760c-4306-982f-0c349b29007f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_ProfitLoss_6d6b852f-760c-4306-982f-0c349b29007f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7256249c-2675-478d-a294-23bb726a20dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7256249c-2675-478d-a294-23bb726a20dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b690378-0143-457a-b8f3-d569b1333db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b690378-0143-457a-b8f3-d569b1333db8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_ca00c752-fc03-4c46-b499-8d30deb6f15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_ca00c752-fc03-4c46-b499-8d30deb6f15f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_12c072fd-1116-4682-bbc2-fdd3124e072a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_12c072fd-1116-4682-bbc2-fdd3124e072a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_920b06db-2066-49e3-8a6f-4c2b75cb9915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_920b06db-2066-49e3-8a6f-4c2b75cb9915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_b5a84a25-695d-43b4-8b55-6480aa6323f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_b5a84a25-695d-43b4-8b55-6480aa6323f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c800c95a-a598-46d5-bef5-8e2262d9329b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c800c95a-a598-46d5-bef5-8e2262d9329b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37566814-30db-49c0-be26-58db124ee13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37566814-30db-49c0-be26-58db124ee13e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5a45fdea-0434-41af-b6f4-964909a4d313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_EarningsPerShareBasic_5a45fdea-0434-41af-b6f4-964909a4d313" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d51ba33a-ab62-4858-9bc8-a1e32fc88c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d51ba33a-ab62-4858-9bc8-a1e32fc88c26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:to="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_632c3847-e8bd-4c7c-8cb8-e7b350c47773_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_632c3847-e8bd-4c7c-8cb8-e7b350c47773_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_ec1793cd-3a1b-4838-850a-1f5a6ce9abcb" xlink:href="rprx-20220630.xsd#rprx_ClassBHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:to="loc_rprx_ClassBHoldersMember_ec1793cd-3a1b-4838-850a-1f5a6ce9abcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_c406df6a-4dd2-4346-9878-c0638caed844" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_c406df6a-4dd2-4346-9878-c0638caed844" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i194d8a87c50c4ceca3169ee6c8dba6ef_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingCommitmentAmountOutstanding_9764b488-cce2-46b8-a5ed-a952a038e523" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingCommitmentAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingCommitmentAmountOutstanding_9764b488-cce2-46b8-a5ed-a952a038e523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_0ba5bac1-a62c-490b-a62e-51474418f492" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_0ba5bac1-a62c-490b-a62e-51474418f492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5a87345f-aee5-403c-85b2-78f8993239df" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5a87345f-aee5-403c-85b2-78f8993239df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_37763d75-14a6-424a-8145-59c6dc17c50b" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_37763d75-14a6-424a-8145-59c6dc17c50b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a99d1b31-f677-4f5a-b23d-5a862db425d9" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a99d1b31-f677-4f5a-b23d-5a862db425d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementExpectedProceeds_8632688e-42f9-40b9-834b-a24cc5ad9b7f" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementExpectedProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_CollaborativeArrangementExpectedProceeds_8632688e-42f9-40b9-834b-a24cc5ad9b7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_cf4b149d-f3dd-40e5-ae77-558f52e8edb1" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_cf4b149d-f3dd-40e5-ae77-558f52e8edb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentShares_d877d4a3-ff6e-4228-89de-8dc094201560" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermPurchaseCommitmentShares_d877d4a3-ff6e-4228-89de-8dc094201560" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_45164ba9-d551-454d-8ed4-4090cf32ceb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_45164ba9-d551-454d-8ed4-4090cf32ceb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_11c7ed30-cb3b-4d17-95d5-099329e97f73" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:to="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_11c7ed30-cb3b-4d17-95d5-099329e97f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67494e4a-3802-4995-a472-f3803a49bd08_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_67494e4a-3802-4995-a472-f3803a49bd08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_5128d09c-02b3-4b65-854e-bf6f92fe9c71" xlink:href="rprx-20220630.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:to="loc_rprx_MorphoSysMember_5128d09c-02b3-4b65-854e-bf6f92fe9c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0338e241-8131-49fa-946d-cbd6a01cd0d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0338e241-8131-49fa-946d-cbd6a01cd0d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b84b7311-ea1b-43b7-87b4-164a33121d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b84b7311-ea1b-43b7-87b4-164a33121d81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b0794810-2b18-4620-aa6a-7e1b2082ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:to="loc_us-gaap_SubsequentEventMember_b0794810-2b18-4620-aa6a-7e1b2082ce36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i7bfd4adc24ff49d6935b316ee7fc340d_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_ae081f6c-90ed-4c75-9d8c-59ef969d2ea0" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_ae081f6c-90ed-4c75-9d8c-59ef969d2ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_6d86460d-12e7-4522-878f-a67974a5c66a" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_6d86460d-12e7-4522-878f-a67974a5c66a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_a312345d-9437-4819-b032-2e7dadff52c7" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_a312345d-9437-4819-b032-2e7dadff52c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_60719f39-9f68-489b-81af-890770005529" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_60719f39-9f68-489b-81af-890770005529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_62f1e3ce-9115-4447-87be-3774c3fa26b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_62f1e3ce-9115-4447-87be-3774c3fa26b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_e648d7f9-9f00-4375-bbcb-2d14c0aa2302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_e648d7f9-9f00-4375-bbcb-2d14c0aa2302" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_f3bbab8e-dece-48ea-b4ec-3836e2eef2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_f3bbab8e-dece-48ea-b4ec-3836e2eef2fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4c6f3dda-306a-4bc9-a4ce-c1a472d80d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_NotesReceivableNet_4c6f3dda-306a-4bc9-a4ce-c1a472d80d3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_1480da23-6b93-4818-a28a-ce5005123110" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_1480da23-6b93-4818-a28a-ce5005123110" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_88bd1ef8-a5fb-4cd3-b9c3-60f80ca8da13" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_88bd1ef8-a5fb-4cd3-b9c3-60f80ca8da13" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceda9674-b46d-4b8e-a163-042e396b6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceda9674-b46d-4b8e-a163-042e396b6690" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9708bb96-030c-4b9e-a8f4-762512e91e94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:to="loc_us-gaap_RelatedPartyDomain_9708bb96-030c-4b9e-a8f4-762512e91e94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:to="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_8a58cefc-9c15-446d-8cc9-78328ed3a2bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:to="loc_srt_ManagementMember_8a58cefc-9c15-446d-8cc9-78328ed3a2bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_1e01fb1d-bf15-41c6-aab3-30dea66ae614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:to="loc_srt_AffiliatedEntityMember_1e01fb1d-bf15-41c6-aab3-30dea66ae614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_205c7e18-1b3c-4bd3-9e24-aa1ca35758af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_205c7e18-1b3c-4bd3-9e24-aa1ca35758af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_62ff17e3-d646-4486-a993-afbb44b24890" xlink:href="rprx-20220630.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_62ff17e3-d646-4486-a993-afbb44b24890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_ea1f86e2-a9c5-44aa-ab36-e84f64e0d08b" xlink:href="rprx-20220630.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_ea1f86e2-a9c5-44aa-ab36-e84f64e0d08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_fb3f7c28-47db-4e4c-a542-d7da39daf466" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_fb3f7c28-47db-4e4c-a542-d7da39daf466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_2a48b01d-822c-4413-90df-d2140c62b5f2" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_2a48b01d-822c-4413-90df-d2140c62b5f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_a76b476a-b199-4985-938e-f7f37da89e4c" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_a76b476a-b199-4985-938e-f7f37da89e4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_1cafcfc9-12cc-49a5-9bd1-d8e17f93c295" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_1cafcfc9-12cc-49a5-9bd1-d8e17f93c295" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_82a53438-ad98-42c0-a532-47ad9a4b3478" xlink:href="rprx-20220630.xsd#rprx_AgreementWithMSCIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AgreementWithMSCIMember_82a53438-ad98-42c0-a532-47ad9a4b3478" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_6b406c77-ad5c-434d-a23b-051936bb9123" xlink:href="rprx-20220630.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_6b406c77-ad5c-434d-a23b-051936bb9123" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7ac883d-ff35-4b44-a206-163b39db3399_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:to="loc_us-gaap_EquityComponentDomain_b7ac883d-ff35-4b44-a206-163b39db3399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:to="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d7215424-1c03-4012-aea7-72f9211f84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:to="loc_us-gaap_TreasuryStockMember_d7215424-1c03-4012-aea7-72f9211f84d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_94bb3f51-d1a7-4b1d-9657-b38436c3c9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:to="loc_us-gaap_NoncontrollingInterestMember_94bb3f51-d1a7-4b1d-9657-b38436c3c9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13f95374-0fad-456f-b4ce-9d5e20eb1e47_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13f95374-0fad-456f-b4ce-9d5e20eb1e47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_7e8c5ac6-89f9-4f1e-acdf-dbefd8bcc0c6" xlink:href="rprx-20220630.xsd#rprx_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:to="loc_rprx_BristolMyersSquibbMember_7e8c5ac6-89f9-4f1e-acdf-dbefd8bcc0c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="i0f74b1f6873441459c1a2f8cea1925d1_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7fb656a0-5ad1-40bd-a80a-3fb5fe456b7b" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7fb656a0-5ad1-40bd-a80a-3fb5fe456b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7accfdc-cb86-40d3-b314-f6375722962d" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7accfdc-cb86-40d3-b314-f6375722962d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_12417125-269f-4f95-9783-b8f4eba3a5bd" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_12417125-269f-4f95-9783-b8f4eba3a5bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_99b6038c-24aa-4e74-a081-26a32ca6899c" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_99b6038c-24aa-4e74-a081-26a32ca6899c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b6140cbe-6849-4aad-aed1-4173f26ba34b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b6140cbe-6849-4aad-aed1-4173f26ba34b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_50714c5b-4a37-4327-ba82-fa3d4952d392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:to="loc_us-gaap_SubsequentEventMember_50714c5b-4a37-4327-ba82-fa3d4952d392" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rprx-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rprx_PaymentsForMilestones_7419fc77-f849-4544-8d12-5876798aac24_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_label_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_documentation_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones" xlink:href="rprx-20220630.xsd#rprx_PaymentsForMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForMilestones" xlink:to="lab_rprx_PaymentsForMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_950df907-f576-4f86-901a-25a5ff3f9ea0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4c550852-36a7-45b0-9b7a-24e3ad1743d5_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4ba9230b-a19e-4dbe-844c-aee19e9f009f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_4c3ceb26-4cc2-4a3d-ab16-deec86f77c4e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b0b9cd7b-f91c-4676-8932-932409dfacb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_328b914e-360e-47e9-8ed7-e5e1d6a3c445_terseLabel_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:href="rprx-20220630.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:to="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPHoldingsMember_b2353ba3-7c70-4b85-b54c-6aaa7de61d36_terseLabel_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_label_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings [Member]</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_documentation_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember" xlink:href="rprx-20220630.xsd#rprx_RPHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPHoldingsMember" xlink:to="lab_rprx_RPHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_3e2c0439-9b8e-445e-872d-f4cfa4df2e39_terseLabel_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:href="rprx-20220630.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_81afdf32-4b2a-4248-b2e8-8404dbf670e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Of Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_33d91ea7-4e55-49f3-90f3-1baaf30fb643_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPCT</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:to="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b16e5fd9-67dc-4cc5-beb4-5e3915a399fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a483c1b9-4148-4c55-8e1b-46adeaab7bfb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_6c410b88-5d75-4f5b-93ed-30aa1c0bcc88_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests- other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_e623ed5e-f416-4f0a-83bb-f3a5c3aa3c32_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:to="lab_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_4b9e3d9c-b94c-4f04-94fb-c6044de03c88_terseLabel_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_label_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction [Member]</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_documentation_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember" xlink:href="rprx-20220630.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ExchangeOfferTransactionMember" xlink:to="lab_rprx_ExchangeOfferTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7a637af3-6239-42ff-8878-84f8a9c35148_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_104c4428-5576-42e7-bc1c-f8953104c188_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old RPI</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI) [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:to="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_0eacea09-7c1d-4010-81e7-0558b48c98ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_429fb03f-d4ba-4f8b-b552-9115e1d72692_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TheNotesMember_684801ee-255c-4033-9211-4f12a1794aff_terseLabel_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:label id="lab_rprx_TheNotesMember_label_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes [Member]</link:label>
    <link:label id="lab_rprx_TheNotesMember_documentation_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember" xlink:href="rprx-20220630.xsd#rprx_TheNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TheNotesMember" xlink:to="lab_rprx_TheNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_2e5e85da-accd-42a1-8119-3c3ba2218ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_22c29eb3-83c6-4357-a41b-0c1d6befb297_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required amount to be drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Covenant, Required Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Covenant, Required Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:to="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_ecb2f078-9595-4d4e-92b9-da94241979fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b127056a-2ed7-4259-8423-42167fc012f2_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a06808be-2e4a-4172-9938-86736d1d0470_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d5b23945-b0e5-44c6-9ccb-c5c88ab58586_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_36130083-ae51-4bca-9314-cf4f472ddee5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_25daafce-229a-4af1-933b-b04ca4a08218_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:to="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a41eb71b-1e4d-4871-ab5a-9a9bc62b99c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon occurrence of a change of control triggering event</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e3378570-90e1-4675-9856-c1c3ee8103f6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_67631672-45e6-4de0-97b4-0b0f4614ab80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_1b279bbf-ad75-4cec-92dd-615a2f111d4f_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_6c4a2a87-d075-4d0b-bef9-87bba5a8acd6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_92a062bc-50bb-4bc2-8428-e967e69973d0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_1a8e4d52-6415-4f08-b2aa-c66f86bfa4d3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of financial royalty assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Finance Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_565d2751-b370-4789-b0d2-54b8675337a9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_686da096-c229-496f-8fbf-8b36567d15d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_a2581e75-1b9b-4eb8-963f-61e984efce38_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_baf21b80-5bd0-4d7c-aa6e-3dbc957e1c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Repayments of Debt by Year</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a2200efd-d2b9-486a-b374-89ffd520444c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_3aa79bd4-4113-4d94-9699-76371ab9def4_terseLabel_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic fibrosis franchise</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_label_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise [Member]</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_documentation_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember" xlink:href="rprx-20220630.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CysticFibrosisFranchiseMember" xlink:to="lab_rprx_CysticFibrosisFranchiseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cc573567-dd32-4f8e-9e6c-40e16842095d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_fc7b5f53-60b7-48e8-87b0-2de140e5ee1c_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:to="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementExpectedProceeds_b844d0ae-dbe3-4ddf-bb4a-6735f8753303_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementExpectedProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected proceeds from development funding bonds</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementExpectedProceeds_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementExpectedProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expected Proceeds</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementExpectedProceeds_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementExpectedProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expected Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementExpectedProceeds" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementExpectedProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementExpectedProceeds" xlink:to="lab_rprx_CollaborativeArrangementExpectedProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a176488a-22ee-40e8-947d-efa380f454ea_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0532bb88-03d6-420f-a0ab-493719f47d89_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_fad0a47f-fbf2-4fa4-8d02-c9fb25dff1b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_6a839884-def1-4e33-88ee-1cbf451077e7_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_b7f6b900-b81c-42f0-a4f6-196b70ac1fef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party, rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a9f608c2-97ac-4542-8827-c4e8a30ff760_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cebed98c-5b93-41dc-bdc0-cd91fb9eabfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_50f91261-5eb1-47c6-b99d-58248bc7a841_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_d954de74-46e4-4cac-846b-dd8e9b607e6e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c18bfb8b-937b-40fd-8d24-56b5dc755019_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_03703b7c-3f3b-4cfb-b453-3e5ecabf77aa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_d4a05fb4-2d6f-414a-8391-a290f8c3aeb2_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio following qualifying material acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_ea8fc3ca-1538-418b-89d8-8e991a00ea58_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, number of tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:to="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_3b8722ba-1617-41d7-9aa9-5804c40a611f_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on derivative financial instrument</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a05f51a0-42ec-4b86-82bc-70e01f3e6dc1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_852f11af-1157-413f-89f4-1dbee281f07c_negatedTerseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_48e9d2dd-01dd-4add-89a9-f5add34ae2c1_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period One</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0d072545-e2e0-4a62-a33b-a17805698b56_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_f2f4823b-addd-4f38-b570-366e128a8f59_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8a540af0-76c3-459c-8b83-67bcf8570b6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_6e98ce7d-d99f-4329-91c5-74b61d2198ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer to Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_08b3450f-3fd9-4492-b3c0-ff9985b0d723_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIIMember_fe799778-e0b8-4f45-b8a1-7ff0c6488f39_terseLabel_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:label id="lab_rprx_AvillionIIMember_label_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II [Member]</link:label>
    <link:label id="lab_rprx_AvillionIIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember" xlink:href="rprx-20220630.xsd#rprx_AvillionIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIIMember" xlink:to="lab_rprx_AvillionIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0a9d4ceb-6f99-430e-bd10-f3637d77cfab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_f427040c-66e6-4975-ae2b-b78f2dbe5684_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, amount outstanding</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Amount Outstanding</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:to="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_b5b76a8a-9cc2-4d76-849d-7fe8ef9b4dd3_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_641ae534-1c6d-40f6-8c73-065c665a5829_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e2bf32fb-9e0f-4a7c-ada4-4e13a76a5550_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e1f3511-a8e7-4c26-bcf1-d12347b35495_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_e7688ea3-e7bf-4958-8f53-b332504de452_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_44904ef0-e7f6-4c4f-b05d-f72cf653b749_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_aa73aa85-0bb1-4b84-82cf-10e697260b74_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, weighted average cost of capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bb5b2c99-82fd-4380-84b8-400449270943_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_9e75b1cb-f0e1-44dc-8e44-2a350355e6d2_terseLabel_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember" xlink:href="rprx-20220630.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_A2020EquityIncentivePlanMember" xlink:to="lab_rprx_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_010ebb5c-0d6b-47ae-909d-609dfdb89809_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_551ce7f1-960e-4157-99d7-5e83928f160c_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_377ada2f-f25b-413a-9d2c-f681673158a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4a9887e5-f303-4005-9195-77e672145db0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_05acbc1a-fb58-482c-83c8-60af5624b800_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_d214771f-cda5-4faf-aa8d-a5c7e8f6088e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_08a618ed-20c0-4244-9538-7a135e087fe4_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c834f29b-27a7-4369-8011-7879a44fc3bd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4440f441-0366-49af-a14c-9f4bce9da773_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_3cb14daa-aa08-420e-853e-05693bb7dff5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2c44da83-75dd-4d1d-837e-eb00fe20a529_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07e83599-074e-40df-8d35-af4c6b943112_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_518d155f-59cc-4d75-8b6e-7a6ee4cc6cf2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_093a8924-cf06-4916-9978-6a57aacf6363_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c4fca17e-a926-4454-b883-f7d953ef37e3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d55b6fd9-1ebb-492f-b8a1-26c32ba20698_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d750012f-b2ae-45d4-befb-b07a58bd10ca_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_8a9f7e34-e421-4f07-a059-522b285caa92_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate royalty amount when patents cease</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_label_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:to="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ead0e9a8-12f0-48a8-a4ae-cab057fde424_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2cf84bdb-7dde-4a93-b0c5-e62211332311_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ee155ce0-4d22-43d6-9d37-13ed1be229b1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_e35b0d13-5064-45d0-a638-8ccf0d80c28d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offering, ownership percentage</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d79298b7-5080-4a82-98d1-6b80a3aa2675_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_d3d5f362-ed38-4488-90b1-b051123f5bf5_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2031Member" xlink:to="lab_rprx_SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_9f1b6ec9-1693-4087-b32a-85bbd982892b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdd1f586-330a-458f-8cd5-c2153314d41d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_401e0a56-6c5e-4352-a8bf-5b2f46d5a82b_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_a5a89baf-9503-4d8e-aeba-4fcb4451d8a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ec5eb03a-da09-4bb0-a1db-3a327bf15d8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8b052ecc-cadb-4dbc-a956-022d37d28e4d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_39ac0be0-ec3f-4555-89d3-d5ce6055c581_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_f5b3d396-6af8-47c0-afe5-25bfdd6a9157_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_c35e204b-fa01-4636-a121-a80cc380cdf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in operating assets:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d53d1e93-2d8f-4380-bd25-5f1dc3360f3d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ec2583a0-99f9-48c4-9839-61a4ff0f741b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_cccc20fe-8e93-485d-8833-ea1b2f39b3cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses)/gains included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_4e91e119-05c7-4159-84b2-63fbd3958da1_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_4b1d9188-0092-43fe-a58f-48c81b3ad6cc_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a3083edc-c694-48c7-8398-43f928dbae66_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_0e6a4d7d-386f-4cf6-a670-3a9fb0bea276_terseLabel_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_label_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock [Member]</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_documentation_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassRRedeemableStockMember" xlink:to="lab_rprx_ClassRRedeemableStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b9441be6-b59a-4e3c-9cd1-06bc291d0909_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_8658d593-09b9-4e37-8844-c597789af8ee_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:to="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_504e3d2e-514e-41bd-a069-efa17cb66b88_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_cac270a7-a033-4294-aeac-f311e40b4a94_terseLabel_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_label_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate [Member]</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_documentation_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember" xlink:href="rprx-20220630.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OvernightBankFundingRateMember" xlink:to="lab_rprx_OvernightBankFundingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_25ab4914-445e-4ab0-91ac-4452308a09b1_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4e5eb535-006c-4284-92bf-04c1b1402a95_negatedNetLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_03d030cb-9f0b-4131-a860-8c9c586b68ee_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a885c30d-e8f6-4f2f-a778-a4c6cd4e3dee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_83e3f5aa-d398-40b0-9bf7-38d60fb80f69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of outstanding Notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_dfa343cf-2270-49cf-bce3-6fb54e6ee42b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_ba747bb2-f042-489b-836f-6ddb996ddf91_terseLabel_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable" xlink:href="rprx-20220630.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedRoyaltyReceivable" xlink:to="lab_rprx_AccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_be23adae-3f95-4ef9-9d89-08ec54161ede_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_f966854e-13ef-41fd-9c66-2271d7bb092f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_5db7c350-889c-4b2b-a267-4cf29f9651c7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_ace65fbf-cdde-4d01-816f-c6ae87625b90_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9463cfd-f6bd-421e-85b6-28635de61cde_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_76580054-7f65-4698-a9d7-c6af1d6348c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_69d99122-de86-4f82-857a-1d35592b218d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_135e1284-28a1-49e0-a784-30f8eddf5f97_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_020c4209-6a42-4850-a139-c794e92fdd20_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_df89c4ff-790f-4c4a-8e2e-92dbf9a818e5_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_af185103-e370-48ab-9e42-e678ff281181_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_272e0e71-431d-49fa-8560-19a97cf3aa40_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1357f89a-8dbd-43c2-b42e-ce1dea24c4cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_61276a15-beda-446d-98d8-c53493128492_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding</link:label>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_label_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember" xlink:href="rprx-20220630.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsCommercialLaunchFundingMember" xlink:to="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_042fc8df-2cc7-4bc7-aa2d-e02372df28cc_terseLabel_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnerships</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_label_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership [Member]</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_documentation_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:href="rprx-20220630.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:to="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_11caf37a-c2b9-4107-84eb-a8f3cf2643f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Royalty Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_4c86bc25-93c3-4ec1-83fd-7c268b2eaeb9_terseLabel_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_label_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial [Member]</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_documentation_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:href="rprx-20220630.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:to="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_0007a0bc-0a19-4fc2-b7b5-4372a78de9c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of other financial assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_ef737b32-8fd0-467f-816a-f8303370b83c_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt" xlink:to="lab_us-gaap_TradingSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_244df2c6-6548-43ec-929f-ef506a563d69_negatedTerseLabel_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income accretion</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_label_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_documentation_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:href="rprx-20220630.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:to="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d965369f-de4f-42e9-91c8-1694e5cab248_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ddf61d2-bf80-48e0-9732-a51f7b515f67_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e841af40-0249-47d0-b0a0-9227f072895b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_dddaa107-0d22-4491-88f6-950964d78321_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:to="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_e0219714-c1d5-4de9-85c5-4dfa0659f662_terseLabel_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember" xlink:href="rprx-20220630.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancialRoyaltyAssetsMember" xlink:to="lab_rprx_FinancialRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f56d046d-cd47-47b0-b407-a5d74a3c982e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_e958e286-611f-425b-a14f-96b0bf228178_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, expected payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Expected Payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Expected Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipExpectedPayment" xlink:to="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EvrysdiMember_d108c3b8-79b7-4d00-8413-586dcadeaa67_terseLabel_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:label id="lab_rprx_EvrysdiMember_label_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi [Member]</link:label>
    <link:label id="lab_rprx_EvrysdiMember_documentation_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember" xlink:href="rprx-20220630.xsd#rprx_EvrysdiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EvrysdiMember" xlink:to="lab_rprx_EvrysdiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesMember_5812e29c-e5f9-43cd-9ef7-f071df1feec5_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_label_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_documentation_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesMember" xlink:to="lab_rprx_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4d232e2d-7c50-43dc-8242-1f0acb7732c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8e98f4c-763c-4179-b1bc-20a8808fe17f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dbfa7cd-255c-4eb9-8b12-402a804922c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_632611a2-aaad-4cbc-91ed-01460c8a58f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f892188b-28a7-4db5-888d-71c47975ca53_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f377f676-efda-4062-87e3-3f9fd4fef158_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_366a4596-8e4f-4e11-8cae-acb272ace7ac_terseLabel_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:href="rprx-20220630.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_34892b3d-fc19-4d5b-825e-d6181f599517_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_214af97c-a462-4e94-a053-d8c381680346_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Multiple</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_26a1f36b-45a1-472a-b9bc-492a4582bc7a_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_cd217ec5-c8e9-4803-8ebb-ce3d7b9733dd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_110a18d7-8987-4257-9305-61c5a089dc3a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_acaf183b-3276-4165-86dc-128c7c3c2e5e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_57eb7128-1b50-47fc-ba20-a87d716f02ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars/pounds per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_fc90b90e-c877-4525-94fd-f5e82a4ac0cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_89c67759-6385-4122-b574-942955b85da8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0b6a03e4-67fa-4f39-994c-9c84d796b0ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a45499ed-6f9d-4cc3-a473-91b361f3036a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f73819ff-4e8c-4346-874d-638c4098fc95_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_dd97f123-87c1-403d-aba9-dcd09079de31_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_d2a5b3fa-922b-4f13-9499-4ef293ea5d20_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount calculated for operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_170e11f5-4be8-4877-b16c-b49e70a284f7_terseLabel_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration List</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_label_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk [Member]</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_documentation_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:href="rprx-20220630.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:to="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_26e3876e-d1a3-45dc-be8f-e877a02e7575_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development funding expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_91cdd863-d941-46ee-8c90-e44c3da44c91_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_bf6cea2b-10de-4b6b-8fbe-95c72f1ff06e_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding commitment, outstanding</link:label>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_label_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Commitment, Amount Outstanding</link:label>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_documentation_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Commitment, Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingCommitmentAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:to="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsMember_6fe5dba0-fef1-4f00-b720-fc4de3aac5c6_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics</link:label>
    <link:label id="lab_rprx_CytokineticsMember_label_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember" xlink:href="rprx-20220630.xsd#rprx_CytokineticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsMember" xlink:to="lab_rprx_CytokineticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e8162fc0-05b7-446f-a365-5751853390a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_156d9ce2-b1f6-440c-801d-f44699767973_terseLabel_en-US" xlink:label="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five Zero Percent Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five Zero Percent Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five Zero Percent Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:href="rprx-20220630.xsd#rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:to="lab_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f89051a0-e84e-40ab-8cf4-218c8f77d3a2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_e7dde441-82bb-400e-9463-21ba9a3960de_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral received</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:to="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0d78ec3-15d6-41d6-9ab7-08f945241eac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_f901bb72-817a-413a-85a6-a27e48412377_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total distributions payable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_1e884c4c-79f7-4dbf-b18b-3477846b4d63_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_824c11a7-8c05-4a5a-b53d-cc08515b7728_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d8977457-ded2-4001-8d59-c44394cc0c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual licensees exceeding 10% or more of revenue (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_78a80518-6c25-4edd-ae29-56e4b933e469_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_446a54c5-e2f7-43d9-bd3b-7a3b05339c7f_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:to="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_40eeffa4-bba8-44f4-afbd-362060a41737_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f2d816c9-4c58-4d56-93ea-ba904980b93a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_82d0c97b-24aa-4c1f-ae2a-8f9892e20af7_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_d8305b6a-5806-4f7a-a5a9-ae093866af35_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_0d2903bb-fbba-44ce-a358-7200a4b80af7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average coupon rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_36b990ab-a982-47e0-b423-0806623709b3_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to fund agreement</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f42b2262-efae-4ba3-bc4b-8675a5991ea7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_7e8af27f-3ca8-4fa9-862b-6a3bd6103c43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in operating liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_b09ea626-66ac-433c-813e-bb783d840c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1a63c08d-3418-42ea-bb89-d979555c9ec0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5b4bad9b-4bc0-4d7f-9a5a-573dd4ed7384_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ba192d5b-2316-455d-aa65-c7c0e05e8228_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9c55fc4f-f021-4214-9663-92f41c5802ac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_8953c3fe-2852-491a-81a4-a1d76d50f4a2_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on selling common stock, period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_97cbfaac-558a-43df-9fbd-51a72dc8855e_terseLabel_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_label_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:href="rprx-20220630.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:to="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_13900a62-2f80-4c35-8dc8-343c78836c8f_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased (in shares)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0f700002-1964-4aaf-860d-bc75de4f761b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cbd422e0-ecd0-4fb5-bafa-7b7f41855bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ff059399-d1fb-4204-91f1-711d85e26c6b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_243a65fa-7b57-4e38-8de0-8b97f8dab6c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3402fbff-9273-4889-8c78-fd4ca6bb8414_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_96e19ecc-f0e1-4271-8069-8a7d7ec05d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_32c54116-d2ea-4cdc-a4f6-498eb3c40ee5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member_5c30d83a-3b99-4f5b-b95b-4ceb4ff888e3_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Zero Percent Due 2051</link:label>
    <link:label id="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Zero Percent Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Zero Percent Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeFiveZeroPercentDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:to="lab_rprx_ThreePointThreeFiveZeroPercentDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_97b9780f-dfef-4a9f-9661-c099b377fb10_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_7ecd9765-6eb3-409e-adfe-46334f0bfc8d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_806469ea-86a7-4297-8158-883bc5e3b5f0_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_6770e27f-3f7b-472e-b55a-141ef5019c1c_totalLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_845879fd-ba97-44b1-a0d9-6142883468df_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5e012660-5627-41cd-9cce-15060826c955_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockExchangeRatio_a3ff6579-3cb8-40e1-b878-83a0e2c0b147_terseLabel_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock exchange ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_label_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio" xlink:href="rprx-20220630.xsd#rprx_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockExchangeRatio" xlink:to="lab_rprx_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d4b1c293-d3d3-482d-9410-31b2ce9a70ba_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24ce6357-54a6-4746-8b7f-e735a274c1fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_3eb23304-63fe-4109-9f45-3562f000b4a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionEntitiesMember_e6b51800-4406-445e-bea6-36da9cc1efe9_terseLabel_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_label_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities [Member]</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_documentation_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember" xlink:href="rprx-20220630.xsd#rprx_AvillionEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionEntitiesMember" xlink:to="lab_rprx_AvillionEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_1345c633-d11a-4e99-8ce8-341847f969ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B ordinary shares exchangeable for Class A ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_431fd8c0-f5e6-4e7e-b99d-494fe157aeb7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6a48e8ef-8d1f-4fd4-9ea8-611af4c16a71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_d886a705-4312-4321-9156-b667094a797d_terseLabel_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:href="rprx-20220630.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:to="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_45a42438-319d-4a78-8668-7df9c327a0da_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2cc96cc8-db12-4005-9be3-19ef26a5f953_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_bc31f5ff-817b-4294-9cf6-79d96fa94658_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared and paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_e82ae939-99e1-48bf-bbee-9b99c7d53b3a_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued as a percent of par value (as a percent)</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_label_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:to="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_3aeed090-00dd-4e91-8004-356855b333cd_terseLabel_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_label_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_documentation_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:href="rprx-20220630.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:to="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_f994486b-abd0-4d40-8018-d843b813a88f_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development-stage funding payments - upfront and milestone</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:href="rprx-20220630.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_90a7f25b-c888-4fe1-b1f5-01c611868736_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_94136d9d-0384-4ab5-9134-7e744514c9d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation and related issuances of Class A ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7bbb95f4-0b2a-4d60-99cc-f959f968b34b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_2eccf615-4779-45a2-9cd7-cf1cb6031c99_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated coverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_452a1497-b735-43b4-ad47-5adf4aa2c150_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_7cc5db3f-25a0-40c5-a8de-9804eacb0c02_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent calculated for operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_203c6123-aac7-4785-bf5a-3810d0cf1683_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_0a776343-cfa2-42ed-82b0-9d455efac1c8_terseLabel_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_label_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_documentation_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes" xlink:href="rprx-20220630.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockVotingRightsNumberOfVotes" xlink:to="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9c082a60-b981-4abe-9a23-4d729971ce89_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_cb7af1f4-0215-4ad1-9249-ceeca0ff4057_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d22f6b4d-4b85-46a5-af4d-ce4764c9f410_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_551471c8-e474-4df0-83a1-89f724d75216_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2051Member" xlink:to="lab_rprx_SeniorNotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_27725ec6-4472-4d81-a378-bbee92acdd79_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_967e684d-3c71-4561-b050-0d854b47e7f4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_00a7954e-3ea2-45b5-9e5e-aea316eaadd7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_3f7b6481-35a8-4114-a718-4572fba01b02_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_ee04cd27-d27b-4d8e-9bc2-6022b0a53d22_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, aggregate amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7ddb571a-2560-4506-9f33-491b63dc9aec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_cfcc7d36-84e1-4c34-9daf-bddedc17a469_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_117b8da1-674e-437b-b2ec-676bafeee451_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_9505c961-2332-4344-86ee-17d8fefcff35_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_755144fd-ae43-4514-ac49-6160651910d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ccd45312-fbff-4446-83f7-223f6f34a8e5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_ceab45f6-386e-4b4a-9617-a5df318d152b_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingCommitmentsMember_30433398-14ae-45e7-b6b1-14c43a2d5c1c_terseLabel_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments</link:label>
    <link:label id="lab_rprx_FundingCommitmentsMember_label_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments [Member]</link:label>
    <link:label id="lab_rprx_FundingCommitmentsMember_documentation_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember" xlink:href="rprx-20220630.xsd#rprx_FundingCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingCommitmentsMember" xlink:to="lab_rprx_FundingCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f4329b3a-fbad-4d62-a889-40828e8dcbba_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_bf78e52a-41f5-4c77-a1ab-543eb3f86585_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_594666a8-cea6-4e39-91cc-788b10cdee95_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6fbc3840-c171-4b70-bc54-36bf8c90fcf5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_a54310bd-01db-403b-8056-74cb1f07aabc_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_15640555-4ff0-41b9-8ec8-e1d979a2ca68_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (income)/expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ba5f3382-72eb-4c8f-90b7-1d90dbbfbfcf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cf4d7e87-946a-4fb2-ab0d-59052d599991_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_92de5a69-4442-40ee-bd7d-28fefd8ff73d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_b8af220d-5b56-4ef0-8687-a0bf724047c9_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_label_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:to="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_38d11339-b07e-48fa-bcc8-f775dc0b50e6_terseLabel_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable stock, redemption price (in euros per share)</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_label_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_documentation_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:href="rprx-20220630.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:to="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_8682fdb6-f5a2-4256-a7b7-d7d31d7825d2_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_92a7deb0-72f6-4818-802f-b8198bc649b6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_619b2473-fe43-49eb-ba58-dc685ab336d2_terseLabel_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, unfunded commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_label_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_documentation_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:href="rprx-20220630.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:to="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_6f8df385-add6-434b-bcfb-f79a5bb47be4_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_label_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_documentation_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders" xlink:href="rprx-20220630.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentOfDividendsToShareholders" xlink:to="lab_rprx_PaymentOfDividendsToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_369d2e90-e927-470e-8e39-726f03071672_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5a6f0507-db28-4028-bd99-85bf4f282f6b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_dd321381-2f71-43f3-af2a-e118b913b43e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_5106e18c-785e-4d6e-b222-3689c5b6dc25_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a2ddbeb0-5cac-4a52-9d72-6f4bcdeac036_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3f84a61a-2994-42d4-bcd4-375ae2daa293_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ed974364-f637-4df2-8c95-d76c7ac27135_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_7bc84dca-4fb7-41a8-b275-ac4363a10597_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:to="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f574f1d0-e31c-4dd4-9e51-d3a246bf0486_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_763c63de-9ece-42b8-932b-dfc9f677aadf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_eee695b7-4d8d-4241-b016-520fcbc85947_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_61e136a2-d3f2-4896-8b72-195bf415b3b9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and personnel payments incurred</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_fcee5b2a-3693-450c-ad15-3b45f02d1675_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests- R&amp;D</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5948d572-3d05-4515-9e3c-dab1a5daf621_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_940647e3-2cfb-4d39-9cb2-54a9a078e5b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5dc1aad3-025a-4f6f-b723-2bb92f20432c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_63b865c6-60d3-4013-b9b9-8a82aade9d20_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2d1b5e40-df41-489a-ad3d-9de052abbde6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e67563bd-32b5-46c4-82c5-92a958e53f2a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_3fbc57fc-f7e1-435a-93a5-e6142db2b254_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MilestoneAccelerationMember_74f8de2c-dfcf-44f7-a701-86327a09e58b_terseLabel_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationMember_label_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration [Member]</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationMember_documentation_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember" xlink:href="rprx-20220630.xsd#rprx_MilestoneAccelerationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MilestoneAccelerationMember" xlink:to="lab_rprx_MilestoneAccelerationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_a40d1d5a-857c-45d5-aac5-2f084ba0d64d_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments</link:label>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_label_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyInvestmentsMember" xlink:to="lab_rprx_RoyaltyInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BristolMyersSquibbMember_fc681eaf-11d5-497d-9d8a-b30decbb64cc_terseLabel_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_label_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember" xlink:href="rprx-20220630.xsd#rprx_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BristolMyersSquibbMember" xlink:to="lab_rprx_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_865d9326-078e-4e86-b17b-87e02c058515_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40df2559-e7b9-4a10-80d0-3e32afa62ed1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_a4120c37-4d48-4875-a7d9-ac618f820a89_terseLabel_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:href="rprx-20220630.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:to="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_f951804b-a095-4917-ac31-daced099001a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_e1ab87c7-072e-4fd1-97f1-5e1bd3fc03fc_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on initial recognition</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d590bb2-8f9b-44e4-b624-0d12f1122591_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_6a217052-6edc-4feb-8eff-c52ff02b1098_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_e7f90a55-1ac1-4a68-8ebe-a8e77229a5ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared and paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_af5662d1-89ea-4d85-b6a9-d11a3806c0c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_13b8868e-e68f-4247-ad41-0e1e5c80dfa3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherCommitmentIncreaseDecrease_2e989254-03fb-4645-b211-61923a2b8d43_terseLabel_en-US" xlink:label="lab_rprx_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in commitment</link:label>
    <link:label id="lab_rprx_OtherCommitmentIncreaseDecrease_label_en-US" xlink:label="lab_rprx_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Increase (Decrease)</link:label>
    <link:label id="lab_rprx_OtherCommitmentIncreaseDecrease_documentation_en-US" xlink:label="lab_rprx_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentIncreaseDecrease" xlink:href="rprx-20220630.xsd#rprx_OtherCommitmentIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherCommitmentIncreaseDecrease" xlink:to="lab_rprx_OtherCommitmentIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8337ce8b-1924-4697-a7e0-cf2913beb68b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cb8d4017-7eac-49ca-8663-765ed3f47839_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value, net</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ed3a9238-70f2-49dc-b72f-74e75ed4127a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MorphoSysMember_3c9d0d66-e7ac-4a56-93a1-c2c66962b67d_terseLabel_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:label id="lab_rprx_MorphoSysMember_label_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys [Member]</link:label>
    <link:label id="lab_rprx_MorphoSysMember_documentation_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember" xlink:href="rprx-20220630.xsd#rprx_MorphoSysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MorphoSysMember" xlink:to="lab_rprx_MorphoSysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_40d2acee-7729-498d-a200-959bd0ce5048_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_5eab867c-5a3e-4ce5-87e6-25832c105f0d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_96475445-e3b3-4b25-a2be-b816cbff541b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassBHoldersMember_95db9b66-8498-4146-894b-76021452a557_terseLabel_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_label_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders [Member]</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_documentation_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember" xlink:href="rprx-20220630.xsd#rprx_ClassBHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassBHoldersMember" xlink:to="lab_rprx_ClassBHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_dd8b6f92-0fd3-4af2-8486-b658571e98c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_c87c9eea-5ae0-4985-a9d8-24bd5d901940_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_48d0abde-12fb-4f8a-bb92-92b27d7b6d77_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eecc0834-b08c-47e4-86ed-eb57d3b5a111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_d1ba417a-23f0-49c7-9b2a-d0748b7a66df_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment repayments, percentage of amount drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:to="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_49fe74ab-4ded-4310-8060-af7ac3134957_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6e7628b-2819-41ab-afa7-3ecef5c71902_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_344d29ca-5b6f-46ce-ba37-34d11e6f4615_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_34377dd8-38a6-4090-9f1a-1aac741ffac4_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ef046d9d-9441-4ca1-9f8e-c4c9737a63d9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_48ac3df6-2435-4971-b44d-b72532e5f075_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_618cb0d0-b5f3-427e-899a-34b80f303a87_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_617170be-2391-47ea-861e-2e4acb6989c1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7909610a-0476-469a-86e0-74e44afc5bf8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_745afed0-38f3-46b8-abab-d10f6645fc38_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ab337863-6382-410e-a63b-fb6e43c94c1b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_4c720400-1ce1-4f8b-bc27-d23b3d513dc9_terseLabel_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly conversion basis</link:label>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_label_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Quarterly Conversion Basis</link:label>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_documentation_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Quarterly Conversion Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis" xlink:href="rprx-20220630.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockQuarterlyConversionBasis" xlink:to="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_0ee78543-f38f-4b85-b7d9-171822d8f0c5_terseLabel_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of noncontrolling interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_label_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_documentation_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests" xlink:href="rprx-20220630.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfNoncontrollingInterests" xlink:to="lab_rprx_NumberOfNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9e7790f5-ac00-43b4-8ed8-6307d3e9d280_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_7e0a785a-4ab2-4e92-a247-20a5f9a1b2c8_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, liabilities current</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Current</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_e469a9b6-d721-44a5-821f-9ea700be5091_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, fixed payment amount</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fixed Payment</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fixed Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c4f4f99-6e06-43dd-83ee-7671ac1f55ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_e52e7569-16ac-417e-999d-c44d005c6d3a_terseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collected on financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:to="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIMember_efdca634-b581-4d04-823d-f514468e1ac5_terseLabel_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:label id="lab_rprx_AvillionIMember_label_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I [Member]</link:label>
    <link:label id="lab_rprx_AvillionIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember" xlink:href="rprx-20220630.xsd#rprx_AvillionIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIMember" xlink:to="lab_rprx_AvillionIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9da0a7d1-ea8e-42a9-88f1-29f22169d743_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3b34b253-ab42-4708-ad4a-3d630ec12741_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_4c9a7246-c6dd-49fc-980d-3da2b7318867_terseLabel_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_label_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset [Member]</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_documentation_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:href="rprx-20220630.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:to="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a63db5b7-5b0e-40c6-a2a1-3329135b89aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EPAHoldingsMember_90457791-f801-49f8-87d4-b47c64106909_terseLabel_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_label_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings [Member]</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_documentation_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember" xlink:href="rprx-20220630.xsd#rprx_EPAHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EPAHoldingsMember" xlink:to="lab_rprx_EPAHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_3d3c1ae7-fca7-4084-a7b8-a5972f0906ab_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start of period of return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_0e18ee50-16eb-435e-883a-842561677273_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from intangible royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e47dfc9-6230-4fcc-a792-838cacd270cd_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9bfc0084-a5bf-43af-9fa3-f36886bca4ed_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Royalty Pharma plc</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_3456dcbc-9160-46df-b503-30080081b558_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec90baf4-3cbf-4dc8-868f-5cfe6440c3ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7194199d-411b-4708-8085-279d4fc22927_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_77258ea7-e437-44c8-873a-2a5b378c9e6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_a7e2420d-5997-4849-81c8-b21e61928d9c_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_label_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember" xlink:href="rprx-20220630.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyIncomeOtherMember" xlink:to="lab_rprx_RoyaltyIncomeOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_962599ad-8b87-438e-a27d-08a190862ced_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_dfe39e54-b69e-4a26-b46b-a00919289f4e_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With Biohaven Pharmaceuticals</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:to="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_96b38aee-e207-4d7b-bfc4-5b31653341c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_bc708504-3d81-4818-9cf5-24cf125cabb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_09afbc5f-db4c-4f7f-a4ba-a15c44cb0bda_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c2224ab2-61ca-4b2a-858c-5187358d1498_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount and loan issuance costs on long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_5e48bea2-22d2-4c00-918f-8a0eff64ea11_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_82fd1ad5-f0d5-4a2e-87c0-ed5736103249_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43f849fb-33c5-43d0-959f-38c9f280c534_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_e29c3b84-f17a-4d72-b119-a2a87b399f1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fa04502-91d2-46bb-b6c2-7943567e456e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c8e2eb94-01c5-4f0d-ae67-7030974c495e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect Cash Flow</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DerivativeAssetMember_7c3c1a0c-0af9-4e3d-9427-e725b9dcace4_terseLabel_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument</link:label>
    <link:label id="lab_rprx_DerivativeAssetMember_label_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Member]</link:label>
    <link:label id="lab_rprx_DerivativeAssetMember_documentation_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember" xlink:href="rprx-20220630.xsd#rprx_DerivativeAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DerivativeAssetMember" xlink:to="lab_rprx_DerivativeAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_ab054067-3e4c-4adc-8892-b92b1670621d_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Purchased [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsPurchasedMember" xlink:to="lab_us-gaap_FederalFundsPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_d738ccf7-6f56-4a94-8bf4-476f8a1b1a6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8b589a4e-4d48-49f2-a993-36c993b13804_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_e16ad03f-6fce-4d9c-8544-fc6f74f515e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_49111599-d34b-415f-a000-d7a2636030f4_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cd5aa104-53de-463b-bb86-a5685ceae032_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-operating expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eb7ecd53-c4ec-4a6b-b492-53b50df7e09e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_XtandiMember_a8ea59c8-c6f6-4876-8b9b-0a0dd0e447a6_terseLabel_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:label id="lab_rprx_XtandiMember_label_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:label id="lab_rprx_XtandiMember_documentation_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember" xlink:href="rprx-20220630.xsd#rprx_XtandiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_XtandiMember" xlink:to="lab_rprx_XtandiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c640ead5-cb8e-4035-b7af-a73bde57f469_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_f79d82eb-9bd1-4d08-bbcd-f5fcfa36bfcb_totalLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value, before cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_57395d10-397a-4764-9531-c7a2685095f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_86263d51-06d3-476f-8157-87c31ab6291c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentShares_b343d51b-0f9e-4a95-be3a-5d076b0876c0_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to be purchased</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentShares_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Shares</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentShares_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentShares" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentShares" xlink:to="lab_rprx_LongTermPurchaseCommitmentShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_0e9ca96e-c77d-47c9-83d7-eaf9d63ac955_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8d1c2e34-e5b4-468a-a471-0052504eb6eb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_c50f174a-2135-42d3-b418-f490d8f98f57_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, quarterly payments</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Quarterly Payments</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Quarterly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c53c8f62-5bdc-47b9-9243-cea4c952a2ac_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d08b1a01-4387-472c-ac13-9787fdae06d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_1e91dc45-2c83-413e-8263-6e2d8e2ad780_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from financial royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_469bb1b6-1a1f-4cbb-8a17-6e139b3214bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_262e1e3b-b651-418e-98af-1d3f421227bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_792ac665-ec95-46f0-a3e2-42aceedb2310_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fb5b3caa-4e4d-401b-9eec-afc14aa80f0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_f72f1d83-d13c-44f5-ac47-22f571387711_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_62117f1e-0905-4482-9066-c9d29e28f8ad_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible royalty assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ce0578aa-7dd0-43b4-a657-83b8def98047_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_f5a51d6c-07ee-4cab-a9d7-8de5add4d2fd_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0bf17cd5-822b-4a81-91d8-d254a2583232_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b1819203-d1fe-4ead-a691-5a75a817e6ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9baf037f-4683-41e1-8295-b7c9e2e938fa_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5ffcc8bc-915c-4d0d-9b88-1fe5362466c7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesValueIssued_cfa16f41-b4f4-45a8-ab61-5a2f7422cea3_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesValueIssued" xlink:to="lab_rprx_DeferredSharesValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_be692337-bce0-4848-b669-2b018629c598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_VertexMember_254f0d7e-d807-4319-8545-05970ad34f93_terseLabel_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_rprx_VertexMember_label_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_rprx_VertexMember_documentation_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember" xlink:href="rprx-20220630.xsd#rprx_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_VertexMember" xlink:to="lab_rprx_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_2d7bc847-d67c-4d44-856c-52e1f320c153_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Manager</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dd8db3b2-dde1-449b-b9cf-10a24dc18b93_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b9140e85-5fdd-444d-9ac0-e1ade77e5794_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Purpose</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_e7eef2aa-df3c-4879-91c0-f524e51de010_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period Two</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3a6f8c26-63f8-4812-838c-519fbf30f0cc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest (percentage)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b15029a3-5833-4922-b40d-4c649995b20c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_1b24188a-2484-48b7-bef3-bab7552eac4b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7474ddc5-a528-4bee-a2bc-c8625e9afa36_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses/(income), net</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4221f3d3-ffd6-48f7-aa5e-ae584156edbc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0b64dcf5-1bfd-4143-b3ef-7a413d8d4a33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_fe7892bd-aac3-4cb5-920f-5c8ab4b564f9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_45a8cd9b-0982-4d47-84ac-f87da84a1559_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bdb424a7-8e96-40a5-95d7-f4eb0a64cda5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation and related issuances of Class A ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_21f248de-799e-4f52-97dd-d66f84f575e9_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesOutstanding" xlink:to="lab_rprx_DeferredSharesSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_abdc6943-7d02-4232-ae92-2f0752332508_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c1b2cf6b-664d-4f9d-ba2e-f0f93508f462_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d8e6091f-83f3-4153-983f-44231abeaae8_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96a37e5f-4bf7-4f8b-9626-89380de22757_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2ec9eabf-a3e6-4f6f-a174-e26da8d176b9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_cce06995-a658-46c7-9ffe-0b782bfddb38_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_dd3f9684-f1a6-4c36-bfb3-c189b7c5b56d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_deff325d-538e-4e65-bf5c-5fb045977ca9_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForOtherCreditLosses_f7cb9b61-f26f-4abe-9cf5-87d72ab2a59a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_us-gaap_ProvisionForOtherCreditLosses_0d602590-d485-4251-9287-3692daaef982_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_us-gaap_ProvisionForOtherCreditLosses_label_en-US" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Other Credit Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForOtherCreditLosses" xlink:to="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_ee93fde0-21f4-4ffa-bc27-f8920afe38bd_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:to="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_66482781-c612-4b8b-af5a-1468c22fc556_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermDebtMaturityAfterYearFour_3589a843-3f28-4dfa-a0c5-e191663085bd_terseLabel_en-US" xlink:label="lab_rprx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_rprx_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_rprx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_rprx_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_rprx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermDebtMaturityAfterYearFour" xlink:href="rprx-20220630.xsd#rprx_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermDebtMaturityAfterYearFour" xlink:to="lab_rprx_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_322ebbc3-24f6-425d-a898-ca19b368eff4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c896268-971e-4526-9398-432dc4db19a5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_136da083-36da-4507-ac07-86a63bd87292_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_17dd83d3-d1dc-4776-8b16-f70c00741941_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TysabriMember_dcc7d6b2-68cb-4ffa-b186-91b3db1726d9_terseLabel_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:label id="lab_rprx_TysabriMember_label_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri [Member]</link:label>
    <link:label id="lab_rprx_TysabriMember_documentation_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember" xlink:href="rprx-20220630.xsd#rprx_TysabriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TysabriMember" xlink:to="lab_rprx_TysabriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_20eacbf8-019a-4afd-aeaf-8d63fdd28030_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development-stage funding payments - ongoing</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_311a664a-95fe-4a2a-9e1a-d5c6f7dc3687_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, initial payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:to="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_c41d2c07-ec10-4de9-b64d-f2c070af8d9e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_711bfa22-610f-4974-868c-914bee64df96_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1a80fa2d-a56e-4cb5-9c4c-4049b2abc0c2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_55058764-8c60-41b4-9cc1-fa01d124c1b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_4d426c8a-15e2-4770-aed1-db4e3de9cc04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains included in other comprehensive losses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_49b02d7c-9706-4e03-9a7c-f4e9371781b7_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for changes in expected cash flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f1236944-7794-4191-8f99-6b55966119f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DPPIVInhibitorsMember_7bee101a-86e7-4091-8d36-93eff0671ce8_terseLabel_en-US" xlink:label="lab_rprx_DPPIVInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV patents</link:label>
    <link:label id="lab_rprx_DPPIVInhibitorsMember_label_en-US" xlink:label="lab_rprx_DPPIVInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Inhibitors [Member]</link:label>
    <link:label id="lab_rprx_DPPIVInhibitorsMember_documentation_en-US" xlink:label="lab_rprx_DPPIVInhibitorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Inhibitors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVInhibitorsMember" xlink:href="rprx-20220630.xsd#rprx_DPPIVInhibitorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DPPIVInhibitorsMember" xlink:to="lab_rprx_DPPIVInhibitorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c470a1ca-62a5-4c1f-8b01-403bd2ce63e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8d28d5eb-ffdc-4159-ab24-9be3e7db9282_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2d345481-271b-48c8-a73b-c2d39be69f3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_bfb0aa39-6a28-4abe-a35f-16ebace8cc6e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_71347ec3-74b7-46e0-b28d-e83e8ef8b72c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_a47ba877-5413-4d6a-ad44-11adf0efee06_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_cdb6526d-b0e5-471d-9e0c-6455d8a3f3ad_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_6c589e0c-b357-4fb3-91f1-eb36a3bf84fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instrument, current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d65da74-9f99-47bc-acfd-3b3bfa0329b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-adjusted discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_a5444648-f68d-44b8-982f-c94eaf84481f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesTextBlock" xlink:to="lab_us-gaap_FinancingReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_31b93d1a-5b07-4365-b7f8-c000b46a148b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_4cefe3e6-2695-4c5d-ab0c-b7f5d4c8ad5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_0fc436dd-6acb-478f-8f5f-899391b1f5a3_terseLabel_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_label_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:href="rprx-20220630.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:to="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_208a898a-538d-4f0b-a437-8b66bdea6b18_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_00bd1235-514d-4e5d-83ff-de467b815298_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9e1aef06-1d85-41b4-93fa-d36bec0a8ca9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_eebb41f8-8db3-4cb2-8987-1267c4ae32b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_3a6c6850-3550-42d7-bc0d-1819a2864e18_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, issued (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesIssued" xlink:to="lab_rprx_DeferredSharesSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e64768c0-3c2b-41e0-bf99-46336b58e0e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_6571bbf4-75aa-4fc4-bb57-17ba5096c96d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of forwards</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_5944a0a3-3a29-4e86-a66e-8e125536635b_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of limited partnership interest acquired (in shares)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:to="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_eb25cdde-72e1-4119-8cc1-761e5a5c6396_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_520aefee-9275-441d-9dbf-e010d0c100b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the applicable par call date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8105a823-2bc0-4e48-8234-a6c146a62b26_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_5dc05d29-eb09-414b-9e5c-e37277bd2815_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty cash collections</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_ba27e69c-e448-4cb8-aea4-898b95959490_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_bbe1cfa9-87c8-4c36-b76a-8d362def01ec_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_56457ec1-b169-449d-a520-f902f805f0cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a5f4b685-3199-4106-8316-fde1ef0cb7a4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ba651daa-1466-460b-9b90-bc0acd39b77e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b692abc6-1154-4927-8ca0-e7ec899d7cab_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7cbc9172-657e-42d9-b69e-749044d9c9e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_c89ed7db-99fd-4813-9386-fca70019f17b_terseLabel_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_label_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:href="rprx-20220630.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:to="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c663abf5-abff-4680-9526-9b860b387025_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_45a1082d-feb7-4499-8dc9-76307130668f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_066e06a4-9ae0-4bd7-8935-21720a31b018_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8ac41309-6edb-4455-b4db-1d8ae44ad7e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_ba56dc6b-561a-4823-81bd-c03d611bbc9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8eb689f7-87ba-4246-a162-0205d27102bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_ebe47c9f-a0d7-4419-adfe-18a53a505675_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_8f58df20-307b-4da5-b474-97d24505895b_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:to="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_be8c2817-02da-4f46-9442-3fdd822507be_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_7b4f8e0c-54ac-4c24-a338-7451417e1837_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_d2acf54a-1b8c-4353-bc7e-cee3a70ba2bb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_6e2da285-5ff3-470b-b544-dbf65903738b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision for credit losses, net</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AgreementWithMSCIMember_c3f81e8a-ab28-4f1c-a8f8-9fd7daa16ede_terseLabel_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_label_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI [Member]</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_documentation_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember" xlink:href="rprx-20220630.xsd#rprx_AgreementWithMSCIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AgreementWithMSCIMember" xlink:to="lab_rprx_AgreementWithMSCIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ba228430-1298-407b-a30c-55aed309136b_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fca9a65f-2182-40f7-bcec-283349a4753c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_736fd3cc-e53a-42d0-a247-8019e26b5501_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_06bcccab-ae4d-4050-b3b6-9dd5f26bbbf8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_9d207914-b7d7-48a1-9b26-0d700f3ce758_terseLabel_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_label_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_documentation_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:href="rprx-20220630.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:to="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_cc3bc807-42f1-408b-a121-9329ebefeb51_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interests- other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:href="rprx-20220630.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:to="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b63faca8-bf50-483d-bb65-9440d76654c9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_18fe038d-44a9-4182-9bd1-26a9ed5c4e64_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ImbruvicaMember_4c9541af-1503-4179-8584-a217c397b093_terseLabel_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_label_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica [Member]</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_documentation_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember" xlink:href="rprx-20220630.xsd#rprx_ImbruvicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ImbruvicaMember" xlink:to="lab_rprx_ImbruvicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_7855e3de-e3bb-4a18-b01e-80f7bfe587d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_576d7513-fa2b-4827-beb2-11d20711a358_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d46e1d5f-6960-4179-b048-7bde9da51ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_4f7d6336-9c71-4c74-81e6-38a328298b59_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_210ca2f1-00d8-40fe-a676-f5794d9bcc67_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Funding Commitment</link:label>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_label_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Funding Commitment [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember" xlink:href="rprx-20220630.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsFundingCommitmentMember" xlink:to="lab_rprx_CytokineticsFundingCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fdc0de95-b7e7-4cd9-a17a-0249637fd032_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_774810f9-ed43-47cf-9e23-8c1fa2a6a758_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_3d5e0f42-5594-46bd-8ddf-aeb7892a6183_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, liabilities noncurrent</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Noncurrent</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_a1a7384e-da5c-47a2-ba87-ed53c0c02108_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_45ae4b6f-0b23-4ddd-b473-889a7bc43c64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_55b9342f-f327-4f50-ac49-b56f4fe7f92d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_5cf014ae-07dd-489a-8e78-a529c5ab2abf_terseLabel_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of stock</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_label_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_documentation_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock" xlink:href="rprx-20220630.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfClassesOfVotingStock" xlink:to="lab_rprx_NumberOfClassesOfVotingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_01e11fe4-6a23-46b5-b815-d7d642bdb33e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_219b9388-45fc-44fc-ae42-55c8694e19f7_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity securities</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:to="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_60c9e495-b131-4f56-8a75-3e5abd3b877c_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption of debt securities</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_50b4e636-9183-4481-b4f6-3ec6c93a34c0_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral posted</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:href="rprx-20220630.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:to="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_2197aeea-b98b-4ca7-bf2d-3f987d596723_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of security investment (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:to="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_75b34721-ea0c-4893-9dba-9c84e889e4eb_terseLabel_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_label_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate [Member]</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_documentation_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:href="rprx-20220630.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:to="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9325ce36-fea2-4f17-a747-88e07a533b7e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_d62ad716-000b-4aaf-a425-4ebcf136a740_terseLabel_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:href="rprx-20220630.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_cd0df897-89e3-481e-ac1c-dcfe9c021d41_terseLabel_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_label_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:href="rprx-20220630.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:to="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_05b7fef4-09b7-4585-8e2a-40d5811dad27_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3adc427c-37e6-492b-a8b7-b79f5c7d7866_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9333ef8d-346f-4888-80fd-ee2b672029ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_0b923b84-5808-4bc2-8349-61f3890c1e52_terseLabel_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_label_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_documentation_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:href="rprx-20220630.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:to="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1349dc78-6cf6-40ce-95b9-512cd7b82034_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ccb86444-33d3-42c5-9f1b-394f935e7c47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_471de125-9091-495f-9cfb-07e2f621f519_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_38b83b57-dfb3-44a2-aee1-f52fbc2592e5_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:to="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d6f84f92-4fee-4103-9e83-43dda6cb8327_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TremfyaMember_e6b85253-14f2-4a50-80ef-921ed2655b6b_terseLabel_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_rprx_TremfyaMember_label_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_rprx_TremfyaMember_documentation_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember" xlink:href="rprx-20220630.xsd#rprx_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TremfyaMember" xlink:to="lab_rprx_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3b57a5dd-a21a-49e0-bb7d-3fcdcf8ff986_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1fe7a8da-3906-49fc-b628-7cd0a420fe99_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7631d4ef-aa06-42b8-b5e3-8b4004fb64c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_81470c9a-0856-45da-853a-ad4deed770c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_960e986b-c195-42c9-a13b-e3aecfd7ca1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity securities still held</link:label>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2311c711-9349-4d89-a63d-7244ff7ba37e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_bf540c8d-c864-4a28-82aa-c9ce17ba2924_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_49db5391-8b0d-4214-b7a5-bd5aca1caa5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_03f97839-1cb7-444f-9bfa-b0da78650a7c_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_04d2e9a5-427f-4ab5-9796-b08f967065d3_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_4b38504e-bf6c-4d40-9853-357d1ca8793d_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_023160f3-50fa-4d69-a183-0f498d5c7abc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01566da6-46aa-4506-b6ac-9536a746eddc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_3c0e828b-3c4f-4ef3-8695-d4e1a32a19d7_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions payable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_212903c2-3187-416f-ad16-17ceba9201b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_036edb1d-ccbf-4de6-8d30-b2dae8e3c57b_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0d0273ee-ef83-4b98-afb0-a549246afff7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_52820439-6bdd-4c26-b71e-7dcfd70f3f2d_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:to="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ca7675f0-28f3-49bd-ab56-a6bbe3e0e720_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5fd27663-2014-40b4-a35d-18c898c79472_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_a7e65590-f171-48bc-b928-98180d4c0265_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_87efd584-67df-4f51-ac7f-88fa0fae738e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_cd327d98-fa91-4cfe-939f-95ed205273b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Consolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_71df2394-ec7d-434c-bce3-d3097e2c3f37_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for operating and professional costs</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_label_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_documentation_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:to="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c9bcbed9-966c-4527-9e96-902f45837139_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b985d0dd-0981-4222-bd41-5a932f1dad82_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in income (loss) of non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_5bc0054d-2096-4140-85bb-3e35e5b7ef75_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:to="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cadba2ae-cbcd-468b-a8bf-07f22feab424_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_a6f90a0c-566a-48b2-be27-a8f31b19044b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; Development ("R&amp;D") Funding Expense</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ca2b20cb-db03-4e7a-824d-fa99e2c5e6ab_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rprx-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b0b4b423-ffc3-47e5-9133-2ff4a2f1daf8,g:f6a226db-421d-4d9c-89a3-4b8d48e515d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b3810c96-3a04-499c-9783-455a187c1e83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3810c96-3a04-499c-9783-455a187c1e83" xlink:to="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e9ec9b75-d1c8-484a-8965-55b273d26867" xlink:to="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf191bb4-138a-41e2-82b1-1db729076967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:to="loc_us-gaap_CommonClassAMember_bf191bb4-138a-41e2-82b1-1db729076967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8da4f463-4b45-4d94-aa03-263641662a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c08fb3ff-b78d-4b3e-b4fb-71d87a10307d" xlink:to="loc_us-gaap_CommonClassBMember_8da4f463-4b45-4d94-aa03-263641662a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_2979f3f8-f2d1-45ed-934c-b1c2da595566" xlink:to="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_553d31f2-e781-4a6e-9b5a-9dd99bc960cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentType_553d31f2-e781-4a6e-9b5a-9dd99bc960cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d3a21fda-d8fc-4c05-a987-98394c9efb97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentQuarterlyReport_d3a21fda-d8fc-4c05-a987-98394c9efb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_da590c7b-546c-4c88-b8e7-f9f739b7f723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentPeriodEndDate_da590c7b-546c-4c88-b8e7-f9f739b7f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d345f175-9ea1-4a3a-ba7d-f7a2859c59c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentTransitionReport_d345f175-9ea1-4a3a-ba7d-f7a2859c59c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_16a7e70b-3005-4d84-82e7-0f41cf556308" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityFileNumber_16a7e70b-3005-4d84-82e7-0f41cf556308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e3a1aaf0-6e9b-4397-9888-e41de69a4207" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityRegistrantName_e3a1aaf0-6e9b-4397-9888-e41de69a4207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8b5214f4-56bc-4b40-9ce8-1fdd386502b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8b5214f4-56bc-4b40-9ce8-1fdd386502b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1a20b71-25a3-4391-964e-157390060f16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1a20b71-25a3-4391-964e-157390060f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f6eb40d2-7435-41b6-9fa9-dc18351623aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressAddressLine1_f6eb40d2-7435-41b6-9fa9-dc18351623aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a3d848f5-2b24-479d-9155-2148030e1909" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressCityOrTown_a3d848f5-2b24-479d-9155-2148030e1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5c0d2684-73ef-414b-8872-b3ae06c13525" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressStateOrProvince_5c0d2684-73ef-414b-8872-b3ae06c13525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7c349ed-1172-4257-b204-181e26b3a1b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityAddressPostalZipCode_d7c349ed-1172-4257-b204-181e26b3a1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0e1caf8b-20db-450e-a938-9e68518622d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_CityAreaCode_0e1caf8b-20db-450e-a938-9e68518622d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68bbef2c-1516-4801-a62c-2c880e6d3568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_LocalPhoneNumber_68bbef2c-1516-4801-a62c-2c880e6d3568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9bdcf227-1720-40a3-86d8-3fba469f0d4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_Security12bTitle_9bdcf227-1720-40a3-86d8-3fba469f0d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_88349fe1-85c8-4f78-80b8-ece738447829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_TradingSymbol_88349fe1-85c8-4f78-80b8-ece738447829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_946e9ca3-8137-4257-b436-8473eec41174" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_SecurityExchangeName_946e9ca3-8137-4257-b436-8473eec41174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_29b19435-784d-494a-8362-4e39ebd07a93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCurrentReportingStatus_29b19435-784d-494a-8362-4e39ebd07a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cbcc5091-2f31-4f15-a9dd-af3cb252fafa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityInteractiveDataCurrent_cbcc5091-2f31-4f15-a9dd-af3cb252fafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6df2039f-48f1-49be-8a35-1bb38f25f42a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityFilerCategory_6df2039f-48f1-49be-8a35-1bb38f25f42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a64e220e-e974-4f9b-9ff6-8c49c7787b0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntitySmallBusiness_a64e220e-e974-4f9b-9ff6-8c49c7787b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0a09e90a-12aa-4529-b015-1e90511dffd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_0a09e90a-12aa-4529-b015-1e90511dffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_61aa5fef-1c47-4ecc-9d20-c08b9cfaed7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityShellCompany_61aa5fef-1c47-4ecc-9d20-c08b9cfaed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2f66a335-2a93-4881-8715-6e8c7818353d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2f66a335-2a93-4881-8715-6e8c7818353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_58eb61d3-d992-493b-b7f1-2275041feec5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_EntityCentralIndexKey_58eb61d3-d992-493b-b7f1-2275041feec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d0bf3620-b710-4b54-8188-d0f36feb3fef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_CurrentFiscalYearEndDate_d0bf3620-b710-4b54-8188-d0f36feb3fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_786f6b41-8d57-4679-8333-5a87f23ebcd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentFiscalYearFocus_786f6b41-8d57-4679-8333-5a87f23ebcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2900377f-2d0a-473d-a6df-a7d24586d8cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2900377f-2d0a-473d-a6df-a7d24586d8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_127f7245-06cf-48fd-8525-583bfeaa6900" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_08f2ede2-23ab-4d6d-bc29-5b73ea5fd0e0" xlink:to="loc_dei_AmendmentFlag_127f7245-06cf-48fd-8525-583bfeaa6900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8f776887-76c1-4d11-99ce-58a69a1c859a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f776887-76c1-4d11-99ce-58a69a1c859a" xlink:to="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0363db8-9bc4-4527-9fe6-7aaace5fa7bc" xlink:to="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf991ebb-c00e-4371-a502-348e5d8aa616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_us-gaap_CommonClassAMember_bf991ebb-c00e-4371-a502-348e5d8aa616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8bec0dd1-7014-48af-a272-13ba3099e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_us-gaap_CommonClassBMember_8bec0dd1-7014-48af-a272-13ba3099e59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_72375e6c-c661-4a1b-adf4-b5a2b314cc82" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2e9b5e67-1320-451c-a9b1-32ec0b0ce997" xlink:to="loc_rprx_ClassRRedeemableStockMember_72375e6c-c661-4a1b-adf4-b5a2b314cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c378db4b-8ecd-4191-be1e-4db7b71ba055" xlink:to="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:to="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a82e20f0-3008-4292-8d57-61c9f768edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a82e20f0-3008-4292-8d57-61c9f768edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_de989412-ab49-4173-9d67-3d8cb08703fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_TradingSecuritiesDebt_de989412-ab49-4173-9d67-3d8cb08703fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0f6c27b0-4b29-4e17-b45c-2f6767bb2451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0f6c27b0-4b29-4e17-b45c-2f6767bb2451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_b8538b61-3f91-415c-825b-515865986c33" xlink:href="rprx-20220630.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_rprx_AccruedRoyaltyReceivable_b8538b61-3f91-415c-825b-515865986c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33750175-f1c1-462f-9ad2-69bcc8c58fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33750175-f1c1-462f-9ad2-69bcc8c58fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_cfc841d9-f68f-465b-8143-abca2763f857" xlink:href="rprx-20220630.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_cfc841d9-f68f-465b-8143-abca2763f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bea18d4b-10b7-41f2-a4db-020c71f1e697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_OtherAssetsCurrent_bea18d4b-10b7-41f2-a4db-020c71f1e697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f4d3ba78-5ed7-45af-a983-ad7e9e32cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea546ffc-8998-42db-9c15-45cfe9cf6bba" xlink:to="loc_us-gaap_AssetsCurrent_f4d3ba78-5ed7-45af-a983-ad7e9e32cdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_f976c46d-6c53-4aea-8700-bc4419ef9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_f976c46d-6c53-4aea-8700-bc4419ef9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ea88b2c-ee0d-4be5-be73-febb7996907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2ea88b2c-ee0d-4be5-be73-febb7996907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e75ab12d-516e-4c21-91f0-aa17c8ea6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e75ab12d-516e-4c21-91f0-aa17c8ea6f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c0a4bdd-9f9b-4438-a991-7ff0e88641b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9c0a4bdd-9f9b-4438-a991-7ff0e88641b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e918dbc-a65a-447c-a6eb-1172a121127e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_EquityMethodInvestments_9e918dbc-a65a-447c-a6eb-1172a121127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_890f5e5f-6cbf-45cd-9b73-2cd8c18bb0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_890f5e5f-6cbf-45cd-9b73-2cd8c18bb0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eba50be1-d4f2-469b-ad3f-d51341bb03ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47299e3d-9cbb-43b6-81ba-28f73eb2347e" xlink:to="loc_us-gaap_Assets_eba50be1-d4f2-469b-ad3f-d51341bb03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6157cc3d-1afc-44ed-8aab-c7aeffd91795" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_62172064-68cd-4792-a7d4-10b48be5ef6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_62172064-68cd-4792-a7d4-10b48be5ef6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bc1d4fc-f5c3-415b-82a2-496f4ed7ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bc1d4fc-f5c3-415b-82a2-496f4ed7ab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_ae8e8160-e944-44e1-989a-f35f5217f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_InterestPayableCurrent_ae8e8160-e944-44e1-989a-f35f5217f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8530d929-3bb0-40a6-81cf-0f5602e06a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62c94d0a-186a-46dc-93f7-7cb16df62257" xlink:to="loc_us-gaap_LiabilitiesCurrent_8530d929-3bb0-40a6-81cf-0f5602e06a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c983711c-5f07-46f5-ad50-7dfc795aed72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c983711c-5f07-46f5-ad50-7dfc795aed72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_f1870279-3d09-4cf3-aeb3-4506c97cfc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_OtherLiabilities_f1870279-3d09-4cf3-aeb3-4506c97cfc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_daa6d5db-01b2-4103-ae5a-76e8e709d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_Liabilities_daa6d5db-01b2-4103-ae5a-76e8e709d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_203ce0d6-a346-479c-a0a9-f9d3ba53720a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_203ce0d6-a346-479c-a0a9-f9d3ba53720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1f3d277-f336-4410-a8f2-4832f03aed23" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_33444ba0-0314-4ba2-b3cd-1b3591879259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_CommonStockValue_33444ba0-0314-4ba2-b3cd-1b3591879259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_4cec2e90-8d21-4553-9741-b49bf8b7b487" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_rprx_DeferredSharesValueIssued_4cec2e90-8d21-4553-9741-b49bf8b7b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_addc29d4-3939-40a2-ab12-e71fc998d775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_AdditionalPaidInCapital_addc29d4-3939-40a2-ab12-e71fc998d775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117500c1-29db-4eb7-8c01-fdbb285d90d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117500c1-29db-4eb7-8c01-fdbb285d90d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d36c1e7d-c4c5-4843-984e-d0a95bb081cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_MinorityInterest_d36c1e7d-c4c5-4843-984e-d0a95bb081cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afe7eb20-fa8d-4338-86cf-7e128d9932be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afe7eb20-fa8d-4338-86cf-7e128d9932be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5da1d4a2-b363-4acb-ad23-fee04b4e0fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_TreasuryStockValue_5da1d4a2-b363-4acb-ad23-fee04b4e0fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b582750-497d-4044-a799-7385c27e8eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b582750-497d-4044-a799-7385c27e8eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8253a07f-4169-4cf0-8f70-455c79c350f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1cb936c7-5017-417c-9335-a37b9ac16c13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8253a07f-4169-4cf0-8f70-455c79c350f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a715550b-7b98-47db-a088-4d2990b9bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a715550b-7b98-47db-a088-4d2990b9bd52" xlink:to="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1718f9bc-2325-4fc5-9766-70ba0a7c273b" xlink:to="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_2b1e0d0c-0b1e-479e-8c4c-cdb7737fec45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_us-gaap_CommonClassAMember_2b1e0d0c-0b1e-479e-8c4c-cdb7737fec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2722f1cf-bda8-42d1-ab4d-c5dbc0012814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_us-gaap_CommonClassBMember_2722f1cf-bda8-42d1-ab4d-c5dbc0012814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_e305f569-4e20-401e-8b7d-0163678d6a23" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f6af635-5675-4734-8e2b-bf150301c531" xlink:to="loc_rprx_ClassRRedeemableStockMember_e305f569-4e20-401e-8b7d-0163678d6a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6e448c93-70db-4759-93b1-0109b9ede0a6" xlink:to="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_32a9f38f-69e3-4e53-b239-03db736d47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_32a9f38f-69e3-4e53-b239-03db736d47f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c692d3a9-c94e-4cea-bff1-7cdcb6568991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockSharesIssued_c692d3a9-c94e-4cea-bff1-7cdcb6568991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c666cd7-8853-4d92-8f7d-0fd80417c6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c666cd7-8853-4d92-8f7d-0fd80417c6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_ee386e45-735f-4d90-b8b6-4a63df92d379" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_ee386e45-735f-4d90-b8b6-4a63df92d379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_86830e1c-84b5-43b1-888c-6985f16d759c" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesSharesIssued_86830e1c-84b5-43b1-888c-6985f16d759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_0e2fa3f5-8189-4893-8305-8195d68ae77d" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bee9a751-d6c6-4bd0-b5b7-0e20ea2f64e0" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_0e2fa3f5-8189-4893-8305-8195d68ae77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1d1f5543-ed97-40bf-92d0-353e9e48c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1d1f5543-ed97-40bf-92d0-353e9e48c9f3" xlink:to="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:to="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e35a36bf-1bcb-441b-88ff-555200dcfb59" xlink:to="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_240502cc-36e5-4ea7-81b0-cba7999c8589" xlink:href="rprx-20220630.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_240502cc-36e5-4ea7-81b0-cba7999c8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_2c7bdafb-fe2e-4c53-90ac-fcd30137b9a3" xlink:href="rprx-20220630.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_2c7bdafb-fe2e-4c53-90ac-fcd30137b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_ff5c34e1-05c7-459f-9603-77e0afd80f43" xlink:href="rprx-20220630.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ccded3f-47af-49f4-bcd1-75f5ace15b7f" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_ff5c34e1-05c7-459f-9603-77e0afd80f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_59ceddd7-54fa-4d80-b38b-8b405f6ae06a" xlink:to="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d84fe314-e98d-4057-9f14-fb83716fb06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_Revenues_d84fe314-e98d-4057-9f14-fb83716fb06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_be6b9cb7-22d8-43c7-aabb-8c9e2c860da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_be6b9cb7-22d8-43c7-aabb-8c9e2c860da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2c21059-f816-403a-a3b9-20c20e273eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2c21059-f816-403a-a3b9-20c20e273eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ac34159e-7473-4a9c-bb4e-9c34569a3471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ac34159e-7473-4a9c-bb4e-9c34569a3471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_24e8c29d-bfe6-453a-af3c-c5817b00036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_24e8c29d-bfe6-453a-af3c-c5817b00036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0a4d40ab-a59e-414d-8b91-8ddf8042992e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ec958ca6-13f0-4562-99af-f3f992a55757" xlink:to="loc_us-gaap_CostsAndExpenses_0a4d40ab-a59e-414d-8b91-8ddf8042992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6438e859-0a63-46f9-b7ab-5f337b182acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6438e859-0a63-46f9-b7ab-5f337b182acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6049406e-b4cd-4cea-84f1-25f2ab7342e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6049406e-b4cd-4cea-84f1-25f2ab7342e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ed2379cc-f365-400f-b162-514d3b256b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_InterestExpense_ed2379cc-f365-400f-b162-514d3b256b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3211172f-839c-4a9a-af60-d27b1333e007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3211172f-839c-4a9a-af60-d27b1333e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd60bcc-79d3-414f-a110-0de632a5f630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd60bcc-79d3-414f-a110-0de632a5f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_41fd00bb-34fe-491b-a05c-dbb28219e916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_41fd00bb-34fe-491b-a05c-dbb28219e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_eaa4b003-b13f-4c3e-b7ab-6effdec0aa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_InvestmentIncomeNet_eaa4b003-b13f-4c3e-b7ab-6effdec0aa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_53d6d41c-b041-4524-b8be-cf2b4b662ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_53d6d41c-b041-4524-b8be-cf2b4b662ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61b846c5-953a-4a8e-a303-68e22537d199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e82d8631-1aac-4140-a056-1fab876aac30" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61b846c5-953a-4a8e-a303-68e22537d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f04413b3-7086-4e25-902c-c4b35e44f322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f04413b3-7086-4e25-902c-c4b35e44f322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_adf7d050-0e5b-4255-b1d2-049e396479ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_adf7d050-0e5b-4255-b1d2-049e396479ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_012f9ce0-6828-4195-8b1f-b389f90900cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_ProfitLoss_012f9ce0-6828-4195-8b1f-b389f90900cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ab008e69-70d7-40b3-92fd-db6aeba0fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ab008e69-70d7-40b3-92fd-db6aeba0fce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e042bc7e-6d31-4376-b39d-aaee84028348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_NetIncomeLoss_e042bc7e-6d31-4376-b39d-aaee84028348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1a40a5d8-a242-4738-b545-7a1134440e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:to="loc_us-gaap_EarningsPerShareBasic_1a40a5d8-a242-4738-b545-7a1134440e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_746fdbf2-55a9-4f05-8251-11161a075a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_e50a25db-a733-44d0-97c3-de1165972c94" xlink:to="loc_us-gaap_EarningsPerShareDiluted_746fdbf2-55a9-4f05-8251-11161a075a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdbc677d-69bf-40d0-955a-7d9c49cbe5d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b338c83-5a7a-44d8-ae6b-a9562bf03907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b338c83-5a7a-44d8-ae6b-a9562bf03907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e95d1709-7e02-4f69-a8fa-78a0720633af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3e71cc6f-f05b-4e09-ba1a-a962a6d1f256" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e95d1709-7e02-4f69-a8fa-78a0720633af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ddfbda3-7529-42b5-a7ef-7a4258a583d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:to="loc_us-gaap_ProfitLoss_1ddfbda3-7529-42b5-a7ef-7a4258a583d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_853ee9bf-8878-4d0d-8af6-66fc4a8febe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_853ee9bf-8878-4d0d-8af6-66fc4a8febe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_58aa21e7-d315-45ec-a7fd-3cd9829c3a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_853ee9bf-8878-4d0d-8af6-66fc4a8febe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_58aa21e7-d315-45ec-a7fd-3cd9829c3a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b535e7e9-cb64-482d-bf7f-98a85fd32534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_853ee9bf-8878-4d0d-8af6-66fc4a8febe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b535e7e9-cb64-482d-bf7f-98a85fd32534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd1af658-3852-4166-b2ed-714bdc4b2b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_853ee9bf-8878-4d0d-8af6-66fc4a8febe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd1af658-3852-4166-b2ed-714bdc4b2b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1fb877d9-e2b1-4209-998b-6bb66c8189e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1fb877d9-e2b1-4209-998b-6bb66c8189e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_88cd6300-df7f-4f72-aea5-447cbb957af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_88cd6300-df7f-4f72-aea5-447cbb957af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_049c9b96-632b-4568-8af7-0a19e6fb6157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b912b191-7271-482a-bcf7-6099e0369b40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_049c9b96-632b-4568-8af7-0a19e6fb6157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_71a9a09e-2551-45cb-94b7-e8e331e559fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_71a9a09e-2551-45cb-94b7-e8e331e559fc" xlink:to="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_16a3b7b1-42d7-466f-8559-1eb7f145c7b4" xlink:to="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3538d585-105b-44a8-92f0-08436b9add25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_CommonStockMember_3538d585-105b-44a8-92f0-08436b9add25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_aa34364f-2376-4529-a10a-1dff2f08a4ea" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_rprx_DeferredSharesMember_aa34364f-2376-4529-a10a-1dff2f08a4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de257c86-dfd8-42df-aa4f-0b4afa3a72ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de257c86-dfd8-42df-aa4f-0b4afa3a72ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0299a04d-f5e1-46f9-9801-898bbacf4fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_RetainedEarningsMember_0299a04d-f5e1-46f9-9801-898bbacf4fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_cdc8239c-00a9-4501-975a-31add3fd8200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_cdc8239c-00a9-4501-975a-31add3fd8200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_41d19c55-b15c-41d2-aada-c021fd1cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_NoncontrollingInterestMember_41d19c55-b15c-41d2-aada-c021fd1cb20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92c814da-4776-4175-9ffd-e67f54d54d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_559b9367-9029-4ea1-afeb-6635fd09b6df" xlink:to="loc_us-gaap_TreasuryStockMember_92c814da-4776-4175-9ffd-e67f54d54d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7686cf6f-a5f8-42d5-8f01-3af798c1e404" xlink:to="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bdbb0931-d1f5-42de-a242-39f63187b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_us-gaap_CommonClassAMember_bdbb0931-d1f5-42de-a242-39f63187b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_d42315ae-3b47-4dd0-83a6-018f8b2426cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_us-gaap_CommonClassBMember_d42315ae-3b47-4dd0-83a6-018f8b2426cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_c11aaf16-cf32-4912-b4f2-e08b6b1adbbb" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1297bc9e-9ccb-41b4-8dbe-5411ebf1bbef" xlink:to="loc_rprx_ClassRRedeemableStockMember_c11aaf16-cf32-4912-b4f2-e08b6b1adbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad952e78-d41a-4b1b-bd3a-663b203ac6ac" xlink:to="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32e1fb55-3eea-42d5-b629-18622a6612dc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b4bdca49-4fc0-41c2-bf48-7291984b7415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_SharesOutstanding_b4bdca49-4fc0-41c2-bf48-7291984b7415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc296365-88c3-4939-8e0a-25e7485ee7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc296365-88c3-4939-8e0a-25e7485ee7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_42b32617-115b-4f34-bfc6-832381e8119a" xlink:href="rprx-20220630.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_42b32617-115b-4f34-bfc6-832381e8119a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_7b6758f9-f770-4312-8f99-4e27135e4085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_7b6758f9-f770-4312-8f99-4e27135e4085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_55863c17-0ace-4212-85f8-2cedf3fb7b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_DividendsCash_55863c17-0ace-4212-85f8-2cedf3fb7b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_d6e54e80-92af-416d-a21e-fcee54943a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_d6e54e80-92af-416d-a21e-fcee54943a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e4a6beeb-ee94-4b62-aa7e-b2e3c23748ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityOther_e4a6beeb-ee94-4b62-aa7e-b2e3c23748ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb8a03c4-3807-48e7-85dd-5d46759b2d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb8a03c4-3807-48e7-85dd-5d46759b2d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e65df832-e34f-46f1-bf3f-463f8116f848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e65df832-e34f-46f1-bf3f-463f8116f848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_170ce244-a74e-4e98-a851-bda7cdb7cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_ProfitLoss_170ce244-a74e-4e98-a851-bda7cdb7cd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d260f03e-2a69-432c-871e-92c2841367c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d260f03e-2a69-432c-871e-92c2841367c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_09139b62-bbee-4fd2-8063-c00b30f209c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_09139b62-bbee-4fd2-8063-c00b30f209c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b2be223a-38f3-4959-a501-26e0be3bc02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_SharesOutstanding_b2be223a-38f3-4959-a501-26e0be3bc02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1ab965c-9cc9-4cfa-a20f-80e8d2ce30c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1e236cd-b45b-4d78-8941-c4e83fa4b6da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1ab965c-9cc9-4cfa-a20f-80e8d2ce30c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9e09bb92-da94-4469-a137-03542d85df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9e09bb92-da94-4469-a137-03542d85df1e" xlink:to="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9193fea9-d284-4c1d-88b0-2a4e72af3cb6" xlink:to="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8c1bf598-f35b-4f09-a845-747ab9d07aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b44d4d1e-c998-4544-a85a-212a30fe8842" xlink:to="loc_us-gaap_CommonClassAMember_8c1bf598-f35b-4f09-a845-747ab9d07aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7db9b4f6-6c56-4d0b-98fb-b6adf5787f66" xlink:to="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_2a120f75-8cf4-4edb-9b4a-e4a9441086cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa295e6b-5bf1-4c9b-aa94-e201c520340f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_2a120f75-8cf4-4edb-9b4a-e4a9441086cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_75daf976-5e03-44c9-bb03-cbb18de7aa45" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_75daf976-5e03-44c9-bb03-cbb18de7aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_43cea3e6-db50-4949-8528-2d55fe1a7bd3" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_43cea3e6-db50-4949-8528-2d55fe1a7bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_4e1b23ba-188f-4840-8f85-82e361d3bf8c" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_4e1b23ba-188f-4840-8f85-82e361d3bf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d4958a6e-fa57-4387-9734-d06b52b13e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d4958a6e-fa57-4387-9734-d06b52b13e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_005c26f0-54cc-4ad1-879c-b08e5725c9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_005c26f0-54cc-4ad1-879c-b08e5725c9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_8c04451f-800e-4001-9547-6597b087bf69" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_8c04451f-800e-4001-9547-6597b087bf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_1c81a220-98c9-44e7-95de-407f07237670" xlink:href="rprx-20220630.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_1c81a220-98c9-44e7-95de-407f07237670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_1bc89a25-61ec-43c3-9e78-be41e8d1a1cc" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_1bc89a25-61ec-43c3-9e78-be41e8d1a1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_c6b35d57-8cec-4068-bf99-8ba38502e9b6" xlink:href="rprx-20220630.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_c6b35d57-8cec-4068-bf99-8ba38502e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_dd3477bb-b311-488c-b927-bc37bcc1dce1" xlink:href="rprx-20220630.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_dd3477bb-b311-488c-b927-bc37bcc1dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ac8af0e1-4662-493b-bfab-bd1a4cd7048d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_us-gaap_InterestPaidNet_ac8af0e1-4662-493b-bfab-bd1a4cd7048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c142742-441f-4d04-89ca-29ce36ba50a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90ffeded-a1e9-4a6d-90ca-49374069d2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c142742-441f-4d04-89ca-29ce36ba50a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_932e54de-3022-4f0b-907f-6d0be3308acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_932e54de-3022-4f0b-907f-6d0be3308acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c51e5aef-864e-43a6-996e-331aa52351ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c51e5aef-864e-43a6-996e-331aa52351ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_82729fe5-93ac-4303-887c-7d69af3b1ded" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_82729fe5-93ac-4303-887c-7d69af3b1ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_89ada7eb-9443-487f-839b-6e716a00080f" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_89ada7eb-9443-487f-839b-6e716a00080f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_11309aa4-1f68-43a7-947c-5c164fc2c1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_11309aa4-1f68-43a7-947c-5c164fc2c1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a44a28ea-3573-4172-be99-1625809b9c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a44a28ea-3573-4172-be99-1625809b9c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c45df1c5-e601-460f-b5a3-3c4e521a960c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c45df1c5-e601-460f-b5a3-3c4e521a960c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_832d6d34-a5fc-43e9-852c-87052e5cbaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_832d6d34-a5fc-43e9-852c-87052e5cbaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_4b93b0b0-7bb6-410f-a3ea-4c6277f3492d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_4b93b0b0-7bb6-410f-a3ea-4c6277f3492d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_72e4decd-bcfe-41b3-bc1e-20f953054664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_72e4decd-bcfe-41b3-bc1e-20f953054664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_eccb4618-1571-4f37-bce8-6ba91c2cacc5" xlink:href="rprx-20220630.xsd#rprx_PaymentsForMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_rprx_PaymentsForMilestones_eccb4618-1571-4f37-bce8-6ba91c2cacc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_acbdc570-3060-4591-8b70-d3361f67935a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_323051fb-e5ef-4efd-804f-2cfcd99caf0f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_acbdc570-3060-4591-8b70-d3361f67935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_84b0eea8-c093-4598-af62-5203bb3e3462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_84b0eea8-c093-4598-af62-5203bb3e3462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_310fd7ca-8d25-4cb5-aaea-775f56349f9c" xlink:href="rprx-20220630.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_310fd7ca-8d25-4cb5-aaea-775f56349f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_3b1fc3e1-1791-4b93-9aa8-ecfc0d99480a" xlink:href="rprx-20220630.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_3b1fc3e1-1791-4b93-9aa8-ecfc0d99480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_be152a50-453d-493d-8ab9-899a07f06509" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_be152a50-453d-493d-8ab9-899a07f06509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_3d19cf96-c7de-4d1a-b83c-b2a110906c1b" xlink:href="rprx-20220630.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_3d19cf96-c7de-4d1a-b83c-b2a110906c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7f52bb4-85b5-4a8b-b535-22632f695a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_feea08bf-49d9-419d-8795-3bff92162faf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7f52bb4-85b5-4a8b-b535-22632f695a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be8bddb8-eb73-4cd0-9dfa-1cc7118f0673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be8bddb8-eb73-4cd0-9dfa-1cc7118f0673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf82bce-7805-4274-9484-83f0225054b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fdf82bce-7805-4274-9484-83f0225054b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37cc9cb0-ba39-4628-82cd-3e32e57d9eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3e27a404-909e-4a2f-9e14-724fa6b92dc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37cc9cb0-ba39-4628-82cd-3e32e57d9eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="simple" xlink:href="rprx-20220630.xsd#OrganizationandPurpose"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_39d88028-ea4e-466a-a5d7-83aa9fd0d799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_894edb0b-99e1-4d5c-ace0-1d4475b9302b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_39d88028-ea4e-466a-a5d7-83aa9fd0d799" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_894edb0b-99e1-4d5c-ace0-1d4475b9302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#OrganizationandPurposeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273b6b13-d240-4a36-ab9c-b45267e31971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273b6b13-d240-4a36-ab9c-b45267e31971" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_54038d22-75c0-436e-a27e-2390ca94aa4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_5d369ab9-39a5-4fa6-b82a-505de95c7985" xlink:href="rprx-20220630.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c36c710d-a5b2-4420-afa5-18d931377e4c" xlink:to="loc_rprx_ExchangeOfferTransactionMember_5d369ab9-39a5-4fa6-b82a-505de95c7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8e3810d5-95d1-498a-93ec-30a88dee9327" xlink:to="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_f5939349-c6fa-4c14-84a7-365e50f8f607" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_f5939349-c6fa-4c14-84a7-365e50f8f607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_2f2e1e7f-d2bb-41ec-8591-15b4f4bb7eb2" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a2d89a1f-a84e-4638-8218-c679aed8b777" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_2f2e1e7f-d2bb-41ec-8591-15b4f4bb7eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a445bfa4-e78a-4191-b799-308242b0054f" xlink:to="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_773ebb51-3fec-42fa-a807-b3edfc68dce6" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_773ebb51-3fec-42fa-a807-b3edfc68dce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_dbedb1d9-7008-4b59-88aa-65a9fb7332d5" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1b182e41-077e-4e45-951f-ac200c5645a3" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_dbedb1d9-7008-4b59-88aa-65a9fb7332d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_09219f9b-85d8-4f39-9e2d-de5d9667731c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_489284b8-2a67-44c5-a8a5-8422efff9ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_489284b8-2a67-44c5-a8a5-8422efff9ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_979cec06-fadf-446f-8dc7-157cbe3dc6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_979cec06-fadf-446f-8dc7-157cbe3dc6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_08250aba-1a62-4887-899e-bdab1a1fc924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_581ea2b7-5e83-4aef-adb7-00068021e35b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_08250aba-1a62-4887-899e-bdab1a1fc924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rprx-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_778508cb-73af-4d1b-97a8-480b0581857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdf9f805-6634-4271-9d61-7824d6a585d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_778508cb-73af-4d1b-97a8-480b0581857f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdf9f805-6634-4271-9d61-7824d6a585d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rprx-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_357c365a-3109-4790-87da-e2214b2befdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_357c365a-3109-4790-87da-e2214b2befdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3e332c31-73aa-4282-9e78-37486c779d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:to="loc_us-gaap_UseOfEstimates_3e332c31-73aa-4282-9e78-37486c779d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e4a9909d-c48f-4dbc-a39c-2eb579a42b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e4a9909d-c48f-4dbc-a39c-2eb579a42b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_47b123ec-e9fb-4e3c-b23a-9d4ae89e3fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_47b123ec-e9fb-4e3c-b23a-9d4ae89e3fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5d07b0a3-34b7-42b2-9b88-06b62d139bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_870fe6d8-041b-4585-9ce1-3487e2cf05a4" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5d07b0a3-34b7-42b2-9b88-06b62d139bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_80fc8e0d-bfec-4dcf-b294-56e8d280b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_80fc8e0d-bfec-4dcf-b294-56e8d280b8df" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0fb1e022-7cb6-4d6e-9cf3-732cc05a608b" xlink:to="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_cc5a413c-bc43-4464-81ca-7974a19f4268" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_228a964b-8270-4779-aa7e-4c4b23ca42f0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_cc5a413c-bc43-4464-81ca-7974a19f4268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d74d5ee2-604c-479a-8407-047b9f44594c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2b3be6e-c15d-46be-bcf8-ed88cb2d31bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4ed6a272-d4fc-4029-879c-9cf4a322248f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2b3be6e-c15d-46be-bcf8-ed88cb2d31bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7b839c4e-a887-4445-a988-a6624bf7e89d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_d8e0c199-25ee-47dd-84ff-d6ef1f68802d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b6260314-921b-4196-853a-4fb3270c04a9" xlink:to="loc_us-gaap_FinanceReceivablesMember_d8e0c199-25ee-47dd-84ff-d6ef1f68802d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_47aa9393-aac2-4abd-9a9b-266e2b5ae647" xlink:to="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_396c9794-b332-4a4a-9e0a-1b2837639db3" xlink:href="rprx-20220630.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9d37b7f4-f002-45df-bd81-6fc0673be7f7" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_396c9794-b332-4a4a-9e0a-1b2837639db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3c1221eb-41c9-4ea5-8e3b-5e367928a556" xlink:to="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_4c985510-db61-4f09-82af-61279893d501" xlink:href="rprx-20220630.xsd#rprx_VertexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_917256ec-6c92-4961-b1dd-81ad1a7ed88d" xlink:to="loc_rprx_VertexMember_4c985510-db61-4f09-82af-61279893d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_30af4684-91d0-4b95-999b-d963e71f997a" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_a443b755-e174-4d0b-b3f4-eafbf3e5eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_a443b755-e174-4d0b-b3f4-eafbf3e5eb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c11f0b39-fe05-4548-9d6b-c2361d0ed483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f560992d-f92b-4ee6-b35f-68ee3693b564" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c11f0b39-fe05-4548-9d6b-c2361d0ed483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecurities"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_527ab062-1316-41e5-b998-b5dc32576622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c894ccd2-fb9e-43ce-b81d-f6c81817968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_527ab062-1316-41e5-b998-b5dc32576622" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c894ccd2-fb9e-43ce-b81d-f6c81817968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_655fd8ca-6ffe-48fb-bed8-d475894d3f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_35cc903a-f576-40c0-9955-8940552873d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_655fd8ca-6ffe-48fb-bed8-d475894d3f82" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_35cc903a-f576-40c0-9955-8940552873d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4cb74a5-6ab9-4888-ab54-629263cb7dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4cb74a5-6ab9-4888-ab54-629263cb7dcd" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c75bbb41-1c3a-4ad4-a596-51a49956a07c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6e225491-d586-410e-9c19-8f588734a323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b395f5e-0ce6-446b-8189-4c4e8eeb66f9" xlink:to="loc_us-gaap_PreferredStockMember_6e225491-d586-410e-9c19-8f588734a323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_68b1ee03-dc54-45cf-a308-6f67d139a24e" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_36bba05d-8226-4016-b361-bf91859b5bab" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_36bba05d-8226-4016-b361-bf91859b5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_50062018-0ef2-44d6-a38a-17f87471fd65" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_6ac03416-bd43-4a80-b987-ba1b4252e207" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_50062018-0ef2-44d6-a38a-17f87471fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49fe2fe0-7e98-49ef-9da5-8ede76fef399" xlink:to="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5cdc0a6b-c2a1-4e57-bd7a-283a0912db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5cdc0a6b-c2a1-4e57-bd7a-283a0912db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2aefc544-8183-49ee-bead-9c34c337186f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_53b8f263-fd90-4786-9bb8-da13465022a9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2aefc544-8183-49ee-bead-9c34c337186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_25cb7664-fc86-40dd-935f-343af6d464fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_9d47e339-7c55-44d1-bae4-7b683e99657f" xlink:href="rprx-20220630.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed7f681-84de-4a81-b6a6-2ebeb11918a4" xlink:to="loc_rprx_MorphoSysMember_9d47e339-7c55-44d1-bae4-7b683e99657f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_47293dd7-b56e-40d1-b8b2-4b938ad5eec9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5a9b59a9-ebe6-4723-8c6f-d4d86b12e77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a049d25-16c1-4ba7-b0c0-a84e4ad345d5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5a9b59a9-ebe6-4723-8c6f-d4d86b12e77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0baa7f77-e516-4f83-913a-ec7517bd365f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_356338c4-ca44-426a-978d-061bb9acf7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_99872da8-b71f-4bd7-9c90-3720dd00c43c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_356338c4-ca44-426a-978d-061bb9acf7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18bac02f-4e8c-49fa-a3fc-3e4022979350" xlink:to="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b9988808-c374-4932-8b51-36bcae11edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7595d95a-f406-430f-a3c5-af4f6345ecc2" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b9988808-c374-4932-8b51-36bcae11edc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27b9b896-460d-4cb9-bae8-cc60aa94c615" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bb913fc3-102c-48bb-b399-f2dee2720a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b60704ac-6ad4-4acb-a887-c4ea8ba59164" xlink:to="loc_us-gaap_SubsequentEventMember_bb913fc3-102c-48bb-b399-f2dee2720a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_11aa0af2-e8de-43e4-aa1c-bc3291c6216e" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_ff00b3ec-91aa-4a91-8242-131fdd57a97c" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_ff00b3ec-91aa-4a91-8242-131fdd57a97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_1d9b2843-8c98-4f63-985c-68761cc23b9a" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_1d9b2843-8c98-4f63-985c-68761cc23b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_06732ba4-eb2b-478a-8db7-5361b969cad3" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_06732ba4-eb2b-478a-8db7-5361b969cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_3ba3c423-9c0b-41fe-9cb0-d20d7cc773e8" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_3ba3c423-9c0b-41fe-9cb0-d20d7cc773e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_6c2cdcb6-c36e-4c3f-a4fd-fa32fb71f622" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_6c2cdcb6-c36e-4c3f-a4fd-fa32fb71f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_45c530e6-3aa4-4f45-be7b-ab68931b66a0" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_45c530e6-3aa4-4f45-be7b-ab68931b66a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_f187e609-281a-4759-912d-9476f7943d59" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_f187e609-281a-4759-912d-9476f7943d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_700e0e40-3b85-40ef-bd53-95bffb5ec5e1" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_700e0e40-3b85-40ef-bd53-95bffb5ec5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_999bc87c-2892-4a75-84f1-1fdf90fdc995" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_999bc87c-2892-4a75-84f1-1fdf90fdc995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_057e0704-c3e6-4a81-841e-c8f5668858b3" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_057e0704-c3e6-4a81-841e-c8f5668858b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_db426798-6c78-457c-afb0-5e324a853744" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_db426798-6c78-457c-afb0-5e324a853744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_0a139f96-f76b-49a0-bc28-618e69e91632" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_0a139f96-f76b-49a0-bc28-618e69e91632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementExpectedProceeds_f6d58fe2-863a-4a59-905d-98a3f4055045" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementExpectedProceeds"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_CollaborativeArrangementExpectedProceeds_f6d58fe2-863a-4a59-905d-98a3f4055045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_4670c05c-e360-4138-a992-a039bc6c0a0a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_4670c05c-e360-4138-a992-a039bc6c0a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_6f79b0a7-607c-49e3-9161-8e10115227b1" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_6f79b0a7-607c-49e3-9161-8e10115227b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad5a34fa-8bf6-47f2-b800-752fedc9fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad5a34fa-8bf6-47f2-b800-752fedc9fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_102c1545-161e-40c7-b56a-be443b18ef01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_29d4be19-8031-4832-88ed-968666c6b5c1" xlink:to="loc_us-gaap_InvestmentIncomeNet_102c1545-161e-40c7-b56a-be443b18ef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd069480-b874-48d4-a68e-e47c5d36ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bd069480-b874-48d4-a68e-e47c5d36ae67" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b188c90-1cae-4cb8-a273-07fa984a0768" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0d96860f-9e3e-4f6e-a5a9-e7a19541a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_us-gaap_PreferredStockMember_0d96860f-9e3e-4f6e-a5a9-e7a19541a19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_2776b7d0-3a6e-4251-b0c9-0918311502c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_us-gaap_ForwardContractsMember_2776b7d0-3a6e-4251-b0c9-0918311502c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_bc5bb13c-53df-48f1-8b09-d0efb3ed8609" xlink:href="rprx-20220630.xsd#rprx_FundingCommitmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_771fe6c8-5599-470c-801a-9cbda38e0ccb" xlink:to="loc_rprx_FundingCommitmentsMember_bc5bb13c-53df-48f1-8b09-d0efb3ed8609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_a0cd50f0-072d-45ed-8e71-c91d7485dbf4" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bac85938-a2c1-4e4c-aef7-5a57eb165458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bac85938-a2c1-4e4c-aef7-5a57eb165458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78b8173f-fb8f-4335-bb1a-7f87e0cc9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_78b8173f-fb8f-4335-bb1a-7f87e0cc9d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ae1fdd4b-840a-4fca-b983-a698c5b6f0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ae1fdd4b-840a-4fca-b983-a698c5b6f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6ac070ca-71e8-443d-888f-d92b0ae858a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6ac070ca-71e8-443d-888f-d92b0ae858a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8430c5ee-6458-4e9c-a841-de24972383b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8430c5ee-6458-4e9c-a841-de24972383b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_d3e03f32-00b5-441b-a2c3-aba1caefd19a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_d3e03f32-00b5-441b-a2c3-aba1caefd19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_fba0138c-0d01-4573-a041-7bb528d6f899" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_d69c0178-8a21-4698-a856-34a71b3b2737" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_fba0138c-0d01-4573-a041-7bb528d6f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstruments"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_878f7509-425e-4dae-8afe-f58179f20d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d26a21f8-5ae2-4ca9-92ff-612f6cb597d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_878f7509-425e-4dae-8afe-f58179f20d10" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d26a21f8-5ae2-4ca9-92ff-612f6cb597d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_62522a0b-3d26-476d-9322-d232caf43e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_af216d80-942d-43f5-a65c-76e00d8f7465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62522a0b-3d26-476d-9322-d232caf43e80" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_af216d80-942d-43f5-a65c-76e00d8f7465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9179deaf-5740-422c-add7-ead9cdccc24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62522a0b-3d26-476d-9322-d232caf43e80" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9179deaf-5740-422c-add7-ead9cdccc24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_4893833f-08d5-491e-aec5-0ca18444714b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62522a0b-3d26-476d-9322-d232caf43e80" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_4893833f-08d5-491e-aec5-0ca18444714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c776f0c6-71ef-4715-9793-d3990a60e556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c776f0c6-71ef-4715-9793-d3990a60e556" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_eb7b94e5-cd24-4483-b2a5-9fcf499bc1d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_6339345b-4797-4e9c-815b-bdbfbd0d9209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_MoneyMarketFundsMember_6339345b-4797-4e9c-815b-bdbfbd0d9209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f1fe593b-ed54-4a80-8375-06396cfc39b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_CommercialPaperMember_f1fe593b-ed54-4a80-8375-06396cfc39b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_c7a09547-6428-425b-a30a-ac506a4b20da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_CertificatesOfDepositMember_c7a09547-6428-425b-a30a-ac506a4b20da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_223c8bc1-2ecc-4c86-b6ee-1966b4cf6874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_796c9c4c-b1d4-49ba-9df2-2f2b9dd5a656" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_223c8bc1-2ecc-4c86-b6ee-1966b4cf6874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1c9163d1-8a0d-4d15-a8a0-6c3fb0c6c0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_459cd430-dd58-483a-b3ab-b4bee0161f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_CommercialPaperMember_459cd430-dd58-483a-b3ab-b4bee0161f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_747cf2e9-ac35-4cbd-b7b5-d43b3de864d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_CertificatesOfDepositMember_747cf2e9-ac35-4cbd-b7b5-d43b3de864d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_16ced758-6cca-4cfb-bb3d-1b7496591597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_16ced758-6cca-4cfb-bb3d-1b7496591597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b7d200ed-4d0f-44e7-8b17-cb16b9bfd8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_DebtSecuritiesMember_b7d200ed-4d0f-44e7-8b17-cb16b9bfd8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_a12b489e-f58d-4ba9-b247-50d25e550b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd3d3109-7335-4218-8f3b-097af3e5c303" xlink:to="loc_us-gaap_ForwardContractsMember_a12b489e-f58d-4ba9-b247-50d25e550b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8f40efb-b2b9-47d4-91a3-71d21f8c52e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_24b1c020-bfd3-4990-804b-662caa5ba0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_24b1c020-bfd3-4990-804b-662caa5ba0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fb59a892-c1be-4791-8fb2-b853eab9954b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fb59a892-c1be-4791-8fb2-b853eab9954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5141f71f-1e40-48f0-bce2-59d8416731fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_050ca36c-f39d-4fbf-8062-7ebe45c19497" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5141f71f-1e40-48f0-bce2-59d8416731fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dcdac034-3493-429f-827d-36e20ee19882" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bb35204f-708c-4f06-866d-13f2afa8d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_24e3d6f8-8e1a-40de-8456-b3e0a6815f55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bb35204f-708c-4f06-866d-13f2afa8d1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9bebe684-9258-4856-ba38-4c114c6b862c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember_f2625c38-05e0-47b2-90c1-caaae2329854" xlink:href="rprx-20220630.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:to="loc_rprx_RoyaltyInvestmentsMember_f2625c38-05e0-47b2-90c1-caaae2329854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember_0e0eaca9-d70c-4a4c-b4c1-932c7bbeefc5" xlink:href="rprx-20220630.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2e0fe83f-2e93-414b-84fd-29a3a5684fa3" xlink:to="loc_rprx_CytokineticsFundingCommitmentMember_0e0eaca9-d70c-4a4c-b4c1-932c7bbeefc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d9676a1c-6c2b-40a2-acc0-6eb89b468b19" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_d7ca98c4-2d85-4dff-86b2-9d6c0521f3e7" xlink:href="rprx-20220630.xsd#rprx_MilestoneAccelerationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824c91b4-7fce-44f5-9bd7-60ee7ce70788" xlink:to="loc_rprx_MilestoneAccelerationMember_d7ca98c4-2d85-4dff-86b2-9d6c0521f3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fecdf337-9fa1-4143-a6d6-551f865acd21" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e684af55-7088-4c22-90ea-4a502e321537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e684af55-7088-4c22-90ea-4a502e321537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_2edfb52a-28c6-4154-872f-4db54a6983bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_TradingSecuritiesDebt_2edfb52a-28c6-4154-872f-4db54a6983bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12106edc-518c-43d7-9e92-53b77d654f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12106edc-518c-43d7-9e92-53b77d654f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_1246fa0f-fa7e-4ce6-8430-0209401e6a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_1246fa0f-fa7e-4ce6-8430-0209401e6a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_a18b9679-253d-451b-85ad-6bf8af7187b3" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_a18b9679-253d-451b-85ad-6bf8af7187b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e82187af-1eb2-453c-aeb6-c17681702943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e82187af-1eb2-453c-aeb6-c17681702943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_090d60b1-aba3-4ac6-9c0c-d4249a28d37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_090d60b1-aba3-4ac6-9c0c-d4249a28d37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_bceff668-1caa-4f77-8867-cddf8a7c1691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_bceff668-1caa-4f77-8867-cddf8a7c1691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_58dd2791-1a3e-4d21-b175-d62ca2d56cee" xlink:href="rprx-20220630.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d9bbaaea-7ffa-4910-9d22-a84f0ac259ad" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_58dd2791-1a3e-4d21-b175-d62ca2d56cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ecf57b44-192e-44d7-b085-eb654bb060a3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d1d6a31c-ac92-4066-adb8-3e92d5a86f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_us-gaap_DerivativeLiabilities_d1d6a31c-ac92-4066-adb8-3e92d5a86f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_0d9ab7c6-51b6-4301-b94c-4c146186c45c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_0d9ab7c6-51b6-4301-b94c-4c146186c45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_5420d442-5c46-48aa-a83f-640a1aeae21c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c9e0f10-076e-42ad-b3b3-fe4c29351e47" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_5420d442-5c46-48aa-a83f-640a1aeae21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cf6f3889-ae54-41ca-8b2c-470ae9a276f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cf6f3889-ae54-41ca-8b2c-470ae9a276f5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ab416edc-2ee4-49d6-b0f5-c40c63d9691a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember_63dc3131-a428-435b-97c7-cc599709401f" xlink:href="rprx-20220630.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:to="loc_rprx_CytokineticsCommercialLaunchFundingMember_63dc3131-a428-435b-97c7-cc599709401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_08c12bde-f8ab-45b9-a850-3393e0b2d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27082a93-1199-49c0-9cfb-5a4438089ee8" xlink:to="loc_us-gaap_PreferredStockMember_08c12bde-f8ab-45b9-a850-3393e0b2d79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bdeac132-503c-411a-86ea-06b754568c10" xlink:to="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_55ac044f-4178-454b-b65b-239916f18b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae02227a-61c3-49c9-b3d7-97abd0f24c8b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_55ac044f-4178-454b-b65b-239916f18b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2d7fba99-063b-4902-a0b7-4ab45e42fbe0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_f4f5aae4-4aad-4264-980f-2ef2db447b08" xlink:href="rprx-20220630.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_f4f5aae4-4aad-4264-980f-2ef2db447b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_a1cd4e60-57a9-42de-8861-9a224f591013" xlink:href="rprx-20220630.xsd#rprx_MilestoneAccelerationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_485701f6-c478-476b-8405-a1261246bf50" xlink:to="loc_rprx_MilestoneAccelerationMember_a1cd4e60-57a9-42de-8861-9a224f591013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4362c5e1-7af8-4d5b-9b09-1f79624ec074" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6ad35566-62e6-4ad7-90be-6913c4efebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f63d3080-25ef-4b60-85f6-c1b8f03d99e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6ad35566-62e6-4ad7-90be-6913c4efebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1058033a-2246-4181-b937-e28c9a438771" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_513e6a65-8f4a-4cd9-9990-feed224c3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_22e7c32a-ab61-4324-88dd-86a7dbe6a739" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_513e6a65-8f4a-4cd9-9990-feed224c3744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1aae4f3-1cc0-497e-b0c0-b6555a7ba515" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_506c89dc-89a9-4599-9631-b4b6533466a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_506c89dc-89a9-4599-9631-b4b6533466a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed3e63af-a256-4a62-b167-5ff726afba93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ed3e63af-a256-4a62-b167-5ff726afba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c25eca09-1e35-4995-941a-dab2bc53907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c25eca09-1e35-4995-941a-dab2bc53907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_493161b3-97a8-4be1-941a-02647a0303aa" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_493161b3-97a8-4be1-941a-02647a0303aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_6592d567-41f9-4a30-9d1d-3b611b9a3b16" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_6592d567-41f9-4a30-9d1d-3b611b9a3b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_9a0f5225-f80f-4ecd-a962-daafdb2ffa6a" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_9a0f5225-f80f-4ecd-a962-daafdb2ffa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_848eeb62-72bd-442e-b4f7-2cbde1600ddc" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_848eeb62-72bd-442e-b4f7-2cbde1600ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_0998cda7-3a6d-4e36-8fa6-ffd48e51ef1d" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_0998cda7-3a6d-4e36-8fa6-ffd48e51ef1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_07ba04e3-17d8-4084-8265-4b9a4c1e631c" xlink:href="rprx-20220630.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_07ba04e3-17d8-4084-8265-4b9a4c1e631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_955d40b6-caa2-4b07-bc4a-23f8653cbdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_955d40b6-caa2-4b07-bc4a-23f8653cbdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_d7834552-e7bb-48b1-9927-0eab62a2964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_d7834552-e7bb-48b1-9927-0eab62a2964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_c0c82218-6568-455c-9a5e-89779c550a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_c0c82218-6568-455c-9a5e-89779c550a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_613459fd-e9d2-41d6-b6a2-ec0902d6796c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_613459fd-e9d2-41d6-b6a2-ec0902d6796c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eab9314b-d70f-4dbf-bcb2-b8e2f2b1052d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_98f89634-3906-42c1-98b2-626afa9a71e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eab9314b-d70f-4dbf-bcb2-b8e2f2b1052d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99427ce4-e3ee-417c-aae7-64d83cd69fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99427ce4-e3ee-417c-aae7-64d83cd69fbf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d4c3bcca-5852-4931-8339-048a9f016d45" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0ff0286b-f7e9-4754-ac90-c2181620bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_EquitySecuritiesMember_0ff0286b-f7e9-4754-ac90-c2181620bb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_cdfbfa57-52c1-40e0-8ac7-a1a370433ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_cdfbfa57-52c1-40e0-8ac7-a1a370433ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3f35eeb7-c7b1-42d3-989a-d3d66e98d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_ForwardContractsMember_3f35eeb7-c7b1-42d3-989a-d3d66e98d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_ec936124-1652-43b1-9e18-862450e08f19" xlink:href="rprx-20220630.xsd#rprx_FundingCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_rprx_FundingCommitmentsMember_ec936124-1652-43b1-9e18-862450e08f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember_68a5fe72-25b7-4291-95ce-958cd08187f2" xlink:href="rprx-20220630.xsd#rprx_DerivativeAssetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_rprx_DerivativeAssetMember_68a5fe72-25b7-4291-95ce-958cd08187f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_68b99e6c-18cd-43aa-9872-f87551a502aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ed261211-cde5-4dc6-b40d-c8ed0438ad13" xlink:to="loc_us-gaap_RoyaltyMember_68b99e6c-18cd-43aa-9872-f87551a502aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebca2352-eb6f-4df6-9889-1d786aeb77c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_62ade9d0-d9b6-4b24-a0b7-9fa1ef1a668b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc5fe9f0-6456-4156-b4b8-7ba79c2457b8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_62ade9d0-d9b6-4b24-a0b7-9fa1ef1a668b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fc7f6bec-bacc-45f5-b673-e8f5a0e3b75d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b6d8db13-9665-4631-a001-2148567a46ab" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_44326fbf-02ea-4746-9a7c-88b205fe11dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_44326fbf-02ea-4746-9a7c-88b205fe11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_447f936c-74e6-4722-a8c9-3819956902d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_447f936c-74e6-4722-a8c9-3819956902d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_72059aaf-32a6-4862-b7df-d98402b6cc28" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_72059aaf-32a6-4862-b7df-d98402b6cc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_aef24a3c-2198-4f14-a7e1-f16eddff63a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_aef24a3c-2198-4f14-a7e1-f16eddff63a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6204c57e-11a3-43bc-8bc5-040b53b05b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6204c57e-11a3-43bc-8bc5-040b53b05b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_7caeb015-7250-40ab-bc2a-b87f154dd467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_7caeb015-7250-40ab-bc2a-b87f154dd467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_92ce5704-5111-4f47-95c3-7cf94a5bc7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_92ce5704-5111-4f47-95c3-7cf94a5bc7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_76aebe8f-d82b-4796-8c0b-83cc231f0d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_76aebe8f-d82b-4796-8c0b-83cc231f0d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2f007c63-6cba-4dd1-a7ea-523135462e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2f007c63-6cba-4dd1-a7ea-523135462e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_6502f4c0-b11b-433d-8675-2c25b6ef1b5f" xlink:href="rprx-20220630.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_6502f4c0-b11b-433d-8675-2c25b6ef1b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ef4ebf3a-48be-4d9a-9a9f-2c3d036128f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e6f0f98-1368-48f3-a6a1-80fadec93a5a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ef4ebf3a-48be-4d9a-9a9f-2c3d036128f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32cc2458-ddea-4f0f-9646-8461df362f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32cc2458-ddea-4f0f-9646-8461df362f6b" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a17e17c-929c-44d2-a903-51304b30f473" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e326b44d-6adf-4386-acd2-f3d277e7f065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3883051e-5d38-42c6-a064-b4cacf8527b4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e326b44d-6adf-4386-acd2-f3d277e7f065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c09e517a-4da0-4440-8f75-37276639bdf8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b1be4f62-c79f-4b34-ba3a-a05261e9f7ac" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8db94c5d-5384-40f7-ad39-5049911d38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8db94c5d-5384-40f7-ad39-5049911d38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c29e843d-7f63-4113-8cf7-1b528ff08631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4eee596f-38b5-411a-8af9-24e3ed61c94c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c29e843d-7f63-4113-8cf7-1b528ff08631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_4ed6a8f9-4a49-46c8-9322-ed588b619a14" xlink:to="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ffc1b733-fca5-484a-a1b8-33924d95abc3" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5c882040-32d0-444a-9561-d3bc3145bf55" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ffc1b733-fca5-484a-a1b8-33924d95abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssets" xlink:type="simple" xlink:href="rprx-20220630.xsd#FinancialRoyaltyAssets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e6c78f40-442b-484a-a79d-0c45eb36a805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock_4284c581-a696-4218-a982-a9a49345044a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e6c78f40-442b-484a-a79d-0c45eb36a805" xlink:to="loc_us-gaap_FinancingReceivablesTextBlock_4284c581-a696-4218-a982-a9a49345044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#FinancialRoyaltyAssetsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2a5a27a5-9494-4dc0-9753-cf5464b9d40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f8e4d97b-f3c1-4426-af7a-5756b15fdaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2a5a27a5-9494-4dc0-9753-cf5464b9d40e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f8e4d97b-f3c1-4426-af7a-5756b15fdaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_ace1fc65-b00f-4c11-b053-d011ce307881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_ace1fc65-b00f-4c11-b053-d011ce307881" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:to="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cebbb6d1-cf99-46c3-8c61-32930113c1b0" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_5bf06487-a20c-434b-9ffb-6e9d5d035819" xlink:href="rprx-20220630.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_5bf06487-a20c-434b-9ffb-6e9d5d035819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_45ec33c5-6afe-42d0-ba32-dc7bc6dfdca3" xlink:href="rprx-20220630.xsd#rprx_TysabriMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_TysabriMember_45ec33c5-6afe-42d0-ba32-dc7bc6dfdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_0ab63dae-ac85-47df-9ed5-98ee32f0bcc7" xlink:href="rprx-20220630.xsd#rprx_ImbruvicaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_ImbruvicaMember_0ab63dae-ac85-47df-9ed5-98ee32f0bcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_5a83591d-5de7-4637-b249-23ce1ae1682f" xlink:href="rprx-20220630.xsd#rprx_XtandiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_XtandiMember_5a83591d-5de7-4637-b249-23ce1ae1682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_7807583e-f227-4009-82fb-595d63f24309" xlink:href="rprx-20220630.xsd#rprx_TremfyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_TremfyaMember_7807583e-f227-4009-82fb-595d63f24309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_9ad3c062-8f1a-4db3-b38c-f53bce587448" xlink:href="rprx-20220630.xsd#rprx_EvrysdiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_EvrysdiMember_9ad3c062-8f1a-4db3-b38c-f53bce587448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_8d4b0a92-1085-4831-92f7-67952461fd1f" xlink:href="rprx-20220630.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4cad7a2-d5ee-49a0-86fb-f5cdaecfb612" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_8d4b0a92-1085-4831-92f7-67952461fd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6dbb2b80-1906-4502-9f96-605ff52b1447" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_dd6a7779-87a4-4320-92a2-bd67614b55e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_us-gaap_NotesReceivableGross_dd6a7779-87a4-4320-92a2-bd67614b55e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ae7bc426-4198-4389-b29a-027e62e19fb4" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_ae7bc426-4198-4389-b29a-027e62e19fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8c53fcda-49d7-4b38-a5ae-0521e3b0b870" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8c53fcda-49d7-4b38-a5ae-0521e3b0b870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_ffd5f81f-5a4d-4886-931b-197cc7169ef3" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_ffd5f81f-5a4d-4886-931b-197cc7169ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_6955f58c-d47a-43b4-b7cf-a0ede915b4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_us-gaap_NotesReceivableNet_6955f58c-d47a-43b4-b7cf-a0ede915b4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_c5f163c9-3f65-4624-bb1c-a2facd81f66f" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_735a446b-74bf-46c1-870e-095d4be4f2b5" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_c5f163c9-3f65-4624-bb1c-a2facd81f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="simple" xlink:href="rprx-20220630.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_c78043f5-7e34-4ceb-a499-19b654c812b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_075a643a-caf9-449f-b39d-b480488f65eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_c78043f5-7e34-4ceb-a499-19b654c812b9" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_075a643a-caf9-449f-b39d-b480488f65eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_a84a1e0f-3ffb-45ee-be29-8ceb8db3582e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_5b5c8837-3ef3-4331-b2ff-76379dad6212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_a84a1e0f-3ffb-45ee-be29-8ceb8db3582e" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_5b5c8837-3ef3-4331-b2ff-76379dad6212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_b85a97d7-652b-426b-9150-08833a36596a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_b85a97d7-652b-426b-9150-08833a36596a" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_c835c0b1-ce23-466e-a9a7-9778cec9996b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_c835c0b1-ce23-466e-a9a7-9778cec9996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_669f9f2b-59fa-4743-ad53-725b9e7a8512" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_669f9f2b-59fa-4743-ad53-725b9e7a8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_89fe4ed1-ec24-4475-8295-115b4a1b0ce0" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_89fe4ed1-ec24-4475-8295-115b4a1b0ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_0d9a2a9b-a92d-4c1d-92b4-8af029f94614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_0d9a2a9b-a92d-4c1d-92b4-8af029f94614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_e80ac262-838c-40c0-8e10-ba24b3140428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward_a4541b4e-fe33-4534-b744-7361b4796127" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_e80ac262-838c-40c0-8e10-ba24b3140428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_8823a4df-7af9-4911-aaf9-3a51efe35b22" xlink:href="rprx-20220630.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_b85a97d7-652b-426b-9150-08833a36596a" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_8823a4df-7af9-4911-aaf9-3a51efe35b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNet"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7924503e-f1b5-4784-993b-d292ee5c0997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_28e73555-377e-402d-9fd8-7c14e1f6aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7924503e-f1b5-4784-993b-d292ee5c0997" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_28e73555-377e-402d-9fd8-7c14e1f6aae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6235a951-0fd4-4289-b859-918b2a304fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_112cff3f-2fc9-4144-bf4d-f115a22d782b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6235a951-0fd4-4289-b859-918b2a304fbf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_112cff3f-2fc9-4144-bf4d-f115a22d782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_582b1471-aa44-4126-b065-6d910a5b1b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_582b1471-aa44-4126-b065-6d910a5b1b50" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d84a6b57-43bf-49bb-b737-83b293d6d275" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVInhibitorsMember_17f744e4-2651-4aa2-8a47-f1e13dafb08c" xlink:href="rprx-20220630.xsd#rprx_DPPIVInhibitorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8bd2a848-64ec-4a2a-ac99-b308930dd2fc" xlink:to="loc_rprx_DPPIVInhibitorsMember_17f744e4-2651-4aa2-8a47-f1e13dafb08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_da4b3035-756e-4265-b8b3-ed30e609cbcf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a88bcc9e-537a-4436-b634-7c085db7a710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a88bcc9e-537a-4436-b634-7c085db7a710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8a96766-a8f6-4102-9cd3-de4c852e3992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a8a96766-a8f6-4102-9cd3-de4c852e3992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2376fdb-1677-4fb6-8bc6-a1e4166d49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86ae8369-f044-41b2-8f30-1ed65fd6eef5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2376fdb-1677-4fb6-8bc6-a1e4166d49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f873c747-74b5-4524-adf8-645c799fb8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f873c747-74b5-4524-adf8-645c799fb8ac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_362c9ebe-edb2-472c-9e5d-48d8d6706e9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVInhibitorsMember_a5ee311a-7e2b-4795-a310-6ac749bd3b62" xlink:href="rprx-20220630.xsd#rprx_DPPIVInhibitorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60e05d95-9330-4281-b6bc-cf93e89d9100" xlink:to="loc_rprx_DPPIVInhibitorsMember_a5ee311a-7e2b-4795-a310-6ac749bd3b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1004f0d8-b7a4-4526-93cf-8fa7578e5700" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1572b2e5-b202-4738-8e3e-1ea24f11e574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d33aded-41c4-4dff-8e42-178188852e09" xlink:to="loc_us-gaap_SalesRevenueNetMember_1572b2e5-b202-4738-8e3e-1ea24f11e574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5172d35c-cfe1-4127-a80f-9919dccad81c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_61726ebd-7d03-4ef3-9a46-845136c96364" xlink:href="rprx-20220630.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_574570d8-d3f7-4159-89c9-b91c35ee8ee5" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_61726ebd-7d03-4ef3-9a46-845136c96364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5c175362-aa28-4085-80e6-94880cdb72fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_afd7a492-576d-42d6-b1bd-c0123331ee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b5e92ac-040b-462b-822d-f6d97522679d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_afd7a492-576d-42d6-b1bd-c0123331ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="simple" xlink:href="rprx-20220630.xsd#NonConsolidatedAffiliates"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3aa07e7d-c0d7-4ff1-b46a-8f7e8f5ca09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5f9aa8f1-e0b4-4937-ab2c-0687d650f01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3aa07e7d-c0d7-4ff1-b46a-8f7e8f5ca09d" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5f9aa8f1-e0b4-4937-ab2c-0687d650f01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4cb2c040-ca0f-4ac0-a237-b7e94093521f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4cb2c040-ca0f-4ac0-a237-b7e94093521f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0e4c16ae-d2f9-40ad-8745-0865e8a3023f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_f6d53291-c1f8-4553-8d3b-4ec911e0c063" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_f6d53291-c1f8-4553-8d3b-4ec911e0c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_4e05ae00-d1cb-4eea-a52c-d801eb07c464" xlink:href="rprx-20220630.xsd#rprx_AvillionEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionEntitiesMember_4e05ae00-d1cb-4eea-a52c-d801eb07c464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_7512181a-a2fe-4178-bac0-665bfcb8a7bb" xlink:href="rprx-20220630.xsd#rprx_AvillionIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionIMember_7512181a-a2fe-4178-bac0-665bfcb8a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_f2f12b88-f278-4964-9b79-337987775bd1" xlink:href="rprx-20220630.xsd#rprx_AvillionIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c9cdff75-1c3e-4b64-b16e-38ea2cf16dc6" xlink:to="loc_rprx_AvillionIIMember_f2f12b88-f278-4964-9b79-337987775bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:to="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_19afba29-85c5-4e3a-9649-304a49617eef" xlink:to="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_26d99088-6c01-40b9-9c6b-6d40a02e1d70" xlink:href="rprx-20220630.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_8d99825f-05cb-4392-894f-cad8c9082379" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_26d99088-6c01-40b9-9c6b-6d40a02e1d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_94419a6c-c867-4582-966d-d9fff6932054" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2c1934ed-d8cf-4cab-8a4f-4d7f9793e645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_EquityMethodInvestments_2c1934ed-d8cf-4cab-8a4f-4d7f9793e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1361a962-1592-409e-9eaf-87004ad08f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1361a962-1592-409e-9eaf-87004ad08f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4f29d6ac-39d1-435e-8565-ae8836292d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4f29d6ac-39d1-435e-8565-ae8836292d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7de9aea7-65cc-4508-a118-3cc0949dce77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7de9aea7-65cc-4508-a118-3cc0949dce77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_fc0e443a-d1a3-4040-b249-0309ca8db919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_us-gaap_OtherCommitment_fc0e443a-d1a3-4040-b249-0309ca8db919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentIncreaseDecrease_2925d695-84b5-473a-a9da-c4be660fdd47" xlink:href="rprx-20220630.xsd#rprx_OtherCommitmentIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_rprx_OtherCommitmentIncreaseDecrease_2925d695-84b5-473a-a9da-c4be660fdd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_20adcdd3-9579-496a-b14c-d56c23c95fc2" xlink:href="rprx-20220630.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5b5b497f-91fc-419e-b687-bc3534d222e9" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_20adcdd3-9579-496a-b14c-d56c23c95fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="simple" xlink:href="rprx-20220630.xsd#ResearchDevelopmentRDFundingExpense"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0175889b-7550-421c-9279-4ba91f23258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_9baf682d-8c77-4f5e-95ae-36104d00318e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0175889b-7550-421c-9279-4ba91f23258f" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_9baf682d-8c77-4f5e-95ae-36104d00318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_cfa02bf7-bf1f-4337-828a-0e7a1e540a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_cfa02bf7-bf1f-4337-828a-0e7a1e540a56" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:to="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3444bd81-e6a5-4bab-819d-9cb7833f92b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember_df0d1d4e-068d-46b5-b585-d356ff8a6745" xlink:href="rprx-20220630.xsd#rprx_CytokineticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a81dd7db-219c-4737-8ab2-c7ac0d13da5b" xlink:to="loc_rprx_CytokineticsMember_df0d1d4e-068d-46b5-b585-d356ff8a6745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_355361bd-344e-496e-84d0-92bafed72acd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cc43e75a-7a1a-4551-b97b-b69ef2e38d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25017ca1-69e0-4d59-aa47-50e8d134e4ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cc43e75a-7a1a-4551-b97b-b69ef2e38d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/Borrowings" xlink:type="simple" xlink:href="rprx-20220630.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aff06113-4417-4243-abad-ba285d2149d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1ab6337e-f8a9-4ff1-9dbf-e83f013a2eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aff06113-4417-4243-abad-ba285d2149d6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1ab6337e-f8a9-4ff1-9dbf-e83f013a2eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3e13a080-a8d5-4be5-88e6-373dcb128015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0da81e86-bff8-43a7-845c-1488247f1ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3e13a080-a8d5-4be5-88e6-373dcb128015" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0da81e86-bff8-43a7-845c-1488247f1ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7b573b68-e485-4ce7-8b0b-fc1451d9c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3e13a080-a8d5-4be5-88e6-373dcb128015" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7b573b68-e485-4ce7-8b0b-fc1451d9c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89e0f731-5625-43e0-9b61-fbcb5757cd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89e0f731-5625-43e0-9b61-fbcb5757cd14" xlink:to="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e4f8d87-16e6-4552-985c-c244000406a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_66d3b750-6cd5-45d4-a1e9-b788c8aa4e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ee009d1-331d-4979-af8b-e94b8e906cf0" xlink:to="loc_us-gaap_UnsecuredDebtMember_66d3b750-6cd5-45d4-a1e9-b788c8aa4e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8af4a5ed-db8d-4f5c-b3a7-d48fe9cd55d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_072f9aa8-91eb-4282-ab7d-251e9a6aabc8" xlink:href="rprx-20220630.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_072f9aa8-91eb-4282-ab7d-251e9a6aabc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_b4280445-4502-4953-9885-dd835480d069" xlink:href="rprx-20220630.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_b4280445-4502-4953-9885-dd835480d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_a1871779-8b7e-4d35-ae66-fcd367e83273" xlink:href="rprx-20220630.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_a1871779-8b7e-4d35-ae66-fcd367e83273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_5aae9dc8-0518-4cf3-ba4b-384e470f4d3d" xlink:href="rprx-20220630.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_5aae9dc8-0518-4cf3-ba4b-384e470f4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_1ec7ae04-3389-4208-b9a8-2dbe5e893029" xlink:href="rprx-20220630.xsd#rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member_1ec7ae04-3389-4208-b9a8-2dbe5e893029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_341265e2-3c7f-4ea4-bbf2-eef9142efecc" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_341265e2-3c7f-4ea4-bbf2-eef9142efecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_38bfed64-1fd3-4f7f-91e4-8b543e46b41b" xlink:href="rprx-20220630.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_38bfed64-1fd3-4f7f-91e4-8b543e46b41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member_b5769c44-10e9-48e3-a097-302779282f02" xlink:href="rprx-20220630.xsd#rprx_ThreePointThreeFiveZeroPercentDue2051Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8774ff0e-b9a0-4b1f-95ec-a77d7abec50f" xlink:to="loc_rprx_ThreePointThreeFiveZeroPercentDue2051Member_b5769c44-10e9-48e3-a097-302779282f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_028fd59d-a795-4bdf-b25d-bb7284074e2b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1da66a8a-e3a1-4447-9c22-ea0b6eb7ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1da66a8a-e3a1-4447-9c22-ea0b6eb7ed07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_ca017951-2023-4711-a824-ac0cc808f24b" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_ca017951-2023-4711-a824-ac0cc808f24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_867e977f-cac0-4d03-b3f8-aec40f321f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_867e977f-cac0-4d03-b3f8-aec40f321f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cafd7b97-62d8-45a8-9214-a8439720c600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cafd7b97-62d8-45a8-9214-a8439720c600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_054f8eeb-7a7d-408d-af32-e691184713f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebt_054f8eeb-7a7d-408d-af32-e691184713f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_82500122-ce62-4a58-97a3-15c6c788ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebtCurrent_82500122-ce62-4a58-97a3-15c6c788ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e4c5e050-4594-49ab-835d-9750cd7c5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d2d35b3-27c3-41d3-a826-06ffc6bd9b34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e4c5e050-4594-49ab-835d-9750cd7c5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_17c726d6-6260-4834-9933-410e695c5664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17c726d6-6260-4834-9933-410e695c5664" xlink:to="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa8cee72-a866-4ee4-9aa6-770157a2c2c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8d7cf39e-62d1-4ad3-8aec-7b61d5bd619c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:to="loc_us-gaap_SeniorNotesMember_8d7cf39e-62d1-4ad3-8aec-7b61d5bd619c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_b60cb20b-a6d5-4d8e-9e83-798193675874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d69318dd-5e07-4ec7-ace3-7013f4185f3d" xlink:to="loc_us-gaap_UnsecuredDebtMember_b60cb20b-a6d5-4d8e-9e83-798193675874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_657fd4fb-869d-4104-b043-9b97db90e163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_eee32934-3a3a-4f9b-aa0a-b9f945990f00" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorNotesDue2031Member_eee32934-3a3a-4f9b-aa0a-b9f945990f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_9393aa6f-abc5-4894-9d46-4298e966bc64" xlink:href="rprx-20220630.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorNotesDue2051Member_9393aa6f-abc5-4894-9d46-4298e966bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_ec196804-c68c-4a5e-a24a-3d45c7d7950d" xlink:href="rprx-20220630.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_TheNotesMember_ec196804-c68c-4a5e-a24a-3d45c7d7950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_f5533f7d-74b1-413c-a857-24234a077794" xlink:href="rprx-20220630.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20abda5a-7d53-4b02-aee5-d29d2e0c83b3" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_f5533f7d-74b1-413c-a857-24234a077794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8f00ae34-424e-4d44-ab89-a046de81174b" xlink:to="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_983c8055-779f-4136-a423-5194ba525c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_983c8055-779f-4136-a423-5194ba525c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_4c718807-0853-4994-8f0a-6f702ac39240" xlink:href="rprx-20220630.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_rprx_OvernightBankFundingRateMember_4c718807-0853-4994-8f0a-6f702ac39240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_12bf0047-13db-45fc-b74d-4f332ae638f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_feb633cc-f4f2-4e00-845c-f38fe4a5a2ca" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_12bf0047-13db-45fc-b74d-4f332ae638f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8259f7fc-ded5-49a0-bad5-1a3da160b07a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81111d86-b475-4032-8956-12e8e69532c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81111d86-b475-4032-8956-12e8e69532c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_eddd6e70-f6c4-4f09-93a7-211826adaf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2eaa6bde-2d72-4445-8523-cd1904b3fbf6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_eddd6e70-f6c4-4f09-93a7-211826adaf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_606b64cc-d237-41af-8ebd-877db0c9d708" xlink:to="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_83d1018d-ff8a-44cc-9375-050d77c66257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c840c05b-7597-4e19-9854-4c65f7185677" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_83d1018d-ff8a-44cc-9375-050d77c66257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3356e29b-a9ca-4616-8925-cdf489c45144" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7da53c46-d5f6-4d39-b06c-3e6d558e21d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8761534b-cc73-4c08-be5e-80738a279272" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7da53c46-d5f6-4d39-b06c-3e6d558e21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1d08edf-1b75-4b14-8194-0a7f80052b49" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_559ed552-cd5d-4cfa-a060-bf9de6d4c7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_559ed552-cd5d-4cfa-a060-bf9de6d4c7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1ff9ca3-f525-4fc0-89c3-a548e4239876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1ff9ca3-f525-4fc0-89c3-a548e4239876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_eda5bf23-8a43-4892-8789-4b7d3e4ed681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_eda5bf23-8a43-4892-8789-4b7d3e4ed681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_545fe513-7c76-4173-bbc5-29dcb81d94e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_545fe513-7c76-4173-bbc5-29dcb81d94e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_de5a48ba-e033-4769-9089-1a454971e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_de5a48ba-e033-4769-9089-1a454971e8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5c064f7b-518e-4836-8fc7-83f3581c844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5c064f7b-518e-4836-8fc7-83f3581c844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_2f4aa91a-089c-46d1-b056-a8fb96ec34a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LongTermDebtFairValue_2f4aa91a-089c-46d1-b056-a8fb96ec34a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a208bd7e-8a24-4487-8054-0efba43935c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentTerm_a208bd7e-8a24-4487-8054-0efba43935c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e5a80ad0-0feb-4103-bb1b-ec1dd92eaa44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e5a80ad0-0feb-4103-bb1b-ec1dd92eaa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a50ba63c-4565-4c0a-b664-b93f8e6ee7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_LineOfCredit_a50ba63c-4565-4c0a-b664-b93f8e6ee7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d8455d2a-4832-47b1-922c-b2afd272d194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d8455d2a-4832-47b1-922c-b2afd272d194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_197a288e-50a9-4456-915d-877b061ebea9" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_197a288e-50a9-4456-915d-877b061ebea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_64b3f0f2-bd42-4106-abe0-d378aff48612" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_64b3f0f2-bd42-4106-abe0-d378aff48612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_afbb423d-562c-4ac9-a34c-d4509fec2192" xlink:href="rprx-20220630.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b958bb36-bcd9-4485-b572-83303f9c5750" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_afbb423d-562c-4ac9-a34c-d4509fec2192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b2df4d7f-0d77-44f9-b5a3-fdd8101f4861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b2df4d7f-0d77-44f9-b5a3-fdd8101f4861" xlink:to="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe1da78e-f038-423a-b2cf-20bc9a0ee239" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9f86c45b-1f5d-4223-b6ec-42e0f433420d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d2a2939a-1b87-43cb-9bf4-1dc68aaface8" xlink:to="loc_us-gaap_UnsecuredDebtMember_9f86c45b-1f5d-4223-b6ec-42e0f433420d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_513a1e72-848d-4f64-b5ac-b7db5a4c2df7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_0a46075b-2f5a-4915-83db-005752602bc6" xlink:href="rprx-20220630.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c0214fe-717c-4bbc-ba91-bc1d1500eea8" xlink:to="loc_rprx_TheNotesMember_0a46075b-2f5a-4915-83db-005752602bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6162e5a-48cf-490c-87c0-09524271a9aa" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_585ac47c-d280-48b0-8b5e-c7a9630a62ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_585ac47c-d280-48b0-8b5e-c7a9630a62ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6669944e-70ce-4be2-8f6e-8545ae3c9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6669944e-70ce-4be2-8f6e-8545ae3c9f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d109dd95-fa6c-47ac-99d5-0ae8831714ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d109dd95-fa6c-47ac-99d5-0ae8831714ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_14c0e33f-f4e7-4532-83d5-48d1cbe5c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_14c0e33f-f4e7-4532-83d5-48d1cbe5c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07ba7181-7a41-43f9-9356-25337082eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07ba7181-7a41-43f9-9356-25337082eed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermDebtMaturityAfterYearFour_a7c85c78-5d54-4d98-8d59-77571b5ad35e" xlink:href="rprx-20220630.xsd#rprx_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_rprx_LongTermDebtMaturityAfterYearFour_a7c85c78-5d54-4d98-8d59-77571b5ad35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_051f2880-69e4-45a8-96d9-5dc3d11f4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_051f2880-69e4-45a8-96d9-5dc3d11f4c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_794d4e72-9780-4ba6-95a8-dbf45062b81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5b8906d0-4e14-4cbd-9b88-d30703220f40" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_794d4e72-9780-4ba6-95a8-dbf45062b81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db8c384e-cfad-4399-968a-357c2887ffca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e4c1939b-9ba4-44c7-9445-bb0e7773621b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db8c384e-cfad-4399-968a-357c2887ffca" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e4c1939b-9ba4-44c7-9445-bb0e7773621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2cbff249-31a6-4b6b-8789-2b0c5f773aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_dca685b4-0aa4-483e-be0d-918cdc501226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2cbff249-31a6-4b6b-8789-2b0c5f773aff" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_dca685b4-0aa4-483e-be0d-918cdc501226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_59c9da0b-5d26-4cf7-992b-00b790fc7815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59c9da0b-5d26-4cf7-992b-00b790fc7815" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f163acfc-8266-4882-b106-fd404cda77c5" xlink:to="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1abc1860-4487-478a-a860-b7573918e9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_us-gaap_CommonClassAMember_1abc1860-4487-478a-a860-b7573918e9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_267f4df9-94c2-44b0-b141-1d86e6ae07db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_us-gaap_CommonClassBMember_267f4df9-94c2-44b0-b141-1d86e6ae07db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_65db2820-a10a-4631-9ff1-f2b878cf6695" xlink:href="rprx-20220630.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc524620-9c8f-4155-966a-3c43796e8264" xlink:to="loc_rprx_ClassRRedeemableStockMember_65db2820-a10a-4631-9ff1-f2b878cf6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_036b21aa-14f6-4f83-a181-9b6f088985e1" xlink:to="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_b431b4a6-23c8-4b52-ae73-2dbf24721b38" xlink:href="rprx-20220630.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e23ee67-6b53-45f3-a5bc-d6f62389fdda" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_b431b4a6-23c8-4b52-ae73-2dbf24721b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4cad050-17dd-42b0-a7e3-cd77a7e2f766" xlink:to="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_e2701582-258b-48a5-a403-40e19314f2cc" xlink:href="rprx-20220630.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7845939b-c492-4f23-a19c-d50b8849c123" xlink:to="loc_rprx_DeferredSharesMember_e2701582-258b-48a5-a403-40e19314f2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_97fadb94-1717-48b7-b5d8-779c75c5a994" xlink:to="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_6564590d-1291-4dac-8aa1-5b20c56b0823" xlink:href="rprx-20220630.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_6564590d-1291-4dac-8aa1-5b20c56b0823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes_4097d3ff-f358-4882-b753-88ef5619d39d" xlink:href="rprx-20220630.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_CommonStockVotingRightsNumberOfVotes_4097d3ff-f358-4882-b753-88ef5619d39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_50330900-eabc-4535-8644-8ae604486eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_50330900-eabc-4535-8644-8ae604486eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis_910b323f-9daf-499b-9bab-b62c9e500b39" xlink:href="rprx-20220630.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_CommonStockQuarterlyConversionBasis_910b323f-9daf-499b-9bab-b62c9e500b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4461a0fe-a399-4aa5-b075-1d0f2bd5cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_SharesOutstanding_4461a0fe-a399-4aa5-b075-1d0f2bd5cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_6700a22e-3028-48f4-aaa7-498417e53391" xlink:href="rprx-20220630.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_6700a22e-3028-48f4-aaa7-498417e53391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_7386bd56-914e-445f-a073-c38c32727f61" xlink:href="rprx-20220630.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_7386bd56-914e-445f-a073-c38c32727f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_fdc4e581-92ea-4777-a419-c9aed3e567b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_fdc4e581-92ea-4777-a419-c9aed3e567b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_12f0ae77-362d-4dec-9207-d4035f886eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_DividendsCommonStockCash_12f0ae77-362d-4dec-9207-d4035f886eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baac1a90-27f5-4fde-a93c-8b643921c1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baac1a90-27f5-4fde-a93c-8b643921c1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dd5194cd-9604-4a6c-b375-5603fbd67d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5dcc1d1-6fea-4a39-b6e1-d3f62bb2ea71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_dd5194cd-9604-4a6c-b375-5603fbd67d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2411a0b-512b-4f73-9671-cfaba9a88630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2411a0b-512b-4f73-9671-cfaba9a88630" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f3c1671a-1798-4112-848d-ede840a65733" xlink:to="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3690e970-f947-4afd-b3a5-f68c3248b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdd11754-5a62-4f63-8189-b4079234df63" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3690e970-f947-4afd-b3a5-f68c3248b98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_95f95893-1c20-43f3-a32f-bd7bacfa4f76" xlink:to="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_7859a60b-9b5c-4988-88ff-4c091a1ad862" xlink:href="rprx-20220630.xsd#rprx_RPHoldingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_fce4985a-67eb-4877-b99e-e70a8bcf0e2e" xlink:to="loc_rprx_RPHoldingsMember_7859a60b-9b5c-4988-88ff-4c091a1ad862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2611711e-1306-46be-810f-d161afc66ea1" xlink:to="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_32dc9fab-3a6f-4446-9c0e-03f9a9f3cc2b" xlink:href="rprx-20220630.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_32dc9fab-3a6f-4446-9c0e-03f9a9f3cc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_de363a6f-51e9-4113-833e-2329c4eabb43" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_de363a6f-51e9-4113-833e-2329c4eabb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_b0a0ffcb-e0c5-4642-b067-ebe57bfbedb8" xlink:href="rprx-20220630.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_b0a0ffcb-e0c5-4642-b067-ebe57bfbedb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_0cc0e3ae-1c6c-4a71-8a9c-489e1cc60bc8" xlink:href="rprx-20220630.xsd#rprx_EPAHoldingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0d97c940-0c81-4595-9ab1-0f7d2d40cb76" xlink:to="loc_rprx_EPAHoldingsMember_0cc0e3ae-1c6c-4a71-8a9c-489e1cc60bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_967eb750-32f9-44ad-9352-2556be840367" xlink:to="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af14a9c2-4fd7-48ae-b969-a8490e31a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af14a9c2-4fd7-48ae-b969-a8490e31a692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_60a391f1-6ab5-41b2-b32c-d8db8d76bbdc" xlink:href="rprx-20220630.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_60a391f1-6ab5-41b2-b32c-d8db8d76bbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bc8a1801-7025-4da7-b4f1-989ce9f669f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bc8a1801-7025-4da7-b4f1-989ce9f669f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2896248-000c-4632-89b7-3c6091b70b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_ProfitLoss_d2896248-000c-4632-89b7-3c6091b70b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_0e09931f-b4d3-4969-a0ae-979f55e0dc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_StockholdersEquityOther_0e09931f-b4d3-4969-a0ae-979f55e0dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_36079b98-1014-4dc5-99d9-8efb9150aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_36079b98-1014-4dc5-99d9-8efb9150aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_75a19d0f-3706-459f-9e7b-7ffbfb97fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_75a19d0f-3706-459f-9e7b-7ffbfb97fbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_69394b61-086b-4351-b964-cc0ffb0e2c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e543d41e-1c00-4ec6-b7a2-959953a08039" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_69394b61-086b-4351-b964-cc0ffb0e2c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_17928d2b-4ff6-4b5a-b476-5298a24ecac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4371a0c6-1b86-4516-885b-92a9baf59b59" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_17928d2b-4ff6-4b5a-b476-5298a24ecac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShare" xlink:type="simple" xlink:href="rprx-20220630.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b1c221a5-4813-4230-972c-36fc492160f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f66d41fb-9bef-4563-9241-d0cd51df3cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b1c221a5-4813-4230-972c-36fc492160f5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f66d41fb-9bef-4563-9241-d0cd51df3cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd5db73b-8256-4ba5-9dd6-fb0c701d1bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_afd556ce-a1d5-43fc-a9aa-42d24d127ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd5db73b-8256-4ba5-9dd6-fb0c701d1bc7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_afd556ce-a1d5-43fc-a9aa-42d24d127ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2d27fc94-a9ac-4cbb-8bcb-f65d2f83ef9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d27fc94-a9ac-4cbb-8bcb-f65d2f83ef9b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:to="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_632c3847-e8bd-4c7c-8cb8-e7b350c47773" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_ec1793cd-3a1b-4838-850a-1f5a6ce9abcb" xlink:href="rprx-20220630.xsd#rprx_ClassBHoldersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:to="loc_rprx_ClassBHoldersMember_ec1793cd-3a1b-4838-850a-1f5a6ce9abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_c406df6a-4dd2-4346-9878-c0638caed844" xlink:href="rprx-20220630.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6823d427-87e4-4e4a-86ce-2e954d089448" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_c406df6a-4dd2-4346-9878-c0638caed844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1e6b3005-fc24-4227-aebe-59658a708829" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_c39b1a2e-82ae-45a7-8dfd-7a6928512eac" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_5b1fb447-44e5-4bfc-8290-888b10ec137f" xlink:href="rprx-20220630.xsd#rprx_CommonStockExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_rprx_CommonStockExchangeRatio_5b1fb447-44e5-4bfc-8290-888b10ec137f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6d6b852f-760c-4306-982f-0c349b29007f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_ProfitLoss_6d6b852f-760c-4306-982f-0c349b29007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7256249c-2675-478d-a294-23bb726a20dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7256249c-2675-478d-a294-23bb726a20dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b690378-0143-457a-b8f3-d569b1333db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b690378-0143-457a-b8f3-d569b1333db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_ca00c752-fc03-4c46-b499-8d30deb6f15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_ca00c752-fc03-4c46-b499-8d30deb6f15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_12c072fd-1116-4682-bbc2-fdd3124e072a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7e201f12-d95d-464e-9440-2c15fbba0595" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_12c072fd-1116-4682-bbc2-fdd3124e072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_93206582-9bc9-4e60-b28a-d9889a6338b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_920b06db-2066-49e3-8a6f-4c2b75cb9915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_920b06db-2066-49e3-8a6f-4c2b75cb9915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_b5a84a25-695d-43b4-8b55-6480aa6323f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_b5a84a25-695d-43b4-8b55-6480aa6323f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c800c95a-a598-46d5-bef5-8e2262d9329b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c800c95a-a598-46d5-bef5-8e2262d9329b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37566814-30db-49c0-be26-58db124ee13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_37566814-30db-49c0-be26-58db124ee13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5a45fdea-0434-41af-b6f4-964909a4d313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_EarningsPerShareBasic_5a45fdea-0434-41af-b6f4-964909a4d313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d51ba33a-ab62-4858-9bc8-a1e32fc88c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_69abde9e-3523-4b4e-b305-4f0bc4c452c5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d51ba33a-ab62-4858-9bc8-a1e32fc88c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="simple" xlink:href="rprx-20220630.xsd#IndirectCashFlow"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_67032a96-4193-4a6d-803b-1033e5304b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_f84164ee-de7e-4f94-8ada-b47f1801d65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_67032a96-4193-4a6d-803b-1033e5304b7d" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_f84164ee-de7e-4f94-8ada-b47f1801d65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#IndirectCashFlowTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_61f4d089-3e94-4c37-950b-632da9c5e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0c5d6b59-1825-4f60-901a-52ba3ed5d7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_61f4d089-3e94-4c37-950b-632da9c5e9c1" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0c5d6b59-1825-4f60-901a-52ba3ed5d7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#IndirectCashFlowDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_92ee8cc8-c8d7-4c3f-bff7-f0fb5df9931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:to="loc_us-gaap_ProfitLoss_92ee8cc8-c8d7-4c3f-bff7-f0fb5df9931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_96165451-a4fa-483a-a0e3-45380f3d324a" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_96165451-a4fa-483a-a0e3-45380f3d324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_df9c3246-70a3-4053-bf48-94988a9f6b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_df9c3246-70a3-4053-bf48-94988a9f6b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9bd0a1e6-36c5-4bb2-8a6a-13b2cfbb29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9bd0a1e6-36c5-4bb2-8a6a-13b2cfbb29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4971f5a1-8e70-4516-bc1c-37615cc1ce68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4971f5a1-8e70-4516-bc1c-37615cc1ce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_542d9c07-59f1-45b3-85e3-a2508df0bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_542d9c07-59f1-45b3-85e3-a2508df0bd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b7a9e462-9942-4967-bb67-259b7a1bb5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b7a9e462-9942-4967-bb67-259b7a1bb5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3270d261-d894-4f75-b5ff-a06626cbc87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3270d261-d894-4f75-b5ff-a06626cbc87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b36a0121-7549-459a-937f-80befda47d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b36a0121-7549-459a-937f-80befda47d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1bebcbda-b5e0-48f4-b1bf-f423030e7b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_ShareBasedCompensation_1bebcbda-b5e0-48f4-b1bf-f423030e7b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_f6bb05d9-ec09-4008-a8ff-e7bf94dc128e" xlink:href="rprx-20220630.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_f6bb05d9-ec09-4008-a8ff-e7bf94dc128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e7ad2272-ae82-457e-86e3-f0478934ce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_e7ad2272-ae82-457e-86e3-f0478934ce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3ea82ed8-8976-44c4-af9b-86a38e69caa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de3cbe7-703f-44e3-905c-e0cc9e78790f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3ea82ed8-8976-44c4-af9b-86a38e69caa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_debf4c6f-d5bb-4b00-9e77-eff11fe589b3" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_debf4c6f-d5bb-4b00-9e77-eff11fe589b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_f30f6a76-7e36-402e-820e-383c9026dbc5" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_f30f6a76-7e36-402e-820e-383c9026dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_f1322ee0-d1ae-4345-ac50-05e8b517cc0b" xlink:href="rprx-20220630.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_f1322ee0-d1ae-4345-ac50-05e8b517cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_6e9f6663-4952-41ff-859b-af91599b509d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e82f12f3-0efa-4a99-baa7-aaa6b9eb931c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_6e9f6663-4952-41ff-859b-af91599b509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8b9847a9-f77a-4ec7-94ce-221a31120b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8b9847a9-f77a-4ec7-94ce-221a31120b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_182a5ac9-efaf-4091-b60c-e26516de74fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8b9847a9-f77a-4ec7-94ce-221a31120b25" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_182a5ac9-efaf-4091-b60c-e26516de74fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_70b28195-d986-4ddb-8c62-28102b5a2592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8b9847a9-f77a-4ec7-94ce-221a31120b25" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_70b28195-d986-4ddb-8c62-28102b5a2592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_53daaa89-0fdc-4235-b264-beee30da6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8b9847a9-f77a-4ec7-94ce-221a31120b25" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_53daaa89-0fdc-4235-b264-beee30da6c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e854d4b-d572-4f31-8e38-e9a53f39eb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4fed0812-32c7-4503-aa6b-b8971688585b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e854d4b-d572-4f31-8e38-e9a53f39eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rprx-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cb11120-a810-42ec-99d0-0be804c72bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fa5f47dd-31bb-44d8-99a2-2d423a8030ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cb11120-a810-42ec-99d0-0be804c72bac" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fa5f47dd-31bb-44d8-99a2-2d423a8030ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae719063-c6b9-443c-a001-beb15abbd224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae719063-c6b9-443c-a001-beb15abbd224" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_45164ba9-d551-454d-8ed4-4090cf32ceb8" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_11c7ed30-cb3b-4d17-95d5-099329e97f73" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_01c3e845-8084-46e9-8674-ff5a64ef85e1" xlink:to="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_11c7ed30-cb3b-4d17-95d5-099329e97f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_67494e4a-3802-4995-a472-f3803a49bd08" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_5128d09c-02b3-4b65-854e-bf6f92fe9c71" xlink:href="rprx-20220630.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5aa4ca96-0b5f-41fd-8293-b71cb23933dd" xlink:to="loc_rprx_MorphoSysMember_5128d09c-02b3-4b65-854e-bf6f92fe9c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0338e241-8131-49fa-946d-cbd6a01cd0d5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b84b7311-ea1b-43b7-87b4-164a33121d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3a43eb0-abb2-43a9-99c9-7218976179a2" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b84b7311-ea1b-43b7-87b4-164a33121d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e0d1430e-23be-4a4d-b2cc-8bdfb6eed327" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b0794810-2b18-4620-aa6a-7e1b2082ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9c71b36-4955-41ca-81ec-907cb1627c34" xlink:to="loc_us-gaap_SubsequentEventMember_b0794810-2b18-4620-aa6a-7e1b2082ce36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_43b30256-f8e7-4eb0-b0a6-4ad60fc9c1b9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingCommitmentAmountOutstanding_9764b488-cce2-46b8-a5ed-a952a038e523" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingCommitmentAmountOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingCommitmentAmountOutstanding_9764b488-cce2-46b8-a5ed-a952a038e523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_0ba5bac1-a62c-490b-a62e-51474418f492" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_0ba5bac1-a62c-490b-a62e-51474418f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5a87345f-aee5-403c-85b2-78f8993239df" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5a87345f-aee5-403c-85b2-78f8993239df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_37763d75-14a6-424a-8145-59c6dc17c50b" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_37763d75-14a6-424a-8145-59c6dc17c50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a99d1b31-f677-4f5a-b23d-5a862db425d9" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a99d1b31-f677-4f5a-b23d-5a862db425d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementExpectedProceeds_8632688e-42f9-40b9-834b-a24cc5ad9b7f" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementExpectedProceeds"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_CollaborativeArrangementExpectedProceeds_8632688e-42f9-40b9-834b-a24cc5ad9b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_cf4b149d-f3dd-40e5-ae77-558f52e8edb1" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_cf4b149d-f3dd-40e5-ae77-558f52e8edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentShares_d877d4a3-ff6e-4228-89de-8dc094201560" xlink:href="rprx-20220630.xsd#rprx_LongTermPurchaseCommitmentShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_370a042d-c1cc-41a7-b786-599aa94a205c" xlink:to="loc_rprx_LongTermPurchaseCommitmentShares_d877d4a3-ff6e-4228-89de-8dc094201560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rprx-20220630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_28127d36-241a-4725-bd81-ac147b4110fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8007ece0-91f4-40bd-88a6-db4bc8e0fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_28127d36-241a-4725-bd81-ac147b4110fd" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8007ece0-91f4-40bd-88a6-db4bc8e0fd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="rprx-20220630.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bf1947f5-5b27-4029-9538-a0e97400519d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1f4ff2de-7fed-4b58-b534-e4231b2c893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bf1947f5-5b27-4029-9538-a0e97400519d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1f4ff2de-7fed-4b58-b534-e4231b2c893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e60763cb-d2a0-46ab-a815-259ec8097057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e60763cb-d2a0-46ab-a815-259ec8097057" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9708bb96-030c-4b9e-a8f4-762512e91e94" xlink:to="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_8a58cefc-9c15-446d-8cc9-78328ed3a2bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:to="loc_srt_ManagementMember_8a58cefc-9c15-446d-8cc9-78328ed3a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_1e01fb1d-bf15-41c6-aab3-30dea66ae614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ab67d702-85d8-4dc0-ba22-a88cb6adf86a" xlink:to="loc_srt_AffiliatedEntityMember_1e01fb1d-bf15-41c6-aab3-30dea66ae614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_205c7e18-1b3c-4bd3-9e24-aa1ca35758af" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_62ff17e3-d646-4486-a993-afbb44b24890" xlink:href="rprx-20220630.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_62ff17e3-d646-4486-a993-afbb44b24890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_ea1f86e2-a9c5-44aa-ab36-e84f64e0d08b" xlink:href="rprx-20220630.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_ea1f86e2-a9c5-44aa-ab36-e84f64e0d08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_fb3f7c28-47db-4e4c-a542-d7da39daf466" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_fb3f7c28-47db-4e4c-a542-d7da39daf466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_2a48b01d-822c-4413-90df-d2140c62b5f2" xlink:href="rprx-20220630.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_2a48b01d-822c-4413-90df-d2140c62b5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_a76b476a-b199-4985-938e-f7f37da89e4c" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_a76b476a-b199-4985-938e-f7f37da89e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_1cafcfc9-12cc-49a5-9bd1-d8e17f93c295" xlink:href="rprx-20220630.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_1cafcfc9-12cc-49a5-9bd1-d8e17f93c295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_82a53438-ad98-42c0-a532-47ad9a4b3478" xlink:href="rprx-20220630.xsd#rprx_AgreementWithMSCIMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AgreementWithMSCIMember_82a53438-ad98-42c0-a532-47ad9a4b3478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_6b406c77-ad5c-434d-a23b-051936bb9123" xlink:href="rprx-20220630.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e048fa1-708e-4ae9-9e87-89d061a35ddc" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_6b406c77-ad5c-434d-a23b-051936bb9123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b7ac883d-ff35-4b44-a206-163b39db3399" xlink:to="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d7215424-1c03-4012-aea7-72f9211f84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:to="loc_us-gaap_TreasuryStockMember_d7215424-1c03-4012-aea7-72f9211f84d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_94bb3f51-d1a7-4b1d-9657-b38436c3c9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c5c8fa1-291e-4ec9-a23a-bbe12f979839" xlink:to="loc_us-gaap_NoncontrollingInterestMember_94bb3f51-d1a7-4b1d-9657-b38436c3c9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13f95374-0fad-456f-b4ce-9d5e20eb1e47" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_7e8c5ac6-89f9-4f1e-acdf-dbefd8bcc0c6" xlink:href="rprx-20220630.xsd#rprx_BristolMyersSquibbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dee5e73-fb63-457d-8eea-8cc3cec51208" xlink:to="loc_rprx_BristolMyersSquibbMember_7e8c5ac6-89f9-4f1e-acdf-dbefd8bcc0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a51aea5f-d538-46a1-8fd0-e15810634afd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_ae081f6c-90ed-4c75-9d8c-59ef969d2ea0" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_ae081f6c-90ed-4c75-9d8c-59ef969d2ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_6d86460d-12e7-4522-878f-a67974a5c66a" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_6d86460d-12e7-4522-878f-a67974a5c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_a312345d-9437-4819-b032-2e7dadff52c7" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_a312345d-9437-4819-b032-2e7dadff52c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_60719f39-9f68-489b-81af-890770005529" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_60719f39-9f68-489b-81af-890770005529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_62f1e3ce-9115-4447-87be-3774c3fa26b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_62f1e3ce-9115-4447-87be-3774c3fa26b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_e648d7f9-9f00-4375-bbcb-2d14c0aa2302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_e648d7f9-9f00-4375-bbcb-2d14c0aa2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_f3bbab8e-dece-48ea-b4ec-3836e2eef2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_f3bbab8e-dece-48ea-b4ec-3836e2eef2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4c6f3dda-306a-4bc9-a4ce-c1a472d80d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_NotesReceivableNet_4c6f3dda-306a-4bc9-a4ce-c1a472d80d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_1480da23-6b93-4818-a28a-ce5005123110" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_1480da23-6b93-4818-a28a-ce5005123110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_88bd1ef8-a5fb-4cd3-b9c3-60f80ca8da13" xlink:href="rprx-20220630.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_88bd1ef8-a5fb-4cd3-b9c3-60f80ca8da13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceda9674-b46d-4b8e-a163-042e396b6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fcb52adf-4f3a-4422-9b44-b65d07c1657b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceda9674-b46d-4b8e-a163-042e396b6690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="rprx-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d15921d0-ab8a-41a3-b61c-f398034a2e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5e7b6e9f-590d-4c03-b898-8c12b14e3de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d15921d0-ab8a-41a3-b61c-f398034a2e65" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5e7b6e9f-590d-4c03-b898-8c12b14e3de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20220630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a46f9128-0e5f-4043-bb68-80e0342a3bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a46f9128-0e5f-4043-bb68-80e0342a3bba" xlink:to="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6140cbe-6849-4aad-aed1-4173f26ba34b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_50714c5b-4a37-4327-ba82-fa3d4952d392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4dc033b-2b04-4893-bb85-ee6c106aec1a" xlink:to="loc_us-gaap_SubsequentEventMember_50714c5b-4a37-4327-ba82-fa3d4952d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9aa32b94-9657-4d9e-8678-669c1adaaee5" xlink:to="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7fb656a0-5ad1-40bd-a80a-3fb5fe456b7b" xlink:href="rprx-20220630.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7fb656a0-5ad1-40bd-a80a-3fb5fe456b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7accfdc-cb86-40d3-b314-f6375722962d" xlink:href="rprx-20220630.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7accfdc-cb86-40d3-b314-f6375722962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_12417125-269f-4f95-9783-b8f4eba3a5bd" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_12417125-269f-4f95-9783-b8f4eba3a5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_99b6038c-24aa-4e74-a081-26a32ca6899c" xlink:href="rprx-20220630.xsd#rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_917e99a8-837f-401b-be48-7bd9dcb2d235" xlink:to="loc_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount_99b6038c-24aa-4e74-a081-26a32ca6899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929221360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Royalty Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1535773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 East 59th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">883-0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary shares, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001802768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,139,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,080,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930930608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,108,037<span></span>
</td>
<td class="nump">$ 1,541,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">290,402<span></span>
</td>
<td class="nump">581,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Financial royalty assets</a></td>
<td class="nump">639,244<span></span>
</td>
<td class="nump">614,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="nump">18,032<span></span>
</td>
<td class="nump">53,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">363,700<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherRoyaltyIncomeReceivableCurrent', window );">Other royalty income receivable</a></td>
<td class="nump">17,315<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">67,119<span></span>
</td>
<td class="nump">6,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,503,849<span></span>
</td>
<td class="nump">2,878,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Financial royalty assets, net</a></td>
<td class="nump">13,423,629<span></span>
</td>
<td class="nump">13,718,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible royalty assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">304,447<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">412,076<span></span>
</td>
<td class="nump">435,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">33,412<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">17,740,413<span></span>
</td>
<td class="nump">17,515,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Distributions payable to non-controlling interests</a></td>
<td class="nump">115,990<span></span>
</td>
<td class="nump">107,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,175<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">54,162<span></span>
</td>
<td class="nump">57,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">182,327<span></span>
</td>
<td class="nump">171,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">7,106,199<span></span>
</td>
<td class="nump">7,096,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">43,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,332,226<span></span>
</td>
<td class="nump">7,267,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesValueIssued', window );">Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,570,585<span></span>
</td>
<td class="nump">3,507,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,446,132<span></span>
</td>
<td class="nump">2,255,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">4,380,938<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">13,177<span></span>
</td>
<td class="nump">16,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury interests</a></td>
<td class="num">(2,752)<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">10,408,187<span></span>
</td>
<td class="nump">10,248,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">17,740,413<span></span>
</td>
<td class="nump">17,515,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Value, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherRoyaltyIncomeReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Royalty Income Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherRoyaltyIncomeReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930980624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesParOrStatedValuePerShare', window );">Deferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesSharesIssued', window );">Deferred stock, issued (in shares)</a></td>
<td class="nump">365,302<span></span>
</td>
<td class="nump">365,302<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesSharesOutstanding', window );">Deferred stock, outstanding (in shares)</a></td>
<td class="nump">365,302<span></span>
</td>
<td class="nump">365,302<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Par or Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929718224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 535,955<span></span>
</td>
<td class="nump">$ 554,963<span></span>
</td>
<td class="nump">$ 1,098,004<span></span>
</td>
<td class="nump">$ 1,127,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="nump">105,714<span></span>
</td>
<td class="num">(243,762)<span></span>
</td>
<td class="nump">290,335<span></span>
</td>
<td class="nump">48,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="nump">101,106<span></span>
</td>
<td class="nump">5,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,733<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">11,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">51,843<span></span>
</td>
<td class="nump">44,921<span></span>
</td>
<td class="nump">103,383<span></span>
</td>
<td class="nump">88,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses/(income), net</a></td>
<td class="nump">158,163<span></span>
</td>
<td class="num">(189,986)<span></span>
</td>
<td class="nump">500,494<span></span>
</td>
<td class="nump">153,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">377,792<span></span>
</td>
<td class="nump">744,949<span></span>
</td>
<td class="nump">597,510<span></span>
</td>
<td class="nump">974,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (income)/expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of equity method investees</a></td>
<td class="num">(737)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="num">(15,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">46,966<span></span>
</td>
<td class="nump">37,426<span></span>
</td>
<td class="nump">94,029<span></span>
</td>
<td class="nump">74,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">(Gains)/losses on derivative financial instruments</a></td>
<td class="num">(71,805)<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="num">(71,805)<span></span>
</td>
<td class="nump">4,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">(Gains)/losses on equity securities</a></td>
<td class="num">(8,024)<span></span>
</td>
<td class="num">(55,495)<span></span>
</td>
<td class="nump">28,138<span></span>
</td>
<td class="num">(1,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="num">(70,321)<span></span>
</td>
<td class="num">(14,015)<span></span>
</td>
<td class="num">(53,742)<span></span>
</td>
<td class="num">(23,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="num">(10,919)<span></span>
</td>
<td class="num">(14,037)<span></span>
</td>
<td class="num">(20,448)<span></span>
</td>
<td class="num">(30,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating expense, net</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income)/expenses, net</a></td>
<td class="num">(113,805)<span></span>
</td>
<td class="num">(61,806)<span></span>
</td>
<td class="num">(22,170)<span></span>
</td>
<td class="nump">8,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Consolidated net income before tax</a></td>
<td class="nump">491,597<span></span>
</td>
<td class="nump">806,755<span></span>
</td>
<td class="nump">619,680<span></span>
</td>
<td class="nump">965,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net income</a></td>
<td class="nump">491,597<span></span>
</td>
<td class="nump">806,755<span></span>
</td>
<td class="nump">619,680<span></span>
</td>
<td class="nump">965,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">187,093<span></span>
</td>
<td class="nump">365,979<span></span>
</td>
<td class="nump">263,415<span></span>
</td>
<td class="nump">455,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Royalty Pharma plc</a></td>
<td class="nump">$ 304,504<span></span>
</td>
<td class="nump">$ 440,776<span></span>
</td>
<td class="nump">$ 356,265<span></span>
</td>
<td class="nump">$ 509,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per Class A ordinary share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average Class A ordinary shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">436,318<span></span>
</td>
<td class="nump">409,344<span></span>
</td>
<td class="nump">435,144<span></span>
</td>
<td class="nump">399,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">607,214<span></span>
</td>
<td class="nump">607,163<span></span>
</td>
<td class="nump">607,207<span></span>
</td>
<td class="nump">607,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember', window );">Financial Royalty Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 515,350<span></span>
</td>
<td class="nump">$ 503,414<span></span>
</td>
<td class="nump">$ 1,026,873<span></span>
</td>
<td class="nump">$ 1,033,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember', window );">Intangible Royalty Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">40,127<span></span>
</td>
<td class="nump">36,123<span></span>
</td>
<td class="nump">76,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember', window );">Royalty Income, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 18,068<span></span>
</td>
<td class="nump">$ 11,422<span></span>
</td>
<td class="nump">$ 35,008<span></span>
</td>
<td class="nump">$ 18,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241931132416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 491,597<span></span>
</td>
<td class="nump">$ 806,755<span></span>
</td>
<td class="nump">$ 619,680<span></span>
</td>
<td class="nump">$ 965,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Changes in other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">9,325<span></span>
</td>
<td class="nump">6,025<span></span>
</td>
<td class="nump">10,950<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(7,988)<span></span>
</td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(16,942)<span></span>
</td>
<td class="num">(28,790)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="num">(7,274)<span></span>
</td>
<td class="num">(5,992)<span></span>
</td>
<td class="num">(17,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">492,934<span></span>
</td>
<td class="nump">799,481<span></span>
</td>
<td class="nump">613,688<span></span>
</td>
<td class="nump">948,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to non-controlling interests</a></td>
<td class="nump">187,638<span></span>
</td>
<td class="nump">362,748<span></span>
</td>
<td class="nump">260,948<span></span>
</td>
<td class="nump">447,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Royalty Pharma plc</a></td>
<td class="nump">$ 305,296<span></span>
</td>
<td class="nump">$ 436,733<span></span>
</td>
<td class="nump">$ 352,740<span></span>
</td>
<td class="nump">$ 500,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241924787728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class R Redeemable Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class B</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class R Redeemable Stock</div>
</th>
<th class="th"><div>Deferred Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Non-Controlling Interests</div></th>
<th class="th"><div>Treasury Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,895,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,865,964<span></span>
</td>
<td class="nump">$ 1,920,635<span></span>
</td>
<td class="nump">$ 34,395<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
<td class="num">$ (2,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">14,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(316,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(138,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,810<span></span>
</td>
<td class="num">(38,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,805<span></span>
</td>
<td class="num">(551,663)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">965,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">11,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,060<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(28,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,588)<span></span>
</td>
<td class="num">(13,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,006<span></span>
</td>
<td class="nump">180,166<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">355,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">10,405,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,415,598<span></span>
</td>
<td class="nump">2,291,966<span></span>
</td>
<td class="nump">28,672<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,857<span></span>
</td>
<td class="nump">214,255<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">321,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">9,837,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,931,249<span></span>
</td>
<td class="nump">1,923,771<span></span>
</td>
<td class="nump">29,452<span></span>
</td>
<td class="nump">4,954,818<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">11,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(170,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(72,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,089<span></span>
</td>
<td class="num">(34,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,263<span></span>
</td>
<td class="num">(486,591)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">806,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">6,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">2,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(13,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
<td class="num">(5,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,006<span></span>
</td>
<td class="nump">180,166<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">355,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">10,405,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,415,598<span></span>
</td>
<td class="nump">2,291,966<span></span>
</td>
<td class="nump">28,672<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">10,248,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,507,533<span></span>
</td>
<td class="nump">2,255,179<span></span>
</td>
<td class="nump">16,491<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">6,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(295,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(165,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132<span></span>
</td>
<td class="num">(4,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="num">(62,222)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">619,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">10,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(16,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,005)<span></span>
</td>
<td class="num">(6,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">365,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">10,408,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,570,585<span></span>
</td>
<td class="nump">2,446,132<span></span>
</td>
<td class="nump">13,177<span></span>
</td>
<td class="nump">4,380,938<span></span>
</td>
<td class="num">(2,752)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,316<span></span>
</td>
<td class="nump">171,862<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">363,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">10,141,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,543,204<span></span>
</td>
<td class="nump">2,224,677<span></span>
</td>
<td class="nump">12,304<span></span>
</td>
<td class="nump">4,364,324<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">2,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(146,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(83,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="num">(1,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(26,938)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">491,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">9,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,523<span></span>
</td>
<td class="nump">3,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(7,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
<td class="num">(3,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">437,139<span></span>
</td>
<td class="nump">170,081<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">365,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 10,408,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,570,585<span></span>
</td>
<td class="nump">$ 2,446,132<span></span>
</td>
<td class="nump">$ 13,177<span></span>
</td>
<td class="nump">$ 4,380,938<span></span>
</td>
<td class="num">$ (2,752)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930080864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends declared and paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends declared and paid (in dollars per share)</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929233216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables', window );">Cash collections from financial royalty assets</a></td>
<td class="nump">$ 1,181,354<span></span>
</td>
<td class="nump">$ 1,094,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets', window );">Cash collections from intangible royalty assets</a></td>
<td class="nump">71,377<span></span>
</td>
<td class="nump">75,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables', window );">Other royalty cash collections</a></td>
<td class="nump">32,716<span></span>
</td>
<td class="nump">14,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="nump">27,502<span></span>
</td>
<td class="nump">22,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments', window );">Derivative collateral received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments', window );">Derivative collateral posted</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForOngoingDevelopmentStageFunding', window );">Development-stage funding payments - ongoing</a></td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(5,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForUpfrontDevelopmentStageFunding', window );">Development-stage funding payments - upfront and milestone</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForOperatingCostsAndProfessionalServices', window );">Payments for operating and professional costs</a></td>
<td class="num">(93,003)<span></span>
</td>
<td class="num">(81,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(86,880)<span></span>
</td>
<td class="num">(64,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,035,222<span></span>
</td>
<td class="nump">1,057,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investments in equity method investees</a></td>
<td class="num">(3,050)<span></span>
</td>
<td class="num">(17,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI', window );">Purchases of equity securities</a></td>
<td class="num">(62,785)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI', window );">Proceeds from equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available for sale debt securities</a></td>
<td class="num">(79,158)<span></span>
</td>
<td class="num">(35,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from available for sale debt securities</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="nump">31,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(234,869)<span></span>
</td>
<td class="num">(728,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">525,907<span></span>
</td>
<td class="nump">868,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireFinanceReceivables', window );">Acquisitions of financial royalty assets</a></td>
<td class="num">(175,093)<span></span>
</td>
<td class="num">(683,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Acquisitions of other financial assets</a></td>
<td class="num">(21,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForMilestones', window );">Milestone payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(19,013)<span></span>
</td>
<td class="num">(473,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to non-controlling interests</a></td>
<td class="num">(215,543)<span></span>
</td>
<td class="num">(238,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToNoncontrollingInterestsOther', window );">Distributions to non-controlling interests- other</a></td>
<td class="num">(72,343)<span></span>
</td>
<td class="num">(86,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentOfDividendsToShareholders', window );">Dividends to shareholders</a></td>
<td class="num">(165,312)<span></span>
</td>
<td class="num">(138,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment', window );">Contributions from non-controlling interests- R&amp;D</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">4,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsOther', window );">Contributions from non-controlling interests- other</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">8,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(449,220)<span></span>
</td>
<td class="num">(451,085)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">566,989<span></span>
</td>
<td class="nump">133,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">1,541,048<span></span>
</td>
<td class="nump">1,008,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 2,108,037<span></span>
</td>
<td class="nump">$ 1,142,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentOfDividendsToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Dividends To Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentOfDividendsToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Collateral Posted On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForCollateralPostedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOngoingDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Ongoing Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOngoingDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOperatingCostsAndProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Operating Costs and Professional Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOperatingCostsAndProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForUpfrontDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Upfront Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForUpfrontDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collateral Received On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932684672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Purpose<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Purpose</a></td>
<td class="text">Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (&#8220;IPO&#8221;) of our Class A ordinary shares. &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd. (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#8217; Class A ordinary shares and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;).  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#8220;Management Agreement&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div>As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;). We are legally entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932506512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Preparation and Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). Income will not be allocated to EPA Holdings until certain conditions are met.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead. As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div>There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241933512832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available for Sale Debt Securities</a></td>
<td class="text">Available for Sale Debt Securities <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) of up to $300&#160;million, which is comprised of five tranches, including an initial tranche of $50&#160;million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#8220;Cytokinetics Funding Commitments&#8221;). As of June 30, 2022, we expect $125&#160;million of the $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#8220;Development Funding Bonds&#8221;) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150&#160;million. Our commitment to fund at least $150&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300&#160;million under the Development Funding Bonds to be funded in September 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221;) at a price of $50,100 per preferred share for a total of $125&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0&#160;million and $16.9&#160;million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3&#160;million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;) for a total of $200&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities (3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">269,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span> on the condensed consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930138736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text">. Fair Value Measurements and Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">508,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,242,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">397,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Milestone Acceleration Option (defined below) recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet. See Note 8&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments as reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 30, 2022. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized gains of $8.0&#160;million and losses of $28.1&#160;million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $28.3&#160;million and losses of $10.7&#160;million, respectively, on equity securities still held as of June 30, 2022.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the underlying debt securities, related forwards and funding commitments (in thousands): </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (1) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (5) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ApiJect Investment</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (&#8220;ApiJect&#8221;) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8&#8211;Non-Consolidated Affiliates for additional discussion. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#8217;s assumed cost of debt, which would impact Cytokinetics&#8217; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;), calculated based on the volume-weighted average price of BioCryst&#8217;s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#8217;s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6&#160;million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250&#160;million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (&#8220;Milestone Acceleration Option&#8221;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $8.6 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the &#8220;with-and-without&#8221; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,254,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,423,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140242020956448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Financial Royalty Assets</a></td>
<td class="text">Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,347,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,439,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(417,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,824,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,110,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,048,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,737,435)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,310,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,062,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196816<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930138736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</a></td>
<td class="text">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets and includes the following activities:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(556,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,985,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $310.8&#160;million related to cumulative allowance for credit losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932470272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Royalty Assets, Net</a></td>
<td class="text">Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.</span></div>Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932603264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Non-Consolidated Affiliates</a></td>
<td class="text">Non-Consolidated Affiliates<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the fair value of the revenue participation right was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $4.7&#160;million and $9.3&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6&#160;million and $30.8&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received cash distributions from the Legacy SLP Interest of $6.8&#160;million and $14.1&#160;million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7&#160;million and $8.6&#160;million in the three and six months ended June 30, 2021, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (&#8220;Avillion I&#8221;), BAv Financing II, LP and its related entities (&#8220;Avillion II,&#8221; together with Avillion I, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0&#160;million and $8.2&#160;million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $7.9&#160;million and $15.0&#160;million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million during each of the six months ended June 30, 2022 and 2021, respectively.</span></div>In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $27.5 million, which totaled $150.0&#160;million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7&#160;million and $11.2&#160;million, respectively, of unfunded commitments related to the Avillion Entities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932420000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research &amp; Development ("R&amp;D") Funding Expense</a></td>
<td class="text">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&amp;D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&amp;D funding arrangements. We recognized R&amp;D funding expense of $0.6 million and $101.1 million for the three and six months ended June 30, 2022, respectively. We recognized R&amp;D funding expense of $3.1 million and $5.8 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&amp;D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0&#160;million to Cytokinetics to acquire a royalty on a development-stage product candidate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241933447040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.9&#160;billion and $7.2&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932622480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of 365,302 thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;1 each.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,756,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,599,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,364,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(295,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,882,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,954,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(316,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Continuing Investors Partnerships&#8217; ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest Held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $165.3&#160;million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $138.6 million to holders of our Class A ordinary shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932482432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932568416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Indirect Cash Flow</a></td>
<td class="text">Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,026,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,057,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932657040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitments</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various funding commitments as of June 30, 2022 as described below. See Note 3&#8211;Available for Sale Debt Securities for additional discussion of the respective arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $250&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125&#160;million of the $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $350&#160;million of the MorphoSys Development Funding Bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $300&#160;million under the Development Funding Bonds to be funded in September 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Series B Biohaven Preferred Shares</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, we have a remaining commitment of $100.4&#160;million under the Commercial Launch Preferred Equity to purchase 2,004 shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8&#8211;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15&#8211;Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932470272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $36.0&#160;million and $77.2&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4&#160;million and $68.1&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPSFT&#8217;s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the financial royalty asset of $118.1&#160;million and $130.9&#160;million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8&#8211;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million is recorded as treasury interests, of which $1.5&#160;million and $1.6&#160;million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241934850496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (&#8220;Theravance&#8221;) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31&#160;billion in July 2022 and committed up to $300&#160;million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25&#160;million in upfront funding and a potential $15&#160;million regulatory milestone payment to support the clinical development of ampreloxetine.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929734608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of preparation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). Income will not be allocated to EPA Holdings until certain conditions are met.  </span></div>All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932576704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Debt Securities</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities (3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">269,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span> on the condensed consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241934716688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">508,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,242,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">397,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Milestone Acceleration Option (defined below) recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet. See Note 8&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments as reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span>June 30, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the underlying debt securities, related forwards and funding commitments (in thousands): </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (1) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (5) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</a></td>
<td class="text">Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,254,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,423,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2E<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498357-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241933517680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Financial Royalty Assets, Net</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,347,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,439,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(417,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,824,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,110,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,048,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,737,435)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,310,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,062,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932606704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(556,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,985,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $310.8&#160;million related to cumulative allowance for credit losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932657040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Royalty Interests</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932556896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Borrowings</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Repayments of Debt by Year</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932570848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Balance Of Non-controlling Interests</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,756,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,599,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,364,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(295,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,882,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,954,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(316,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Continuing Investors Partnerships&#8217; ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241933481200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241932568416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,026,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,057,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241931114960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPSFT&#8217;s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930939568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Purpose (Details)<br></strong></div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember', window );">RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember', window );">RPSFT | RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Exchange offering, ownership percentage</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241924661008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Current portion of Financial royalty assets | Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241925576000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 07, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 05, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAmount', window );">Long term funding partnership, amount</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipNumberOfTranches', window );">Long term funding partnership, number of tranches | tranche</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount', window );">Required amount to be drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipExpectedPayment', window );">Long term funding partnership, expected payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple', window );">Installment repayments, percentage of amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,158,000<span></span>
</td>
<td class="nump">$ 35,170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,919,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,037,000<span></span>
</td>
<td class="nump">20,448,000<span></span>
</td>
<td class="nump">30,635,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income | Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Commitment to fund agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementExpectedProceeds', window );">Expected proceeds from development funding bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital', window );">Payment of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Commitment to fund agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn', window );">Period of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate', window );">Start of period of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period One | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period Two | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementExpectedProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expected Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementExpectedProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSalePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSalePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Price, Multiple</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Covenant, Required Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipCovenantRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipExpectedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Expected Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipExpectedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241925415872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 269,359<span></span>
</td>
<td class="nump">$ 204,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">113,641<span></span>
</td>
<td class="nump">65,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">270,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">363,700<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(43,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">278,759<span></span>
</td>
<td class="nump">204,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">84,241<span></span>
</td>
<td class="nump">49,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">253,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">28,100<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">28,100<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">63,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(35,600)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember', window );">Funding Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="num">(8,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">$ (8,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241923250832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">$ 290,402<span></span>
</td>
<td class="nump">$ 581,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">363,700<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">304,447<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(43,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="nump">63,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">1,242,781<span></span>
</td>
<td class="nump">1,301,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">304,447<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">397,262<span></span>
</td>
<td class="nump">474,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(43,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">21,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Cytokinetics Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="num">(8,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">307,797<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">275,662<span></span>
</td>
<td class="nump">226,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">275,662<span></span>
</td>
<td class="nump">226,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Cytokinetics Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">508,084<span></span>
</td>
<td class="nump">636,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Cytokinetics Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">426,900<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">28,785<span></span>
</td>
<td class="nump">43,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">121,600<span></span>
</td>
<td class="nump">247,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(43,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Milestone Acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="nump">63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">21,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Cytokinetics Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="num">(8,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">87,622<span></span>
</td>
<td class="nump">207,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">87,622<span></span>
</td>
<td class="nump">207,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">178,766<span></span>
</td>
<td class="nump">374,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">178,766<span></span>
</td>
<td class="nump">374,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">24,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">24,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(35,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forwards</a></td>
<td class="num">(35,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">63,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forwards</a></td>
<td class="num">(35,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">307,797<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">307,797<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">181,681<span></span>
</td>
<td class="nump">13,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">181,681<span></span>
</td>
<td class="nump">13,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36,001<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36,001<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_RoyaltyInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_RoyaltyInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_CytokineticsFundingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_CytokineticsFundingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241923023696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain (loss) on equity securities still held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="num">$ (28,100)<span></span>
</td>
<td class="num">$ (10,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod', window );">Restrictions on selling common stock, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember', window );">BioCryst Pharmaceuticals, Inc. | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember', window );">Milestone Acceleration | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instrument, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember', window );">Cytokinetics Commercial Launch Funding | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Interest rate volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-adjusted discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Milestone Acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments', window );">Preferred shares, quarterly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleFixedPayment', window );">Preferred shares, fixed payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital', window );">Preferred shares, weighted average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleFixedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fixed Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleFixedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Quarterly Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Price, Multiple</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930561168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 62,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">28,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Losses on equity securities</a></td>
<td class="num">(21,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfer to Level 1</a></td>
<td class="num">(40,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="nump">28,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">314,000<span></span>
</td>
<td class="nump">$ 226,800<span></span>
</td>
<td class="nump">253,700<span></span>
</td>
<td class="nump">$ 214,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">14,579<span></span>
</td>
<td class="nump">17,585<span></span>
</td>
<td class="nump">79,158<span></span>
</td>
<td class="nump">35,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition', window );">Gains/(losses) on initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Unrealized gains included in other comprehensive losses</a></td>
<td class="nump">9,325<span></span>
</td>
<td class="nump">6,025<span></span>
</td>
<td class="nump">10,950<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized (losses)/gains included in earnings</a></td>
<td class="nump">31,800<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="nump">8,921<span></span>
</td>
<td class="nump">5,115<span></span>
</td>
<td class="nump">10,842<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions', window );">Redemption of debt securities</a></td>
<td class="num">(15,625)<span></span>
</td>
<td class="num">(15,625)<span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">240,400<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">240,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">22,400<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized (losses)/gains included in earnings</a></td>
<td class="nump">38,221<span></span>
</td>
<td class="nump">13,515<span></span>
</td>
<td class="nump">22,242<span></span>
</td>
<td class="nump">22,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="num">(8,921)<span></span>
</td>
<td class="num">(5,115)<span></span>
</td>
<td class="num">(10,842)<span></span>
</td>
<td class="num">(10,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="nump">28,100<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
<td class="nump">28,100<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember', window );">Funding Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="num">(8,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition', window );">Gains/(losses) on initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized (losses)/gains included in earnings</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="num">(8,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember', window );">Derivative Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gains on derivative financial instrument</a></td>
<td class="nump">71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="nump">71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the period</a></td>
<td class="nump">$ 21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241934027392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 18,254,440<span></span>
</td>
<td class="nump">$ 19,047,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Carrying Value, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 13,423,629<span></span>
</td>
<td class="nump">$ 13,718,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929248304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 16,048,153<span></span>
</td>
<td class="nump">$ 16,027,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(1,737,435)<span></span>
</td>
<td class="num">(1,384,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">14,310,718<span></span>
</td>
<td class="nump">14,643,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal', window );">Cumulative allowance for credit losses</a></td>
<td class="num">(247,845)<span></span>
</td>
<td class="num">(310,804)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Net carrying value</a></td>
<td class="nump">14,062,873<span></span>
</td>
<td class="nump">14,332,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember', window );">Cystic fibrosis franchise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,347,911<span></span>
</td>
<td class="nump">5,335,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(54,609)<span></span>
</td>
<td class="num">(48,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">5,293,302<span></span>
</td>
<td class="nump">5,287,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TysabriMember', window );">Tysabri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,759,427<span></span>
</td>
<td class="nump">1,846,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,617)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,759,427<span></span>
</td>
<td class="nump">1,829,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember', window );">Imbruvica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,439,443<span></span>
</td>
<td class="nump">1,438,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(417,165)<span></span>
</td>
<td class="num">(236,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,022,278<span></span>
</td>
<td class="nump">1,201,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_XtandiMember', window );">Xtandi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,053,621<span></span>
</td>
<td class="nump">1,100,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(153,154)<span></span>
</td>
<td class="num">(172,101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">900,467<span></span>
</td>
<td class="nump">927,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TremfyaMember', window );">Tremfya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">876,834<span></span>
</td>
<td class="nump">881,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">876,834<span></span>
</td>
<td class="nump">881,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_EvrysdiMember', window );">Evrysdi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">746,524<span></span>
</td>
<td class="nump">727,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(1,992)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">744,532<span></span>
</td>
<td class="nump">727,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents', window );">Aggregate royalty amount when patents cease</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">4,824,393<span></span>
</td>
<td class="nump">4,697,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(1,110,515)<span></span>
</td>
<td class="num">(909,916)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">$ 3,713,878<span></span>
</td>
<td class="nump">$ 3,787,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_ImbruvicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_XtandiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_XtandiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_EvrysdiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_EvrysdiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929412048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward', window );"><strong>Financing Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Beginning balance</a></td>
<td class="num">$ (1,694,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense', window );">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="num">(556,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense', window );">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="nump">202,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Current period provision for credit losses, net</a></td>
<td class="nump">62,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Ending balance</a></td>
<td class="num">(1,985,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal', window );">Cumulative allowance for credit losses</a></td>
<td class="nump">$ 247,845<span></span>
</td>
<td class="nump">$ 310,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241924680784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 606,216<span></span>
</td>
<td class="nump">$ 606,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">606,216<span></span>
</td>
<td class="nump">600,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember', window );">DPP-IV patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">606,216<span></span>
</td>
<td class="nump">606,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">606,216<span></span>
</td>
<td class="nump">600,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241931074560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember', window );">DPP-IV patents | Revenue Benchmark | Individual Licensees Concentration List</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Individual licensees exceeding 10% or more of revenue (as a percent)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241931058192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 412,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">$ 15,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,502<span></span>
</td>
<td class="nump">22,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="nump">30,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember', window );">Avillion Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">$ (7,900)<span></span>
</td>
<td class="num">(8,200)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_EquityMethodInvestmentsUnfundedCommitments', window );">Equity method investment, unfunded commitments</a></td>
<td class="num">(35,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember', window );">Avillion I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember', window );">Avillion II | Merck Asset - Phase II Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherCommitmentIncreaseDecrease', window );">Increase in commitment</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_EquityMethodInvestmentsUnfundedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Unfunded Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_EquityMethodInvestmentsUnfundedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherCommitmentIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherCommitmentIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929413392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 3,122<span></span>
</td>
<td class="nump">$ 101,106<span></span>
</td>
<td class="nump">$ 5,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_CytokineticsMember', window );">Cytokinetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_CytokineticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_CytokineticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241922914528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">$ (193,801,000)<span></span>
</td>
<td class="num">$ (203,930,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt carrying value</a></td>
<td class="nump">7,106,199,000<span></span>
</td>
<td class="nump">7,096,070,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 7,106,199,000<span></span>
</td>
<td class="nump">7,096,070,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">99.322%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.284%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point One Five Zero Percent Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.263%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.556%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.306%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Five Zero Percent Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.565%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance As A Percent Of Par</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentIssuanceAsAPercentOfPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFiveZeroPercentDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFiveZeroPercentDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929826944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000,000<span></span>
</td>
<td class="num">$ (193,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of outstanding Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000,000<span></span>
</td>
<td class="nump">$ 7,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Prior to the applicable par call date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio', window );">Maximum consolidated leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition', window );">Maximum consolidated leverage ratio following qualifying material acquisition</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio', window );">Minimum consolidated coverage ratio</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241924645136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of Repayments of Debt by Year (Details) - Unsecured Debt - The Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="num">$ (193,800)<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241930342304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>noncontrolling_interest </div>
<div>shares </div>
<div>class </div>
<div>vote </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>noncontrolling_interest </div>
<div>shares </div>
<div>class </div>
<div>vote </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>noncontrolling_interest </div>
<div>shares </div>
<div>class </div>
<div>vote </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NumberOfClassesOfVotingStock', window );">Number of classes of stock | class</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CommonStockVotingRightsNumberOfVotes', window );">Number of votes per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CommonStockQuarterlyConversionBasis', window );">Quarterly conversion basis</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NumberOfNoncontrollingInterests', window );">Number of noncontrolling interests | noncontrolling_interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends declared and paid (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared and paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.3<span></span>
</td>
<td class="nump">$ 138.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember', window );">Deferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">365,302,000<span></span>
</td>
<td class="nump">355,217,000<span></span>
</td>
<td class="nump">365,302,000<span></span>
</td>
<td class="nump">365,302,000<span></span>
</td>
<td class="nump">355,217,000<span></span>
</td>
<td class="nump">363,521,000<span></span>
</td>
<td class="nump">361,170,000<span></span>
</td>
<td class="nump">321,128,000<span></span>
</td>
<td class="nump">316,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">437,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,139,000<span></span>
</td>
<td class="nump">437,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends declared and paid (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">170,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,081,000<span></span>
</td>
<td class="nump">170,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RedeemableStockRedemptionPricePerShare', window );">Redeemable stock, redemption price (in euros per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockQuarterlyConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Quarterly Conversion Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockQuarterlyConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfClassesOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Classes Of Voting Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfClassesOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RedeemableStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Stock, Redemption Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RedeemableStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241926232544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 10,141,879<span></span>
</td>
<td class="nump">$ 9,837,033<span></span>
</td>
<td class="nump">$ 10,248,545<span></span>
</td>
<td class="nump">$ 9,895,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">11,519<span></span>
</td>
<td class="nump">6,203<span></span>
</td>
<td class="nump">14,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(146,967)<span></span>
</td>
<td class="num">(170,808)<span></span>
</td>
<td class="num">(295,942)<span></span>
</td>
<td class="num">(316,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">491,597<span></span>
</td>
<td class="nump">806,755<span></span>
</td>
<td class="nump">619,680<span></span>
</td>
<td class="nump">965,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">9,325<span></span>
</td>
<td class="nump">6,025<span></span>
</td>
<td class="nump">10,950<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(7,988)<span></span>
</td>
<td class="num">(13,299)<span></span>
</td>
<td class="num">(16,942)<span></span>
</td>
<td class="num">(28,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">10,408,187<span></span>
</td>
<td class="nump">10,405,365<span></span>
</td>
<td class="nump">10,408,187<span></span>
</td>
<td class="nump">10,405,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">4,364,324<span></span>
</td>
<td class="nump">4,954,818<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">11,519<span></span>
</td>
<td class="nump">6,203<span></span>
</td>
<td class="nump">14,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(146,967)<span></span>
</td>
<td class="num">(170,808)<span></span>
</td>
<td class="num">(295,942)<span></span>
</td>
<td class="num">(316,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">187,093<span></span>
</td>
<td class="nump">365,979<span></span>
</td>
<td class="nump">263,415<span></span>
</td>
<td class="nump">455,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="num">(26,938)<span></span>
</td>
<td class="num">(486,591)<span></span>
</td>
<td class="num">(62,222)<span></span>
</td>
<td class="num">(551,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">3,802<span></span>
</td>
<td class="nump">2,677<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(3,257)<span></span>
</td>
<td class="num">(5,908)<span></span>
</td>
<td class="num">(6,937)<span></span>
</td>
<td class="num">(13,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">4,380,938<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="nump">4,380,938<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | RPSFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">8,409<span></span>
</td>
<td class="nump">13,841<span></span>
</td>
<td class="nump">13,528<span></span>
</td>
<td class="nump">12,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(5,754)<span></span>
</td>
<td class="num">(12,476)<span></span>
</td>
<td class="num">(16,013)<span></span>
</td>
<td class="num">(26,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">19,275<span></span>
</td>
<td class="nump">11,367<span></span>
</td>
<td class="nump">34,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">8,882<span></span>
</td>
<td class="nump">20,640<span></span>
</td>
<td class="nump">8,882<span></span>
</td>
<td class="nump">20,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">1,756,269<span></span>
</td>
<td class="nump">1,882,655<span></span>
</td>
<td class="nump">1,809,269<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(103,385)<span></span>
</td>
<td class="num">(127,747)<span></span>
</td>
<td class="num">(207,586)<span></span>
</td>
<td class="num">(222,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">61,642<span></span>
</td>
<td class="nump">133,743<span></span>
</td>
<td class="nump">112,162<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="num">(2,337)<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
<td class="num">(5,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">1,716,186<span></span>
</td>
<td class="nump">1,894,027<span></span>
</td>
<td class="nump">1,716,186<span></span>
</td>
<td class="nump">1,894,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | Continuing Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">2,599,646<span></span>
</td>
<td class="nump">3,058,322<span></span>
</td>
<td class="nump">2,649,154<span></span>
</td>
<td class="nump">3,125,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
<td class="nump">2,808<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(37,828)<span></span>
</td>
<td class="num">(30,585)<span></span>
</td>
<td class="num">(72,343)<span></span>
</td>
<td class="num">(67,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">119,224<span></span>
</td>
<td class="nump">212,961<span></span>
</td>
<td class="nump">139,886<span></span>
</td>
<td class="nump">251,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="num">(26,938)<span></span>
</td>
<td class="num">(486,591)<span></span>
</td>
<td class="num">(62,222)<span></span>
</td>
<td class="num">(551,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">3,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(3,571)<span></span>
</td>
<td class="num">(3,958)<span></span>
</td>
<td class="num">(8,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">2,655,870<span></span>
</td>
<td class="nump">2,757,019<span></span>
</td>
<td class="nump">2,655,870<span></span>
</td>
<td class="nump">2,757,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | EPA Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | RP Holdings | Continuing Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_EPAHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_EPAHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RPHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RPHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241922929184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per Class A ordinary share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CommonStockExchangeRatio', window );">Common stock exchange ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 491,597<span></span>
</td>
<td class="nump">$ 806,755<span></span>
</td>
<td class="nump">$ 619,680<span></span>
</td>
<td class="nump">$ 965,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="nump">187,093<span></span>
</td>
<td class="nump">365,979<span></span>
</td>
<td class="nump">263,415<span></span>
</td>
<td class="nump">455,839<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Royalty Pharma plc - basic</a></td>
<td class="nump">304,504<span></span>
</td>
<td class="nump">440,776<span></span>
</td>
<td class="nump">356,265<span></span>
</td>
<td class="nump">509,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares</a></td>
<td class="nump">119,224<span></span>
</td>
<td class="nump">212,961<span></span>
</td>
<td class="nump">139,886<span></span>
</td>
<td class="nump">251,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Royalty Pharma plc - diluted</a></td>
<td class="nump">$ 423,728<span></span>
</td>
<td class="nump">$ 653,737<span></span>
</td>
<td class="nump">$ 496,151<span></span>
</td>
<td class="nump">$ 761,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average Class A ordinary shares outstanding - basic (in shares) | shares</a></td>
<td class="nump">436,318<span></span>
</td>
<td class="nump">409,344<span></span>
</td>
<td class="nump">435,144<span></span>
</td>
<td class="nump">399,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Class B ordinary shares exchangeable for Class A ordinary shares (in shares) | shares</a></td>
<td class="nump">170,864<span></span>
</td>
<td class="nump">197,773<span></span>
</td>
<td class="nump">172,035<span></span>
</td>
<td class="nump">207,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Unvested RSUs (in shares) | shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares</a></td>
<td class="nump">607,214<span></span>
</td>
<td class="nump">607,163<span></span>
</td>
<td class="nump">607,207<span></span>
</td>
<td class="nump">607,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember', window );">Class B Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="nump">$ 119,224<span></span>
</td>
<td class="nump">$ 212,961<span></span>
</td>
<td class="nump">$ 139,886<span></span>
</td>
<td class="nump">$ 251,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember', window );">Legacy Investors Partnerships and RPSFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="nump">$ 67,869<span></span>
</td>
<td class="nump">$ 153,018<span></span>
</td>
<td class="nump">$ 123,529<span></span>
</td>
<td class="nump">$ 204,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 54<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2603-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 44<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2062-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2600-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2597-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2538-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2538-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 51<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2574-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_ClassBHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241925473792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 491,597<span></span>
</td>
<td class="nump">$ 806,755<span></span>
</td>
<td class="nump">$ 619,680<span></span>
</td>
<td class="nump">$ 965,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets', window );">Income from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,026,873)<span></span>
</td>
<td class="num">(1,033,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="nump">105,714<span></span>
</td>
<td class="num">(243,762)<span></span>
</td>
<td class="nump">290,335<span></span>
</td>
<td class="nump">48,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,733<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">11,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,683<span></span>
</td>
<td class="nump">9,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gains)/losses on derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,805)<span></span>
</td>
<td class="nump">4,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses/(gains) on equity securities</a></td>
<td class="num">(8,024)<span></span>
</td>
<td class="num">(55,495)<span></span>
</td>
<td class="nump">28,138<span></span>
</td>
<td class="num">(1,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of equity method investees</a></td>
<td class="num">(737)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="num">(15,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,502<span></span>
</td>
<td class="nump">22,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss', window );">Interest income accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,942)<span></span>
</td>
<td class="num">(28,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="num">$ (70,321)<span></span>
</td>
<td class="num">$ (14,015)<span></span>
</td>
<td class="num">(53,742)<span></span>
</td>
<td class="num">(23,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease/(increase) in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables', window );">Cash collected on financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,181,354<span></span>
</td>
<td class="nump">1,094,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,254<span></span>
</td>
<td class="num">(988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable', window );">Other royalty income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,292)<span></span>
</td>
<td class="num">(4,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,555<span></span>
</td>
<td class="num">(913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,534)<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,222<span></span>
</td>
<td class="nump">$ 1,057,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInAccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Collections On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Royalty Income Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241929827056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingCommitmentAmountOutstanding', window );">Funding commitment, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount', window );">Required amount to be drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipExpectedPayment', window );">Long term funding partnership, expected payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementExpectedProceeds', window );">Expected proceeds from development funding bonds</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital', window );">Payment of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember', window );">Funding Agreement With Biohaven Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermPurchaseCommitmentAmountOutstanding', window );">Purchase commitment, amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermPurchaseCommitmentShares', window );">Shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementExpectedProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expected Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementExpectedProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingCommitmentAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Commitment, Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingCommitmentAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Covenant, Required Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipCovenantRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipExpectedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Expected Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipExpectedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermPurchaseCommitmentAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Purchase Commitment, Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermPurchaseCommitmentAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermPurchaseCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Purchase Commitment, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermPurchaseCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241923354736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 08, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Total financial royalty assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,062,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,062,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,332,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,408,187<span></span>
</td>
<td class="nump">$ 10,405,365<span></span>
</td>
<td class="nump">10,408,187<span></span>
</td>
<td class="nump">$ 10,405,365<span></span>
</td>
<td class="nump">$ 10,141,879<span></span>
</td>
<td class="nump">10,248,545<span></span>
</td>
<td class="nump">$ 9,837,033<span></span>
</td>
<td class="nump">$ 9,895,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,752)<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
<td class="num">(2,752)<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
<td class="num">(2,317)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,380,938<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="nump">$ 4,380,938<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="nump">$ 4,364,324<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
<td class="nump">$ 4,954,818<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember', window );">Agreement with MSCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionInitialTerm', window );">Initial term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts', window );">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments', window );">Quarterly payments to affiliates, percent of security investment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount', window );">Amount calculated for operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent', window );">Percent calculated for operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Operating and personnel payments incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Former Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Operating and personnel payments incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Total financial royalty assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired', window );">Number of limited partnership interest acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Initial Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number of Partnership Interests Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Adjusted Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateAdjustedCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Value Of Security Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateValueOfSecurityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140241933774576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interest, Additional Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>rprx-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rprx="http://royaltypharma.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rprx-20220630.xsd" xlink:type="simple"/>
    <context id="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i52760d2b07c440c88f705e4f29492dfe_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i6f1203bc2aec47828c8f208e84b90129_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5bce62e7437a4451aba53bcceaf66c3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if96a29a0235747acb515705fba4cd81f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if43def283e414c978ef1f9e00d58466d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19484314d7814df68d24568f06200a2d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i44d4df0714f34eb1a565d4c996780d0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31b8cd4406014f3c9e543595ef591d8a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9152e53d53c4a94b5dc2379eada56ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic89465228e464b4db926b3506aa69ce5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ab0e06da69042fa9b6cd6f4ccbca52c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i61fe3fac5bec4e398fc4873084eba949_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e9d15ae87c34585a03ab9e32a13a2e0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64033553961b494aa24564bcfa09d64e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iad03cc6dacc54582a74b8ee9859a3668_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf93cd9df7684053a5502441454a22cc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id535c2ad3d594a9ea96cbabcc62e08eb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id9bea35421f24cb28ad1d0b36f56b112_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id33f02594c6141be947d8164ca9d9c2f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib533fb4284214d818817d4f74f5eadba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc41c410425b42d7abcdade3c8154e0c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i43f91e61c3dd491c96060d2cd0475caa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i24af4b775fdd421ca76221754d6cc72b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie033c0ebfe694b18a9324c6432dfa2cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3131abfb53a454494b73f6ebe89c392_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bb23fabb1e14fb78211172951d31a08_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if45953d0a97b4ab4a331eebb7376a3cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4a1f6430e214497599d013c1c8969e8d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22fe98e0e7a94704ac3fdfff181f9502_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5339fc8ea38b46fa9a86916bc074eca4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2527d56cd62046479c1173dcb0b0f5b2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i02556876a6a14a828978826651a01c40_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iefecccbe9aeb4eda97cf4d50e61ebc9d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9b0a2c2185f841d1bd0ae1256b144310_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12ebb3a392fb49adaca1a85bc203cbec_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i176f226ee22a48e38c48b5d77aff5fe1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i39f7632b52e24947b5542bc50c2d3c30_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2105ff37cbf54c04ba010a8c52924650_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica342df70a2842ffb246d1630ba9eb5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i305f1861941e45fbb293aa1942d05488_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i622a95bdb08e47f7acf229df1afae29b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia71ca76e55df4684b26c0aa01421d9bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c89af6243f0463eb180fef51c293c8c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b43a0bf90e547dbb6fbf1dd47972a2a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78b916b52b23472ba3549f7931482243_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iade2ebd58086471fbf60d5e06704e135_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieff3e647fe0147108d0196b5815a9c6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibf1a04cc8cc84280933c35ae3b8d8d94_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iffade55c2b5644739b00e4201220367e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib2b8266d2b4a41d0a8dab2958a2d956f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i100aaaeaffba486fa3044462ac9475b3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac2ae29b2c9b4f06af0cf0034f33a3a4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e39280da19945f6afec914c5d523b2b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6d7ac128c7c744138c4d180baa58e508_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic48ab397b18842dea811ef845e7f9159_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i030828ed817644a789470b5495e7c36e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i589baf01d5dd4c2caae101de2f597840_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia146a7ffd9eb4c388b427f68bf59099a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0d5332e18aae41968464d7e40f3879b0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i31d0005fb24b41b7be1fed5796c78265_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f837639fd8f42d18127b22713c22bff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e1903e1e4384e289320f606987686f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cb49e5d1da64984b7dab1f207cb821b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48669715cbaa4a4ca2f245e9fb5f1995_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i290a4cb4e651436abde84028a4766f89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9e401b08b73c499dbf77eb4e227d5e2f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if96dac154fa240898e743b8ff8fc9059_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05594336aff54167b344569f8bc28d05_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i509463e2205845eb855c04c67b225ba8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f7f0975039c4b47a8013da696977787_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74012a9aba134af29fa48477d04dde00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad1b46dfcb7f40ebb639788c968daf3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice7b784e492241448627593176cad967_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i972173b5752144889ef69fee1cfc51dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf7802275df47c59d3e1f7df579b50e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i592c6aa1733545c6a94d49a0144e42e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb3f673cf22e4af289ea139885dca16b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0b19f0203cf486094b8b552ce743af7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cade76361ba4fcba710604a8c023a58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i660048b273ba434f82a3033be439995d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35d05a9e48b54e568c0c8b5a3e8ab180_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice8047411077489696941648f5280f81_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee6a414fd23744eb89554b7564759f43_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8aec56c066c44c0c9505da67fbc972b1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic15dd32149b64228b3e0062543709fcd_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i8fc135510e2d49c6b0cd406c917f4076_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i4664ea2072fe497b9a2bdfd6d8b604dc_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i3af9b0efe9a24584a5d0beab8491a70b_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i870dbc439abc462d939ae18d7d1c13f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="i902af37f112d47b59465fb1587d35546_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia97d19761a80439aaf1c248d0d1cc56e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if3b647dc49674f03b93aec721c35aafb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="if50973d0a69a4908932e02a923662f68_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="icd5c1bcea18e4e42a9671f6beadbf2fa_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i01bf1c77beb0485bba6517474b519b3a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9e38949c6aa4cd6866cb944e9722714_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id75ac419666144e9ac3c194e9261e33c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id978345eb4784af985d02a10ba404dc9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i578d8f8ce4bc4f43841fb347caa2a50d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id49f4fcd2b764a89bc0488726370049d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7a47ace66d74b15afbe0039fd04291d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9290af25cfb841918df88507b267637a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbba88c267644fd3be79fa0c3675c0f5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6700642e5b124bf1a3547c30d346a79b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65ac760695004feebc1b6b592162d7c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10b1800e67dc44a981720a7b46c2e79d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0870484004364ecb8b093f2046454b41_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ide2e274fed7a481fba6833bfbf3cce5f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1c80a2ae1ba645d8abc23c5ce5fd6c3a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3505ef986d8e447e9494c8ba914f66d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefd435d72f144bbcb6e42e3f0d53768f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3de23eaeb284126b429fb1b2832c3dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5576abf606bb4661bbc57aac01aa20ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8546e9f6e24b4217b84ced51c46b1e0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie6ef74a0dac44216a515c0217153b14a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4eb473791033401b851d996ace3fb0d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i08423e6c0ac54c738abebce60150775e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i694256d7751f443599a66a50b84c5c04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i335547d431054d37aa47757fec28e211_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b9d3fdba80d4a0ab2392959204e54f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i274c91a324f74a50b47e0f39cc9a6471_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dcaa33e9c8c454ea8d9ad358405d5c0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8a0b0bfcc4f426fb9507705a90045ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic1e68fb94a79461caa836857c65a594b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia2ad8d24abf44259b70281a4a03fd5ab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i74e4ce8bb43f44bd81105b431942f8a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5229c7a11d840c385003a2de7d5a560_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f0f2a63eea644fc9b8acb08a1096965_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5a3c10ce0834373af301afc9cb06554_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7f7d2dc311341ed8ab580778cfb7424_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40a5bcf20dbe4092b31de7276a1233af_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i164534f9debb47d283bba03bb38b42a8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3724a5f5971340ee9b2c75df324f183e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7de1f8630b5044af9d51c4a863878a19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ae65db56ba049b8b7016f1d57247db5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ca01372241f4621b26e3c24a6b0ac4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8847225dbd934083a96c5b022eb001dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4faebbed44242b588fd22db4532d6a2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i47e2f72945114b8e97557817665eb22a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ide527eedf0c8430ebdd7f8b7e178695d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d54454653d14877997e8cc8a446a36b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9240e834904c4b7980784391c35ae5d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i057686b000924406a6e92a555bcefbe8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6562ec75eae34ba19dcb404ea71fccac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c7cf57e9bdd49e3a5aab2cd19221140_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b4c1ac3b3004925ba20d1eb0829987d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i37a847973ce446648b13fdedff22c715_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia78911c3736d495e8cb2fa5ea8e81e2e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4c70858e246f4c259aa4add3106bb74c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i42664d0a6f0744bc8d3dc6057491af00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11d0d65a59844aa3bee4beb15d323337_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e5608ca68f141c5ab7e851371cbc63c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3099777568874b56a4d873cc01719626_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab2e747c9c9b43f69707587cc843a451_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i872d2b73bb3b4a8da6deb68b730f21af_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i306cb19b43b645968b07140915241260_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if290e213185d45f3b68d456d7bba18b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i354de3a504f7447f946701a70bbbdd32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67a185b6e27d445c892d2b91c0a23d94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48faa4921ca5490ea5d8274518df219c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id24d238620954975bfcdbdd367836c85_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id366640cb83544df99f3ad8a3131c185_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf20ea8448ab403080a8058146fe9940_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i97aa147f94524d7496766953b7a86882_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i509709b18bc34c46b002ff7583a3eb02_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if40208096a5d4db6b4b3971989763e71_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3efa9883f6e24af785319eb40fa00bfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i557255cd129a42a9a7bb3e235e002c30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d47e0f671754f869e7a625979b2f609_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie23d4f24f8d04a988e40dbf86515109d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d78244fc88c4181b2440708f971ee96_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cfe1cd3f4e7415991895ae425a914d6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i316c6f99df2b4a26ba23e4e48f5c3abd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9792ea77bdea40d1ae7f65287f922717_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i333a9ec1ff53481696d2280a621e9863_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9f25260f20c04074b3fc492d72c935ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4694ad59207646ac874c75e17fd2b37b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if69f87b5bc8e4ea1a497545b599999bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9455f5d9a104f0e81d0b8107254f72f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fce1c2f895246eebae070dfcc9e49e9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i27a38f2819984010b545afc636533f8b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5803bf99b3b473cb7589dbc5dab874f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i81b8f5d307bb4b9b990828c40cf681b4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf836c86dd4f40bf98e8953f69ac75fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e58c615de2f4b659329480870108ef1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83281e2c15c7428f83706175489d6339_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie57b86b9d1184e09887d985686c79f0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc0ee976221e43ac94bfd0056a40c5bc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9140bfbcfc3e413ea3287f2bb5976940_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4fabb30765e4fef8c46e1acdc00d9dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba21e49a07e840aeb4ca72218e5782fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0fd0ae0498ad4e29b327a69dfe2286e8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35d03139bb3743808afda3b7bddd5bc2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie35b86bd79ef41a28f7e6d1d00c42f48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iac8317e61e1f41c784239c68f2108a60_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idc3cce41829e46588da12635d7616283_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i353de01dbec74abcad269b32e3cdb25f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfa854c1e4c4436a8ea3e2512d5ef979_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c70708fcd054afa8e309da96db8d7d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i365769dd85514fa18d6a39ba5d363336_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie06ed27505284260adf0648d3d31568f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i68a1621fc32f497988a0e96ba9b1feef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d029a55997348e4a5f520d12893009a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2661ba948f9948bf99cd3662bded664b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib82dc1c2627b4d718f85effdf12e3a8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i369c65d0b3874042b691cd5c31ea13dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4925acb858a43cc8cc6487a6f052e4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2625fc2cdae04a5a832d2df168c76071_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf40b5c13abe46518f36da6af058fe32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eaac71ae55f4517bcccf4879bb27679_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eb1edf8c46140688a4ed0d57e3927b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia18d1f6254b04c1eaf3b2e9a61f02662_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7602807328d94e3ea160b1356604c56f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8320a1e985dc497d99e7ee8e4fb2680c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe40e0e708a24e1485c00e06f6c33811_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a44308643464db9804f8317e68d3593_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:CytokineticsCommercialLaunchFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i62c078144e5641bebb3f8f5b775cc14f_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ic5b00b1196a842a18ae4bbfc65e35bca_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5940ed238dbd4c118100d14a7e5ad7a1_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i1dc0e13f8a8149dda55dd457a53e6897_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49ec77ad5db44776871a0182cf263586_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c8b4208854b4a00a19fae7046aab65c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib1d52494a67e479ebd68a8c3b8f69060_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5adddf24c7f04202a9c712798093983a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7caf3f5c79647e18539159493607558_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic40b42e2790c47ef8f7f4808b0958e59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i280cfe154d93462092b3209bd9f8e4b9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2861968b06bc49ad84cee28144700724_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id1fbfcb89cbc4602b2230f697892cd1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i814da027f61b45e4b7e1a8b98de0f86b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i212af950addc45e6a29921885da2a4e0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9473a880a5344144a8d65facb9f75109_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if68b0902cea7416f9dd59258eb674bc1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib719fc62cf904acc863f4c031cfadf8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c1ce1553bf74d69818557e322f52767_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i898a964c879840d78fe00d3bdfc2571f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i618646a4dc484b23bb5596e4471fb6fe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a1ee997727d476f941c9f5cb772f235_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9fb0f3822f7448c3b9edb5542ba8571e_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1652d07294b14089a0592537d2026e6f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i373eee1b26c541e8833b248c7988a139_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife00a507d4204c9bbdf7447e8c4d1429_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84eb422d2b40477e9258c52a15372639_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i620523eb4a204e25acac2ef3e9967411_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1bbd0e73cf3d42dcac55b07236105ba5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79fa516152564be089415fb655f74d77_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fef318c94084992aa959a03e78ce32c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i156b8175434d4e1db0d0fd57caa92008_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i30c73e53d86c471680151e41da485930_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibdda7de8d7244be2b32f9b7e729092c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i691fe772f8474c9883cd86d770776fc5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:CytokineticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id3e6f22ee9884362b21300a0550d1dea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5277bbde55dc4ff3aac4ba9a24308df5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib5db792457664c249f4f34f68ae84ee7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3998c09aa68e48dfba459528066155e1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2520a38f28f24d8abe1664a0fa276108_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaeb3b048ad644ef7a5f6894758c0ec22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i473f0b55243f46238d71fb088fbcbd08_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iba61f5d65e924374ba352a9226aa644b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6514393b77b142479d7fa249d2437d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i246c4d7bf81f4ad88af37091381a6fa0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9de03c81c754dc7bb15c6c52caf92be_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i813d79deba2f4673b7dfac7f74be1e42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i803cb24ed48a4da1b85d42425a8acf1f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ca85d756ed8402091fc1700a7ab767b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i54640267ea864316a9bed44de2313208_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89293daeea364b87a0f53da7fa772357_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i22abfbc03ed3462fa495b3d35e9f63c2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07f4360f02cb429f873526aa4abb90b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i850321a4707144d5aa10067c9606b155_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf45fa61bd9d44eaa6acb1fcc1c764c2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66677b99bf9e422f895af82a4346163b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id77ed6261fc14df9845a99e3f1b47d5a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie38fcca043734f5c8ff85a24cb230791_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFiveZeroPercentDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5a03d177ab2440997f9376d5899a918_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="ia0c7820636114a409ceede5a921b1d09_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i3197e12bdd3a4d309fc770d7447285e2_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i164ffc87f86f4075b11ef1a172aeefb8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a92e44b4b344661af4757ad9a229064_I20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-02</instant>
        </period>
    </context>
    <context id="icf036923cf324ce78882338a4fb17702_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1e250b66e64341b09584ce80e7cba81e_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="iba76a3f80e5c49e3948452772ef55ef9_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="i4c364b452a2e4075809d3b9b42a5c9e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i022d32cb77944ea29be1667bb225e44a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8378863f6fb54944bdf6267872f7e32a_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="ifc406544d3744be8af475bd920f1691e_I20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="ia209b3983b4840c0a0ae77de9566e43b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1cd001fdda914fffa3ca20031e15926d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3f318ef84894bd4b707d34d44ab34f1_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="i2a66b8b6943547f2808825744d348a6a_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="i3b0545a0e18343f2842f30b29d72abac_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="i464e075cb1d04ed28a402c8f7149fe47_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i63f4135a52e24cdc8a877de0528e91ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i957a4d6b1a8f46acaeae11abefb3a081_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81ac24325a784997a2a2834a39d26946_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife05da3ee4b44968baca4702397077dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58ff712c0f0e4721b11f310c9a7ba814_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iac973f489d7a4fc9ac38195a2164de93_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie068a9d4a59444e886f94818184da48d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e0d9dd3824945d09335073108634a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52d62fb2227b41378a04fa7cf96ec2e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icac8a13c10554d4e8c579493cc60ccd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff4eb9e0f8c94eca9757ffe4eb666c7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61b4d35516324aa095d83be2bba73156_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6316c883f648449c968ab6316d93a13d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i094b01ea23224dbd8928efbf7993356b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88246dd04abf4793a1634e975c03750b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i715821bde2d34b7aa686a6dfe08ae077_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i771cb54e67794bd7841999b1e5270715_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2140ef6f670745a782880740ef79a12d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife8b00699867481fb50c4fef1515ba9e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id3a9d91774c148d1bb20516e42535cc5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i20897a0731394ab39cdbf6f569451ecb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i564ee5a80f984273b26344ca0417004e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bbbfac68ec4488cbbc6b6f3a3f7e632_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia70dd8a979be46a0a140e37dcbc10470_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58a1efb8258c4f90b003132a7c806d37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd4499f27b8c415c83b4aa5e390c611c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibd5518beaff545de976d2821f78d8146_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie59134a7c071446a8dc6d06dd7272373_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i7cf25b5c44074bba8349a3ed917b9828_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89da6075574744cd88689bc056f4784d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e85d625927d4a208e60107fcdc3e4d1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1723835775974da9ace43244c9bf89d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i839baaa9ddce4c7a8bee9fbd533f440c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4e57903f579943a3acd517f95ac47e2d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbf2318e4b6145d29623e3758709b640_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i716b09853e4a4174a28f2a27d873f6cb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i212df1108fca4c628a85996199e48189_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d396452af104e75bfbf02ca11bf7445_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i934116fad2e6442e88d42ee191199a43_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iade6caaa03d24c1db457fe31fe5a9a4d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib720c19bda424da0a54ac76bd380e694_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e368ed2beeb4e9bbfd7a428cdfe20a7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id600e57f7adf403dabaeb1fd595d2aea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i27cc09d1626c4c12831b9b9ed5f1707e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75026c18f8e94d4d89a49b9629256c1e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica95079874234fdbb0b75f9d0967a000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69334c4cb99348768c6cddd1b7d09954_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="ibad559122e374240aa4d76a955a15563_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="ie1a96d121b274fbd8dbe1ad563a91052_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd9849608bf44ab2b4553b4ce907b20e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia627a511f205448c8f15096957f33520_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i6458b426c5a0473fbba13389985422c7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i46117034b4ae4c55b35944ccab8ad2b3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i89beaee57e374c50b2a774f5e339e12b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0bf7a05a6178471d83f36a54fc1b58f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>rprx:tranche</measure>
    </unit>
    <unit id="class">
        <measure>rprx:class</measure>
    </unit>
    <unit id="vote">
        <measure>rprx:vote</measure>
    </unit>
    <unit id="noncontrolling_interest">
        <measure>rprx:noncontrolling_interest</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8xLTEtMS0xLTEzNDUwNQ_414bc690-26ee-4c7d-8694-9ab5640e261b">0001802768</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8yLTEtMS0xLTEzNDUwNQ_df00d29f-7e38-4815-b826-3020fec96544">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF8zLTEtMS0xLTEzNDUwNQ_6efce71f-4030-4281-92a3-a41b60656159">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF80LTEtMS0xLTEzNDUwNQ_d1150f60-e168-4a8d-a3ce-1505aa2af076">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80L2ZyYWc6YmFmNjYxN2ZlZTQ0NDRhMGI3ZDA3Y2Y1YjAyZGRkN2EvdGFibGU6ZTNhNjdmODg1MGJiNDYxMGJlY2E4ZTQ1ZDU5YTRmYTQvdGFibGVyYW5nZTplM2E2N2Y4ODUwYmI0NjEwYmVjYThlNDVkNTlhNGZhNF81LTEtMS0xLTEzNDUwNQ_9de2f501-c782-44f7-b230-57c19394a3a2">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTI4_d6bfd733-860f-4bf7-a62d-683f8fa36b33">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6ODYwOGY0ODhkMTk1NGM0NDk5ZWU1MWFlMTE1ODZiMGUvdGFibGVyYW5nZTo4NjA4ZjQ4OGQxOTU0YzQ0OTllZTUxYWUxMTU4NmIwZV8wLTAtMS0xLTEzNDUwNQ_ceacc7cb-c5e9-441e-99eb-87a34c506079">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8xMzQ_f868d0a7-9f87-47b6-90a6-3bb553cc475b">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6ZGU3YWZjOGI0MGFmNGE1OTk0MTlkYTZkNzg2MGFjNGMvdGFibGVyYW5nZTpkZTdhZmM4YjQwYWY0YTU5OTQxOWRhNmQ3ODYwYWM0Y18wLTAtMS0xLTEzNDUwNQ_1a20497c-fdfa-4a70-8269-fc3e96c091d4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTI5_898178cd-b4b1-4168-8e7c-a38ca732153e">001-39329</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTMz_c05dea79-9795-4763-bedb-47c82e08df4f">Royalty Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8wLTAtMS0xLTEzNDUwNQ_e4277bfd-8ff5-4776-bd45-0a8c4c439c3f">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8wLTMtMS0xLTEzNDUwNQ_3d62ace1-be7f-4f92-92f9-bfd368672b6f">98-1535773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl8zLTAtMS0xLTEzNDUwNQ_d5d32ae5-9b4b-46c6-87c4-f15918a91ad5">110 East 59th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzQ_550e598b-dbb2-40a6-88f7-4b0fa8715c28">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzg_285a0213-19ca-4ada-8182-590c668e46c2">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6NWRkY2Y3MGU3NWJhNGE1ZGE1MjcwZTkzZTcwNzE4ZmYvdGFibGVyYW5nZTo1ZGRjZjcwZTc1YmE0YTVkYTUyNzBlOTNlNzA3MThmZl80LTAtMS0xLTEzNDUwNS90ZXh0cmVnaW9uOmVkNWY0NTE1MWUwMTQyOGU4ZGMzMDZiZTc0YjFjNjFkXzEx_b2c94229-ab53-4c6e-a644-cff5290cb86b">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTMx_fe19548f-22f7-4111-ae49-3f282df34897">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM0_3fd2a752-3180-4b71-bff8-cbddd62f9f82">883-0200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTAtMS0xLTEzNDUwNQ_948ab340-85ba-4135-868a-1dd739bee9d8">Class A ordinary shares, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTEtMS0xLTEzNDUwNQ_f8978805-3d3f-4a2b-ad13-8f18d9b34b08">RPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjM1NzlkOGYwODZjNGEyM2IzY2E3MzYyMzM4NDNmN2IvdGFibGVyYW5nZTpiMzU3OWQ4ZjA4NmM0YTIzYjNjYTczNjIzMzg0M2Y3Yl8xLTItMS0xLTEzNDUwNQ_8ee3c385-c25a-422b-af49-f67884c69d19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM1_89481da1-a5db-4ceb-bad0-83d8cf5b2fca">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMTM2_f0f072e5-f623-42d9-8669-9103ffa989b4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18wLTAtMS0xLTEzNDUwNQ_f37ed9b8-3e86-468a-9bfe-a7aac53cde0c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18xLTMtMS0xLTEzNDUwNQ_86214ab6-d278-4be7-a0ad-f1dc88f21dbe">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGFibGU6YjI0MGE1YjliMmVmNGNhNDkzNzNiNTNlYTAwNWM1NTMvdGFibGVyYW5nZTpiMjQwYTViOWIyZWY0Y2E0OTM3M2I1M2VhMDA1YzU1M18yLTMtMS0xLTEzNDUwNQ_22e17cca-fa21-4fea-b9c8-81696f888111">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8zNjI4Mzg4MzcxODc4Mg_80707dfd-b21d-468d-969e-24b6bd8d7985">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i52760d2b07c440c88f705e4f29492dfe_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMDQ1_0f00c64b-8337-40b2-a021-c1e87c540340"
      unitRef="shares">437139178</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6f1203bc2aec47828c8f208e84b90129_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xL2ZyYWc6NjA4ZTcyMzQwNzk5NDQ3ZmI1M2YzNzhkZDJkNWEyYjQvdGV4dHJlZ2lvbjo2MDhlNzIzNDA3OTk0NDdmYjUzZjM3OGRkMmQ1YTJiNF8yMDg4_fef5dd72-1e9a-432a-b98b-f64ac1b3c205"
      unitRef="shares">170080791</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNC0xLTEtMS0xMzQ1MDU_204cf68e-fb2f-4174-8965-88a7e83e6486"
      unitRef="usd">2108037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNC0zLTEtMS0xMzQ1MDU_787329c2-2bf4-4987-9b6b-487183df10d4"
      unitRef="usd">1541048000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNi0xLTEtMS0xMzQ1MDU_a21c3ba1-c42c-4793-87f5-0b8a3a3f7f96"
      unitRef="usd">290402000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNi0zLTEtMS0xMzQ1MDU_a645371c-30f1-4808-8684-c7ab8791ec09"
      unitRef="usd">581872000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNy0xLTEtMS0xMzQ1MDU_dc2eda2e-5622-416b-8c6c-68a90d188e8b"
      unitRef="usd">639244000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNy0zLTEtMS0xMzQ1MDU_9e107989-6b64-4ed0-96d4-a124b1160320"
      unitRef="usd">614351000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <rprx:AccruedRoyaltyReceivable
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfOC0xLTEtMS0xMzQ1MDU_000aadcf-2fc3-4d50-9030-de1e3dee44ea"
      unitRef="usd">18032000</rprx:AccruedRoyaltyReceivable>
    <rprx:AccruedRoyaltyReceivable
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfOC0zLTEtMS0xMzQ1MDU_3ec8d5a2-6f8d-484e-9cdc-be45a517e654"
      unitRef="usd">53286000</rprx:AccruedRoyaltyReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTAtMS0xLTEtMTM0NTA1_5b62f29c-e48b-4b96-87be-64d5159e1468"
      unitRef="usd">363700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTAtMy0xLTEtMTM0NTA1_9d5e50ed-3194-4b2d-84e0-0735c684713a"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTItMS0xLTEtMTM0NTA1_9de81ac1-e634-42a5-8a14-b827668c527b"
      unitRef="usd">17315000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTItMy0xLTEtMTM0NTA1_6386c830-b56f-4c25-a0e3-f3da300e9bf2"
      unitRef="usd">15023000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTMtMS0xLTEtMTM0NTA1_ce90bbdc-6d04-4de4-bea1-21340c526388"
      unitRef="usd">67119000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTMtMy0xLTEtMTM0NTA1_5c48dd65-15bc-43b1-9c6b-bf84e6e6676c"
      unitRef="usd">6631000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTQtMS0xLTEtMTM0NTA1_54362ce8-e61c-4a2b-9461-4548f668b485"
      unitRef="usd">3503849000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTQtMy0xLTEtMTM0NTA1_72fbf677-e2b8-43d3-95db-a2541fa2c8aa"
      unitRef="usd">2878211000</us-gaap:AssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTYtMS0xLTEtMTM0NTA1_ef2af0ae-1753-41b4-b3f7-dd987df14d4c"
      unitRef="usd">13423629000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTYtMy0xLTEtMTM0NTA1_cbfe53a0-6b74-493e-b547-ecbe69ec56b2"
      unitRef="usd">13718245000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTctMS0xLTEtMTM0NTA1_20984163-aeff-43bf-93a8-2b7358d2a3c6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTctMy0xLTEtMTM0NTA1_89dd5877-8b4c-4cd9-ace0-6ba15e3399d5"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTgtMS0xLTEtMTM0NTA1_655ed78c-cb23-4ff6-b1fc-2c796f15b5e1"
      unitRef="usd">304447000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTgtMy0xLTEtMTM0NTA1_2e2e4100-d8b0-4929-8020-891fc5265160"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTktMS0xLTEtMTM0NTA1_85aaadc7-7e2a-4c4f-8aed-ec4bd3b4eae1"
      unitRef="usd">63000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMTktMy0xLTEtMTM0NTA1_e7ef5a7e-7c1e-4de0-86bb-ca341d064bff"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjEtMS0xLTEtMTM0NTA1_ba7b951a-f73d-4e65-8dac-03657f7acc52"
      unitRef="usd">412076000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjEtMy0xLTEtMTM0NTA1_eda9c6c1-3c8d-4459-8bb1-1c5659e007ce"
      unitRef="usd">435394000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjItMS0xLTEtMTM0NTA1_5f2b58c9-4b87-402c-bafe-4a38ace5add8"
      unitRef="usd">33412000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjItMy0xLTEtMTM0NTA1_8715ece1-748f-4885-8ec2-947b118ca81e"
      unitRef="usd">4145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjQtMS0xLTEtMTM0NTA1_363f9100-8c54-4323-a67f-bb96b6947ac2"
      unitRef="usd">17740413000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjQtMy0xLTEtMTM0NTA1_7e5ecde7-1f2f-4a32-9ae0-e00ba6a4ae8e"
      unitRef="usd">17515865000</us-gaap:Assets>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjgtMS0xLTEtMTM0NTA1_d396b193-ffbb-4cbb-a8c3-7e5fefa6d115"
      unitRef="usd">115990000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjgtMy0xLTEtMTM0NTA1_ca518bf8-c9be-4a9a-b376-7ae26c3fc7df"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjktMS0xLTEtMTM0NTA1_f88c63c1-c7a5-4699-a6f5-8389b7a9d4e3"
      unitRef="usd">12175000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMjktMy0xLTEtMTM0NTA1_3b84199e-aa33-4ca4-b7ab-38e357cd9cfa"
      unitRef="usd">5620000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzAtMS0xLTEtMTM0NTA1_c26b39fe-afde-44bf-8f62-7c4df9463b53"
      unitRef="usd">54162000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzAtMy0xLTEtMTM0NTA1_1ede38d1-9563-47af-95bf-b62b039c7d2f"
      unitRef="usd">57696000</us-gaap:InterestPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzYtMS0xLTEtMTM0NTA1_df5052fe-74f0-4609-9ed4-5b9755ff54b0"
      unitRef="usd">182327000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzYtMy0xLTEtMTM0NTA1_1dc2b824-5026-4606-9501-faf04c30f9ea"
      unitRef="usd">171250000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzgtMS0xLTEtMTM0NTA1_29d322dd-4325-4673-a0ea-e4c12a3b03aa"
      unitRef="usd">7106199000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfMzgtMy0xLTEtMTM0NTA1_ae71dbc4-6d72-4416-a32c-9a375531aa0b"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDAtMS0xLTEtMTM0NTA1_def748a2-63c0-4882-ab1c-42cf579c3e04"
      unitRef="usd">43700000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDAtMy0xLTEtMTM0NTA1_c3a3eac6-e5e0-40c7-8bdc-c78efe51973a"
      unitRef="usd">0</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDItMS0xLTEtMTM0NTA1_94d7b3a9-4a6f-43c4-9ff0-322dce64c07c"
      unitRef="usd">7332226000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDItMy0xLTEtMTM0NTA1_11855b5d-9e84-4070-8871-98eb5df558be"
      unitRef="usd">7267320000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDQtMS0xLTEtMTM0NTA1_9d430fa6-934b-4189-9893-6371cd545ecd"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDQtMy0xLTEtMTM0NTA1_41057dda-7e9e-430c-99cb-3fa9542eaf94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if96a29a0235747acb515705fba4cd81f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfMjk_10c1e575-680d-41f7-8abc-cfedc1b7f815"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if43def283e414c978ef1f9e00d58466d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfMjk_5e86893c-a079-4f7e-bce6-d2f39fdffc35"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if43def283e414c978ef1f9e00d58466d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNDM_2610e4b8-0f2b-43d8-8c0e-13b7e8f2d9f7"
      unitRef="shares">437139000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if43def283e414c978ef1f9e00d58466d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNDM_8af88074-76e6-482a-a6b0-d88fe5ed997a"
      unitRef="shares">437139000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if96a29a0235747acb515705fba4cd81f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNTA_0b57032b-2a2d-4f89-96c2-b206d9e5bfe6"
      unitRef="shares">432963000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if96a29a0235747acb515705fba4cd81f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZjlhYTZkMWY1NDUwNDIzNjkxYjEyNjdiZThlZGY5NDNfNTA_1e1f2e5f-c1d1-45ab-8229-0f0994d7b6e0"
      unitRef="shares">432963000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if43def283e414c978ef1f9e00d58466d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMS0xLTEtMTM0NTA1_d50ac832-bb43-4d7a-a101-16a0b6ca9388"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if96a29a0235747acb515705fba4cd81f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDctMy0xLTEtMTM0NTA1_87a17fc2-61e4-4644-b4b5-25de32cdbcea"
      unitRef="usd">43000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfMjk_079a05df-18e8-48ba-93d3-45840c23de73"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19484314d7814df68d24568f06200a2d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfMjk_2a28a024-c286-4313-9406-1cfc77bf0f3a"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i19484314d7814df68d24568f06200a2d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNDM_2321f4f3-b8af-4332-8aad-a41ad1769241"
      unitRef="shares">170081000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19484314d7814df68d24568f06200a2d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNDM_d9336fe9-1c75-423c-9174-4e877c7ed3ae"
      unitRef="shares">170081000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNTA_ac4917a2-756b-43fe-96f7-84f4c3b227d1"
      unitRef="shares">174213000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246NzMyYmE1NGFhMGUxNDlmM2E2MjNlNWIyMzUzZmE2MjVfNTA_f0a523e1-6ac6-48b1-b727-de3a2a6762d0"
      unitRef="shares">174213000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i19484314d7814df68d24568f06200a2d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMS0xLTEtMTM0NTA1_9bf46faf-688e-499b-a040-d8029df97d87"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie8e4fb5f920b4d00b0eef79aa23afc9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDgtMy0xLTEtMTM0NTA1_79e93282-7ead-4463-8e28-e764c0086fb5"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfMzE_0c675d08-65d1-44b7-877c-cbfc653f3a77"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfMzE_f63525e1-68c1-4ec6-8d6b-3947c8cf1b7e"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNDU_0363353b-33ec-45b0-b825-5331552562d4"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNDU_d638b728-4418-48e0-9c30-1195bebbed54"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNTI_21a578a4-5dbd-436f-be6a-cf59cd1b8095"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMC0xLTEtMTM0NTA1L3RleHRyZWdpb246ZmE4N2ZhNTdjNDllNDBkOTgzYWExOTQ2OWRmMDE4MjhfNTI_e3ec3451-5787-4838-8e68-6538a8eb806e"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMS0xLTEtMTM0NTA1_749e76b5-e1f8-4083-8fbd-29c1966ef212"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i44d4df0714f34eb1a565d4c996780d0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNDktMy0xLTEtMTM0NTA1_5c6cf53e-03fe-48e8-9c3b-f509f502e643"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMjE_13a9999f-ff01-4bea-bb11-27ff5e7aa8ee"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMjE_30eaa7f5-b862-40ea-a4ab-8829ac99807c"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMzU_73d0e249-087c-43d5-aa6f-598990dfc1a8"
      unitRef="shares">365302000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesSharesIssued
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfMzU_f78c5696-689f-4f83-bb55-6c47fc2303ab"
      unitRef="shares">365302000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesSharesIssued
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfNDI_46870d9f-a37c-48e2-a331-7ce1e622c138"
      unitRef="shares">361170000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMC0xLTEtMTM0NTA1L3RleHRyZWdpb246MWQxZmE0YWM1NjJhNGNkNmFlMTVlOTVlYTIwYmYyOWVfNDI_ec1c3591-1e94-4699-aeb1-72ec9538b43f"
      unitRef="shares">361170000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesValueIssued
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMS0xLTEtMTM0NTA1_889679e2-51e6-4d69-9866-8d9b96b9d17e"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <rprx:DeferredSharesValueIssued
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTAtMy0xLTEtMTM0NTA1_6ead2b82-f57d-45e7-a587-c3d0353e3ceb"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTItMS0xLTEtMTM0NTA1_e8d300e9-e39f-43cd-969d-0845338de44d"
      unitRef="usd">3570585000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTItMy0xLTEtMTM0NTA1_1569f527-8e4e-43a1-abb6-149dd2d199d7"
      unitRef="usd">3507533000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTMtMS0xLTEtMTM0NTA1_8bd71817-ac08-4480-83b6-c76ef33535d9"
      unitRef="usd">2446132000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTMtMy0xLTEtMTM0NTA1_84fc1cb1-5c43-4ed9-bd8f-41147c33ab2e"
      unitRef="usd">2255179000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MinorityInterest
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTQtMS0xLTEtMTM0NTA1_7109faed-f727-479c-94b1-699da1bfc556"
      unitRef="usd">4380938000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTQtMy0xLTEtMTM0NTA1_bcd6c4da-a978-4844-aad4-b8ee012b8489"
      unitRef="usd">4471951000</us-gaap:MinorityInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTUtMS0xLTEtMTM0NTA1_1f0b3de9-676e-4482-a973-603294366481"
      unitRef="usd">13177000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTUtMy0xLTEtMTM0NTA1_04242e7a-93d3-4f11-9f2d-ce27fe58fac9"
      unitRef="usd">16491000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTYtMS0xLTEtMTM0NTA1_8e2d4aa3-92a2-43c0-a1e1-0c9cd84bb43f"
      unitRef="usd">2752000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTYtMy0xLTEtMTM0NTA1_0ec9d93f-ce97-45fa-b7d6-c4b3dea9dbcb"
      unitRef="usd">2715000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTgtMS0xLTEtMTM0NTA1_c76d2092-5774-4c7b-9460-c8855ec74c67"
      unitRef="usd">10408187000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNTgtMy0xLTEtMTM0NTA1_8e65a01e-8d32-4027-8697-6713f2471c38"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNjAtMS0xLTEtMTM0NTA1_ae0f86e8-c55a-45d0-b597-5e19b9542b06"
      unitRef="usd">17740413000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xOS9mcmFnOjY2NWNhMDJjN2Q1ZjRjYzk5NmNjMmMzZDk5YmM2Yjc0L3RhYmxlOmZmNDdkYzQwZGViZTQxNzRhODVkMGE1OTE4MWRjZWE5L3RhYmxlcmFuZ2U6ZmY0N2RjNDBkZWJlNDE3NGE4NWQwYTU5MTgxZGNlYTlfNjAtMy0xLTEtMTM0NTA1_912e7d16-36c8-445f-a4b5-735c387b37df"
      unitRef="usd">17515865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ic9152e53d53c4a94b5dc2379eada56ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy0xLTEtMS0xMzQ1MDU_8e59d508-5cde-4820-b25a-dccfa9274fad"
      unitRef="usd">515350000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic89465228e464b4db926b3506aa69ce5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy0zLTEtMS0xMzQ1MDU_dc13b182-d22c-4de5-b248-4a031c5f3c08"
      unitRef="usd">503414000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ab0e06da69042fa9b6cd6f4ccbca52c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy01LTEtMS0xMzQ1MDU_73daf754-4fb5-419c-b6a4-5481f5ba9060"
      unitRef="usd">1026873000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61fe3fac5bec4e398fc4873084eba949_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMy03LTEtMS0xMzQ1MDU_3412ecc0-7319-48a8-b4e8-fd821df8ef62"
      unitRef="usd">1033039000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e9d15ae87c34585a03ab9e32a13a2e0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC0xLTEtMS0xMzQ1MDU_0ee8349e-c6ce-49a8-bb28-08f32c5c2bfb"
      unitRef="usd">2537000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64033553961b494aa24564bcfa09d64e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC0zLTEtMS0xMzQ1MDU_199cc3f4-679a-4d6c-8201-1eb92e2830c4"
      unitRef="usd">40127000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad03cc6dacc54582a74b8ee9859a3668_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC01LTEtMS0xMzQ1MDU_3824d27a-5ba5-461d-9096-fb037d86d4e5"
      unitRef="usd">36123000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf93cd9df7684053a5502441454a22cc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNC03LTEtMS0xMzQ1MDU_12ea23ab-9473-4b46-a392-eeb076c5cc8a"
      unitRef="usd">76188000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id535c2ad3d594a9ea96cbabcc62e08eb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS0xLTEtMS0xMzQ1MDU_6d60e578-f40b-4f76-bd7d-a91fbd420b4d"
      unitRef="usd">18068000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9bea35421f24cb28ad1d0b36f56b112_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS0zLTEtMS0xMzQ1MDU_a1f732e2-d4bf-493f-b3e6-557521780a8d"
      unitRef="usd">11422000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id33f02594c6141be947d8164ca9d9c2f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS01LTEtMS0xMzQ1MDU_eb56e492-1704-4d88-9b63-274571d2a3c9"
      unitRef="usd">35008000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib533fb4284214d818817d4f74f5eadba_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNS03LTEtMS0xMzQ1MDU_a40c7aee-00a8-49c1-8dc2-168aff853686"
      unitRef="usd">18763000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi0xLTEtMS0xMzQ1MDU_a5c863e5-f636-4408-8882-8300e4b1aa87"
      unitRef="usd">535955000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi0zLTEtMS0xMzQ1MDU_9f8f88be-607d-4453-b039-1babd3f87d22"
      unitRef="usd">554963000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi01LTEtMS0xMzQ1MDU_3c860d53-4724-43a7-ad32-ba1f178f5a19"
      unitRef="usd">1098004000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNi03LTEtMS0xMzQ1MDU_f12550fa-187e-4145-aee8-9f4c9f13fc03"
      unitRef="usd">1127990000</us-gaap:Revenues>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtMS0xLTEtMTM0NTA1_d10fabc0-e8b7-444b-a0b5-b96aeebafdcb"
      unitRef="usd">105714000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtMy0xLTEtMTM0NTA1_37575766-aca4-4e9b-a99c-49959fee67ad"
      unitRef="usd">-243762000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtNS0xLTEtMTM0NTA1_af9cb821-04b0-4d54-88a2-dba59096e8ab"
      unitRef="usd">290335000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTAtNy0xLTEtMTM0NTA1_0abb7384-8949-45a9-9aed-b7dcef53f900"
      unitRef="usd">48499000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtMS0xLTEtMTM0NTA1_8ea6dff7-8bf7-4a47-a712-53a8f9f438c6"
      unitRef="usd">606000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtMy0xLTEtMTM0NTA1_659f6afe-ae33-478c-b50f-7158ad002622"
      unitRef="usd">3122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtNS0xLTEtMTM0NTA1_04d127fb-b2fd-47b1-8c79-cbfdf407b2e4"
      unitRef="usd">101106000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTEtNy0xLTEtMTM0NTA1_094e1e4c-0d11-40cf-8dd8-1a15ab06d22e"
      unitRef="usd">5763000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItMS0xLTEtMTM0NTA1_de669f31-0bc2-4e4f-b01f-8f65a467cc15"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItMy0xLTEtMTM0NTA1_d094221b-95af-41b1-abb8-b13d4d3f3dfd"
      unitRef="usd">5733000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItNS0xLTEtMTM0NTA1_f2ac5dc0-988c-4b33-94a0-a321c4533b1b"
      unitRef="usd">5670000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTItNy0xLTEtMTM0NTA1_bb2b29fe-8168-4d87-a8c8-a03a9213b9ca"
      unitRef="usd">11404000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtMS0xLTEtMTM0NTA1_702c6524-4aca-47b3-8c17-2bb5464702de"
      unitRef="usd">51843000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtMy0xLTEtMTM0NTA1_f65408cd-370f-4481-b513-2638ddb54b03"
      unitRef="usd">44921000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtNS0xLTEtMTM0NTA1_ef57d153-eeb9-443c-b4ed-e6ba82943554"
      unitRef="usd">103383000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTMtNy0xLTEtMTM0NTA1_0e1e26e0-b3f1-479f-82f6-8b7742d65e7f"
      unitRef="usd">88077000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtMS0xLTEtMTM0NTA1_b6a2ff00-a4ea-4977-980a-694b6be267aa"
      unitRef="usd">158163000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtMy0xLTEtMTM0NTA1_a7b0e0af-efa5-435b-949a-9418c0683e73"
      unitRef="usd">-189986000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtNS0xLTEtMTM0NTA1_eb61e975-667e-4c21-bbe3-1ddfd5e89dfb"
      unitRef="usd">500494000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTUtNy0xLTEtMTM0NTA1_415b580f-8a9f-437a-b015-cf4b644a039f"
      unitRef="usd">153743000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctMS0xLTEtMTM0NTA1_e3da336e-ec05-4b7f-81e9-a5333c9074c4"
      unitRef="usd">377792000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctMy0xLTEtMTM0NTA1_63bae399-754c-4327-a61e-8f54a6fa9196"
      unitRef="usd">744949000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctNS0xLTEtMTM0NTA1_381c5d4a-d1fc-4587-baa2-d451d053b530"
      unitRef="usd">597510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMTctNy0xLTEtMTM0NTA1_ce18e3b9-fdcf-48d4-9759-da0058492abf"
      unitRef="usd">974247000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtMS0xLTEtMTM0NTA1_ac3cda5f-f47e-4b81-96f0-ebcba061248c"
      unitRef="usd">737000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtMy0xLTEtMTM0NTA1_5ab5abac-7975-4eda-b5b4-b274450def2c"
      unitRef="usd">17701000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtNS0xLTEtMTM0NTA1_4b1d97d5-ed8d-43bd-a382-c0c95f91ca6a"
      unitRef="usd">1134000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjAtNy0xLTEtMTM0NTA1_8fddbb54-a39e-4152-9677-758bb2b48dde"
      unitRef="usd">15783000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtMS0xLTEtMTM0NTA1_95007cc0-9343-4b7d-a291-f97e68611294"
      unitRef="usd">46966000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtMy0xLTEtMTM0NTA1_eeb9e6af-7baa-4308-979c-c50e05ed50f9"
      unitRef="usd">37426000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtNS0xLTEtMTM0NTA1_f40e08fb-ad7d-48a6-8fb7-96d47a874288"
      unitRef="usd">94029000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjEtNy0xLTEtMTM0NTA1_e4b8b47d-1518-46a3-b222-6c8cd8facb47"
      unitRef="usd">74841000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtMS0xLTEtMTM0NTA1_f02ac26d-ce35-49a0-b607-d14b639ca5e1"
      unitRef="usd">71805000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtMy0xLTEtMTM0NTA1_04f260db-b3a2-4c7e-bf83-3badcfcaeebe"
      unitRef="usd">-1909000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtNS0xLTEtMTM0NTA1_dcd364eb-0eeb-4403-84ab-41ee7be89f0b"
      unitRef="usd">71805000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjMtNy0xLTEtMTM0NTA1_8f2bccda-f285-49ab-9205-4cb3816c38b7"
      unitRef="usd">-4464000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtMS0xLTEtMTM0NTA1_9b12cd0d-35ed-410d-adc4-b6174e18a79c"
      unitRef="usd">8024000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtMy0xLTEtMTM0NTA1_70f3e603-230f-4249-9ed1-e1fa27520d6d"
      unitRef="usd">55495000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtNS0xLTEtMTM0NTA1_fead2abe-3b44-45a8-a732-450fc554d580"
      unitRef="usd">-28138000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjQtNy0xLTEtMTM0NTA1_83027556-6cb1-4d14-a8c9-85ab82368695"
      unitRef="usd">1309000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtMS0xLTEtMTM0NTA1_29dcb533-f370-4716-a418-83ba7dfb6ad0"
      unitRef="usd">70321000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtMy0xLTEtMTM0NTA1_739534ac-5587-4afe-9b34-ddebc502aac4"
      unitRef="usd">14015000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtNS0xLTEtMTM0NTA1_a950babb-363d-4dfa-b799-4cae60e45459"
      unitRef="usd">53742000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjYtNy0xLTEtMTM0NTA1_54e530bb-6f56-47dd-bc92-b4b1ce1afab1"
      unitRef="usd">23130000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctMS0xLTEtMTM0NTA1_85617b0f-a8e6-4496-a728-86f0692eef9d"
      unitRef="usd">10919000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctMy0xLTEtMTM0NTA1_84856d84-7323-4f00-aff3-82e9b1f1bb05"
      unitRef="usd">14037000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctNS0xLTEtMTM0NTA1_a6804251-9316-4196-88bb-8e347ca16e24"
      unitRef="usd">20448000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjctNy0xLTEtMTM0NTA1_b6c6ddc2-86b6-4f73-b9a7-89e1d719e785"
      unitRef="usd">30635000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtMS0xLTEtMTM0NTA1_9e66f567-1909-4564-ab08-07541238dfaa"
      unitRef="usd">-1035000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtMy0xLTEtMTM0NTA1_aaff27ca-5ddd-47ed-a45a-f835ebef36ab"
      unitRef="usd">-107000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtNS0xLTEtMTM0NTA1_673293e2-f551-4ab0-bcab-00fc94a96483"
      unitRef="usd">-2792000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjgtNy0xLTEtMTM0NTA1_97f26ee1-2243-4d54-9cc9-6e8cd2f49f72"
      unitRef="usd">-65000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktMS0xLTEtMTM0NTA1_21f2b31f-70aa-4de8-a2e6-d45bf36f32cf"
      unitRef="usd">113805000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktMy0xLTEtMTM0NTA1_877e3545-2108-430f-b5e6-bbbce2c274b1"
      unitRef="usd">61806000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktNS0xLTEtMTM0NTA1_a83a4620-e8c4-41b9-865d-ec7aa49506d6"
      unitRef="usd">22170000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMjktNy0xLTEtMTM0NTA1_aca1c020-726e-4614-a748-5b8982020054"
      unitRef="usd">-8513000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtMS0xLTEtMTM0NTA1_3404fc5b-e95c-453c-b8e3-9a74ae35948d"
      unitRef="usd">491597000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtMy0xLTEtMTM0NTA1_7e70fa21-3452-499c-99ee-fdebb2ed1680"
      unitRef="usd">806755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtNS0xLTEtMTM0NTA1_7c959ae2-1bd6-4f3c-bf3d-317c4e846b5e"
      unitRef="usd">619680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzAtNy0xLTEtMTM0NTA1_aa3b57e9-301b-4f8f-aa54-cb8ec321c35c"
      unitRef="usd">965734000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtMS0xLTEtMTM0NTA1_2a32be88-dda7-404e-9aa0-e80668d2ddde"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtMy0xLTEtMTM0NTA1_4a9d3a67-b668-4cb1-bed7-c685457870a0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtNS0xLTEtMTM0NTA1_6174c34e-af53-48ee-b7da-3873d8c3e36c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzEtNy0xLTEtMTM0NTA1_5738ac75-2e85-4a31-b708-ff595ca8ad15"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItMS0xLTEtMTM0NTA1_e7118f64-25ad-4d4d-bf48-4500b8bbbc69"
      unitRef="usd">491597000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItMy0xLTEtMTM0NTA1_98ddf8ae-9df9-4b63-9076-7abc4841db22"
      unitRef="usd">806755000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItNS0xLTEtMTM0NTA1_cd7d2ecd-f1b1-4009-846e-d63f4ac8233d"
      unitRef="usd">619680000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzItNy0xLTEtMTM0NTA1_c56ac1d0-e062-4c67-a596-8bb3a1ae3e51"
      unitRef="usd">965734000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtMS0xLTEtMTM0NTA1_fc73a3c1-ee37-4f67-85c3-ae1df0e4ef57"
      unitRef="usd">187093000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtMy0xLTEtMTM0NTA1_72a08491-b692-4e53-88f0-e07061eda6df"
      unitRef="usd">365979000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtNS0xLTEtMTM0NTA1_2bae658c-f362-4ee4-bc08-015eda3081f4"
      unitRef="usd">263415000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzQtNy0xLTEtMTM0NTA1_e21ac6b5-545e-4554-a413-bde0aa91d810"
      unitRef="usd">455839000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtMS0xLTEtMTM0NTA1_3bb65b34-1aa3-4a30-8b4d-8759a7958bc3"
      unitRef="usd">304504000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtMy0xLTEtMTM0NTA1_c4b01402-ecdd-4301-b817-1239f5f199d7"
      unitRef="usd">440776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtNS0xLTEtMTM0NTA1_0540b0d7-04b1-47b9-8c75-cd675cb35ed3"
      unitRef="usd">356265000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzYtNy0xLTEtMTM0NTA1_0f2f95b7-20de-47d5-80bc-90cf9ac6838f"
      unitRef="usd">509895000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktMS0xLTEtMTM0NTA1_9337e47c-3af7-4e02-ab20-ac17a74ad78d"
      unitRef="usdPerShare">0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktMy0xLTEtMTM0NTA1_21740370-c9a4-4640-908b-9a7972881767"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktNS0xLTEtMTM0NTA1_7209d1f8-0848-4485-8598-7841475a0420"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfMzktNy0xLTEtMTM0NTA1_734fcf22-12b5-45b8-b44e-d259940c39e3"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtMS0xLTEtMTM0NTA1_8bbcb694-16cf-4f7a-b13c-8800ae8e3da0"
      unitRef="usdPerShare">0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtMy0xLTEtMTM0NTA1_cc3b599c-ecb7-4402-bee3-a066cfe370e9"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtNS0xLTEtMTM0NTA1_4f63fc7d-191b-42f5-a936-4c0197343595"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDAtNy0xLTEtMTM0NTA1_7082bea0-5a24-41d0-b6e6-80d981659583"
      unitRef="usdPerShare">1.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItMS0xLTEtMTM0NTA1_bede2af6-5cce-4941-b979-72d50422fd9e"
      unitRef="shares">436318000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItMy0xLTEtMTM0NTA1_76827603-1aaf-440d-9092-c974d4ac3632"
      unitRef="shares">409344000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItNS0xLTEtMTM0NTA1_352cf2cb-3cfb-4160-94b5-687f59b05cbf"
      unitRef="shares">435144000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDItNy0xLTEtMTM0NTA1_5a7ec08e-ccfe-4fcb-aeb5-5f74fb309e16"
      unitRef="shares">399606000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtMS0xLTEtMTM0NTA1_b9f864aa-6707-46a0-b688-02f38423174d"
      unitRef="shares">607214000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtMy0xLTEtMTM0NTA1_5ae6ce22-e5ed-46e3-945b-4ec4d4127da3"
      unitRef="shares">607163000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtNS0xLTEtMTM0NTA1_91b7e11b-25ef-4ae9-a19d-6cfdb422c581"
      unitRef="shares">607207000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yMi9mcmFnOjNiNTA4OGNlMDI3NDQ1M2Y4ODMyYWMzMzc4YjYwNzNkL3RhYmxlOmQ4NDQ2MWM1MjUxNTQ2ZmQ5NzhjNDUxNTRhZGFiNTA0L3RhYmxlcmFuZ2U6ZDg0NDYxYzUyNTE1NDZmZDk3OGM0NTE1NGFkYWI1MDRfNDMtNy0xLTEtMTM0NTA1_ed4701d3-5672-4b6c-b3bf-40445d7892d2"
      unitRef="shares">607151000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi0xLTEtMS0xMzQ1MDU_e7118f64-25ad-4d4d-bf48-4500b8bbbc69"
      unitRef="usd">491597000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi0zLTEtMS0xMzQ1MDU_98ddf8ae-9df9-4b63-9076-7abc4841db22"
      unitRef="usd">806755000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi01LTEtMS0xMzUwNzE_cd7d2ecd-f1b1-4009-846e-d63f4ac8233d"
      unitRef="usd">619680000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMi03LTEtMS0xMzUwNzE_c56ac1d0-e062-4c67-a596-8bb3a1ae3e51"
      unitRef="usd">965734000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS0xLTEtMS0xMzQ1MDU_0e6cca94-0439-4b75-a421-1078fc6a431b"
      unitRef="usd">9325000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS0zLTEtMS0xMzQ1MDU_dc532d9c-ce41-4387-809b-078408a7d1b0"
      unitRef="usd">6025000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS01LTEtMS0xMzUwOTA_29e48871-d9c4-45e1-9823-8ac0dbb13fe9"
      unitRef="usd">10950000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNS03LTEtMS0xMzUwOTA_f5fb4e72-dcf6-4be3-96c2-3fcb076269c5"
      unitRef="usd">11150000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi0xLTEtMS0xMzQ1MDU_b29dfbe1-a04d-4fb3-9939-03afbb065334"
      unitRef="usd">7988000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi0zLTEtMS0xMzQ1MDU_454b58e7-11dd-4b2a-9cd1-73e27a433895"
      unitRef="usd">13299000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi01LTEtMS0xMzUwOTA_0cb4383e-62af-40ab-8b7e-07f1a2a38303"
      unitRef="usd">16942000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNi03LTEtMS0xMzUwOTA_1231197e-258c-42df-87e2-a8bbc483db20"
      unitRef="usd">28790000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy0xLTEtMS0xMzQ1MDU_8f0392bc-c1cd-4e4a-bdc7-12040b98452d"
      unitRef="usd">1337000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy0zLTEtMS0xMzQ1MDU_654916c3-bfd2-4fd2-983e-813e5b2693c0"
      unitRef="usd">-7274000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy01LTEtMS0xMzUwOTA_3ab46fe3-670e-40d3-bc94-abf7bd9d2bdf"
      unitRef="usd">-5992000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfNy03LTEtMS0xMzUwOTA_e6ddc4cd-3cd8-4106-9c12-0319f0e15113"
      unitRef="usd">-17640000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC0xLTEtMS0xMzQ1MDU_08dde041-1b1d-4cd7-86f0-330877e5f0ab"
      unitRef="usd">492934000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC0zLTEtMS0xMzQ1MDU_ad0e0153-05a6-4f11-a81e-1c0696440730"
      unitRef="usd">799481000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC01LTEtMS0xMzUwOTA_dd0ad472-ec81-41f1-a0b6-7efa1cd6dbb7"
      unitRef="usd">613688000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOC03LTEtMS0xMzUwOTA_71746cb3-b1e3-4ddd-8638-063b3e3c97d9"
      unitRef="usd">948094000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS0xLTEtMS0xMzQ1MDU_10648827-d1c4-44da-b425-ed384dd84793"
      unitRef="usd">187638000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS0zLTEtMS0xMzQ1MDU_187cf806-0b8e-462a-9914-f276a1d1385d"
      unitRef="usd">362748000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS01LTEtMS0xMzUwOTc_6e2cb6d6-aabb-4bf1-94d7-c688fb82b339"
      unitRef="usd">260948000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfOS03LTEtMS0xMzUwOTc_3810514f-d73b-40f2-9d6f-81613b9911a9"
      unitRef="usd">447727000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtMS0xLTEtMTM0NTA1_bd02c2ec-693c-440f-a280-9132a4336726"
      unitRef="usd">305296000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtMy0xLTEtMTM0NTA1_61c79c93-debc-4632-b4e6-6dc86718b0cf"
      unitRef="usd">436733000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtNS0xLTEtMTM1MDk3_1c097814-7d0c-4952-bc6c-a23b5f95a01f"
      unitRef="usd">352740000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yNS9mcmFnOjJmZmZkMDEyZGJkYjRiY2E4NjhmYjU2OTAwOGM5NmJiL3RhYmxlOmNmZjM3YjkwOGI0OTQ4NmY5ZTJjYzJhYmQxNmM4NjlkL3RhYmxlcmFuZ2U6Y2ZmMzdiOTA4YjQ5NDg2ZjllMmNjMmFiZDE2Yzg2OWRfMTAtNy0xLTEtMTM1MDk3_5a30d5cd-8734-4e92-a95e-972962f4dcec"
      unitRef="usd">500367000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibc41c410425b42d7abcdade3c8154e0c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xLTEtMS0xMzQ1MDU_1d217ea9-c2cc-4640-b8b2-423b7fadd2fe"
      unitRef="shares">435316000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc41c410425b42d7abcdade3c8154e0c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0yLTEtMS0xMzQ1MDU_3f3519c2-dd9d-4f19-8ec9-fcd5bec6a24d"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i43f91e61c3dd491c96060d2cd0475caa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0zLTEtMS0xMzQ1MDU_a2a8eefe-a6e5-43ae-9272-af0154135c35"
      unitRef="shares">171862000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43f91e61c3dd491c96060d2cd0475caa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi00LTEtMS0xMzQ1MDU_e2acdd60-2197-4489-834c-ac8028d2d06b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i24af4b775fdd421ca76221754d6cc72b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi01LTEtMS0xMzQ1MDU_18df262b-f49c-412f-8d4f-62735756be5f"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24af4b775fdd421ca76221754d6cc72b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi02LTEtMS0xMzQ1MDU_7e132cb0-6d3e-472a-a572-339879a9e7db"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi03LTEtMS0xMzQ1MDU_05641e53-f332-4998-930a-092768b4e075"
      unitRef="shares">363521000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0707ca76e3664880bb1cb07e4e38c3a3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi04LTEtMS0xMzQ1MDU_ced48435-eb50-4687-915c-3a787d9c2eed"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie033c0ebfe694b18a9324c6432dfa2cb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi05LTEtMS0xMzQ1MDU_14437f87-d832-45e8-8feb-3210c76c6b06"
      unitRef="usd">3543204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3131abfb53a454494b73f6ebe89c392_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMC0xLTEtMTM0NTA1_8256dca7-7f84-4658-b55d-3f0175464ff4"
      unitRef="usd">2224677000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb23fabb1e14fb78211172951d31a08_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMS0xLTEtMTM0NTA1_ce2e0d19-7d60-4266-b54b-7c58f158e38a"
      unitRef="usd">12304000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMi0xLTEtMTM0NTA1_91408530-0463-48f5-9970-72384eb904c6"
      unitRef="usd">4364324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if45953d0a97b4ab4a331eebb7376a3cc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xMy0xLTEtMTM0NTA1_0bc56999-4624-4a86-a618-49eee77eba5a"
      unitRef="usd">-2736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a1f6430e214497599d013c1c8969e8d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMi0xNC0xLTEtMTM0NTA1_493b857e-1958-4c01-ba6e-5a5ce46b3a18"
      unitRef="usd">10141879000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMy0xMi0xLTEtMTM0NTA1_a4c2eaa5-7bfc-47f7-8d80-f718b119793b"
      unitRef="usd">2881000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMy0xNC0xLTEtMTM0NTA1_e0cf8042-0939-4bb1-bd89-fa6e724dcb07"
      unitRef="usd">2881000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNC0xMi0xLTEtMTM0NTA1_d217e1ee-22d3-41ad-b97e-63d1ab7a0b2a"
      unitRef="usd">146967000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNC0xNC0xLTEtMTM0NTA1_40a0f472-d536-4c1e-b97d-23fb7bb44125"
      unitRef="usd">146967000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i22fe98e0e7a94704ac3fdfff181f9502_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0NTZiZDFjNjQ3ZDM0YmZlOTZhNDk4NmNlZDZjNDQ2OF8xNQ_01800b65-b1a2-4112-97bd-b2aae6e15082"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0xMC0xLTEtMTM0NTA1_06366f90-4eee-4c17-b12a-a59ad45a48c8"
      unitRef="usd">83049000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNS0xNC0xLTEtMTM0NTA1_b8334441-caef-479d-b189-4a3ab7b86f1f"
      unitRef="usd">83049000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xLTEtMS0xMzQ1MDU_47190b0d-1d2e-4343-8257-3ef5d6b30247"
      unitRef="shares">1781000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0yLTEtMS0xMzQ1MDU_28510bd2-ed85-4269-8241-0e2080a48cac"
      unitRef="usd">-1000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i5339fc8ea38b46fa9a86916bc074eca4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0zLTEtMS0xMzQ1MDU_cbeff7f7-67b4-4364-8881-b68fc4a2942a"
      unitRef="shares">-1781000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i2527d56cd62046479c1173dcb0b0f5b2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi03LTEtMS0xMzQ1MDU_2eec1137-2fd4-4c6a-b50a-13f882c2a2ee"
      unitRef="shares">1781000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi05LTEtMS0xMzQ1MDU_adcaedfd-7686-47c0-96f5-efb187402cca"
      unitRef="usd">-26872000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMS0xLTEtMTM0NTA1_8d6b606d-13a6-46ab-be49-053870a207ba"
      unitRef="usd">-81000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMi0xLTEtMTM0NTA1_6ae741c0-c6a1-4b62-b021-38251c997296"
      unitRef="usd">26938000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iefecccbe9aeb4eda97cf4d50e61ebc9d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xMy0xLTEtMTM0NTA1_d235fa41-378f-4d31-8fbe-bfe20f22445a"
      unitRef="usd">16000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNi0xNC0xLTEtMTM0NTA1_4ee4f79c-73f6-4180-b868-281dcb5037c8"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icdbad66dbd0d470e89e5c1a99c96499e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy0xLTEtMS0xMzQ1MDU_f9139fb5-5280-4aae-bbb0-09a7273586e8"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8058b3c86841410bb524bf14e4d59d09_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy05LTEtMS0xMzQ1MDU_fe27e73b-06e0-45c0-be72-1fb888f87ce4"
      unitRef="usd">509000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfNy0xNC0xLTEtMTM0NTA1_25b6c798-ac70-4bed-a949-1b4215f5fc45"
      unitRef="usd">509000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="ifa66d749c3cc43adbc34114e56e6a86e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xMC0xLTEtMTM0NTA1_8ef405c9-4517-4962-8ea7-4f35f9c15500"
      unitRef="usd">304504000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xMi0xLTEtMTM0NTA1_a091d21e-2f3a-4fd3-9d3c-5b724596bacb"
      unitRef="usd">187093000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfOC0xNC0xLTEtMTM0NTA1_419267c3-20d7-4e27-ad5e-42e38db7f1f6"
      unitRef="usd">491597000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTEtMS0xLTEzNDUwNQ_344570d0-2d84-475d-b451-5e346bd1d5cd"
      unitRef="usd">5523000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTItMS0xLTEzNDUwNQ_2cf2c932-bd5c-4fcd-bdf3-8bf2f50ed5cd"
      unitRef="usd">3802000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTAtMTQtMS0xLTEzNDUwNQ_c9faada9-76ea-4de3-8bd2-8a7ce878348a"
      unitRef="usd">9325000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i02556876a6a14a828978826651a01c40_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTEtMS0xLTEzNDUwNQ_6003ce7b-b6cb-4e9d-9180-260f2127981c"
      unitRef="usd">4731000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTItMS0xLTEzNDUwNQ_437b2d12-6272-437a-95cb-f70d7d6ef4aa"
      unitRef="usd">3257000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTEtMTQtMS0xLTEzNDUwNQ_e6581669-3a4f-4879-834c-bda216e1fa98"
      unitRef="usd">7988000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMS0xLTEtMTM0NTA1_edcd3f1a-eaa9-42e2-b81e-de4a2b864617"
      unitRef="shares">437139000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMi0xLTEtMTM0NTA1_e9720ebc-0962-448e-98ca-0c00af52edf8"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMy0xLTEtMTM0NTA1_e6642fe3-5cd4-4711-9eba-acbf3263647a"
      unitRef="shares">170081000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNC0xLTEtMTM0NTA1_e9f4a252-efa4-41cf-828b-ad6f4b99ed77"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNS0xLTEtMTM0NTA1_6fc0a706-d42c-441f-b74f-03ec741d7d7a"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNi0xLTEtMTM0NTA1_0d1865a8-a610-4b06-a616-cd64a598cf47"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtNy0xLTEtMTM0NTA1_721248db-5dc6-4963-9407-d34aa1e5373b"
      unitRef="shares">365302000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtOC0xLTEtMTM0NTA1_a84d9569-7800-4024-a61f-9c37a1913f26"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtOS0xLTEtMTM0NTA1_b5c5f202-aff7-43c5-ae9d-2c94973a818c"
      unitRef="usd">3570585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTAtMS0xLTEzNDUwNQ_440ff3da-7eee-40a2-a32b-99969d77486e"
      unitRef="usd">2446132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39f7632b52e24947b5542bc50c2d3c30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTEtMS0xLTEzNDUwNQ_6e111fa3-e6c8-41f6-a204-65fc27c1e54a"
      unitRef="usd">13177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTItMS0xLTEzNDUwNQ_5e102793-f890-4af3-bd71-07a78282a6d0"
      unitRef="usd">4380938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTMtMS0xLTEzNDUwNQ_981d6cd1-98ea-42c7-847f-14ae36ee5936"
      unitRef="usd">-2752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjdiZTRhOTgzNDk5MjQyMWE4NmM0MjkyMGY5MmZiNDM3L3RhYmxlcmFuZ2U6N2JlNGE5ODM0OTkyNDIxYTg2YzQyOTIwZjkyZmI0MzdfMTMtMTQtMS0xLTEzNDUwNQ_efb4866c-e476-4c9b-b476-101d0dc12df7"
      unitRef="usd">10408187000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ica342df70a2842ffb246d1630ba9eb5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xLTEtMS0xMzQ1MDU_fec06683-90b6-4816-ba13-90850169cc5d"
      unitRef="shares">392857000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica342df70a2842ffb246d1630ba9eb5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0yLTEtMS0xMzQ1MDU_e7628499-b15b-4330-a75b-28007f0706d9"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i305f1861941e45fbb293aa1942d05488_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0zLTEtMS0xMzQ1MDU_855e3032-2628-4388-b68f-6c47734a29f3"
      unitRef="shares">214255000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i305f1861941e45fbb293aa1942d05488_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi00LTEtMS0xMzQ1MDU_fab1ae5d-0b44-4292-a19b-115eeafa3566"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i622a95bdb08e47f7acf229df1afae29b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi01LTEtMS0xMzQ1MDU_0c90b542-f98f-4918-9d0e-275f66315213"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i622a95bdb08e47f7acf229df1afae29b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi02LTEtMS0xMzQ1MDU_d83dbfeb-41e8-4323-9681-7c9c1ce18978"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia71ca76e55df4684b26c0aa01421d9bd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi03LTEtMS0xMzQ1MDU_949a3c96-8c06-4f7b-b7e1-9652dd07d47e"
      unitRef="shares">321128000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia71ca76e55df4684b26c0aa01421d9bd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi04LTEtMS0xMzQ1MDU_c5b9e113-fdc2-4159-826e-5eed7e40d775"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c89af6243f0463eb180fef51c293c8c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi05LTEtMS0xMzQ1MDU_e1be3d0a-bedd-4475-b465-028fb1a1effc"
      unitRef="usd">2931249000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b43a0bf90e547dbb6fbf1dd47972a2a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMS0xLTEtMTM0NTA1_192cdc17-39be-4c85-bf0d-1931b86ebc14"
      unitRef="usd">1923771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78b916b52b23472ba3549f7931482243_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMi0xLTEtMTM0NTA1_afce0f6f-b348-4434-9a48-e1dedb7f201a"
      unitRef="usd">29452000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iade2ebd58086471fbf60d5e06704e135_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xMy0xLTEtMTM0NTA1_52182079-e61a-42ff-83c4-049e5dd779e3"
      unitRef="usd">4954818000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieff3e647fe0147108d0196b5815a9c6b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xNC0xLTEtMTM0NTA1_00f035db-3bfa-46c5-87ee-c93d13492e3c"
      unitRef="usd">-2359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf1a04cc8cc84280933c35ae3b8d8d94_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMi0xNS0xLTEtMTM0NTA1_07cde7e5-a250-4fe3-8e4c-472469b2fe8f"
      unitRef="usd">9837033000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMy0xMy0xLTEtMTM0NTA1_de60fd35-d9d5-4371-a6d4-5b2aab3245f9"
      unitRef="usd">11519000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMy0xNS0xLTEtMTM0NTA1_7a285c91-0f6e-4a9a-9c44-8590f5d61b1f"
      unitRef="usd">11519000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNC0xMy0xLTEtMTM0NTA1_e59fa629-17a3-460d-ab01-efc653e68fc5"
      unitRef="usd">170808000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNC0xNS0xLTEtMTM0NTA1_4201c32a-6bc2-4ce1-9008-39b6239f0d92"
      unitRef="usd">170808000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iffade55c2b5644739b00e4201220367e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo3YWMwMDRjYzZhM2U0MjcwOGE1MjJlNzAxNThiNzZjNl8xNQ_192a2c64-b031-4a7e-8d25-6f6a585e3b31"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0xMS0xLTEtMTM0NTA1_9cb74076-cb69-484a-88b2-a5e7e68730dd"
      unitRef="usd">72581000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNS0xNS0xLTEtMTM0NTA1_b373554d-9d4d-41fc-85b9-d331215be8df"
      unitRef="usd">72581000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xLTEtMS0xMzQ1MDU_288c5975-609f-47c0-bab8-7c0add18f5b7"
      unitRef="shares">34089000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0yLTEtMS0xMzQ1MDU_53176d41-4732-43d6-b809-34d1ae9d3b02"
      unitRef="usd">-3000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ib2b8266d2b4a41d0a8dab2958a2d956f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0zLTEtMS0xMzQ1MDU_306a704f-acb2-4bfd-b4d0-71e92c0c4f92"
      unitRef="shares">-34089000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i100aaaeaffba486fa3044462ac9475b3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi03LTEtMS0xMzQ1MDU_2afd1182-7af0-49e6-9c95-bf49cbb4500d"
      unitRef="shares">34089000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi05LTEtMS0xMzQ1MDU_1a162b7a-1285-4f2a-8e73-08932eae8ea5"
      unitRef="usd">-483628000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xMi0xLTEtMTM0NTA1_25e1033f-4aa1-4122-8c10-fd6b7db385a1"
      unitRef="usd">-3263000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xMy0xLTEtMTM0NTA1_bc60009d-9d53-419e-9143-a02a118350d3"
      unitRef="usd">486591000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iac2ae29b2c9b4f06af0cf0034f33a3a4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xNC0xLTEtMTM0NTA1_9331c545-f5b7-40c3-ac6c-bc27c6fb2ba1"
      unitRef="usd">303000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNi0xNS0xLTEtMTM0NTA1_b57cedfd-bb95-44d3-a07e-1d00d8b14c3b"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i51499afcfd5e40bb9aab2ca5e2fba7b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy0xLTEtMS0xMzQ1MDU_d2bc46fe-17a7-47d3-9a26-20c8481c3062"
      unitRef="shares">60000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i85d9e3ea3c3f443ea94ada6706be28ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy05LTEtMS0xMzQ1MDU_b8646b84-3170-4807-a471-dac7c06c8875"
      unitRef="usd">721000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfNy0xNS0xLTEtMTM0NTA1_2da2cf03-51d8-462d-a045-2e36aa4d20b2"
      unitRef="usd">721000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i2e40a65386194ec9b8e3f5fe94d28196_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xMS0xLTEtMTM0NTA1_832a028a-d99d-479f-aa6f-ae73a0a39a41"
      unitRef="usd">440776000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xMy0xLTEtMTM0NTA1_fbaf5a6c-de28-497f-9a60-ca4ef5f5ac5f"
      unitRef="usd">365979000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfOC0xNS0xLTEtMTM0NTA1_1d676334-9aa4-4d8e-81fb-6ff2774e227e"
      unitRef="usd">806755000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTItMS0xLTEzNDUwNQ_748d9f4e-67d6-445d-81fd-645882037d3a"
      unitRef="usd">3348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTMtMS0xLTEzNDUwNQ_9bdcb776-4b93-407e-81fa-4c0c3cee8c71"
      unitRef="usd">2677000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTAtMTUtMS0xLTEzNDUwNQ_601f1f7d-4a6f-4886-8ae5-d7f609cd3811"
      unitRef="usd">6025000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i104f5b0ab05b4ec7a8b6797f2b829a18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTItMS0xLTEzNDUwNQ_60153c55-9726-47b4-85e1-2e0bab93ba3d"
      unitRef="usd">7391000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTMtMS0xLTEzNDUwNQ_99d6c953-5c89-4dc8-80e2-2b041ce5b79c"
      unitRef="usd">5908000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTEtMTUtMS0xLTEzNDUwNQ_4f847ef5-920c-4aa1-9d27-a662c3ebae3a"
      unitRef="usd">13299000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMS0xLTEtMTM0NTA1_8b626bcc-a9ea-4c89-aa48-763beaaa3989"
      unitRef="shares">427006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMi0xLTEtMTM0NTA1_cb86424f-f485-4066-bc7a-e5f3c0a1b8aa"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMy0xLTEtMTM0NTA1_9f9f97e2-0d55-4a9c-bbe0-bd9468b477f4"
      unitRef="shares">180166000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNC0xLTEtMTM0NTA1_636123d8-8c1f-4851-8691-73e80a6e9d0d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNS0xLTEtMTM0NTA1_dec1e185-d97b-4e3a-a6fb-4f8a7948c158"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNi0xLTEtMTM0NTA1_bfb7bf32-276c-4d81-b0db-9dacf1607931"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtNy0xLTEtMTM0NTA1_ebcf524a-8152-424e-ad82-322cc8992aa1"
      unitRef="shares">355217000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtOC0xLTEtMTM0NTA1_2e70bf03-87e4-479a-9348-4247650cbba5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i030828ed817644a789470b5495e7c36e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtOS0xLTEtMTM0NTA1_79730bee-1b09-4b60-883d-0c722def9704"
      unitRef="usd">3415598000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i589baf01d5dd4c2caae101de2f597840_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTEtMS0xLTEzNDUwNQ_8093f7ab-9c9e-45ec-93e0-f0d32d11b227"
      unitRef="usd">2291966000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTItMS0xLTEzNDUwNQ_9b17ae62-6f28-4aee-b8ff-97c57f54030f"
      unitRef="usd">28672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTMtMS0xLTEzNDUwNQ_6f6ea74f-3675-4db2-818c-adcca7a8671d"
      unitRef="usd">4671686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTQtMS0xLTEzNDUwNQ_b7fead45-319e-42c8-8fbb-42b4461a0203"
      unitRef="usd">-2662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjY5YmZlNThkMjVjZDRkMGY4Yjg0OTY4NjgxODA5MDc3L3RhYmxlcmFuZ2U6NjliZmU1OGQyNWNkNGQwZjhiODQ5Njg2ODE4MDkwNzdfMTMtMTUtMS0xLTEzNDUwNQ_60ec8c5a-15e2-40b9-af53-cedac1b38566"
      unitRef="usd">10405365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i31d0005fb24b41b7be1fed5796c78265_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xLTEtMS0xMzg4MzY_cebf2e77-77c7-4c8c-9738-308fa5e1a3e9"
      unitRef="shares">432963000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31d0005fb24b41b7be1fed5796c78265_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0yLTEtMS0xMzg4MzY_a3f0a442-92ff-40cb-a3ae-994131ddf838"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0zLTEtMS0xMzg4MzY_5b1811ef-230b-48a2-ac12-7f5b7276bb8e"
      unitRef="shares">174213000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9a4f84d35ae4c69a98036f49a1160cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi00LTEtMS0xMzg4MzY_7b42a723-9719-43be-8d84-15652287e44b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi01LTEtMS0xMzg4MzY_4bc07b16-b8af-4788-bb9e-30a08bfd440a"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if60bcd7e82264b3c8bc4d408e2bee2a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi02LTEtMS0xMzg4MzY_2538def6-9863-4f34-a782-faccbc796cdd"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i5f837639fd8f42d18127b22713c22bff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi03LTEtMS0xMzg4MzY_2d7aa30c-e018-4815-811a-01d7505eb75d"
      unitRef="shares">361170000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f837639fd8f42d18127b22713c22bff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi04LTEtMS0xMzg4MzY_d85e3220-81e7-4558-8f73-3eb713c7bde5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e1903e1e4384e289320f606987686f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi05LTEtMS0xMzg4MzY_5a9a97c5-8836-42e5-ad0f-b5df135a3fc3"
      unitRef="usd">3507533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cb49e5d1da64984b7dab1f207cb821b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMC0xLTEtMTM4ODM2_ba3b5f25-35a9-4ed2-9ca7-c12e20af1e8a"
      unitRef="usd">2255179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48669715cbaa4a4ca2f245e9fb5f1995_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMS0xLTEtMTM4ODM2_249b8686-6d04-4f74-90aa-37f4fd23a028"
      unitRef="usd">16491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMi0xLTEtMTM4ODM2_53e07f68-dcc9-488c-b81f-f9e1018174d8"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i290a4cb4e651436abde84028a4766f89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xMy0xLTEtMTM4ODM2_3e648161-9402-4668-8cac-b8631ba61e28"
      unitRef="usd">-2715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMi0xNC0xLTEtMTM4ODM2_c2fe9e42-f36d-46eb-aeef-a3ef3048ac6e"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMy0xMi0xLTEtMTM4ODM2_0822c4c1-f603-4718-a0f3-3f3fa9751535"
      unitRef="usd">6203000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMy0xNC0xLTEtMTM4ODM2_8b5da761-2564-4681-b15f-f4516d7ccd60"
      unitRef="usd">6203000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNC0xMi0xLTEtMTM4ODM2_ae6aebd0-5230-443f-a554-32ae1dd96f9f"
      unitRef="usd">295942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNC0xNC0xLTEtMTM4ODM2_dbd2c4b9-36d2-42c6-a96a-605b47b1d899"
      unitRef="usd">295942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9e401b08b73c499dbf77eb4e227d5e2f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0wLTEtMS0xMzg4MzYvdGV4dHJlZ2lvbjpkZmU3ODk2MzliMjM0NDI4YWZjNjliNjE3NTg5ZDBmM18xMDk5NTExNjI3ODQx_3614ee78-d82d-4b2b-9ab5-1f83d447c1e3"
      unitRef="usdPerShare">0.38</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0xMC0xLTEtMTM4ODM2_c421ad9a-e487-48ca-bf61-6eb5d93c3c3e"
      unitRef="usd">165312000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNS0xNC0xLTEtMTM4ODM2_dcb72e00-2793-4e8f-966a-15bc482220ba"
      unitRef="usd">165312000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xLTEtMS0xMzg4MzY_54bb6213-1891-48fe-910f-7066c0349d82"
      unitRef="shares">4132000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0yLTEtMS0xMzg4MzY_52042dd7-eb18-4fa4-a65c-2c41da1eb01e"
      unitRef="usd">-1000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="if96dac154fa240898e743b8ff8fc9059_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0zLTEtMS0xMzg4MzY_0e832f9a-350a-40eb-bff4-4fac1822ab98"
      unitRef="shares">-4132000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i05594336aff54167b344569f8bc28d05_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi03LTEtMS0xMzg4MzY_c32ebf5d-9643-416c-a96e-8e1123b890fd"
      unitRef="shares">4132000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi05LTEtMS0xMzg4MzY_9bf996e4-91e0-4726-8333-ca9d0517ebba"
      unitRef="usd">-62047000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMS0xLTEtMTM4ODM2_68bc6241-bd40-4fc4-9359-a2988c5740d3"
      unitRef="usd">-211000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMi0xLTEtMTM4ODM2_4364cc80-d76e-41e9-81f6-1ccb041dd68a"
      unitRef="usd">62222000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0f7f0975039c4b47a8013da696977787_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xMy0xLTEtMTM4ODM2_fe0b01a6-b354-43c3-a406-4b14743f03a0"
      unitRef="usd">37000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNi0xNC0xLTEtMTM4ODM2_6d2ed285-98c5-42a5-8c25-c712bd4d642a"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic0023659a7ba40288c8569bb80e116c0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy0xLTEtMS0xMzg4MzY_44cde20f-b4fa-41da-8c10-d911176df3e6"
      unitRef="shares">44000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0814468d2c2a4f2da313b5a602d7b834_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy05LTEtMS0xMzg4MzY_1832783b-7438-42e3-aa09-b7bfc263d2a6"
      unitRef="usd">1005000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfNy0xNC0xLTEtMTM4ODM2_0f1acd11-004f-47ac-8526-2f47119e9bfd"
      unitRef="usd">1005000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i5496365d7b6e4e1196055624cd123e4f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xMC0xLTEtMTM4ODM2_e00e9ff4-3ad2-482e-bc74-df6d47384b3c"
      unitRef="usd">356265000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xMi0xLTEtMTM4ODM2_2a433aa2-73a3-47f4-8aae-33977542469d"
      unitRef="usd">263415000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfOC0xNC0xLTEtMTM4ODM2_dab6044f-9e71-49f5-8ff6-be1872d53b95"
      unitRef="usd">619680000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTEtMS0xLTEzODgzNg_83d946fe-4ab4-45d1-90fd-93168da0e48c"
      unitRef="usd">6480000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTItMS0xLTEzODgzNg_dba8e2a8-d3e0-4a4e-ae4f-2f89ce87b4d3"
      unitRef="usd">4470000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTAtMTQtMS0xLTEzODgzNg_86fff252-f2e5-485c-97a9-98942dfeeded"
      unitRef="usd">10950000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i509463e2205845eb855c04c67b225ba8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTEtMS0xLTEzODgzNg_6a98bea9-4f5a-4c88-8884-f506156419f8"
      unitRef="usd">10005000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTItMS0xLTEzODgzNg_837ac4d7-223a-46f6-90e6-b12d787663e2"
      unitRef="usd">6937000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTEtMTQtMS0xLTEzODgzNg_d7c92554-36ac-4a3c-9d95-88b65f66a17e"
      unitRef="usd">16942000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMS0xLTEtMTM4ODM2_251f1662-118d-4047-bbdc-ab6a9a0070bd"
      unitRef="shares">437139000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b0a2c2185f841d1bd0ae1256b144310_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMi0xLTEtMTM4ODM2_b787644d-d623-446e-8edb-3b79a3ab99a5"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMy0xLTEtMTM4ODM2_a187e381-62fa-4c22-933a-334da099beef"
      unitRef="shares">170081000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12ebb3a392fb49adaca1a85bc203cbec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNC0xLTEtMTM4ODM2_a6832655-1550-4912-b2af-1144680649ca"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNS0xLTEtMTM4ODM2_234bf0bb-8235-4e5b-b297-202db1e5c376"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i176f226ee22a48e38c48b5d77aff5fe1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNi0xLTEtMTM4ODM2_e7d125fc-00b3-4125-a9f2-22ef208b4b45"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtNy0xLTEtMTM4ODM2_4776f912-4078-40a1-a322-98ecc0511f45"
      unitRef="shares">365302000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtOC0xLTEtMTM4ODM2_3c063624-7864-4355-b14d-68c9e2b3d42f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cccff448cbb4c2e9d0e776fd264e8d0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtOS0xLTEtMTM4ODM2_2cab498c-584d-4606-ba8e-7da72060106d"
      unitRef="usd">3570585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6efddaa2aa04bb083c6c3dbe7e70f08_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTAtMS0xLTEzODgzNg_a29d8433-c19c-4f65-8206-c33a2cbbdee5"
      unitRef="usd">2446132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39f7632b52e24947b5542bc50c2d3c30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTEtMS0xLTEzODgzNg_ec3fbf84-3205-4175-8cbe-a918e9d10cc7"
      unitRef="usd">13177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTItMS0xLTEzODgzNg_c1a06aeb-75a2-44d1-b407-5a3e78d1edd3"
      unitRef="usd">4380938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd28cd313d6c4b209e408dd7e4bb0671_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTMtMS0xLTEzODgzNg_c273293e-89ce-4738-8ca5-e2ddf6a0d3b4"
      unitRef="usd">-2752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjRjZGFjMDFkNDgzODQ3NGVhOGYzMmFmNDE2YjE2Y2Y1L3RhYmxlcmFuZ2U6NGNkYWMwMWQ0ODM4NDc0ZWE4ZjMyYWY0MTZiMTZjZjVfMTMtMTQtMS0xLTEzODgzNg_ebaa5791-3991-4a98-a0b1-91a228e19af4"
      unitRef="usd">10408187000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i74012a9aba134af29fa48477d04dde00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xLTEtMS0xMzU1MzE_588691d0-65ea-4377-8bb1-b9955d14c95b"
      unitRef="shares">388135000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74012a9aba134af29fa48477d04dde00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0yLTEtMS0xMzU1MzE_8f5d4857-e9a3-4f12-8e2c-77e6507aec50"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0zLTEtMS0xMzU1MzE_ebbd8ead-b1f9-4561-98d3-2f804eec9ec5"
      unitRef="shares">218976000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4a9e9d9f37a4504baabcb2b4cce360f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi00LTEtMS0xMzU1MzE_04fe06d1-3511-43d1-9af1-fd778a251b79"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iad1b46dfcb7f40ebb639788c968daf3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi01LTEtMS0xMzU1MzE_2ed6414e-aabf-4c90-8673-5fab861b70cc"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad1b46dfcb7f40ebb639788c968daf3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi02LTEtMS0xMzU1MzE_b263c648-567f-4524-9c33-676065a22948"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ice7b784e492241448627593176cad967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi03LTEtMS0xMzU1MzE_32f68db0-4a12-43ae-a39e-fcd2d26f6c3f"
      unitRef="shares">316407000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice7b784e492241448627593176cad967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi04LTEtMS0xMzU1MzE_3627aa03-7356-4ee1-b363-b86b9de10c77"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i972173b5752144889ef69fee1cfc51dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi05LTEtMS0xMzU1MzE_1b702c35-91a5-4cd1-8f25-0dc132b03296"
      unitRef="usd">2865964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idaf7802275df47c59d3e1f7df579b50e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMS0xLTEtMTM1NTMx_f7dc6957-4548-4c5e-9d6f-a4d17311b2fa"
      unitRef="usd">1920635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i592c6aa1733545c6a94d49a0144e42e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMi0xLTEtMTM1NTMx_c86ee86f-1705-4eb5-be78-020313ed23f3"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb3f673cf22e4af289ea139885dca16b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xMy0xLTEtMTM1NTMx_2fca4618-a725-4cdb-b36e-848361e23dc1"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0b19f0203cf486094b8b552ce743af7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xNC0xLTEtMTM1NTMx_52d9587a-e3ba-430a-bbae-40ce2ff3824e"
      unitRef="usd">-2317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cade76361ba4fcba710604a8c023a58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMi0xNS0xLTEtMTM1NTMx_04692c30-d067-437d-998b-95444fbedcaa"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMy0xMy0xLTEtMTM1NTMx_03015d56-edfb-442f-98cd-0f124796dee7"
      unitRef="usd">14772000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMy0xNS0xLTEtMTM1NTMx_f00f0a3c-730b-4b53-95ea-f26849f392d0"
      unitRef="usd">14772000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xMS0xLTEtMTM1NTMx_d44f09e3-5d13-4876-b4e2-3affdb25517c"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xMy0xLTEtMTM1NTMx_7b1a6ea9-15ad-4bb0-aeca-db646e3a742d"
      unitRef="usd">316186000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfNi0xNS0xLTEtMTM1NTMx_0dc5d17b-ea1f-4909-9e11-b6db10e1f070"
      unitRef="usd">316186000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i35d05a9e48b54e568c0c8b5a3e8ab180_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMC0xLTEtMTM1NTMxL3RleHRyZWdpb246ZmNiZTA5MmNkMWU3NGRjNGI3ZDIyOWQ3NTBjYzcyNDZfMTU_e48dc214-5940-4b5d-bc85-24027ae98808"
      unitRef="usdPerShare">0.34</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMTEtMS0xLTEzNTUzMQ_354350bf-cdab-4397-b30e-e012b0382d07"
      unitRef="usd">138564000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTItMTUtMS0xLTEzNTUzMQ_50f2915d-e487-4ff0-89fa-63cc5db39a69"
      unitRef="usd">138564000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMS0xLTEtMTM1NTMx_06f4963c-0060-48f5-bc15-019a734bc6f8"
      unitRef="shares">38810000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMi0xLTEtMTM1NTMx_3fbb8e3d-3409-4799-a571-b0b006f3d5f3"
      unitRef="usd">-3000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ice8047411077489696941648f5280f81_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMy0xLTEtMTM1NTMx_b4cac470-eddb-4c88-bb5e-1299f88baab7"
      unitRef="shares">-38810000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="iee6a414fd23744eb89554b7564759f43_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtNy0xLTEtMTM1NTMx_f795b64a-b9e4-4e7b-bb90-ca91d1c3f023"
      unitRef="shares">38810000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtOS0xLTEtMTM1NTMx_f47c724b-a233-4343-bfc4-39a62b5c69a5"
      unitRef="usd">-548200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTItMS0xLTEzNTUzMQ_9c7b4b3a-6bee-4165-b72b-eb7d3db7fe3f"
      unitRef="usd">-3805000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTMtMS0xLTEzNTUzMQ_8e27e1c4-c30f-41c6-b389-36afd2613c36"
      unitRef="usd">551663000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8aec56c066c44c0c9505da67fbc972b1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTQtMS0xLTEzNTUzMQ_284b9803-2a55-441f-8dcd-6f5de0f7d7d1"
      unitRef="usd">345000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTMtMTUtMS0xLTEzNTUzMQ_e40116a5-6fdd-4f6d-b285-f1d34b3e6144"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idcd2dd03d41445bfb95ca169752f2b75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtMS0xLTEtMTM1NTMx_7eb01821-3f3d-4bf1-90e5-6b16a4841a42"
      unitRef="shares">61000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic9aa86591b06446f89c9dc8fb04dc275_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtOS0xLTEtMTM1NTMx_900dffc3-3135-4e82-adc5-d2bc7d508f93"
      unitRef="usd">1434000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTQtMTUtMS0xLTEzNTUzMQ_41e137f2-7961-4bc7-81ce-0be3c48f3ace"
      unitRef="usd">1434000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="ib7e73e7584ee4ebe9cdf598f85ac12a8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTEtMS0xLTEzNTUzMQ_4ddb25ec-f194-4fe0-9d36-46053fc083d0"
      unitRef="usd">509895000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTMtMS0xLTEzNTUzMQ_858247d8-e471-4d23-8c11-a3212671dae4"
      unitRef="usd">455839000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTYtMTUtMS0xLTEzNTUzMQ_8babef5c-7a45-4411-b3d0-6bbe1671e336"
      unitRef="usd">965734000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTItMS0xLTEzNTUzMQ_ca6bcc6b-335b-499d-a11a-5553431f2e9e"
      unitRef="usd">6060000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTMtMS0xLTEzNTUzMQ_22366f51-2514-420d-bc49-f050bdde60ee"
      unitRef="usd">5090000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTgtMTUtMS0xLTEzNTUzMQ_17ac338a-fbed-49f7-b81d-3114de33fbd9"
      unitRef="usd">11150000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i3fa7b812f19245e5a1aacf282cfa3497_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTItMS0xLTEzNTUzMQ_eda71da3-e3e1-4a47-b9ca-1361dea71f63"
      unitRef="usd">15588000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTMtMS0xLTEzNTUzMQ_84091417-aa02-4148-8cbf-db815697e290"
      unitRef="usd">13202000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMTktMTUtMS0xLTEzNTUzMQ_7b733a43-b512-4623-aa2d-7560c590d2bd"
      unitRef="usd">28790000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMS0xLTEtMTM1NTMx_ec57398a-feb1-4d91-935a-120d8f0ff37c"
      unitRef="shares">427006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e39280da19945f6afec914c5d523b2b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMi0xLTEtMTM1NTMx_038dfb1b-548d-4b14-a778-b58dc8185ddb"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMy0xLTEtMTM1NTMx_cee8aa3f-6704-4261-ac6a-63d1ecfd0206"
      unitRef="shares">180166000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d7ac128c7c744138c4d180baa58e508_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNC0xLTEtMTM1NTMx_6b8da8df-fa23-4549-b038-8e8a4efe832b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNS0xLTEtMTM1NTMx_1c17bfb5-349c-40d6-81c0-533a25befae9"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic48ab397b18842dea811ef845e7f9159_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNi0xLTEtMTM1NTMx_163bb248-7f90-4f38-a97a-f0bb4788803d"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtNy0xLTEtMTM1NTMx_d98013bd-02d8-49fa-9693-6380df5f4ce8"
      unitRef="shares">355217000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia01bbd10ba674f84ada8d3814ce2b44c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtOC0xLTEtMTM1NTMx_f7bd6c54-3c51-46d6-aad4-4da4fccc9fc2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i030828ed817644a789470b5495e7c36e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtOS0xLTEtMTM1NTMx_802883a8-0107-411a-a2b8-e2a0421f7c2a"
      unitRef="usd">3415598000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i589baf01d5dd4c2caae101de2f597840_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTEtMS0xLTEzNTUzMQ_3674ae55-1bc0-4a89-82b1-d67856874f14"
      unitRef="usd">2291966000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i800f820b55c8400aa5cd8f8be0dbd9e5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTItMS0xLTEzNTUzMQ_c876b173-2e29-4574-98cf-421dad1878c2"
      unitRef="usd">28672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTMtMS0xLTEzNTUzMQ_5a7b1389-6caa-443b-89eb-bb53ac05b01c"
      unitRef="usd">4671686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a570e7f8ec43a0b54aa1b0ae85d3a7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTQtMS0xLTEzNTUzMQ_96016756-50d1-4e6f-8993-aac266551836"
      unitRef="usd">-2662000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8yOC9mcmFnOjM5M2E3ZTcyZGUzMTQ4MmNiNDY2Y2RiYmJlNTJhY2Y4L3RhYmxlOjYzNWQyODg3MzYwNjQyZTlhNThlNmY1MTI1ZWFhYzcyL3RhYmxlcmFuZ2U6NjM1ZDI4ODczNjA2NDJlOWE1OGU2ZjUxMjVlYWFjNzJfMjEtMTUtMS0xLTEzNTUzMQ_c2358b62-829a-4f2a-8562-debae37d207a"
      unitRef="usd">10405365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMy0xLTEtMS0xMzQ1MDU_8bad4510-69e0-49ef-ae2f-536431df9c46"
      unitRef="usd">1181354000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMy0zLTEtMS0xMzQ1MDU_83984bb4-f52e-41da-b2dc-1e495c5e1b23"
      unitRef="usd">1094094000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNC0xLTEtMS0xMzQ1MDU_0f94cdec-36fc-4973-9c47-c57758ae8b71"
      unitRef="usd">71377000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNC0zLTEtMS0xMzQ1MDU_f0af3f05-1099-4b2b-b602-2cc96cb79c39"
      unitRef="usd">75200000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNS0xLTEtMS0xMzQ1MDU_b86fd12b-861c-4330-81d7-d139dffdc2d9"
      unitRef="usd">32716000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNS0zLTEtMS0xMzQ1MDU_9abe3f6e-26a8-4bb3-aab0-39c23013e526"
      unitRef="usd">14088000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNi0xLTEtMS0xMzQ1MDU_fa68a810-587c-41ce-a005-4f249607912e"
      unitRef="usd">27502000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNi0zLTEtMS0xMzQ1MDU_854ea47e-5e3f-45bf-8caa-32cc25264a34"
      unitRef="usd">22003000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNy0xLTEtMS0xMzQ1MDU_049e3786-94b7-445a-8c8c-3e6d1e786bcd"
      unitRef="usd">3262000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNy0zLTEtMS0xMzQ1MDU_8356c856-7f15-471e-864a-8a87571a8308"
      unitRef="usd">2332000</us-gaap:ProceedsFromInterestReceived>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOC0xLTEtMS0xMzQ1MDU_c69c8d08-46b6-477d-837a-25a49a75a9bc"
      unitRef="usd">0</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOC0zLTEtMS0xMzQ1MDU_e8d95e16-256a-4644-bb5c-99b41b2763ab"
      unitRef="usd">11470000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOS0xLTEtMS0xMzQ1MDU_03e2f4d0-12a9-4582-88c2-279bcd1d8b04"
      unitRef="usd">0</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfOS0zLTEtMS0xMzQ1MDU_8effe013-29d8-4c3d-803a-8301a7b9b9de"
      unitRef="usd">9340000</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTEtMS0xLTEtMTM0NTA1_34221826-30d2-4067-bea5-a31df0a6e84a"
      unitRef="usd">1106000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTEtMy0xLTEtMTM0NTA1_58a85c27-96e4-4592-b4f4-258c45fe40ea"
      unitRef="usd">5763000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTItMS0xLTEtMTM0NTA1_ad2440e2-bb54-4a92-a204-8756f2539600"
      unitRef="usd">100000000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTItMy0xLTEtMTM0NTA1_509acf66-4b2d-465f-a42a-ad126bcefe3e"
      unitRef="usd">0</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTMtMS0xLTEtMTM0NTA1_7f2bbb05-790c-481e-9200-0ef802545473"
      unitRef="usd">93003000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTMtMy0xLTEtMTM0NTA1_b6b0f8c3-df77-421f-b58d-af6a4d6651eb"
      unitRef="usd">81764000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <us-gaap:InterestPaidNet
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTUtMS0xLTEtMTM0NTA1_8208144c-7d41-410c-b9bf-e119ca6b524a"
      unitRef="usd">86880000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTUtMy0xLTEtMTM0NTA1_a27d7a6e-0813-424f-9f13-e0a2823b5070"
      unitRef="usd">64500000</us-gaap:InterestPaidNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTYtMS0xLTEtMTM0NTA1_6c3c23c6-7902-418e-a64c-c1787a9f30ce"
      unitRef="usd">1035222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTYtMy0xLTEtMTM0NTA1_6f283401-3f97-4de3-910d-febc677ab2a6"
      unitRef="usd">1057820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTktMS0xLTEtMTM0NTA1_2b4d1707-bcd3-40db-a289-4e8ee1796b63"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMTktMy0xLTEtMTM0NTA1_4544931a-81d4-463f-aaa9-0eae23255295"
      unitRef="usd">523000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjAtMS0xLTEtMTM0NTA1_9617a876-590b-421e-bf2b-66112bbac1c4"
      unitRef="usd">3050000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjAtMy0xLTEtMTM0NTA1_835c8b18-3bf3-4fd2-bf08-21bd5a0e9385"
      unitRef="usd">17427000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjEtMS0xLTEtMTM0NTA1_9aee6330-2d92-45da-961c-03603a31bc69"
      unitRef="usd">62785000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjEtMy0xLTEtMTM0NTA1_a4dd82bd-e95f-4d6c-ba2b-516d31fe7641"
      unitRef="usd">0</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjItMS0xLTEtMTM0NTA1_2a00b831-e723-4151-8012-6216a6569db0"
      unitRef="usd">0</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjItMy0xLTEtMTM0NTA1_386adc0d-f3ef-4f7a-839b-acda3cc01587"
      unitRef="usd">109367000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjMtMS0xLTEtMTM0NTA1_e322f688-63da-491d-8dfe-18cf45f341fb"
      unitRef="usd">79158000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjMtMy0xLTEtMTM0NTA1_9a5a2823-8990-4268-af54-ca3c0a11f504"
      unitRef="usd">35170000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjQtMS0xLTEtMTM0NTA1_4b54d40d-cd7a-4963-b503-36f6fa37017d"
      unitRef="usd">31250000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjQtMy0xLTEtMTM0NTA1_ec2e5ee9-26fa-4fd8-9b7f-4873857b1ced"
      unitRef="usd">31250000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjUtMS0xLTEtMTM0NTA1_62acc1e4-0057-4a96-a8a3-bfc59b405386"
      unitRef="usd">234869000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjUtMy0xLTEtMTM0NTA1_f39100e9-4f59-4413-91f9-7ee5907be44a"
      unitRef="usd">728025000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjYtMS0xLTEtMTM0NTA1_7e65ac77-4cf6-4432-8635-0208e189a154"
      unitRef="usd">525907000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjYtMy0xLTEtMTM0NTA1_873d896a-80ae-4cf1-a45a-e4600d281df8"
      unitRef="usd">868689000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjgtMS0xLTEtMTM0NTA1_36ae6d20-8d53-4394-aefb-a631427e6c4f"
      unitRef="usd">175093000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjgtMy0xLTEtMTM0NTA1_c50eaff8-dd81-4f4b-bd08-408550ee5d6b"
      unitRef="usd">683741000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMS0xLTEtMTQ2MzA3_7b1d5c9c-f8e5-4cad-96b5-c6e3f6e894f4"
      unitRef="usd">21215000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMy0xLTEtMTQ2MzA3_8e947f53-ef2a-44a6-ba74-a66db174589b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <rprx:PaymentsForMilestones
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMS0xLTEtMTM0NTA1_27a7683b-d8f7-46b2-8570-7e74d73c0540"
      unitRef="usd">0</rprx:PaymentsForMilestones>
    <rprx:PaymentsForMilestones
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMjktMy0xLTEtMTM0NTA1_c041b567-4598-478c-ade1-8cdafaa4b45e"
      unitRef="usd">18600000</rprx:PaymentsForMilestones>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzAtMS0xLTEtMTM0NTA1_a3958cb8-4df9-48f1-90d2-6a1025b04ea6"
      unitRef="usd">-19013000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzAtMy0xLTEtMTM0NTA1_75b06f57-ca8f-4331-8ddd-2f6bf48f4882"
      unitRef="usd">-473134000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzQtMS0xLTEtMTM0NTA1_2ca537f4-69ec-442c-a5f8-2b38f9f40799"
      unitRef="usd">215543000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzQtMy0xLTEtMTM0NTA1_ecfe26b5-437f-4a88-be89-6d95e255927f"
      unitRef="usd">238197000</us-gaap:PaymentsToMinorityShareholders>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzUtMS0xLTEtMTM0NTA1_34c8d1c1-d7b5-44e9-9c3f-97e90c2ff6e8"
      unitRef="usd">72343000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzUtMy0xLTEtMTM0NTA1_80791d88-89c5-4f5d-b50e-bb94928813e3"
      unitRef="usd">86978000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzYtMS0xLTEtMTM0NTA1_2ba818ef-3369-4ff5-be9e-7124f5a5fe8b"
      unitRef="usd">165312000</rprx:PaymentOfDividendsToShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzYtMy0xLTEtMTM0NTA1_7cdd23ce-9d60-49be-a5bc-55d7abb66db2"
      unitRef="usd">138564000</rprx:PaymentOfDividendsToShareholders>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzgtMS0xLTEtMTM0NTA1_e378327b-13ea-4fd4-840e-4ba0ec7477f4"
      unitRef="usd">731000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzgtMy0xLTEtMTM0NTA1_7952638f-1dbb-46d5-bc6e-e358875d8e6d"
      unitRef="usd">4080000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzktMS0xLTEtMTM0NTA1_79c1007c-1750-4550-b6c8-62ce6e375176"
      unitRef="usd">3247000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfMzktMy0xLTEtMTM0NTA1_b86ef173-2edb-433c-9a15-8dba68a7ac6b"
      unitRef="usd">8574000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDctMS0xLTEtMTM0NTA1_8dec7306-9d4d-4ea2-8143-2c31be53309b"
      unitRef="usd">-449220000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDctMy0xLTEtMTM0NTA1_54bd46d6-0738-4739-97cf-ce41cf8c2703"
      unitRef="usd">-451085000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDgtMS0xLTEtMTM0NTA1_75d796c9-46fb-4b21-9942-d8f7db87dc90"
      unitRef="usd">566989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDgtMy0xLTEtMTM0NTA1_be7d209f-0d8a-40e5-8062-c934b83538cd"
      unitRef="usd">133601000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDktMS0xLTEtMTM0NTA1_c1a4770e-3fa8-4ac7-aeab-8345af584aa9"
      unitRef="usd">1541048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2cade76361ba4fcba710604a8c023a58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNDktMy0xLTEtMTM0NTA1_3d0eaa65-2bfb-46e8-8b7b-09abb61babc5"
      unitRef="usd">1008680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNTAtMS0xLTEtMTM0NTA1_656208ae-eaae-4e4e-a9eb-bb5145f24587"
      unitRef="usd">2108037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0d5332e18aae41968464d7e40f3879b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8zNC9mcmFnOmFhY2Q1YTJiODUwYjQ5NjRiZDRkMjI2YjIyMTQ0YzQyL3RhYmxlOjcwNzFhMDU0ZTA2OTQ0Yzk5NzA1YWNkNmVmN2UxMTRhL3RhYmxlcmFuZ2U6NzA3MWEwNTRlMDY5NDRjOTk3MDVhY2Q2ZWY3ZTExNGFfNTAtMy0xLTEtMTM0NTA1_e702c11d-7e40-4ad0-b163-f655a4050baf"
      unitRef="usd">1142281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfNDI0NQ_226d8f2e-f2a9-4209-bbba-1f356e97595e">Organization and Purpose &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (&#x201c;IPO&#x201d;) of our Class A ordinary shares. &#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#x2014;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We control Royalty Pharma Holdings Ltd. (&#x201c;RP Holdings&#x201d;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#x2019; Class A ordinary shares and RP Holdings&#x2019; Class B ordinary shares (the &#x201c;RP Holdings Class B Interests&#x201d;). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#x201c;RPI 2019 ICAV&#x201d;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#x201c;Old RPI&#x201d;). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#x201c;Continuing Investors Partnerships&#x201d;) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#x201c;Legacy Investors Partnerships&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RP Management, LLC (the &#x201c;Manager&#x201d;), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#x201c;Management Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer Transactions &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#x201c;Exchange Offer Transactions.&#x201d;&lt;/span&gt;&lt;/div&gt;As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#x201c;RPI Intermediate FT&#x201d;). We are legally entitled to 82% of the economics of Old RPI&#x2019;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#x201c;RPIFT&#x201d;) and RPI Acquisitions (Ireland), Limited (&#x201c;RPI Acquisitions&#x201d;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#x201c;RPCT&#x201d;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#x201c;RPSFT&#x201d;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="ic15dd32149b64228b3e0062543709fcd_D20200211-20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMjg1NA_73388fb1-89f2-4731-84fc-c9c8ca3edd8e"
      unitRef="number">0.82</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMTA5OTUxMTYzMzIzNw_a8a43eeb-43d3-457e-8b6d-8905652b9a29"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i64afaaaa948b4ed98c16d7bcd10f01c7_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMzczNA_0a3add85-207f-402f-9f79-97630a73e1b1"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i8fc135510e2d49c6b0cd406c917f4076_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfMzk1MA_c947bba7-2b48-456d-b42d-9739111bcf52"
      unitRef="number">0.66</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i4664ea2072fe497b9a2bdfd6d8b604dc_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80MC9mcmFnOjI2MTdiNTMzNzU3NDQ0YTlhYmVkNDE3MDc3MGJmZDA0L3RleHRyZWdpb246MjYxN2I1MzM3NTc0NDRhOWFiZWQ0MTcwNzcwYmZkMDRfNDA0MA_f3af57db-d805-4a3c-948f-5788b7dce870"
      unitRef="number">0.34</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU1Mg_881d7af0-f98c-41a5-87e4-e2ffdf36b6a9">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Preparation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships&#x2019; ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships&#x2019; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP&#x2019;s (&#x201c;EPA Holdings&#x201d;) ownership of the RP Holdings&#x2019; Class C ordinary share (the &#x201c;RP Holdings Class C Special Interest&#x201d;). Income will not be allocated to EPA Holdings until certain conditions are met.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp;amp; Johnson, Merck &amp;amp; Co., Pfizer, Astellas, Novartis, and Gilead. As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0Nw_8e238798-c49d-4e18-af51-61d1a7c67188">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0OA_8e89f09a-b97c-4f61-a05c-0be8297757e7">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU0NQ_e432a150-6412-4e6f-b8de-5b9aec93d1c2">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships&#x2019; ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships&#x2019; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP&#x2019;s (&#x201c;EPA Holdings&#x201d;) ownership of the RP Holdings&#x2019; Class C ordinary share (the &#x201c;RP Holdings Class C Special Interest&#x201d;). Income will not be allocated to EPA Holdings until certain conditions are met.  &lt;/span&gt;&lt;/div&gt;All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i3af9b0efe9a24584a5d0beab8491a70b_I20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMjk3OA_ec61dd5b-38cc-4706-abd5-3c72a5ce62ce"
      unitRef="number">0.18</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfNTU1NQ_09f99103-f3b2-408a-b6e0-e8060b744e14">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp;amp; Johnson, Merck &amp;amp; Co., Pfizer, Astellas, Novartis, and Gilead.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i870dbc439abc462d939ae18d7d1c13f2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMTA5OTUxMTYzMzM1OA_93ef3be4-9986-4a9d-817a-0a1e7a3a6c29"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80My9mcmFnOjIyN2UxMmIzOGJhNzQ1Mjg4OWRjNDE1MzMxNWI3M2IwL3RleHRyZWdpb246MjI3ZTEyYjM4YmE3NDUyODg5ZGM0MTUzMzE1YjczYjBfMTA5OTUxMTYzMzM1OA_f33e53da-c5b1-4c9e-84d3-0c7f9775f13d"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzMxNQ_f14a63f6-b7af-42ba-a9b8-26f15c5392eb">Available for Sale Debt Securities &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cytokinetics Commercial Launch Funding&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#x201c;Cytokinetics&#x201d;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (&#x201c;Cytokinetics Commercial Launch Funding&#x201d;) of up to $300&#160;million, which is comprised of five tranches, including an initial tranche of $50&#160;million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#x201c;Cytokinetics Funding Commitments&#x201d;). As of June 30, 2022, we expect $125&#160;million of the $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of June 30, 2022 and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MorphoSys Development Funding Bonds&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#x201c;MorphoSys&#x201d;) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#x201c;Development Funding Bonds&#x201d;) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150&#160;million. Our commitment to fund at least $150&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300&#160;million under the Development Funding Bonds to be funded in September 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of June 30, 2022 and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#x201c;Biohaven&#x201d;) at a price of $50,100 per preferred share for a total of $125&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Biohaven Preferred Shares are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0&#160;million and $16.9&#160;million, respectively, of the unrealized gains were reclassified from other comprehensive income to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3&#160;million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Series B Biohaven Preferred Shares &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#x201c;Series B Biohaven Preferred Share Agreement&#x201d;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#x201c;Commercial Launch Preferred Equity&#x201d;) for a total of $200&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Liabilities (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;269,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;383,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;363,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;383,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt; on the condensed consolidated balance sheet.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <rprx:LongTermFundingPartnershipAmount
      contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzY5NjU4MTQxMTg3MA_cdab2622-049e-40aa-a7b3-a4dfde40ed46"
      unitRef="usd">300000000</rprx:LongTermFundingPartnershipAmount>
    <rprx:LongTermFundingPartnershipNumberOfTranches
      contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5_50201c1e-66d5-4e27-b555-f5655400fdb3"
      unitRef="tranche">5</rprx:LongTermFundingPartnershipNumberOfTranches>
    <rprx:LongTermFundingPartnershipInitialPayment
      contextRef="ib51ffa317e2b426684502864dfacf80c_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDg0_b525793c-c9e1-4aa8-8e8e-1454d3305989"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipInitialPayment>
    <rprx:LongTermFundingPartnershipCovenantRequiredAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTUw_a18ed830-74f0-4f3f-984f-40beb597f9e5"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipCovenantRequiredAmount>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzE0NjgyNTU5ODY0Ng_78532465-18b5-46ee-8d57-88cc10c3ddc1"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:LongTermFundingPartnershipExpectedPayment
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTMxOTQxMzk1NTI4NzM_e39fa64b-4da0-4261-a998-4591acebc955"
      unitRef="usd">125000000</rprx:LongTermFundingPartnershipExpectedPayment>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzY5NjU4MTQxMzE1MQ_78532465-18b5-46ee-8d57-88cc10c3ddc1"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfODk4_76ad7772-c331-47fd-ac3d-70aa34ef0408"
      unitRef="number">1.9</rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital
      contextRef="i902af37f112d47b59465fb1587d35546_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTgzNg_9bd8c49e-e1fe-4628-82f8-138c68bbcd16"
      unitRef="usd">350000000</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjAyOA_f221d9fb-41ed-4a2d-a9c7-6f61043f06ec"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="ia97d19761a80439aaf1c248d0d1cc56e_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjA2NA_c7f77a20-38ae-46c5-8e48-e4ae171302c5"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="if3b647dc49674f03b93aec721c35aafb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjIwMA_cdc5e1a7-62a1-4d00-be05-854d2cf176a0"
      unitRef="number">2.2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn
      contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjI5NA_d9b3cc88-4037-43be-a11c-10ac48733c52">P9Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate
      contextRef="i374debf9f24c4853ab6f7349c8d5408e_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMjMzMQ_a11e6ee7-d0a8-4343-aeee-c9590cc8b6c0">P2Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate>
    <rprx:CollaborativeArrangementExpectedProceeds
      contextRef="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMTI2NDQzODM3NjQzMzg_2ab8b718-f42b-49ba-81a2-e670b47a0a3d"
      unitRef="usd">300000000</rprx:CollaborativeArrangementExpectedProceeds>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="if50973d0a69a4908932e02a923662f68_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTIwOA_0f08881b-dbe8-4966-b5d6-ddba4a892a8b"
      unitRef="shares">2495</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="if50973d0a69a4908932e02a923662f68_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTI3NA_ddcb91bb-98ad-4ecf-8583-2fc6334bbbcd"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icd5c1bcea18e4e42a9671f6beadbf2fa_D20190405-20190405"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTMxMw_b33344e4-75eb-4804-a1e7-c9b2c979822f"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="i01bf1c77beb0485bba6517474b519b3a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNTQ0NQ_764b48b2-924b-4c73-a2de-4673e0f24258"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ic9e38949c6aa4cd6866cb944e9722714_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNjAwNw_fe54b931-4115-42b5-9a2f-b8c75364e429"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <us-gaap:InvestmentIncomeNet
      contextRef="id75ac419666144e9ac3c194e9261e33c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjA0NA_c84c6b53-f5a1-453e-8a66-7e9d4b2d5833"
      unitRef="usd">-8000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="id978345eb4784af985d02a10ba404dc9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjA1NA_51f0cb18-1811-4ba1-a678-cf2609b6573e"
      unitRef="usd">16900000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i578d8f8ce4bc4f43841fb347caa2a50d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjI2OA_e20eb38f-f621-4057-b71b-76990a1bb58d"
      unitRef="usd">13300000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="id49f4fcd2b764a89bc0488726370049d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzg0ODI5MDcxMjI3Nw_ef374e79-3405-4288-9111-b342addc4faf"
      unitRef="usd">28800000</us-gaap:InvestmentIncomeNet>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfMzI4NTA_893ed017-8446-4503-b78e-a5c2c0996a47"
      unitRef="shares">3992</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0Mzk2NQ_0665323c-bbb8-4a27-a70e-2a87686f6eda"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id80cdc181fbc4493af07ef5e4bbf9f14_D20200807-20200807"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0Mzk4Nw_d70ff466-86d3-43c2-8b5c-990aa36e797b"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAwNQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443"
      unitRef="number">1.8</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAxMQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443"
      unitRef="number">1.8</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="i250cdb517dc84c3aab3dd6672c303fa1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjU0NDAxNQ_4292e45a-8d3b-49c7-bd3a-12cab89b0443"
      unitRef="number">1.8</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="ie7a47ace66d74b15afbe0039fd04291d_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNDM5ODA0NjUzNzExOQ_da298403-21d0-465b-8585-0d0397842f9b"
      unitRef="shares">1988</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RleHRyZWdpb246ODI3MWJjYTE5YzYzNGExZjhmODE0OTAwNWFmODA4ZjRfNzMxMw_344ab0b0-3c90-4e68-a04e-bfc7a332e005">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Liabilities (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;269,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;383,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;363,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;383,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt; on the condensed consolidated balance sheet.</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xLTEtMS0xMzQ1MDU_9b7e93fc-d705-42ec-a913-668bfd24d90f"
      unitRef="usd">278759000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0zLTEtMS0xMzQ1MDU_6d191e19-2744-4d40-a57f-8aa6e02e181b"
      unitRef="usd">84241000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi01LTEtMS0xMzQ1MDU_89b9bb15-00c9-4484-91e4-9701c2cf0888"
      unitRef="usd">363000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi03LTEtMS0xMzQ1MDU_66670a38-ea3a-4184-a558-d5fdc336aa3c"
      unitRef="usd">300000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi05LTEtMS0xMzQ1MDU_d22816a9-ebb9-4c08-8b27-67327afd6127"
      unitRef="usd">63000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMS0xLTEtMTUzOTg4_92c587e4-fe94-42e2-8fda-df3ccacc7c49"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMy0xLTEtMTUzOTk1_ebf52313-6cf7-40bc-a530-ae2b8e16f5b7"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9290af25cfb841918df88507b267637a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMi0xMS0xLTEtMTM0NTA1_89d6fe5f-e885-460a-aa76-bc6b4ca008fa"
      unitRef="usd">363000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xLTEtMS0xMzQ1MDU_146046a3-a798-4d46-bbf2-9444ca6c4b03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0zLTEtMS0xMzQ1MDU_1982b645-3784-41bf-979c-73404811ef0c"
      unitRef="usd">28100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy01LTEtMS0xMzQ1MDU_a9604482-dccc-427c-93ab-4341955d5a23"
      unitRef="usd">28100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy03LTEtMS0xMzQ1MDU_443c612e-0c81-4ad5-bcc8-eb2d3ff42037"
      unitRef="usd">63700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy05LTEtMS0xMzQ1MDU_9e90741d-7cdc-4bd1-a037-bacb06d6796a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMS0xLTEtMTUzOTg4_4efffd2a-a843-4ce0-b9ff-2c202bbdf7c3"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMy0xLTEtMTUzOTk1_796c682e-f691-49af-804d-b38ed6be857e"
      unitRef="usd">-35600000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id17b6950f8ed4cd09d0cf04b810c0fbd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMy0xMS0xLTEtMTM0NTA1_49e5a4aa-2689-4e15-807b-ee1517ff9c83"
      unitRef="usd">28100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xLTEtMS0xMzQ1MDU_6a59adb3-05c4-46c6-9e94-ba1ee23b07f9"
      unitRef="usd">-9400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0zLTEtMS0xMzQ1MDU_1c1cdafe-c977-4614-918b-84f961791d16"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC01LTEtMS0xMzQ1MDU_820ddafb-08aa-4281-8eb7-59c25d60c9d0"
      unitRef="usd">-8100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC03LTEtMS0xMzQ1MDU_262f9a6b-2ba7-4458-a2e6-69ea24945839"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC05LTEtMS0xMzQ1MDU_d0c9235c-e683-428f-aa7b-f38ec47c3b8c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMS0xLTEtMTUzOTg4_f956a04c-9c87-4bb9-87d7-f4ed9ab05d3f"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMy0xLTEtMTUzOTk1_d0276414-bbb8-4c82-9c23-fd1f5bba643d"
      unitRef="usd">-8100000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbba88c267644fd3be79fa0c3675c0f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNC0xMS0xLTEtMTM0NTA1_540cb1b8-5ed2-4d0b-ab43-c5563ad1e575"
      unitRef="usd">-8100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xLTEtMS0xMzQ1MDU_ac54d21a-8009-46d3-b9f6-cd45394e2a15"
      unitRef="usd">269359000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0zLTEtMS0xMzQ1MDU_fda22c93-2859-44fd-b54d-319859768239"
      unitRef="usd">113641000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS01LTEtMS0xMzQ1MDU_54c9e5b7-79a0-4ac5-b592-2b5f0fa805f2"
      unitRef="usd">383000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS03LTEtMS0xMzQ1MDU_a0460e5c-c6d2-4c31-9993-0038a9a51877"
      unitRef="usd">363700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS05LTEtMS0xMzQ1MDU_4f889c7b-b8eb-4429-bfd8-015bfff2b875"
      unitRef="usd">63000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMS0xLTEtMTUzOTg4_1b2b8698-6c20-4073-a2dc-38dbeedc8a53"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMy0xLTEtMTUzOTk1_07e081e0-cc3b-488b-a519-4d0e51689d5a"
      unitRef="usd">-43700000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfNS0xMS0xLTEtMTM0NTA1_cd684c1c-064a-45ba-9caf-a99e91f2e9b7"
      unitRef="usd">383000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xLTEtMS0xMzQ1MDU_0cf0b2ad-6e44-46d5-86b9-c737124da78f"
      unitRef="usd">204509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0zLTEtMS0xMzQ1MDU_42157ce6-6094-4325-b80e-4da1d79cbbc3"
      unitRef="usd">49191000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC01LTEtMS0xMzQ1MDU_48db7109-4723-46f8-845e-b689d8451c25"
      unitRef="usd">253700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC03LTEtMS0xMzQ1MDU_4d478b22-008a-434c-b008-0c83c67bc41f"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC05LTEtMS0xMzQ1MDU_75b3d22c-2722-4618-ac82-897e887bc22a"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMS0xLTEtMTUzOTg4_fe76fe67-8917-4312-a525-9727fa4465bc"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMy0xLTEtMTUzOTk1_b73f68fa-3204-4236-a855-43e1cfcdc007"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6700642e5b124bf1a3547c30d346a79b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOC0xMS0xLTEtMTM0NTA1_b731aeb2-96f9-4b61-b14f-5e74be32d701"
      unitRef="usd">253700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xLTEtMS0xMzQ1MDU_5ee2fa34-bd3f-4b9b-8c1a-41cdc9e82bc5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0zLTEtMS0xMzQ1MDU_1141b697-aa60-4673-8615-7dacbe289676"
      unitRef="usd">16700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS01LTEtMS0xMzQ1MDU_3de02466-c221-4c92-b36b-c375892d9c03"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS03LTEtMS0xMzQ1MDU_84cebba0-4398-415e-a1f1-42435acfa806"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS05LTEtMS0xMzQ1MDU_e4558242-e50c-4bd4-bb74-76566edac91b"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMS0xLTEtMTUzOTg4_7d5c7aca-20c0-484b-8cfd-2a4487da67a3"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMy0xLTEtMTUzOTk1_d5401807-4698-4a78-8f2e-ee1fa45f3d15"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65ac760695004feebc1b6b592162d7c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfOS0xMS0xLTEtMTM0NTA1_f9346280-f72f-43c0-b09c-35c1c7579fd3"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMS0xLTEtMTM0NTA1_db6ff97c-9086-422c-b427-979dc679999a"
      unitRef="usd">204509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMy0xLTEtMTM0NTA1_11b6a5cb-2c88-44fe-b168-838336f7652d"
      unitRef="usd">65891000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtNS0xLTEtMTM0NTA1_53c54315-a0a6-4254-a517-f542b1c40d15"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtNy0xLTEtMTM0NTA1_c188e095-0195-4b47-852c-856fd2f3f941"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtOS0xLTEtMTM0NTA1_bf2abef9-734e-4e45-bb1c-5ee6ad08409c"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTEtMS0xLTE1Mzk4OA_0e3645e3-459b-4da6-b782-4ac0e925e58b"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTMtMS0xLTE1Mzk5NQ_73440e7b-1230-4573-bf7c-ced9ea29eddf"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV80Ni9mcmFnOjgyNzFiY2ExOWM2MzRhMWY4ZjgxNDkwMDVhZjgwOGY0L3RhYmxlOmE1Y2JlNjIxOGJhMDRhMGFhZGVlNDE2MDI1ZmY2NjMwL3RhYmxlcmFuZ2U6YTVjYmU2MjE4YmEwNGEwYWFkZWU0MTYwMjVmZjY2MzBfMTAtMTEtMS0xLTEzNDUwNQ_3a2de279-31c7-47e0-9aec-e18f28e3eec5"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzk_42151bc3-7eb4-4f95-8f11-eeee520e929d">. Fair Value Measurements and Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instrument (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;307,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;508,084&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;426,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,242,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instrument (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty at fair value (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;275,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;121,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;397,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Milestone Acceleration Option (defined below) recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet. See Note 8&#x2013;Non-Consolidated Affiliates for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the fair value of the Cytokinetics Funding Commitments as reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2022, we recognized gains of $8.0&#160;million and losses of $28.1&#160;million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $28.3&#160;million and losses of $10.7&#160;million, respectively, on equity securities still held as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including the underlying debt securities, related forwards and funding commitments (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in other comprehensive losses (1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in earnings (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1 (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Redemption of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;363,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;240,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to transfer restriction expiration of BioCryst common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on initial recognition (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in other comprehensive losses (2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in earnings (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1 (5) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Redemption of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;363,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;240,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to transfer restriction expiration of BioCryst common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Inputs for Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;ApiJect Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (&#x201c;ApiJect&#x201d;) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8&#x2013;Non-Consolidated Affiliates for additional discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cytokinetics Commercial Launch Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#x2019;s assumed cost of debt, which would impact Cytokinetics&#x2019; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioCryst Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#x201c;BioCryst&#x201d;), calculated based on the volume-weighted average price of BioCryst&#x2019;s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#x2019;s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MorphoSys Development Funding Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6&#160;million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250&#160;million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (&#x201c;Milestone Acceleration Option&#x201d;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $8.6 million was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the &#x201c;with-and-without&#x201d; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#x2019; consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,254,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,423,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzg_977c70cd-04eb-4d6c-850a-04f9d7df7f4e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0NzY_5418afb4-d716-4dfa-91f5-5b57ef3e614a">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instrument (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;307,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;508,084&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;426,900&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,242,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instrument (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty at fair value (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;275,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;121,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;397,262&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(43,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Milestone Acceleration Option (defined below) recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet. See Note 8&#x2013;Non-Consolidated Affiliates for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the fair value of the Cytokinetics Funding Commitments as reflected within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;June 30, 2022.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i10b1800e67dc44a981720a7b46c2e79d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xLTEtMS0xMzQ1MDU_caaf1a5b-0935-4e68-9cef-58e087494de4"
      unitRef="usd">307797000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0870484004364ecb8b093f2046454b41_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0zLTEtMS0xMzQ1MDU_6f9f3249-e479-4050-a7dd-3feae6d61316"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ide2e274fed7a481fba6833bfbf3cce5f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi01LTEtMS0xMzQ1MDU_c7e5a742-f6a6-42b0-bb60-ef800d2e2459"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c80a2ae1ba645d8abc23c5ce5fd6c3a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi03LTEtMS0xMzQ1MDU_0ef40ba8-5f5c-4b4f-8193-08bea8c9f1ec"
      unitRef="usd">307797000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3505ef986d8e447e9494c8ba914f66d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi05LTEtMS0xMzQ1MDU_b9a89258-2e36-48b4-af2e-0a3fdd1e9687"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iefd435d72f144bbcb6e42e3f0d53768f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xMS0xLTEtMTM0NTA1_e93fdc04-a48a-4f40-b181-9e137d51a439"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3de23eaeb284126b429fb1b2832c3dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xMy0xLTEtMTM0NTA1_6a176349-4e92-4cc7-8bc1-5e62392bf954"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5576abf606bb4661bbc57aac01aa20ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNi0xNS0xLTEtMTM0NTA1_ea599a5a-9869-46d7-b028-bb0694c80173"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8546e9f6e24b4217b84ced51c46b1e0f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xLTEtMS0xMzQ1MDU_30019ae3-87d6-4d51-91d0-dd5c3ee33164"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie6ef74a0dac44216a515c0217153b14a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0zLTEtMS0xMzQ1MDU_d7ff8a32-3783-4222-b918-c1073883f993"
      unitRef="usd">181681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4eb473791033401b851d996ace3fb0d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy01LTEtMS0xMzQ1MDU_26d7a18a-e107-4ec0-bd1e-ea96ddd4eb2a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i08423e6c0ac54c738abebce60150775e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy03LTEtMS0xMzQ1MDU_e0a8b8c1-15f2-44be-b770-8065ac9fc00e"
      unitRef="usd">181681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i694256d7751f443599a66a50b84c5c04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy05LTEtMS0xMzQ1MDU_3a5c7781-073b-4d95-8431-c9dc143301b1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i335547d431054d37aa47757fec28e211_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xMS0xLTEtMTM0NTA1_cad22de9-1516-4d99-aec5-41fee0924274"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7b9d3fdba80d4a0ab2392959204e54f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xMy0xLTEtMTM0NTA1_56e1376d-1d33-4207-87e6-2e5112ca8227"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i274c91a324f74a50b47e0f39cc9a6471_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfNy0xNS0xLTEtMTM0NTA1_21e799d3-1b3f-40a5-9a51-e35083e675fb"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2dcaa33e9c8c454ea8d9ad358405d5c0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xLTEtMS0xMzQ1MDU_22c91557-656c-456b-af03-c0fd013bfae2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib8a0b0bfcc4f426fb9507705a90045ed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0zLTEtMS0xMzQ1MDU_454137c8-4284-4ea1-8b45-ec6f781370e1"
      unitRef="usd">36001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic1e68fb94a79461caa836857c65a594b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC01LTEtMS0xMzQ1MDU_7e58ded8-9070-4785-bee9-b2af5a742f37"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia2ad8d24abf44259b70281a4a03fd5ab_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC03LTEtMS0xMzQ1MDU_b1262f6f-6fa5-4f70-959b-7f93b8b257ad"
      unitRef="usd">36001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74e4ce8bb43f44bd81105b431942f8a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC05LTEtMS0xMzQ1MDU_e7ebca27-4035-443e-bdd1-86ed77d4102c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if5229c7a11d840c385003a2de7d5a560_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xMS0xLTEtMTM0NTA1_6bb8d294-0c73-48a4-b929-ce4d0fe53989"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f0f2a63eea644fc9b8acb08a1096965_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xMy0xLTEtMTM0NTA1_588e13ae-a223-4bcb-88dd-b79bcee34efd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie5a3c10ce0834373af301afc9cb06554_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfOC0xNS0xLTEtMTM0NTA1_b78209d2-b599-4a2d-831e-ff95cd9b7f0a"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ic7f7d2dc311341ed8ab580778cfb7424_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMS0xLTEtMTM0NTA1_3442bb41-79ef-4aca-a528-741a2664ff24"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i40a5bcf20dbe4092b31de7276a1233af_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMy0xLTEtMTM0NTA1_55d1499a-f7cf-4d43-861a-c03412ba720d"
      unitRef="usd">87622000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i164534f9debb47d283bba03bb38b42a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItNS0xLTEtMTM0NTA1_6cee224b-1ac5-4cbc-8d57-6b1601e97f50"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i3724a5f5971340ee9b2c75df324f183e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItNy0xLTEtMTM0NTA1_e481c7c8-89b0-4fc3-8568-005feeacb333"
      unitRef="usd">87622000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i7de1f8630b5044af9d51c4a863878a19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItOS0xLTEtMTM0NTA1_f2987b21-2a1d-4bd7-b1b2-490fd56c4c95"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i3ae65db56ba049b8b7016f1d57247db5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTEtMS0xLTEzNDUwNQ_ae4d4af9-e1ef-498c-a95b-c24598a2f0a8"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i9ca01372241f4621b26e3c24a6b0ac4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTMtMS0xLTEzNDUwNQ_06b366c6-fdd0-4fce-b552-b7b35830c233"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i8847225dbd934083a96c5b022eb001dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTItMTUtMS0xLTEzNDUwNQ_708bd7ea-cc04-49a8-a82e-f0c95a704f3a"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ic4faebbed44242b588fd22db4532d6a2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMS0xLTEtMTM0NTA1_afdfa9e9-6c5f-4bc7-be8d-593e19478bdf"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i47e2f72945114b8e97557817665eb22a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMy0xLTEtMTM0NTA1_1497fd96-c93a-4f3a-9eb1-4d9842523fbc"
      unitRef="usd">178766000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ide527eedf0c8430ebdd7f8b7e178695d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtNS0xLTEtMTM0NTA1_901f7aeb-c84e-44a6-8626-6df088ee3b04"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i6d54454653d14877997e8cc8a446a36b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtNy0xLTEtMTM0NTA1_e27e0a5e-ec7e-48d8-930f-4189ad6de477"
      unitRef="usd">178766000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i9240e834904c4b7980784391c35ae5d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtOS0xLTEtMTM0NTA1_85edc5cb-bda1-49cf-ac35-0b0f8e1aedbf"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i057686b000924406a6e92a555bcefbe8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTEtMS0xLTEzNDUwNQ_e62d6c56-94dd-4474-95d3-24fd75208375"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i6562ec75eae34ba19dcb404ea71fccac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTMtMS0xLTEzNDUwNQ_b8322781-9333-43c8-a0d3-e074f59694d2"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i6c7cf57e9bdd49e3a5aab2cd19221140_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTMtMTUtMS0xLTEzNDUwNQ_fa1aff1a-28de-4eb0-99cb-a420ec43b15a"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i3b4c1ac3b3004925ba20d1eb0829987d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMS0xLTEtMTM0NTA1_e85f8019-c092-4b49-aa6b-14f680cf002d"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i37a847973ce446648b13fdedff22c715_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMy0xLTEtMTM0NTA1_f9828efb-193f-4bad-aa6d-dbea770b33bc"
      unitRef="usd">24014000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ia78911c3736d495e8cb2fa5ea8e81e2e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtNS0xLTEtMTM0NTA1_161ddbca-3a83-4585-825f-e9051b627a06"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i4c70858e246f4c259aa4add3106bb74c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtNy0xLTEtMTM0NTA1_7e39ae71-1d5e-4038-b56c-43e9199126d4"
      unitRef="usd">24014000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i42664d0a6f0744bc8d3dc6057491af00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtOS0xLTEtMTM0NTA1_3b39ad25-6c6d-4d54-bcae-07672dbcacaa"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i11d0d65a59844aa3bee4beb15d323337_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTEtMS0xLTEzNDUwNQ_512b43af-2809-4daa-aa17-ce26e54d93e3"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i1e5608ca68f141c5ab7e851371cbc63c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTMtMS0xLTEzNDUwNQ_a2f4f84f-6855-464b-9543-e24997fbfe38"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i3099777568874b56a4d873cc01719626_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTQtMTUtMS0xLTEzNDUwNQ_a2513892-9e9c-4b67-9ac0-e09640db28fb"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab2e747c9c9b43f69707587cc843a451_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMS0xLTEtMTM0NTA1_3e7de4e5-8ee3-4e66-9291-d5b69828d1dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i872d2b73bb3b4a8da6deb68b730f21af_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMy0xLTEtMTM0NTA1_3d0e3725-8277-4931-9008-f04fdac76e8e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i306cb19b43b645968b07140915241260_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtNS0xLTEtMTM0NTA1_aae88864-2384-4a24-8f85-78e035755b72"
      unitRef="usd">300000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtNy0xLTEtMTM0NTA1_55f314f0-422d-4c1c-a971-16ffb8711157"
      unitRef="usd">300000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if290e213185d45f3b68d456d7bba18b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtOS0xLTEtMTM0NTA1_d3d6487e-2e79-4d36-89db-97a9a7321193"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i354de3a504f7447f946701a70bbbdd32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTEtMS0xLTEzNDUwNQ_2fe7e640-6d77-4e27-9d6c-d187f383c20d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i67a185b6e27d445c892d2b91c0a23d94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTMtMS0xLTEzNDUwNQ_966d6e26-5575-4e80-baf6-0521f45ea019"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTYtMTUtMS0xLTEzNDUwNQ_3ef8c3f9-b8ba-4cae-b441-cc7dd179907c"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMS0xLTEtMTU0NDgw_14297aec-50c8-4c4e-962e-d615f13f65b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id24d238620954975bfcdbdd367836c85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMy0xLTEtMTU0NDgw_6681bea8-f2d8-444a-aef9-ed8b27c74b5b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id366640cb83544df99f3ad8a3131c185_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctNS0xLTEtMTU0NDgw_feee0471-5332-4041-b3d1-a311179f97f6"
      unitRef="usd">63700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctNy0xLTEtMTU0NDgw_f1f6495b-9cb6-4593-bfb8-652cd3890cde"
      unitRef="usd">63700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97aa147f94524d7496766953b7a86882_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctOS0xLTEtMTU0NDg4_65aa24f9-b51e-45fc-949f-d9da8eafd92e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTEtMS0xLTE1NDQ4OA_294eaf4f-1ae7-4b25-b15c-cfa748ed0ba2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTMtMS0xLTE1NDQ4OA_b2a462fb-2c42-4b20-aba9-9417e48a856e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTctMTUtMS0xLTE1NDQ4OA_a718f964-7cf4-416f-abd8-3b6ed7524660"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMS0xLTEtMTU0NDgw_ab459557-ec1a-4450-96a8-cfe423bf91be"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMy0xLTEtMTU0NDgw_d8a27a5d-6246-4cb0-a2ae-9c21bf48950d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNS0xLTEtMTU0NDgw_d10f61af-f646-4857-a083-f2525ca6c8b7"
      unitRef="usd">63200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNy0xLTEtMTU0NDgw_edb3bca6-0fef-4333-abb8-7e1a21e21ec7"
      unitRef="usd">63200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtOS0xLTEtMTU0NDg4_f996a06f-b37b-41bd-aad1-3497eaf8f151"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTEtMS0xLTE1NDQ4OA_e552b3f5-4a83-4584-b172-4ec897086814"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTMtMS0xLTE1NDQ4OA_7126b3aa-72af-4aa0-85ee-c50019ca3680"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTUtMS0xLTE1NDQ4OA_f579bc23-f91c-4528-b448-9ae0a30935c7"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMS0xLTEtMTM0NTA1_202f0191-6ebd-494b-9cfc-89ff927c4797"
      unitRef="usd">307797000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMy0xLTEtMTM0NTA1_37d6e99c-421e-4076-a2eb-0567798494f2"
      unitRef="usd">508084000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNS0xLTEtMTM0NTA1_dc4a72a6-27e0-4434-9a6b-cda8ed9f966e"
      unitRef="usd">426900000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtNy0xLTEtMTM0NTA1_89d035e7-8072-4360-bd73-15a167f53595"
      unitRef="usd">1242781000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtOS0xLTEtMTM0NTA1_6b01815a-b455-4a1c-9e37-4cda4f0f8f0f"
      unitRef="usd">598253000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTEtMS0xLTEzNDUwNQ_393420af-8681-4880-b8ad-b46b0b732231"
      unitRef="usd">636823000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTMtMS0xLTEzNDUwNQ_b6da07e6-0117-4405-80a5-e292febcf389"
      unitRef="usd">66000000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMTgtMTUtMS0xLTEzNDUwNQ_7dac3afe-8901-489d-a52c-dce48efb867b"
      unitRef="usd">1301076000</rprx:AssetsFairValueDisclosureCurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMS0xLTEtMTM0NTA1_8ed12804-b81c-4353-bc3f-46143b90a399"
      unitRef="usd">275662000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMy0xLTEtMTM0NTA1_1e358b6a-5e83-4f3a-bfe6-547dbf59e26d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtNS0xLTEtMTM0NTA1_776e2f76-e858-4388-bc32-f325825d04c3"
      unitRef="usd">28785000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtNy0xLTEtMTM0NTA1_968a680c-85a0-4b99-9992-1b92948f7cbe"
      unitRef="usd">304447000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtOS0xLTEtMTM0NTA1_b37f1403-95ca-4966-b94c-567d8b3e1b07"
      unitRef="usd">226787000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTEtMS0xLTEzNDUwNQ_f31cf5f1-867b-41d1-95ab-4084adf5cc63"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTMtMS0xLTEzNDUwNQ_fad00ecd-d5f4-43a9-a305-1f1dcb5eaf1b"
      unitRef="usd">43013000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjAtMTUtMS0xLTEzNDUwNQ_5236fc5d-2f9c-450f-943e-cde6ede6cbc2"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iab2e747c9c9b43f69707587cc843a451_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMS0xLTEtMTM0NTA1_65575166-06ab-435f-b3f1-28103233dca8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i872d2b73bb3b4a8da6deb68b730f21af_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMy0xLTEtMTM0NTA1_6d94fc91-ef55-4926-bd11-7793c55a1660"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i306cb19b43b645968b07140915241260_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItNS0xLTEtMTM0NTA1_9d0b46d3-abe7-4271-a799-df585dd67756"
      unitRef="usd">63000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9fbe4ba4546c48a5865f62bc2438caa1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItNy0xLTEtMTM0NTA1_a32300d4-b4c6-4724-b48c-299a02af56f7"
      unitRef="usd">63000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if290e213185d45f3b68d456d7bba18b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItOS0xLTEtMTM0NTA1_0fc15260-ad13-4833-9dd2-4c790a924a11"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i354de3a504f7447f946701a70bbbdd32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTEtMS0xLTEzNDUwNQ_8ff15ad7-c01d-41fa-b476-8cdd877c8499"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i67a185b6e27d445c892d2b91c0a23d94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTMtMS0xLTEzNDUwNQ_4ea83734-93fe-4478-87c3-908741e9d9ba"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0b03ce4a4ea24ef091e0d2d54c7ad4c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjItMTUtMS0xLTEzNDUwNQ_f5a73cb0-3428-48d7-a01b-8db53ed3afd9"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMS0xLTEtMTM0NTA1_3291518f-5665-4a5c-a98b-b98ad09e95c0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id24d238620954975bfcdbdd367836c85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMy0xLTEtMTM0NTA1_51a853bf-7765-4d2c-a476-ed2e5e11762c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id366640cb83544df99f3ad8a3131c185_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtNS0xLTEtMTM0NTA1_549fd8ad-36d6-4f0c-bba5-80a9a1fb3f54"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtNy0xLTEtMTM0NTA1_d6c56535-9616-43b5-8bb3-35651f51e58b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i97aa147f94524d7496766953b7a86882_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtOS0xLTEtMTM0NTA1_b4be7934-2938-447c-af81-8a1805550c19"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTEtMS0xLTEzNDUwNQ_c8dcf46f-9e5f-4301-8cd0-3f1eca339de2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTMtMS0xLTEzNDUwNQ_c152b70e-5634-49b2-8d18-6af58ef4f7fa"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjMtMTUtMS0xLTEzNDUwNQ_37cf8a87-5181-4440-bfa3-4af4e28e5c0e"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMS0xLTEtMTU3OTk1_b799905d-41ee-43ff-b9ab-85aa1b288dd6"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMy0xLTEtMTU3OTk1_1aaf4d5b-f4ed-4ef0-8473-d2b161eaf0a9"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNS0xLTEtMTU3OTk1_57eb65ff-90a9-4f94-b212-5cb7db09a95f"
      unitRef="usd">8600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNy0xLTEtMTU3OTk1_fad4b5be-5549-4956-aa2f-ea5a9042ac0b"
      unitRef="usd">8600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctOS0xLTEtMTU4MDAy_40c9eddc-3c78-40d7-9cac-d0d1a41b8a0f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTEtMS0xLTE1ODAwMg_50a99d4c-bdd4-409e-8d98-b27c748cf200"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTMtMS0xLTE1ODAwMg_861e2422-1569-4094-b2a3-522c3e3d2e46"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTUtMS0xLTE1ODAwMg_378ae19e-8c47-4f82-906a-47b64dfc54cd"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9cfe1cd3f4e7415991895ae425a914d6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMS0xLTEtMTM0NTA1_2e509cae-e3e4-4af5-882f-5bff986bcdfc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i316c6f99df2b4a26ba23e4e48f5c3abd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMy0xLTEtMTM0NTA1_05350ca5-1edb-400d-a080-f68ce8f2fc3d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9792ea77bdea40d1ae7f65287f922717_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtNS0xLTEtMTM0NTA1_bbecd2c2-536c-4c13-a50c-baa16279657b"
      unitRef="usd">21215000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i333a9ec1ff53481696d2280a621e9863_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtNy0xLTEtMTM0NTA1_0958b0ca-8219-42b0-a6f8-3a8cd1120354"
      unitRef="usd">21215000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9f25260f20c04074b3fc492d72c935ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtOS0xLTEtMTM0NTA1_03f82f27-699f-4299-881a-fe6cb4bc43c8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4694ad59207646ac874c75e17fd2b37b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTEtMS0xLTEzNDUwNQ_e3e02857-bac4-44c2-a6a2-2caab8d7da70"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if69f87b5bc8e4ea1a497545b599999bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTMtMS0xLTEzNDUwNQ_1a2019dc-e4f7-4610-82bc-a1ef3ce190c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib9455f5d9a104f0e81d0b8107254f72f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjYtMTUtMS0xLTEzNDUwNQ_368caee3-a2ca-4b54-8f31-eec4f1685fae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMS0xLTEtMTM0NTA1_6c919aa4-f302-48fc-8a54-db3e12b425fc"
      unitRef="usd">275662000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMy0xLTEtMTM0NTA1_3c937a2e-da66-4a7e-9816-673b0783fd9e"
      unitRef="usd">0</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNS0xLTEtMTM0NTA1_997fa5c0-f4ab-455b-85ac-8d9b09c6a426"
      unitRef="usd">121600000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctNy0xLTEtMTM0NTA1_146705ce-6778-49f1-8919-324ef8286cf5"
      unitRef="usd">397262000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctOS0xLTEtMTM0NTA1_a861b66d-1325-4afc-b9d8-54647a082716"
      unitRef="usd">226787000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTEtMS0xLTEzNDUwNQ_963a8f58-2a5b-4e47-be02-3b594d14d5f7"
      unitRef="usd">0</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTMtMS0xLTEzNDUwNQ_51b7f310-3c19-4c0c-8384-3c4045c8e8de"
      unitRef="usd">247413000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMjctMTUtMS0xLTEzNDUwNQ_78ad0136-7e61-4a4c-9c2c-db861a77a13a"
      unitRef="usd">474200000</rprx:AssetsFairValueDisclosureNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i48faa4921ca5490ea5d8274518df219c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtMS0xLTEtMTU0NTEx_4cfc44ab-40b4-45de-9fd5-68c4dcade8d1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id24d238620954975bfcdbdd367836c85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtMy0xLTEtMTU0NTEx_e6582985-f3a9-4e8e-8999-846d59805dcd"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id366640cb83544df99f3ad8a3131c185_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtNS0xLTEtMTU0NTEx_6da732e1-adcf-4b88-b8f3-f3250e35918d"
      unitRef="usd">-35600000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibf20ea8448ab403080a8058146fe9940_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzUtNy0xLTEtMTU0NTEx_e71e73b0-9236-4e5f-9ff9-d36817a05be5"
      unitRef="usd">-35600000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i97aa147f94524d7496766953b7a86882_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtOS0xLTEtMTU2Njg1_f9378dd0-6b69-4265-abad-ee9faff11ef2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7560708b5bbb4ac2af0c81fc19a5ffd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTEtMS0xLTE1NjY4NQ_d170702c-5a34-4241-884c-6afec2347b68"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i277c50af3b4f495b8a6eb8bdb7a1d12b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTMtMS0xLTE1NjY4NQ_793f86a0-b43e-4aaa-81c0-cda0a1af3e9a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icdf79eb118c54d6fb2a88b1d9bb92f60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTUtMS0xLTE1NjY4NQ_5b33dbc1-f7b6-406d-9c62-684e75752cf5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i0fce1c2f895246eebae070dfcc9e49e9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMS0xLTEtMTU0NTEx_94cf8153-08ca-409b-8616-b41395bdd735"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i27a38f2819984010b545afc636533f8b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMy0xLTEtMTU0NTEx_421da6f4-7c16-4416-a4cd-55452f10fcbc"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ia5803bf99b3b473cb7589dbc5dab874f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtNS0xLTEtMTU0NTEx_90eb2349-6615-4963-9f51-1e4bb54dae80"
      unitRef="usd">-8100000</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i81b8f5d307bb4b9b990828c40cf681b4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtNy0xLTEtMTU0NTEx_bd9b76c6-0633-43e7-a8c2-2feb18bb81ec"
      unitRef="usd">-8100000</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ibf836c86dd4f40bf98e8953f69ac75fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtOS0xLTEtMTU0NTE4_fc12f7dc-78a2-462f-9adc-df3d83e05c3a"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i5e58c615de2f4b659329480870108ef1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTEtMS0xLTE1NDUxOA_110eebe6-ecba-4aa8-a287-f4f787f04c91"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i83281e2c15c7428f83706175489d6339_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTMtMS0xLTE1NDUxOA_1e97bdbe-912f-4239-9684-ff151e16cd87"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ie57b86b9d1184e09887d985686c79f0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzYtMTUtMS0xLTE1NDUxOA_ead25be1-f741-4884-b7ba-c78db9f16208"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i509709b18bc34c46b002ff7583a3eb02_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMS0xLTEtMTU0NTEx_de5a8594-e367-443c-bc37-33475dd05737"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="if40208096a5d4db6b4b3971989763e71_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMy0xLTEtMTU0NTEx_3ce5a370-d2bb-4c1b-9961-7be2699cbb93"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i0d78244fc88c4181b2440708f971ee96_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctNS0xLTEtMTU0NTEx_894d02ce-5ef8-4912-8c0e-08a257521cc2"
      unitRef="usd">-43700000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i467ecc55a5c146ce9f323a91de3f9cf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctNy0xLTEtMTU0NTEx_2a1470ca-448d-469f-9342-0afdc71b32f2"
      unitRef="usd">-43700000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i3efa9883f6e24af785319eb40fa00bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctOS0xLTEtMTU0NTE4_033fc2b7-c031-4c67-9bf4-a93bfe0c611e"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i557255cd129a42a9a7bb3e235e002c30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTEtMS0xLTE1NDUxOA_d0503ccf-1409-4dca-8440-30cce26d5e46"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i0d47e0f671754f869e7a625979b2f609_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTMtMS0xLTE1NDUxOA_ede317ba-8fb5-45f7-8e99-22168f135a2b"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ie23d4f24f8d04a988e40dbf86515109d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjk4ODZhYTUwOWRkZDQ4NDVhMDk1N2JhZDI5ZjMzMWUzL3RhYmxlcmFuZ2U6OTg4NmFhNTA5ZGRkNDg0NWEwOTU3YmFkMjlmMzMxZTNfMzctMTUtMS0xLTE1NDUxOA_2b890611-514d-4e34-9693-1d041d839edd"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI0Mw_1924d930-b57d-4321-9468-7ec3107ac57f"
      unitRef="usd">8000000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI1Mg_8efb5c4f-5a22-4be9-8300-0cd5a16e6b82"
      unitRef="usd">-28100000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI2MQ_268595f0-de6e-478e-8be1-d70bc1435d14"
      unitRef="usd">28300000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDg5OTI3MA_ac2d664a-2336-48b1-9ad2-51d88eb102eb"
      unitRef="usd">-10700000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0ODE_df372bd9-3f0c-4668-b41e-1a0357f67264">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including the underlying debt securities, related forwards and funding commitments (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in other comprehensive losses (1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in earnings (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1 (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Redemption of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;363,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;240,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to transfer restriction expiration of BioCryst common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on initial recognition (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in other comprehensive losses (2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains included in earnings (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer to Level 1 (5) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Redemption of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;363,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;240,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to transfer restriction expiration of BioCryst common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="icc0ee976221e43ac94bfd0056a40c5bc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xLTEtMS0xMzQ1MDU_78d04caa-60bc-4510-a63f-623d40515e40"
      unitRef="usd">62538000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9140bfbcfc3e413ea3287f2bb5976940_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0zLTEtMS0xMzQ1MDU_334a5b2d-74e1-496c-ae7e-e2b770a85ae3"
      unitRef="usd">314000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie4fabb30765e4fef8c46e1acdc00d9dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi01LTEtMS0xMzQ1MDU_01abab29-d893-4f3e-9067-60fe4f70e6f8"
      unitRef="usd">-1200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iba21e49a07e840aeb4ca72218e5782fe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi03LTEtMS0xMzQ1MDU_4ac6f24d-e5e9-49b7-b066-3585cfefa038"
      unitRef="usd">-8400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0fd0ae0498ad4e29b327a69dfe2286e8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi05LTEtMS0xNTQyNDU_03ae4c04-0baa-4fc5-a22c-13aec12a563a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i35d03139bb3743808afda3b7bddd5bc2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi05LTEtMS0xMzQ1MDU_29b9a250-f628-4ef6-bc11-b553b5d554d4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie35b86bd79ef41a28f7e6d1d00c42f48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xMy0xLTEtMTM0NTA1_a66879f4-eb49-463c-a530-0a0b5c13bbc2"
      unitRef="usd">226800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iac8317e61e1f41c784239c68f2108a60_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMi0xNS0xLTEtMTM0NTA1_9ae7017f-be27-491d-8bca-d7f38f4c7d45"
      unitRef="usd">22400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0xLTEtMS0xMzQ1MDU_c6b9e0b1-ebbc-40ed-9151-da0a51b1744d"
      unitRef="usd">28785000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0zLTEtMS0xMzQ1MDU_ba74b5da-0065-4cef-90b3-d010ee14e966"
      unitRef="usd">14579000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="idc3cce41829e46588da12635d7616283_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy05LTEtMS0xMzQ1MDU_9e4f0705-1c10-4521-ab7b-a2bac7d511f1"
      unitRef="usd">21215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMy0xMy0xLTEtMTM0NTA1_cfa0c690-11a3-4ec3-8858-00a6dd65134f"
      unitRef="usd">17585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNS0xLTEtMS0xMzQ1MDU_dfbcf76a-931c-485d-b0b2-135c0acf8031"
      unitRef="usd">-21846000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i353de01dbec74abcad269b32e3cdb25f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi05LTEtMS0xNTU2Nzc_7406521f-b7a4-4e3f-8a77-c5004a7dd273"
      unitRef="usd">71800000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi0zLTEtMS0xMzQ1MDU_787fc43f-7c17-4aa8-88dd-e60bf48fd2ce"
      unitRef="usd">9325000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNi0xMy0xLTEtMTM0NTA1_7a66c011-55bc-44b5-868c-94fac0847893"
      unitRef="usd">6025000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0zLTEtMS0xMzQ1MDU_3bee7869-579a-4ea2-a3a3-03e0b2c4af3d"
      unitRef="usd">31800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy01LTEtMS0xMzQ1MDU_75bb872b-80d9-458b-85de-29bc6dd5420a"
      unitRef="usd">38221000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ibfa854c1e4c4436a8ea3e2512d5ef979_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy03LTEtMS0xMzQ1MDU_ecd28a31-fe83-450b-967e-8e3e087f4bef"
      unitRef="usd">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0xMy0xLTEtMTM0NTA1_b69a8669-cfd8-4de7-9365-d79b20f38250"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfNy0xNS0xLTEtMTM0NTA1_7b91e413-ac81-46e8-b83e-c487e102ac91"
      unitRef="usd">13515000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0zLTEtMS0xMzQ1MDU_c5cdab8d-c7f2-4483-b73a-43250bd4dc87"
      unitRef="usd">8921000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i32b37d6d10874d538e7d47626ae804b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC01LTEtMS0xMzQ1MDU_9a9c7885-8fa8-4bcc-bda1-f05b951fad75"
      unitRef="usd">-8921000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0xMy0xLTEtMTM0NTA1_aedd764a-9f55-446a-9e4b-939f2e893faf"
      unitRef="usd">5115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i120f52ba4cc3488e8ab938bf50084905_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOC0xNS0xLTEtMTM0NTA1_419e8f62-cc57-4f9d-8faa-38493962c772"
      unitRef="usd">-5115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i59bbdfcdcaa94b2ab8d2b85200034bb2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0xLTEtMS0xMzcyNTk_a175a561-f1f4-430c-a39b-19fc19f74de6"
      unitRef="usd">-40692000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="i7bbec76b9b2e43f8a0b3e5dd96b4a8e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0zLTEtMS0xMzQ1MDU_aeb04367-f362-4bb6-b507-b4a9ddbd8dfa"
      unitRef="usd">-15625000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="i4e834c46bb8f4fbc842eaec9e968c1cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfOS0xMy0xLTEtMTM0NTA1_0fb6f2d4-b217-483b-a117-3b2570b440de"
      unitRef="usd">-15625000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i8c70708fcd054afa8e309da96db8d7d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMS0xLTEtMTM0NTA1_01ea2717-4246-4fe5-9f7a-2d40ec36b440"
      unitRef="usd">28785000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i365769dd85514fa18d6a39ba5d363336_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMy0xLTEtMTM0NTA1_bab84060-5ba1-4afa-b736-06c171577eee"
      unitRef="usd">363000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtNS0xLTEtMTM0NTA1_6d9a0475-0b96-43bd-9394-45f3a3b13bc6"
      unitRef="usd">28100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie06ed27505284260adf0648d3d31568f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtNy0xLTEtMTM0NTA1_6261351d-8e87-4d16-9f16-db96d6dd8d84"
      unitRef="usd">-8100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTItOS0xLTEtMTU0MjQ1_b7a24184-0ade-42e9-a7d7-0973361eb17a"
      unitRef="usd">71800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i68a1621fc32f497988a0e96ba9b1feef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtOS0xLTEtMTM0NTA1_96e1f514-6224-4850-b6a7-8a69d238c654"
      unitRef="usd">21215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6d029a55997348e4a5f520d12893009a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMTMtMS0xLTEzNDUwNQ_c6cc323f-a7dd-43ac-8297-e9ee1afd276d"
      unitRef="usd">240400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2661ba948f9948bf99cd3662bded664b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjEwOTQ1ZTA0YzMzMzRiYWU4ODliMWI4ZTg5NDQ4MzAyL3RhYmxlcmFuZ2U6MTA5NDVlMDRjMzMzNGJhZTg4OWIxYjhlODk0NDgzMDJfMTAtMTUtMS0xLTEzNDUwNQ_f5364520-7be1-43d6-adaa-6d23463d281c"
      unitRef="usd">30800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ib82dc1c2627b4d718f85effdf12e3a8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xLTEtMS0xMzc0NTY_7c45fd03-da6c-4781-91e6-2a09839eb80a"
      unitRef="usd">43013000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i369c65d0b3874042b691cd5c31ea13dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0zLTEtMS0xMzc0NTY_cba5b80b-0894-46f4-8352-97317db19a2f"
      unitRef="usd">253700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ib4925acb858a43cc8cc6487a6f052e4a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi01LTEtMS0xMzc0NTY_230d3ea5-9d58-4d6b-9373-480e0b656f89"
      unitRef="usd">16700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2625fc2cdae04a5a832d2df168c76071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi03LTEtMS0xMzc0NTY_a4d24253-ee83-465c-830f-61bacef7944d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="idf40b5c13abe46518f36da6af058fe32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi05LTEtMS0xNTQyNjk_068dff00-5d75-404c-8f76-4009e436b8a5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1eaac71ae55f4517bcccf4879bb27679_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xMS0xLTEtMTM3NDcz_c90e52f5-23fe-4765-8807-65254f86919e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i3eb1edf8c46140688a4ed0d57e3927b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xNS0xLTEtMTM3NDc1_4b46d4cf-a3d0-4a85-8e58-e340fa9715a8"
      unitRef="usd">214400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia18d1f6254b04c1eaf3b2e9a61f02662_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMi0xNy0xLTEtMTM3NDc1_bbb719ec-70e4-47c6-8164-1c0f3f66d991"
      unitRef="usd">18600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xLTEtMS0xMzc0NTY_2ada3eb4-9a8f-46fd-8d59-b7ef3c694f0b"
      unitRef="usd">28785000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0zLTEtMS0xMzc0NTY_aca7bce3-d193-4d6f-b09d-047ef24e156c"
      unitRef="usd">79158000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i8320a1e985dc497d99e7ee8e4fb2680c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xMS0xLTEtMTM3NDcz_8bc63012-beaa-416b-b961-70f1e061b68d"
      unitRef="usd">21215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMy0xNS0xLTEtMTM3NDc1_5108b7f3-1adf-4c6e-b49c-3be2bf8ef22c"
      unitRef="usd">35170000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNC0zLTEtMS0xMzc0NTY_e46e2086-f032-46cb-9936-5ab7a5cd7ee5"
      unitRef="usd">9400000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition
      contextRef="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNC03LTEtMS0xMzc0NTY_0a16fdcb-3397-4b99-b467-2e6e72014936"
      unitRef="usd">-9400000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNS0xLTEtMS0xMzc0NTY_12f15e37-d81b-410d-b098-eefa63a86cbf"
      unitRef="usd">-2321000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="ibe40e0e708a24e1485c00e06f6c33811_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi05LTEtMS0xNTU2ODg_4e75656e-cd0d-4c39-9b72-46c7b7ccbffd"
      unitRef="usd">71800000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi0zLTEtMS0xMzc0NTY_b0ae9039-f82d-4822-b59d-2470537d2f0a"
      unitRef="usd">10950000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNi0xNS0xLTEtMTM3NDc1_84e570c6-077c-4ad4-87f2-61bb9c189b2f"
      unitRef="usd">11150000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0zLTEtMS0xMzc0NTY_2f485fbd-ecc1-461f-b842-baebf8ca212d"
      unitRef="usd">30200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy01LTEtMS0xMzc0NTY_3aed7439-871a-4b10-8527-79b9fac273c2"
      unitRef="usd">22242000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i2a5f3a9349424112bcde9884c2060da4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy03LTEtMS0xMzc0NTY_cdedd0c0-9d98-47ab-97bb-9b4acbcb77ae"
      unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0xNS0xLTEtMTM3NDc1_02413f0c-1f7a-4274-89c7-6d275bfc3f7a"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfNy0xNy0xLTEtMTM3NDc1_a712cbb6-c309-4a70-b946-7e71f82e994d"
      unitRef="usd">22630000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0zLTEtMS0xMzc0NTY_e2fdf13d-865c-4c74-a172-1dd57940e585"
      unitRef="usd">10842000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i4ea1b6dee7774e34958cf6b990c70789_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC01LTEtMS0xMzc0NTY_f27c3896-3b91-41cc-b20c-b653d8e31f85"
      unitRef="usd">-10842000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0xNS0xLTEtMTM3NDc1_d37bc46c-ac98-4026-9dfe-dc0c0ebb06ba"
      unitRef="usd">10430000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i53285ffaa6084fc5955c4935add7c351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOC0xNy0xLTEtMTM3NDc1_e103ea5e-7d63-4499-abf8-cdfe0ced5054"
      unitRef="usd">-10430000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i7602807328d94e3ea160b1356604c56f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfOS0xLTEtMS0xMzc0NTY_ee130cf9-0f1e-4705-8a51-e42eaea96868"
      unitRef="usd">-40692000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="ib8e796eea5aa445e92d05a2d2685f0ce_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTAtMy0xLTEtMTM3NDU2_c8613d5c-600e-4189-8c02-a308ddc76b24"
      unitRef="usd">-31250000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="i0bf6fc0317b74778bd6b9a326045a0b5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTAtMTUtMS0xLTEzNzQ3NQ_659a3877-2365-4e17-a10e-adb9eab795ff"
      unitRef="usd">-31250000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i8c70708fcd054afa8e309da96db8d7d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMS0xLTEtMTM3NDU2_002f2f7e-882e-4b88-8c3e-0dcaa3aa87f3"
      unitRef="usd">28785000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i365769dd85514fa18d6a39ba5d363336_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMy0xLTEtMTM3NDU2_670442c6-5eaa-45b2-b0ee-75943e99649d"
      unitRef="usd">363000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia08c9f57e5fe42cba1161f75d19bcb88_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtNS0xLTEtMTM3NDU2_b3306a5f-3a27-47ee-9067-b08a17a55cb0"
      unitRef="usd">28100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie06ed27505284260adf0648d3d31568f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtNy0xLTEtMTM3NDU2_89f6d4fd-6ab4-41a7-8cda-1560e7c6cedf"
      unitRef="usd">-8100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ib6aa0f67aa164c49bdef4eb5c60a9cd9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTItOS0xLTEtMTU0MjY5_8432beb3-6222-498b-9c76-79f2a60b1362"
      unitRef="usd">71800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i68a1621fc32f497988a0e96ba9b1feef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTEtMS0xLTEzNzQ3Mw_7b513c1d-fd21-41be-b625-d37e7c46fac0"
      unitRef="usd">21215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6d029a55997348e4a5f520d12893009a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTUtMS0xLTEzNzQ3NQ_b5e4b750-7447-45aa-8df5-dd00685dd745"
      unitRef="usd">240400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2661ba948f9948bf99cd3662bded664b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOjczNWJmZTQ4ZjdkYzRlZTg5NDBiMmM1OTlmYTI1ZWY4L3RhYmxlcmFuZ2U6NzM1YmZlNDhmN2RjNGVlODk0MGIyYzU5OWZhMjVlZjhfMTEtMTctMS0xLTEzNzQ3NQ_d136b8e4-3af1-42f3-80cc-42c8d2d41c24"
      unitRef="usd">30800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2a44308643464db9804f8317e68d3593_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzg0ODI5MDcxNjUyNA_302df34f-36f4-4361-b344-159254539b7c"
      unitRef="number">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2a44308643464db9804f8317e68d3593_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzg0ODI5MDcxNjUyOQ_b62a8123-e827-4726-a2a9-f8528ddca6ee"
      unitRef="number">0.152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i62c078144e5641bebb3f8f5b775cc14f_D20211101-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfNjI1OA_f818197d-24e5-4541-95bf-c19065217e0a"
      unitRef="shares">3846000</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod
      contextRef="ic5b00b1196a842a18ae4bbfc65e35bca_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfNjU0Nw_41337f28-1bab-4439-ba0d-746f7f79f59c">P6M</rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzU3MzQxMjc5NjE4NTU_0543c8cd-b33d-44fb-a47a-b96776b99bc3"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments
      contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfOTQwNw_0ab61c84-bc8c-4d98-b1cb-985314588aee"
      unitRef="usd">15600000</rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments>
    <rprx:DebtSecuritiesAvailableForSaleFixedPayment
      contextRef="i5940ed238dbd4c118100d14a7e5ad7a1_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfOTY0Ng_0d6356ae-445c-4a56-99fd-b76034afbaee"
      unitRef="usd">250000000</rprx:DebtSecuritiesAvailableForSaleFixedPayment>
    <rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital
      contextRef="ie17bdaff0060430085f4d1bc02582625_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTA0MDg_ebaef0c4-41c6-4d2e-9611-cb25f4ab427f"
      unitRef="number">0.137</rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital>
    <rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital
      contextRef="i1dc0e13f8a8149dda55dd457a53e6897_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTA0MTU_b6f94d50-7174-41c3-b4aa-08ad141c589d"
      unitRef="number">0.095</rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49ec77ad5db44776871a0182cf263586_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUzMw_2187986c-ab7c-4e74-b55c-2be20f11c52b"
      unitRef="usd">71800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUxNw_d10f61af-f646-4857-a083-f2525ca6c8b7"
      unitRef="usd">63200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia0ca371d03bd454eb2a2247bfc0ac021_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUyNQ_57eb65ff-90a9-4f94-b212-5cb7db09a95f"
      unitRef="usd">8600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49ec77ad5db44776871a0182cf263586_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMzI5ODUzNDkzOTUzNw_2187986c-ab7c-4e74-b55c-2be20f11c52b"
      unitRef="usd">71800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RleHRyZWdpb246ZjgxMzg2ZDg1NjA3NGM2NmE2YWFlM2I3MmIwZDdkY2RfMTI0Nzc_465f9ce6-c45f-4fb3-b855-ada96b633a39">Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,254,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,423,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i5c8b4208854b4a00a19fae7046aab65c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi0xLTEtMS0xMzQ1MDU_e9b9d671-82f6-4006-8036-fb998f21ea6f"
      unitRef="usd">18254440000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="ib1d52494a67e479ebd68a8c3b8f69060_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi0zLTEtMS0xMzQ1MDU_761c246a-e4e6-4b66-865b-3ce7654c80bd"
      unitRef="usd">13423629000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i5adddf24c7f04202a9c712798093983a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi01LTEtMS0xMzQ1MDU_ec004fde-eb26-42d5-b69a-0e76c536ff2a"
      unitRef="usd">19047183000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="id7caf3f5c79647e18539159493607558_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV81NS9mcmFnOmY4MTM4NmQ4NTYwNzRjNjZhNmFhZTNiNzJiMGQ3ZGNkL3RhYmxlOmY5YjhkMDRjZjAxOTRmNmI5NzM1YmYzZjQyZWRmOTA3L3RhYmxlcmFuZ2U6ZjliOGQwNGNmMDE5NGY2Yjk3MzViZjNmNDJlZGY5MDdfMi03LTEtMS0xMzQ1MDU_b0e0fa64-1f0c-4cf7-91f8-b38632a235e8"
      unitRef="usd">13718245000</rprx:FinancingReceivablesFairValueDisclosure>
    <us-gaap:FinancingReceivablesTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjcyNQ_2a11fa6e-00fb-43b0-b5d9-cb40ec53152a">Financial Royalty Assets&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,347,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,293,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,759,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,759,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,439,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(417,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,022,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,053,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;746,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,824,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,110,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,048,153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,737,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,310,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,062,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjcyNg_b94538ad-c0ea-404c-8979-98dac2a368a9">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,347,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,293,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,759,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,759,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,439,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(417,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,022,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,053,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;746,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,824,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,110,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,048,153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,737,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,310,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,062,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableGross
      contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy00LTEtMS0xMzQ1MDU_75219c8a-ec54-4a21-ae87-3424f348be72"
      unitRef="usd">5347911000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy02LTEtMS0xMzQ1MDU_a0973ad9-4d47-4008-a217-ae5b5fbb959e"
      unitRef="usd">54609000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic40b42e2790c47ef8f7f4808b0958e59_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMy04LTEtMS0xMzQ1MDU_2cae58d8-26a3-4af8-85d4-1f8fc450225d"
      unitRef="usd">5293302000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC00LTEtMS0xMzQ1MDU_8e316cb1-4a17-4fc3-83d1-4a28b048b07e"
      unitRef="usd">1759427000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC02LTEtMS0xMzQ1MDU_9cf41af8-2470-420d-96fe-e1c052791085"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i280cfe154d93462092b3209bd9f8e4b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNC04LTEtMS0xMzQ1MDU_ccd7a554-38b1-4e4b-9c21-42c2071b3bb6"
      unitRef="usd">1759427000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i2861968b06bc49ad84cee28144700724_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS00LTEtMS0xMzQ1MDU_61251ca3-c1ec-4f10-a63c-5ec69f5acc37"
      unitRef="usd">1439443000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i2861968b06bc49ad84cee28144700724_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS02LTEtMS0xMzQ1MDU_52324e8e-6336-4d7c-9c5a-a14d69c922be"
      unitRef="usd">417165000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i2861968b06bc49ad84cee28144700724_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNS04LTEtMS0xMzQ1MDU_a4071429-5f43-4d07-b0b8-51c389a26a74"
      unitRef="usd">1022278000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi00LTEtMS0xMzQ1MDU_80e73025-9c88-4d5b-9b39-6fa1e7aa12b4"
      unitRef="usd">1053621000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi02LTEtMS0xMzQ1MDU_acaf5fca-fe44-4a7e-bdc2-bcb8ad7c6034"
      unitRef="usd">153154000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="id1fbfcb89cbc4602b2230f697892cd1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNi04LTEtMS0xMzQ1MDU_c9002b20-4eb0-43dc-8c1e-1286bad6309f"
      unitRef="usd">900467000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy00LTEtMS0xMzQ1MDU_fea6078e-63a0-404f-b7fd-5849af116086"
      unitRef="usd">876834000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy02LTEtMS0xMzQ1MDU_3814b5b9-d192-4cd0-bed2-76848e4f8d60"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i71394c4b7aa74cf7b14fb9f3db2abca8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfNy04LTEtMS0xMzQ1MDU_5a7778f6-f884-495a-89cf-3cd2286a269c"
      unitRef="usd">876834000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC00LTEtMS0xMzQ1MDU_cd4bb549-43bd-4acf-b798-ac3bf1183ebe"
      unitRef="usd">746524000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC02LTEtMS0xMzQ1MDU_901e6896-eea0-44fa-814f-c94a91c95130"
      unitRef="usd">1992000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOC04LTEtMS0xMzQ1MDU_ef0a272d-e8bd-47bb-ac4d-8442980c8b2d"
      unitRef="usd">744532000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i212af950addc45e6a29921885da2a4e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS00LTEtMS0xMzQ1MDU_cbb1abc7-9bbc-4c65-9381-5985db8c6b5a"
      unitRef="usd">4824393000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i212af950addc45e6a29921885da2a4e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS02LTEtMS0xMzQ1MDU_0928882f-a46e-4600-b61d-18457ad03484"
      unitRef="usd">1110515000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i212af950addc45e6a29921885da2a4e0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfOS04LTEtMS0xMzQ1MDU_9bcea861-83d9-4fad-8efb-f55cc327bb0d"
      unitRef="usd">3713878000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtNC0xLTEtMTM0NTA1_c6f4c1d3-d6d8-483a-98f2-3a695198a518"
      unitRef="usd">16048153000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtNi0xLTEtMTM0NTA1_935a910f-d75d-4cda-9f71-0d7ad8d8fa7a"
      unitRef="usd">1737435000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTAtOC0xLTEtMTM0NTA1_497eb7b3-fd47-4bd2-a76f-c93b98b2ff2e"
      unitRef="usd">14310718000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTEtOC0xLTEtMTM0NTA1_79bf8094-4c24-422b-8ed4-3f6cf30463fd"
      unitRef="usd">247845000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOmNhZGZhZGMzYjRiODRkY2NiMzIyOGZlZTJhNDhjZmY4L3RhYmxlcmFuZ2U6Y2FkZmFkYzNiNGI4NGRjY2IzMjI4ZmVlMmE0OGNmZjhfMTItOC0xLTEtMTM0NTA1_5c332427-71a9-4ff5-8811-6461020cad70"
      unitRef="usd">14062873000</us-gaap:NotesReceivableNet>
    <rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents
      contextRef="i814da027f61b45e4b7e1a8b98de0f86b_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMTUzMQ_5ae7fbdb-9c6f-479f-9ae4-045ee9ea44be"
      unitRef="usd">1300000000</rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents>
    <us-gaap:NotesReceivableGross
      contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy00LTEtMS0xMzQ1MDU_af5b21a2-cb94-4e5e-b3d2-58f3ae22e468"
      unitRef="usd">5335641000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy02LTEtMS0xMzQ1MDU_a6e3e477-ea96-4cdc-8080-665c3eff9488"
      unitRef="usd">48636000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i6c7443092bdb42e9ad69485f1e2c1be7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMy04LTEtMS0xMzQ1MDU_4b1bcd65-d8c5-40c1-a6f3-ef21a5735c6d"
      unitRef="usd">5287005000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i9473a880a5344144a8d65facb9f75109_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC00LTEtMS0xMzQ1MDU_038faadd-c507-4af7-be25-713c9b28f0b7"
      unitRef="usd">1846069000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9473a880a5344144a8d65facb9f75109_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC02LTEtMS0xMzQ1MDU_06409fe8-25e1-478c-8cac-f1b724373e3f"
      unitRef="usd">16617000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9473a880a5344144a8d65facb9f75109_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNC04LTEtMS0xMzQ1MDU_4c1898e8-7411-49e2-8be4-1b3283833a6e"
      unitRef="usd">1829452000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS00LTEtMS0xMzQ1MDU_b8335ea1-5f64-4d30-b967-fff6919d0880"
      unitRef="usd">1438730000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS02LTEtMS0xMzQ1MDU_701b27f3-9a4a-4868-aa0f-3b313c50b13c"
      unitRef="usd">236871000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic724ac857a9d4b1b8d7195d3d0b4790c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNS04LTEtMS0xMzQ1MDU_558cd39e-7aff-4512-a2dd-3e68496105ef"
      unitRef="usd">1201859000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi00LTEtMS0xMzQ1MDU_af226c96-0712-4881-8cd9-a37ca0060094"
      unitRef="usd">1100065000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi02LTEtMS0xMzQ1MDU_9408f105-b571-4d36-b8e1-01fe10e7ae23"
      unitRef="usd">172101000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="if68b0902cea7416f9dd59258eb674bc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNi04LTEtMS0xMzQ1MDU_607bc52f-7641-42ad-8057-4d0890aecca3"
      unitRef="usd">927964000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy00LTEtMS0xMzQ1MDU_0e8cde75-ccd1-4c61-9247-b3d780be7b29"
      unitRef="usd">881671000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy02LTEtMS0xMzQ1MDU_6d7aaac2-55df-4105-9c65-8ff80063d965"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ib719fc62cf904acc863f4c031cfadf8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfNy04LTEtMS0xMzQ1MDU_0e646ee6-a2b6-4819-b439-d295b2edb4d2"
      unitRef="usd">881671000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC00LTEtMS0xMzQ1MDU_afbdd0e9-7d82-443d-982e-b6f45bf6d304"
      unitRef="usd">727774000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC02LTEtMS0xMzQ1MDU_a2ba76ba-7a84-4b24-b4f8-1c55f0679ab3"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOC04LTEtMS0xMzQ1MDU_ba99c2d3-46a3-4d35-b675-0587995744a7"
      unitRef="usd">727774000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS00LTEtMS0xMzQ1MDU_636d978b-b3cb-494e-a384-08ad18187439"
      unitRef="usd">4697591000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS02LTEtMS0xMzQ1MDU_83d9acb3-3a32-498e-85ef-262542d6587f"
      unitRef="usd">909916000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i7c1ce1553bf74d69818557e322f52767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfOS04LTEtMS0xMzQ1MDU_08229189-e0c6-473b-8fc4-8105cb4be281"
      unitRef="usd">3787675000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtNC0xLTEtMTM0NTA1_4ec8b753-fc15-473a-98cd-7ff6381209e5"
      unitRef="usd">16027541000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtNi0xLTEtMTM0NTA1_d6df23cb-7138-46a9-b279-02adc458711e"
      unitRef="usd">1384141000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTAtOC0xLTEtMTM0NTA1_cdce5ca5-4444-4bd4-8a40-751068805f27"
      unitRef="usd">14643400000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTEtOC0xLTEtMTM0NTA1_31ca04b1-fe32-4b4e-8b6a-a502e94020ee"
      unitRef="usd">310804000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RhYmxlOjk0NjdjNmY2NzkyODRkMGRiZTY2ZjdiYWM5OTcxYjY1L3RhYmxlcmFuZ2U6OTQ2N2M2ZjY3OTI4NGQwZGJlNjZmN2JhYzk5NzFiNjVfMTItOC0xLTEtMTM0NTA1_cc4c1a69-44f8-4755-8fad-7c99fc19ed25"
      unitRef="usd">14332596000</us-gaap:NotesReceivableNet>
    <rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents
      contextRef="ic024b43fdc034ed3b81bbcc25f153bbe_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82MS9mcmFnOjVhMGRhMWQ1YTliMTRhYzZhY2M4YmQyOWY3MjdjYjUxL3RleHRyZWdpb246NWEwZGExZDVhOWIxNGFjNmFjYzhiZDI5ZjcyN2NiNTFfMjU5Nw_b36b7eb4-dc9d-40d1-8fcd-5419e6dcd271"
      unitRef="usd">1300000000</rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTM3MQ_dd506a5a-e552-4ad5-9554-842696330f1f">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheets and includes the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#x2019; consensus sales forecasts, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(556,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,985,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes $310.8&#160;million related to cumulative allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTM3Mg_b474b0b0-7c98-4acc-826f-1fb7ee8cc2d9">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(556,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,985,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes $310.8&#160;million related to cumulative allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfMS0xLTEtMS0xMzQ1MDU_68c89a0f-d9df-4a36-b0d6-afd2904c8333"
      unitRef="usd">1694945000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfMy0xLTEtMS0xMzQ1MDU_bb9d3cc7-2931-4083-93a2-8b0bc0ccc752"
      unitRef="usd">556020000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNC0xLTEtMS0xMzQ1MDU_473702cf-5929-4d40-84ac-66e4309c46cc"
      unitRef="usd">202726000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNi0xLTEtMS0xMzQ1MDU_690f7133-2145-44bd-83dd-14decb99285d"
      unitRef="usd">-62959000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RhYmxlOmJiNDZmYjJhMGQzODQzMGI4YzZjZjNlNjc3NWRhMWQ1L3RhYmxlcmFuZ2U6YmI0NmZiMmEwZDM4NDMwYjhjNmNmM2U2Nzc1ZGExZDVfNy0xLTEtMS0xMzQ1MDU_4d7bc90b-1d0f-4ccf-a262-a0e908abd880"
      unitRef="usd">1985280000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82NC9mcmFnOjRhMDgzM2RjMjViNTRkZWNhOTdlZmFhYmU3NGRjNTM5L3RleHRyZWdpb246NGEwODMzZGMyNWI1NGRlY2E5N2VmYWFiZTc0ZGM1MzlfMTE1MQ_00f72ee9-d46e-416c-b305-811cf4414fda"
      unitRef="usd">310800000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTE3NA_7b6fc11e-53dc-4f00-b4e0-9d1002f6fca0">Intangible Royalty Assets, Net&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.&lt;/span&gt;&lt;/div&gt;Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTE3NQ_5c7f1dbf-1fc9-4c2a-8385-969467e0825a">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi0xLTEtMS0xMzQ1MDU_8ad13d25-5dd4-45a7-808e-36a1855f14d2"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi0zLTEtMS0xMzQ1MDU_f0518f47-a1fb-4c67-8d96-9160ad3bf487"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i898a964c879840d78fe00d3bdfc2571f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfMi01LTEtMS0xMzQ1MDU_f35996ce-42d4-435b-8976-7a2e00d2d86d"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC0xLTEtMS0xMzQ1MDU_90c6fba4-131c-4eb4-bbaf-a6c43545697e"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC0zLTEtMS0xMzQ1MDU_cdea0c26-0576-4efb-9261-99186204c99a"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOjBkNzc4NDc4OTVlOTQyZjg5MWVmYjNiYmNjOWRiMGEwL3RhYmxlcmFuZ2U6MGQ3Nzg0Nzg5NWU5NDJmODkxZWZiM2JiY2M5ZGIwYTBfNC01LTEtMS0xMzQ1MDU_d690f8e1-889f-414d-bdb1-03edfff10c35"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi0xLTEtMS0xMzQ1MDU_d07ec405-102d-415d-8f4a-b8d413e58a2e"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi0zLTEtMS0xMzQ1MDU_661899bb-4ebe-41ab-8d89-8b457eb0bf32"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i37a2db27b0cb44d19d4f29da2ddf6c10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfMi01LTEtMS0xMzQ1MDU_00736960-bf9f-4d57-a8ba-f9f51406cc15"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC0xLTEtMS0xMzQ1MDU_a70515a7-ec72-4370-aa61-08ab05783688"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC0zLTEtMS0xMzQ1MDU_3b0ab977-3980-4151-ad7d-1dc4de5112ad"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RhYmxlOmJjNTM2ZTYzMTBlMjRkODE5NDI5OWE5NDg1ZGJkMDNlL3RhYmxlcmFuZ2U6YmM1MzZlNjMxMGUyNGQ4MTk0Mjk5YTk0ODVkYmQwM2VfNC01LTEtMS0xMzQ1MDU_33a730b0-5d87-4edd-84da-eba6a0f5d630"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMTA5MQ_4e61bd4b-1053-4a93-9ac9-abe499791eff"
      unitRef="number">0.90</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i618646a4dc484b23bb5596e4471fb6fe_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMzI5ODUzNDg4NDgxNw_a1c477f2-c52d-47a9-a28b-1e3d50dcf79a"
      unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7a1ee997727d476f941c9f5cb772f235_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV82Ny9mcmFnOjVhZGM3YzNmZjc5YjQyYjJiZjJkZDIwYTY4ZmI5MTM3L3RleHRyZWdpb246NWFkYzdjM2ZmNzliNDJiMmJmMmRkMjBhNjhmYjkxMzdfMzI5ODUzNDg4NDgxMQ_572bf45d-a6da-4710-8281-39bef5c2ce19"
      unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzgxNw_0666193a-d3bd-4fdc-95bb-06653a0b5585">Non-Consolidated Affiliates&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ApiJect&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the fair value of the revenue participation right was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Legacy SLP Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#x201c;Legacy SLP Interest&#x201d;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#x2019;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management&#x2019;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $4.7&#160;million and $9.3&#160;million, respectively, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in earnings of equity method investees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6&#160;million and $30.8&#160;million, respectively, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in earnings of equity method investees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received cash distributions from the Legacy SLP Interest of $6.8&#160;million and $14.1&#160;million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7&#160;million and $8.6&#160;million in the three and six months ended June 30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Avillion Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our partnership interests in Avillion Financing I, LP and its related entities (&#x201c;Avillion I&#x201d;), BAv Financing II, LP and its related entities (&#x201c;Avillion II,&#x201d; together with Avillion I, the &#x201c;Avillion Entities&#x201d;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0&#160;million and $8.2&#160;million, respectively, within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity in earnings of equity method investees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $7.9&#160;million and $15.0&#160;million, respectively, within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity in earnings of equity method investees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#x2019;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million during each of the six months ended June 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $27.5 million, which totaled $150.0&#160;million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7&#160;million and $11.2&#160;million, respectively, of unfunded commitments related to the Avillion Entities.</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i9fb0f3822f7448c3b9edb5542ba8571e_I20200211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNDQy_a0ad8f5d-98d3-4310-a38d-d633b6108bda"
      unitRef="usd">303700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjczMg_a2c2ac07-8e89-4571-af67-53632087151a"
      unitRef="usd">4700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1652d07294b14089a0592537d2026e6f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjcyMw_16ede580-146e-4bef-8c5d-62bedd07227a"
      unitRef="usd">9300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc2MA_6f75b05e-7af5-4f3a-a95f-1de47ec62faa"
      unitRef="usd">25600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i373eee1b26c541e8833b248c7988a139_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc3OA_3d5ea6dc-83de-44c7-9a65-f3033df3c7fa"
      unitRef="usd">30800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i794a094d87bb411097fc5a94bbcdcaba_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc4Ng_45c20585-e8c9-483f-a3ad-05d5f7d07312"
      unitRef="usd">6800000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1652d07294b14089a0592537d2026e6f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjc5MA_6ce016be-c238-4f03-bbc3-a34bdec9fe46"
      unitRef="usd">14100000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i30bb3f2787d6442d81d3bfc5f28b8c52_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjgxMg_634aaad6-d27b-45d1-96e6-3f6b5f1feb41"
      unitRef="usd">4700000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i373eee1b26c541e8833b248c7988a139_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzg0ODI5MDcwMjgzMA_93de74b8-76fc-492c-a52b-e351a2967209"
      unitRef="usd">8600000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ife00a507d4204c9bbdf7447e8c4d1429_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjQ3Mw_9993cbea-b1e6-40bd-bfa4-e8689f002f93"
      unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i84eb422d2b40477e9258c52a15372639_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjQ3Nw_700274dc-e9f4-43e0-aac6-b1e1cb8b24c7"
      unitRef="usd">-8200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i620523eb4a204e25acac2ef3e9967411_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjI5Nw_302f2163-5cd0-422e-8e3e-a5845e78731a"
      unitRef="usd">-7900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1bbd0e73cf3d42dcac55b07236105ba5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfNjU5NzA2OTc3MjMwMg_c5128122-4108-42b7-bd93-471db5145a45"
      unitRef="usd">-15000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i79fa516152564be089415fb655f74d77_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMjk1Mw_0085ee38-76b2-48dd-87c5-fcee8122f3dc"
      unitRef="usd">13400000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i8fef318c94084992aa959a03e78ce32c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMjk1Mw_e8733eed-6971-492d-bd04-988982902174"
      unitRef="usd">13400000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <rprx:OtherCommitmentIncreaseDecrease
      contextRef="i156b8175434d4e1db0d0fd57caa92008_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzI5ODUzNDg5NzAwNQ_b4dacb61-70fa-45b0-930d-c0e966ece60f"
      unitRef="usd">27500000</rprx:OtherCommitmentIncreaseDecrease>
    <us-gaap:OtherCommitment
      contextRef="i156b8175434d4e1db0d0fd57caa92008_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzIwMg_52b1be59-9887-447b-a2d2-42261b6ddb97"
      unitRef="usd">150000000</us-gaap:OtherCommitment>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="i30c73e53d86c471680151e41da485930_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzU4Mw_aeaaa7a3-d148-490d-a4bd-d5109f24e430"
      unitRef="usd">-35700000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="ibdda7de8d7244be2b32f9b7e729092c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83MC9mcmFnOmNhZDdkY2E4OTgzYjQzMDA4YjRjNDAwM2FjZjc1NGEzL3RleHRyZWdpb246Y2FkN2RjYTg5ODNiNDMwMDhiNGM0MDAzYWNmNzU0YTNfMzU5MA_13b91990-ec33-497c-a06a-a20320487d49"
      unitRef="usd">-11200000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTE1NA_b5e3787a-5b98-410b-8152-9eb62615a83a">Research &amp;amp; Development (&#x201c;R&amp;amp;D&#x201d;) Funding Expense R&amp;amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&amp;amp;D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&amp;amp;D funding arrangements. We recognized R&amp;amp;D funding expense of $0.6 million and $101.1 million for the three and six months ended June 30, 2022, respectively. We recognized R&amp;amp;D funding expense of $3.1 million and $5.8 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&amp;amp;D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0&#160;million to Cytokinetics to acquire a royalty on a development-stage product candidate.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ2Mw_ca6cd136-0e2a-4167-aad1-c5f4f4d02a05"
      unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ2Nw_b726acce-e516-4768-ae23-3b0b25a2af73"
      unitRef="usd">101100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfMTA5OTUxMTYyOTQ3MA_2b059804-6fac-4dea-b663-da8cd0f1842a"
      unitRef="usd">3100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfNjQ5_1983e0ba-1ac2-4ba6-9e16-3bbb7ff3a870"
      unitRef="usd">5800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i691fe772f8474c9883cd86d770776fc5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83Ni9mcmFnOmMzOGFmOGU2MGUxNzRiNzM5NDJhN2MzZmFlNDIwYjBmL3RleHRyZWdpb246YzM4YWY4ZTYwZTE3NGI3Mzk0MmE3YzNmYWU0MjBiMGZfODM4_b238926b-5ba0-499e-8998-bf52040d3431"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1Mg_4f245d60-a137-4722-99c5-da09ffcabec3">Borrowings&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,106,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,106,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Senior Unsecured Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#x201c;2021 Notes&#x201d;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#x201c;2020 Notes&#x201d; and, together with the 2021 Notes, the &#x201c;Notes&#x201d;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.9&#160;billion and $7.2&#160;billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Senior Unsecured Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#x201c;Credit Agreement&#x201d;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#x2019;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Principal Payments on the Notes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1MA_91abeddc-7257-47a1-9c8c-cfaa4ab2eaa8">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,106,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,106,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N180_e4b91e22-fa13-4527-9052-772f2293d233"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N184_2ee4eb60-1a62-4423-9f84-45828cbcab35"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i5277bbde55dc4ff3aac4ba9a24308df5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNmY2MmVkYjA4NTI0YmVmODYzMjE0MGUxM2Y3YmI3N18yMg_cd065912-8f52-48b6-b1db-95707fd028a2"
      unitRef="number">0.99322</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3e6f22ee9884362b21300a0550d1dea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi02LTEtMS0xMzQ1MDU_4de273f5-ea97-407d-99a5-49ad5569e1ef"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib5db792457664c249f4f34f68ae84ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMi04LTEtMS0xMzQ1MDU_c4756ff8-5ca0-475f-a0e1-9d7cb357e458"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3998c09aa68e48dfba459528066155e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV80_138b6fdf-9a68-44cb-8d66-a44d5d6380eb"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3998c09aa68e48dfba459528066155e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV84_1a007df8-a1aa-43da-a8a5-4b7ee31f909a"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i2520a38f28f24d8abe1664a0fa276108_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowNDFjYTM1YjNiNDM0YjQzOWYyMzA4YTk2MzgwNWY4NV8yMg_55ebd9ba-2fd6-4f48-b5c3-9e4a90fb0ea1"
      unitRef="number">0.98875</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3998c09aa68e48dfba459528066155e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy02LTEtMS0xMzQ1MDU_8ae693f8-2112-4fac-bc39-7466abbe7e1d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaeb3b048ad644ef7a5f6894758c0ec22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMy04LTEtMS0xMzQ1MDU_25eb21e7-6cf5-41b1-a5a3-16e14d01336a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM180_1e2db740-ba9f-4012-b035-339903fdef5c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM184_37df300d-ae0b-4f9c-8d03-e7fe9bd87be8"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="iba61f5d65e924374ba352a9226aa644b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplODI4MzY2NGYzNGY0MWU5OGU1ZDU1ODlhMDA4YjdhM18yMg_45eb5d3c-84a8-4461-9935-f1f03129af3b"
      unitRef="number">0.98284</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i473f0b55243f46238d71fb088fbcbd08_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC02LTEtMS0xMzQ1MDU_03465f21-edf9-4593-bb4a-3abcb2440cfe"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6514393b77b142479d7fa249d2437d74_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNC04LTEtMS0xMzQ1MDU_04b3b615-4528-4944-b8cc-bc35c954aebf"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y180_6f47dfd3-91c6-4fe4-8c84-05dbe255e129"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y184_f8149a9b-5d5b-4c84-b3ae-598a0dfe83b4"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="id9de03c81c754dc7bb15c6c52caf92be_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowZTU5OWJmN2U2YzI0MmVlOGQ2MjllMmE2ZTcwMTE1Y18yMg_b14ac08e-dd13-4f5d-bca0-79a072458227"
      unitRef="number">0.97760</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i246c4d7bf81f4ad88af37091381a6fa0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS02LTEtMS0xMzQ1MDU_b9e6fc36-ca1b-4382-8fad-5fff61de32fc"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i813d79deba2f4673b7dfac7f74be1e42_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNS04LTEtMS0xMzQ1MDU_c4306426-deaf-40e0-a97a-9b9b9ef1c26b"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM180_e6ef2460-7ca1-4bff-ad33-515538263429"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM184_eeeb5f58-d8e5-4572-9e3c-190e2128baf4"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i9ca85d756ed8402091fc1700a7ab767b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjpmNGIwM2M3MDY1Y2Y0YzI5OWFmMGE1ZTc5M2QyMDEzM18yMg_3cb7581c-671d-4e97-a822-03259363402c"
      unitRef="number">0.98263</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i803cb24ed48a4da1b85d42425a8acf1f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi02LTEtMS0xMzQ1MDU_18737704-0dd9-4b4b-8cc7-ce2c447b5ffe"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i54640267ea864316a9bed44de2313208_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNi04LTEtMS0xMzQ1MDU_a83fcbc1-ce51-45a5-bba9-55498f601701"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i89293daeea364b87a0f53da7fa772357_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y180_c88e7a83-a295-4ceb-9d99-e096682de22c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i89293daeea364b87a0f53da7fa772357_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y184_86abcbf0-3cfc-46cd-b58c-7a1896fa33c5"
      unitRef="number">0.0330</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i22abfbc03ed3462fa495b3d35e9f63c2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjplYjhiZDJmM2U0Yzg0Y2ExOGRiN2YyMmNlMWIzODg2Y18yMg_240140e5-f696-4d6b-90fa-abf3a2216247"
      unitRef="number">0.95556</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i89293daeea364b87a0f53da7fa772357_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy02LTEtMS0xMzQ1MDU_8a58a07e-997e-497f-a208-1f9e6c1c07b8"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i07f4360f02cb429f873526aa4abb90b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfNy04LTEtMS0xMzQ1MDU_3a0b4e1f-7b7f-4453-83d6-588c5f15ea1e"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i850321a4707144d5aa10067c9606b155_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV80_b788e105-76da-4bad-981d-572938724deb"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i850321a4707144d5aa10067c9606b155_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV84_47ecb2f6-8ab1-466b-aee1-9087f7ed8700"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ibf45fa61bd9d44eaa6acb1fcc1c764c2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjowMmNkZGMzZTczMGI0YTA2YjAwNjdhZjAyZDA5M2EwMV8yMg_8f733cbb-5d2a-4bc8-8545-d4f0a8f53bb6"
      unitRef="number">0.95306</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i850321a4707144d5aa10067c9606b155_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC02LTEtMS0xMzQ1MDU_3e90f607-26c3-44e3-821d-98451103d925"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i66677b99bf9e422f895af82a4346163b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOC04LTEtMS0xMzQ1MDU_4ee01477-8651-48a8-8268-a0ee556dd1e5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM180_ddd019f1-721d-4bc8-b88a-b8af4294f92b"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM184_b6fa5999-edf3-4379-b964-56c5d8afed5a"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="id77ed6261fc14df9845a99e3f1b47d5a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS0wLTEtMS0xMzQ1MDUvdGV4dHJlZ2lvbjo0Zjk1ZGYyMzQ0NmY0MjUzYWEwNGY1NmUzZjU3MWJmM18yMg_0df47ac9-e038-4795-af1a-788ecbf10db3"
      unitRef="number">0.97565</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3bf5be0c7bf64fce938dab6be3ae33bb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS02LTEtMS0xMzQ1MDU_a631b87d-34d1-4dda-a858-cd8a0bfa48d1"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie38fcca043734f5c8ff85a24cb230791_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfOS04LTEtMS0xMzQ1MDU_5006b54b-d74e-42fb-8c74-365a5d46ff28"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTItNi0xLTEtMTM0NTA1_ca72079d-1ba0-473d-86f0-8fa48a454a60"
      unitRef="usd">193801000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTItOC0xLTEtMTM0NTA1_cd9f9816-d248-40ca-bc6a-204d44a234b0"
      unitRef="usd">203930000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTMtNi0xLTEtMTM0NTA1_17c32ba1-864f-4d90-9f10-8d19033e3b15"
      unitRef="usd">7106199000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTMtOC0xLTEtMTM0NTA1_5b702fa4-066d-4506-9458-67ac9930210b"
      unitRef="usd">7096070000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTQtNi0xLTEtMTM0NTA1_2f04ebaf-850d-413e-9b94-a36d5a57a223"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTQtOC0xLTEtMTM0NTA1_b7af7ab4-267e-4c8d-9433-2d08d77a4a74"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTUtNi0xLTEtMTM0NTA1_9a50ff86-8115-462c-ac6e-b992d320852c"
      unitRef="usd">7106199000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjA2NzllMzljOWIyOTQ1MTA5ODJiNGE0YzhkNmFlMDZhL3RhYmxlcmFuZ2U6MDY3OWUzOWM5YjI5NDUxMDk4MmI0YTRjOGQ2YWUwNmFfMTUtOC0xLTEtMTM0NTA1_fe0b3f47-d4a0-44f1-81d0-d46a944e990e"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie5a03d177ab2440997f9376d5899a918_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTUy_8566e543-3c48-49db-ad51-e5cf59952e79"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia0c7820636114a409ceede5a921b1d09_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjEz_55ea0708-b9d6-4f83-98a0-eb7d56642555"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3197e12bdd3a4d309fc770d7447285e2_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjY1_a28cdbca-309c-4aba-9342-5d138d687c9a"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ie5a03d177ab2440997f9376d5899a918_I20210726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTU2_cd3503ca-a855-41a5-8d6a-f05ddd8eef5c"
      unitRef="usd">27500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i3197e12bdd3a4d309fc770d7447285e2_I20210726"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTky_637b831a-c627-4e7b-8202-81675a9b91ae"
      unitRef="usd">12300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i164ffc87f86f4075b11ef1a172aeefb8_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNzYw_e149412f-bda8-4db3-8404-8e53f489a30d"
      unitRef="number">0.0280</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i164ffc87f86f4075b11ef1a172aeefb8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNzY3_2f40b976-d613-45cf-99ec-76e10d76a5f6"
      unitRef="number">0.0306</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfODE5_f9e1d5cb-f7ef-4f3b-ba8d-0be2392f1273"
      unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTMzNw_e9be1bbd-e994-418c-a3aa-700f60403b03"
      unitRef="usd">149000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i2a92e44b4b344661af4757ad9a229064_I20200902"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTM3Mw_ae76c43b-d962-4174-b4f6-abd696509a23"
      unitRef="usd">40400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTU0Mg_5993b85e-9c05-48f0-82ad-6531c785013c"
      unitRef="number">0.02125</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTU0OQ_484627b1-61ff-4abf-8130-6b1d1b6829e8"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1e250b66e64341b09584ce80e7cba81e_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMTg5Nw_54af2e21-cd66-4090-ae02-cdcdec1e4fd8"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iba76a3f80e5c49e3948452772ef55ef9_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMjU5Ng_a589ed3e-66eb-4b03-8723-4a84f2fd1654"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4c364b452a2e4075809d3b9b42a5c9e7_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzA4Ng_28126d2e-e57f-4cc6-ad0c-8fbca5dd15b2"
      unitRef="usd">5900000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i022d32cb77944ea29be1667bb225e44a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzA5Mw_4a76d525-83d7-43a0-bd1c-d69d01bfab94"
      unitRef="usd">7200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8378863f6fb54944bdf6267872f7e32a_D20200918-20200918"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1MQ_3f92e421-9ba0-4f7e-9a36-ebc0da14d455">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifc406544d3744be8af475bd920f1691e_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzU1OA_bf6ccaf0-3487-4c51-9e51-a1c7bd64431b"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ia209b3983b4840c0a0ae77de9566e43b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzcxOQ_01f65993-7dfb-4ecf-b3ce-b5549a58b465"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i1cd001fdda914fffa3ca20031e15926d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfMzcxOQ_28be45b8-8fb8-4206-af2d-be1b8d418708"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id3f318ef84894bd4b707d34d44ab34f1_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA1Mg_3a949644-57df-4ebc-a657-3038cf594e1f"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2a66b8b6943547f2808825744d348a6a_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA1Mg_7ce12486-f2c6-462e-93a5-6cdd7bb5b689"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3b0545a0e18343f2842f30b29d72abac_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDA5OA_9da36584-3121-4713-aa87-00ef23284f6a"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio
      contextRef="ifc406544d3744be8af475bd920f1691e_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDc1MQ_08157693-13e4-44b9-93d0-3178b17b78ae"
      unitRef="number">4.00</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition
      contextRef="ifc406544d3744be8af475bd920f1691e_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNDc3OA_50de9472-5334-494b-99e2-aca3c77c7a73"
      unitRef="number">4.50</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition>
    <rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio
      contextRef="ifc406544d3744be8af475bd920f1691e_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNTA2Mg_53c6392c-e8db-4a32-b9ab-b68ca637f599"
      unitRef="number">2.50</rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjE1NQ_b6bfc054-d9f2-4915-9749-09d9d7bd41e1">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfMi0yLTEtMS0xMzQ1MDU_852edc94-a0dc-4af8-9757-e776e35bcb61"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfMy0yLTEtMS0xMzQ1MDU_0c95d7fe-8ea9-4890-882e-0992e44eea85"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNC0yLTEtMS0xMzQ1MDU_3a53d909-0c16-41c9-a58d-c9036a94e2df"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNS0yLTEtMS0xMzQ1MDU_f79460be-8554-4fc1-b1e3-7224a6ccee95"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNi0yLTEtMS0xMzQ1MDU_668bbf90-c730-44eb-81e3-6d13b71d6ce0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <rprx:LongTermDebtMaturityAfterYearFour
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfNy0yLTEtMS0xMzQ1MDU_1b9ed2b2-91c8-42d3-b5e8-3b115ffa780e"
      unitRef="usd">5300000000</rprx:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RhYmxlOjJkZmY2MzQ0YWUyMDQwZmI5MDFlMTBhNmI5M2QzODU3L3RhYmxlcmFuZ2U6MmRmZjYzNDRhZTIwNDBmYjkwMWUxMGE2YjkzZDM4NTdfOC0yLTEtMS0xMzQ1MDU_a30ca25e-ce45-46fc-96f6-785894515067"
      unitRef="usd">7300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icf036923cf324ce78882338a4fb17702_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV83OS9mcmFnOjNmZGE5ODA4MGJhNDQ4ODlhZDE4YWJlNzgwMTAxNmQzL3RleHRyZWdpb246M2ZkYTk4MDgwYmE0NDg4OWFkMThhYmU3ODAxMDE2ZDNfNjAzMQ_70bf26f6-2b0e-4e46-afeb-2d9678133942"
      unitRef="usd">-193800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTI5NA_5441d47a-50c4-4ed1-945c-65655e5921b9">Shareholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capital Structure&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#x201c;Exchange Agreement&#x201d;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of 365,302 thousand. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#xa3;1 each.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,756,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,599,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,364,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(146,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,716,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,655,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,380,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(207,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(295,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,716,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,655,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,380,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,882,655&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,058,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,954,818&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(127,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(170,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(486,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(486,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,894,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,757,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,671,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(222,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(316,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;455,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,894,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,757,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,671,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Continuing Investors Partnerships&#x2019; ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;RP Holdings Class C Special Interest Held by EPA Holdings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#x201c;Portfolio&#x201d;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#x201c;Equity Performance Awards&#x201d;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $165.3&#160;million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $138.6 million to holders of our Class A ordinary shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Independent Directors Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSU Activity and Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally one year as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt; in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses.</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <rprx:NumberOfClassesOfVotingStock
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTg_ca22c2ec-2f6a-4937-a8e4-650962be4fc2"
      unitRef="class">2</rprx:NumberOfClassesOfVotingStock>
    <rprx:CommonStockVotingRightsNumberOfVotes
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTU4_3f1b9511-404d-438b-97f5-c6c923001c2f"
      unitRef="vote">1</rprx:CommonStockVotingRightsNumberOfVotes>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if43def283e414c978ef1f9e00d58466d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTA5OTUxMTY0NTU0OQ_cca67210-1f64-4597-b1df-72e85f810501"
      unitRef="shares">437139000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19484314d7814df68d24568f06200a2d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTA5OTUxMTY0NTU4MQ_89d6fc08-0168-42ed-98ed-2399524ec2a8"
      unitRef="shares">170081000</us-gaap:CommonStockSharesOutstanding>
    <rprx:CommonStockQuarterlyConversionBasis
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfODI0NjMzNzIyODY0NQ_a07b0282-b657-4570-94a7-ff827db580d0"
      unitRef="shares">1</rprx:CommonStockQuarterlyConversionBasis>
    <us-gaap:SharesOutstanding
      contextRef="i3398ec60c9ae485e8b45f7d4470a9dba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTM1Nw_7b8cce4f-de33-44ab-b3b4-c54adef05c71"
      unitRef="shares">365302000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i31b8cd4406014f3c9e543595ef591d8a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTM5Mw_188e2982-5c4c-4a6b-98fc-378135bed760"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <rprx:RedeemableStockRedemptionPricePerShare
      contextRef="i464e075cb1d04ed28a402c8f7149fe47_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTYxMw_94a7366e-ace1-46a7-ac91-467721065777"
      unitRef="gbpPerShare">1</rprx:RedeemableStockRedemptionPricePerShare>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTI5NQ_6e314a88-c276-43a4-983d-07e118ae9f26">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,756,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,599,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,364,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(146,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,716,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,655,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,380,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(207,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(295,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,716,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,655,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,380,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,882,655&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,058,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,954,818&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(127,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(170,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(486,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(486,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,894,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,757,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,671,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(222,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(316,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;455,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,894,027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,757,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,671,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Continuing Investors Partnerships&#x2019; ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <rprx:NumberOfNoncontrollingInterests
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfMTY4Nw_b5c9ac30-0bdd-47e4-9240-83bb897ea340"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63f4135a52e24cdc8a877de0528e91ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS0xLTEtMS0xMzc3MTg_e41de92e-7437-4a64-9766-a4a732ce5e3d"
      unitRef="usd">8409000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i957a4d6b1a8f46acaeae11abefb3a081_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS0zLTEtMS0xMzc3MTg_cc688db5-edb9-4d3f-a086-bc6f231c2d40"
      unitRef="usd">1756269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81ac24325a784997a2a2834a39d26946_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS01LTEtMS0xMzc3MTg_5a6844a3-ce8c-4d24-a6b4-192710318d62"
      unitRef="usd">2599646000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife05da3ee4b44968baca4702397077dc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS03LTEtMS0xMzc3MTg_160c5086-435f-48f2-b561-41aabeefc3c8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a03d2808d134bb78c9e34be7dcd1ccd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMS05LTEtMS0xMzc3MTg_8fe5442b-a303-4ae8-b415-1fadc306df93"
      unitRef="usd">4364324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi0xLTEtMS0xMzc3MTg_b95c9a4b-427d-4225-b2a9-521a94bb7326"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi0zLTEtMS0xMzc3MTg_bf7ca6be-f4fa-4cf6-bc0f-c324c5075cd7"
      unitRef="usd">1425000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi01LTEtMS0xMzc3MTg_554aedac-58e5-47e3-acd5-bee7684cdd54"
      unitRef="usd">1456000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi03LTEtMS0xMzc3MTg_4d63fd75-ab6b-4f9f-a384-3e78b28f7e31"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMi05LTEtMS0xMzc3MTg_80e20955-8fa5-46ac-b5ae-2a341adbf582"
      unitRef="usd">2881000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy0xLTEtMS0xMzc3MTg_9b9f1d79-05df-4268-b3b2-1db78d0c0861"
      unitRef="usd">5754000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy0zLTEtMS0xMzc3MTg_4b04c0ca-21ed-450c-b197-49a7e01d85c2"
      unitRef="usd">103385000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy01LTEtMS0xMzc3MTg_14417410-9e3c-457e-ad31-9895d1d3d68e"
      unitRef="usd">37828000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy03LTEtMS0xMzc3MTg_8366e96d-d1bf-427d-af0e-1fdf34e8ee64"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfMy05LTEtMS0xMzc3MTg_b0801318-f89a-4584-9c13-234cbf421f69"
      unitRef="usd">146967000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC0xLTEtMS0xMzc3MTg_577f81e8-efe8-485b-aea8-0fb463fa917a"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC0zLTEtMS0xMzc3MTg_1cb752d5-9f19-4841-8660-d674dfec3066"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC01LTEtMS0xMzc3MTg_7db0a167-bc12-48c2-ae05-c877e3939331"
      unitRef="usd">26938000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC03LTEtMS0xMzc3MTg_909225e5-07a8-4a2d-a9bc-191f2c2df2ef"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNC05LTEtMS0xMzc3MTg_e258ce30-edaa-42a8-9308-ab532aaa9942"
      unitRef="usd">26938000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS0xLTEtMS0xMzc3MTg_0eccef71-7f69-4717-a09a-71dba92f2299"
      unitRef="usd">6227000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS0zLTEtMS0xMzc3MTg_3981be84-f4bc-4b3e-9c33-cf9806cc1f6d"
      unitRef="usd">61642000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS01LTEtMS0xMzc3MTg_d255cded-1bc0-462d-8dd9-86be7a008d85"
      unitRef="usd">119224000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS03LTEtMS0xMzc3MTg_6d1949f1-bebd-4b8d-938c-9c71c274769f"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNS05LTEtMS0xMzc3MTg_52e267f4-8322-491a-97b2-1b44abab0ee2"
      unitRef="usd">187093000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy0xLTEtMS0xMzc3MTg_67fa1400-d26e-4245-9a82-04ac5a8aa114"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy0zLTEtMS0xMzc3MTg_0648c41d-4740-4318-9c0c-2875187e7731"
      unitRef="usd">1639000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy01LTEtMS0xMzc3MTg_13859898-e1c7-424b-9097-7bf6c9fd0949"
      unitRef="usd">2163000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy03LTEtMS0xMzc3MTg_c97c2eef-6915-45fa-b55f-724b7980d329"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfNy05LTEtMS0xMzc3MTg_c21f336e-7ae1-449c-a5c7-d3678ac068e8"
      unitRef="usd">3802000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i437a8e8db9dc41ec8a9e145e9a06ec93_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC0xLTEtMS0xMzc3MTg_22fec25f-35d4-478d-b1d5-3728277ecb8e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i9e6784ed25614dfdb2f4ea4d8c8c94b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC0zLTEtMS0xMzc3MTg_7ae9cc58-bd43-4b00-bf86-bb1445d292a2"
      unitRef="usd">1404000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i3306357bf01342bd954ad1cb3d41470e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC01LTEtMS0xMzc3MTg_ffe090be-8991-4289-802f-e314202e5c19"
      unitRef="usd">1853000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4e04b0d535b245b082fe1c55a1536755_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC03LTEtMS0xMzc3MTg_36435eeb-2ecd-4e38-91a6-9ad41ffa2615"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i24013fcd32ef4fe0ad453120b98d1162_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOC05LTEtMS0xMzc3MTg_b63b86ea-6b31-4b1f-940f-9315948f8a26"
      unitRef="usd">3257000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58ff712c0f0e4721b11f310c9a7ba814_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS0xLTEtMS0xMzc3MTg_a3dfcce7-69c7-4400-8765-2dbcc12d5d45"
      unitRef="usd">8882000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS0zLTEtMS0xMzc3MTg_3d673c09-991f-44d8-8a76-985af8601abb"
      unitRef="usd">1716186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac973f489d7a4fc9ac38195a2164de93_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS01LTEtMS0xMzc3MTg_27ecab41-f6de-4139-a9e7-92437cc82846"
      unitRef="usd">2655870000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie068a9d4a59444e886f94818184da48d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS03LTEtMS0xMzc3MTg_59465d97-7eec-4ecf-8a6f-7b3ac1b7f9d4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjEzNGM2MWM3OTFhMzRlMjI5YzFiYTZiOTg4ZjM0OTdkL3RhYmxlcmFuZ2U6MTM0YzYxYzc5MWEzNGUyMjljMWJhNmI5ODhmMzQ5N2RfOS05LTEtMS0xMzc3MTg_6012390d-f650-46d0-95fa-2b21eee357ef"
      unitRef="usd">4380938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e0d9dd3824945d09335073108634a8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS0xLTEtMS0xMzQ1MDU_c1f7ca5f-ddb8-41d6-b1cf-f3317ecdb204"
      unitRef="usd">13528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52d62fb2227b41378a04fa7cf96ec2e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS0zLTEtMS0xMzQ1MDU_e7dde938-1c73-47c1-b03f-8366aa4d00d1"
      unitRef="usd">1809269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icac8a13c10554d4e8c579493cc60ccd0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS01LTEtMS0xMzQ1MDU_92de21c6-deee-4c4b-a799-3fbb73e66bc5"
      unitRef="usd">2649154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff4eb9e0f8c94eca9757ffe4eb666c7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS03LTEtMS0xMzQ1MDU_c54c15d8-b64f-4c68-8707-2e3cc54dfe75"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d31c6d21fd04c6aa2d0563368c6f5bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMS05LTEtMS0xMzQ1MDU_f2a8d462-7441-4cd4-8487-0ac01a1d0303"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi0xLTEtMS0xMzQ1MDU_ef0ed4c6-403b-4cf9-94f4-84dcdf0ddd92"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi0zLTEtMS0xMzQ1MDU_3d3e94ed-38f6-465c-9364-166359550533"
      unitRef="usd">3395000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi01LTEtMS0xMzQ1MDU_87d422dd-0d86-44cd-a47c-a642f5882c2a"
      unitRef="usd">2808000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi03LTEtMS0xMzQ1MDU_fe1e17b0-c918-4350-a000-125495bef16d"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMi05LTEtMS0xMzQ1MDU_1256e588-c6c1-4fbd-a12e-a279081a319c"
      unitRef="usd">6203000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy0xLTEtMS0xMzQ1MDU_c5ca4749-c29a-4320-8e59-796f43ac8c2e"
      unitRef="usd">16013000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy0zLTEtMS0xMzQ1MDU_59686974-57ff-4b6f-b567-3e692f9b7900"
      unitRef="usd">207586000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy01LTEtMS0xMzQ1MDU_d68dbcfe-c40a-4a4b-bb46-6bf19aa00a66"
      unitRef="usd">72343000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy03LTEtMS0xMzQ1MDU_12b0a6a0-2a0a-4f59-bdc8-9d55c75b7c0b"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfMy05LTEtMS0xMzQ1MDU_7fcb40ef-a304-4d50-8b32-f3fa3d08bc6f"
      unitRef="usd">295942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC0xLTEtMS0xMzQ1MDU_afe55ff2-40e7-4dfb-91fb-0001e5660210"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC0zLTEtMS0xMzQ1MDU_c0587210-3ab0-4abb-8ee3-72bf069565b6"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC01LTEtMS0xMzQ1MDU_62a48790-db2e-45ce-8b73-5506f9e36b41"
      unitRef="usd">62222000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC03LTEtMS0xMzQ1MDU_de62901a-d17c-47c6-b743-d4c7aa2014eb"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNC05LTEtMS0xMzQ1MDU_b37ecf77-7bc1-4305-9557-75ddf7318f45"
      unitRef="usd">62222000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS0xLTEtMS0xMzQ1MDU_ea082929-6060-45b3-9c71-c745c521b439"
      unitRef="usd">11367000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS0zLTEtMS0xMzQ1MDU_a8225916-d77b-4efa-a548-dff4e002acbc"
      unitRef="usd">112162000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS01LTEtMS0xMzQ1MDU_e20c74ef-b26e-4e14-984e-231676abcf58"
      unitRef="usd">139886000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS03LTEtMS0xMzQ1MDU_2be4a858-7ee9-4699-8388-ae364c024f39"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNS05LTEtMS0xMzQ1MDU_5b15aca7-ad39-4520-ae5b-a2f5a69db50a"
      unitRef="usd">263415000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy0xLTEtMS0xMzQ1MDU_c3a51e7f-4eec-492a-8601-b69defac1b46"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy0zLTEtMS0xMzQ1MDU_da1c2a5d-b34a-42d1-85c2-a3f97359045d"
      unitRef="usd">1925000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy01LTEtMS0xMzQ1MDU_dd34d82c-3440-4043-af9b-a51c4d8b1756"
      unitRef="usd">2545000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy03LTEtMS0xMzQ1MDU_10226780-5fcf-44cf-9615-996ec1556f11"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfNy05LTEtMS0xMzQ1MDU_4ba81249-72f7-4b57-8b45-74afa413a02e"
      unitRef="usd">4470000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i61b4d35516324aa095d83be2bba73156_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC0xLTEtMS0xMzQ1MDU_01d4bb83-2ecb-4bf9-8ac3-74a64a2ca668"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6316c883f648449c968ab6316d93a13d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC0zLTEtMS0xMzQ1MDU_ed3e9f57-e0fe-43b1-a0c8-9f0e1c3fba5c"
      unitRef="usd">2979000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie26fdd8d2fc64eef87e3b5bd0b717bf6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC01LTEtMS0xMzQ1MDU_89fde489-282c-4bfc-8384-2b14a90b24a4"
      unitRef="usd">3958000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i39a65761d91d41b794af65efcaea9c7f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC03LTEtMS0xMzQ1MDU_39c83f25-6b0b-434c-afb7-53fdd3adc2cc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5da86104b78e4cf4b64d5fed3de83b18_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOC05LTEtMS0xMzQ1MDU_9e6c728e-b817-498c-94f0-2b5172ec18cb"
      unitRef="usd">6937000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58ff712c0f0e4721b11f310c9a7ba814_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS0xLTEtMS0xMzQ1MDU_51a5fdb1-c095-4413-b806-2d59a3181b85"
      unitRef="usd">8882000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i091ec5b3fab34e24a9f27e7d186d2f0f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS0zLTEtMS0xMzQ1MDU_45a16ac3-e920-4621-9b83-9f1265bd23ce"
      unitRef="usd">1716186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac973f489d7a4fc9ac38195a2164de93_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS01LTEtMS0xMzQ1MDU_f028377e-d9da-458f-832e-733657ce1666"
      unitRef="usd">2655870000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie068a9d4a59444e886f94818184da48d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS03LTEtMS0xMzQ1MDU_12291253-ae65-400a-a448-8494e7bbb038"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2105ff37cbf54c04ba010a8c52924650_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjRlYjlkNDFkNDQ0ODRkYmFhOTUxYzcwMjM2OTZhZjk3L3RhYmxlcmFuZ2U6NGViOWQ0MWQ0NDQ4NGRiYWE5NTFjNzAyMzY5NmFmOTdfOS05LTEtMS0xMzQ1MDU_45bced38-dc69-4629-9153-d7b1abf04265"
      unitRef="usd">4380938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i094b01ea23224dbd8928efbf7993356b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS0xLTEtMS0xMzc3MDM_f2825f15-6d35-4283-b24e-16716f3e16ac"
      unitRef="usd">13841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88246dd04abf4793a1634e975c03750b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS0zLTEtMS0xMzc3MDM_f13f7e43-4ed9-471f-a9e4-fe67552d8566"
      unitRef="usd">1882655000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i715821bde2d34b7aa686a6dfe08ae077_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS01LTEtMS0xMzc3MDM_f0cdc320-494a-4971-b7ab-d106114fbe41"
      unitRef="usd">3058322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i771cb54e67794bd7841999b1e5270715_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS03LTEtMS0xMzc3MDM_53b17080-5837-43be-8520-b053dbe970ee"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iade2ebd58086471fbf60d5e06704e135_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMS05LTEtMS0xMzc3MDM_ebbc3c88-eefa-418c-90c8-6c945dc18170"
      unitRef="usd">4954818000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi0xLTEtMS0xMzc3MDM_a803ff0d-6004-4ca2-a713-716a559dc9d9"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi0zLTEtMS0xMzc3MDM_b7855884-b617-4d4c-996f-2bbb0288b70c"
      unitRef="usd">6654000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi01LTEtMS0xMzc3MDM_85c34ab8-8214-498b-92ff-5126dd1449b7"
      unitRef="usd">4865000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi03LTEtMS0xMzc3MDM_62ad463b-3865-48a4-9261-693a7bf9e899"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMi05LTEtMS0xMzc3MDM_6c83eef2-e1ec-4f04-8b27-7545ad23fc1b"
      unitRef="usd">11519000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy0xLTEtMS0xMzc3MDM_15422376-76eb-4ecb-ac11-e32c45da1223"
      unitRef="usd">12476000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy0zLTEtMS0xMzc3MDM_1fba16fa-9088-418f-9404-9ca3dd662b00"
      unitRef="usd">127747000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy01LTEtMS0xMzc3MDM_ff46aecf-1101-4cc5-9257-39807bc2fba6"
      unitRef="usd">30585000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy03LTEtMS0xMzc3MDM_7c1323c5-3aaf-4955-b39d-e4af7b5dc5dc"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfMy05LTEtMS0xMzc3MDM_9da5ba06-5171-48b5-8a98-38cf42dc7278"
      unitRef="usd">170808000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC0xLTEtMS0xMzc3MDM_a023a9b4-24de-4d49-a592-3ba645ee92ae"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC0zLTEtMS0xMzc3MDM_337fe10c-5316-4e28-a006-92236b418147"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC01LTEtMS0xMzc3MDM_b224ae0f-af5e-49b1-bc27-74d8389b651e"
      unitRef="usd">486591000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC03LTEtMS0xMzc3MDM_8d8e31da-cf95-4583-a791-5040b2d6b942"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNC05LTEtMS0xMzc3MDM_15c52d0c-4f44-4bed-80f2-2b07f57b4b87"
      unitRef="usd">486591000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS0xLTEtMS0xMzc3MDM_a2d7cadf-b678-4e97-a3d4-e67074c8602e"
      unitRef="usd">19275000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS0zLTEtMS0xMzc3MDM_a258f282-c84f-41a7-a0e3-ee06250e63f2"
      unitRef="usd">133743000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS01LTEtMS0xMzc3MDM_862d9d4e-9c8e-473e-8ea9-e8a9c58ce4ab"
      unitRef="usd">212961000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS03LTEtMS0xMzc3MDM_451fe8bb-a8ed-4c5c-8cc1-5fe85c05698a"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNS05LTEtMS0xMzc3MDM_76ea38aa-b04c-4c49-aee1-48cf60abcd87"
      unitRef="usd">365979000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy0xLTEtMS0xMzc3MDM_d339fdd4-6918-4fc0-be50-3a766efe6d47"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy0zLTEtMS0xMzc3MDM_1c12cf14-ed2e-4850-84fb-ca21fc40ec28"
      unitRef="usd">1059000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy01LTEtMS0xMzc3MDM_be10319a-c622-4c34-ace7-038b57b16d9e"
      unitRef="usd">1618000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy03LTEtMS0xMzc3MDM_33729060-d174-45be-a467-e425889e4583"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfNy05LTEtMS0xMzc3MDM_3c5d1133-5a73-42f4-bf10-d12a9262f1ac"
      unitRef="usd">2677000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="iada64bfa14f34bc89d9afd9f4e6986f8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC0xLTEtMS0xMzc3MDM_268457a5-372f-45ca-b6b3-e04f00c063c7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5a27cf5f68ee4ffa83a6a17d3dd674f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC0zLTEtMS0xMzc3MDM_cf1ec595-d867-4e03-9db3-2bbf88375c31"
      unitRef="usd">2337000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id2feaf3d092b44a29ea45a19e1aa4c5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC01LTEtMS0xMzc3MDM_7ddeaf25-ce4d-48d9-8f28-f70e7aea7867"
      unitRef="usd">3571000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i2140ef6f670745a782880740ef79a12d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC03LTEtMS0xMzc3MDM_5c324dfc-503d-4357-ba9e-ce4c27fd1fa5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i030a481b71ae4208a5daf944fa92b2c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOC05LTEtMS0xMzc3MDM_4da59712-64ee-4b0e-a62a-98861c1b18b9"
      unitRef="usd">5908000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife8b00699867481fb50c4fef1515ba9e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS0xLTEtMS0xMzc3MDM_b5053d77-7db5-4b51-ab02-c8c6ccc3a288"
      unitRef="usd">20640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3a9d91774c148d1bb20516e42535cc5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS0zLTEtMS0xMzc3MDM_df332561-71e2-481b-bfa8-ee7fbc73f56d"
      unitRef="usd">1894027000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS01LTEtMS0xMzc3MDM_f09aba59-15da-44eb-a49d-4afb072e9aea"
      unitRef="usd">2757019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20897a0731394ab39cdbf6f569451ecb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS03LTEtMS0xMzc3MDM_e4ce1fb8-0414-4050-822b-2ede9c28b155"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOmE2YWIzNTAxMWNmZjQxOGZhNTRlZGNmNzA3YmQwZDRkL3RhYmxlcmFuZ2U6YTZhYjM1MDExY2ZmNDE4ZmE1NGVkY2Y3MDdiZDBkNGRfOS05LTEtMS0xMzc3MDM_e6a99d5f-c902-4f7e-9d95-837f1fd9d157"
      unitRef="usd">4671686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i564ee5a80f984273b26344ca0417004e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS0xLTEtMS0xMzQ1MDU_db0a337a-e720-49b7-b42e-2962e0e6ad43"
      unitRef="usd">12436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bbbfac68ec4488cbbc6b6f3a3f7e632_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS0zLTEtMS0xMzQ1MDU_6e422040-14d7-4fae-b624-47fe458d5be3"
      unitRef="usd">1939509000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia70dd8a979be46a0a140e37dcbc10470_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS01LTEtMS0xMzQ1MDU_9a8ba915-4f81-4960-a7f7-12798174c034"
      unitRef="usd">3125091000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58a1efb8258c4f90b003132a7c806d37_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS03LTEtMS0xMzQ1MDU_11bb9b14-2ff0-4e8b-912f-97b348e86458"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb3f673cf22e4af289ea139885dca16b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMS05LTEtMS0xMzQ1MDU_446a7462-5016-40b5-81e1-3f263c631a6a"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi0xLTEtMS0xMzQ1MDU_96727dfb-8743-492c-bfec-f75da4f1261d"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi0zLTEtMS0xMzQ1MDU_55baded5-a6cc-4c55-98ed-e411ab5c381f"
      unitRef="usd">9907000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi01LTEtMS0xMzQ1MDU_5ded4d76-2b40-4c5f-900d-733a40ebbb01"
      unitRef="usd">4865000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi03LTEtMS0xMzQ1MDU_30c647be-319f-4438-95fc-1892511185de"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMi05LTEtMS0xMzQ1MDU_62e8ffdf-9233-4900-91b7-1af8dc19280c"
      unitRef="usd">14772000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy0xLTEtMS0xMzQ1MDU_e5607c13-58d1-45f0-a2c8-26b84368ef4f"
      unitRef="usd">26129000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy0zLTEtMS0xMzQ1MDU_b8461c37-110a-4e16-9237-597022c4f011"
      unitRef="usd">222289000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy01LTEtMS0xMzQ1MDU_c0290032-0b73-4a21-af02-8c111c88843a"
      unitRef="usd">67768000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy03LTEtMS0xMzQ1MDU_a27168c1-dbe1-4ea2-bb1e-e1a11629bf77"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfMy05LTEtMS0xMzQ1MDU_8c384712-7f67-4abb-a388-57fe0c933793"
      unitRef="usd">316186000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC0xLTEtMS0xMzQ1MDU_d1584274-578b-4123-bd20-a84ebc0683a1"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC0zLTEtMS0xMzQ1MDU_2b832f11-d582-4ef6-adbe-ccea1a3da3c2"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC01LTEtMS0xMzQ1MDU_547d629a-eb7c-42a6-8fa4-2057acd51454"
      unitRef="usd">551663000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC03LTEtMS0xMzQ1MDU_6f9f8d8a-1f60-4627-9482-7d44a4e0c24d"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNC05LTEtMS0xMzQ1MDU_99a1f894-5cb8-48d7-b6c5-3e7b744041b4"
      unitRef="usd">551663000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS0xLTEtMS0xMzQ1MDU_901c0269-c34d-4d9f-827c-3096df42e5e0"
      unitRef="usd">34333000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS0zLTEtMS0xMzQ1MDU_214c641b-85b5-4dca-9a3d-c9a83389a329"
      unitRef="usd">170000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS01LTEtMS0xMzQ1MDU_89d1905f-178c-4d0b-8169-cbdc5d3e4e77"
      unitRef="usd">251506000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS03LTEtMS0xMzQ1MDU_fbf6f5c4-203b-4e87-a2a8-a45001d619a2"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNS05LTEtMS0xMzQ1MDU_5e0466dd-212f-4e57-a5be-022c4d895db5"
      unitRef="usd">455839000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy0xLTEtMS0xMzQ1MDU_41175d46-cf05-4c1b-ad5e-c2426c3fd964"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy0zLTEtMS0xMzQ1MDU_8710328b-a850-4a12-a32f-0c2229655f1f"
      unitRef="usd">1960000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy01LTEtMS0xMzQ1MDU_23f29124-62ab-44b2-aa48-0ffe3702e715"
      unitRef="usd">3130000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy03LTEtMS0xMzQ1MDU_9a3c373b-b926-46c0-a1b1-5703573c691f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfNy05LTEtMS0xMzQ1MDU_66cb7c07-2e38-4ab6-b07a-a2cdbf5ee580"
      unitRef="usd">5090000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ib86519930d1c4430ad7b16456dac2c3a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC0xLTEtMS0xMzQ1MDU_222282b0-e562-427b-bc15-da7ec42f2e15"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i19fad898d9ad42c982284c7e50e2fd95_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC0zLTEtMS0xMzQ1MDU_1340947e-11f5-4596-958a-141d47acf7b0"
      unitRef="usd">5060000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic3b0b1cba9ec43e191d66c1d98db4c4e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC01LTEtMS0xMzQ1MDU_191cf229-9a16-46c6-9e34-bd5eadaf86cb"
      unitRef="usd">8142000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icd2efab88f0a4ee19d1d157dc6c3acc6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC03LTEtMS0xMzQ1MDU_cde7563f-bb32-4fcf-9170-be49a5be2102"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i660048b273ba434f82a3033be439995d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOC05LTEtMS0xMzQ1MDU_bd2851e7-d460-424b-bde5-5cc370330d3f"
      unitRef="usd">13202000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife8b00699867481fb50c4fef1515ba9e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS0xLTEtMS0xMzQ1MDU_57347799-0dfb-4932-9ba4-7e2d7299b422"
      unitRef="usd">20640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3a9d91774c148d1bb20516e42535cc5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS0zLTEtMS0xMzQ1MDU_0ea8b760-4661-44d4-9a21-dfef7d200662"
      unitRef="usd">1894027000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9f20f5654b5416aab1d6d26bba6fc5e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS01LTEtMS0xMzQ1MDU_97b09304-e461-4fcc-ba78-58133214cbda"
      unitRef="usd">2757019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20897a0731394ab39cdbf6f569451ecb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS03LTEtMS0xMzQ1MDU_e273b1e7-1079-4614-9003-09da28f3087b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia146a7ffd9eb4c388b427f68bf59099a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RhYmxlOjZhOGRhZWJiZWE0NTQzNWViM2MxMjhkNzYzMTIyNTMzL3RhYmxlcmFuZ2U6NmE4ZGFlYmJlYTQ1NDM1ZWIzYzEyOGQ3NjMxMjI1MzNfOS05LTEtMS0xMzQ1MDU_f50e6bac-4366-46be-acb3-98017d80e5e5"
      unitRef="usd">4671686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="icd4499f27b8c415c83b4aa5e390c611c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNzE0NjgyNTU5NDA1Ng_8c79126d-aba4-4ab8-8b7b-f17f36a9bf83"
      unitRef="number">0.28</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ibd5518beaff545de976d2821f78d8146_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNzE0NjgyNTU5NDE3NQ_98ba299c-114c-498e-9a88-f4a91a8d1a1f"
      unitRef="number">0.72</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDIwOA_4eda9c66-945a-49fc-a677-b00509bd6865"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDI2NQ_3c4b2898-4ec4-4d22-9acd-ea5fbb538037"
      unitRef="usd">165300000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDM3NA_da24dfbf-fa7f-4c3a-86bc-cacab63214c1"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDQzMQ_54a96a9c-c1fe-4d8a-bf23-bb0e04ca75ce"
      unitRef="usd">138600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie59134a7c071446a8dc6d06dd7272373_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNDY0Mg_1b846291-962d-4428-ba25-0903fab2a433"
      unitRef="shares">800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84Mi9mcmFnOmU2YTZhYjlhMjBkNzQxNmM5NmNjM2M3ZjVkOWNlMDZhL3RleHRyZWdpb246ZTZhNmFiOWEyMGQ3NDE2Yzk2Y2MzYzdmNWQ5Y2UwNmFfNTA3OA_49672dfd-6f0f-46b6-9d0a-09fcc25661d4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMjA1MQ_09f626f7-d705-47b2-b3ca-1ed4362ee55e">Earnings per Share&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;965,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;436,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effects as shown separately below&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Class B ordinary shares exchangeable for Class A ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <rprx:CommonStockExchangeRatio
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMTE5NQ_a850c1ec-95cb-484b-8295-a1e7fce1893d"
      unitRef="number">1</rprx:CommonStockExchangeRatio>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RleHRyZWdpb246Yzk0MDhhMTE3MTFjNGVlMGFlN2M2Y2IxNTBjNTIxNDdfMjA1Mw_7a05a003-8ffb-4bb7-bd2d-c6f8b52d2bb8">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;965,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;436,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effects as shown separately below&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Class B ordinary shares exchangeable for Class A ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy0xLTEtMS0xMzQ1MDU_166d6015-ac44-45cd-8c45-5ec810850332"
      unitRef="usd">491597000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy0zLTEtMS0xMzQ1MDU_5978da10-a60d-4e00-9981-d472b50af96a"
      unitRef="usd">806755000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy01LTEtMS0xMzQ1MDU_ea9b762b-b812-4f09-9d19-a8f324ec1beb"
      unitRef="usd">619680000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMy03LTEtMS0xMzQ1MDU_a5d0e3e7-b591-4230-ab33-c009aa3fe27d"
      unitRef="usd">965734000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7cf25b5c44074bba8349a3ed917b9828_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC0xLTEtMS0xMzQ1MDU_af3dc8c1-088c-4501-8e1a-256328061f14"
      unitRef="usd">119224000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i89da6075574744cd88689bc056f4784d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC0zLTEtMS0xMzQ1MDU_4d17e0e3-3238-4f9a-9ea1-f83a6f095dee"
      unitRef="usd">212961000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5e85d625927d4a208e60107fcdc3e4d1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC01LTEtMS0xMzQ1MDU_959faeb2-7b09-4a4a-bbb0-900f466c2227"
      unitRef="usd">139886000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1723835775974da9ace43244c9bf89d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNC03LTEtMS0xMzQ1MDU_be8dea14-3d41-49e3-acf2-5724b7fac0eb"
      unitRef="usd">251506000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i839baaa9ddce4c7a8bee9fbd533f440c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS0xLTEtMS0xMzQ1MDU_b513dba1-8ab5-49e0-9556-eb27f564d513"
      unitRef="usd">67869000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4e57903f579943a3acd517f95ac47e2d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS0zLTEtMS0xMzQ1MDU_d245232e-7de8-4d0d-bc06-85e542237db7"
      unitRef="usd">153018000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifbf2318e4b6145d29623e3758709b640_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS01LTEtMS0xMzQ1MDU_01cefe2a-63e8-49c2-8f15-99bd340d4615"
      unitRef="usd">123529000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i716b09853e4a4174a28f2a27d873f6cb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNS03LTEtMS0xMzQ1MDU_11b51600-b9b9-4c58-a9dc-e25929e775ab"
      unitRef="usd">204333000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi0xLTEtMS0xMzQ1MDU_360701bb-0067-4561-a4ac-fd3f7ea60a91"
      unitRef="usd">304504000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi0zLTEtMS0xMzQ1MDU_727eddaa-49a4-43d7-acd1-590fabe3e08b"
      unitRef="usd">440776000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi01LTEtMS0xMzQ1MDU_1d02b7c4-057a-4866-82d1-3ec5904eece3"
      unitRef="usd">356265000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNi03LTEtMS0xMzQ1MDU_9d87c56f-0975-418a-8ccc-fe99f54b7ac8"
      unitRef="usd">509895000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy0xLTEtMS0xMzQ1MDU_0c0afd09-fd77-4204-8531-0e9097ee6d9a"
      unitRef="usd">119224000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy0zLTEtMS0xMzQ1MDU_3df9b32d-5e1c-4982-91b1-33eee0b6ba56"
      unitRef="usd">212961000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy01LTEtMS0xMzQ1MDU_fa2b61d6-4635-49d0-ba19-692cf58ae8b4"
      unitRef="usd">139886000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfNy03LTEtMS0xMzQ1MDU_01f8b50c-3c87-4310-b168-baf134914a0e"
      unitRef="usd">251506000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC0xLTEtMS0xMzQ1MDU_d390d06f-86a2-445d-807e-154f91beb7b8"
      unitRef="usd">423728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC0zLTEtMS0xMzQ1MDU_fd0cec41-217f-46fe-9c98-d2e9f73f1c2c"
      unitRef="usd">653737000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC01LTEtMS0xMzQ1MDU_89189e3b-4412-4329-9ccc-56bfda5b40e0"
      unitRef="usd">496151000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfOC03LTEtMS0xMzQ1MDU_74a68ff2-d8fa-48b7-9691-ddf1b231c22f"
      unitRef="usd">761401000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtMS0xLTEtMTM0NTA1_1fd73a6e-a5b6-4055-b664-97acae6de46c"
      unitRef="shares">436318000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtMy0xLTEtMTM0NTA1_0fabe635-298d-412d-b359-67b5226899c0"
      unitRef="shares">409344000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtNS0xLTEtMTM0NTA1_599f00c0-2a68-4979-9675-0b2bdf84f8e8"
      unitRef="shares">435144000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTEtNy0xLTEtMTM0NTA1_80f956cb-3eca-45f1-857f-654d64b0c616"
      unitRef="shares">399606000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtMS0xLTEtMTM0NTA1_e0fbfd32-ca4e-4c6c-aa15-fc81a19c8a3c"
      unitRef="shares">170864000</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtMy0xLTEtMTM0NTA1_144bd189-7f59-42a7-a85d-4fd0565c27fe"
      unitRef="shares">197773000</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtNS0xLTEtMTM0NTA1_43130d09-0bfa-49da-8fa6-770d30d66718"
      unitRef="shares">172035000</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTMtNy0xLTEtMTM0NTA1_a8b49034-5538-4544-ad6f-cc5bc39a0ad0"
      unitRef="shares">207508000</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtMS0xLTEtMTM0NTA1_6f4acb05-d12a-4a57-8058-ca9a30853d4f"
      unitRef="shares">32000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtMy0xLTEtMTM0NTA1_dea64a33-672b-4d06-ba2f-85a0dda1584b"
      unitRef="shares">46000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtNS0xLTEtMTM0NTA1_efd46d93-da5a-4dbd-adf8-611671e53ce5"
      unitRef="shares">28000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTQtNy0xLTEtMTM0NTA1_db43d133-b8b0-42c3-bd99-7501e0b663f5"
      unitRef="shares">37000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtMS0xLTEtMTM0NTA1_ba4daf7d-4b9f-4b15-9c8e-5d0305a73510"
      unitRef="shares">607214000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtMy0xLTEtMTM0NTA1_6a31d207-7909-4945-9f3e-c7062a389b23"
      unitRef="shares">607163000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtNS0xLTEtMTM0NTA1_124762d3-cfd2-4a5b-8aef-93e264bf413b"
      unitRef="shares">607207000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTUtNy0xLTEtMTM0NTA1_f7149a7d-c7e2-4685-ba18-a8403ec37d99"
      unitRef="shares">607151000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctMS0xLTEtMTM0NTA1_1efe5991-c094-4bb5-95e8-cb81444388f5"
      unitRef="usdPerShare">0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctMy0xLTEtMTM0NTA1_bfefc636-7691-430a-9f83-e87be8239514"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctNS0xLTEtMTM0NTA1_d73ba742-d119-4b92-9d6d-82e17a65f019"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTctNy0xLTEtMTM0NTA1_363ec1e0-8b1c-4fc8-8388-fd230a4fa807"
      unitRef="usdPerShare">1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtMS0xLTEtMTM0NTA1_7a0c0f1a-ea9d-4891-9743-b09d00e12f67"
      unitRef="usdPerShare">0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtMy0xLTEtMTM0NTA1_cc79e26d-97dd-4fc5-b7aa-f822547785e5"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtNS0xLTEtMTM0NTA1_66fccad6-2f0f-4f1c-80b7-558f6ac855e3"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV84OC9mcmFnOmM5NDA4YTExNzExYzRlZTBhZTdjNmNiMTUwYzUyMTQ3L3RhYmxlOmYzZjJiMzI3ZjdmYjQwMzZiYWVkZTNlYzcyNGQ1MjdlL3RhYmxlcmFuZ2U6ZjNmMmIzMjdmN2ZiNDAzNmJhZWRlM2VjNzI0ZDUyN2VfMTgtNy0xLTEtMTM0NTA1_fc8a6a36-2c13-4b5a-bad0-65ca172376bc"
      unitRef="usdPerShare">1.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RleHRyZWdpb246NzI4M2I3ZTA3ZDY0NDc2MmE0NWQ2MjgzZDMyZWY5MjBfMTYx_90ceb5da-c6ab-40a8-9766-66d6aadb4fac">Indirect Cash Flow&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;965,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,026,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,033,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in earnings of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,181,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,094,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Increase/(decrease) in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,035,222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,057,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RleHRyZWdpb246NzI4M2I3ZTA3ZDY0NDc2MmE0NWQ2MjgzZDMyZWY5MjBfMTYz_74ee92b1-410f-47e6-821f-b6f27cd65b60">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;965,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,026,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,033,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in earnings of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,181,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,094,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Increase/(decrease) in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,035,222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,057,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMy0xLTEtMS0xMzQ1MDU_f5e71968-5416-4305-a590-2af122c004b7"
      unitRef="usd">619680000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMy0zLTEtMS0xMzQ1MDU_094c304f-2b80-43d2-b263-c1a6e716b6f2"
      unitRef="usd">965734000</us-gaap:ProfitLoss>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNS0xLTEtMS0xMzQ1MDU_fe0f28ea-127e-47ed-bf70-c16986a55234"
      unitRef="usd">1026873000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNS0zLTEtMS0xMzQ1MDU_796246ff-24ec-4cf6-b9c3-87d78481c028"
      unitRef="usd">1033039000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNi0xLTEtMS0xMzQ1MDU_fddadb11-3117-4d32-be4e-fb9210139ba0"
      unitRef="usd">290335000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNi0zLTEtMS0xMzQ1MDU_cc93ddca-978c-4609-8ee6-c45175a369fb"
      unitRef="usd">48499000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNy0xLTEtMS0xMzQ1MDU_d161b735-b1a1-4302-8481-95385ab34200"
      unitRef="usd">5670000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfNy0zLTEtMS0xMzQ1MDU_8f7a1db2-ef48-46d9-ab43-48b6fdb88cd0"
      unitRef="usd">11404000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfOC0xLTEtMS0xMzQ1MDU_a725cf94-51e8-4d37-b84f-efe85882a431"
      unitRef="usd">10683000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfOC0zLTEtMS0xMzQ1MDU_96a2fcfb-1d58-4fb6-a8cf-058bc3d818fe"
      unitRef="usd">9583000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTAtMS0xLTEtMTM0NTA1_ba531287-837e-48eb-80a1-bab03723fba4"
      unitRef="usd">71805000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTAtMy0xLTEtMTM0NTA1_b88c6601-b7da-4026-862f-8abd48c90dad"
      unitRef="usd">-4464000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTEtMS0xLTEtMTM0NTA1_cc87a7be-8579-482d-a5d4-348337f3e6bb"
      unitRef="usd">-28138000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTEtMy0xLTEtMTM0NTA1_06964671-0310-49b6-a121-788a98387456"
      unitRef="usd">1309000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTItMS0xLTEtMTM0NTA1_ce1573e1-ee09-405a-a8b2-4f92183f644a"
      unitRef="usd">1134000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTItMy0xLTEtMTM0NTA1_e8f9a712-cdee-47e5-8953-576a1522617e"
      unitRef="usd">15783000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTUtMS0xLTEtMTM0NTA1_6768d5a7-decf-4f6c-96c2-aad82d374e69"
      unitRef="usd">27502000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTUtMy0xLTEtMTM0NTA1_d7268fc1-0065-4289-ae6d-5b4c9e81cd2f"
      unitRef="usd">22003000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ShareBasedCompensation
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTktMS0xLTEtMTM0NTA1_8c953192-b183-4a74-880c-f5234f5cc998"
      unitRef="usd">1005000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMTktMy0xLTEtMTM0NTA1_3a05d0fc-0c13-4e27-8230-ecd4df355052"
      unitRef="usd">1434000</us-gaap:ShareBasedCompensation>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjAtMS0xLTEtMTM0NTA1_00a4cc04-ec57-42fa-8a23-0787f2f1c617"
      unitRef="usd">16942000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjAtMy0xLTEtMTM0NTA1_710d550b-45b1-452f-883e-528153234362"
      unitRef="usd">28790000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjEtMS0xLTEtMTM0NTA1_7a7eb9cc-bf4c-4496-99b9-170c32145f79"
      unitRef="usd">53742000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjEtMy0xLTEtMTM0NTA1_a343f920-63d7-4094-811a-ea87b40f6e86"
      unitRef="usd">23130000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjQtMS0xLTEtMTM0NTA1_57632a90-eb9f-4438-9b27-186f90618223"
      unitRef="usd">-2657000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjQtMy0xLTEtMTM0NTA1_0a004f40-3d44-45ff-934f-3e487ee95835"
      unitRef="usd">-2049000</us-gaap:OtherNoncashIncomeExpense>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjYtMS0xLTEtMTM0NTA1_d1941593-4875-41ab-82b7-93d2c1a5ea2b"
      unitRef="usd">1181354000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjYtMy0xLTEtMTM0NTA1_82439d8c-7f82-4c95-a3f5-6dd3dec1bf76"
      unitRef="usd">1094094000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjgtMS0xLTEtMTM0NTA1_eaaccb50-64ac-43a2-81d0-e31d2c05dec5"
      unitRef="usd">-35254000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMjgtMy0xLTEtMTM0NTA1_0949c627-c994-42fa-9400-267e20a512e4"
      unitRef="usd">988000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzAtMS0xLTEtMTM0NTA1_04811894-bf87-43c4-8a51-b0af1e941861"
      unitRef="usd">2292000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzAtMy0xLTEtMTM0NTA1_445fd180-352f-4ee3-b845-324b3d84ac7b"
      unitRef="usd">4683000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzEtMS0xLTEtMTM0NTA1_47b8fb06-1614-4933-adbd-71ba5e66f9ac"
      unitRef="usd">-2711000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzEtMy0xLTEtMTM0NTA1_21f1328b-9ffe-4d8d-9336-b3cb44a54865"
      unitRef="usd">-3703000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzMtMS0xLTEtMTM0NTA1_8a19ed21-4bbf-4306-a847-ec3329743559"
      unitRef="usd">6555000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzMtMy0xLTEtMTM0NTA1_52cf4bfa-f00c-4ef6-95a6-8e0fb544da2a"
      unitRef="usd">-913000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzQtMS0xLTEtMTM0NTA1_b710fcac-505e-48be-85fc-5732f9362451"
      unitRef="usd">-3534000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzQtMy0xLTEtMTM0NTA1_f7cceb58-3ce5-4c1f-8ab3-0fe463e563b9"
      unitRef="usd">758000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzUtMS0xLTEtMTM0NTA1_d673c9f6-e6e6-4fcb-8cae-f9a60ee4a289"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzUtMy0xLTEtMTM0NTA1_cd387cb7-75e3-43ec-9f3e-1de8c21154ba"
      unitRef="usd">2730000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzctMS0xLTEtMTM0NTA1_c225d782-aa33-49d2-bae0-c3f773d6b7ee"
      unitRef="usd">1035222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38a9887fbbd3488fa171bc53d0bf0c4d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85MS9mcmFnOjcyODNiN2UwN2Q2NDQ3NjJhNDVkNjI4M2QzMmVmOTIwL3RhYmxlOmY1ZTU2ZWE3ZWE4NDQ0OWNiMWMyNGViMTc4MjQ1MTgzL3RhYmxlcmFuZ2U6ZjVlNTZlYTdlYTg0NDQ5Y2IxYzI0ZWIxNzgyNDUxODNfMzctMy0xLTEtMTM0NTA1_7b29461e-4173-448f-874d-87c81f744834"
      unitRef="usd">1057820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMjgyOA_095387b8-0937-48c5-b7f0-eeabe92406af">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have various funding commitments as of June 30, 2022 as described below. See Note 3&#x2013;Available for Sale Debt Securities for additional discussion of the respective arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cytokinetics Commercial Launch Funding&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June 30, 2022, $250&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125&#160;million of the $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MorphoSys Development Funding Bonds &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June 30, 2022, $350&#160;million of the MorphoSys Development Funding Bonds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $300&#160;million under the Development Funding Bonds to be funded in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Series B Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of June 30, 2022, we have a remaining commitment of $100.4&#160;million under the Commercial Launch Preferred Equity to purchase 2,004 shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8&#x2013;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15&#x2013;Related Party Transactions, which are variable and primarily based on cash receipts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rprx:LongTermFundingCommitmentAmountOutstanding
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMjQ0_11aceaa2-7ab0-4c98-8040-91299b3b04d6"
      unitRef="usd">250000000</rprx:LongTermFundingCommitmentAmountOutstanding>
    <rprx:LongTermFundingPartnershipCovenantRequiredAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMzQ1_a18ed830-74f0-4f3f-984f-40beb597f9e5"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipCovenantRequiredAmount>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNDIx_78532465-18b5-46ee-8d57-88cc10c3ddc1"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:LongTermFundingPartnershipExpectedPayment
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMTA0NDUzNjA0Njk3NTc_e39fa64b-4da0-4261-a998-4591acebc955"
      unitRef="usd">125000000</rprx:LongTermFundingPartnershipExpectedPayment>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMTA0NDUzNjA0Njk3Njg_78532465-18b5-46ee-8d57-88cc10c3ddc1"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital
      contextRef="i902af37f112d47b59465fb1587d35546_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNTUy_9bd8c49e-e1fe-4628-82f8-138c68bbcd16"
      unitRef="usd">350000000</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital>
    <rprx:CollaborativeArrangementExpectedProceeds
      contextRef="i6e2fbb199ad44998bacea26b48bc8815_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfNDM5ODA0NjUxOTEwNg_2ab8b718-f42b-49ba-81a2-e670b47a0a3d"
      unitRef="usd">300000000</rprx:CollaborativeArrangementExpectedProceeds>
    <rprx:LongTermPurchaseCommitmentAmountOutstanding
      contextRef="i212df1108fca4c628a85996199e48189_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfODM2_7c1a7b3d-7647-4682-8464-a4e253e2c716"
      unitRef="usd">100400000</rprx:LongTermPurchaseCommitmentAmountOutstanding>
    <rprx:LongTermPurchaseCommitmentShares
      contextRef="i212df1108fca4c628a85996199e48189_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV85Ny9mcmFnOjgwOGM1NzJhN2Y4NTRmNGU5M2VlMDZiYTNkOGQ2ZWE1L3RleHRyZWdpb246ODA4YzU3MmE3Zjg1NGY0ZTkzZWUwNmJhM2Q4ZDZlYTVfMzI5ODUzNDg4NjI3NA_dd37a0fd-5a1c-490d-b6a7-59b0f1cc5d17"
      unitRef="shares">2004</rprx:LongTermPurchaseCommitmentShares>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQ4NDk_4d606b24-bcff-4f57-9251-0d4f4e9cd0d4">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Manager&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#x201c;Operating and Personnel Payments&#x201d;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $36.0&#160;million and $77.2&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4&#160;million and $68.1&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distributions Payable to Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distributions payable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#x2019; non-controlling interest in Old RPI and RPSFT&#x2019;s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distributions payable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition from Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#x201c;BMS&#x201d;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#x201c;Purchase Agreement&#x201d;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#x201c;Assignment Agreement&#x201d;) with a wholly owned subsidiary of BioPharma Credit PLC (&#x201c;BPCR&#x201d;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, the financial royalty asset of $118.1&#160;million and $130.9&#160;million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (&#x201c;MSCI&#x201d;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#x2019;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#x2019;s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8&#x2013;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million is recorded as treasury interests, of which $1.5&#160;million and $1.6&#160;million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#x2019; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <rprx:RelatedPartyTransactionRateAdjustedCashReceipts
      contextRef="i2d396452af104e75bfbf02ca11bf7445_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzY4MQ_6f0e4c7c-7535-4572-a535-650239edbb52"
      unitRef="number">0.065</rprx:RelatedPartyTransactionRateAdjustedCashReceipts>
    <rprx:RelatedPartyTransactionRateValueOfSecurityInvestments
      contextRef="i2d396452af104e75bfbf02ca11bf7445_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2Xzc1MQ_84ed3fc0-8e53-406f-b019-f670992af2d2"
      unitRef="number">0.0025</rprx:RelatedPartyTransactionRateValueOfSecurityInvestments>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount
      contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzEwODI_8c4464b6-2a71-4ef4-9147-38788d7aa6a5"
      unitRef="usd">1000000</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent
      contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzExMDE_3d60c510-3d25-40e4-a824-684cfb657ea9"
      unitRef="number">0.003125</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="iade6caaa03d24c1db457fe31fe5a9a4d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2MTA_66878e82-0523-4b24-8551-a30bcdd02c18"
      unitRef="usd">36000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i934116fad2e6442e88d42ee191199a43_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2MzI_93309179-aaf4-4025-9d54-762c8e2d0766"
      unitRef="usd">77200000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="ib720c19bda424da0a54ac76bd380e694_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2NTQ_44cc94d2-8c45-4865-aa80-06dd1b0df1fb"
      unitRef="usd">32400000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i1e368ed2beeb4e9bbfd7a428cdfe20a7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzU0OTc1NTgxNDQ2Nzg_9b995f92-5a29-4b91-b0df-6fcb385f5209"
      unitRef="usd">68100000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQ4NTA_c989a929-0ded-4f19-9298-b5d1d21f47fe">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distributions payable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#x2019; non-controlling interest in Old RPI and RPSFT&#x2019;s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distributions payable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="id600e57f7adf403dabaeb1fd595d2aea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzEtMS0xLTEtMTM0NTA1_c6b85238-23bb-4bc1-b150-e6ebf3507667"
      unitRef="usd">107886000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i27cc09d1626c4c12831b9b9ed5f1707e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzEtMy0xLTEtMTM0NTA1_d6b27050-7930-45f8-a2ee-cd0310affd54"
      unitRef="usd">92608000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i75026c18f8e94d4d89a49b9629256c1e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzItMS0xLTEtMTM0NTA1_b0492972-6df6-4d75-b309-6795b469dfae"
      unitRef="usd">8104000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="ica95079874234fdbb0b75f9d0967a000_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzItMy0xLTEtMTM0NTA1_d75b2d61-0959-475f-ab40-11d4c8f3a17b"
      unitRef="usd">15326000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzMtMS0xLTEtMTM0NTA1_725b1944-027b-4f2d-b63c-e628751721d5"
      unitRef="usd">115990000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i5bce62e7437a4451aba53bcceaf66c3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90YWJsZTo1YjBiNGM5MzUyN2Y0Y2FjYTAzMDk3NDE2NWExOTQzNC90YWJsZXJhbmdlOjViMGI0YzkzNTI3ZjRjYWNhMDMwOTc0MTY1YTE5NDM0XzMtMy0xLTEtMTM0NTA1_9c863d89-800c-4f00-ab28-2578585008fd"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i69334c4cb99348768c6cddd1b7d09954_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI1Nzg_09a5a9c0-5f14-4781-92f7-6170272dbda8"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ibad559122e374240aa4d76a955a15563_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI2NjM_a8001d19-7c7b-4a15-ac05-8b27c628c843"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:NotesReceivableNet
      contextRef="ie1a96d121b274fbd8dbe1ad563a91052_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI3ODU_a37ffc02-1165-41d7-8da3-6e2e0a92eb00"
      unitRef="usd">118100000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="ifd9849608bf44ab2b4553b4ce907b20e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzI3OTI_7ae01b08-e295-4156-a3ca-92d952fd1c34"
      unitRef="usd">130900000</us-gaap:NotesReceivableNet>
    <rprx:RelatedPartyTransactionInitialTerm
      contextRef="ia627a511f205448c8f15096957f33520_D20210416-20210416"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzMxODI_32d1c1a7-0958-4f11-a18e-2b0170d997b0">P7Y</rprx:RelatedPartyTransactionInitialTerm>
    <rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired
      contextRef="i6458b426c5a0473fbba13389985422c7_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzM5NjE_b6d83a68-3182-48b3-b7d1-27e0c335a715"
      unitRef="shares">27210</rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46117034b4ae4c55b35944ccab8ad2b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxMzQ_73688632-74cb-48bc-af6e-38a84e501eca"
      unitRef="usd">4300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89beaee57e374c50b2a774f5e339e12b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxODE_36787c25-8733-4fe9-be5c-7271c7418bde"
      unitRef="usd">1500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf7a05a6178471d83f36a54fc1b58f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDMvZnJhZzpjZGU1ZjA3NzdmMjI0NzRhOTVhOTUzYWRjYTQyOTBiNi90ZXh0cmVnaW9uOmNkZTVmMDc3N2YyMjQ3NGE5NWE5NTNhZGNhNDI5MGI2XzQxODg_61785a3c-575b-4ac5-a49d-910c5b0dab38"
      unitRef="usd">1600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzMw_87602324-6cc0-496f-ad9e-b2b947bbb577">Subsequent EventsIn July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (&#x201c;Theravance&#x201d;) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31&#160;billion in July 2022 and committed up to $300&#160;million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25&#160;million in upfront funding and a potential $15&#160;million regulatory milestone payment to support the clinical development of ampreloxetine.</us-gaap:SubsequentEventsTextBlock>
    <rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1Nzc3_f5684b00-15b0-4dd1-9a14-0ef359b6f307"
      unitRef="usd">1310000000</rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments
      contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1Nzky_203daf4a-f139-4c26-9482-1fec55f02fb2"
      unitRef="usd">300000000</rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments>
    <rprx:LongTermFundingPartnershipInitialPayment
      contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1ODA2_78a4be39-9771-4389-9ec5-de2d362d66a0"
      unitRef="usd">25000000</rprx:LongTermFundingPartnershipInitialPayment>
    <rprx:LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount
      contextRef="ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MzAzYzZiZjBiYzRiMzI4ZTliNDhiY2I2YTdjMTM5L3NlYzpmNzMwM2M2YmYwYmM0YjMyOGU5YjQ4YmNiNmE3YzEzOV8xMDYvZnJhZzpmODUxODU0YjYzZmQ0YzlkOGIxNjcwOWQ4ZDVjMzBlOC90ZXh0cmVnaW9uOmY4NTE4NTRiNjNmZDRjOWQ4YjE2NzA5ZDhkNWMzMGU4XzEyNjQ0MzgzNzI1ODE5_79cc6a84-49db-42d9-946a-7aa587f008d0"
      unitRef="usd">15000000</rprx:LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@OM"F0W@^Z64>K=@?J!\+6?\/U!+ P04    " !42015B\N!+3D'  !9(P
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M+@60@5;$CZL?2UO$IE+(L)6V'&84HIM5/="+^/&UZ]M2FK7*('5MI3;E7$%
M;#)Q0G$43M4Z[%C $CZC=D 8\3.L3UV>=& #B3&0.-5GFW$RNZ8&;A$_N/JD
MY5%GPX=$$<><L*E EV5 @CB<$SF@BL3?5>P6N7C(B_EYZ27>J27ON;R-8QZ
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MH*5<B7VN/ZGGG^71H*#F6ZB\:OZBYR,63]!B7VFU/0XV3[#-BO:_^'ITQ,4
MPP,/H,<!U![ !P:PXP#VVCOPXP#^VCL$QP&-Z=/6]L9Q<Z'%W4VIGE%9HPU;
M_:'Q?C/:^"LKZD3YK$OS:V;&Z;N9*I8F['*)S*=*Y=E2:'/Q69M_)A]TA=0*
M_6<G2U''M4)7Z,OG.7KW_7M4;40I*Y05Z/>-VE>B6%8?T/>]ZYNI-H]8WVBZ
M.#[.0_LX=.!Q&/I-%7I3H=0\UA(8/_>/#SWCI\8U9__0DW\>J)?PUWWQ$3'\
M 5%,*? \L]</)Y Y_]_=T__Y[CUGL'.RL(:/#_!]D@=9["48UW9DV(RLJ]/A
M+F!!$@0WT\.ENP!8P).0]6%S%T9P$F/,^[@4P!$:)0D^XWJ&\K.AO!G(!@P]
M)GRQ1O+KKIX>H,G<YZRZPE]7.[&0MQ-3PBM9'N3D[H?O2(C_!>71F&3S,<G2
MD<AZ@0C.@0B\&?=8JD/6-"73$]%B(XIU6W/JN"SJ2K40U0:M3+^KT*I46[3*
M"E$L,I&C4GT3N?Z&1%5)#0:PO7?0R[(@(E:2S5S8%>4L"JF5M"Z.)I@Q:PJD
M+HS'/$G@C W/C@I?F)J5%.5B@TS=-8WR8!3 KJ[?:+4OEA>)#+DA=!XHQ*'E
M Q?#"+4=X((()L3F2EU8$%U4@)[]T=G^R&O__5:5.ON[Z5)UR\H*;7(E>\JE
M)_Z1\R#8,MM%!!&SBQ4 "B.+*75!A/"+>M:S.CY;'7NM_DD6IE#E3=#%TLB#
MK-)UX3I(;^&*W0<F,;?,FKDHSI.ZC_2,=U'$Y'QLD:4N+(YQ%,'F)V?S$Z_Y
MORMMC%=.L9Z^RXJ%VLKW'U A->2!Q'WJ("9V&YJYL"L2)TEL9?3<Q06F5R5V
MMX+NRB(^D/H$=QH.>_W0M:O6;E!W87<&1U&46'-X!N B$W>>6"8#N"") F+G
M/8!+(D[Y0.C)A7 E_AZM-[)$ITA//?7M2#12HQZ5;3XJ6SH66S\DM L)]>9A
M^M<^,PVW;L^B+$P^-JL'V7Z[E7JCEN;'@ZRTA O3D;\WX2(6V2D*H$@48;LT
M@3C"[%D)PH(H'IJ6G5HF?KG\2Z&E<;/V]=XC1:_*ADEHMU\ 9@H'M>L0 $LX
MIHEML0N+C 8A P9WJIEXM>#=NY]$5E3OI[DR+=?$OC!*I,P.;4/JA)G!Z'+?
MK"Y!EW @"4B,[:4$@",)=NK4Z]A2 ,=Y.-"?2:=?B5_ NBXY3H=*+O9EIK.!
MB0!HSAA36YE"L'H]%=A. *1I3%AL^P"@(PP/2%/2:5/B%Z=?BE**//O;R/5U
M[8[:#>(@LES4^JQ6]I4P'Y;R2;_D%U<[7D68V:ID!N&,W"*.8P!<W9*I[1D
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M!84-7\J9;'_1OL<Z%DIKJ7C9!\,,RJ+J_LFGWHB# . Q!WA]@*<'!"<"_#[
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M$Y\Q'$MDE!(+B(X&;U_WF(WW_?C%FR+<L3&9XL8>'C-,Q\+2!KQ?&..;+W1
M^Z/+Z3]02P,$%     @ 5$D$58?7R$Q:"@  ZQD  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&ULK5EM<]LV$OXK&'622688V9;=-)<XGI'5I$W:-*J=
MI!]N[@-$0B)BDF !T++NU]^S"X"D7YOKW1>;+\!B7YY]=I<ZWAI[X4JEO+BJ
MJ\:]GI3>MR_W]EQ>JEJZJ6E5@S=K8VOI<6LW>ZZU2A:\J:[V9OO[S_=JJ9O)
MR3$_6]J38]/Y2C=J:87KZEK:W:FJS/;UY&"2'ISI3>GIP=[)<2LWZESYS^W2
MXFZOEU+H6C5.FT98M7X]F1^\/#VB];S@BU9;-[H69,G*F NZ>5>\GNR30JI2
MN2<)$O\NU4)5%0F"&G]&F9/^2-HXOD[2W[+ML&4EG5J8Z@]=^/+UY,5$%&HM
MN\J?F>W/*MKS/<G+3>7XK]B&M4>'$Y%WSILZ;H8&M6["?WD5_3#:\&+_G@VS
MN&'&>H>#6,L?I9<GQ]9LA:75D$87;"KOAG*ZH:"<>XNW&OO\R7D(AC!K<:XW
MC5[K7#9>S//<=(W7S48L3:5SK=SQGL=YM&LOC[)/@^S9/;*?BP^F\:43;YI"
M%=?W[T'/7ME94O9T]J# ]UTS%8?[F9CMSV8/R#OLC3]D>8?WR+O#2O'/^<IY
M"[#\ZRZ#@[RCN^51 KUTK<S5ZPDRQ"E[J28GC[\[>+[_Z@%MCWIMCQZ2_C^&
MZO\E6YQ*IQTM7%K52BM#<C6%^.P4/7[CO$:V8.6G4B'K<E.WLMF1C*Z17:&]
M*D1N (G&A2L'T86DQVO=R";7LA+.XP&2WSLAK1(MGX45NF&1ML ZA5SQ)=]'
M)5NKL;VM</A&-<K*JMK1>]7ZL-=#I<\-JW#N64EH/*^5A;WBR>/O7LQF^Z]^
MFL^7?'GPZNE4O N[3*L;LA3K:]F KTBY3. $(8NO2-2@+)FC"T6J-BI7SI%7
MO1&,!WAT+;6%3B013T =K '=ZL9#C5JT^&L*)TIYJ<1*J09O\JI#!K&7^0#G
MA6DJ#E=#W%3Q*ZORSEKRPTBCJ5@HZ\'.$!,X/,5K;8QOC%>BT"ZOC.N@T.C4
M(43&"E-K3TZ3CO2+-QT66$'>FHJY Z_G919-&4[JE6?O SF_=]+"4FA_IEIC
MR1)!!"L.]I_]+EQINJJ !H)*#&V"'E^[)G XQYM.&.'HK] #2X.W*UY$%CMZ
M8A7"(MG]P1N6U^V4M$(188D?$<!Z!1,/#YAR\'=LC>FLF#=-A_-N6_++E.'?
MCG($!_V]! A.()=JOPL^(*?#I#\[34$; $E0J^6%$JK/0C)..A3=EK0@TZ47
M<KU&68R.(=TIMC6E47"(<RKZKM)RI2OMM1I\.0"&%D,W2CXZ_;Y]X20R,:']
M[E@YL5644.Y>S1  4ZL,[RY5TT6=U%5+OG2BZ!C^PV8F!4XH0#3W%*N4=K7<
MP1#XP8JU-34V&3?R6XA?6IS0<3-)B9N J#[7-6"MFP)L0LT&*7Q3PKJ#@02R
MJ?A#1=]UBN-F0$SI'' FXA,54V+Q\<N['Y\=_$. 2@M5ZYRP1@!$=Q;@%3E@
M\"M><!:")V&+8>]G(H]D +:_4+ E9CR<2B%018 ''3G:3W:TUA1=3D% &I8Z
M+Q$J8;;HS,Q.5ASF$6.Q^I"VVMVM_E3\;+8(H<WN,:\$!LBQ)4A "HJ():.B
M7Z+Q(P;M_9#0A]0H*%WH#IH6AL6M5*5QK-!>@(I ,0Z>6R%HE;Y0%3-UK!+K
MS@/?TZ'<+?H\I60F</S=;&8*"3062A?+/V,_[L2RE/!Z2%M I99?C84AS^#K
MH01X:ZH*MZY;H=QH $^Y;)P_EW@$PR)B@6IPFN=LS! ^/"&G$'HYU( TU:D5
M:B8J/\3M$CJ3,=SZ@O);V*XN9=7UG$:!:!%,#J4UW:84EX83SU)'[*A\.%WK
M"KP:GF3DY@+,%1F(._/ %$S&AM@YZ+L+>*P-#'!#8T)9%I! ^\-*JM@'/[QR
M0D%M0QBZE@$@YNO!2?X8W$%HQBKR"AC%D+U0%,T$DV8#6M]_E/@K'<(J4^6+
M6F0D"):A0Q&_8:8*? 4&]%:O.L\A\83%YED*([DJ1<DE:-^#J!&.KH,>I0 P
M@^28NCG6H";<5)=K.8!D7:G; 1NHA2"%4-8&8\@YJ[Y7:14/4+=41WVCE0R8
M0+H/6)>J<%*4*#K"Z)96+A:7D?4CM',ZAYR CIV+I$3!N^'LE^+)P5,^[E>U
MD?D.'=TEQ!MPWQ*ZQV-=Q,]($0)C"]Z[XHH S!V\>$0>^H@&Y6SY+A-/9D'N
M(K XF?JMLB'F; D2K KL<GWF0)JVUU6@ \9+%Q6JK#C%2=%-T./P*4@2G((!
M$9GFAL#R,8M/HE05^^EL>?[V$Y/(DZ.G9(1XLYSWLC/QZ[)/H]0-CQ>DKOA!
M#9.Q0=$%((?'1"^NI.@\H>51]FV[%N(<0"/*3/:-.W'.I:T&Q04R)X8T>4+4
M6%-!$T'5ESM*)QW+ W2HE4<_ #'LJ#BA"(Q]C9/Y4$56LB+R&%<VU \X6<9Q
M(A_7A"GA@/(NY205#0P"J#5GVEV(MWTUT U&S"ZD,?,;@/V5V! PAATCHJ,3
M;HC,@TA+(M,P$ A<AXD@EZX,=8(NJ$<$7]-96:SZG!>.AH58$.2E!#W34^I2
MG+SQ>BAC-M:HT.=E@)R%<*(%ER80A0>0!#[X2#1&*HS:4UJD.47XMJ6ADHHO
M.ELW?G'-0V;TYMG&RF*LWC 3&/8A452:MRQU-K+5/C9'W!PCY(2(H4,(2 DU
MOTD]G5+4Y9,[!I(=F727>_GAG1X>@!3FC?==H_KO&+SMUJB!,@(U.&W90)Y6
M\=?2ASK:<2J;B]'P&G1+A3SJ3)-@ZC"N5T]UE2L5FOFWL!2#,E1 R0.PWC5H
M[+GK6Q@+@@Z%/H0H-,6I)4G5_SY\W(0$/*O18G-3R^5!QHX\[=K NE%6<!&"
M(T-6#'VF"1T:X=2%J:J@>9+,76G3<O^4J\[#V&KH6^^:_C/QIK-PUFA*I-$Z
M4-K6V*K(@OL?3D-V#H06H9&GS2MKT+G"CZ$&#^TV55+*VI1MK63%!^L@H!M&
M+>KC5'#U1AF ORUI$?LP5#QNA,>^B19'_Q":.4U5D4;2P2%](U^"-D=2F".#
MREPV*LSBH9 7'1)S%XI^KD&;1 .AI<6"C$8UK.,.#B^^@'[5529.M<%\F(GY
M:O5%8PIY;TH09R,>R[I]E>XR\0%<?!$?+LPT$\NU_C<UEG.'^HOZD(G?S"4=
M3:0%#_VD23/^^O!M:36H%&?,%!A>CEA0PJ]O^Y26YCO,ACG0CMC23+"F+"F!
MZ"QE662,P]FC)(0^R 2BZQN=O\B6^*$H)B>:YDVHXP5:Y(*RY1LTYEYL/$[>
M.14&$F,8 ^J^1 /H^J]1P1X;FSL"Y7#"M4QU)B3KEJB6P=?RQQTRRB6C"/),
MOWE)&9&2$:U.3"-L6R.6HT&50"DOPW1-\SW2 #K3 +2[5B K0P>%+(U=:LK!
MG&:D//D]=N+&IF\'_11Y+0S3_^[C:OB2NS?Z  \^WO#/#"XX,7R+[Y_VOV3,
MPP?\87GX&>0#(H[JAY1;8^O^](?O)V%L2C?>M/PY?V6\-S5?ED@"96D!WM-G
MO71#!_2_[YS\!U!+ P04    " !42015O-M9[)(+  !=*@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6S56EMOXS86_BM$&A0)X'%\2^+,)4 RT[13
MM)U@,FT?%OM 2[1-C"2Z)!4G_?7[G4/=?$ODM.CNOM@219[[^<XAI;=+8[^Z
MN5)>/*1)YMX=S+U?O#XY<=%<I=)US4)E>#(U-I4>MW9VXA96R9@7I<G)H-<[
M.TFES@XNW_+8K;U\:W*?Z$S=6N'R-)7V\5HE9OGNH']0#GS6L[FG@9/+MPLY
M4W?*_[JXM;@[J:C$.E69TR835DW?'5SU7U^/:#Y/^$VKI6M<"])D8LQ7NOD8
MOSOHD4 J49$G"A)_]^J]2A(B!#'^*&@>5"QI8?.ZI'[#ND.7B73JO4E^U[&?
MOSL8'XA8366>^,]F^8,J]#DE>I%)'/^*99A["HY1[KQ)B\6X3W46_N5#88?&
M@G%OQX)!L6# <@=&+.4'Z>7E6VN6PM)L4*,+5I570SB=D5/NO,53C77^\NI>
MZD1.$B7@8'$G<?%!3;RX4U%NM=?*O3WQX$.S3Z*"YG6@.=A!\TS\;#(_=^*[
M+%;QZOH3R%<).2B%O!X\2?#'/.N*8:\C!KW!X EZPTKI(=,;[J#W,;M7SB.T
MO.L$=646B^_^R+5_;&@N_G4U<=XB</Z]S0B!QV@[#TJFUVXA(_7N -GBE+U7
M!Y???M,_Z[UY0H-1I<'H*>HO=-M?I2G>/WKS%<N\CG!CTE392,M$_"3S+)J+
MFSR+=383GS+QH\QR)+DX#T[KB*42L+>R*A8Z\T9(D9AL]@HCJ9@6Z^3,*D5N
M01+X^0JWCOB81<8NC)4>)(Z^_68\&/3>-*?P4/_-L0!UER\PU8.R]7-ED:?W
MP)\%TS93(:<ZDJE7&3M^87#E28^H4DG_*1DU,-FDBB;K>T$7=J*3KKAR8B$M
MTP+]30587[Z+29R%-?<Z5B*2"^W!9YOXN^U9*09N^8+H'0Y[/:!!DD!$L)IK
M3-:.Q%]8[< 3,Z= .X'H!2$%\^DL2O(@9(8;S?H6CVGZX6E%$2I)N$ ZU@O4
M\@4&H\0X+._"$:RSGT,[D89,5SP/>:JJ/ TF2,,36K"7OTE+B(PZXQ2OM@KI
M2=$36[D$79-GOKNZ!!:H9F$Y3VRJI>%X$2GK4:M@*[@\FZDL>J2%J0H@,(?6
MQ,XLV/TEF2 !%3F2^W!0FS\8AY=$R!,+@FS/DH]5LSR1WB 7B'Z$K$/L)2L1
M"5+ (Y,AP[9&1IE7%"$ZX%89$QR*8+=I>O6P0.43A_W!:25K$:XK\D/%H)F0
M%0"0VRU/;9GQ<:Z($+M9?U6)GAL3ASC:8HB&ODM((3+CQ42Q#R:/ )U(I1/P
M'_:#.EWQG02O,EC)11S#A";.OYI2''(>RT>R31A8**L-)X+3#TB\!($HK?@#
MJ(1U2(BI2="1(%3 <CC:G$%+=>:0K@D[R:I7!0,*3@R3WOWNA?!H4D+0A*CD
MB$'!^AT^H.:C"/^IU%;<RR1O!I>,(EY"B-O>W!T( S"DQ*+$@7%7L=L1=L>$
MW:[&[B)*$?<Q>BHLQ94SB8X94"<RD12YW$G .K"Q1F :YTG&G% W>:0NC#0*
MVF;2YU9M0*"%FV:<U5WQ95VE+9%<X1<#5&D<QQZ%,DMI8PA_7\2CRR<..4X.
MJ;%-6L46F67Z3^B"H&L8N[#0)ZX#B9; [V 0N9DXS+2]20.%]7CM[V7J8*0\
M ](E+'TT)_O!'"L14QL94UHF)2FS$51;/%#9KQE1O]82S9"^'#_R>9/H)U5'
M-GD5>%)A18YRE841?D9MGYN[1P=SUL!8"GL-<H[;"O+6()@Y%)@L0P)%Y/5&
M@:&NS:N9CJJPI&J=(:OG>A&*3<WPZOL*=:O!;;V$)DM%J"].EZW!>\B.Q$A"
MKW [E]@G1"KWA/"A9>D6((CB2669-$ >]4^#"JT:"<X.JL9E,=7M"C#)KA[0
MVH0H*&M^R8(\LJ--J6U3MAN-*DJUK6QCB&YANIUN:YH2(,_@2)A[IQ8^Y$U_
M4.)\S7A;+9>T =)IGG*_TJ]EZHI/N>7F+40TK2 U"0D2=!!^979IZ]V!QLQK
M.'%/3A<W :0@!&4UZ]<LP%Q?(T7=F,05,),E&'0'FY6CR.\"/W8+B$+$:4@Y
M618LA!6VI[K 2O0I2CPJ296.XYVC2UO8HJAB<,9,9]S/^*4)<]$8^P)HRS !
MP:*>;6TT:H_-9<R%/#A89H^E4G4SL5,A;BHY,]:I@J*>:NI!0T'VC@M_MM*=
M-=OA-NR*4"RLC72J8S'$X4M*]W/QL7])I>[#YG4E?99#$;=-&/^'RY[A//R[
MR]Y+%/^'Z]<=VDTLOQ+7VLSE/7:6M_"LLH1?=Z@+BLO7%;9GB6#P[U]TQ.?;
MCS=?RC DMHO<P@Z.%1]T1A>G;>A.K4D;CU>*D/C!)&6Y7U!._N0!5&6Y*Q=5
M$ V\E*@".BJWA)T^,@MJ8K#DZH@K&U"&/CB@<;W+"*Z5"ZHFX>DOV(6K2'SZ
M\(6 GQ3]M7O7A??0H%/H?;#Y3%S%A.Y<N2G#2AEO/EQ5XL$Y-VIB^6 !$=>#
MTUV>^)##L@*V8C,2$(.PK<998S5 #U)5EJZTI<<MK%U"+SBB/H%2#;^-W8)K
MH.ON<OVSA!!U_F"&R6?S7;/7$V[TU%9\E337(T@DLZ(6A9:HV,UP !&=6A4H
MK-*%;U3+YTT#<:;U4S6=,JQ1T!6Y39T#9+0F$4AHZFU ."/1>!=(Z];VWI',
MX:**)I?2&(U1)SB<SB/@BD*1#O,RN8<7 D:T<&<CXH,[:1?[]X9,MWZ4RL="
M V*,Y4"Z\H#Z)>+OLL-+E0JIV\9L@( HD<Z%XHR*T&X'^G?4A_6*W#IU_SM5
M@@_EU)S>8]R3_+A7:YE+&$BG%$\=IAV.NW6/0PL.^V?=B_H0$ I2NPD>R6.G
M-$J^KMY2A:U>[3I.?L-=PC9)*70^%B<MY=!+:^1^.@.T#OO#[G!5Z<&X._Z_
M4KJ(R^MG&H-\EH-7."WO;9Z6-R)\-R5Q6R;S576P6I;1YQ=7:ZIRR_N&:OYR
M3F9<JF*?Y</&C#?$&!]V+BX&H3=@$[10NWVST=QG;AYWU(3#&YQ*_O4>I7GJ
M^>0.:J+\4JFV9;L\9FE7LC=WJA4$MW+RCMUIM:YHB9M5AZOK1*ULJ(LJU)8E
M5YDP#Y8,166J'S"CMEW53^QCOM,]S#?L;:ULW&D^Z#3LI_K AWV+]Q.J_R--
MC7:N:EG10 +!>"1NE459_-*^J&5R[F?HH,O>5OYK+=(3I/=HD?;6K]SZMU%P
MUVL:#I "16/1[UR,QWO!Z,L.*]H&UC9D*8\D5TZ-R<@S5) 9C->^'=SCE/QW
MVL D6A7IM*EE^X,5USQ:V>\DHJ7=-FSV/W!"05IZ)CVA3W&*SW# WG%7WH)S
MI<#J"Y9=!TJ;!T1'++O)'1Z[X]?B/;FL88;OV0PW1/HW)OV>7ZAZ)(]#$(A?
M3/9J;:B\_:EQPM6<UAP_&AZ++]P-;$G&\*U#0]NC_K$X%(/S<>?\] )7XU%G
M,.KC8G@V[/302N"JURNNJB%J/OJ#-RM7Y8(J&(X&Q]7CP9C;GN(/,\_Q5SXL
M_X^&IYVS7N^XG%8>@D6-ESA$].BB,Z)I_0Z=B![QY.,-:A75XGGY'VS3(A!@
MEK.+SI#-TN\/.V?!+N/*+H4:6^UR-.*'QXT55SL.%'>XI#?JG/:(]^BBT[\@
MUH/3BN%9P; _/B^&MKFD7+#5)?TS?E;\K8VN&[$8WL=VE?QGIYUQD/^\1XYK
MRD^S1KOE+Q:013B+^).=Y[? 5O''2/S2+S76!\ #@>X&F:<PKD&F?GM!9V,Z
MWNAH-Z V8J!VSJ")]P4<ON#MY@J^-Y$Z6SU*)5SLLG^_\ Z&RE9F6 JW78RJ
M@WY6VO4<7+/+\U(!D3X'/9XXLM_VO=A)XY,_&&C&'S;2%T!P1/CZKQJMOIV\
M"I\,UM/#AY?HQV>$NXF:8FFO>WYZ(&SXF#'<>+/@#P@GQGN3\N5<R5A9FH#G
M4V-\>4,,JB]*+_\#4$L#!!0    ( %1)!%5(<2=:8!8  (U@   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;.T]VY+;-K*_@IIUML95M$:DKN-;U7@<
M;[QE)SX>)WDX=1X@$I(04X0"DJ-1OGZ[&P )2J2D<2;V;NUY&8DB+HV^=Z.!
M>;Y1^G.^%*)@=ZLTRU^<+8MB_?3B(H^78L7SGEJ+#-[,E5[Q A[UXB)?:\$3
MZK1*+Z)^?WRQXC([>_F<?ON@7SY799'*3'S0+"]7*ZZWKT2J-B_.PC/WPT>Y
M6!;XP\7+YVN^$#>B^'G]0</3135*(E<BRZ7*F!;S%V=7X=-70VQ/#7Z18I-[
MWQFN9*;49WQXF[PXZR- (A5Q@2-P^+@5UR)-<2  XW<[YEDU)7;TO[O1W]#:
M82TSGHMKE?XJDV+YXFQZQA(QYV5:?%2;'X1=SPC'BU6:TU^V,6U'_3,6EWFA
M5K8S0+"2F?GD=Q8/7H=I5X?(=H@(;C,10?F:%_SE<ZTV3&-K& V_T%*I-P G
M,R3*3:'AK81^Q<LW7&KV"T]+P=X+GI=: ,:+G/$L86]DQK-8\I2]S?)"E_3F
M^44!TV+GB]A.\<I,$75,,6;O558L<_9]EHBDV?\"P*U@CAS,KZ*# _ZSS'IL
MT ]8U(^B ^,-*AP,:+S!<1R\EGF<*D1#SO[W:@:K!K;YO[8UFR&'[4.B*#W-
MUSP6+\Y 5G*A;\79R[__+1SWGQT >%@!/#PT^L,0[> 4[0OHL7O/[/?X00K-
M=;S<LE\%2$XA-#"T8,52L#FVNJ56:LYXG@L[:"KY3*:RD$"0,I?98K?YT@T:
ML,U2QDLF\H+/4@DBD4-;+01+Q:U(<QQ89NNRP)]Y 4*T93,!@XJ$%8JMS'+\
MH7G.YBH%M94_97__VS2*QL_8.QR+A4_9SQE/?@/YA-Z_EPH_UEK&,*=TJ@9F
MT)^%FX[#V#R&!KF<I?"UH(6L:B2RA!<PO=),)O H8YX&K,P ^04,C!-8M$ +
M#RN]'="BI^Q_=N'9 R13A0,21IM7A),>X1 2@U&>IBR7BTS. 2@ U&(1!U(S
M9 W MPB8D+ BS1*I0>.F6QQ99NYI%\S!4_;!P*<,NCDI:8)0B]]+Z-:@%DXV
M4\6R 0B0;8<;?'PB^Y19#6&/_51V+3968&;R G$&R)((_9S%/%_2*/0%@8))
ML'E@,8JCLES$I292!-2FV#9^2H2&;HAJ>."W7*;4"[&;PVCP?E8T.FBUY2D,
M(C,0$""^E0.5+9Z@Q%"''KO^!K"9^80NP-:W@0DDTF*M-/$J\3?0!=ZMA6&U
MFDY ]8PIH ;@'9@=11 IH%*)0I" G4V!2  _VC5@\3>=7&HY%*:.N=;2S%Q/
M%!"#D ) 0>C2'4SF9-L3IDPC$'I8D^VXHSB@[>E,")-*Z(@"K44!8O"N04A"
M:;TRAU2G %LQRE?P@_R#<(9XOP\JV:PL/,GV*8*3)<;\B:3'/BUQ;G3K4.FV
M([\!W[W 0(E>J3*KQ'N]UNH.9*]HL$F/7=6FX)UG"JSQ(:QX%@;=//81&58C
MU*\X"#6MQ.AQ,A]&,,@'!23F7<9FY<W@6R><05<SS&@&J\QQI3GIO!C7'+ X
MA<&!3V 4L@JQT@EA80.JLIL9$Y''6LYP[ID"N3DGSE5E#C#FCY\"3I EP0L2
ME1=D?WLM8K&:@1(>A/1[Z.R5,PY.^[)/J@!B'GYK</_4Z!I/Q: _)[96S[!Y
M"5"Q1P#*))A<3N ;:OHP>M;X5K\=74Z#:#3H:.?>7JO52FCBN#5?PXI<DW :
M!N-IV/T\""YAGIW':]!:)+!((4!4 ER;RZ)J-A@'_7[8]3CL!Y>CX>[C^S8]
MVPWX=!*,@5 =CQ'@9SB:[#T? SR<3(/)>-SY/)@,@V$XVGO^N7?38PO@+IV1
MGO)64($P#/KAL.NQZ_/JN!EYO?-\'C[>&V;0[P,)^M7G[OOQF'ZV'V ?-EP#
M&YY'^T.-!\$$FYJ/8_"_KFRBI^K8^:!UW,B,&YTPKA$IU!ODFQBETY"+_C3H
M3X?P;1B-@TL8\A$+@V@8!1-@;U]NQL">TXB^F>5CPT$_#/J3,?M^U\RS:#(*
MQF./U8!#IB.8&3AA.&'@E,%SS7G# =!YP*+Q93"%L1^(GH"EOD%6&S5#D 8D
MCOL\2,]CG^'8C&4^3J?G-!A#>_/WV!P?G:%N&(?SX?ZH$= 0Y,U^G,8EF<J>
M['&*(Z.O+4,8=DP,,+B<!!&]=?3TVT5#T"8A<LP0Y!_9U3.F3T^A\4&*G ]&
M",;C^LNQ=;X!HX'V,P9M*0OC39R/6D:>!B$-;#_OCS_?IK>;G/,A:8;'S:]M
M+?>_(:M_%'/,,>4M@2S^<@,,"'-?L5=2+?FMR"#P$7.AT;>X67)M_6K;[%5W
MLUZ;X0\J/XJGN0(6C],R:8NIZ9<2,S ,'38,MNROU]M"?89 '$+.AOEZQ\L,
M?$1+JAY1_L!:T?E3$'@O*)++T2_&^:@ECT$K@=FB%TV\'%@P!N#@:H'3!#^A
MRP1^T(Y8\!97"+%I6[<($F]WE'I='I2)( R2#8[UE^'@-?I6:DWJQ['_*X6^
M4\LR]P'OH/Y#P; A(&AA-10_44#O2Y -CTYQ\GND9#^*E%[9*.F]3"&N O>1
M7<6Q2,'C)4[\:4T?YXF 0 ,'PF3QXSVL&'AV"0IK,R]<?N1>, X1QK9IOF2T
M&R'8CPIBF"DIB/#9CT#':[_#U7P.N"1O#G4M3Q*2"A WC+W*')/=/5*%.YC;
ME^:&W#IJ7GL*]<%)VB9N)CC'$4RR#<F1RSNV,CE?01IGAVDW@D@+,31&L0N(
M,6G<1]->GZUDFE*ZGI(>0 /S*IKV0O<N\)(*Z3; %>PE-UA>0&.V%&GR(%"'
MW5 #:(,NL,-^;_*@8&,P:V(.2LMFA9,6/Z0E>BYYMA NZ0%V=D:2Y7LKE2 !
MS)[">8S3NDBP-?!WJ59-+(H<VI)<XGLI(OPM:77'$()3<F/&O+DL,%HSG6[Q
M<3^+9J5G[OP62K2T>1T[P;7CBT_$%_[.Q8Z9.;%AZ#SRFQV'^:;%N6J38L^!
MK?/JO@/J;U]T#?S*BK'-5,S$0F:4V+&Z! )5J1*,**)@-)BB0QD.;6QQ'J+'
M2.[1-!AV>T?H>$ZI!\@XM&,?2@U<B*)@0PX8<C2Y['3>K(\<3H+1M':5WUEI
M:I.6<^@R'8[O'R.XSW\8*<Y\OFQC^:,#34):>]?KGS,M>.HI#NNH46)(&;.F
M5B#22]SOO!5.A_BAU&4PB(Y'$! 1>JT.SBNX1AYH^O0#LY !!)O NX.6-8TP
MN!H$(R#5C2B*U"0Z@9$J6?.CJVEP">.<TT<WG49!",.=T\=C]DGS+ =7$#6+
M2U&AH3X?]H/QY1>$A%78)A*Q6COG=S?&J9UZB&*BEFAD+SK9;;@C9F!&]@3,
MB@((F(V%Z:?02)J-<AXY=GKD9 )#N#X)%:8,Z)T)/9J>RQZYT2(=#^[D01<@
M+^##Z"+<%&FP*;"36IF1R]VY=>W '(^!7'CQU=>CUM8)-0Z9L2O5K+45]0RG
M'?YX !/4;=[X=NB0*^Y:[GHHA_RI1@AH7;Y35_%G8L)J,<=<41<+M =.O"BT
MG)6>L[N/-MHEV( ; 71&G8/NVJI,"YX)L-WIMDZI>['FZ:&F\VAD4T,>C.@/
MANHFKJ@]>*?1W'8N0B?NUM(&0# R#':MMWE!W@G\!&%2_+GF@AOP3D_P1@XV
M^P_S16PF$G3?R.1N'[FDWK'T3 2>AE&6H<GG[;DBD\L@'$V/N2(#,$B3V@*2
MMW!Q;FSS8U1&,H/%X<:="0Q,%-NPV4//@IY?&O_IF%TY[/* &W# DO['>SR>
M>0]QH^5X,C8,@9;]TV:N?1[/1P'QP)PHJ-)H&%$NO=WK@0;C0;_3ZQDV()_"
M4.?FLYM:\'XXZ%,[^.SP?$9?S_,![R\:G<"A>PV_ON=CX]^<K:ULFX(7K%91
ML:TF40R+ FXKL&B;&9HUMYD[!/F;N21_G8LU^'\7J]7%.I:P:G6P[K&.K^5D
M#?_+G*S1 SE9OU0%:&]-H0_R:5U'TE7U2#7-N!SN96_= NJB-EL\1)6&\\Y*
M)J]8A.=51085OMA<W,J?^T U4X]=K>4_D47?9K> "A* 7X%9"VE8E8I5 &!D
M:F%+R.:XE)4HEJ"K3:&EF]: [R??8!$".C7ZUF*WH4IH7,8M +005*9DZNG6
MLL"J1DP8YH6I]MFG_K[/XT;6 %$&C=8<Y"B6:X->C=,YWC6<B4PRUVI5(>('
ME2+DL(JW60R,@V8KZC^SK^DI?/88D7H%YB&UR5:L%ZP =7MH?VKM\%RF"2R$
MYRH##4LEJ(F< ]<BD6 1E(W,40)MXGX&CK6KM:D6;BK+R-+>6C^$&T5MP6S)
MUFYH:F B6V9)O>WJ&HEA ^-,^&5N .D2E@;"A>6G"I1$#U6-\50>8LOC1&7X
MJP_SP5W.4[5KRPXBH-S("C8 CV%F=DNV3ZJ2WU;IB7D:EZFU=,=D"*A0+T3+
M_//^X$PCWSG6\N"HZ*>QE"Q-D5;<&2!R(+)"J]3P1I/\H!I!H=MR-+,!AX:)
M;ZT)L3:3(#P*%FZ1Y551]I<"R+ *R>BDLM;4]S"0MEZX69;Y6YDL2%6VB_&A
MI9TDHV*GTX/)ZU\FKH2&.]R :B#9)QOQFEQYP;B*S:Y0; KS.VEX(L[JP3F5
MR9>H$KOX%J&1<Y:KX*&140/D=:U.)! -5SSC"UM(CAM46TM,$'!-E9Z]4W31
M*7NT>^K'J Y.>1P8@NM4&4?,T,T8:96JA94SZTSE52,KD&[?S3#H"L3,S.G&
M_X> P (=)?9*JTTF 27O%4[QQ-1"8SR%+5<J$2EN/<J\,;F=SFXXIO*S2.52
M*8K\YF51ZAT9 >?Z+A:BVK\S&E0C7K=D/";/J!P7Q""I#"<&'DV1D*LU<$X#
MM;8W-(YE;B,_<8?: BPIUE^KM0L($\TWE%GAM(%9%:>C\Q@O1<LR,0#3X+K3
M"JI]T=9R;^,(M"I[MZXF46X5THMD#]8ZZ']G]&K=_)">@A[AJ!=]1YQ(H8GK
M5<NT%'70U91EBX %DE!I.JX1IQ &@Q7#'6M3IE&Y[(1S0V@;'590TT"6WA:+
MA@-LW= ]U6_0PKL>FO;-H31[[02&MR5<K>%4W43(6QOK_>^OS:M(YMI$,C<8
MR8!W"\[8K:E@JJH67((D80/<+:VVNUENRJQ,RJ$*AQIQT@=HLN*Q*.E TJ[_
M[)HY!SJH?" J'?$.5  % 1]/]OQCD[/Q9JP401,D=!&XRR6MP07WU$BJ<L]B
M413(8Y/!N<J):BWO"#,4ZWHGK"AF -JG;NS6>-%D1>J4@7>XP((C6H'YM6%C
MV@U&^X0=16M-%#L\F"XV&8;:Q(F9TP-M<7+%IS!5TQ!67JU=7WU*#QBK<)JU
M\N':%X '['@1+UO=O#9X#NOAY(!CW92LIH+M!+"N:+'1(R5W#!U/\"H;\U02
M[&F<-G5CO)\F@ >EX-ZZQ!&\G29?TU5Z76I'F^/;F5T\87(YJ#RL#6A?%[*P
MZUXE GC%,9@4KG+K5.37 [='KY?J9IL?J)#\U"JOQW*,G16J^\*,<%<"S8^&
MF,Z-.S&.]))OO,V+(4':-]8F"&3_79%29Z5M-W>8HW+H?X!_F?5.J?IN9ZA3
MRL6_C*7(1M0IJZ2DRKTR-P)238=P;!1&:M:Q5UHN)*9K=C9:3@=XS;>TFR!I
M0Q-&@C^Z0$>-J,G3M-HK> 0>[;BJIFQ:UC>OK\P.#B#,5&P6R#5H^C/Q9"M
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M@^$>"K6F"^>!;0JUHJ]+P2'LQ@;P?J[ #MH'G*#Z#P0O_P502P,$%     @
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MW2*7*9+3,;=<%L3&(&KQB1!Z$<PCT'M5X53FKBT3MSY";>NAJEU _5'3Q4
M'?&?^'+.[L6&,%*L[R&N)P:O'F462@VR=X?2D^[WQ7_!->X&\>2EB@SP O[
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M\RR9]&\;X\"JUKV4K96UJG:?I>"%T"2 ]8T"8,. -C@^G5[_&U!+ P04
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MO(&^+PU-B^J!'33_-4S_ %!+ P04    " !420155R(GVRP#  #<!P  &0
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MGH):R9MF^.FSRXM%5]&+-=WT:UV@E;D(HVD8^U8K(IMO"C:FMV/8WD-5<X0
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MX @M+<#WS!C?/- &[67V^3]02P,$%     @ 5$D$59HBGD&, P  50D  !D
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M%H'MAGBW(=.$P7EOB,=P6%;\W8/6"_#]TAC:;;R!X4MJ]@]02P,$%     @
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M8'7M>$$0B@<97D -*S@(_R>SOM;H:7:V8A:UKZU+JJ $+3B7]V2(9<?_<8M
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M28(  7Z3>.K" HA.DHD/FCR(L@BK21X%:1C1F[OL0\G]:H9[SN0V )TF>9#
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MOD8Y6H#?%Q;45][0 ?57IK/_ E!+ P04    " !420157$6LYD8#   C!P
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MY9":@=X1D#RI)FX5S%YQU7+<XG[_"JVG+CKH)CXZ!JW03>!J)!1=?X"-1=)
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M->+0[F\D(;V<QT8"-*9/P.#=2B#77JJM]PT;/8K2 L;_BWWVXU%ZU94"\^(
MV<.(<($,;U[;$@D;$&HBW<W.7]'O;ZE!B(YO70.\^P%TJ-3&2K8[^&2)GF_!
M'V8)PA 7OEYV=[MOOV?ADV>_/'PX?B_M @8ASG-LW1L_?3(*+V_:"V]J_@ *
MZO&FY)\Y*JRRM #/Z4-+>T$'=%_$3_\+4$L#!!0    ( %1)!%7W]P4;. 0
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MXTX46U$8'NQ[D6_Y3K#7_SAYF) E:)<LT#%V3]"RX%NVXQ_J'FJO'RG/]*5
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M2;(@S0(X7RL -B[X@N-'P:M_ E!+ P04    " !42015]RNY GT#  "2"
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MC*.H&^:,RR#I^[6I3OJJL()+G&HP19XSO1FA4.M!T RV"S=\L;1N(4SZ*[;
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MH_&8' 3P^<Q:?W,3''2?48[_!E!+ P04    " !42015G?NYAXH$  "4"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R=5MN.VS80_96!&A0)H*QU
ME^S:!O:215,D@6'O-@]%'VAI; F12)6DUNN_[Y#RK>G:F_;%(FG.F9DS9TB.
M-T)^4R6BAN>FYFKBE%JWH\% Y24V3%V)%CG]LQ*R89JF<CU0K4166*.F'@2>
MEPP:5G%G.K9K,SD=BT[7%<>9!-4U#9/;&ZS%9N+XSGYA7JU+;18&TW'+UKA
M_=C.),T&!Y2B:I"K2G"0N)HXU_[H)C+[[8;?*]RHDS&83)9"?#.3C\7$\4Q
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M^8(3+3LKF;J)LP!W1,Z'6AC.[6KOJY>2"*!X91J.5]>05+SGK**E5\C-1B-
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MQSH]E!0R,IG)T-4*AEJ,F1O, CT0&; \I(\D.Y9*12MIH%W3W%/.L_I-J8S
MJ_T2:6ZRKBVB:5=:S U6@>BR;I-U*^A%?C?3-IH)'7VBT:T$@78-<D>7=+NK
M4P/1Z*5,!.U2#AJD 0Q"??3WLXM-=A@B?0*<M5,9:&4$=*\CH)[5XQ ;%F!#
M]N][6FB,>^(EY_'4]]BM D!V!7!K&>WVHD-7'J=HL5.TQ!6:V@EMZH_>>>J/
MG*;^3M%BIVB)*S2UI]O4'[U5ZH_T5/T":BODW&"&D!YW#&8PU/-^DUD4GHPZ
M;=J/[&G_CR<?R)"F1TA;B@UF4*3SW;7(8(8$;=VUV&@6GEJ+4:L-D%T;]$]
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MJHG-#4IO2C2IX=+MXKW5M,H)9Y-+QC4\,E$@W" SA4;:(FN R0PNN60RY4S
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MA;GO@;0!9GXFA'[NV!M%=8,,?P%02P,$%     @ 5$D$525-#^C= @  A@@
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MCUB]M;8^$713[4Z]HT+0K#I<DVA)6-E OG]/)7#M3LH!F@W.B_\!4$L#!!0
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MO8?WFH<YO^?5(B]K4HBYQ@=GY[I$5-OG(V]GE%PUS_.]ETK)93/YH(,5E5E
MOS^74GV?,8\(WCVE>OHG4$L#!!0    ( %1)!%58K)@Z%0,  )0*   9
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M8%*RM#R,@(; 50.\OV1,;D]4!\T6^>0?4$L#!!0    ( %1)!%7R-2]!;PP
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M%!N]D31C2]-?9K4 S'N(>R=ER5>?.)N*G-K)'QUPV"=KGC<K)'O4T:!4)MI
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M[R:#=EF) :NEEK5\$M5D,!HPMS+;WXV53T9[KN:E-4I-!DFWX5Y8+\L7S?,
M><<7KFWQ?#'C #(9C$=PP*6TSK?_:(_/@7$CX,_=6N/-E51>V"GWXJLUS5KJ
MAW 8N(IA=!EM'/:_71#/[+\)HUDN92FFIFQJH7T71RM4 -1N)==NP#2OQ61P
M83;"ANN!$UQ7W;5Y@(HB9<\D;+#758M'B:(KH9VH&"PYHV0%'!7[PA77I6 1
M9(I ID>$_"N-(#,$,CL*Y#S@P*X19(Y YD>$[$6R0""+8T)F$>08@1P?$S*/
M(-\AD.^."5E$D.\1R/>TD-_L ]?RJ=W N*[8;6/7QHF([@-"]X&6;M[4-;<[
M9I9L+A^TA-VX]NR\+$VCO8Q[\1'6C8]H,<\W7"H.YV2P.YMS6)B*A6=S4396
M^A@3M0VQ;JZXM.R>JT:P/P5WC0U=HW?M;;^2<2>98+Y)B(4#*& 6R16;F1U7
M?L?.G8.D(.;#5)-0NZ:IF]"\$>Q<*;-M71UBZ%>"W?92"TPV";%MKB&OTP_A
MI#_%\5=V(WK/)&:;A%@W-T:?]KK'<]A325CLW6_,-0FQ;&;""6[+%7O#Z_5'
M>+,W0IEUV(F=O'ELC/\X:[=,NY6W<=Z68/Y)B 7TQ5AKMI!G]T*)R28AMLU\
MQ:U8&54)ZWYAEX\-C%!B-DPU";%K+KG5(59L+: /#Z!Q_HWI)276R[6NI(4Q
M'[O@;L6NH,N)R3"CI.0#F+J6_MDB\"9[B*& [KOW_J;H^(78)[/0"#W++;?0
M!]Y9KAUO!] ]0LPH*;%1YLW"B<<F]"B7FQ#,& QS2$KL$#3_ZHU84DPB*;%$
MT/RKCXF))"46"9I_]3$Q;:3$VG@M_V(G=[PE><;$7)(2NP1-P_K1Q+22$FL%
M3\/B7"'#'),1.^8Y5_AQF]W;& V33$8LF4-)PT%(3#(9L61>9@\'$=$2&;%E
M7J81!Q$QWV3$OGE=U2UJC(GY)B/VS6M%$W8R%9['98D,\TU&[!O<WG$I+\-\
MDQ'[!K=W#Q/S34;L&QPSKCEFF&\R8M_@248<S1SS34[L&QPSCF:.N2<_9LFL
M5\/-,?ODU"4S%',<8V(&RHD-]&IF><I"7Q5CHM,TU/,T:&;9>X4P"^7$%D(S
MRUX"G&,6RHDMA&/VHHE9*">V$%*(#%J/,3$+Y<06^H_%R/YC@'DI)_92-,"
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M]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0    ( %1)!%47R,P;VP$
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MKYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]_GS&'_4/[$.
M]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'096CJ,I16.4H
MKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625
M*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D
M52BR:A19-8JL&D56C2*K1I%5H\BJ4635*+)J%%GU?\KZ9.WZKW^RZ.]Y:^KN
M/9\-?[)<O0)02P$"% ,4    " !42015!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %1)!%48M,^/
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( %1)!%697)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 5$D$5=\Y?XTZ!@  HB,
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M965T-2YX;6Q02P$"% ,4    " !420150SD2MBD1  "SQP  &
M    @(%J)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M5$D$54S&A&+$ @  3 D  !@              ("!R3@  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %1)!%5[Q5Q4_@8  !D?   8
M          " @<,[  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " !42015=,EZL*P&  " $0  &               @('W0@  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 5$D$58?7R$Q:"@  ZQD
M !D              ("!V4D  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " !42015O-M9[)(+  !=*@  &0              @(%J5
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %1)!%5(<2=:
M8!8  (U@   9              " @3-@  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ 5$D$50_V9]0M!P  1A4  !D
M ("!RG8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !4
M2015C7UX/W,$  !!#   &0              @($N?@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %1)!%57(B?;+ ,  -P'   9
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M970Q.2YX;6Q02P$"% ,4    " !42015'0TO)GX&  "W$0  &0
M    @('GJ0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M %1)!%5*HM44L00  )D*   9              " @9RP  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ 5$D$57O'=.T_!P  6Q$  !D
M             ("!A+4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " !42015DI0\AMX)  !Q&@  &0              @('ZO   >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %1)!%5<1:SF1@,
M ",'   9              " @0_'  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ 5$D$512KFW)O"P  '1\  !D              ("!
MC,H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !42015
M]_<%&S@$  "2"@  &0              @($RU@  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( %1)!%6#-M<Q? H  *<H   9
M      " @:':  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ 5$D$56I)Y4#(!@  (!0  !D              ("!5.4  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !42015]RNY GT#  "2"
M&0              @(%3[   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( %1)!%5;YCUCX0(  /H&   9              " @0?P  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 5$D$56B?0'4/
M!   D0H  !D              ("!'_,  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " !42015Q1/H!/$%  !2$0  &0
M@(%E]P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %1)
M!%6=^[F'B@0  )0*   9              " @8W]  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ 5$D$53L^ICS*!   K H  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( %1)!%5N25Q1#P4  !L?   9
M  " @?P= 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M5$D$5=KLIC!#$   VZ4  !D              ("!0B,! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " !42015G.\LM5$*   W=   &0
M            @(&\,P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( %1)!%5L<XAR\P<  (DZ   9              " @40^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 5$D$5=N4B OB @
M8@D  !D              ("!;D8! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " !420157AAMHDH&  !7)P  &0              @(&'
M20$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %1)!%6$
M['SC>P,   P+   9              " @0A0 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ 5$D$53C^Y5;I @  30H  !D
M     ("!NE,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1)!%7C2(>KU0@  +%:   9              "
M@>EI 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 5$D$
M55BLF#H5 P  E H  !D              ("!]7(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " !42015.G"V'(8(   V6P  &0
M        @(%!=@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( %1)!%7=3FL"50H  'I0   9              " @?Y^ 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ 5$D$51P<59TH!@  JR
M !D              ("!BHD! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " !42015F%V<02X'  #,)0  &0              @('ICP$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( %1)!%67^9''
M;@0  "X7   9              " @4Z7 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ 5$D$5?(U+T%O#   ;)P  !D
M ("!\YL! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !4
M2015:# 'E/P"  #^"@  &0              @(&9J $ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( %1)!%6U!>?A?0,  )L8   -
M          "  <RK 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 5$D$59>*
MNQS     $P(   L              ( !=*\! %]R96QS+RYR96QS4$L! A0#
M%     @ 5$D$5;C[U#+5!   BB<   \              ( !7; ! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( %1)!%59=@'X]0$  #@C   :
M      "  5^U 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( %1)!%47R,P;VP$  -$B   3              "  8RW 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(  )BY 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>436</ContextCount>
  <ElementCount>303</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>112</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Purpose</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurpose</Role>
      <ShortName>Organization and Purpose</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Available for Sale Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</Role>
      <ShortName>Available for Sale Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Fair Value Measurements and Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Financial Royalty Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssets</Role>
      <ShortName>Financial Royalty Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Intangible Royalty Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</Role>
      <ShortName>Intangible Royalty Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Non-Consolidated Affiliates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliates</Role>
      <ShortName>Non-Consolidated Affiliates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2139112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2142113 - Disclosure - Indirect Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlow</Role>
      <ShortName>Indirect Cash Flow</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2147115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2150116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Available for Sale Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables</Role>
      <ShortName>Available for Sale Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Financial Royalty Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsTables</Role>
      <ShortName>Financial Royalty Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FinancialRoyaltyAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Intangible Royalty Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables</Role>
      <ShortName>Intangible Royalty Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/Borrowings</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ShareholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsperShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Indirect Cash Flow (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowTables</Role>
      <ShortName>Indirect Cash Flow (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlow</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Purpose (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurposeDetails</Role>
      <ShortName>Organization and Purpose (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/OrganizationandPurpose</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Available for Sale Debt Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails</Role>
      <ShortName>Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Non-Consolidated Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails</Role>
      <ShortName>Non-Consolidated Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/NonConsolidatedAffiliates</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails</Role>
      <ShortName>Borrowings - Schedule of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails</Role>
      <ShortName>Borrowings - Schedule of Repayments of Debt by Year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsperShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2444421 - Disclosure - Indirect Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowDetails</Role>
      <ShortName>Indirect Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlowTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446422 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449423 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="rprx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="rprx-20220630.htm">rprx-20220630.htm</File>
    <File>rprx-20220630.xsd</File>
    <File>rprx-20220630_cal.xml</File>
    <File>rprx-20220630_def.xml</File>
    <File>rprx-20220630_lab.xml</File>
    <File>rprx-20220630_pre.xml</File>
    <File>rprx-20220630ex311.htm</File>
    <File>rprx-20220630ex312.htm</File>
    <File>rprx-20220630ex32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1133">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rprx-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 31,
   "contextCount": 436,
   "dts": {
    "calculationLink": {
     "local": [
      "rprx-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rprx-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rprx-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rprx-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rprx-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rprx-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 556,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 84,
   "keyStandard": 219,
   "memberCustom": 65,
   "memberStandard": 41,
   "nsprefix": "rprx",
   "nsuri": "http://royaltypharma.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://royaltypharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Available for Sale Debt Securities",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities",
     "shortName": "Available for Sale Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Fair Value Measurements and Financial Instruments",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments",
     "shortName": "Fair Value Measurements and Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Financial Royalty Assets",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssets",
     "shortName": "Financial Royalty Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Intangible Royalty Assets, Net",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet",
     "shortName": "Intangible Royalty Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Non-Consolidated Affiliates",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates",
     "shortName": "Non-Consolidated Affiliates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Research & Development (\"R&D\") Funding Expense",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense",
     "shortName": "Research & Development (\"R&D\") Funding Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Borrowings",
     "role": "http://royaltypharma.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Shareholders' Equity",
     "role": "http://royaltypharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139112 - Disclosure - Earnings per Share",
     "role": "http://royaltypharma.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142113 - Disclosure - Indirect Cash Flow",
     "role": "http://royaltypharma.com/role/IndirectCashFlow",
     "shortName": "Indirect Cash Flow",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - Commitments and Contingencies",
     "role": "http://royaltypharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147115 - Disclosure - Related Party Transactions",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150116 - Disclosure - Subsequent Events",
     "role": "http://royaltypharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Available for Sale Debt Securities (Tables)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables",
     "shortName": "Available for Sale Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Financial Royalty Assets (Tables)",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables",
     "shortName": "Financial Royalty Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "rprx:DeferredSharesParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "rprx:DeferredSharesParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Intangible Royalty Assets, Net (Tables)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables",
     "shortName": "Intangible Royalty Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Borrowings (Tables)",
     "role": "http://royaltypharma.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://royaltypharma.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Earnings per Share (Tables)",
     "role": "http://royaltypharma.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Indirect Cash Flow (Tables)",
     "role": "http://royaltypharma.com/role/IndirectCashFlowTables",
     "shortName": "Indirect Cash Flow (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i8fc135510e2d49c6b0cd406c917f4076_I20200211",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Purpose (Details)",
     "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails",
     "shortName": "Organization and Purpose (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i8fc135510e2d49c6b0cd406c917f4076_I20200211",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskPercentage1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskPercentage1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
     "shortName": "Available for Sale Debt Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i467ecc55a5c146ce9f323a91de3f9cf8_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:AssetsFairValueDisclosureCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "icc0ee976221e43ac94bfd0056a40c5bc_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "icc0ee976221e43ac94bfd0056a40c5bc_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5c8b4208854b4a00a19fae7046aab65c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5c8b4208854b4a00a19fae7046aab65c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails",
     "shortName": "Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails",
     "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
     "shortName": "Intangible Royalty Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Non-Consolidated Affiliates (Details)",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
     "shortName": "Non-Consolidated Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i9fb0f3822f7448c3b9edb5542ba8571e_I20200211",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails",
     "shortName": "Research & Development (\"R&D\") Funding Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i691fe772f8474c9883cd86d770776fc5_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
     "shortName": "Borrowings - Schedule of Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ie5a03d177ab2440997f9376d5899a918_I20210726",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ie5a03d177ab2440997f9376d5899a918_I20210726",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "icf036923cf324ce78882338a4fb17702_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
     "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "icf036923cf324ce78882338a4fb17702_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfClassesOfVotingStock",
      "reportCount": 1,
      "unitRef": "class",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i4a1f6430e214497599d013c1c8969e8d_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
     "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i63f4135a52e24cdc8a877de0528e91ef_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CommonStockExchangeRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - Earnings per Share (Details)",
     "role": "http://royaltypharma.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444421 - Disclosure - Indirect Cash Flow (Details)",
     "role": "http://royaltypharma.com/role/IndirectCashFlowDetails",
     "shortName": "Indirect Cash Flow (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingCommitmentAmountOutstanding",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446422 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449423 - Disclosure - Related Party Transactions (Details)",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipInitialPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - Subsequent Events (Details)",
     "role": "http://royaltypharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731",
      "decimals": "-7",
      "lang": "en-US",
      "name": "rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i74012a9aba134af29fa48477d04dde00_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i74012a9aba134af29fa48477d04dde00_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Purpose",
     "role": "http://royaltypharma.com/role/OrganizationandPurpose",
     "shortName": "Organization and Purpose",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20220630.htm",
      "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 112,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rprx_A2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2020EquityIncentivePlanMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalty Receivable",
        "label": "Accrued Royalty Receivable",
        "terseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "AccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Of Limited Partnership Interests In Affiliate",
        "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]",
        "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate"
       }
      }
     },
     "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AgreementWithMSCIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with MSCI",
        "label": "Agreement with MSCI [Member]",
        "terseLabel": "Agreement with MSCI"
       }
      }
     },
     "localname": "AgreementWithMSCIMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssetsFairValueDisclosureCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Current",
        "label": "Assets, Fair Value Disclosure, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureCurrent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssetsFairValueDisclosureNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Noncurrent",
        "label": "Assets, Fair Value Disclosure, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureNoncurrent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Benefit of Payment Stream",
        "label": "Assignment Agreement - Benefit of Payment Stream [Member]",
        "terseLabel": "Assignment Agreement - Benefit of Payment Stream"
       }
      }
     },
     "localname": "AssignmentAgreementBenefitOfPaymentStreamMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssignmentAgreementFundingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Funding Obligations",
        "label": "Assignment Agreement - Funding Obligations [Member]",
        "terseLabel": "Assignment Agreement - Funding Obligations"
       }
      }
     },
     "localname": "AssignmentAgreementFundingObligationsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion Entities",
        "label": "Avillion Entities [Member]",
        "terseLabel": "Avillion Entities"
       }
      }
     },
     "localname": "AvillionEntitiesMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion II",
        "label": "Avillion II [Member]",
        "terseLabel": "Avillion II"
       }
      }
     },
     "localname": "AvillionIIMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion I",
        "label": "Avillion I [Member]",
        "terseLabel": "Avillion I"
       }
      }
     },
     "localname": "AvillionIMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BioCrystPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioCryst Pharmaceuticals, Inc.",
        "label": "BioCryst Pharmaceuticals, Inc. [Member]",
        "terseLabel": "BioCryst Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "BioCrystPharmaceuticalsIncMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Bristol-Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassBHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Holders",
        "label": "Class B Holders [Member]",
        "terseLabel": "Class B Holders"
       }
      }
     },
     "localname": "ClassBHoldersMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassRRedeemableStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class R Redeemable Stock",
        "label": "Class R Redeemable Stock [Member]",
        "terseLabel": "Class R Redeemable Stock"
       }
      }
     },
     "localname": "ClassRRedeemableStockMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CollaborativeArrangementExpectedProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Expected Proceeds",
        "label": "Collaborative Arrangement, Expected Proceeds",
        "terseLabel": "Expected proceeds from development funding bonds"
       }
      }
     },
     "localname": "CollaborativeArrangementExpectedProceeds",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "terseLabel": "Commitment to fund agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "terseLabel": "Payment of capital"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "label": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "terseLabel": "Period of return"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date",
        "label": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date",
        "terseLabel": "Start of period of return"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Exchange Ratio",
        "label": "Common Stock, Exchange Ratio",
        "terseLabel": "Common stock exchange ratio"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_CommonStockQuarterlyConversionBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Quarterly Conversion Basis",
        "label": "Common Stock, Quarterly Conversion Basis",
        "terseLabel": "Quarterly conversion basis"
       }
      }
     },
     "localname": "CommonStockQuarterlyConversionBasis",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_CommonStockVotingRightsNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights, Number Of Votes",
        "label": "Common Stock, Voting Rights, Number Of Votes",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_ContinuingInvestorsPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing Investors Partnership",
        "label": "Continuing Investors Partnership [Member]",
        "terseLabel": "Continuing Investors Partnerships"
       }
      }
     },
     "localname": "ContinuingInvestorsPartnershipMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CysticFibrosisFranchiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystic Fibrosis Franchise",
        "label": "Cystic Fibrosis Franchise [Member]",
        "terseLabel": "Cystic fibrosis franchise"
       }
      }
     },
     "localname": "CysticFibrosisFranchiseMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsCommercialLaunchFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics Commercial Launch Funding",
        "label": "Cytokinetics Commercial Launch Funding [Member]",
        "terseLabel": "Cytokinetics Commercial Launch Funding"
       }
      }
     },
     "localname": "CytokineticsCommercialLaunchFundingMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsFundingCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics Funding Commitment",
        "label": "Cytokinetics Funding Commitment [Member]",
        "terseLabel": "Cytokinetics Funding Commitment"
       }
      }
     },
     "localname": "CytokineticsFundingCommitmentMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics",
        "label": "Cytokinetics [Member]",
        "terseLabel": "Cytokinetics"
       }
      }
     },
     "localname": "CytokineticsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DPPIVInhibitorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DPP-IV Inhibitors",
        "label": "DPP-IV Inhibitors [Member]",
        "terseLabel": "DPP-IV patents"
       }
      }
     },
     "localname": "DPPIVInhibitorsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "terseLabel": "Maximum consolidated leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "terseLabel": "Minimum consolidated coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentIssuanceAsAPercentOfPar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Issuance As A Percent Of Par",
        "label": "Debt Instrument, Issuance As A Percent Of Par",
        "terseLabel": "Debt issued as a percent of par value (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceAsAPercentOfPar",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleFixedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fixed Payment",
        "label": "Debt Securities, Available-for-Sale, Fixed Payment",
        "terseLabel": "Preferred shares, fixed payment amount"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFixedPayment",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Liability, Current",
        "label": "Debt Securities, Available For Sale, Liability, Current",
        "terseLabel": "Available for sale debt securities, liabilities current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleLiabilityCurrent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Liability, Noncurrent",
        "label": "Debt Securities, Available For Sale, Liability, Noncurrent",
        "terseLabel": "Available for sale debt securities, liabilities noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleLiabilityNoncurrent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "terseLabel": "Number of shares purchased (in shares)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DebtSecuritiesAvailableForSalePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Price Per Share",
        "label": "Debt Securities, Available-For-Sale, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePricePerShare",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Quarterly Payments",
        "label": "Debt Securities, Available-for-Sale, Quarterly Payments",
        "terseLabel": "Preferred shares, quarterly payments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleQuarterlyPayments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]",
        "terseLabel": "Redemption, Period One"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]",
        "terseLabel": "Redemption, Period Two"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Multiple",
        "label": "Debt Securities, Available-For-Sale, Redemption Price, Multiple",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPriceMultiple",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Restriction Period",
        "label": "Debt Securities, Available-For-Sale, Restriction Period",
        "terseLabel": "Restrictions on selling common stock, period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRestrictionPeriod",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "terseLabel": "Preferred shares, weighted average cost of capital"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DeferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "terseLabel": "Deferred Shares"
       }
      }
     },
     "localname": "DeferredSharesMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DeferredSharesParOrStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Par or Stated Value Per Share",
        "label": "Deferred Shares, Par or Stated Value Per Share",
        "terseLabel": "Deferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "DeferredSharesParOrStatedValuePerShare",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DeferredSharesSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Issued",
        "label": "Deferred Shares, Shares, Issued",
        "terseLabel": "Deferred stock, issued (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesIssued",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Outstanding",
        "label": "Deferred Shares, Shares, Outstanding",
        "terseLabel": "Deferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesOutstanding",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesValueIssued": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Value, Issued",
        "label": "Deferred Shares, Value, Issued",
        "terseLabel": "Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively"
       }
      }
     },
     "localname": "DeferredSharesValueIssued",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DerivativeAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Asset",
        "label": "Derivative Asset [Member]",
        "terseLabel": "Derivative Instrument"
       }
      }
     },
     "localname": "DerivativeAssetMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EPAHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EPA Holdings",
        "label": "EPA Holdings [Member]",
        "terseLabel": "EPA Holdings"
       }
      }
     },
     "localname": "EPAHoldingsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EquityMethodInvestmentsUnfundedCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Unfunded Commitments",
        "label": "Equity Method Investments, Unfunded Commitments",
        "terseLabel": "Equity method investment, unfunded commitments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsUnfundedCommitments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_EvrysdiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evrysdi",
        "label": "Evrysdi [Member]",
        "terseLabel": "Evrysdi"
       }
      }
     },
     "localname": "EvrysdiMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ExchangeOfferTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer Transaction",
        "label": "Exchange Offer Transaction [Member]",
        "terseLabel": "Exchange Offer Transaction"
       }
      }
     },
     "localname": "ExchangeOfferTransactionMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition",
        "terseLabel": "Gains/(losses) on initial recognition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "terseLabel": "Redemption of debt securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancialRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Royalty Assets",
        "label": "Financial Royalty Assets [Member]",
        "terseLabel": "Financial Royalty Assets"
       }
      }
     },
     "localname": "FinancialRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "negatedLabel": "Cumulative allowance for changes in expected cash flows"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "negatedLabel": "Cumulative allowance for credit losses",
        "terseLabel": "Cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "terseLabel": "Aggregate royalty amount when patents cease"
       }
      }
     },
     "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "totalLabel": "Net carrying value, before cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, Fair Value Disclosure",
        "label": "Financing Receivables, Fair Value Disclosure",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "FinancingReceivablesFairValueDisclosure",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FormerOperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Operating and Personnel Payments",
        "label": "Former Operating and Personnel Payments [Member]",
        "terseLabel": "Former Operating and Personnel Payments"
       }
      }
     },
     "localname": "FormerOperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Commitments",
        "label": "Funding Commitments [Member]",
        "terseLabel": "Funding Commitments"
       }
      }
     },
     "localname": "FundingCommitmentsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ImbruvicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imbruvica",
        "label": "Imbruvica [Member]",
        "terseLabel": "Imbruvica"
       }
      }
     },
     "localname": "ImbruvicaMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Royalty Receivable",
        "label": "Increase (Decrease) In Accrued Royalty Receivable",
        "negatedTerseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "label": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "terseLabel": "Cash collected on financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Financial Royalty Assets",
        "label": "Increase (Decrease) In Financial Royalty Assets",
        "negatedTerseLabel": "Income from financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancialRoyaltyAssets",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Other Royalty Income Receivable",
        "label": "Increase (Decrease) In Other Royalty Income Receivable",
        "negatedTerseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IndividualLicenseesConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Licensees Concentration Risk",
        "label": "Individual Licensees Concentration Risk [Member]",
        "terseLabel": "Individual Licensees Concentration List"
       }
      }
     },
     "localname": "IndividualLicenseesConcentrationRiskMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IntangibleRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Royalty Assets",
        "label": "Intangible Royalty Assets [Member]",
        "terseLabel": "Intangible Royalty Assets"
       }
      }
     },
     "localname": "IntangibleRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "negatedTerseLabel": "Interest income accretion"
       }
      }
     },
     "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and RPSFT",
        "label": "Legacy Investors Partnerships and RPSFT [Member]",
        "terseLabel": "Legacy Investors Partnerships and RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRPSFTMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust",
        "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships",
        "label": "Legacy Investors Partnerships [Member]",
        "terseLabel": "Legacy Investors Partnerships"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingCommitmentAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Commitment, Amount Outstanding",
        "label": "Long Term Funding Commitment, Amount Outstanding",
        "terseLabel": "Funding commitment, outstanding"
       }
      }
     },
     "localname": "LongTermFundingCommitmentAmountOutstanding",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "terseLabel": "Long term funding partnership, aggregate amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Amount",
        "label": "Long Term Funding Partnership, Amount",
        "terseLabel": "Long term funding partnership, amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAmount",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipCovenantRequiredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Covenant, Required Amount",
        "label": "Long Term Funding Partnership, Covenant, Required Amount",
        "terseLabel": "Required amount to be drawn"
       }
      }
     },
     "localname": "LongTermFundingPartnershipCovenantRequiredAmount",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipExpectedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Expected Payment",
        "label": "Long Term Funding Partnership, Expected Payment",
        "terseLabel": "Long term funding partnership, expected payment"
       }
      }
     },
     "localname": "LongTermFundingPartnershipExpectedPayment",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipInitialPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Initial Payment",
        "label": "Long Term Funding Partnership, Initial Payment",
        "terseLabel": "Long term funding partnership, initial payment"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInitialPayment",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple",
        "label": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple",
        "terseLabel": "Installment repayments, percentage of amount drawn"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_LongTermFundingPartnershipNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Number of Tranches",
        "label": "Long Term Funding Partnership, Number of Tranches",
        "terseLabel": "Long term funding partnership, number of tranches"
       }
      }
     },
     "localname": "LongTermFundingPartnershipNumberOfTranches",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount",
        "label": "Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount",
        "terseLabel": "Regulatory milestone payments"
       }
      }
     },
     "localname": "LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermPurchaseCommitmentAmountOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Amount Outstanding",
        "label": "Long Term Purchase Commitment, Amount Outstanding",
        "terseLabel": "Purchase commitment, amount outstanding"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmountOutstanding",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals",
        "label": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]",
        "terseLabel": "Funding Agreement With Biohaven Pharmaceuticals"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LongTermPurchaseCommitmentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Shares",
        "label": "Long Term Purchase Commitment, Shares",
        "terseLabel": "Shares to be purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentShares",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_MerckAssetPhaseIIClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Asset - Phase II Clinical Trial",
        "label": "Merck Asset - Phase II Clinical Trial [Member]",
        "terseLabel": "Merck Asset - Phase II Clinical Trial"
       }
      }
     },
     "localname": "MerckAssetPhaseIIClinicalTrialMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MilestoneAccelerationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Acceleration",
        "label": "Milestone Acceleration [Member]",
        "terseLabel": "Milestone Acceleration"
       }
      }
     },
     "localname": "MilestoneAccelerationMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MorphoSysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MorphoSys",
        "label": "MorphoSys [Member]",
        "terseLabel": "MorphoSys"
       }
      }
     },
     "localname": "MorphoSysMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_NoncontrollingInterestIncreaseFromContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase from Contributions",
        "label": "Noncontrolling Interest, Increase from Contributions",
        "terseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NumberOfClassesOfVotingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Classes Of Voting Stock",
        "label": "Number Of Classes Of Voting Stock",
        "terseLabel": "Number of classes of stock"
       }
      }
     },
     "localname": "NumberOfClassesOfVotingStock",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_NumberOfNoncontrollingInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Noncontrolling Interests",
        "label": "Number of Noncontrolling Interests",
        "terseLabel": "Number of noncontrolling interests"
       }
      }
     },
     "localname": "NumberOfNoncontrollingInterests",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Seven Five Percent Senior Notes Due 2027",
        "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]",
        "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027"
       }
      }
     },
     "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Zero Percent Senior Notes Due 2025",
        "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]",
        "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025"
       }
      }
     },
     "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Personnel Payments",
        "label": "Operating and Personnel Payments [Member]",
        "terseLabel": "Operating and Personnel Payments"
       }
      }
     },
     "localname": "OperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OtherCommitmentIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Commitment, Increase (Decrease)",
        "label": "Other Commitment, Increase (Decrease)",
        "terseLabel": "Increase in commitment"
       }
      }
     },
     "localname": "OtherCommitmentIncreaseDecrease",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtherFinancialRoyaltyAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Royalty Asset",
        "label": "Other Financial Royalty Asset [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFinancialRoyaltyAssetMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OtherRoyaltyIncomeReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Royalty Income Receivable, Current",
        "label": "Other Royalty Income Receivable, Current",
        "terseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "OtherRoyaltyIncomeReceivableCurrent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OvernightBankFundingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overnight Bank Funding Rate",
        "label": "Overnight Bank Funding Rate [Member]",
        "terseLabel": "Overnight Bank Funding Rate"
       }
      }
     },
     "localname": "OvernightBankFundingRateMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PaymentOfDividendsToShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Dividends To Shareholders",
        "label": "Payment Of Dividends To Shareholders",
        "negatedTerseLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentOfDividendsToShareholders",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Collateral Posted On Derivative Instruments",
        "label": "Payments For Collateral Posted On Derivative Instruments",
        "negatedTerseLabel": "Derivative collateral posted"
       }
      }
     },
     "localname": "PaymentsForCollateralPostedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Milestones",
        "label": "Payments For Milestones",
        "negatedTerseLabel": "Milestone payments"
       }
      }
     },
     "localname": "PaymentsForMilestones",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOngoingDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Ongoing Development Stage Funding",
        "label": "Payments For Ongoing Development Stage Funding",
        "negatedTerseLabel": "Development-stage funding payments - ongoing"
       }
      }
     },
     "localname": "PaymentsForOngoingDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOperatingCostsAndProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Operating Costs and Professional Services",
        "label": "Payments For Operating Costs and Professional Services",
        "negatedTerseLabel": "Payments for operating and professional costs"
       }
      }
     },
     "localname": "PaymentsForOperatingCostsAndProfessionalServices",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForUpfrontDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Upfront Development Stage Funding",
        "label": "Payments For Upfront Development Stage Funding",
        "negatedTerseLabel": "Development-stage funding payments - upfront and milestone"
       }
      }
     },
     "localname": "PaymentsForUpfrontDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities, FN-NI",
        "label": "Payments To Acquire Equity Securities, FN-NI",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "terseLabel": "Additional milestone payments"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Noncontrolling Interests, Other",
        "label": "Payments To Noncontrolling Interests, Other",
        "negatedTerseLabel": "Distributions to non-controlling interests- other"
       }
      }
     },
     "localname": "PaymentsToNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PointSevenFivePercentSeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Point Seven Five Percent Senior Notes Due 2023",
        "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]",
        "terseLabel": "Point Seven Five Percent Senior Notes Due 2023"
       }
      }
     },
     "localname": "PointSevenFivePercentSeniorNotesDue2023Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "terseLabel": "Other royalty cash collections"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "terseLabel": "Cash collections from financial royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "terseLabel": "Cash collections from intangible royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collateral Received On Derivative Instruments",
        "label": "Proceeds From Collateral Received On Derivative Instruments",
        "terseLabel": "Derivative collateral received"
       }
      }
     },
     "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "label": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "terseLabel": "Proceeds from equity securities"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Other",
        "label": "Proceeds From Noncontrolling Interests, Other",
        "terseLabel": "Contributions from non-controlling interests- other"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Research And Development",
        "label": "Proceeds From Noncontrolling Interests, Research And Development",
        "terseLabel": "Contributions from non-controlling interests- R&amp;D"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RPHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RP Holdings",
        "label": "RP Holdings [Member]",
        "terseLabel": "RP Holdings"
       }
      }
     },
     "localname": "RPHoldingsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RedeemableStockRedemptionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Stock, Redemption Price Per Share",
        "label": "Redeemable Stock, Redemption Price Per Share",
        "terseLabel": "Redeemable stock, redemption price (in euros per share)"
       }
      }
     },
     "localname": "RedeemableStockRedemptionPricePerShare",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_RelatedPartyTransactionInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Initial Term",
        "label": "Related Party Transaction, Initial Term",
        "terseLabel": "Initial term"
       }
      }
     },
     "localname": "RelatedPartyTransactionInitialTerm",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Number of Partnership Interests Acquired",
        "label": "Related Party Transaction, Number of Partnership Interests Acquired",
        "terseLabel": "Number of limited partnership interest acquired (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "terseLabel": "Amount calculated for operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "terseLabel": "Percent calculated for operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "label": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateAdjustedCashReceipts",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Value Of Security Investments",
        "label": "Related Party Transaction, Rate, Value Of Security Investments",
        "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RoyalPharmacySelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharmacy Select Finance Trust",
        "label": "Royal Pharmacy Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "RoyalPharmacySelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships",
        "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]",
        "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to RP Select Finance Trust",
        "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]",
        "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyIncomeOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Income, Other",
        "label": "Royalty Income, Other [Member]",
        "terseLabel": "Royalty Income, Other"
       }
      }
     },
     "localname": "RoyaltyIncomeOtherMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Investments",
        "label": "Royalty Investments [Member]",
        "terseLabel": "Royalty Investments"
       }
      }
     },
     "localname": "RoyaltyInvestmentsMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaCollectionTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Collection Trust",
        "label": "Royalty Pharma Collection Trust [Member]",
        "terseLabel": "RPCT"
       }
      }
     },
     "localname": "RoyaltyPharmaCollectionTrustMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaInvestmentsOldRPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Investments (Old RPI)",
        "label": "Royalty Pharma Investments (Old RPI) [Member]",
        "terseLabel": "Old RPI"
       }
      }
     },
     "localname": "RoyaltyPharmaInvestmentsOldRPIMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2031",
        "label": "Senior Notes Due 2031 [Member]",
        "terseLabel": "Senior Notes Due 2031"
       }
      }
     },
     "localname": "SeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorNotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2051",
        "label": "Senior Notes Due 2051 [Member]",
        "terseLabel": "Senior Notes Due 2051"
       }
      }
     },
     "localname": "SeniorNotesDue2051Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Revolving Credit Facility",
        "label": "Senior Unsecured Revolving Credit Facility [Member]",
        "terseLabel": "Senior Unsecured Revolving Credit Facility"
       }
      }
     },
     "localname": "SeniorUnsecuredRevolvingCreditFacilityMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TheNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Notes",
        "label": "The Notes [Member]",
        "terseLabel": "The Notes"
       }
      }
     },
     "localname": "TheNotesMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Five Five Percent Senior Notes Due 2050",
        "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]",
        "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050"
       }
      }
     },
     "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeFiveZeroPercentDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Five Zero Percent Due 2051",
        "label": "Three Point Three Five Zero Percent Due 2051 [Member]",
        "terseLabel": "Three Point Three Five Zero Percent Due 2051"
       }
      }
     },
     "localname": "ThreePointThreeFiveZeroPercentDue2051Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Zero Percent Senior Notes Due 2040",
        "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]",
        "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040"
       }
      }
     },
     "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Five Zero Percent Senior Notes Due 2031",
        "label": "Two Point One Five Zero Percent Senior Notes Due 2031 [Member]",
        "terseLabel": "Two Point One Five Zero Percent Senior Notes Due 2031"
       }
      }
     },
     "localname": "TwoPointOneFiveZeroPercentSeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Senior Notes Due 2030",
        "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]",
        "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TysabriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tysabri",
        "label": "Tysabri [Member]",
        "terseLabel": "Tysabri"
       }
      }
     },
     "localname": "TysabriMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_XtandiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi",
        "label": "Xtandi [Member]",
        "terseLabel": "Xtandi"
       }
      }
     },
     "localname": "XtandiMember",
     "nsuri": "http://royaltypharma.com/20220630",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r358",
      "r498",
      "r499",
      "r502",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r115",
      "r116",
      "r294",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r203",
      "r348",
      "r350",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r204",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "The Manager"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r203",
      "r348",
      "r350",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r201",
      "r271",
      "r272",
      "r348",
      "r349",
      "r542",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r201",
      "r271",
      "r272",
      "r348",
      "r349",
      "r542",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r115",
      "r116",
      "r294",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r58",
      "r67",
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r56",
      "r57",
      "r58",
      "r594",
      "r618",
      "r622"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r507"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r387",
      "r388",
      "r389",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r208",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r101",
      "r313",
      "r324",
      "r325",
      "r483"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r101",
      "r260",
      "r265"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r67",
      "r68",
      "r69",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r112",
      "r189",
      "r193",
      "r199",
      "r232",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r409",
      "r417",
      "r460",
      "r505",
      "r507",
      "r562",
      "r592"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r31",
      "r112",
      "r232",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r409",
      "r417",
      "r460",
      "r505",
      "r507"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r218",
      "r255"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r214",
      "r219",
      "r255",
      "r567"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r217",
      "r255"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r217",
      "r255"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value, net"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r11",
      "r103"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r103",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r469"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Indirect Cash Flow"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlow"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r110",
      "r112",
      "r140",
      "r145",
      "r157",
      "r160",
      "r162",
      "r170",
      "r171",
      "r172",
      "r232",
      "r277",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r330",
      "r331",
      "r334",
      "r335",
      "r337",
      "r460",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r572",
      "r598"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Dividends declared and paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars/pounds per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares outstanding",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r507"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r78",
      "r579",
      "r603"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Royalty Pharma plc"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r65",
      "r77",
      "r407",
      "r421",
      "r578",
      "r602"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r203",
      "r458",
      "r459",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r203",
      "r458",
      "r459",
      "r623",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r203",
      "r458",
      "r459",
      "r623",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r175",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r179",
      "r180",
      "r203",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)",
        "verboseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r203",
      "r458",
      "r459",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses/(income), net"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r241",
      "r248",
      "r249",
      "r251",
      "r252",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r178",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r307",
      "r314",
      "r315",
      "r317",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r19",
      "r20",
      "r111",
      "r117",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r324",
      "r325",
      "r484",
      "r563",
      "r564",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r318",
      "r564",
      "r590"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r290",
      "r322",
      "r323",
      "r482",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt issued, amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r38",
      "r321",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39",
      "r111",
      "r117",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r324",
      "r325",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to the applicable par call date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Upon occurrence of a change of control triggering event"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r111",
      "r117",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r322",
      "r323",
      "r324",
      "r325",
      "r338",
      "r341",
      "r342",
      "r343",
      "r481",
      "r482",
      "r484",
      "r485",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r303",
      "r481",
      "r485"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r303",
      "r319",
      "r322",
      "r323",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized discount and loan issuance costs on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average coupon rate (as a percent)"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 4.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative instrument, current"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Forwards"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r344",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "verboseLabel": "Dividends declared and paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r32",
      "r114",
      "r280",
      "r282",
      "r283",
      "r287",
      "r288",
      "r289",
      "r499"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Distributions payable to non-controlling interests"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r40",
      "r114",
      "r280",
      "r282",
      "r283",
      "r287",
      "r288",
      "r289",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Total distributions payable to non-controlling interests"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r137",
      "r140",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r435",
      "r436",
      "r580",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per Class A ordinary share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r140",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r435",
      "r436",
      "r580",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r67",
      "r68",
      "r69",
      "r119",
      "r120",
      "r121",
      "r124",
      "r133",
      "r135",
      "r169",
      "r237",
      "r337",
      "r344",
      "r387",
      "r388",
      "r389",
      "r397",
      "r398",
      "r434",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r495",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r74",
      "r96",
      "r101",
      "r599"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Distributions from equity method investees",
        "verboseLabel": "Distributions from equity method investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r12",
      "r190",
      "r229"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Non-Consolidated Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Losses on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r228",
      "r605"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "(Gains)/losses on equity securities",
        "negatedTerseLabel": "Losses/(gains) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r224",
      "r591",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Gain (loss) on equity securities still held"
       }
      }
     },
     "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r438",
      "r439",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r442",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r442",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r438",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r439",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r438",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r305",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r305",
      "r351",
      "r352",
      "r357",
      "r359",
      "r439",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r351",
      "r352",
      "r357",
      "r359",
      "r439",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r439",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Unrealized (losses)/gains included in earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Unrealized gains included in other comprehensive losses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "terseLabel": "Settlement of forwards"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfer to Level 1"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r305",
      "r322",
      "r323",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r448",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsPurchasedMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.",
        "label": "Federal Funds Purchased [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsPurchasedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Current portion of Financial royalty assets"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r241",
      "r245",
      "r246",
      "r247",
      "r251",
      "r256",
      "r257",
      "r258",
      "r259",
      "r316",
      "r336",
      "r425",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r29",
      "r207",
      "r240",
      "r242",
      "r244",
      "r568",
      "r647",
      "r649",
      "r650"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financing receivable.",
        "label": "Financing Receivables [Text Block]",
        "terseLabel": "Financial Royalty Assets"
       }
      }
     },
     "localname": "FinancingReceivablesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r14",
      "r264"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r264",
      "r266",
      "r543",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r264",
      "r547"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r264",
      "r543"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Value",
        "verboseLabel": "Intangible royalty assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forwards",
        "verboseLabel": "Forwards"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "(Gains)/losses on derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gains on derivative financial instrument"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r189",
      "r192",
      "r195",
      "r198",
      "r200",
      "r560",
      "r575",
      "r582",
      "r606"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Consolidated net income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r74",
      "r101",
      "r187",
      "r229",
      "r574",
      "r599"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in earnings of equity method investees",
        "verboseLabel": "Equity in income (loss) of non-consolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r134",
      "r135",
      "r188",
      "r394",
      "r399",
      "r400",
      "r607"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Decrease/(increase) in operating assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase/(decrease) in operating liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "auth_ref": [
      "r142",
      "r143",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r162"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares",
        "terseLabel": "Class B ordinary shares exchangeable for Class A ordinary shares (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r162",
      "r360"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Unvested RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Royalty Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r186",
      "r480",
      "r483",
      "r581"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r94",
      "r98",
      "r104"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "negatedLabel": "Interest income",
        "verboseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r561",
      "r584",
      "r627",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available for Sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r112",
      "r194",
      "r232",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r410",
      "r417",
      "r418",
      "r460",
      "r505",
      "r506"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r112",
      "r232",
      "r460",
      "r507",
      "r566",
      "r597"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r37",
      "r112",
      "r232",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r410",
      "r417",
      "r418",
      "r460",
      "r505",
      "r506",
      "r507"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r20",
      "r564",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Outstanding borrowings"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r304",
      "r320",
      "r322",
      "r323",
      "r564",
      "r593"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total debt carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedNetLabel": "Less: Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value of outstanding Notes"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r117",
      "r275",
      "r309"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r117",
      "r275",
      "r309"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r117",
      "r275",
      "r309"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r117",
      "r275",
      "r309"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-Term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-Term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r39",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r112",
      "r232",
      "r277",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r460",
      "r565",
      "r596"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest (percentage)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r61",
      "r64",
      "r69",
      "r75",
      "r102",
      "r112",
      "r123",
      "r128",
      "r129",
      "r130",
      "r131",
      "r134",
      "r135",
      "r158",
      "r189",
      "r192",
      "r195",
      "r198",
      "r200",
      "r232",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r436",
      "r460",
      "r576",
      "r600"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Royalty Pharma plc"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r64",
      "r69",
      "r134",
      "r135",
      "r413",
      "r420"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net income attributable to non-controlling interest",
        "verboseLabel": "Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r138",
      "r159",
      "r162",
      "r189",
      "r192",
      "r195",
      "r198",
      "r200"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Royalty Pharma plc - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r139",
      "r146",
      "r147",
      "r148",
      "r149",
      "r159",
      "r162"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Royalty Pharma plc - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r136",
      "r166",
      "r211",
      "r212",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r387",
      "r388",
      "r389",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r402",
      "r403",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r478",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r544",
      "r545",
      "r546",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r344",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income)/expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r205",
      "r206",
      "r569"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Financial royalty assets"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r24",
      "r209",
      "r240",
      "r246",
      "r250",
      "r253",
      "r254",
      "r646",
      "r647",
      "r648"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r205",
      "r250"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Total financial royalty assets, net",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r189",
      "r192",
      "r195",
      "r198",
      "r200"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Purpose"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurpose"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r30",
      "r507"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r62",
      "r65",
      "r67",
      "r68",
      "r70",
      "r76",
      "r337",
      "r470",
      "r475",
      "r476",
      "r577",
      "r601"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Changes in other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r65",
      "r407",
      "r408",
      "r415"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r223"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r56"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (income)/expense"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other non-operating expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r89",
      "r216"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of available for sale debt securities",
        "verboseLabel": "Purchase of available for sale debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireFinanceReceivables": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.",
        "label": "Payments to Acquire Finance Receivables",
        "negatedLabel": "Acquisitions of financial royalty assets"
       }
      }
     },
     "localname": "PaymentsToAcquireFinanceReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Acquisitions of other financial assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to non-controlling interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Shares",
        "verboseLabel": "Debt securities"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r88",
      "r96"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distributions from equity method investees"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r87",
      "r216"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from available for sale debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r61",
      "r64",
      "r69",
      "r95",
      "r112",
      "r123",
      "r134",
      "r135",
      "r189",
      "r192",
      "r195",
      "r198",
      "r200",
      "r232",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r407",
      "r412",
      "r414",
      "r420",
      "r421",
      "r436",
      "r460",
      "r582"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Consolidated net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "auth_ref": [
      "r243",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "negatedTerseLabel": "Current period provision for credit losses, net"
       }
      }
     },
     "localname": "ProvisionForLoanLossesExpensed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "auth_ref": [
      "r100",
      "r573"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions.",
        "label": "Provision for Other Credit Losses",
        "terseLabel": "Provision for changes in expected cash flows from financial royalty assets",
        "verboseLabel": "Provision for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "ProvisionForOtherCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r358",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r358",
      "r498",
      "r499",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Related party, rate (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Operating and personnel payments incurred"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r358",
      "r498",
      "r502",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r496",
      "r497",
      "r499",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r391",
      "r541",
      "r631"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development funding expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research &amp; Development (\"R&amp;D\") Funding Expense"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r344",
      "r507",
      "r595",
      "r617",
      "r622"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r119",
      "r120",
      "r121",
      "r124",
      "r133",
      "r135",
      "r237",
      "r387",
      "r388",
      "r389",
      "r397",
      "r398",
      "r434",
      "r613",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r72",
      "r112",
      "r184",
      "r185",
      "r191",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r232",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r460",
      "r582"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Exchange offering, ownership percentage"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r179",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of Financial Royalty Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r39",
      "r117",
      "r322",
      "r324",
      "r338",
      "r341",
      "r342",
      "r343",
      "r481",
      "r482",
      "r485",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r140",
      "r145",
      "r160",
      "r162",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r112",
      "r231",
      "r232",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r261",
      "r263",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Royalty Interests"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Repayments of Debt by Year"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r110",
      "r170",
      "r171",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Balance Of Non-controlling Interests"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r21",
      "r22",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Debt Securities",
        "verboseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r21",
      "r22",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Interest rate volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-adjusted discount rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r347",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares, outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r110",
      "r112",
      "r140",
      "r145",
      "r157",
      "r160",
      "r162",
      "r170",
      "r171",
      "r172",
      "r232",
      "r277",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r330",
      "r331",
      "r334",
      "r335",
      "r337",
      "r460",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r44",
      "r67",
      "r68",
      "r69",
      "r119",
      "r120",
      "r121",
      "r124",
      "r133",
      "r135",
      "r169",
      "r237",
      "r337",
      "r344",
      "r387",
      "r388",
      "r389",
      "r397",
      "r398",
      "r434",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r495",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r169",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r337",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r344",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r68",
      "r112",
      "r119",
      "r120",
      "r121",
      "r124",
      "r133",
      "r232",
      "r237",
      "r344",
      "r387",
      "r388",
      "r389",
      "r397",
      "r398",
      "r405",
      "r406",
      "r419",
      "r434",
      "r460",
      "r470",
      "r471",
      "r476",
      "r495",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Shareholders' equity",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other exchanges"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other exchanges (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r477",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r508",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r8",
      "r18",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r316",
      "r336",
      "r425",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r43",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Interests"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r43",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury interests"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "(Gains)/losses on derivative financial instruments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r173",
      "r174",
      "r176",
      "r177",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r139",
      "r162"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r137",
      "r162"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average Class A ordinary shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2062-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2574-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2597-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2600-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2603-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196816"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498357-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926"
  },
  "r633": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r634": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r635": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r636": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r637": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r638": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r639": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r640": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r641": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r642": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r643": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r644": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r645": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r646": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r647": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r648": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r649": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r650": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405"
  },
  "r651": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001802768-22-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001802768-22-000035-xbrl.zip
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M?9GN[?,HI%!:&DL8C"P9"E7O2VQ5G+B>9)::88MYT.T#BBZAQ(H9P8-W(BF
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MR49LKW)E0[Q@YT6:-].0"Q@?3.9CBVC>0X, U-GS8@N5*QN"QD6' ;6A+QF
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M+1?/7ZR_Y.4/WYPNFT$U3IE>A+(?%;,4P8%S%I1,$!.4'M AAE2&*@;D/*>
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M5'I7^S#G7$O?LV/B$F-S5,A>H,64?(X6H[*CU#"*!A$VH9'R' N5IL6)K4\
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M3,"$OO9:S#]4)O17I\K6?]D?],>]@*:4G\H_+Q_4%)A+P ]@'"P=\;=ZOC\
M<[E,W"BCF\J$A\'IJWZ(LR9T#/MV<#SH?_63NQZI5V]B1[<^[7S9I3 _L*=;
MG_Y]D.WH/?C;//3?]MI?SF \&&N3[QWM7CXD@/MV#O?*^SS9/=H$._IOL+T_
MGK;._MG=;K= Z*RS9OO@:*\[UXZ.G"KE4D ZI2QFE$0N<(&PU9Y[SHQG(&8V
M>_M=VPM%_OO)=N/P2HOZPL;[D<ODC%W]4VQ&Y1B2K&:HN,20TP^?"T.V[<G6
M-.+,ETSYB V.^V:SYF4V8T%2ZR,!'4XEQ).AR-!D$' >DUHJZB2PF=$(;!>A
M%+L&?\T7<93\0L0],TDVWP/\1RE<BOZ@Z(\.XJ X' \ZP] I(U>S MKY41"5
MMPWV;:]S5O[^YS* [H;; JKMD]N3K=6=U0^KQ>;1<;=_"IOR,_(4K?[JO)6?
MSP)LA@-NL"N_N?7:>B6A]\AU-Q57RQ8=ZR$,XG X_<];V&Y2BXW?B8VS.=I9
M$(%1&P4RCH/I+[U$6GF.$A&&:&MR]8&'43^ 'HI-.QP5PBS%TRI6M;C&1%X>
M]R>N^1>#G''0^1I?9LL?L54RQSAW=ACS""MKHX.ES/IZ:U?DTC=Q]!W0+HOZ
MWP'<TN&F(E+AOG#J%?RX/6CWO]4VY&]1"L^@U >#]_[W /NCOWOVDQEO'_T-
M<]O%K38\^]/';\WV^_R^?.]-\ZRY >O6]K &KP];AZ^__._9^\]"P,X9[5!P
MCB*>@U*T3@IQAY/5B@A/]<I:)JC=_N#+969I+#/(Z"<B*;7&[<&[0?\K:(AS
M/!+#?$/V2.0!:G?$O9/2_F<*VXPI88@8GV,"@D6::(I$;I L=03Y2:\FI7NC
MI'=]()7N7N=XXMFJR>1>R63SY+.CWG!*#;).,,2]C,A*SI%/25"@%:>ER\']
M<X+@;AS+\#M1>J63:_DR=G+Z,B7*;/D>#P#9.L>V6\23Z,=9FX*/P0B#IV7/
MWUGG&+@B_"*EX*JWG9?_5LE%NN*(:HG0D)6/]4&TCQ8,[G3.>?(Y16($UPE1
MFJ4^(039R UBB6H:$N/:J)4U2F98\<]E O;;/FC([P[ZO><:9M'$GUD*U"J1
MDZ@U!GU,$>12TLB[$(*DR20-XE1KAG*[[\6=.S\X)%X$'_S?83&*W7B<"6$:
M6-3(#L+N.)M8A06^72PBWG>\21GHMIQ8J=\N=OGL#R!H!F#!PX"3D_\XB*$X
M'@^&XQP",.H7<$?I R3T#_=G%E,Y)F_=CUY<36&5BP$P9E4+=JOH;[T*:NW"
MP[\I?)&:A0];SE8N(JI\NB43]^9,AO?T:M[@V8L5"4B_GH^CW1EUR[B7:/U!
MX7.3Y&M$)S^;U1G8$FB'IT>NW_UC^.>BUF;J(G_"2]>:QE.5=!5/_('M[<,'
MO>+;00<^N0#;GY;T=UQYE6C^N23#E>MZ+P1[U FA&Y^<RW(J*4\)=25H/$J5
M=.(Y@'%)ZZS[9?O-[K?MC;W#UIO-TR;=.MNEFS#G71BKR5L;K:,6W;J<-P+O
M\)%M?WK/]^"YK3S'-GP/;/O=MC]K'6Z=-<_V,3R;[79ACK,G*H9KZQC'2 MG
MP=Q@ FFI+2(A*&9RR_:@5];*9O7%>@%TV>G9P6DQ/ !=;]@HCNV@^&J[XUC\
M=UD;A=PBM:3FE:7SRE1N?"C%1LTHUV"4S<N,DL#NUAH+Q )+B%OJD V$(9V(
M#@98R.7B_3OO=O[WH5C@?F3X$^60<VFR.=4,)F'V,U&6</71'V?<'Q-M768B
M'2/S3 ODJ0!I0S,3)6Y0DL!;W$L3B $M%PS:EAT&^Y^B+)I:Y-HM<52\??OJ
ME[PUW_-\G_Z%ZSE4MGHA!_+$PIT6_B#""Q[EXC3?#F(9@)7M^8NH_Q?%'^3/
MXL .RVRN4-AN%Z[F/-KL(?C/N)/] Z-^X>+T!ACTNXN Y7BM26[BU%'P@W_A
MG-2S\R!?SKF)18"K8&#D6X\'T<?2W""T* L'#(L_8#Q@BF(X!IUY>-#/N0?G
M68"C SNZ-/GBF_UYEF5&6OGEZ3O\^;)TI?]!)^\("@?LQM@=PAOD^\M;<Y%$
MF,5TG+)993F)<I(YYL+@(MC3X>K]Y+C-W]3_\U]$XI<__OLP7J0?)K/T [Q7
MX\$ =F.2UIWUBY$=C8>/$AKOY!LFGS7HT218@JS(.4D^.N1L *V:!>V3<#1Y
MN[*V.QLHOD12N1'AWG &ZX..[=[UN=-".P_]ZI7BW%:_*@OR0!3!*T 1USF]
M.!P/1YUT6I6,V.HK,J5\!]%^U!F-0!DHVR<.^KUL6G1/BPAFQFE1%F3.19._
MQF+#CFR1$[LOJSD78V3-X;@_'%TZ(=D9PY<X%EFIV8G[X^XD:/H#:A=_Y U6
M+RFCJ],;1@>=,HOR.&=1+EO]F4S]^[R_JS=Q^.?J/67H/QHDO(<,N^_$EFEM
MJLP\/^V%?DXX807K"78896"6!8.TE 89@EE*UFCC>*V]5%E[>7!;H]9;;J$U
M5,0I0<2-93G(3%MT[6 _%M9[D.6#W,6@%&6#!LBWN9\6@!QH[H7A$2@!\)3!
MN24)<'\$:W#:R X,& ZL_AQDL%_L#_K?1@?GEU>+#S&6<PLQ=7IEYD,9NO=_
M_DL#[+^\:H;E9?+R_+;?WG#E_,[ORQ)]>N\54SV_L].;Z">$.D3/O3(_NF)6
M'T\8AS*KE)E;A7&054,7'\9!^"HE;/%A'&I5+R$ZA)!5R:XWV]O7'/QECLO3
M\N%?U((:O )>WN\/3N>X\,N;2B[WTYL>N3<_UQK<)+N'W4[SZ.^CUIO606OC
M"]P/SVC#7-KKWUJ?FJ35GJDYV&GF6H/MOSO;G[9.]W+-0;J)M]M-UJ3YF7\?
M-#?6R>[91]*<7W,P,16#<1JQJ"7B^=C8N!215=9ZP7R(V*^LO9V/P8^M!N'+
MY=O^URS9>4GUO"+S^ODLV_5P9WV6 .OUNS'97=9RERF<KK5^E:2UUCP]=YZ-
M4M/>76GO>2[;]<CPPU562[V.E2F2/=%9RYWZYW@(3QX.GVY]['O254_F%!S2
MDA)NG42!*HVXBPI9; -*)'BM$R7!Q=_7Q[ZQS+M!M9O%%\9Y=.QX/5C;G.]@
MJ4&M8J!VOD]ORFUZ-=FE&MSN"&ZG<\"-TDB4]Q8(A1+$4[3(&:^1)M+(I+4F
MA-P8W!ZN-^3USL"O.K)<U+\/[I8O6TINI5^XOW/NY5RO?2?-.WPOC]S!'.GU
MRV/R\7#B.H?MG/0GFE/8OS\HG]4]S0__UH%'PV.+'KQ:/^N57SO#TKSIV9[O
MV&[V\N3RHV6*TLCV@AV$89%K@'3"55F,[ _[YUPW^$W/P^]VD$.O-#,>( N5
M_I2%^G#G0OAVYT+#@]CMGM-H\0=07GDZ,RE:/7OX 9O]YVIQ%1N6I\X/<K)(
M\ S*E.1Q/=AX@*UZL#/8F96Z5]8E]V.B9:*>I\2\2)V3"(:$[0X?9P[:K8-'
M<L0_;Y[MPU]_LKWA>7/_L\8*JY "<F!2Y3.!@(PT$5'NI LZ**/%[YLL7BMV
M_U(5.)%;-<R6O[O<@/SB<+34W?'%5ZP;]KOCT=5?67 UEZN;H$_^/1A<6"S[
M$;E!M%^033# "]O]9D^'*W\MNO7Z@P20K)<G]NOC?3"'"C)IMM<H9CLY@ [S
MO8?BZS)P"_2'<:\SX?))1N+*SYPOJ)(X4(>5YQQG0U]A$7FBAAL:4OR\53*\
MQF0%9)3O' $3_\_*5NOUG%CW_M%1+L3>]U\^E(_:'H]*'0>4G9_QH#<^0J$_
M0M,!P>X$8Q+&PL\+'4Z;&^_)9YPP]I([I!E3B&-'4:Y)ACR)6GG!,>-X98TS
MU2#,-(C2YYAPOL-KQ17)IT7_8@/*^(N;D89,H&8QYZF-GBM-M=<)*"%J[@PF
MU-2DL532V.>?4TPB!$41B<8BSFBV6K5#27+KB6.>8A 51.$&[$)#&7(5:?SS
M5Z1QW7":>P^> 6#.&=.WB9XQ>M7@JR_/"1RY+"M_U??CIUQ4>F7&Z&P=Z%F/
M04G423',O'0).\\=HSH:Q[7S3EKE@>L_JY6'\#)<TR:\3E^[^D_]I_Y3M3^W
MLR;N'W=F:BR6N+.SO;O^MKU;O/O7^DYSO7B7<Y\78&!4\$VW6AN;_WL?+W?/
M-<[TJM3\-N)=KS)]=43I;:--]2J]9K#I3495=!5,^84/*U=!!W\RD;'7/)%[
MM[[3+K96KXR$G.W%\1C>ZO56:[WU:FO];0'&TS9@66Z;?#_1GC= N)26M@23
MF8/)-^VA\V+< ^29]%WXAZW,7(J#03:,_^OW^CIA8);]XR_[B[B(&]@;RPV5
MN.VMBX_O> R\NC6*1P6Y&H$>YUN]Z@.1]_)))?Q4&K-E5.;K[\>692^#25V1
M&I@>,S#)&I@J%7A6(6[_I^T"M\?BPT&,P.>V/'3X][@7"X8G9PZE$WDC^IC+
M6A=L<A)!BC_&/3L.'1CC.M56:W"H+#B8&AQJ<)@/#C\H ( *V\=Q0F<79<;:
M0&:Q!(@/G9.BV2^K@6R645.S&%+#QA."#4I7UF@-&S5L_!8V<G#0(![ ?;E\
M4>[??A1K *D!1*RLL1I :@#Y+8"4P2,'_2[0V#"7"R'J9;'YGW%G=%K#2 TC
M>F6-US!2P\CO]1 [/"A>=_O?+LR7&BR>%U@POK(F:[!XWF#1ZH]@L%&_N,GY
M1XT 3P,!<E2UJA'@";)U>49+G]H9;=/V['Z)05/+9UAL=(9^/!SF4/ZLH*SW
M;/=TV"E5G OHRM@V25G-]^S$X;A[V8E;X]@CQC&"S<H:PS62/54D8T\-R=[G
M%/?.J,P^+$$)/NB>_YXQK=L?CG.2RKKKCT?GO8UV.L,O-5 ]9J 2V>:J#YB?
M+%#QIP94H#J-!O *)4B]&_1]#!F7:A1ZU"BD (7J\^I'PX23F/\G%_2_W?[7
MYDX=\/]44$7B&E6>LF[SY$+^W\9]VYTH-64/KUJK>=SXPVK\>=+XL_[4 "C[
M<XK7UH_Z@QI['C?VR!I[GC+V/+FCM(^]24'.F)N.?K#=6)Z'30,)?^C_GMT^
M'X<Q7YPJ2C52/6ZD,C52/66D>G)'91LQV?*\_N-Q[L\<>YW^X >$JM'H,:.1
MHC4:/64T>G+G84WX!/2E%$%-^N&<OD:A1XU" E"H3K]ZLB@DGAH*;9=M%;9Z
MD[+!0/<U_CQJ_-$U_CQE_)%/#7\V3PXZKC.JU9Y'#3N:_ YV;ENLF^"5M:67
MH*V_5G^M;O"RN 8O-RI^W<G9@@!.JQ-%Y-=O\MAHZ08"9UE%KW&NPOSA.);Y
M2SE)L]B)^S9WL-@O7O<'W^!']+;?_Y)_O\C,O/N&4OK#CB[N?>GOA!H1/W:S
MNV>=IGQX^Z SS&D8 ]CO[BDL=^Z'7?1[>;F/"H+1^R+WAK&=WA"F]CT7%J1M
M[IB8]Z$_'A1?._';L+!EUD;^/8U'XT',K1)+6RT7%QP=V%$>:CCJC !HBIS+
M1O.;37:U.]W5BV>4-Y"796O%3J_,U3^*ME<^<M(=[]V@\S6WW_OAX.XM_&>_
M5 [@5?*S<PN]?#\Q1JR"[5@,<^DA;X=QV"A.^V/XL0?B'1[82:=YU&'\\3U=
M65_DIQE^Z^?.C<.Q/\B5$J>O<61/&^<3/O\HK_+E#[]UNMW+GPT/^N-NN/QI
M/ $V& TO?WS<A<V^_&'.JO&=8YCUS"47NYWX=?;S"/MP-.\+QX,8.O,>#-P(
MC['=\\_[@_-+F4 ZO7'\_I6\.;VX/\GKF6Q6;J@9!T>3H]5^:<B771 '9>'Y
M?*G3 Y+?/UTMVN7=5Q-&88&T<J-.(-U1?Y#5Z"+9/.7" ?V!;IA'SS<YFS.[
M@1: /@;PU6*RJ)/<QT;Q?0W*21T/^H>3SIOGE#R&>S(UGW][>M<PCU%F, V'
M<32]!X!D/!P-3B>_E:N>IB\+O\.=XZ/C<NSS]YOS/OO AK"5<7(J/8>'\G#Y
MYN'8Y:GF!/9!9_@%IC"&RX/,I=^/KR=KG"9A-HT)V<.HWPXZF7#SXL33_G1Z
M?I+N4'XO=%+J^'&W''U*#.4%GZD4V"7W1H51Q[#J@VE.*=R9OP;/R\N9.Q8"
ME*1!_PAVOC_,;51AH&&Y%X.\L1'X;S3I>9E)Y>JM+A<+YIKGVSG*T)0[:4Y?
MZAQ2+J95+O5/4VL47:#^;G[SW!CI:V<$._3CDO;S-PXRBTSVXE>O$F\]ZD\+
M "\"U!$RMOSF[9<C&!Z!5-H%8)[ 8A&_VNXXHSSLQ*] X<B&."&HWPJT*=E-
M>YZ=2Y->[K38'P\G+)7[9'7/&[.^@]&*K:(T-XOSJ+SIKU,,_#&H[1P&X9N9
M(M=[O4R1LS/Y?]^+T*1.[G96G$8[*"8-AV>*[<XVZ[JI4O=P/=59J6ADU)NL
M;8:3GQ&KT_/=,6S@.6N7)DSNN]Q_<>6K37TLD[[R3)Y[6:8J'2)Z"1K=]<BW
M) "YG'ZWUYK"RY_6ADSME6$9\#0E[U2X3O^X["#IX[AT1F7A%L8^%PGH307%
MMXQY/F9I-RB[3L)FS3:!KG?DECM2"BS7Z>;P,Y \W7[93GHX[DSZ\4P4C'S%
M^O^,.X-8+_W"EOYG_+G FQ*/R^6>]GL'3NED:QBTQ8Q31<BBOW^<I0X"^;,?
MKV:D;%R$LJ30A2J8NX&/XGZYWS"O.</-^3+<F[][?B4+DM3O=OHU/2R,'LIM
MOU#3)]*]>WINX;KQ$(89@I[1#[%;K_NR(!#L:@_+G,99[XXG8-F/)GK]8-KT
M^$?6/.>E>CN6)I$ G089E"9FXM%Q''5*VQ>6/O;V1P>U-K"XM9^:KJ6;X=S;
MDJV4U.WX2>6F<T%4.L5*234I#C4HO]3)O@2PWKN=+#3JC5FL;)@R!>S"SKOB
MHB97HWC[]E7Q1[YE:@I.MV1J!?Y9"OK1*#=F+G=I$+/641S ,P'B1J"3][+F
M ;(]Q;*DE^W6>[?8O8LIQ8D;V!_8WOY$H1K9$X"W_<ZP:[\72<LHES\_/Q=[
MF3^M]V*1>W$]AV4V/+][Y6-W&+^5?L#K^7=*+)SX7J:# NOV]H<7J/EQ]</J
MY7R?S9,)<>1F!4>=DA/OXG-9[LG2]7PNZ]W107^\7YKQTX. \O5_=(.?'^5<
MQQU;^F$'T0X!I, ^;<"ZG4[<9U,O[\6H$[<L@%I^9!^>#J-;#PL.8S4FCFP8
M;NI0;?SNN=\=^7.>!'#9GS[NIZ>4ISW=O!H71Q 7=/83_4V>7_J@AE.3S_YP
M'C#U6L^?W#5I<NK-S&Y^E]<PGVK&[XN0O<,PU@2(W&DQGCJW2Z,OG_B4,_]N
M@_1+]S^H89FDN]T\XM3='%:+9G\08=4'C:(7.^6[?LO'"X/)9I4?',?!,"->
M-G=*XW=X#"O9F4JX<Z?D9"']Z=3[?W3<C:"4E,]/%SO_Z[.:U>+3Q'L_<9;V
M^D483S3+\7$HO;K7&Z<HS_[+:95?*[_RVT4?]4OU*?\^,9]S$LT/@Y:.E9].
M,N#Z('[M9&K[D<AF@>"Z(4%LY:;H4<F0C@>+S;A-^,5=HS8>IM=W6>Z(K((6
M221^.?OOKYL%WWCNZ_ELZXH9R]])EW+"LUWDK\L4<I8I[GNUI[5=KESMJ_Y]
MM=W:V&Q]V-PHX*</VV^W-M;;\,O%YGQHPP?-S5;[P^W7Q]Q#'.$]+CC/3=!W
MMG?7W[9WBW?_6@?:+=Z]?57Y*5^QU_]<?PM[O5E\^-?F9OM#%=ZB'/%%!VS)
MCO\UXY;O]<=6J4B-8=20PR!.?#P>%<=V4.2SUOAG%5[IUR_P<;82_^6Y'MG!
M/@B>4?\X9PV\G#?UR2'+=P$*"MD P2MT[?$POCC_X67H#$$%.WW1Z943*;_T
M<CKZ5.KF!UR*Z"Z?-[E\(?!6\43H3?,!ID^>7EXM+YW'E/]T3<I5K>F5E_$J
MN?+:KX;-9AEGMQKVU]<$N_JA=YJLN-:P]Y)S,:&B^\E/T+^-F\2ET9\%U/I/
MW7MOD*KPE)?CQVB*GY;DF9)*;FWTC$DCQ]/<A R<]5_V!WVP8=%TAM['F-++
M2F0O7>^=U\M8@FML^I4O.Y606:+"NQ9EMYSB?-XW()7?KN9=QKCY)&^\]ZG\
M\YCV_M5Y .OM:>#22]]JBY8]QH*XN,C_5:M*5&53KZA1GGO9E:ZY_$/\S[CS
MM3Q+FMG?F[P^+BI%SO/?_+_O](8_OMD@CUJE5_M'Y^1%K]][G4\+LR]XW.N,
M=G)FXW@85LXC5LL/.M(R(A+!GOC$K:366NRL5<H9*U22G[>RE,>2X94B1-\Y
MLMWA_ZP@X(>>/8IY1+1O[?&+3$?KO9#_LWE!1.NC5W8PR.$O?V>;<*68)-W#
M<T]&+WKC(Q3Z92IF'A8X#%8OEKQ6>C@"^_O4;?2_OJ4[7W=9<QP.-[_NO3&'
MVT?PV]GZV>[97F?O\)^=W;.=3O-LB^^UNYW6QD%GEV[1W78X;+:;XBUK=7?/
MCH]:9\UO3=JDNT>[WW:/FGCWL'FZ_>:CV#U\SW>/6IW6T2;;/=L\V_Y;GVQ_
M,$?^Z'5O^W"7MCZU#IH;_SYLT?=D[W#G</?LBV@=M0Z;1\VSO8TO L:BNX<>
MOV4[![M')]WMH[VCUD;XLGOV_MO>F[\[>^WW)ZVSG8/MC;^_--]LDNWV)F]^
MVCG<^[0ISK\#SQKOT8]R[V@7M^C.86OCGU_V/OV[V]K89*TWF[SUZ?VWW?9'
MT6SOG^R]@?=I=U/K%3YYV]X<-3_@D^;9>]+<^/B98NZ3U!$E1Q/B1'&DC11(
M:ZNB9E%R+4%K:1"L&YBI?_SU,Y5,5=V[<,4Y[-V .Q8IX6N(>I(0)9R/DD;%
MF;*<"V*=%<S!&]LDI6>^A"A"*",U1%4+HLXN0Y32BE'C*:(N<<2-5L@XZ1#7
MBF@60 X%OK)&&H*3!N:Z0A#U&ZWPW+T'DXV_1K7[NG-!!LDC46,G3;XFGMC?
MES>D-UN&N;+B,2/JHI2^]L#F1;H(@=F(;E0CZ,(0M#.KY%E*/'.6(,^I1UP9
MAK1* F&G+;,LJ62RDF=P@V-Z5_S\!20L2\6[KG7_W%EX44I1S<++9N$9)<A*
M+I@B'C&<"*@^6",M-4=>6:>5(='GEJQ"DX9656+AY^48N^B _#UGY-=^SU\A
MTG4-T,>,2(M2*G+!EB'8:6_[,.V=,FTTZW6M.)HZH&MT6A@ZG<XJ&,'3&"R-
M2$A*$2=@G6DO/9+:&AR(UE&[7/K,-"CG%3+0%GU*]-S9>5$*1LW.]\G.,\J&
MB00KHPV23G+$8\#(R,"1)90[ LS*:&X]2'B#"5(A=GY>[HMU[P?C&+ZK&H/O
M?%+[,):D;@R.!R<OINN^,UGV"W2J,6E1F+0]YZ *2,C:X!.BR3/$@P!,P@S#
M^I+(0HR<1[NR1O(I597LG]J%42T-H^;@^^+@&:V"1:^#L!3)I /BFD=D?/#(
M12ZL("I*P5?6!&M0+2O$P4__$.=1NUS6O]I.MSS#R<F#N<X4\+T;W?5$YSE8
M:XMROGS?@M?]0>YL^+-?^.*WVG9;,,HVV^LEPI9(VV[B5GN=?!9.TD2-1Y%K
MA[@S$FGE(I*@,Q$!IAV7>F6-2=90&%?(>*M],=72E&KNK@)WGU[B;A-$%#@&
MQ(CAP-TT(%"D,,**"2\U5X2!&21E U>*N9^^$O6H74F3]E;GCJ1.S^>2S;4_
MZ7[\2>7B3VW1K7+I+RS2&E07#JI;LRJ3"5$3ZPF*D@&H4BN0MH0CIZF24GM!
ME5M9(ZH!NUTAR[3V+55+8ZJY^4&X^;**))F67C.,G) )<4\%LC@RE%BP#.-H
M7*+ S:*!*:L0-S\OM\U$X_#7RPY\[J;<HAPUY:)/LG%K*%HX%#5G%0L?#78N
M>"0#!L4B1- IHB6($L8QJ!4 5;D3J6H08BIDK=6NF&HI%C7_WA/_7E8EA.<Z
M!"D0@2U$G#F"C)<.N:1YE%%*)3WP;T.R)Q@&4PWU87Y9@79_E M4WUU]F+[Z
MM6HW5!&;YB_/0QP"U;"T'%AZ/^>(AS-)?=0H2@*P9*E#ADN"N. :)(IV7(N5
M-=80F#4TG]4LEE*<^7I2\W;VU;79\Q&Y4IXOY"SL9*J&G*5!SF5-2-'DDE0*
M1>HT:$*!(2."0Y8*3I*E7EN;ZT1HI1NP=S7D7%=+.Y_(>>WE$D_N8H !7DS<
M/_=6QNHYU=IZ).ZUJQ+1<F7V47V<]V#9:*U^S]?R:M'R:G=618Z)VH1M1$0)
MACAQ'#F6% K!:!42X8&#Y4Y8@U/6D/3.WK?Z6*^R7+W\I+2:JY?$U9>U4.]2
M%,QB))W*I8!81$YP4$J]B])$+Z2C)5<K FHHK])A_?,ZWMOJC6QOOY/#LA>E
M@#R'@X)%*2"@_G5&\6WG:PP7.S$QEP&N?@:IU#F) 9W%0;_&IQOADY_5.B@V
MFA/)D 52S><%"1EF-:).,:$#M<S+28LT0E]6Z,2@/O"KILIQ$SZNE8T[,O-E
M94.;$(16"FG'/>(^&&1]S+J')2(R9DP0*VNB(=4CBK1^8GZ.7),3=(NZ?-^]
MJ1:3%;](^WC]=VNKMG^6 4G[L_J%%"(&I3WRCC+$4Y+(D>01]<K(1(03D:RL
M,<P;G-^Y5G/MTJ@L,R]*OZB9^1Z9^;)^02.-'+8>!>TPXH8:I#'%2!M@:4&E
M &Y=6:/2-/3=<[EJ3T:=7_Y858[K9J#6R+4,Y/HRJX9H87,M'H54I!8L(YZ0
MMC&@Z+D+S/%HLQHB6<624&LO1S6UD)J_'YB_+VLF4<4DK(I(>1)SV@(H)=(Y
MY"WC)&#)74JYE1V8&95B\#K+O-*JU-19<Q1'!_U0='I?XW!T-*]M6&WG+<5I
MTRP7?NMBW6L871B,'F[.JDG.PCZ!6$1)L8!XS&VU@O4(,PF;IZP'*V]EC1/:
MP*I*%<]J;TTU]:2:B^^#BV>4H6"-EYX@YG/90BX,TLX11+R0PD2,E0=YSIEH
M,'/GVN:UF^9.^>1U'OE]YY'7-MDR8&A.C1J1J!/:&\2=5HACZI&S":PSR[3U
M40#=YK)^K 'Z1(5,LMKG4DU=HF;AY;/P3$")(B+Z2)#B.B&N-=@#T5-DN'*$
M:&\UR9I$@]P]<+5VJCR#]/?YVLZM$]NJW.IX_C)<O]7QS=Z](L*B8KG]M718
MG'28D]3/)$LFAP-H+SCBC#)DI4K(.2.=!!EA/2V+$"J.0<F;+5WV=%)LJ^3%
MJN&TAM.EU"VHX72A<#I3L"""KAVB0B31E*UDT+-MQ"AB$('2<AMU+.%4$-'0
M<E;CKN'T7LH5W+T  (,W"OUQ#M'ZZ6TK5*/@6E-\!G;+VXYUG6X9S%'8'I#T
M@1W$@WX7UFE89D6IET4L3SFN].$NXD#J(<=8D%N^RKL\K<A3="]V^U;;N4!>
M7-H8SRN"8Z,S' TZ;IP%Y+ XMJ=E8.RH7X#@1%E7&O2[\*W]H@-JTR .;^Z=
MJ+#2/']);JPT5U$UKLS)TL8XMOL[L6M',;RS@[JOS%+4Y3F918$9Z8AA*"7G
M$/?PC]6>(5"C4TQ6!D($J,N@*QM3I62$>[+R:UBJSJL]@,5>P](]P=),P1<K
MB'9)(V]</NLV%CFF)%(V4MC Y%5( $M8-0RK@V\>L!,YO,OH0B/,MIV=MB>/
M)\>Q-ZS3I)9_2C/=A7>335COA6F?XQ^L[AJU%HY:<_*CDM9>,D^05U8@+HU!
M5B:!--/&*6L"CPQ0BS:(JM))?QVK4TWMHV;LAV+LR^H(<YH38R*REC&PDBQ'
MP,\.,1V94#X8GVQ9$H8^HK2H)^:CVIJZGLZ5D3JY:,EZQ_F"3^&I1J)%(]'9
MG"[?GDK'3 (D2@$,(^X2TDE2I#P/R7#)G  50_ &D7<.!ZZ>NZ;FX06K&#4/
MWP,/7]8F2 R1Z4"0$1*T"643_ 2,["1UF!FO DW PZHA3972 Y]:0' ]X7K"
MCWW"3R%LX.>>;M<)'KB&@^$.X9F/.51Q4;I][6%8IDXPIV]%2 (+"GJ]X@DC
M+K%!)@:.A#-*B)0$=WAEC6C:8'2VPN/CB5F\$7L^(H?F,\6;1=DA-=XL&6]F
M;)#@J=,4  93F?%&@@V""=!3PMPSG$RT.4R:-*B8]6G6>+/P&.EYGH];MW3[
M763XG<.E%Q@M>P\MW1[U(?O;?F\?C>+@J*P_6I^F+UOSA>5NPVKG$H1UAOPR
MI-&<*$1J J,TA)S^F _.%4,61XLB]X1:YC#+7495@V#9(.;.3=OJL_/*LO'"
M%,J:C9?/QI>52AL5"<YS)(.BB',BD674(V,9&+&,9$C.;(R-;.#'U#WE"?@%
M'_79_J3*UUU=@\_A8'"AI;Y^L,IKY%P4<K8VYASKAY@4UY8BR3S.)8(HLHYX
MQ*E/0AG/(N:YV&!#5:HE1'VL7TWMY]?<6W=^O#WCSB0J,,NB]1)%$8%QL<]M
MXX)'7NF8HB!&,;NPSH_U8?XS. BM#T"KH/_4JL]2$'1.@5/#@W+,&@3;E7OG
M@OEH4L(H.X1 &G*/E<]&(V.T0>EL0%1]%O'0#JEG"C5+./NLH6:A4#-SZ$FT
M$$X$9*+FH*PIC+16!!D=X=,DA'8Q0PV5 #=S4CEJJ'EF.N3CJ[3TJG]TU)GT
MARBS<3-BP=1CS]^V&L]MCFF7HZ^=##LO>IWN_ZR,!N-X&45_>/'U7GCUXVM_
M!TY< ^<U@'-.C5(3.,/)2F08=X@3;0 S#4.2*>*#X+GD7F:R&;Q\##$%RY'X
M-;'>%[%>EO*<8*%"L$A%$\&@P!X9XQUBR1K!*6R6X5<2ZS-P,WQ8;/&])U"M
MK=940N?K^=C3(5"^_X4\#S][ )7W5=<.AQ.]=[T 0._T[.!T4CIRV"C^^U>X
M_2X.2BJ_A-_)2$N-Q90)E>MJ.T&$PB(YRWW0),VWV+9:K^?A=[_W8=3W7][9
MP?;@PRA7"/K;=L?QXM$UCM\ Q_VH^>IG'(?QNO%?.Z=[G\*QHUSN'78/=MM[
M7YJ?=DEKX^,WL/#.6H=?3G8/-T];AP'F=M#=>[,K6ANMG,3_.>N442B!I,8!
M=):DD+;.(Y]B\,2II'-EL]M0$6<A)JI9Y(1[DQW]).6&8$%H+F68[V*LJ>A1
M4I&(6H*FZY'%RB">5$19"42!)F922,DSH"*\"DA(YJ@4ESXHCNV@^)HW^&5Q
M)>5-$&XA1#?K;/J!YDH"&VZ/1\,16(H ^;7WJ:J4V-IH?J:2X,B=1CA1L,%8
MT$A['!%A3D6=:#!)_0+/[I>JMH;#<0PU0569H+1-6F/%D9( :%Q3BZQT& 6M
M4Q0Q&*-LCCE1#<)F0VYGL2V[FVY(?K?2QVI0>R(TV%[_C!UL. ,\HY:"DI:R
M8TEZBAR 3C!1N!3EC4%M6515@UKU"8I$DF@4"7D2".+".J0I-2 TL2E/FF7$
M&=1HP\AYK90N@UJGW/,2V_H7H-(H@!R.(]SS-78OW"9@1==!;3->TR4H&:6-
M5//:37EM)NI48.LU [AUG"'@#M  "":(2(N=]-8PK8%9JE1@MXXX73!S+EY8
MULQY*^:<[1IKB4J@"TD2.>*2<^2X$XB*$!GUP?E8JN<58L[[/CRIN-?ZGXOQ
M6D<=>7(B&8H=#Q@[#(NFC+64V>3-%7%&M;_Q'MAV_[?Z*[SSZ>[1)FF]>7W0
M?//QI+71A=ENTN9AJ]OZM'7://MXMG>4?_^[]#=BV%@L0D)$1PU&N;/(L #"
M&70E["EH4HK=RFM-#-><$1#R&OY)4@?*A=0)2XHQ&%^UU_H)41%8TQID.D>>
M:HE@VQDR'$M$?/)*N813SDHHO=9+]EO?CNQJ8_S1DV'ILF:4))X8<MKFT&ZP
M-+2U 5E.;"!*&LK)3;T[2R.HVF?X2*@J&,9DB@;03 G$*?/($ 4J<M1*>14#
MLV6'5]S ^CK8=G._]>TTLAK4'C_YM=<_6\^!W"Q%2LA\#I<B,C('%_#$/7.4
MJG!C4%L:0=6@]DBH*F$K*(L$R9Q,"GH_04Y1!?O#++5221IR_4?%&Y14P&_]
M'$K1+$'3F+K&ZF3LQ?#@3)BZ2UPF4#6EUA%Q8QRRF.<3;4Q-2$8%K1:6C%T7
MD:HLYRY!G-:<NU#.O>SL5B8:1C4H51'L0\XE0SI2C:+*"<!82]C.*G)N':<]
M]7@7.Z!:A!B/RCZ0Y^[NO#'LY96<N^^.K_!6<AY Y&)%>&(\.F*%%(%[8Z32
M.&!7^[P?C'N__#YFXPB^2_<.6K 6H/=V\[C;[?VSW4^;)]OM]W3[T\Y1<P/F
M<WB0FF>;G[&72@2L$>PQR3V-P)@"2QYYE[P4+#&K?A79>#45,>*T#YQCB3,A
M>1,%9\*(F(0A0=O:Y_V$J"A))JC(%I3V0$41S"@=P$)GABNO?2).9;?0,IW=
MMZ.WFYKQM:[Q8'36VOCX&3/)F&! 6"QZQ(7#R&DJD&","*! L-3Y3?T_2R.<
M<X=B33,/2C-!,NT4Z+.<DWRJ&S$RGF%$B!$N.A># )J96VC_[M[JV^E2-2H]
M'@IK;WVFL*U*6XY$<+F,MDS(16F1!P3Q > %FU]EN]TOX=2H5 F:B2# &!<$
M >4H0"6FP>B660UGVNH(-"/C-5&I#I.^L]-J"3I '8EY*S:[[%96W$0EG4"1
M))#>6#.D$Z L-9X8*6.BA*ZLS4DGJ,.DGPIS+D$4ULQY*^:\[#D67H*.PR+"
M^22>YZA)4*T=2@(;^$NCY*QBS%F'2:^L;<04!P-0&>X2&7V["HP_^/<&QX.3
M%^=3F>BFM7]O$9S:7O^MMMK\]/X$-%:\^ZE)6H?_/FB]:7UI';WN-MM_=[?A
M[VY["]9B]W3[4XYIW?Q,F#7P)Z&4,$'<18N<(P11E9*(RH+&&F\5&7V[DL$U
M%3U**F(XPM8F@9R6%'0YH"++<Y*HIL:"/-=EM>'[B(R^:Z7J.517QWP]'EH\
M^_A9L8 CY09AK7RNZ"&0S36PA='&X) \L?JF/INE454=FEI]@DI*>R&-1%*#
MG.0)#%7GA$#2\YQ)R#"S;F6-2=%@F"[%UWS7FM@U^3U2\FMM;'WF4BL<@/(L
MRWBF(X6?&$'*1P)403UA-\:SI1%4+24?"55%$&5,&()(-#D/VAADHP.JHM$;
MP;3C+&50(PTRIZ5@'1E=P29S<YBRM)+F@7P=97E[3KSLR-;:2&4 E@7)%;^"
MS&6\98Z3,<Y(9P+)(3+5B[*LXZ.KU6:NYM_[X=_+OFX9;:!.4Y2$"HB+J) 5
M6B$/AB03+#(?717Y][F6WWXDW7778=*90FRW.+:=@#J]PMOCSLAVZS:[2VXS
M=['T[V#EMWJO)NM>6R2+P]$Y+>>B#@SC:%!DIFPY%Y"1)B"LN6!,A\AY ).B
M(11N""TJ='18G^M72Q.J^?@^^7BFGYN0)@FJD(X\=WJQ!%GG)"+<A$ #,2:H
MDH^Q:@!C5XB/%Q0"\$@4C)TXLO!A**(=]&#Z=VIL^Z3Q:%%ZQ?F*;TX7?-W[
M\=&XF\^CP6[K^,ZHAJ;%05-SCJO%!44T 0/-XQSVKS'2#*#)*QE3SA\1P:RL
MT0;GLD'8[&%,[6QY*BR]*!6C9NE[9NF9@JP\ 2P[@H3/U9)C,,@%#?8#(5QY
MQJRC,;,T%:)!U&S'A,KZ7YZ8.Z/5[Z',@8-^%R[N%QU@QD$<CFZG=3P'*VA1
M6D>ST^L/.J/3K>F*UX"T.$":TY55$6R2C0&E7"F**^.1X8!/$NP>2USR0LB5
M-=Y@&C<,TQ4R?VHW1C5UC)J!E\K ES4*YX/T/%ADC<IIP9PC:P-'3L>("76:
M:Y,9F"O2,&(V&K7V7]S3 <F%JEWT1P=Q .]\=#R(![$W['R-H&' [[%V:BS[
ML.1B&[;S+KSZ<1.VRCUXVQ\.6W&TG=KVI :OQ8'7QUGM@R3L6(@&225C]G#0
M#&,,2<RHX4Q*KLG*&F%@"ZD*V4*U>Z.:JD?-W _)W)<U$\PIATT];SZ1"$$F
M42#L2%6*0B?K03,ALL'-G=62VM%Q2RYM#Z(=C@>GS]7#\<<#Z"#G:WY54= :
MB>Z"1+MS#E(B#=Q:A@RU-,=J8&1)) A[XX/F;A+^31M*S!ZB_%G[-IX ZRY*
MPZA9=\FL.Z-$1&^"80FT!J,0%\DBIX)$GF?#P9K@O"M9E\R&6#T(ZS[].-4[
M5I)8*E*H^4I.?V2[DRH1!_UNB(-A&=^L7A;Q/^/.Z/0N7A?7'\" :-0_?I%)
M9MCO=D*1WZC2B#I_G1Y %RJ!=+HIF^5F@)W6'>>%>]<?Y%FLCT:#CAN/<E'H
M=K_5[_UP+E?[F!</PG-Z(G@E \6&(J%RCR2O'#)<8N2U%B)ZQ;U48,GA!L>Z
M0?2LJ^:<P1Y 2[B=(7D]KGY$_J-G"E.+TOMJF*H@3,T$UT0I+"81Z<!R798<
MU"M!:Y2*L$2Y(C[GC@-,4:X;@L\JC#5,S5-ESV<QG>^DW->B+=1KC''ER_[X
MOG=YP,-,\MGHW]V.=9UN9]2!<7/F_/7U\6NRP>057S!8]] ?YQXB)2O<0?15
M;2'_^T%6YJDH XNR6=Y>$/)Z+\RJ!K687YB8/YQ3@<!&G+2,&GDA+.(B8.0$
MB'D1B7%&<.JPS&T.&XJ#13*WT^'C%/-WXN('ME5J"*\AO$+V7 WA]PKAERTU
M0V / Y&(29\SFT1"ECN!%!-@HRG'5$@EA LB&EH^'4OM02"\M##^*CT3Y^6H
M?BCG_,-8/F9'Q10$UO[A!G^M_5S%ZAI?6]AN$'R^'>6(+W(N=,?_>H-HWJ /
M,1;6Y^A*VSO-R1N]_@B>-^H7HX,XC  O=APZ.0X3H"7$WG#R4[GH97AFZO1L
MSW?RD4&NOGL$KS=<+8HKE^+<,.8PX>/^L$SB?C&(79L+@;W\U@FC@W.D^^%;
M4U+ %U^Q#N8P'EW]E7M<\U^N,+E4V^R'?_-L2TQ,BF'FI4O8Y;,ZJJ-Q7#OO
MI%6>,/.9TI7S+QU\]S$<V_V(W"#:+\@F>,$7MOO-G@Y7_OII'8XZO?,)*0HS
MOKQ>UR?@3B8 >,W5BR+F"_S:0S+-51*7\YQ,O;V[_K:]6[S[U_I.<[UX]_95
M%?C\EU-^M0U2IO5A<Z. GSYLO]W:6&_#+Q_:\)_F9JO]H=A^76R_V]Q9;V_!
M#55XG^OC5OF&?VSU *'Z8Q@U#!M%//$1 /\X#B:>DL(>@5P9#?^LPJO]^D4^
MGB/LS>=Z!?>!C)TTA3W'SE)>P@MU[?$POCC_X>7Y 7>G5TZK_-++(SO8!\28
M FX.R+LD+LO)3"Y?8$DNWYWQ9.J:FSYY>GFUO'1)^$^N";S*)+GR,EZ]^MJO
MAB5X51AQJV%_?8UI7D_V,4U68GJM87_C6/ZMM]O,W#K'O)XP;Y6LR=?]05;T
MBO;! !3!)MQ_,"PV06"'XM_C7BP8;EP9[_%\5N=#Y^0::W-7$OK!871="Z?:
MRY<=Q->@GM^_[;-:,K((AGN*"U/3TAUIZ1D<GD[REB:UQLN\T4'\&GOC.'QQ
M'>*Y<>3 G0_3KQNT5$^RTI-<:!I453ALOD=WRF%IT#_ZP?<WZ)_:[NBTL,-A
MG,V*NG,Z1=46X?KG4O/>L"+G2W?.1/6&"!H%"X)Y;@UW(GC*E(DV6"&=_;Q1
MA@AP3-!UB^A-P/I1'"B=-COG!TKP>7N=;[]I=9L;6ZRU\9[ "'Q[HWFZ^ZEY
MUCSS?/=P]UOKK/7EXD#I/8?[:/-3DS0//YZTVN_IWM%[T3H[.&QMY-]W#O;>
MO,[CXID#I8U]W-K8/=D]^WC::F^2UL;>T=[&%[;])A\8P>]O7G_9_;1%FAL[
MZ?MAT@=\TCR#>6U\_*RC,$%@C80/N8$GQ<A185'P/EE#%4\VK*SEPR0VIQ7U
MHZ]A4X/1TP0C;;@4E.K()7<\.$.E P*6UDKCHRC!B)R#$:G!Z$' Z.PR& 5/
MF".:HD"I1SQ$ 6#$->(6,^)%8AYK "/,&ISP&HQJ,'H48"2LPQ'+ -"#.06I
MZJ0/,G'OG;>"^JEF1&K-Z"'!B%P&(\6"34IPQ),3B!/CD9.6(\$U2<)9@R5>
M62,-3&5#JRJ5-Z_AJ(:C7\1RDQ19LEZXZ'ED1B?/@7ZQYA&(FINI;D1JW>@A
MX8A=AB/&"8W>8Z08,6"H68T<CQJEH"D)2<<D:0E'C,'?.]<_KFJUPFHCS)05
M)@ZQ3F]D>_N=''SQ:X_83;)1JYQS>F=H8M$$(FS4RC,NM+"Y9;*)C%K"+(VX
M]B$].#2U7LWZD'",FG$3D9<^(FXR-#FJ$=:)42\\=:FL-")878KPZ3*OY"!Z
MA&!&$L<-MY9R(;GSR6(3)(^USZ4*S#OC<R'&>,\21U(9F[O2>J3!&$4D.D,C
MU0Q[OK+&<8/0FGN?+O?:@)GW,ECO!8A>:A7/=;"-%L8R*77MI*@"]\XX*9BF
M/%!ED7!6("Y)0 8;B9+#3 4M X\BMV<'[KVSAZ+FWLIR;TB&^6!"4E)S+)@5
M E/."1?<4NI];=-7@7MG;'JPZ"T%$P<9KACBCDMDF:$H1H>5!,W9:[NRIH![
M]9W[AU2USF^U#?KM2=S8U'R_0Z>!1ULK]"8H)!@8>S:P($#_-]$:Z9UUH%:
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MY9:>?T24NQ'*?9RFG'<I%8>9^51\LPJIF.?6,(LA@@.1@I0;FXZ;KM7+*C=
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MCHORS9(4@HMN8].I+H?9>?K5@VYD>T0W4I@4)H778DF-1N@;&Z%GUL6"4PH
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MJIMB9NL\D(="'LKM>2A*>9>CX=%C!J>S"Z"+30"6HT\!*033#KQ,AV!LG=V
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MPJ0P*4P*D\*D,"E,"K<B'K+T<MI/AH/2&_\Y&%%U@:7%.0ZVY]32SIQGWU0
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M\,L+'JT*C_8'<[EU6"9N 'H0QA(CKI- SA.!,#%6,>Z\3'IK&\!($UQ2Z]9
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M2U505D8$BLR ^/"$3()7$5NJ*7,"*[RU+7E3K(O7]1ET (%E7Q>B.^MU<_6
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MSG$_N0K*1.>)9F!*Q\04C\H@EKWTG&J-# %,!\VC-@301)NVMJE^,=_GO5%
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MM=PU5>U^O1@3X-!&+,D(:3,(8#U$Q!;YG5 1:9.DKW%C*V["M32/X850KC?
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M%1_/U]J>3$<'=;1-F5XEFHR,VARQ[J4NS/MX2R$;_1Z#"(.YC]WL][A']W@
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M[L"?;4]P<T3CF254QA,VUO;>MCOS9)V\ZZO@5E>!>3SZ]_'T'QQS\;%2-UL
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M+Z;M,E,T/T0UG*?O%Q[4R3BU9Z<#-DV^F!D'!T<\"&7ZM\<7 I9[]!NK."T
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M+H'7'[[&:T!;;?2L0$NBF'3VMK1"F54%LW3>HRZ!;Q[#\Q*8(*C<3D:$F*2
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MKRV*G76:]3!+2 82JEAR @F$7M6<L3NX!P+@!0=W"D;K5C@OFE:.Q^0@4#*
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M!7240BHLLU51.G5H#QW:._/03AK!Z9J$SM 25VLI,&%DT:T\L>$5K.M2^P%
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M KH@LP@6I8 4HX@Q:J%2U!%"];EE@S<2-@$63^!V,*\+F%>5PK*#^?; O!#
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M$< ;47123A%6B?U,U / ,,J,QJLB32I@@9)&K<&GFB5FJ2_"L+TJAOM&R_6
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MRM".D>UNA:*VFN:0,IB\NC*9'=N#Q3:X"%ALU-([<)B#A^PM*5^+3L;?6GZ
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M>6'L"GJC20DLN0I((8@4JF%P:RO)V,C*U,:6L>?F:5A033N.[R&.4]6L.P>
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MR*C9M]3IVESX8/.X [,U>KQ$)U<;@VWZD_8.7K=$C:=+<O35P7XYMYN+#;\
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M$6%U[AS,5[SIXRHA?4'E@LK34_*(#B1)L+H<>,5@B"?F:#16DH2IE+2@\J-
MY9,+J.R<4V!B>Z1PY&!_>XDTD1P1CQ-+4@9CR-H&T1U90+G=K1>7+AZ_T/*W
M51B^F.A_'0_]@1U=L=6!+C??A9KK 5%\\;270'$E,07WF5$=#(\L6I 21YB0
M$D!=R/1QJSZ5@V""?OKQ'#/J%4B_,T@_F2^5IC98<+$X,E:G7)87D ["(*=B
M8EX:GK"KSSU5>OZ$CA_K=]NB1N4%"6;[)*(R,D8KK.5<1$,#%I8&*K5(V,>"
M!(\-">8*=*VWROG(4""&Y5JPA!PV 6$.4$!Y)$+ZM0UE.D3H@@2KA023B'BA
M4J%2H5*ATA.@TA*VCV846Q*-%L%SHX(Q4<6H(T\.S!_LB^WSV&R?^<2R=A[(
M2BART5K$B73(&4F0PHE$+(F3.EQZ4.'C@8+[B$,]=7C!+LGD,2/**:Z4=D$Z
M8QF5F N+G:CAA4SAY><>9U3@Y5[@92Z;*0C63B6&B T)<2\C<MQXQ%RD+FGP
MKV@^T$ATB)J/FS\>>'F44-!2>["UB80V=Z%93.$_\GD.O_W2&P!DCG[-!SMT
M >YSH_\A .Q^OVD#?^88F:48?\%Z/&;&7TS^5A2P/4HJ/400>'@T_':79DH6
MP#]!^G;[KQO!>W,J=\5RN2O+9>?%?% X<ADIUA(ES"CBTCMD#)-(6*>L\ $<
M9;&V8186815@:#4P%/A>!2K]LLQ^82L2LX9QPRDGA#H?HM&:>X!J'"R_ 7Z/
M8+[PJ0#YB@/YW-9B;(E, >";,:,0=\: !RH5HE%&!3S! =4O _(YN[:@0TO0
MH6!XH=)J[_0IE%\IRA<J_3PJM3:"MWJEP'_6H;L<N8O-\26CZ_N@/\I@]3+N
MQ!U4!U]P)Z89K.8,F=->]*^^['2GKD%Q ^[,#7@[7^Y+:"(B,H6")@YQ@D,N
M\M,(H,Q*9K7T+G?A[+!\#-(/NP$E!;4*"JQ0J5"I4*E0J5"I4*E0J=3'%<H7
M^6P%E5H;^%C1TJ4<]PBGYQ>F;M_V?2Y?ZEY_DF$)^)6P;*%2H5*A4J%2H5*+
M:C4CQQ%'A;7->[.Y%A[#'V22GC%-R-*;UK*EL-L_/>;X])3CT5_#.+;?2F#^
MS@+SYUI-OZ.[6_L?>51""AF1#S@@[IE!QJFZY%(YY;U+*:QM*-+1I=)RU<3Z
MT8%OJ?]XJI0O5"KU'RM8__&N/XPPBN\Q5/MU1*3;][WC +]V^]5@?!"',//#
MHV$\B/U1CI$T>[VJ7^BOU=,J$&EI2+ $;A]\4]<];#^?UOR\GDCCZ_YNEL47
M9T41K@T.8ZD,NF,'9&ZGE\,V&@QN1](4'!!-*7+"!$2YPH*I0%,^,YW@CA%E
MB_J*P44!]4*E0J5"I4*EE:52J3QY6IV9BFG\8*;Q?/LFS:-0V$N$E?*(V\"1
M5HGF<WF=\40;1Q/8QJ1#BFV\:GC14DW1VN#?ZM5 71G\BW;8AWF,JE]8:=_4
MAJAWR4T\C4C?RXG@D6*[W)GMLJ"K/TT<J.\"BMX3Q"5)R&E.D;/1)>TM0$!8
MVV"X0TM=P2/&!AXM<3+$J)3BD7$CM$_@[1CL%5;:%&QX_-A +F(#LS$HS@PX
M,\0B[@A&6E"%E'$F64\5\W1M@](.Y;1@PZ/%ACMH&U:P8<6Q8:Y?&/! "-AC
M9(+1B"OKD%$.?CANO?-.*0L^).FP8C:L&C04QZ]0J12-MI?RCS:#<49U%^V\
MC':>STA@L-18PAZ1I,!TIXHC;;Q",E E7/(,_KRV(8IR?L3"+QC5(B5K)=8\
M>6&$\-PP 7-6G@G26N$O=OL=(L/%(]JM(M0[)Y%GV"!N%4;.<(E45"1I&HWA
MH7;J@1U:#PXMR8+]K&&4.\N=3^W.)[#[Y&T<CWNU-JT&*6N_KW881M4O_,<R
MSJ74HA3$M,,";7/&^53H2G7<G5F<NXN."*(I),("TE)XQ#VXHI8HBD@(0AF.
MH]"BWCBB;Y]%*ECP<[%@F7;1=Y!BOJ1==$&%UJ/"7&XY4>69-A(Q9PCBQ'OD
M*(8?4K"@(P-?]')4*)VFVPH(Q80K5"I4*E1J189O92G_2#)\Q9BZ'V-J/MT7
MF'*>2X^LS]4XF$ID0HHH>.QQ= Y+UVS.Y[</ZK<88!XE&"SC8]U!RJ_X6*L+
M"Q=S?9%@%JV(2 7)$.?&(.N21AZP ?L8!!;\4EAHD9/5VES#ZFUVVQO"LRD.
MJ_&@^C-^B;V*5+^('^QBM;)5%.TXYNP.,75*UM'N\7@WU81E!5SO#%P7G)06
M(V'8)X-P(A'E)DA(6T%0Y#3::(W44J]M<-R1YC8!K%)?M0I.=Z%2H5*A4J%2
MH5*A4J%2V>Y1*%_DLQ54:FWD9/6J--_$$ ^/ZFC!((&#[\9/]I3X1Y>9?)14
M6B;(=0>5FA>"7,.CX;>[C'"=BE_)&MQ98&M[;W.\?2YK\(Y^]%H2%H1'$N.(
M.-$&:8\IL@SK$+R2CO*U#48Z=$$WPQ9E#0H<%- N5"I4*E0J5'H<5"H%=/=@
M^MY!!5TQ?5?4]-U[5^=TP?S]OO/];[;S]T<I@/9:*429%(A'HI E8 ;;X$RT
M3AF14C%^5PX06JH*6AN>:W-ADUI(X=]MS_9]K.RX&A_$*O9##M/ECT?POD%8
M-B;K!L,0AZB9TC,&9 ^#8\#L*L]D>G4\.'J6.6(TZ'5#<^5:V6C;POW/@ZQ,
M2]!B\9(L83WHO'D1Z^0#%MPFJR/#)E@C@]-!!?'Q]4_?V5R_IA@*=V<HO)P:
M":<Q,HQIHDE%I#6-B#NMD?8L(AR\M<Q:K1);VZ"ZH[28,Q.F O<@>O!'\E-W
M(?$/G'TL<%_@_@[@'IP")4T(6@C"DR4Z2,N,LR(PR1B3!>X?!=Q?3(E(A3FG
M7B(1K45<.(H<CA$I83B+QDAN\BD)DG7P@I:*!>\+WA>\;\^2+('W%FMODE!1
MI @ X"PADB0E C'.@]57\/XQX/W.1?/>,8:E%0DQ2Q7B"J#>8*D ]+4ER@KA
M':[->U+@OL!]F["MP/VMDD$1RYA;9&-!-:<2VY"PY#JPP(B0.EV.]_>_QZ\
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MO>'1QO*),>'NWM]?P:/%UDGB-4<.N _Q8#1RQ#MDM&"$"ZWM)*TZ'^]IFM
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MFRWOZ>:HJ:NR-6V*<2^-D,2Z%C<8V(+89M:)B*V3!8HL[^5JPAF_D N!EE+
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MHLP)IRA]9,&H&0^J8WC=_V4.^Y_[W]BGKPLWO0 &A#^. ;CV]V%I^_N;AV#
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MOW@VYLY!WN1Q50G8F+(?.X"Z85,_#HO 'PM7^"Z725AIN-&L#![K+H#=@[$
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M[,&^@X5VV.$<H:!1+GZ.-)4)D>14C-I[&LQ50+JTX.Q"5Y>(@,;$OP9T79R
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MS87N5X!@050TNKUA12#Y+NO:G=R-'5XDM ?VX* ?#V  H)N9J90)3.?9<'8
M#QH3X$'L'?3MR>'9I+SWS'I4<P:.&!ZV<]_%2@_E73BV9V4>;EQT/(S7$@8_
M@R_[G^,P]F%%7H^;Q"]@CRNLVK]FPZ[R+,PF/QCF 01E.ZN-S2[0;3N,;&?F
M%>-7'V.6DPV"_]. 20!_ES*Q=WR,]1XD=]Z/7$+]6D@ HL#%_E540".V3 BI
M".5>:4-LM-8PH%C/A->E6C+!O*J63*XF'M"KZ.!5KYOC!_MEY3^T!Y_?Q7[^
MP!Y$,E7_B#Y-_?\=Y9+71//]/H^2N, =(E@PQ&&9D;'>(! "W!AE2$SIV4LS
MK[O_,T,-@]O(X7HA/TO%9 F)41(MN;0<+$3-'67."6%DY%R1Y&2*M[2CJXGQ
M;L1X#D!U?><<@"J'OU];I_N6>*Y4HLB+' RF+- DU4"GD06!@T\J9P$:MH P
ML^R_WRXK2V($<E=4!:YD,IQXDX1W\$FB3(Q%#JE%SD/N,H@?H:A+7 1D)=@,
MP%08::H)8L9%6'_J(S&PR_Q!Q,_-+4 *V>3=S;ITD/LC@SW9.5N=!XB->W0?
MF,&$8UPF. "WD]Z@G<=Z7CJ(P(,N$H8R:)NY:VSFX(M;K .+9C2\_I:YP/F?
MA#V)OH*T9_Z]>^\1A9]-;CKL7^0*'$3D^M%^1C;!&SZWG5-[-GCVU^4:\^WN
M9$:*PI279\$6MSCYL+6[]G9[M_'NOVL?FFN-=V]?W6Q@+,&46UO;&Q\;VUN-
M[?]N-%YMM=8W6A\WUO-/'[?>;JZO;<,OKS=;:ZU7FVMO&Q^WX8/F1FO[X]*_
MV!\[K;6=]4V8_Y_7L/L=9K26(?;WS*-R3("FZ56ZY'EE7;1SF$7C:?ZYA_"\
MB3@NF^,_FCKTHS<CVOC?".S29AP>]L)F]TNLNK@M7T\BUIRT93MN'>ZMA\^[
M=(-O;1^<P[7GS?4UOGOTX:BUO@;CO3X"=$%:;S;.KZ*(7?KZ<XM^.-K=/@"$
M ..OP_-A;JTW30QCG.]^:L&<=O#N=@M01,&'6$I)#+,H5Q%$/ 6/C' .P>>"
M60PP78NK77Q GVBB#;4A8=@B::FSV#B&??!,,W.U+TRKUT4 Y8H#L4I^2ZG=
M:6<'PZT-B;[)@[3067/[K"^_)1AR\'G*5R0>M-46,^Q(E!J0+;9D@>[[R9XJ
M0H&E/L7**Q,+X0-FF])\QF\^]H<6_@N_MXO_SPX;MM$! -@!;&>'$S=*=J&<
MMH>'E[JQM;NI,XH R5<;\)2Q.5B,P>+FF7V4'4PF<%Q8[]*7<,/%]X/H1_UJ
M+GFDT\,V#'4Z>8E.Y0#+L#/9=G_29^<D;^OU;?WNW;[M)\C%,N+S]A >Y^\@
M*==.VO_ 6CP,?RP9W9877!\5?^3=O'2GF?R ?K+GV_>.X5*8+LCP8GS8J4/C
MQ.;3A_9))07*B41EXXQ7L]#QC3166A+.$'K5WND22XW':KCH[6@0&^UA]KD6
MWTH_IDYE &4S*[M<LU^WC#^X9;B*Q?IC]WL_CE^V3*?\W,@','F*MG-Y"6:F
MU$Y3AH<=@Z?TNIGE\\W^L V+%%8;VU=>NVIA-2<]BL>SGP%4WHXL&F#01VE1
M>0<664Q!&W,"Y9'G=^-L,B5>):G*LWT3=2[_*F^5DZ*Q1^!G+O#XX "4=L@.
MSBP(9B"&LYW2#'9P&.-P4=^UU4:KE\_;1MW)$5R8N$ G[+/PKL>1P,NI=+)L
M>!L/K#]K?'S[KK&9[<@X^(65T&8W4U$W5L[. H RC6U\]8>V>Q ;6RD!\6_W
MX1&5 VUP61?91O9XM8O;_;B<HV4F[\;^X+!]DCUK9?TFCK3QTE9F2:\_:+R[
MN'C0^"-?DNL)4?QBP2:4;\B+/RN2S=>^JN!KUJ+7#)E5SGW:;9OD<&+PG*0X
MUYXY$P-8!!R0LQ:*Q!)8@G-LR>)VV[<884^B7_8/-\Q:Z^_/]BVV02<1D-&!
M(<X(1I;I@()DS$F"M2O=LC%;5;=TR\Y@?T*^>?_;@T$AD<$AX("".+*^S^?[
M[="V_;/5QMJ@0*C!J#,LU)V!S7&\GK;O1,X5T%A QY4ID@]XP>0 >)-'RN@#
M5&:&'2" 3V*_T$D6YZ$]&/;;;E0H]\2>5;"I6"ZGO5$G5&:#BS%_VPZ3 0\B
MS -F/IGQ6!/?S( %2TY[6.?^XKY2U;D!*!A&L,*VGT^QVX,JJF+^RG8Q<^#!
MB^=1JH6I%X4QP?XMS)=W,=]1\,!T1<9#WV7>*Z4S*5QYJ6/I^,XR6UC%+,<J
M2^ZZ;<FA"?U8M3[-:W&M/3<)56G:KCW(U#"H,&M^W.2S.Z_W83GEOQ1/$+_&
MOF\/XG6FZ/:M W=[C4ZOF^=Q ;E*3_&9E^B=G,!J95G8GAR$S"I^G&>WDE\U
MF[HK\]W(KUG"^/5D;%WTILW,>U]@)D-06W>9>UE*4(V@7ORP<];HG6;B W9'
MA5AZP.3 S+.:90NXX,.[S<="*LN@IK<O.&*&V::*\)J]F,:;9&*&U\ZQ&XTQ
MO=VR"?T<7P(B:1AG%?I8\.1O9_>Y'S,I55*B8P^*; 7FR50VYN8,42O"@6F!
M?.@/<ZC+^,;5,==DLIP*B.E\X:ZI;58">V#[!S>_>AH'OTSL3Y"G[5ZV+CJ=
M'#@S.JD0<[X,Y@-OGP/VQ@K@XM#OXB6J^U<;<Q9[9N";#P>+/IG:-W-;6/#V
M?0"*,MQBPX-6SO'L%5;)"VNX<SYXZ^S80<RO"2N81RJ;94IO>X/!:UC2&K?<
MSZ&,M]8W17/=GS:/_'GS8-]23ZW'"NFH#>( &9%-4B'!)*-8*R((H!A^*X;)
MA'4?LB!2T( 5!4(@'&MCL3!4,!6 "&24Z99HDYHL'H\LSIJG^T3&$(7&B' 9
M$7<Q(>T!ZTKJ8LC[1E6.25F=#TJY1!:7 PQ6EM-=LC$OK"]$^"4L%>/@9[I3
MOD6>DX>6YPP[QQ)56@7).0V:Y YP7B2J'9 (O25FL6;<QV-<VES;ETD)AT5$
MRB:!>&(662,2(B%R%;VDR0+C4K%Z7=;7MPITIEB,D3@JO> D:@U6,.7:*Z.U
MS=$M-P>6U73Q>'3!MM;V61#1RN"19@$$.O<*&2L%2@PS%A+S*A5OQ:K^W23Z
MZD]UD7\JPCGFA*Z&MX/#2^Z36ZR&GXW$W_5[.5SY!OY<SR'.H)0&6_WUV??Z
M$(>C?G<KO;(G>5-K+KX#%_/6P3X7GF*A!8K: UK7+"'+;$!8!)$4X#)&<LFT
MVYCXYZ/UFG1^).F(# Q\Q$2ZB#QE&H !9@@8GP']< ?+95+D\ME+PE?)[=[J
M^_D3+L48-WZ@P'MPJ%I3[0^DVH.OS8-]R;BU-D@4J'*(BT"0 8&#6)).))(B
M:++'<$\\.)JM2>='DLXY"#P#0%=QIY&2R2-NJ$=64(<B$\12(Q7%)H>WWF8(
MW4_>7<VIN(^+_\4O&!27SP'6OHR7<F,<TOCK'GM<";K,AVZ+P@NJ,++)LKQN
M=VW7EZ" E0;HNTQD[6&.,JH:44PC0?\8QQI,[]R<A!BL-/Y>^S([T+U'VEP9
MC]48]@YBB2 JP1475U1':E=OG.SI--CAQKC2203>AW>;K[?O?Y0X/IA;1%,/
M<-AA&YW>8+#PO&KN<??%(KD+O!58!5[Z^CD7<L"& AS/ ^'4W,'XRBL"/]5^
MDH>+XSC:$:WS-;JU[5GSZ#UKGNX;8YAWT:(<1HXX=@&Y9#D87%*;A#%-AF7
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M\8)<E\:WV@K?!&+JS?[>S6Z=[CM%I?4^HBB(1%Q)C6RD##&'@=$MM0"?P2#
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M%(B0,,0%5<A@05$^*J#4L$!9/HU= 6+-?^=<TBN-:PD-]AD4Z8^AM4F-W0\
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M80/6P6>]T+#=T&B/;7UX^\%PL"SGY+_%&+_DV=D?]SD\LXR(1+ G/G$KJ;4
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MA.D@M?+&EOS8!R01058;DY))#;@S6G_8R,H-KH6;LB"ZD$ -ZWU_E/\[+-_
M32?19R.O <@O-DY@2-N%/1WGRS5.[%DV6F' XS;*W]@.*+]VMV'[8!;U!_F)
M3=N'1])RR\S,\M/+9,[@0E"3AVWXV<4#T-D7-Q4E2E<;VY>G>0JOT[BH%V0;
MPRHH?)+-=T^Q^6W*%HE[)VR\Z\,ZC8[7NJ%<.LXW?)73#5NQYIR%G-/:WJ'[
M/C"!F2]E(03BQ H$#&-1PB*$H&-,PH/5KE;GB_U<9IQ,A(#(O#TI&#8G@MJ3
MDW[O*ZSQ, +M/KXL793HDR+P2WC=[D[IX4V_-QC4%+&8(CZ?[4NFG&;$(B^I
M0CPJAP#Y4*2)5 !XG"$V=SVAUZ*T"46 L"K)))>S?[.$/;9],! *&NN-P5@Q
M?$_[[6'..DDQ#FX43:?MX2$(I\I@R)3V)?;M07["Z 2>7$1J)L@%E\24QH*W
M/1'>Y7*8P_VJHQ')4_):)2T3QTHX0F(BEBAJ@6N<7GR,R!>)MD_C2:Y5<YPM
MQ/?DZZ%].S&>[Y[N1\(-)S0A%RQ8#,$QI#GF2(.QG[@VEN$ XFE5+VK"F2G@
M1^SIO2HK;DSH[Q<JKO@]>\SV*2RU,TJB( E#'&Q!9$ST2,E(0.9+*Y+,Q0T7
M-2U8F4%2G;/56_P?B_P83\C_,8/Q"GS#W^H#H6"W1LX==XQS*8E-7 EE@[&4
M&BRKOF08&TQK'\@#4OO6^H;83R:2(+Q#2<4$UBQSR%D=$':1,D,3H8J!-7NM
MH7)O'PB^Y /)0G$%4/U!A*OZE2*];*JL-&;NO^0^66U\BHU15MCYBFX<@B[O
M94?(H)'ZO>/)..,'P@P!?($ZO_HX^\6V.\6X\79PF&V2P_&D@)G![LG (8TZ
MG3)>;S0<#.'K# NNVF:5G94C\#H]X*P*0\ =_7PE+,QX?2:KX^&?]K"1K&]W
M &=DB'&[_89_LOTVA4'X<2RT;Q,%M87V@YRFS?,6@"#C(G$NH&@,!QM->V29
MM4CAW"""8^8PB Q 2K=Z-Q[42'LXTJF-M/L1!6N>[MNHI.>@/8*1%(A"<>1X
MDLBZ((T4&'8!B(+C5?X09MK4:7Z]G;9(0"V#G>839M)0YA.CW$>EM::,:<N3
M(TIANAC3+Q1PM9VV^&0'-P_VA3',:1&1\5@@KG-I'FH#DH(1K[3 A&5'TBJA
MB\I&W]]4^[9M76A^UX;:G39YZ_T^UUQ2Y0B2)*7L9T]($X:1="00)S4U4>=-
M%@O,\=_*5%L;'8Q 8K&9L^HL1CNQB#@ FU\]@-Z#6('DK.>N L[3PRQ'?>P/
M+4CHPUX'Y.Z@$3NP@!F ]P#X%K@+M[6S#="/!^U!IMYP"3-7)D$>/_5CUO##
MO@T%F4ZG4%TR/ 0T663WS$BCR2, GP*(+JBYL>8+RB2&L5]Y%[-:J[;B&&P2
ME]<EQ'A<P>YL9/1.BI@J(#Q_=US]#KH2E&C\'R#^LDTPS % _F$V35+CC_:?
M]_5)12JPDS)*SCAQV @-\D[CJ'P.BXFE"T.!6>B;K/8/TZF_RS.OI5V6=@<"
M<+?@-M%("?)!2L1A99&-L,P^>%A?$GD*(.W(@HJ[_YE8D(N.$X=3P@+RN$17
MH 3_: .!Y"L&8$M.!XF#G)=?BC%-C5.PIT R9!X?^,,81AT8 :S.O*7EFIE'
M9Y-TQM*]=@)_@$SHC 89=,$ TULJVS=,J#F,8=@%S?\Y-3\OKIKAB.H&X)1B
M#5?&<,/907MJ3@^!00:C_EF!>"N-$Y@$7'UL/T=T"J*O+$&V'AMV *2=@%?S
M&Y5;*U$!!GZVYBN[V=L!##*9=7[[4??$MF<6(3^Y,\C^AO^-VOUJTK,+<>V;
MKOZZ\F[G9$P:/5]%X_OR[K8QU51%+O5[(-;Z[8.#XMMIQ"]Q7.0U]$Z[!Z!<
MXF1G<D@C7 'W96E9$9P#!73:JT@8]-'$)P/2!FAUXGN:*+LL=\<[U!@-QOZA
M41_F,P"SH=-I@%8[L?T)4[4G#RD2^8H8OF?[9*ND90F$K/#<1&8 ^ BJ%(U)
MB)A,+7,?(8YC1[0.]JW0)@86$2@\A[C##&E%&6!-S1--@4C!L\R=+_$YE;GV
M /3M0?'*W4GZ3D@J3 3/]8)CI=$&CNB>K<Q+B,DHJPM"8'\9&;&588_KM ]*
MJ.Y@!A^..0\X-;MNS\:+!TP52H)"\7X>C&S?PDK"VH(<^/"N\5]@=! 1P/86
M4&BWR'JX#@0)7#(8N4$[M&W_K/B=;4&F%^*ZP.FSRL,P0<F^!]+(9OUWX0H>
M3RP[&8I:_&?4C0V&J_B7 LPKAT6W&K%=7""5WP(DC#V!CWSEK)X,_@OK@+7Y
M)2I+MQY]Y9QF9&+1Y$U/%F1N0243*3]K>E0K#W "?GX+>J+3H+#,)W!%XQ3V
MXML=C]PSR1T(9$MC/J75V 3FC./4"F^BNB:!5]^4@_8:7N7?_";UT=5"Z7R^
MQD$Z4TVH##2B*!38_]Y+9 /V2"?GK0B!"$>?O12KU^7=NAD_]'UV'+8S,.J=
M4CE-S=+L$)=2.4>IB)S;:[(.ZQW_KAT7S=-];G.X'A5(LZ 09Q8C%XA'09J
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M-$+? J-OI6K.DRDW+6"PT?'?D[F^&D^UUHJ+M>(.V5K;=TEZ;Q-&C&O0BEX
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MM,4QGLA"/'L/O_C?^5#HXTD_VK#5_=?VV]GSEH,QR._K&&^MKY'FP3ZSAAM
M%DB : ?)[CRR4BC$,-,Y>YI'DFZ0[ NWDUHIG7;2<":X2E1CK:E0&6ER;>5B
M\Z3>SH?83N4CH5Q+E*B7N8X=F"S,"B1]",HYX:0VSU[B!0CRFNBI/U@E%WH
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M+[&9H\+N6%2O%GQW$'QG\X(/>R."2A'I: T"XQXCV.2(L"FU$F.T6CQ[25:
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M3))0C)$(.!Z)LSX09EGF@<?,4ZX6>4&!_*#*7K7(=P_GEE"7N#0A"4I2=(X
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M@GAKP49$D2P@80J3$>=*!F*% L*4$M)*2:40I=Z8L+("?&D!GKC*,9K(<U"
M?J/127CI(_6:E7.\*L 7!>"M10"C(W >(Z'1(, QY"$.="!. <_2&!ZX*XL
MAK938RK EP7@PCHEM6+1L@C,:PLN*YER<,G9HC17_WS^L=T2EG-B"?F9DF"9
M(2 D)0YG'&%<@I4^9?30JG^^_.B6T1G%*'AM$D9IX!5$F5,4,6$4SDPUWXL"
M\99@B5!6"<TT"2HP MFC^68\$<>UI88YP6Q8655=3F]]NFHM"GP=>*[WQK?4
M!1?V,,CKU#6?F3!XLLJRV1L,1\W:RH27UM,W7OIN3"Y;8/ESLD)3:6MFM'5\
M04:^#!AE@"6!6X>>":?$)&F)MBJ#<,$$GE96F>I2=IO#3>HQL'.,_%F)AA7Y
M<XS\EJ H<9R5U4!**A-!5S03+Y4F(BG+L\70D]*554YU5UY0][1"?QF@/S,Y
ML4)_CJ'?DAJC,M&'G$@ BD;?@2?>@R+*9V;1]Z-.J955S;L"JM%?'.0_A,QX
MM\"O$N1-,=^2(!GW"&M'"7<%\QE]?!^#(39*&;3T.E _,PFR(G]^;?[,-,AJ
M\^<8_RU]4N?@@:9,G*! <,@QT/>"DRRR$Y$:'U1&=]_*KH7V:38/8O0?0=)B
M<_A?)WT)>V[P(=6TQ7M3)]LYX,U05/=C!O2S]:RM,[J<I,R9$^0@C?23/;$,
MO^ $8TDJ13FC=07T$0!YUF)C!?*= KDE&P8JC4:P$N$\)>"\)R8E033WF2HK
ME?2J GE!@?R@VN&5D%S#@EO!N24%*N[ :$M)]#P1D"%A6* %D9*J;)-0'MC*
MJN)=SF\3%50@SZU%GKD46"WRG4*XI>S%I+BES)'(="BEG!3Q&@2)$+1S.'*0
M9J?L52#/KT6>N;)7+?+=P[DEU'FA4\A:$^U+(J&@DE@I\5<98]:"F5P.G9XG
MB_P(D@BWTF%G8Q"&^^EQ91 ^I$2W,QKFWN'+X;BN#,R.<"XHRIL<-=QR2Q15
M&-%++PCZ?8P$C>& Y#BLPJZL,M852M>%P>7%[ZR5N8K?.\%O2Y%SAG-IF2)1
M:T\@94><!$-BJ5I&*7?!AX)?WF6J[3%4 "\+@&<NR%4 WPF 6QI<XA1M;<K$
M<Y40P R(-9 (1_+5ROF0I2E5\6W77)")6P&\+ ">N1)W&8"K^'93[+;$-^X3
M."--.7;8$E#6$B.,(2X)!8%RR,5YKFEURX[=F6MOU?C>"8!;<IOT3+K@-'%1
M(( EIXA=Z8GC63IEHY>TE-U0H@OLUI5U:G+<]9/CPG#_8)3VTF#<^Y0ZO4:$
M^^V7/@+CUZ=7.%?NYNL)]1[U'N?O,2.INT&\GF_TO1V,$K;B:XJ=#ZXW&'?0
M +I/KM=O3GA&D]09H^%!&^8/.^,4CD:]P]X-,U@?@X,P<WF\8<=G9\EQLD#Q
M;=RFIV_^@:-7_(CMP9O385H;]<9X:1U_'7S8P6<?QJUTN)UWW9<:*LS"T[AH
MJ[UPDB6=,<)/@8#ECAB%P^W1RTC9!9P@L\N<JZ'"_#+!K(7V^V&"&GC<B@Y:
MLGUT+' G(_$"' $>&3$R<.)$MEI(2T'&<@*;Y?,4=E0RF'/1OI+! I!!>T=^
M%! -#T0 4 (4!''9>H(>0\ +GFFI2O%/"94,EI<,9KX 4&.$^>:!]BY]'%:E
M#24RAUR* &=B%9/$EB-XF90J,U9CA.5G@IDO)U2W8 'HH+4X =X9QL$2S;,F
MX*4FQH,D&@V# R8<+=7YRBE(=([(8$9+$XL@DKY.H>_&XU[&]C28'F:$];T)
MIPN[K6$>A=/">N?'<RU^/!H?[J?!8:EFLK;];./%</0&AV\[?Z/'ZA7-D :W
M+R@>0-$=]MX(PE/P2(/9$N."*#2HP/'@E#)UA]."4L&#EBJ])RZH?M&M"*&E
MG:9R&%)&;RC1G B@1TP<+<7,,DTLB.R=#$4NL=K.QQ:IR@3S7GV@,L$B,$'[
MU"2;8P)C"2_J*;H&H>1? N&>@;/4H\L(Y5@T*]NG)E4FF%<FF$?-M(8'<\(!
M+=%4V( N(9=$>8KA@8! 7/::2($F0K@8> @U/%A0*GC0 @C5*5@$0FC)IC:I
MH+E)Q!NF"5@3RG'(%)T"R31/@9G@RUE,5K0W--<*"K?%L;X0QW\=#5)'T&ZG
M(.^ZJK0?CF(:D4G[GPKLY3@\*FIJ:?;)U</AP=,R .-AOQ<G5WY*=_/62__W
M(#TS)P;@XBZY#O^;G#7C@6::0'/F&<N"T6"=+@LI\,_&3>O>(.WWCTJ'[0Q'
M#=D?3LI:%TG_LK+6E>-GQO$75*V0S,D</2.!6DD F$"VIXKP**T3S#!OY,JJ
MZ1K3WO-^ K('<&=NMBHW"Y0_\-)^I?A*\3.@>&I9"M*+[+R Q,'9S'72D1D5
M>::Y4OS"4GQ+Y0?IF"KK?,ER2D!Q1FQ9!;29<25]Y"*4LPF[FJDNNZ R0J7Y
M2O.5YN>G2ZY!\RY8+3(8&[6#C Y\$(99Z3A3$),5E>87EN9;2SB9<B.T3B3:
MZ A@$$>,X(EH(934(3&EFMQW)6777)#H5FF^TGRE^?GIDNNLXE-EG(W@I 6
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MK2O'SXSC+ZA:@6,K1=2:Z.@E<KQDQ'E:-L$'%4(0#N. E55.NPIHB^1/4/8
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M!15769.HRZ&2VG/B17"$I0A"\92D3.<CLF ,]5$&1Q,#JIUS0I8M&MDXQY1
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MME$\?0E[;O A-0G<:"(N4^FJ(G>/BMS&((S2?AH<NOYTD;;YV.^+F$Z.KOR
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M<D;N>V6@I6:@6VJ6E8'NAH'.QP\^IQR44$27XKH@J",V&T&2T3X9+JQDY;S
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M^C>)PML37'>EWSJM$&WF_=:AX=FFI9-(4TWJ6'X$DE8/0/KX6$ANK>>W7B&
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M6\O!<]M)6X]DD-8OC_8-;154?0?,I3 R52,D/J&^%H669X4ZH61%7Y"%^5F
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M]2.'J!:Q-<<U'0T8<F38Q#*C0/,M-S+7=;GU.'+?.'+Z'<_((D:@6(Z%,8_
M4HCIA8JGJ8'EJR'Q#1=Q9%6N=(TCS#8;T81%H.^@:<BLU^\IVUAOZT8PF!V
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M+_9$1V:RY]">3 #=L;<>F0 X,4&8&ZQ 8*=IAB?##C7C2;VS&V86.AH&;$^
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M=))VJCDS5M&$=7%,*\.F55AUQ@#=6(O-P23,6WI*:_E$?,QJY7G<*>:/ (6
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MHTT'9*PF8.R2]=*<X>XL[S:GV':R6'P(C:/V0>Z,Q@1BU#98M#AGU,)NJ44
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M5-+4?]=,M+Q.UJ1,$\K@O< ,XHS[FXH1>GA$@BYW_[+$K24>X/5%+Z<Z#)L
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MA,5S 2NPFJT:B8N9TMIR;ONYJ&O/:5GE:;N79M_=3;'-U!6>L' #DW9AWL*
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MT'WN]R/M$UJ/<0Z^%1?%H_ =ENV&RI\377[*I,L=D[E%B^L/*S:6999ELL)
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MRU7N6-I&C:'W/N987!E0+BT53JOFTZKF=*!*KHZ.XDV+LDH]N@GUR0(IHX
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MI4.KU7^"@5466EGKDNP+/+M9?9NEO.]I?V<>"%Y&](4_ST"LKH?;9Y+MEB$
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M;.LY5BT(TS$/E'.S7QM,,*IL]M[5I^#>%6!C6H(^$/@>*"9 R6JZC4+!<1
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M H5.10T88=><>V;#G^%328-J!%J(>@MHQR9\E#B8/KP\VY.A=6((WP-4.)A
M:'1@_![TA^:"-H.'@'[XU&T/QMS59J!/\-7KX_@K9+R=,ECWM?T7]0GEN@9Y
MT13 \L_6MY;VR??'!+8/07RG78Q!,SAA% C$)/C\].%B":'PC-O ^0X(8^7X
M @IVQX%,GY3CJX?.NQ_?337#V!)?F*:C3R7S,9(_A.)**)#%T#3:S8H3UI)3
MCLBB$>;+O1,%8#2PB&VP!XZ  I@7H\DL1H>6$P$B[N.E=@="AVJ\\NR*?W,9
MJ#4TR^ HLLSH"5R\3 <X!C)A[%6:P$Q;B/R\+75(RW3Y+4#.7CCCLQ'\&\O7
M/%1O5/(6\+L8K!\XZAWW-AF'ST4,2AEN5H9R*%*C5-][QP?J>(1QP!/_SD5;
M71Q-_<#YDV4%>UH8CVP@4H_[,1+]OV4U'W!$,@4*723D%)H8,@\1+ &?.6*.
MUPQ<76<._D]HNYQHNI6>R@W]Y:,Y$3#+6!BV**D9>6(NCU+A"'S-([!BLSX'
M$/%T5@<X,8SG\&DY+VCD -CO<+P &))4R HR G[,KE>X7() ROBO?2V& VPQ
M7RB!)1X JTEC+_'TI*:1-Y4N.]A'#J5&&9YSA!#BXPV,>WKY>*N1^?@&J<6+
M^"X&#;*&N45@278 R<E6(^W+U]\OX*CQ>*%QG*\JJ!\\1(Q(.3_@G?R[-O:1
M;X4B3/@:G,4 RTB0-UC1NG*\K9G]1AXJG/H/@F667KW%ZV@VVA@+9D0UC(M^
M,35S37#@G[T0"CTK/E@]"#J[U#2%/O2][)G*+'-0TB%<WIX"&%/!DMJ+XL03
M\*0+T (5#/C=UA(?+JO0SO:!&J6,*RKC=/IE;;-#2WR9O_M3+Y0E:=G/"?<F
MH^A^^>WKOR2_I@Q=&#9=9KS^#C9@Y-LN^U%NO4Z<((S.*=!H@Y7J@8WI+F;S
MJ6\OT-YT>?P=N%@,L@YGS'6+?Z:?9QBLGOD>L24<&'0M0 7>1L/S./G1YQ/,
M:89Q<.^@*0Y\@],C[2F F\U&L0V6R=R%W_AP_#B*_XQG;"2&A>9.N.2-K3^N
M4-4"5F1-H)#!P/I,,NXXEA($'H1B2OCZ=,EL6JB[R'V!SP&:R:>;-F>*: JO
MT$KIA^8WI/^%MM.2@9*Z1;8?@SOBVW:,1LPCDY$.WX,LJ,J+T>AWAY?9P11)
M^("JQK$C[1)$?)1R4/IKH(</H.X>T$<G$(=A3,;IF-MB9N=49%]0HR#=T@[0
M9(2>B$]G_/O X3& $6<LX[83G%XJ<A:,O#EX:3KEBK31A7LO=?U8^\(BVQ>4
MG[P^V>#ED&&))KHT0CES,=GF3YV10^>1/N,B(PMJO@%@++\W]B)@5N%' QPE
M!.7]P*EV JRUOP[XO0,:VUVD0"8+DK);N+8,52>\!<?Z"KM<%.0F]CC(#3[+
M@F,^53\G1Z$DC$<U_9=H@O\1<^36]$UC'RC&\Y,)I?#DQ<HUX!L!KC!#.07G
MD9/!*&]CF3JF6V+**,SYV&&(;7B8#1)*V@AAXB4=,ZLD*LK4UXB5C&]$XG91
M-#612!+M]>W7JR\?A4A.J+*@-%+&RZLPH$$?'G\^9I@2IAFM&;N0OAAQ;\QF
MP-!X_L")XA\.:HZS]S>O1<8C_=6,89+#HQA)4<@#4<:"]\&K<\+O^-K$*LRI
M, S4C4$!39$?L24PGPLL6(RIESIWF<U'OCCJ^YL-)UJ*&HVU7C>)%05)^!<9
MP>,/F!QWV)WGA^2CPQ4P=IAJYAEHOW_A1YDV0]I%A]9U_8?SF#+"@TZK+S.6
M8NCQ$D WGC*/&ZE2&> 4?A'24F-W49BV3?/<@;+DGV:<X22"2>QJ9LNBZR4*
ME@0 QC[%B=<;#F<].#X!YK5VCR&#&^VLT^K(7TF]SR8\HO6$X%>G/:"K]Y1F
M.KGH.-$:+H''(#CC-[Y[F-<O/HT:"7+[/0#A"'J&#SP\>_\B<)A[A%:^G#U>
M=\3M,ULD=@:0ENLRD9"]GL!S@C7!M]2WE*O?ML@<S7C$B EM,#<"X&U^CM/9
M'>I&@:?AWX!WD8,W='F\'(W6I\"^@=7.9R, ]M9HD& G&0$_!61>@?4OVGM\
MBL8';+Y&:R3JP>HLJ8>\(MCX6!GO3]3FQ<WEKQ^_25>&!*2W ]+E7J U*EJ^
M(T)A((S0>3QRG7 J2I',MC$\;BO'3?))DB160[D!EV[2".?0SGU4%#1@GK.Q
M'Z=3Y!.L??S\_N+F'Q*BR,$8G3HG*L%VF!SNEC"5%B)Q3.F 3^%.\-FB:$UE
M<FI6*U_ ">2V]O7#;>W1HTRUI$U])?H$$Q"I0LE.GRJ5.14$1:)OL:!A9@[X
M-_!B/<<,8E #;FXIZA\^=T(?/I1^B8Q@]+T"^)2-&9*0DMF>9G2U*; ,L]%)
M98L0W*M 6*/'+&'2S%LF8E !;<(<6 (@2[9*Q?V^P&B6=@;B76ZO>$V_'_G2
MCF5V'*U!K_2NA7.!@HS!H\3:'J":^73ALA^.&(^V@F1:Y4&:9#65C2'Q[),L
MBIC]_420+3ES:U0OBH$1C!U-P&4BEDS#(%KLB0H@])OE<Q\<=#SD</3D!:W2
MOV+<%K ;DFV#F_=$P3&@-3T8ADN8B_J,RIE%U$D^"ZGIE8$[R]J$0_HZA9MI
M=Q>E@R,_$D$CDC<_J$?9I>KQ5D^3DZR6#H>!V1G[SK-Y\  1VQ4Y%(H186PH
M/6*:+8VF3C ^QP;PA>B<3K9,D2G&QWPV3Z('CU\\?2I^D<\H40MB<<(#1$D8
M^?9W83Y1Q04326Y@B73Y#9;MPIDYP@N<4&%+6"]/X;4HZS)-V5!E?1OX8^[>
M+VKW O-U%[\X(!_'!2D@M'0BZ"<Q<D82@Z5B+W&-M=HW]G!WF"V*R5U?A%K8
M^)[1\^%+.6L3#-*YR\\]?B=4/F;+05I+V_/L]LO[R]>9-$_#6-&#3P_RQ5@"
MK(]8@"<UPR>2V^+@9KY"'9,PB&=TZMP!9%A-<%1Z34?49_A!),0.5K&M1A O
MOEU^_'(K7"$UK" KCNBHXH@-X*&S/LZ%.8,YK1L$;6W;W.4B0)U/C!28,@XS
M6VB)-Q]AQSC O(:+3J)DP93WYFG^)%_S-*>T43RC@0I@6J%* U-ZYB?1 ]2$
MW*%D"4MVE\TH?8F!"7S2//*#<T/SRSYP#M2,3S#@/I09\F7HH!0.&#9-*U"+
M+$OM!").C,7WQ,!@$*%B!_'#@IEV>_/U^M?_E<Q<W;.MBXIR2?L5(DK3WF!P
M8,<%+:\ARX,%M)3=EE:3<.Y+4MHYTD!1O!(+R@O C 9)+)-W-?9C4 +P+LJM
MN5G4G!+IY:]-Q\ \I,^/1YC'GLM5E,Z&,?B';ZU_M2,_BP^NX!3+#%V7C?P@
M5U/QF0?V=YD)N_1;8K, MN0!]X"CE2*FK![C'WP1!?&8;:AM0)DRYSY6*6TC
M1)!2CKKD^POFAS;@J&KI:HH?0@'XHWX6>\V'.E:B[H]:7ZN(>7YC*J6"@BDE
MNE/(CTE+#Y:MJK6IV;Q<@0-CL#.%T<8H=V<H1J2F53(R?;<B?X!##)KY)3HE
M9?5/KS5,?D.PG$]!VMCP@/0N]M1WQ!37O)9K:=HQTWNQQ6&%W*D2.BP&#9"F
MDD2KC#H7Y195-F$)]&*EM*)$FLER4%Z6C\^X!QZY]-T4;\"$SOGU![ S$M9*
MY9[CY:5>CETP,"XJS$0R.T;;1CHF7[Y=_G;YNJ5=B+EO2;B]<$=]Y2849: B
M;;)V[EQ_E%HCUC*\\E?;47!O2LS1#8Y73%^D\WNQ#">EV14*P?%U+,DMH8&=
M!KB$W)'?7,*<-""IMH"Y<$;^G8(YA=IE))<,:;)Y2NP,!D&+G3*^ZXBZPB(-
M"M0<*V:*93PKTF1%*219PL3X6TYMH>'N7'X[;YL2_GG&D8(]%>39BOA208Z(
MF')VC\4]X/"<$RO!H7Z]^?_>_/KQQCS/<U Q5K&FWH;T*??&OAT0;XKWZ-KE
MAW]TWO0RMT9D@%%L@KBC8+78>[^B:;(ZTAGV[T=A"B!XR]QW)-NOK5=Y$)4X
MN]3(8 Z9U&^^#VR;^B1Q:J)PX8DYLQ5T8A>Y< B6[[*BO ME6@SE'14GYDMW
M6MIU)OC@NR,NBXZ2K!$Z%;).K\0[2?R,LNJ=@L565JDC;2C $18$JK!KW:W?
MR2KTVE.D.3L*W(://[CK8"[KL31I>@'AB!44>FI\ P\P::B 5V\['A;!G]U<
M7K[>8!^4F17O@:$CW]4^+T!T:M_^B)W1*#6COLZ!$OVE8&DA[)*7S)=3;G__
MC&;;\..-L&IH\*](&I68<ME-40B)EZVK?U]A6G@J#J[%B .5R:Z5@-2_3K7'
MSGVN:XY6+4A]$<:8[_*<317_&Y !8&\)+I91&E',*_!^-0_79EA3G&\+G,0M
M7&?^%8]TO!9%H89^ V<Y =GK.)!(NV7?^5@TDGSU<CH[RP(@R\Z9<-(S\)=Q
MS1(Z"CC8X)$C5H[6!"\I=RO!S!B@X;AEAA_UP^,$HTM_ZH./U2M:?L9(N_SZ
M[?/5Y3G.KTU]ILUX A[_,V]UKW6/;);T])W#P1R,FD;+M5%I,X.PZ<=/>YJ,
MS&!%%_?RX?;$"!7EUCXV%,H"NRP^ P;3G^!U1(#',1$9&SDHT +\%+,YO2=&
M&<U</VF?A'>,/2?TL2G_$UE'*#BS=2?R'J",UO.4$PD#"[/U\QB$)ZU%S[HW
MJ'U86(,)<^21DE0\I_K#SN$Z0V\K>_\(_LWON72G+K]^N;VXO(7/Z*L.]1Q8
M,DK]:>E^@5PG:'(/6S 3-9AX)&UMQM .#>ZY$/UP,$>TM4UBG&VUU)F2]&@_
MOYUW>FG#KDH;/EF:;FTXELB7@(T=GPFKR/''U+_")P'\!HE][$PF/* J4U&'
MN@A\9URHY]W"(A0<;1E&D3F/V31);3^S%&,K:F_B>#D7--%YLOZVS-=?L817
MXNDIV,W$"A>**PFK(AI'_I\8)$6;]U'%F5C)?@"NL?S&6O**O83 4F-TRN'3
M/CHK($J#S&%)X@0% ,BV'D]FD?/].1X%&"*L,Q1B?!44?O#$NQTW:29!_5*G
MQ(E*C.*4N,!=*=K%*]FKK7-6CR04UXH>23:XVRZ54_!5:K0$A>;(&2>K@BU?
MUB#<1-&"33,+P7A"S5*>"]M0Z'/X])!K/%AG[Z6BQ,*B7)#O=SX"+9$TPM3*
M1<!3\M U#R2^*]KH,5XW=UQGEF>Y$I]W[5<J"AP*.E(N,.+GB.&Y[P>B_0%<
M,'UM*%7/Q1HIP)^+DRXU"FZ(-T2E<>R6=A%1R0OM982G)N?,!T<3%MHN,JIO
MC!MLP,#8H1VN^<@JADASMQUQCT^<**D\I<8<M/OS V*C9'M/7GDMGS%GRE,;
MYYBJ4J33(0MFA49,VQ[1J*'YLXA$Y%YZ";#E'+_[@,4LQ1:8$N]C[VQ;^_2%
M%,R8G,T*"9RD"3V4SE#F+U')U/I^'R'Z4X_+$-U?Q82B6+"9?,0296BE0GTO
M 2D5&]\<&_]X'RS"1O2E9O'1&Q][<1Z)C\J#EYL8X9PLR%D,,@7M2Q91YXAV
M]NWSQ>N"ZL!\FRSX0-/DCF?#3?4D4Y:FY66/NQ!K\"CM=C'G&IR8_FTB?=-/
M5M*^0J4R23HOQ%@!37P""P2$?4#U=3Z.1?1X'("LQG5W<V?C8MEC;(G-53 F
M6$7_,45U(0J[@FO PS%;9)F%OI8M4#M.\P!CZ3S1B'MIY"V!+=4&BAH$QYLP
MY +1RI/G!5=&&Q&Z*Y7Q!<\^L5C2^694V",RIL42W)N+JR_OO_[KT]6W7[/N
M88\_C/S "Q./5#I[Z>5F[-]^(%<)8D(^7,SF$4 6-4AR_$)\-+DFLZ<8)AQ3
M7GF&<Q(B'_/I80QOP;&&<A <'3=IQJ$GD,I[8"Y5= A/ /SF3$JDY'=XTQ6.
M7Z%]#5PVY@N_8;G>Y%CEDDT'ZUJN"TAS>4(1>52'(MH>;>JLQQ([)Q)^Q)WC
M8V\9T\Y^O?CXFFH=Y<30_"N$27UWY(.XEV;)7H(4B!XS(E*L+'4?IV/8[#C
ML(,&X$U;1O/F \@%,1(GM1I.&,3Y=A0B:PY.Q9>DY>)7SEP0KE<>^($TN><;
MQ570*\9^;"Q%PMC+I(B4 NT7]#Z@Y$C=AP,:/_#UAQO/_*K>PS/,^*E=NLM
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M42N+[NTP6:DT\[&>U)_-?*_X]7VXA*>7<.ZIA//VJ<NT+-'&EDV@<RGXTMK
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M^+-,J,>NC7_%'X$Z0#CB)H7D>DLVT(,86X=3"*D8ELVP%C%[/75Y;UM*-SQ
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M1-DF*2?*!V6)0I*P[]*\SFPN(IF.<#CXZ.I1KCPPR"(@R?0WJY^YSHYY)<+
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M:$(;LOK5&@22C7RU!N>@\]%K$IKZE6$.6_W4[ :#[)71,K21_&]I?(< RID
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MI\UB<*9(M-HL#BFB43RKOJ17>T:KG:K5EU"C2TJ#%%N)7L4'N2P&,**4DF#
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ML9SI/94EIB8(.J#H-XY!$.4?&"*X[V2/7DF7;QX'!8D7(SBK@>%ABE8XBFS
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M .B).(0]G!AVTCR"QH?B4R,G$,/(</VA38Q"A!3#L^G7G\+C$AI!$-*.E.?
M/L 09Y?,0O%>_?!!"4;'H[/2ESY,[>#6\90[T9XMNP!("OSQAWMG%$W0>ZG5
MR8-1NDJ^67Y<HX\6_!G^K%VO-3O6RH_KM=6?/;9LJUMK-?NEEGU"Q3YR/S=$
M$14L@H<ALQL7%H2Q[PT=RA)-&Y64:%.R5Z>\SC%"<A\9&F>N'8;.V&%6RAU[
M2]>S&P9+>67UK'8>K]'/IAJ *I$1EF\;^3)B*4XBV"]B*9<G]RP2J21XMDPB
ME623-4FD?&7"D4B2SXYG@[X]=$GR!*LPSHUW:B+>+[_.;(?GXNU"7) !O -
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M2Z _WQ.EO@S[# 3"1B#7)@!2#^(9/#@5?(3S[1UOZ$\%O0:_"4C!$3S M/B
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ML&-@'&E+V<8$T(&O<\*A,T,,C1)IP2)T*$+)AO!-LL7P?!&[8#8XJYXSC:<
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M=^# 4*33X0!YX<H<R;%E  >KJ$'"(=^P2"-N4+XJ\D^(UXMXW)N)N@^45=S
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M^9H4CC=3>0ZUHBWO''&H.T8^9LZP(@#+6MRB8 *K]98C *3$0&H9_XY!EXG
MG2=H1C&5HMS&: Z@%8X,N@1#1I1,$] '+MC^&THSV#5GK"DZ+DG?RT"?<1H$
MZ-:0RW*8X'F4_BX\XV^V%Z,X0-XIR"S(N'K*5TTO^$FAG<TC_R>L##J,Y(YT
M&Q-W3=ZJ-^MUE9!% 4CYZ3N5@Y!=Y2P-1DI?4.(KR2-+KW<QPPHXG,P?\"YI
M"^AB@V+/;XW#<0&A/^M6HE.(MM<4C5L4'DG\,Q,4=?[#W(C"="KP84 S_A"
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MC=4?5W"SS5++ROY?"S:6Q9Q<W+^F0JV_UFAW00W8R-/P8UAT%)9IPUZFRU8
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M9H G6MXJU[@-!- )=Q+BCN-9@P2>7"WP6&86OYXZ=,KY< N39M#H8+:''[!
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M2O\7,IQK?'&F3F0G'=7/%>=[(@Q!:B4:\'"]CM,$Q^$\!&O(E'X'3B&:^/?
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M$ICFZA*87P?^: Y_3:*I^]O_!U!+ P04    " !42015**%+!)<6  !,"@$
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M'[$[V^,N$5'*I+4KQ$&@'\$7!M$)YG4!RW44(:K&LM\(9!O)NX<C^<,7NX\
M]PAI2"6]8IQ[FE)&RT*QHJ8RH#3!<5-ZC&4WG,GY^:,");"0R6X#>7A!%.:1
M)\:3\C&9DD)V1S[B'DP0>R=IWQ&OWF>MV[%W-OWP'KN3NI->?I*24X9KP3#6
M=)Q2:/^L,2B>Z$'"K U-M+7<-R(9DL?<3/:'KWG;7>ORQ++C0CDN&:K@F<8B
MR%W7BLE@;>&"9BUB'QO6CH=6]Q F/DCF!ZWST X@3(F<NV)9RH:P*X-D7:-C
MB:L$.0MO8G@ !Q#['?+-IDLL_X3)*8Z$Y,;ZJ%E6JN8N K%!6$=N*W*B"]D<
MO+5I?QW#D';'>^#7ID._O45T\(-6TR)'S[$@J?3\[B/0=)8H7L[GIYA'%ITP
MD@/S3I)C4C)A044_,AKR5J/,>,T;N)EG>?<00]HO[Y$-#>70+MJ4\[A.&B9_
MP)C\U6?P:;R R4@)":%D8$D*58^B X-,8+))6*30!DBLC4-*FZ$,:>,=@"II
M(;!F['F+"QA/,?\&W90F.'^:TNG)Z3)GE'@^3N,%V2?&9I""E23(@:#O8#%'
MFK4W6O(LLXVMO<_OHQI2&'L G&HLQF;T^GT\G77+!3F;9+8NY@2*E<QS#<@7
M!C4Z ](Y)7+,*NO&9+J.84AA[ %0YR 1M4P.7Q-VZ=.0O?6IPX\XG8\_(ZW)
M[ 1?S>;UF.]->0]?1R+P)+5 \I*"I!E;SH(GW6EE,MG9%%5HG>^[(\0A!<4'
M0+,^!=R,A>\[A/EI]^V2G:_0:6--9)B!;#J0GH&5]!)]%O1$V"1:$^TFBAW#
M[.Q')].!<FJ<U':>6V^2M2$@,SEI4IPT&8"J.$-2SJ$+7+2.:M^1%+9'& +F
M'VM&*_U3Y?H9)LL<U\4SZ+IO)+K50KL83."E,-HCPNH4+#IZ,,FW\:$D"9G[
MUK&);8 -*6"Q/R]NQ!V:RZ2ALH3ZS%\]-A^%)'-PA52V,XXF:R0#FC>+H0A,
MWG!TK1^"C4"&%+%H1X?#U_P("9/G$_7@4'/%8JP>1\F!>>"612]\EN@30NM#
MZN^"&E(LHATMVLJB3;CR[-[@V]5UZPM0(^M ZY 5DRJE>C/"D+)2D1F=>2I"
M12NNA?EOB5;>-L*08@.'R[C=8AX]P6T];>]M,;%>,C:)3+VB/(%,]?J43%FZ
M9$UJG1>[(\0AQ03:J84^Y=1&22Q=P3-6KYS "VZO466N33#1,]1>5M6EF)=:
M,0?9E:2R==<#V;?HBRT&&Y+3WDAUM%[B/C+;UCADBBE)*UG 0(8,YY)%1?M5
M0B-!!Q6C:WWN>1/%\'+:6NB" U?[FM3__N3ZXKRBUVU+Q[Q;T,]EYN6LO/F$
MW7*8=C5D;OGZ_HK);#.?1E5ER/"["*F-7%$J\NSJ!?WJ'B2R FVE308''I.%
MV#KKZ@J 0Q7%']VLC!?+J>@0G"D&&,\VDJ-K"@.-P$0)5DL4]%RTMB0N1A]2
MA&%_"5]7#'NN;CL_\O),MHL<VE*$%)*E$I%V*P<L&LN9RR"TDZJ0H],GGUO=
M29;'BMBV(TN_PFH8FYC.5AJV(JEX?_OZJ2IDHK@+,AO.N"876'.;:-Z%=M2B
M@D>ODHRMP_FW@CF\%,Y:$B](Y+?=6A#<&%I_QY875[05A@6C"N&T,D<G;('6
M*G,K8(/2IDWX<K->3FOY-*^BM)YF2%%&7QV @C1-ZS2CV4$-)0<; TA36A_+
M7X,P+(79$Q_V7_1FDO]/&$\K)=],GV-'7N!B>?PZ7W3+\ISU_/6/#A?P=>2B
M*)X\ 6:=)&?#)N(EHF<BN!2T5E)AZT#^MMB&%,3MARJ]2*F_.\^?7X__G'8(
MD_'_8EYC'R6$()7RK/!J3G*)M8Z#8C)+XVE1DBC]7%#\'K(A!8C[X4\/$FK&
MGJNQQ^LQR@THP2B%QGN6K/:,G)3,0D'#9(A1H#!D2K8^1]H5XY#BQ_TPJE>I
M-;1KUH;5:N:U+$3T)2=5(I/%)/)W1*W.98%!5(F <"53ZQ(,&V ,*;+<EWES
MV-JW#2S?/D=7O-&>Z BZ>J0&+&&*BH%!+QT&P5/KTHEW(QI2P+D?:C242$-5
M<=D[6Y7Q.R5H%Z'97[',NK/<Q/?P%>>_?5UT0 (93Z'[]I+6<7Y+T(-6PTN>
M.#.\5ED-P;!*>%9KT;OBK"_-JW/V.)V#G\>K4E_N#AZ+]S)GYF+='524Y/^:
M0)L%:HST';9Y[<H-,(84@Q@*'V\\NP=*[PA!/6N<**@L<]Z2_M#),2\3V1O!
M<Z^]5D&V)M-!ROQ8>6=#I50;2;:S%S8P7$%2*CGB=:6YCHIL%EMO5!<GHN"2
M]J36M^>^JY_VN=WU&:>G.!\%X7(,T1%^K>L!OV7@M&7DY@4MK)?%MWY"UF,/
M2<<>*NF;UZ[V6-^&M:'GRQ+$9P\/345:X,H[9G3- XT\,V_)3E,Y@D?MHFL>
MQ;V.85!AW-;B/FC!FXG]TH&M *ER*I8%&RV-+SP#825#\K'1.EZ<;VUGWG8<
MOJ\!3KO.V7+^BE.DKQY%R<D-T(X)Y>A9\F#($=#D#6"JN:J:>VA=!N(6*#NJ
MKG[)O*?8-Q]*';;J#\('2T)P$0LPJ5'612*GDG0RLTX5B0:X<:VS7H[F@]VO
M6=F4B?<O_![WXQR,A4C[ 1D 9,UB;;;B#,OH,\_1TE;4^NC][OUX'PMRCK0T
M]0[2<S)V)K-/-<"W-M>5 (4U(9$K6V^2BT!F#]D^$4&'XG36JO5=L#L!#<G6
M/(@--PW-5F)H:89\'M?VCR]FW>I&;X=YI19HLE ,F)PEXR(%II,D%>$QLB2D
MCUP*!:JU]KT3T)#T9U-FM!-#N^LA)_4:\/\NE^)-N5ZI>R1#46BE8[&4I<-D
M6" ;@QGC$EJ5,:?FM8[O1#2D=(*FW&@HB';Y)V1O=C"IC>7RR7@ZGB^Z97;#
M>5(,J:ML(K"2C&%:^AI:=)Q 070\)O+16BN.[T :4K9 4WJT%,4]WP_84$WB
M*K)&%P4VC7.<&P/?G6&CJP,;QEG7Y-BKS$,J4ML@)4NUZ*SFQ*0 -C&;@A$<
M3,+FD<?&4V@8K\E!\.(3>=4)?'5+H%[ K;58#;A@G)"RM;T\S.L+]\FR.RY
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M5R75BS746NJ!EE%)*QP3HHJK*')+2[+,*ZF\0"]$@*W\[QT??)J&U+L*>F@
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M%3J;/OTIZ["-R'IX75_DO! BC-[",+\:OX1/PSF,+L%EE,8E;UDN>3&UO#
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MREOZP7A^AO-A@M%-N+WQJ-Q\YB.1JMRS\#6&%2.4TL;3*ZR%UMS&F!(%:=Q
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M2BCG4#<_&Q_)6A[*6CZ6L>RB@M95.K]^26<PKI%KP>DU:)=9-Y.5#1 #4X$
MZ0*612^!&6XR!I-<6&?%OJ-0Y_[G/(+/W5@MDWYDVC /D'$X^!T_PNC7\9S.
MS(5A>U2>5FA8G77+=/# @L+$% ?O,V)0\KY)#C-,?_DX^?P3??3RO:<OKE[W
M#0]\MOY%5^$WC+ JE"6*2SO?!L<6?L/#QG#]J8?U!SJ+?])0=@VW\%MX0&8?
M*#JO=R-8V3P]\U)XEJP+@-E'Y[J]T/WK\(Y3NC<5[B*RUJ=O75"ZW%XFT]E;
MF,XO\S.K'N!B@@I*!X)3)QTGH9G7X)BR!@TOOECNMCJ 'WS4X<[@;BJ8]":_
MUH08]Z![,<Z7DQ'?+F[HWN,(TWPYWQ0_3"^^=6'*(E&@*RS+6 N(R;J]"8()
M$W71,3J,LJO^MP5S8A;2BPX:CXC^EJ]=['>@M8D%-$-'6YT6A"&Z0(XD]U++
MR+G1+<9"WWCHLW79NHF_(1_##2"K]V$+* W'PZ\]_O!#X3LH8I,Z.TBQKQ=\
MU3 2A9>H!>,47S*-NCHW==]+DO-DK#;KLZ*/5Z'WS'OO1Y^["*^G&='+HV2Y
M^RQZ,-Z,\KNWKRY/$MIH,$8CF"ITB&A9"6/KH(>H,)=D?4YHMSK-MWG:86='
M=]+%AHG1[039VJV[ ?#E9%2]!A+K=8\A1\Q1Y, <YW3>1!.8]P#,&@@E.J5D
MWBYM]O"S3D'+W85XY]O<MN+O_<7Y.3D9D_)^^'&\8/0>SU^D-+D@7[7R[8R&
M:8BS#A6 NSV@145@AR6M5PAZQ8-+"4N6.L@<C-88R4&7P*4-,-CM41VIA/#/
M:Q\]G8SIR[3LBGLS?;E(S[X:7_^-X3@-24&_?[ON+L;R0,M@)4CR^A$M[2ZF
M,.L1E0TJDG4WOACI#/KQ*GSH"%?1&<-0.+UL[8BJT(D.)1:%AD*D9USA<UAK
M;%<$M(M6>Z$*&%=\TT5-\;OA[%JEI:A=T(5'BN0*<E/KRST+V4:6I+(B<\S:
M;^4I[U1I?S>>YV94S733P[7WOI)9)@L4AZ*MURP05/([ ODT(426@U7H1 G!
MM1ZWV GPH<K#'M?>#J?3QRX9VW33P4L4R&L%0HJU<])61HFBF%,R)6[ <G]?
MD=B3N:@]H);ON9G=1=I]WN9M@^,$;V9W$O]=UWK[R*Y/74KI(5@=F9=U^KAS
M83E$5B<=I4J@9;F/#O<8=+C#S6P3%>XBLL/?S*9D0 N56$Q:U68,S;Q(P%QP
M&D0H6MJUCJLG>#.[DPIVNYG=17Z'B"U^_OJ!_G1AO=GI;! ELUPG6G4 YC5W
MC&L7"9@VH7E-Y#UPGL]9W%HW?7"4KD.KP"Y?EFV@]47[<#>LQZF\;J;"ATRC
MH_Q[806X&Z+&;$$ZR;(N!+$2-WL7Z@#!HD%)*;5OSF1Z:--XH,SZ,2QC%['W
M81$7= B>UPFA:Q!7$U]D5!')1TK"9*8M[<\Q%<\P>Y_JS'>Q3H?8W2KNA_0(
M#!*MU+=N%@UE?Q@WY&<<I[-SF%[R_$:O0M+(H+9@:GH'& 3O&5@K=2P.?6A/
M,W<_IN\.22<M]3"JY3:^%;H5M_<6^ [EFJQA.QK_I(-&'S27!NHXA*>RCC-:
M:;D2],Y(42L?@V7>*&"Z1$4!8>(:PDF8R^X^RP&M91<M]& EEQ6Q[S#A\'/=
M2E<1?/;(DPB!25-GD[N<R5LKA66+113K/9>MCZ:[L!R!O])):Y,>1-[06[E=
MLJ<=0*VL9P!),@TQLP!TFDIK448#:/5]C29/JA3Y\'Y'-WDWG,RUJ>9K&RBG
M6WN\DR+NJ57=1XH]UQZ'K.KP!\T*YP3)Y,)B]H+9DKAU%"6YTO2=/HK:XU;Z
MW$5XCU)[K()-P07-HJI3 T #"UC'RD;IE;,JY+A6+_-D:X]WTL7.M<>["++Q
M&?P'_)_)=)716(X+5TE(*;!Z&&DQ!<XPCRHR@ZJ67GHP9BN:Z0=>VMM/?EZG
M<4?)W[:#O0<D5C1+RH(;F"Y-?QM0#0_G.X$<_ICNJJ%)7^)M?&K?#2X()XW%
MQ&A_JG-AK&!1U A!0!;@:D9SJWCLN'1^STE^$)7O(M76!_M_X'2.7U8#65/P
MQ@C.<B0,"P9D+Z$P*Z0+/JALN-CJ +_^J8<]J!M)>=)"1 <BB7[Q&8:C>O24
MR;3VK/Z"<?X>T\64/AIGKV%:,PB?N[!&[_B$%DTC71:UUC4"V0B()48$58F4
M M=6!BB^!,^E@L&.S^I(F)7.,%^,EGQ =8;VU9->C/.;^=F"T*?^PXO9#.>S
MW[_5MLJ0=41!!L<5F9XGU]![I&#">FMMLM$DL<WFNPN/UKY@NU5&3<8?/^#T
M_+>+\6+(^%5ESXOSZG,-"GG=L=)P! % _G$0K+9Q,J%$R=DX""YMM4\]]*1'
M8(TZB'G<+*1J*>[F#!=W@GM]426YI-4BH<T&(@>*C[1B/M5Q ,4J1GLU[??>
M69&25#% 1ZM8?^8SMX].*FA>3WDGS%=5*3!Z"U]K##>H ;J,M1<\UAZ!VA#N
M*\NL45;$8$."O%V:8MLG/G,KZ2#^AN5U#X!\.?F,8QC/W^%_70RGF"^W/A5!
M)2W)C!.O'G^I5<:1O#_)LTNI-HEO68*[XY.?N<TT4$?#(HB'CLF<%[KY9N.S
M%Q\_3O$CS/$2MTTRY5JGGBJSITZJ,- ELP)*ENA$L7)+CJ7]03QSBVJKI(87
M8 _@_O7+)TQSS*OM4YMD%$?+%(4R=,1JPR*ZR"!:"C]%M!9X1U-:>^0S-YPN
M"FB8E'WPD)W-832J"-_AIY6%+PS[ERG\.?[C8C2O.>I!$=ZAY8%)+\B9=R:0
M6R])0MK9XH)6V83.WL]V6)ZY8?6BLML69[O-6)^,Z$>390;DQ71:+S\6B(<?
MS^8+H<71\..B1&5V^8:\*2_ATY"6-G"<(T?-F8K>,,VQWI(9.KU-+"4:3 :W
MRR=V0?$LK.Q@:KIM7^Y@]O4'?!F>7YS7T7W#Q:WIATE]JP;U>BUYE^C]J)E=
MJ$.;=1%,E%P"+SF%L!T74@,PWZVM!Z7=-CK?R>AN)GB_I7]_6Z9_WV'&\T\5
M_-OI,.&W;9@;A]QQ3?XAG?X:O"#$=?JD+\9:[XW?LKQAK\<_"\/J7S&W32D<
M[GS$Z7"2WY1W.+^8C@<Y:FE=\,PF5\>7TKL A8)9@TK2(HQR6K<_'6]@>!9&
M=2 5;<AG=DM][X_[_9R\S%\HLAUP$"J48%EQ-C(=@+.8)*U'>+0!@[!JN\1#
M S#?C:T'I6VPNFYI]+L6\"T,GDX28IX-BLW&%R3!V%IS#C4JX89$Y$$5S8WA
MNIO7M?[$9VT_G<2_P4BZY='O/Z=7UT+OSV"*L[<7TW0&,\P#;6M3@DD,E>5,
M"^49!'+^@"OR!6WBP+>[H-OK\<_"?/I7S 9;ZI97OQ_RPM.CC7(!>5#3'9&#
M8Y;34:P#4I J++E[*+@01DH7MTLH[/#0[W;300D;K&7O1/E*/*O\_8?)B[2X
M'5J'>[60NJP!9 -*%V ^%@H/7)$L>LZ9,[(@Q9GDT+6NF]D1XJF;V"$TM\'2
M]LZUK_!>U>>_&J?).;[&^4!PF831AI')(],\.1:-!1:Q,IF2AU::6],&&,_%
M8KIJ8(-5[)T/WU<2R[8 (8!.4;)@])E0*]0,0%1N*B6#2%8*BXWM9B^@!QL%
M_2CVU+_N'IO;\V:#[Q!&]9II>E$_<E&^GIR),6K!1%K$#9G68BC6- )T"/0>
M\?7:R48MU;>@/-K<G_YM8&.S=3==]-!VOQ@<6FI?PSB_Q^GG8:J\W&4#VEFE
MRIEM_J?5+-,MUM(3_T?+=3P.5T@3 YD<F7:/W6)55,$4@XRG>FV@;61>^%"9
M)]$C1FM+:^J1X[?4!VA*CMY0=U%J#P;ZENP$IU/,B[%QESU#%J4T.@B6C2=,
M@M>JQ>J_%..]4Y5@K/4<@4TX#A\S/)YFUP//KFIIW=:P]47GXHI@\8I9'P4B
M5RPGHYDVJ3!0W#-;K,M"!9#ZP4:N/9]]^I[:(932NIA]-[B7;]$V@#>[:4VL
MZ3&<K(/H=G\[ZJ"8UBTT^P&'Q)46EL5<6;;!<Q:#=RR"B%H:B7++^=''8TEW
M.$%/Q)!VT,?C&M";,:X(3VR,4&\OO91T%/.*7M4&[1*$-R&:"+$'&_H&X'"N
MT8'TNK\5[:>4Q_6//OPYN<1L.+>2"\\XD@.@=;;TJGE@PA7OM!,EV^V*$O8$
M\-V0.BJEAYCL_1SFB]SJRQ',9I<3O9?,7*&@+,B9P]JN&K"PD!=\'AF=+5A4
M:)T!N!/,Z?O8;?71!\?Q-3PK#KTM$/7%:GP+S>/D)ANI:YV2MHVL^Z LOHW,
MJ.B+M(J5'.J,&F]9B-&S#$)I:TAS[4F*#Z3]!_)]!U/^+B+NXXR@(XLVO(UY
M(I-RXK"8+0F":31T5&8'3'H%O#9B1=EZ=L(]<!Z!A[BCMM:W_T:B[F%4PA+:
MSQNA2<!"X5L=(>55M7=D$2&SD)1.2CGA;>NY*O? .1$KZ"[JQM1W+VOW)4X_
MP73^M5*)+;8Z:5)TUFI64DT4\TQ0ZE!1I144F[75I07KW:9GG[Y7V$3JC?FH
MW^&GR]K8%Q^GN#S_UB"NIM=M ;(A&>;6P Y/CME=AY-#*:#QGK$]6,3LBEVT
MI]7WHS:J10N628P8A0C"PU8C[(_;2NZATWPD(]E%[JU3HG],II_.)N^_KN8K
MA*P=*A682\;49 AA =HH7;1>80C6N#4_XHX,U=H''Y9FLR?93QH)K@??L%Y0
MORG7.G(NN=UE4#DO*E!K+6H%Y:.LM,_*0YTTEYK7D&P"<OI^0CL]-"1E68&Z
M!J>N^_5D#%<_651!0%IVPU^RR&X!MZ>TTHY0'R?GU$#)D\-KJ(>\Q*ZP'7 =
MLJRU\8D"Z BT )XX Z]10U;:9'.*!O5 &NOQ[6D7Q?0RAVUS6^DUI/\YG)]5
M=J*O'R9W_?8J2P,AF@"!T1%>VW)DY?NTA66=O8U"HFM>0MX2_^%S)[T:RZU9
M;X^DZ1Y\KG>8:M9I6(9IT3'_YF).;W%*%^<7(YCCTK]X.3G_-,6SNA-\QF67
MT.+MYA' %><8&D'8BZ]MB@H8)F>$BUE9TSIAUP7O\_'@#J;5AEQH7;%?!D/;
MH._)[^N&_''<P,-92B,3[:#F'@[]CJL(P3N9P;/*?4JG$#E*(07.E),\9\Z3
M5JV/^6,TT@=<RZ=JH[MH]XAL<U6;9JQ2/FF60&NFI046G,^,6Q%C@%0<M!X,
MVPWQX9W.0]I'(]/<0[E]W *O:AY^_:^+X?QKQ3D9+USW^LH*'R%Q22)!7]DO
M"C!0)3%R@<AB@@O*\,:6=R^@Y^,WMM-+0Q+3%;@U3)<OT3:@>O+W-@)ZY JR
M[HJ;]"7U'HZXS>"<"28' ZQH3D>^XK49(!D&I8Y+T093DD_7%+8M)SN0)>PB
M[#ZRMU='WFN<7W&9_)VP_3Z9S>C4&UTL6,$GTX7LY_/I,%[,ZU;Y8?)Z,J[<
M$"1B^OR/K^KE&OW]Y1D9Z7SVGGN6E*,S,E02C&@$4S8F0"$PIZVNDG=)]/:V
MFL,[1PW,93TA?!RZ[L,?NH@S_*^+^M9^KHE$^K/EO;V+(?I @K(\,YUBJ!>R
MA#)9#A!TLJ+U7<,=4)Z1#]1 %PW9M.^!M:K/V0)83Q[0G: >R0MJH;J'S:&#
MW/NHJ[X38+25LAL2LY4L@KZ(#+QW+&D$\@-,$+;U 79@@WC(%SJH/>PB[O[M
M8'6PQ2#(P5.L4KHQ[6-D487 BLR(TDD. OJU@<?R/QHIZG[U[R'E.]V'0XXL
M?G]Q?@[3KY-R_Z_U-M!XQ^?W/^ZXBT#6AB$K,$)9Y4522F=N8M19"*FST@)R
MY@\,0]X1R6.-2LXV)"Z<9QZDH(TT>'J)C&5*@Q-11>F4:[VQ''I4\K? 8ZT/
M=ZU+][R&&_^-^>5D-O\99G3 4)#M3:@<S[)6%Z!.#+ X9L XC,(:;7SKT'%'
MC$^)WG076[L5-/:INQY"P0?P7H7 ?Y]2R/N/\11A5!=0@^"?ZU:!'^#+P/GH
MA5.%E>@+!4#*L!@%L-H.CCRED'7KHMDFP+];95]:[B/W=B^U]-5W \ ZQ5Q'
MYC4'IDN"2H>@&)#,DHFV\-SZFGM;;,_5X)KHJB'=UJXX7UY,IU@GRD(B9YY
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MTC_&DSC#Z>?J+2TNL>F?)P1M-(1+25\R\@5??+#U>B%PR[2L'C&MGED20($
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MQ8Y8%QT)CD6!\9B%ZJU.1Z=&?R>C/3-ZB+UZ]?,L37].TY6__&,:2Q,X6#Z
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M?>U<J1JXAYJW_1@VZIG$* 48Y8GQ96B,4HP$9P()9;PZ!V&3J)VS\RB@\7?
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M;@R]--:M$O\8<8]'AJ2=8#:AY0)JRN!90WP$01"<R))9E7>K*%X4"8[IQM"
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M'?8.HC<;1%R;+%.I#):QM L/"(9)1DI[>- >J$FU6T\\1'%.JCY&L+73WM9
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M49BW;^W35PLUT?2\HL0K5V5^@A]7B_@-??:+KPNX&:V[ W&35-H%9,5"W,[
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MVT,49\: @6*N6&SZF!/WOLC87Y8+NPF3B !W)(+62I0(P!)?9CM%4.B?873
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ML 2!%P2[_UK\E7H4412$4$H60I2("*9^&,) 2D0"Z7,B\<7]7V5,@B#F%*+
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MPFAJXMYVBYF:JUMK"AI5+T"M+%#: JVN&4V<0+:;((;#RS$U](7*F"3,D#A
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M1=P-S_J*1]%<"ZOOQC1A95IKBU@$RQXQB/UP / XG+>JH_.N5?U7Y>W5N>1
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MIUW_K9HSZ2OX#T$LPW>L.\7,QW )M6/>V43YMZU[IUI]6"4IK?#^HS(!:!M
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MK$P#CXUM@*R-L[CSY/Z[Z&:TZ?7V&)O_FV&,K;F@LO<"M%_"ILF@M1E41E^
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MH[]EY9\?Q((]/)+BSS974Y(&*::)8CVLW!&" YAB[L.88H^$A 1Q8G=Q^83
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MHUY(("=>"A&E'B0^IS D89!0Z4?<+LCKB)RI<>Z'O"CR'VKNM>348S":,>0
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MX]6#7*IWG]3<6!]GESKL\C2[UL7DUW52VE7)B:NNY_2@&<L.WR^.^72#*R_
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M&]6;-#9_UW<T?[$?_]P51.^6?M>%0JMB,?IVT4S()$QH&$ LN0=1G$B=I(5
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M/TZ1B!BA <(F'O@Q 5-SOFL=P5I)H+4TX]&C(';/;$- XWB&LD3%F(-.F7[
MV59+HK_<YR_OU:NUGZU^6+O71QL<A2Q.F=,.^I//]8TW+X5ZZ4$G<1 O8IX_
M:4JY+ J=BEC_V-YUNLMO12'SXE%12;6.+[^L8](YE['/ T@EUO<3A0?31*W
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MQ_[>H=KEDRCS,BS2S@J@3[^HR[! GBZL_@8E7*[R19G/,UYM;MRJG]CK^HJ
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MN;">J&W9N_DQ*UZ>B\%.'<RSF^NW0?9;MLB+ZNRV#?#C@9\(%D$=Z0>16N=
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M.:Z#2GB6*8X45%$2:X\L1I#D>0I)HE#,,QPEE+OER0V&=9I,N5;,"L^W2^V
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M2!DA+I("ZO\P$[ S;0YX G.]P"RB62H2^\*X 8+,S=X:58">Z/L1A^E>FSM
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MR*^;YWW"()>4H4SE,-4G?8@8HI#D<0%I)E0:8Q%GB57'J $RS,ZDU5J 8S5
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MNHLP-X-JQ =JN?YS"\S/Y+AKX%[V_W"SF1[K8F<NQT5[9$NIA0<5V*WX@+V
MGXP&H%S][:BEW$&+4?AH_4$,9" ]!)C4-OH#=&X6!XPT,!'\EW(EC<'=+G+%
M>(I1!'ELN,58$4'&,P33G"G,2:2X<K)XEU/,S:(=-08V,E9^AW?"]P%(.Q,U
M#)Z139 C,OZ)W1?*A\[F/DSP.BG<%PIVYFU?/NGW:?^Z_B'KQFN_EJOUIMR]
M[%NPK9?+]^O-GW0C%E0?#^.("1C%@D$4I0SB*,MA@3B+5510RIPJ:JUFG9\!
M6/-_?ELO-;C;?P--/8,UUXM1##2:.5H-NS6R,R3!D1_=MHP/NK-!<@(QD(VR
MFW-2L^4$P[DE<WO9\R2W7NW/'34;UL]_/<G55B[B+$=1EF40*15!%#,"L31T
M_K$@!:$)ISG>%]6N=W1I>6[KFM#JBSHKI-U/.][75<T!UA5YV$]E)?#?_BYK
MD;=W8"4MTTIN VYY$AN$WT0'KB,96X[GGQHQ ](:WH0BU+&I<YYI3T>WU+TX
M!-U\P<]F_$XWI=E73 ?:-F9.,Y6F.(%%(K7WP[&")&(%U+8B$HPII@\[+M[/
MY11S<W5:":ONRIXA[BM VAF!8?",_/4[(N/\V7<K'^A[OS+!I!]ZMX+G7WC/
MDYY5/=UT'O_8K+>&:@.)0N("$I13[1JP!%(6"9B1*$M$1O3_.96TWYIP;I_]
MV[5M'JDUI':??$B@1C8 _00_=Z"2-V#MCB4RH>IV;DTW;<V.I?(7]3JV[PVL
M#GSSLO_C?Y;:%]GP;R^F#'%9MU](A,QH3DR%3@)1)"5DHA P,<7L BM5I,*K
M/K!WVKG9E$.1&]@+"^A*@(_WOWN19EBB;VEX@F,ZMOD9 *=_X: 5.J%+!_LG
M?9WB02L@.LL'[=[V8MU0<K.1XLLWJG]LG^CF85-%BD4UUR>YJ?[%@F&JDL0X
M-"PSU]2F:V&NW1T:,=.V,$(%MZI8=IAS;N:HE1IL36#QSE#X@A_5Y_13N0)B
MO5S2S1;H@R78&O&[#_3>B]!OF$:"=F2KM$>UEOC.U _J7R^HI6[LE9:[_O?A
M,77BP B-[61T%T$P=B6V<$'K!H>%U5!3TE6XZ';&3.'TJD\]I112?J_HW(RA
M,O_X_:FJF=F4_/##3[&(XS0ED$6%A @K"AGG&*JBR 2/6!9)^SZT=G/.S:(?
MI&YM^F8O.'@RDE>F73YKS]_/L%NNA85A#X_PR(;]"-PO-;@'F4$EM)=9MT34
MI=8Q.+)3U3:&0-BQH-$)J_X"1KNA)BQ8=-+MM$#1[57/5"JY,7E9GS;M#F*F
M:HK$M"^>*,%RJ#+3<2W1/CHM6 %%(=)8%#C)1++X(3=L;9U5U3V;RZ=P/.>(
M5_V5L. >[,6MOPC'%*L>@$E""R%9!(M$Z?,/CC'$4:(@PS'!C.>(,*O=,C"\
MTYQ[V,Z&S-<94[LX2R"D1M[MNGZ!(W R60 2*KFM9Z9IL]QNJWR1[F;QBH=S
M7:<1_2IWW];BP^J'W-95E[^M3&,?*8X*,1=Y3%B"BA2JBN2-2 89S3 4/,<9
M96F:"_MF2/;SSLU\-(E7WRO10;F7_0X\-\(#[E57[K 4%O[U. "/;'4:;&NI
MP9'8=Z 5W+-HWP%<!U=[') G<K=#@>WF<;M#UNMU.PPWG>?MKN.)]^WQNH?E
M;VCS']2[TM1.K,3VZ[IRZYL4TT6NL% ISB 5(C<<U-K><\6@*@C-&$,%D\BA
MVX;5I%:?R?1=-O;2FA3;[9&\#A;H)MX61CT(?),VTP /"AS0^[H&7T9"S\%J
MAT1Q(EL]"$TW VV+3J]9OCG(=,;85I\3$VS]DC\?2<5 6/6)^RR?UIO=(LV)
M2"2)H"1) 5$128A-^6R1Y"I*HR+."RO_NF^2N3G3>\:-@Z"@EM2=D>0"T'Z#
M&@JFL>\3W1'RXB3I@F 0*<G%H).SDG2I=8V6I/-9]X_\%XWY\M.W]4I^?*YB
M0QG5'W$6%5"P!$,4Z?]B@A"(,Z:02G"B<BMVSVN#S^VCKN0#E8"@EM#^8[X
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M*EE'.5=8H1+(?^B?:U+_P4KM<__![B6/I.M?RZ7<[M8K><^Y7%:9">M52YR
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M./XM1,_R2?VWK[)P=CO69$LQ\H9F)&LH_'X^AO\@.Z@?,:MT]I?';X2LJ0R
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M<[/4Y]J ]?/.?#-'"H$][^%!I2;N[7;F'KB0=D?SZ99GY)U@V,J,P) =!ME
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MEKKL""YXD1":D*PD=A43>\>S^3:'*9"X%K>)+62/.I.L!M6L*3S&=/X?TRU
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M3FSJ4HHGF#"D+)H2YH)39>ID&:1(_11S3 1"A!<"VX1B'@YA11 #Q%H^Z#%
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M3CZ0/R>2LTCMOS-("U$H<XV7D,0%@5&"RCPM)(_2Q+K]3P!!Q\;^6_GI32T
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M(H2A$M(LETB*0I:)7;SSD4%&QS!K&4$CI&/D\3$X#5GE0I!"\X@M/DXY3Z<
M\)CI=##$X/E-IY0\EM5T\EH'=^ZW%^T0OI--90-1W\F_SI=J&6V2I289DU&,
MB(!1H<P+I"P+B$6!(<F2DF6$)H1*8\]MWTAC^_!;6?7RR%II]8^UEM3"'=@+
MK8&_U1=@@4F@P^I.@DY0_6,K:IL.Z0LR"V>I+^@&\HNZ0VCG_C2!I=?3V?N
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M:]-BCZ%1RQ:+QP[?OL5>YZ.M7!P>X["NW L] O].%LNWAP69U80U"YGZ9;,
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M3Z:X?(EQ-<GHG5=<0(C*T^EM)?A,7I_,+D7F+).E==?GK82,Z]*TA]#QTNX
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MG0GPT%P1E$P774-"K,-*&&'>19OI9#;26)=-N%U@^P-,:#D$"TTEV8'AV%)
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M:4W0,I1\QPZ?OF?I.P/JC),,>0*GHJZ=FSCM I?H%':Z<)/)84P'P&3O@VC
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MF,X7FR'(WS&P6X[X(Y_8)BE\'[(;98'?N'"HJSV;Y4W3J^MEKS)XM; A,B.
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M-7^MWD;(N-7QIX_.C]=&!Y"Z07Z5T^_S6;C^R8WIS9<[Q@:F?!8:N$D4",1
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M(X,,$DI647BI>5:M[TOWHZR3ZKG1[_('T&-7A^0=_B:))X.2D]<9/?F?S!C
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M3*"$4> =JRUYBDA!*1O8UJ78C@N&IU9Z#MT;#M+L?"@QCXV9QUI1((])9<-
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MG=ZT%3:"J:AM!LY1UC=Y\O!"U, 4"UH&IH-I_3+T&#V_PA/X )ALIL(.X#C
M&?)Z%B\N4TZO9^]67_*BMC9=Y"]YMEQOWSC_FM>"LA%S8%R#%9J!8A@@1($0
MG"U<JY14<ZR/QNRO\-#?M[<_(/A^]5WZ!RYF]"M+/O$B9FV9 LTYIZ-4V9K,
M(\'&XA7J$&W,SVE+WG#V*W3[>V[[[SA8_5J;[6->K2ZNGFTGMC[Y9T=ADQ,!
ME/4&7&0!G*3X2?+"DAELH%U33GZ%SH5];Z9C8?-K;9Y/"YPMB8GEN\O5NTWM
M_404QFPT$DP,"'10\QKM(6B2A=2JSK_L^,WD(99^A6:+?6^GDX'T"UT*W_:8
MIE!5,U%4G1?&.9D6*>N4/*M!1$%1:BX\Z*W>$</? =^A[Y=HR]CQG>^Q4/BU
M3IFK]]5<5 Y%8FT<F,D:> 2/OA#_,K%:)N/*.8:I#_\4__^_Q9\5*R>^Q?\Q
M2[WTFXI?<KJ\R//RQW(U_5I;P-[\\^5Z/A$1LSY9KV1YKBY31Y(U0F^I%@(\
M1T<I*6)-%G:04DTUH7T'WBB*.I3AJ4@C2O/6"&?I*'7[[7=EO9M?T.:ZGOSX
M=KZZME@O5C?_Y"KI5.5DT*W'PBCZ'Q,=>"D$Y*2="X9[Y(--^CR6Z$[RLD[%
MUTY;?A9E]N3H/%YI0E3;7/MP>>$C*)4$H&<2-)=,!<F*LH,UXSF]HNR<.!P2
M+L?5D1VBNYX0N5=-BG1.,LTSZ"1=;0-J )E1$%3$6)P6-IQEC/VSKB,[""$G
MU9$=HJZ>L/A U5*6P@22%1A,A2):1ZQ$DER125B;;6%FL#S1YUU'=A (#J@C
M.T0C/8'KMQ]WQ'85#-9=&9G/FMMZ=XB,=J5BX(K5(*VPQD@?4AFL1/9ADCK)
M*1[[L#U96SV![U:8M9CGQ=?Y9>TV?+51 P]9%2,@6D\;*DC:HRB1=JL6AF=?
M++9NR[\/79W8NA9 >#K\.$TK'2#M_7RQ5LWM9GR RXT%5SEG[4T!Z8(&Q3F"
M0]JO0F5)>Y='WWP@S@'D=8*[9MB8GT=1'6#P^D;L7=F#-Y<"4:\3:.D4*%8L
M8)(>-%/><TX^2VH=4AQ"W[@H' PDVRFP0VFL S1>-_W_D+^1-,E/66_AW>Q%
MX;-3,H$M1E8Y2G"1>.1!"U<*<T:V3NPYD,1Q'<-S87)(O74 RP<8V=.[?G-3
M"JZC<X*1RR-%6CL_"%X;#DF&*+G2H>C!@N+CR>ZD]FO<N.9,6A\]U>7JZ:SN
MXIBGZ\?9Y0,RF)02>;!20HE(AL(13\B# RF]4,EK)-;VRUW9;\'NG,MA43 ?
M6"7]SF"Z?KK=-"*\RF8XZAG[X2\U>GG>@\Q&C\5WM'[SAI=-M*ZH"J.:E+I6
MM?4)6%0Z!TG6CK4^1QX@X^03]0%@?R*I_4:_],^)$HZ<5L<!C:\3S+@#]*Y>
MO9,5EXJ<5]6\I\UC!(UK@4Y%P;USK9GLGYDI6;L$#0W*YGM#FI6'2![0N C4
M*"P=(5YY5=O',O!62XA%*Z."3XJUKD(:P+A<Y_N0KQCC^@Z(#NB\?#/'V?+%
M38K07?S?PK^X3 >F#5!D'3&@A $L%D%;;0+7)2&V?LX_@=S^#-,A"+HW^N%,
M>GMF9NMF-.+#__EM7IV2\7?BDD,:OR,9'] ^8LR\1*,AL#KK-')./Q&Z$^,\
M9LFL<ZWOF_JPC^M@VJ001' ,^'JPK&8"?"$GP3!=BA:!*]6Z;/Q(4ONSBX<@
MIX%=/%A?(UX^+!>KR9_X7_/%R\OE:OZ5OG?U6IA#""9Q.CK\^NJFWA%2T"R%
MER0T,O-AK[H ^OP=I-&?;E'V\,KC@N<LRIXWD_S(N'F+7TE2/_&P>>]#%3%9
M%)!TG93JD8$SA?P#'1/F6(+A>TU9>@(^.PD8!T4M-#IO+=ZQ+S9?_EBNIO'5
M-"SFR^GRU8(VT)?I\OHM0H?"C'(64+ (2JI &X<X,=DGG9BD6'B_L4B/+C,>
M'!KI<#Z(0,>&QJ<?2PR+Z?43F,Y1RJC!8,EUS!>K.0(DGVA#-*FDN!W\[8#"
M3Y\=YPEP(-4?+["Q5?WZ:UA<?I]&O!YJB<%(8A8P.@VJ=M7S.5'@ZG*6HK 0
MMT?![%#VUH?'>3(;2-VG"&ULA?\_*YRE:Z1J=%)[GD"G;&LG;@M!* ]"DF..
MF1LG]BNXOOO5<1H'#J3JH\4UMIX_+?+7\N,:H=8QJYW,4(0@RAGS0+0&T%XG
M(XM0DNUWG/_TV7':\0UEPX\6V-BJ_N/[XL?R!J0>DXS,"'"%UZ32("%(%TD
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M1 Y4[2#KR/T%KYQCD5P(45K7&O^:]\"'8.J$>^!#]-7WP7KOMHBX(E<V9(K
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MO :6P@SG$I3B%I10$C!@@H#"Z22X\JGU-<?#E)QJ77[^ZNW-'\=@*(S.0%Z
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M%E 9%47!14#.Q7,EB(D8]P/7P6N/V]5@ ' -*_U^P%6WSB,'O;[ASH62DU'
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MF$DFB :L95Q;%%%LMSO_BU1'':3<?:JC#I%TAVC9O' EXR5W*0&Y'[:.;K>
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MV:T9*UI+66P"2[X6'9XR4NRO+0@EI$)FK?6'V(3]5NTI^:*=G1A XAVXI/_
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MO/[MW8?KHFL1R 0K"URF $J7",&JVG=)2H'9D,P&R!U]FK!QO9G&!J>]*CK
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MZJ<[\-UY_5Q,XUVV=&1&%1M <Y=K^QT#KD1+ BQ2.QZ=4L/VP]U)6D_WL$,
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M&[7M3UU7YN805-PS-\,HY!D9FK<4:F#MIW-"K<(>7QW*^#Q._C!F2/OH$[)
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MLSR0>]IMF@7GE(]<M!YY\2 AG5R7G*[H>6NICWU$74]_63^97!>%9F$9UTZ
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MT7*QFKS[UXR^\V7Z;;VEO"Y>.R^!1\%JTTX)2 8:0K(!Z:2G8W^OQ&OZ\AW
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MA[]-OL//@K-9,%ZX($GI5$N:,Y [P$!$KDL(R+1O_8)X)*GCGH'MX7=.S74
MT#OIYR:9X+0H8$U-/Z\]7[RC/[(HE0^TR=BVI3IWFO]@5NPLRMZ=^'^(Y#O
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M=5^'4ML_)J-;^U;[TC9RU4YK]-QK^3Z$BKJM2-W>\<=7SN_XTC"&:<#*^?T
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M_G #/18#KQ8.D$Y#,DHY@O>) 0O9,16M",U'8!Y$X,G=EO99[$Y#']1%V91
M\GI#KI(C<2#Y"HGL-3HF&3;ON700A>-&&<-AZUX+IN'TUFWSDD<LQ0E]3/;X
MZN"&;LCN)H=A$K/EGF0#T01/0)$1D#$*17/@&D-(0JCG;._>S&>?/^7%U_>;
MF=&WBU]-[%4R2":T@>(RN1HY, @,*2S"9%B)/O+0NDW3$R0])XMV"'JV+5I+
MS700'NQFY[<?+W&5/\\7/]Z5.M'W^C?2BW]/EY-:S:@"Q5I)ZUI+IA(YH4G5
M"R$6"SG N?E(M"-)'1>83>&R-Q3;Z:YKB.Y@\O?Y5YS.)HQ'F9W2X)@CYDSV
MX(Q54(I&HW)Q.K=.[SN2U%XAVA!&>T.WG4['3GW9S>.KRW6?Y1>?%WE]A?"?
MT]67WZ;S+_@]S]ZOW;&8+U?3B!?+/W-MTCSA/-J<)(,8)#G&B==.@DD#\W7T
M0/:VV/URL1H2U2MJ&R)HWH$Z1X3Q<K$BS^JRWL634E8_WN+7O-[Z)#"OLD*0
MCM7J7*\!E150Z,\25>W1L=?I3PO<,:OTIUN3NFOM<1]%ACC.FTAY9)1\R-\V
M$KG9!=LL;?:?1E2Q-G1F09>:@D&GAO 2@N4Q".FEW&_D\Q/0V9N@<:Q8&YW/
MAU; V$?HG_/%MR_SCS^N[:;FPB7F(S 1ZBP"0V9<UX$$Q10O2O;1\KV.P:T/
MCP>"@?0V;R3$#MS_3_1[[\J=:4SK?<*D=%DH#HY+<CY]0?#*)#I04ZUECHFE
MUDE.#Q(R[@/ID-'EZ7+O #QWAWB]F*6W\QG>_LTG^FF)5ZGVF[U1R,;**B:L
MC<64I.C&^^C!"E[+C;CUV#H3Y$ 2Q_6Z&X!BNYO6@!KJ ("UF@/#?+%NP?3B
M0<YJN/"^&OLZ6_'AW][P'IP*5G(.&7FH\Q4M.!L44!R.4G+!DVM]H]&2_I&[
MP0X)M'O/7B-IO0/$?[P,R_S?ET3_']\KR_3/UD8BL\259!F$#)E.()4@B!C!
MA52"R10."]L8O#M(&3?_>,@SNX7L^X30Q@DNU3D-M3[):TU.<$0Z<^J#-+,Q
M<"-LE*W?_782,_8L@ :J?AH^1\B]/P!=&U)FO:HY#"+P.L2UIC34UK$V\R"8
M$S'+UG, 'R2D.^ <H^3'H7.$Q#N S6[3_&8ZR_4V>3F1EB%3@IQ;3KM*<;04
M@3L#VGM$KU PW3K3:@^RQLV.'.>1\SB=C'VE=<W/YM'@EIT77^N]S]V9ON1E
MJJ"<@Q@S>: F.$"=$Z#7 AF%7%H<]NCS])J]OND<J>N'WF\:"[XS/-608D9?
M_C+]]G).EAAGJP]DEZ=$U16?$Q90!XP<T @2H&>A_I1!<V65XJZH[6*7_5#U
MY,J]OMRTQU9;)?2+L!<I3:O^\.(]_K@*K#]_7JS+7S=\:G16*ET <R:7@DER
M1#6%T]855]\ZI4_E1+ ]242O5[2#XJZM:OJ%8.T*%5<Y;;@D45HCD]7 574P
MA*H^K-(DRFA2Y#;J/7L\[+UDK[<)@\+K%+&/#:9=UVT?ZG3T>C7X+EQ,/Z\U
MN-SP5X=P?INN\&*"WB>*D3@48\F5+1HIO)8):#<9D8(2>GL^Z@Y\G4)%K]Y^
M \B=33F]HO!F9RWF,>>TG#@CA7'_I[MKZXTKM\'O_2\$=+^\%,CN=HL 2781
MIWTU=*&\TSHSV[D4R+\O-9?8L3WVF1D='[DO><@D1Q3YB9*HCZ1#6E6E%A"-
M'IQ4=%X0*B4=LH]VV!8Z=,1I&Q9,@JZ+E#XUDHYK[/'-)A45N?(9BLR9YD4[
M?ZBEP[1V10MTF.,P L4)@T[;5N!5-LC6JN\74MM2WJOK[*S-*D@HQ=1%(FHY
MSHS@<F)>"<:U81?B:#?2M(7])P+/&4KN-AON,]Z&[4&Q/G7>>V7]4?!A.7!'
MO]4F\VV8J(WRW8X-=E<]UW%ALS0@"%.@K- 0L^,0$E<V*LY9:5U+["69+HVO
M'_O^4ZF@CC&+"1EX7FI.0<S@'-TMZ!@7DT.:O&W]6'.">-/&29MBYV' ?2PC
MO3D/]657A;:AG_IRKZ[M:-[J*;%?RV?%PKVRA>[]4=A:0]2#U]+5_L7>*L8T
M;U[_<&R?=97^P+RYQ=_*LPJ_6Q.T$DH1M$W;@G3.B]I!U%(!*B%Y%,EYV5H'
MI\K8N?<Z!46/WJ''-->;<V$7U!MXZ9/C.K$Q*PV\B#\TS!J9(F01&"@38BU]
MH6OO04R.><MT:Z;:]%[LIV\__+)]MP^:!PRZ%AJ7E;Y16]F6S "Y=IR0HD+S
M(^A9@G;NST[!T^G^[%+#=<"[&3:U+;V-E.5BK%DPDM%M.WJL[9046",T%^@Y
M^M8$P.'234SL&A\J Z\*%]JM,T3NV7$A&ILM$^!T)D7EQ" &(6@:+D43<G&F
M=9G&QU+TZ>DNM?<SL#I#^1.GPGX,\_ #?]\%[1*6!#Z1TU<U,<:EFDC@I'"8
M91"Q# '."QFO#\?M!RKGV'#12*$3@^%=*;/;6=7$W^;K;4O67?X_,EXBST!7
MG2W3UD (48)D&8,Q 0T?M(N] (FG1Y^6A]40& V4V]E6<\^I;KUH?3NPR!WP
M**L7S1(\"D7SX2E(;;4+@US'Y:>=Z4LO='.\.=DR_8)LOP M,N4*J88V[9HS
M@IXFXVQ];6*&TW1R;LUI?U:@?K:NB\P^#$YGV&#JY^&[JL3S_#M]<C&?XW>>
MX=X+&U$*MR@A&U7;-#KRPMY+""5&I:)0S@][(1XP6)=X.<>NBQ&5/#5H?ETL
MO^)RR*PP<-KRD0X /M7S70@0:EH2.E6,0I;9PSKD1Z S>,A^CD0- 32.PJ>&
MT;ZKV"^SU7HYBYNJJ'V3B"^+#W@3TK==]^[%<G6/K_H]J3O*8I.@DX#-$12J
M!$$K =GF('T.11DS"%H7B3$M(WTDN+V>87J&X.??K["V[]PU[L0OR\WJ<&T5
M0;G(>"W;4W,^%*_MD#.=3 57+!D1=1F6>'/>^-/RU"< 72-33(VV=ZO5[&:^
MY10>*D3]A',LL_5O9>_'K]9+#%_W<PO61&5-@,B]!^6=!B])J\4628O)^7M=
MVI^%V8D#3TM*'PE?8RJ_0V#M$SWN<>P/,9442BK) Z^U!)0/-*^8.62'W!8O
MD_##>O.>,.BT//37 U03I4\.IOO%3S]>_?S^$*L504M5R1O9T^8N$J-]70K:
MYNDO@HI263<,.$\/,"VY?"R0-%#FY(!(_]G,5ML<Q-_*A]G7V5Y/^W/?H<';
MZOW\>QCW<*F-BIED+<U2I]H?.$,0,D+E_4@3H^<#T][/%F%:TOE8H'H5@W00
MZ[PB4^VR>FC"ZV\_+[[^N9AO,V!K!"_:D)R3&4J1=->-2M%DF %N9*2+1I32
MM^Z<\:Q T]X%7S^HWLXZ'4#MP1P.E5J33MLE*CS'VH?0U_5"9\*(7!1OO9.M
M(?:D(!/34=H9>M%:ZQU YTMM,[E9?KM:+]*_]XXV6\&U$@IX8A(4XP)HG5FP
M)+_@O#B56S=5>4*,:6'3P+@/"]E>J.D.P/)I,4^+^9J^2O_BYK!5[^?B58RR
M:+H7U-PS55^^O=$6HG1*FB23+ZPQ:IZ39]I8>GOX---]CXT<N"Q>2ZN E9!!
M:5,@UI:Y/FL4#"-'-8CJ/%8CA]'BD:]W\&FB^S?3WD%F1(U60HF&'*NVM2D0
MADK0D@F3YJ))9Y"WVM[A))N?U=[A% -,'2/X:3E;K1>W'[_1YZ[(<<>X=ZL6
M7=(A&;K5UO(+A9QV2#4^'[%D%U-B:=@SW;$1WD+#AY,LN6BMU@Y./4<\\X?O
MJ?<E12T"34 5VLR5$@)\O4E$HS.SB=-.W+IA^4LR3=RFO!>.W'DVFMH?'9G,
MYUHT+?]KLZ+?:I/VSYAP]N=Z=1V0.5Y,K9!;<P>3U>3(70+ML7CCL\ PC.-T
MXL!=\IW.-/GBE?3?,;;^&6XWM&2O,&V6='G9T22V_)QKDYU1AF7@HE;.U:1*
M9UV!8*RW*NAD'B:=G(ZPX\-W28L:%V>-;-$IVAZ3P;[7A_PYW*;-[<ZXNP*1
M07(AE:8;K9(T7\<]1"8%T.PS:;UHD>PEV#M%F"X94^,A<30[O6E<TB^)_N;:
M,,M]D1Y\,71><3Z"XZ'0J999RQC36@RKP=A"FBYI55,C\QQ+]7OAN,)MZ._O
M.*>YW]+$W^6OLWFEG&WK"-;B@?,5KGXEZ]P_:M?'^_M?K&QMCK+>]ODV;TUM
M&_D@2&M5DB4($UN_"XT[HRXI7Y=AOT,H=+ P?ME4/N7=!&:XJF'QS;+:Z1J-
M<MF6NLH9 ]J$-,28(HC,56(A",E:-\U[5J NB6-M8-G.$!V@ZIEC^'61,8;H
M$#)=]FCGP !180+II$&!6,1K5;^KXG3),AO5T9ULA [P]&FQQM4V./#?&M?Z
MA.MKE4PMMQI ,D.:B?7AK\;;$Z]=E;-C6;9.H'TL19=TLC;HN5#EG5Y'WL]G
MZUFXK<59K[DBB<ES NW(LMZN' 3A B34M1*9D)Q?%..[-]8@G/@WA9,QM-PI
M:#YMZAM+30MXS*G<<B])S&OG8N98:C^A$D&E+"'Z1--FQ;$47 Y\&+?U B&&
M18_9_PW.FANF@ZUNRV7Z8W%+MEKM*"_OY^EVL^W2L5AN;;G>943M<J&>)K%<
M)\S!&TNZK4545-WJ S<2F!(HO8G&/$S2;D"&;2'Y, R_K2>0"6W;;6'+!VTE
MSZID^>@;;4I7/B]:HUJ5#P?Y7E,P<^T%S[4[-6V3B@?R5X8G*-([)E40:'3K
ME7M$EL;-6E=WM5DUVFC0%]">U?<]1I-TWH%+7$2N4&9L'5@X*DQ735O/P\$+
M/5O/5/R;\1T7%,,]]JEQ/,F8Q6^/ BDH4SP7#AAJVK:8(I-'0R9G2#@2H88"
MWJ9#V9%<? A21*]V_%R5/8(SU@%M@W0SS:%VP1MW?AV4JFUB_9>ZAI^L[A[.
MTT>ZJ9,O52Q%!..4!Q5"AH"9DZ.UL@@3@U2M&69'1.D*.&?8^.56\R<KO$_<
M[-F;J=8QE#*"B$S5I\^ZHIP&1),X,P%)1>,CIXM$L!:F?AD^9^B]/P#MB;J:
M6:Z2CJ252NF0PD(,3D ),BNO198/>S2W!D\/J6"-C/P\=,[0>'^PN0L\>&[1
M^T [M[1U(^<1(BH'-F:?4Q19R)&/.1].HD*/5RYTY!WK/)5/';L^I;WJ/_XD
MK<[7AQ:_MD2C36"@0W72M==3<"R +%$75-K$AV3[(Z'K\V7HRAV="8!SF]U>
M8(VI07>H-OAEL0^W[ZMV'4*5=[W*/\YN:X6X.1[^RW6P(:62$Z3H#,VSQN4E
M5U",M-H*X8W(@U!W@1!=.;(&L'LM>TR-N^/MR_=/CX?%Q 6=.;G0((RO(7NO
MP5M78UY%(9U#@X[#0#9TQ(F+?C1'U"B:[A<^G_&F$ET7RV^/%LB[FYLEWM2$
ME1TYV_MHF'0)1*VJJM J",QQFC^=1%(PSOMAU?A:2#-QRO4KPFXD"XT?Z][_
M4/^(885__<O_ %!+ P04    " !420151Q20)60(   6)   %@   ')P<G@M
M,C R,C V,S!E>#,Q,2YH=&WM6EMS&CD6?M]?H<&U&;N*6P-V'.RXBF"RH<IK
M>S#93)ZVU-UJ4%G=ZI'48/;7[R>I,=B8!,]D)L[6YH'0K:.C<_G.3?CTI_.K
M_OCS]8!,32K(]<=W%\,^J=0:C4_M?J-Q/CXG'\;_O""=>C,@8T4SS0V7&16-
MQN"R0BI38_)NHS&?S^OS=EVJ26,\:EA6G8:04K-Z;.+*V:E]@T]&X[._G?Y4
MJY%S&14IRPR)%*.&Q:30/)N03S'3MZ16*ZGZ,E\H/ID:TFJV6N235+=\1OVZ
MX4:PLR6?TX9_/FVX0TY#&2_.3F,^(SQ^6^&M5HL='1V']#@).F_B]G'08?0H
M[H2=X#AAG=:_ PC9 +G?H\U"L+>5E&>U*;/G=U^W<G,RY[&9=H-F\^\51W=V
MFLC,X#"%S?ZKY[')B:H)F(72&)EV \NL?&5DWCW"HV%WID8%GV1=I[%_P;,8
MRG7;H*CXTY8<(RFDZNXUW;\3NU)+:,K%HOOSF*=,DTLV)R.9TNSGJH;;:IHI
MGGA"S?_#O!#N<5ZJ"#Z"9VRI<M"R>@[NICSDAK2#>O!0R:WJ->N.]YI&$91@
MZH%*S?IW5*H_&(V'[X?]WGAX=4G>?2;]#\/!>S+X==#_.![^:T"NWF-U,$(\
MC&X^]B['9'Q%;K X&HZ'@QL0]C_T+O\Q(+W^F(P^7@Q(T.[5@LX^/:B2W@WI
MG5]=CP?GC[>[T]K-%MB3\8<!N>F-WO4N!S>UJU\O!I\=,ZRTFLW6CI;>"J2_
M$C>=)TT\K))K&@I)+MA$*L4,K9*(*<.3!3%3:E[M'1Z?D.?H^4(4"^JO]H*C
MYLGFYY!,Z8P1Q6:<S9'2S)1K\DM!%; O%F3$<JD,D1EY+U5*@F;M%R(3B+2@
MPBS(]92JE))<1##-FY,?T#*MK99Y1S7L <W3!;G-Y%RP>,*JWD#*FR66$"23
M* @XA_*,T&Q!BLRH@D$/E A7+6 O2E(\*4X%26B$5XK(% G*2$^W09"QB&E-
MU<*2I/26X=PUGAKO8@B#(X4K-3C#$D1<H;2 +,-V2!(S1>93'DV)+NS':O^<
M*58RL0JD7 O4(%O.YMQ,H:#.6>0$M'QSB"9CJ#G#MIB$BW4S_*BN;S_?]8PD
M/(-QK9]6QJS"[R#'LEI;YUF"D*&V\\#W2!0Q>,)A:Y:KPMG<AED.>UNH6 @)
ML<)"Z0;]Z&C +78M3=52% ($ ("$E]QQVLD343TEB9!SO42'8A.N#?HA0ZA]
MZ>6&E-4U)^NE,!O2_JA^[FSU\_B!45[M';>"UR>Z]&29^&U(R"3A>'3F&A*J
MF',,#,U#P:P!"0,:0L'UU));LA3IP*8$^QQS'0FI"^RSB4))X3V4*QFQ&*\U
MV8=#8@8/>ZL/[J(IS2:,]!"#HT(P[04.VK06'.ZS [<_.(S]DW_DME_)/#SL
M(<1&ZQIJO!>M0%\]C90')0\.2G"05?8QED!ABXBKCL_!1TYCFW%J@B4>("\%
M,6B)MD'FG&DTA[";2ZA?]VS5YOJ(%GKW+3;IA@P.*D_R:5P6"@P0HS.N7>2#
MBF6.CVU-5CEC/>\H)JCS>)G'5UZKECG)+G+D#\BBI>"QFVMT$6H><ZJX58#[
M:N,R868Y%=I6 !<EVI4+ER<P.$$@3#1N4XX.@D>%H#:]02TGQ*J28(>O2^OE
M%-]"9@F1@;"?Q<_.."\74>&.B-HYB#> M7OX[XPO8'+&8PL;JC$_VV1'-2!G
MVPN+):KBI5^!-$Y#+CBZ0I2;IXZU*'<0<-[U 'U NM:>N)QZ5RJ4%RH'NK0K
MCU$D5>P$<(W*A&6H>@(@PPK++7HM"9HP#R2@G.<N?P)*N[;NY3#X<M$4'9!M
M<!K,J"A<%%M;LR1!_\!GL))^H@^X+WD[9"7_^'1KX-"#C<@HVC<@H2S,=@EV
MR9OTGIK9[BKY>B-*PF7?Y@*">4M 'N]\'+#A_ZVW(6O86+]- 0Y=X]7UF77&
M-NY7EKN64%IMH2$R;&$VMWSE2L9_3M62<TXGK!8B)F]K-$&(=*F8TX6N_'77
M0"\W,.+M@7'N,;>)73NTE0V06WDR0)Z176TUEE%4*(O0M=+W!-=4:H/W]JH)
MO'0$1K_YV9OL;]F2(-20]QY1EX*CYV=NWK2C:%;<RW7@I9I2?=\GV(SI0I/%
MKI0X>Y1I?H&I\I:)<OA\1%_]PR;:'HXO?Y@X_,;#A+M]B9?0K*Y2F,VHZ_!8
M93/KX&>T"1NMW[UH%.V?D4K?5V;W BS3E!O#V!?J12A1^^UZS"&?8[(/$"$]
M:YO^\;]M0I?(9[\5'.([E!=9Y&;4@_^I<6%KUNEAG+=]%H?3[;!DQZZ(,WB)
MZ:7R?Y+,CF.7&RIXM(,6Y$\6YXN'^Y&YG&#F*&VV6_ =G^L77*_JKLV6EQS/
MB@(_;/S?WBM[*_9TNJ<Q3*C9?;;?FCO*7A];D #0DE=]\Z;1N>DB1?A"&I=8
MRBK[Y,78[ZH$+S</A%_( V@R$H4$6P46F:L)0+.[>BUA7_4UFF<S*6;,%NH,
MC9Z_059E&6%I+N2"874^E;YVT ?I!4'P3;J8^N_JE#>=]9T\<0Z;^A]K>L6D
M0!'M5-VOL5LE?X"IUX]^"72_;4(3XR;@^_Y>86RN02-!<\VZRR\G*.:YH(LN
MSYQ<;M/)0\L<@O_,=@1HX<HSW'%^N>S5#SOUP\ZA;=<-3&[BY<%E)U]WG7S#
MQ)MK;X[K;YK;ES'=WJ\U'&_/'QKHG&9O*^W*([-T6_D="1X:Q5IJ0PF9?R>'
MO]KK -_N\_%/>/<^WT'?TJGV9TFH2]R-&+'2G_PPEO@#VO\P.O:GG"5D<,>B
MPL[@Y,JWU)NZ-ESTO;1Y?[EEXX\-OM=OH%N2_3>3X_6.,?QTZ=Q^)]+P?S'C
M_G;G[+]02P,$%     @ 5$D$55J(3_EJ"   .B0  !8   !R<')X+3(P,C(P
M-C,P97@S,3(N:'1M[5IK4QLY%OV^OT)C:C-0Y;?-0 RARC%FXRH&,L:I3#YM
MR=UJMPIUJT=2VWA__1Q)[0<8!Y.=#&1K\\%QMZ2K^SCWW"N9TY_.KWNC+Q_[
M)#:)(!\_O;\<]$BI4JM];O5JM?/1.?DP^O62M*OU!ADIFFINN$RIJ-7Z5R52
MBHW).K7:;#:KSEI5J2:UT;!F1;5K0DK-JJ$)2V>G]@T^&0W/_G'Z4Z5"SF60
M)RPU)%",&A:27/-T0CZ'3-^22J68U9/97/%);$BSWFR2SU+=\BGUXX8;P<X6
M<DYK_OFTYC8Y'<MP?G8:\BGAX;L2?WO4#,:L==Q^&[;:8WI,Z7'(6NWC( @/
MHZ/CZ-\-*%G#=+]&F[E@[TH)3RLQL_MWCIJ9.9GQT,2=1KW^SY*;=W8:R=1@
M,X7%_JN7L2F)J@F$C:4Q,NDTK+#BE9%9YQ<\&G9G*E3P2=IQ%OL7/ UA7*>%
M&26_VT)B((54G;VZ^W=B1RH13;B8=WX>\81I<L5F9"@3FOY<U@A;13/%(S]1
M\_\PKX1[G!4F0H[@*5N8W&A:._MW,1]S0UJ-:O.^D5O-JU>=[#6+ AC!U#V3
MZM47-*K7'XX&%X->=S2XOB+OOY#>AT'_@EP,KKI7O4'WDEQ?8+0_1#X,;SYU
MKT9D=$UN^KU/P\%HT+\A_=]['[I7_^J3;F]$AI\N^Z31ZE8:[7UZ4";=&](]
MO_XXZI\_7.YV:]6;$$]&'_KDICM\W[WJWU2N?[_L?W'",-*LUW?U]%8@_9VX
M:3_JXD&9C)@"800,:3Q/69D$3!D>S8F)J7FS=WA\0IYCYBNQJU%]L]?XI7ZR
M^3D@,9TRHMB4LQD8S<1<D]]RJ@!],2=#EDEEB$S)A50):=0KOQ$90:4Y%69.
M/L94)91D(H!KWI[\@)YI;O7,>ZKA#UB>S,EM*F>"A1/@P3E(>;>$$HJD$O4
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M):K"15R!-$['7'!TA2@WCVUK4>X@X*+K 7IOZEI[XCCUKC HRU4&=&E7'H-
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M&?(7]T*K9W5%92[+COX$4$L! A0#%     @ 5$D$56H II)M9 , JVLM !$
M             ( !     ')P<G@M,C R,C V,S N:'1M4$L! A0#%     @
M5$D$52BA2P27%@  3 H! !$              ( !G&0# ')P<G@M,C R,C V
M,S N>'-D4$L! A0#%     @ 5$D$54)NN\.1)   &&H! !4
M ( !8GL# ')P<G@M,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0    ( %1)!%4?
MWA';'8T  )H;!@ 5              "  2:@ P!R<')X+3(P,C(P-C,P7V1E
M9BYX;6Q02P$"% ,4    " !42015H;8Q;CP" 0 5V0H %0
M@ %V+00 <G!R>"TR,#(R,#8S,%]L86(N>&UL4$L! A0#%     @ 5$D$5?+7
MV%.:J0  ^*$' !4              ( !Y2\% ')P<G@M,C R,C V,S!?<')E
M+GAM;%!+ 0(4 Q0    ( %1)!%5'%) E9 @  !8D   6              "
M ;+9!0!R<')X+3(P,C(P-C,P97@S,3$N:'1M4$L! A0#%     @ 5$D$55J(
M3_EJ"   .B0  !8              ( !2N(% ')P<G@M,C R,C V,S!E>#,Q
M,BYH=&U02P$"% ,4    " !420152&?QGI4$  "'$P  %0
M@ 'HZ@4 <G!R>"TR,#(R,#8S,&5X,S(N:'1M4$L%!@     )  D 50(  +#O
$!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
